<SEC-DOCUMENT>0001213900-22-030420.txt : 20220531
<SEC-HEADER>0001213900-22-030420.hdr.sgml : 20220531
<ACCEPTANCE-DATETIME>20220531163120
ACCESSION NUMBER:		0001213900-22-030420
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20220531
DATE AS OF CHANGE:		20220531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40439
		FILM NUMBER:		22983804

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>f10k2021a1_neuroone.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:39 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nmtc="http://originalsourcemusic.com/20210930" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt;"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>Form
<ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K/A</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Amendment No. 1)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Mark One)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">September 30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition period from ______ to ______</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission file number
<ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-40439</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="font-size: 12pt"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName">NeuroOne Medical Technologies Corporation</ix:nonNumeric><br/>
</span></b>(Exact name of Registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><b>27-0863354</b></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">(State or other jurisdiction of<br/>
incorporation or organization)</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">(IRS Employer<br/>
Identification No.)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-size: 6pt">&#160;</span></td> <td style="text-align: center"><span style="font-size: 6pt">&#160;</span></td> <td style="text-align: center"><span style="font-size: 6pt">&#160;</span></td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">7599 Anagram Dr.</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Eden Prairie</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></b></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><b>55344</b></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: bottom; text-align: center">(Address of principal executive offices)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: bottom; text-align: center">(Zip Code)</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="-sec-ix-hidden: hidden-fact-0"><span style="-sec-ix-hidden: hidden-fact-1">952-426-1383</span></span><br/>
</b>(Registrant&#8217;s telephone number, including area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse"> <tr style="vertical-align: top"> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><b>Title of each class</b></td> <td style="padding-bottom: 1.5pt; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><b>Trading Symbol</b></td> <td style="text-align: center; padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><b>Name of each exchange on which registered</b></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><b>Common Stock, $0.001 par value per share</b></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><b>NMTC</b></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Stock Market LLC</b></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(g)
of the Act:</b> None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: justify">Large accelerated filer</td> <td style="width: 25%; text-align: justify">&#9744;</td> <td style="width: 25%; text-align: justify">Accelerated filer </td> <td style="width: 25%; text-align: justify">&#9744;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> </td> <td style="text-align: justify">&#9746;</td> <td style="text-align: justify">Smaller reporting company </td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: justify">&#160;</td> <td style="text-align: justify">Emerging growth company </td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, the last business day of
the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of shares of the registrant&#8217;s common
stock held by non-affiliates of the registrant based upon the March 31, 2021 price at which the common equity was last sold was $<ix:nonFraction contextRef="c1" decimals="-5" name="dei:EntityPublicFloat" scale="6" unitRef="usd">82.5</ix:nonFraction>
million. The number of outstanding shares of the registrant&#8217;s common stock as of December 13, 2021 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">16,187,722</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are filing this amendment to our Annual Report on Form 10-K for
the year ended September 30, 2021, as filed with the Securities and Exchange Commission on December 15, 2021 (the &#8220;Original Form
10-K&#8221;), solely to correct an error in the content of Baker Tilly US, LLP&#8217;s Report of Independent Registered Public Accounting
Firm.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AmendmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beyond this correction, there have been no changes to the financial
or other information contained in the Original Form 10-K.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation<br/>
<br/>
FORM 10-K<br/>
<br/>
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2021<br/>
<br/>
TABLE OF CONTENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="padding-left: 0.125in; text-indent: -0.125in"><a href="#a_001"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART I</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 80%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</span></a></td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1B.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL PROCEEDINGS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_008"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART II</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>60</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7A.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9A.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9B.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9C.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2" style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_018"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART III</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>109</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_024"><span style="font: 10pt Times New Roman, Times, Serif"><b>PART IV</b></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>124</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM 10-K SUMMARY</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_027"><span style="font: 10pt Times New Roman, Times, Serif">SIGNATURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Unless the context requires otherwise, references
in this Annual Report on Form 10-K (this &#8220;Annual Report&#8221; or &#8220;Report&#8221;) to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;the
Company&#8221; and &#8220;our&#8221; refer to NeuroOne Medical Technologies Corporation (the &#8220;Company&#8221;).</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report contains forward-looking statements
that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled &#8220;Risk
Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221;
but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221;
&#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;continue&#8221;
and &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future.
These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you
that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about
which we cannot be certain. Forward-looking statements include statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
timing of and our ability to obtain and maintain regulatory clearance of our cortical strip, grid and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">even
if our cortical strip, grid electrode and depth electrode technology is approved for commercial sale, our ability to successfully commercialize
our technology in the United States;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to achieve or sustain profitability;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to raise additional capital and to fund our operations;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
availability of additional capital on acceptable terms or at all as or when needed;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
clinical utility of our cortical strip, grid and depth electrode including technology under development;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to develop additional applications of our cortical strip, grid and depth electrode technology with the benefits we hope to offer
as compared to existing technology, or at all;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
results of our development and distribution relationship with Zimmer, Inc. (&#8220;Zimmer&#8221;);</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
performance, productivity, reliability and regulatory compliance of our third party manufacturers of our cortical strip, grid electrode
and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to develop future generations of our cortical strip, grid and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
future development priorities;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
impact of the COVID-19 pandemic on our business;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to obtain reimbursement coverage for our cortical strip, grid and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
expectations about the willingness of healthcare providers to recommend our cortical strip, grid and depth electrode technology to people
with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological
disorders;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
future commercialization, marketing and manufacturing capabilities and strategy;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to comply with applicable regulatory requirements;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
ability to maintain our intellectual property position;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
outcome of legal proceedings with PMT Corporation (&#8220;PMT&#8221;);</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
expectations regarding international opportunities for commercializing our cortical strip, grid and depth electrode technology under
including technology under development;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
estimates regarding the size of, and future growth in, the market for our technology, including technology under development; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
estimates regarding our future expenses and needs for additional financing.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are based on management&#8217;s
current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#8217;s
beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and
other factors that are in some cases beyond our control. You should refer to the &#8220;Risk Factors&#8221; section of this Annual Report
for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to
be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any
other person that we will achieve our objectives and plans in any specified time frame, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements speak only as
of the date of this Annual Report. Except as required by law, we assume no obligation to update or revise these forward-looking statements
for any reason, even if new information becomes available in the future. You should, however, review the factors and risks and other information
we describe in the reports we will file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;) after the
date of this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>ITEM 1.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</span>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Overview of NeuroOne Medical Technologies
Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were originally incorporated as Original Source
Entertainment, Inc. under the laws of the State of Nevada on August 20, 2009. Prior to the closing of the Acquisition, as defined below,
we completed a series of steps contemplated by a Plan of Conversion pursuant to which we, among other things, changed our name to NeuroOne
Medical Technologies Corporation, increased our authorized number of shares of Common Stock from 45,000,000 to 100,000,000, increased
our authorized number of shares of preferred stock from 5,000,000 to 10,000,000 and reincorporated in Delaware. On July 20, 2017, we acquired
NeuroOne, Inc. (the &#8220;Acquisition&#8221;). Immediately following the closing of the Acquisition, the business of NeuroOne, Inc. became
our sole focus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Overview and History of NeuroOne,
Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne, Inc. was incorporated under the laws
of the State of Delaware on October 7, 2016. Its predecessor entity, NeuroOne LLC (the &#8220;LLC&#8221;), was formed on December 13,
2013 and operated as a limited liability company until it was merged with and into NeuroOne, Inc. on October 27, 2016, with NeuroOne,
Inc. as the surviving entity (the &#8220;Merger&#8221;). As a result of the Merger, all of the properties, rights, privileges and powers
of the LLC vested in NeuroOne, Inc., and all debts, liabilities and duties of the LLC became the debts, liabilities and duties of NeuroOne,
Inc., except for the Exclusive Start-up Company License Agreement, dated as of October 1, 2014, as amended on February 22, 2017, March
30, 2019 and September 18, 2019 (the &#8220;Original WARF License&#8221;), with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;),
which was not legally transferred until May 2017. The purposes of the Merger were to: change the jurisdiction of incorporation from Minnesota
to Delaware; change the ownership of the LLC&#8217;s underlying assets; and convert from a limited liability company to a corporation.
In December 2019, NeuroOne, Inc. was merged with and into the Company, with the Company remaining as the surviving entity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a medical technology company focused on
the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography
(sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. Additionally,
we are investigating the potential applications of our technology associated with artificial intelligence. Members of our management team
have held senior leadership positions at a number of medical technology and biopharmaceutical companies, including Boston Scientific,
St. Jude Medical, Stryker Instruments, C.R. Bard, A-Med Systems, Sunshine Heart, Empi, Don-Joy and PMT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing our cortical, sheet and depth
electrode technology to provide solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation
and ablation, all in one product. A cEEG is a continuous recording of the electrical activity of the brain that identifies the location
of irregular brain activity, which information is required for proper treatment. cEEG recording involves an invasive surgical procedure,
referred to as a craniotomy. sEEG involves a less invasive procedure whereby doctors place electrodes in targeted brain areas by drilling
small holes through the skull. Both methods of seizure diagnosis are used to identify areas of the brain where epileptic seizures originate
in order to precisely locate the seizure source for therapeutic treatment if possible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deep brain stimulation, or DBS, therapies involve
activating or inhibiting the brain with electricity that can be given directly by electrodes on the surface or implanted deeper in the
brain via depth electrodes. Introduced in 1987, this procedure involves implanting a power source referred to as a neurostimulator, which
sends electrical impulses through implanted depth electrodes, to specific targets in the brain for the treatment of disorders such as
Parkinson&#8217;s disease, essential tremors, dystonia, and chronic pain. The effects of DBS as a potential treatment for Alzheimer&#8217;s
is also being evaluated by researchers. Unlike ablative technologies, the effects of DBS are reversible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">RF ablation is a procedure that uses radiofrequency under the electrode
contacts which is directed to the site of the brain tissue that is targeted for removal. The process involves delivering energy to the
contacts, thereby heating them and destroying the brain tissue. The ablation does not remove the tissue. Rather, it is left in place and
typically scar tissue forms in the place where the ablation occurs. This procedure is also known as brain lesioning as it causes irreversible
lesions. In August 2021, the Company announced a strategic partnership with RBC Medical Innovations to develop a radio frequency
(RF) ablation generator. The following month, our RF ablation technology was tested by representatives from Emory University in Atlanta
Georgia in an animal study. The product remains in development.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical sheet electrode and depth electrode
technology has been tested over the years by both WARF, the owners of our licensed patents, and Mayo Clinic located in Rochester, Minnesota,
in both pre-clinical models as well as through an institutional review board (&#8220;IRB&#8221;) approval at Mayo Clinic for clinical
research. In December 2020, we announced the first human commercial use of our Evo cortical electrode in a procedure performed at the
Mayo Clinic. Regarding our ablation electrode, the Cleveland Clinic has performed testing in bench top models and pre-clinical (or animal
testing) modes. These pre-clinical tests have demonstrated that the technology is capable of recording, ablation and acute stimulation,
although our ablation electrode technology remains in product development (meaning that additional testing will be needed prior to it
being cleared for sale by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;)) for recording (or diagnostic) and therapeutic
modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We received 510(k) FDA clearance for our Evo cortical
technology in November 2019, and in September 2021 we received FDA clearance to market our Evo sEEG electrode technology for temporary
(less than 24 hours) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical
signals at the subsurface level of the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Epilepsy Market</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to initially target the diagnosis and
treatment of epilepsy. Epilepsy can be caused by a variety of conditions that affect a person&#8217;s brain, some of which are: stroke,
brain tumor, traumatic brain injury and central nervous system infections. According to the Centers for Disease Control and Prevention
(the &#8220;CDC&#8221;) and Citizens United for Research in Epilepsy (&#8220;CURE&#8221;), there are approximately 3,000,000 patients
annually suffering with epilepsy in the United States, with an additional 200,000 diagnosed every year. The CDC and CURE also estimate
that epilepsy costs the United States $15.5 billion per year. Approximately 720,000 of these patients are not receptive to pharmaceutical
treatment and therefore are appropriate for surgical treatment of this disorder. In addition to poor quality of life, epilepsy also is
associated with fairly high mortality rates. Sudden Unexpected Death in Epilepsy has an annual incidence of 1.16/1000 in epilepsy patients.
Despite the large market opportunity, it is estimated that there are only 16,000 craniotomies performed for epilepsy cases each year in
the United States with 18,000 performed in Europe.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span>
These numbers represent an underpenetrated market due to the invasiveness of a full craniotomy required just to perform the diagnostic
procedure. After the diagnostic procedure, a second therapeutic procedure is required and at times even a third surgery if the seizures
persist. We believe patients are unwilling to proceed due to the long diagnostic times (one to four weeks in the hospital with a craniotomy),
infection rates and 50% rate of success in the diagnosis and treatment of the disorder. As detailed above, after the diagnosis is completed,
if successful, the patient must undergo an additional procedure to have the affected area of brain tissue removed. The average cost for
the diagnostic technology per procedure is $10,000, with ablation devices costing $15,000 and brain stimulation devices costing $25,000
to $30,000. We believe our technology, once developed, will offer an all-in-one solution with diagnostic and therapeutic capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><sup>1</sup></td><td style="text-align: justify">American Association of Neurological Surgeons National Neurosurgical
Procedural Statistics 2012.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many leading neurologists believe that the limits
of today&#8217;s current technologies are the reason the exact affected area of the brain causing epileptic seizures is not well-determined.
We believe our technology, which has been developed to date by physicians at WARF and Mayo Clinic, will provide a number of advantages
over the current commercially available technologies, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
proprietary thin film technology under development has a smaller footprint with many more electrodes.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
expect that our technology will eventually be able to be implanted using a minimally invasive procedure utilizing a dime sized burr hole
rather than a full craniotomy.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
technology may provide more accurate detection of irregular brain activity over currently available technology. In limited clinical testing,
doctors at Mayo Clinic have documented pre-seizure activity (micro-seizures) during their clinical research with their patients using
our cEEG technology.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
expect our technology can ablat</span>e through the electrodes as well as perform brain stimulation, allowing for diagnosis and treatment
through the same product and in the same procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Parkinson&#8217;s Disease</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parkinson&#8217;s Disease Foundation estimates
that as many as 1,000,000 patients in the United States live with Parkinson&#8217;s disease with an additional 60,000 patients diagnosed
per year. Over 10,000,000 patients worldwide are living with Parkinson&#8217;s disease. There have not been any drugs introduced that
have been effective at treating Parkinson&#8217;s disease. The average onset is over 60 years old but some people have been diagnosed
as young as 40 years old. Parkinson&#8217;s is a disorder of the central nervous system caused by loss of brain cells throughout various
regions of the brain. It is attributed to the loss of dopamine production in the brain, a messenger in the brain that allows for movement
and coordination. There are no objective tests to diagnose Parkinson&#8217;s disease, and misdiagnosis rates are still very high. Doctors
look to find two or more signs to make a diagnosis, including balance problems, rigidity and tremors that occur during rest. In 2011,
the FDA approved the first imaging device called a DaTscan that can capture images of the dopamine system in the brain. By itself, these
scans cannot diagnose Parkinson&#8217;s but can help confirm a doctor&#8217;s diagnosis. Parkinson&#8217;s disease is typically not fatal;
however, complications caused by the symptoms of Parkinson&#8217;s, such as difficulty swallowing causing food to travel to the lungs
resulting in pulmonary issues or falls related to loss of balance, can be fatal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Today&#8217;s primary treatment for Parkinson&#8217;s
disease involves medications that have not proven to resolve symptoms but rather ease symptoms. Years ago, surgical procedures such as
thalamotomy and pallidotomy targeted certain parts of the brain and involved destroying the tissue. More recently, these procedures have
been replaced with DBS. A doctor evaluates the patient by reviewing the patient&#8217;s symptoms and medications taken and administering
detailed memory, thinking and imaging tests to determine if they are appropriate for DBS. According to the Michael J. Fox Parkinson&#8217;s
Disease Research Foundation website, patients that seem to do best with DBS are those that have had the disease for at least four years
and have benefited from taking medications prescribed to control the disease. In addition, DBS seems to help with reducing the issues
with motor functions such as tremors, stiffness and slowness but not for balance issues. Doctors are evaluating treatment to other parts
of the brain in an effort to address more symptoms to treat walking or balance issues. In addition, research is being conducted to provide
stimulation when the symptoms return as opposed to all of the time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Essential Tremors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Essential tremors are thought to be due to electrical
irregularities in the brain that send abnormal signals to the muscles. It is a progressive condition that worsens over time and is linked
to genetic disorders that typically appear in people who are over 40. Essential tremors usually occur alone and without any other neurological
symptoms or signs. The tremors usually occur when the hands are raised and primarily affect the hands. Muscles in the trunk, face and
neck may also experience symptoms. Sometimes misdiagnosed as Parkinson&#8217;s disease, essential tremors are an involuntary rhythmic
shaking of the hands that is not present at rest. It is apparent during activities such as drinking, writing and eating. Symptoms can
worsen due to stress, anxiety, smoking, caffeine, fatigue, etc. Genetics Home Reference estimates that as many as 10,000,000 people in
the United States are affected by the disease. Treatments for the disease include medical therapy, weighting the limbs and DBS. Patients
need to eliminate any medications they are taking that cause tremors as this can exacerbate the symptoms. For some patients, using wrist
weights may ease symptoms allowing the patient to function. Other patients may also use relaxation techniques as stress can increase symptoms.
Medical therapy is also used to treat patients&#8217; symptoms. Primidone is typically the first drug prescribed as it has had success
in some situations for epilepsy. Botox is also used at times to control head tremors. When these fail, surgery is the next alternative.
A surgical procedure used years ago created lesions in the ventral intermediate thalamus and was highly successful with treating essential
tremors but is no longer commonly used due to increased risk of developing speech problems. The latest therapy is DBS, which, unlike other
therapies, is reversible and programmable, helping to adjust the settings to maximize patient benefit. Similar to Parkinson&#8217;s disease,
the ability to detect this irregular brain activity before it causes a tremor is highly desirable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dystonia</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dystonia is a neurological condition recognized
as a motion disorder that involves over activity of a variety of different muscles simultaneously that work against each other. It presents
itself in a variety of symptoms but typically involves repetitive, patterned and often twisting involuntary muscle contractions resembling
tremors. According to the Dystonia Medical Research Foundation, over 300,000 people are affected in the United States and Canada alone.
Dystonia is the third most common problem seen in movement disorder clinics. Because it has many different manifestations, it is often
misdiagnosed. In addition, similar to Parkinson&#8217;s disease, there are no specific tests that can positively diagnose dystonia. A
doctor typically will evaluate patient and family history, potentially do genetic testing, EEG testing, blood and urine tests. There are
also many treatment options for patients but depend on the type of dystonia. Botox and certain medications may be helpful or DBS may be
used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Spinal Cord Stimulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failed back surgery syndrome (&#8220;FBSS&#8221;)
is a condition that produces chronic lower back/leg pain due to one or more failed back surgeries. Typically, it is related to patients
that suffer with pain after surgery of the lumbar spine for degenerative disc disease. Re-operations are usually not recommended for these
patients due to low success rates. These patients experience greater levels of pain, a lower quality of life, varying levels of disability
and higher rate of unemployment. Spinal cord stimulation works by placing an electrode(s) in a targeted area of the spine which is then
connected to an implantable pulse generator that sends electrical stimulation to the electrode to block the pain signals from reaching
the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The back pain market includes the following indications:
FBSS, Ischemic Limb Pain, and Complex Regional Pain Syndrome. Over half of this market is comprised of patients with FBSS. Certain studies
have indicated a benefit for these patients suffering from chronic back and lower limb pain when they have been treated with electrical
stimulation. Prior to the patient receiving an implant, they undergo a trial period that allows them to determine if they are receiving
relief from the therapy while preventing a surgery to implant the pulse generator that provides the stimulation. If the trial period is
successful, then the device is implanted in a follow-up procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Artificial Intelligence</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brain consists of approximately 100 billion
nerve cells, which are small wires that pass electrical signals to control all of its functions. There have been a number of successful
clinical trials in which small metal wires, known as electrodes, are implanted in the brain to correct nerve damage using wireless communication
between implanted wires to simulate functional nerve cells. In addition to correcting damaged nerve cells, certain scientists have theorized
that if millions of wires could be implanted in the brain, these electrodes could present an opportunity to use artificial intelligence
to create infrared sight, increase hearing or perfect memory recall. However, there currently is no commercially available manufacturing
platform capable of making thousands of wires that can be placed within or on the brain and work reliably for the lifetime of a subject,
and are soft enough to match the tissue of the brain, that avoid damage to the brain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Limitations of Currently Available Therapies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are a limited number of currently available
products for diagnosis and treatment for people with neurological disorders such as epilepsy. Although the currently available systems
provide diagnosis and treatment for patients, they have certain inherent limitations and shortcomings that we believe limit their use
and validate the need for improved technology in the market. These limitations include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Lengthy
diagnostic times:</b> Patients spend one to four weeks in the hospital waiting to have seizures that will allow doctors to determine
where the seizures are occurring.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Lower
Accuracy:</b> Historically, clinical electrode manufacturers primarily provided electrodes that sample brain tissue at approximately
centimeter spatial scales. Advances in digital EEG acquisition have made recordings at sub-millimeter spatial scales possible, but high-spatial
resolution EEG has been slow to impact clinical practice. Existing, higher spatial scales increase the potential for missing data that
may be critical in the removal of brain tissue causing the irregular activity.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Need
to perform a full craniotomy (invasiveness):</b> Currently available cortical electrode technology is placed through a craniotomy, which
requires removing the top part of the cranium and is a very painful and invasive procedure. Procedural times for a craniotomy range from
a minimum of four to eight hours. A variety of complications can occur when a full craniotomy is performed, including but not limited
to: stroke, bleeding, infection, seizures, swelling of the brain (which may require a second craniotomy), nerve damage, which may cause
muscle paralysis or weakness, cerebrospinal fluid (CSF) leak, which may require repair, loss of mental functions and permanent brain
damage with associated disabilities. The invasiveness, procedural times and possible surgical complications have limited the growth of
surgical treatment of epilepsy.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Requirement
for a surgical incision</b>: Currently, when patients have been implanted with paddle electrodes in the spinal area, a surgical incision
has been required. A technology that allows for percutaneous placement is desirable.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Limited
number of contacts on an electrode</b>: Paddle electrodes currently are available in a variety of sizes and number of contacts. Physicians
want to explore adding a greater number of contacts on the same electrode in order to be able to be more precise in stimulating targeted
areas.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Solution</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the inherent limitations and inconvenience
of existing systems, we believe that there is a significant unmet need among people with neurological disorders for cortical strip, grid
and depth electrodes that provide diagnostic capabilities through cEEG and sEEG recording in addition to therapeutic modalities, such
as brain stimulation and ablation, offered as an all-in-one product. In comparison to currently available technologies, we are continuing
to develop applications of our strip, grid and depth electrodes with the goal of providing the following expected advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Reduced
time for diagnosis:</b> If we are successful in identifying brain activity more quickly, in offering a minimally invasive procedure and
developing an all-in-one solution, we expect our technology will reduce overall procedural times. While our pre-clinical and clinical
experience to date is limited, our cortical grid technology has demonstrated the ability to provide high fidelity recordings that have
allowed physicians to identify the affected brain tissue causing seizures in hours versus weeks. This represents the potential for meaningful
cost savings for hospitals and patients and improved quality of life for patients.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Improved
accuracy of diagnostic technologies:</b> Because we believe our thin film technology is capable of recording at higher fidelity than
current technologies used in EEG recording, we believe our technology may be able to more precisely determine the brain tissue causing
seizures. In December 2020, we announced the first human commercial use of our Evo cortical electrode to perform recording, functional
mapping, monitoring and stimulation of the brain. In the procedure, performed at the Mayo Clinic, our electrodes were used to record
evidence of pre-seizure activity, which may be critical in developing treatments to prevent the onset of seizures. We believe our technology
may be able to improve outcomes compared to using other diagnostic technologies regardless of whether we are able to offer an all in
one diagnostic and therapeutic solution.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Implantation
via minimally invasive procedure with fewer post-procedure complications:</b> We are currently developing an approach to deliver the
cortical electrodes, including minimizing the invasiveness of the procedure. We expect that patients who have qualified for this therapy
will be more accepting of a minimally-invasive procedure. Such a procedure would potentially reduce the patient&#8217;s pain, bleeding
and other adverse events associated with a full craniotomy. Our technology is expected to also have fewer wires, also referred to as
tails, exiting the patient&#8217;s head, which can also reduce the potential for infections. Furthermore, the material we currently use
in our cortical electrodes has shown in pre-clinical evaluations to cause less inflammation than current electrode substrates as it appears
more compatible with brain tissue. As discussed under &#8220;Our Strategy&#8221; below, our technology has been and will be implanted
via a full craniotomy until such time, if ever, as we are able to develop our minimally invasive procedure.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>All-in-one
diagnostic and therapeutic technology solution:</b> Due to the expected high fidelity recording capabilities of our technology under
development, we have received feedback from physicians that they will attempt to perform the diagnosis and treatment in a single procedure,
thereby eliminating the need for a second surgical procedure, reducing the likelihood of patient infection, risks associated with surgical
procedures and minimizing the diagnostic, procedural and hospital costs. As discussed under &#8220;Our Strategy&#8221; below, our initial
product offering offers diagnostic-only capabilities while we advance the development of our all-in-one approach. Currently, we are developing
a combination recording, stimulation and RF ablation technology that will perform both diagnostic and therapeutic functions.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Percutaneous
placement of spinal cord stimulation paddle electrodes with scalability options:</b> Due to the thin film nature of our electrode technology,
we believe that it may allow for percutaneous placement, thereby preventing the need to make surgical incisions to place the electrodes.
Minimally invasive and percutaneously placed technologies have become almost a requirement for adoption with patients and physicians.
In addition, our technology offers the ability to increase the number of contacts on a film that traditionally offers fewer contacts.
Increasing the number of contacts may allow for more precise stimulation in the spine, potentially improving the therapeutic outcomes.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to be the global leader in cEEG and
sEEG recording, monitoring, deep brain stimulation and ablation, owning the procedure from diagnosis through treatment. The key elements
of our strategy include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Introduce
cortical strip and grid electrodes for the diagnosis of epilepsy in United States</b>: In December 2019, we announced that we received
FDA 510(k) clearance to market our thin film cortical electrode technology for temporary (less than 30 days) recording, monitoring, and
stimulation on the surface of the brain. Our initial product offering has initially been and will be placed through traditional surgical
means involving a craniotomy until such time, if any, that we launch our minimally invasive procedure. In July 2020, we entered into
a development relationship with Zimmer, pursuant to which we granted Zimmer exclusive global rights to distribute the cortical strip
and grid electrodes, and Zimmer will use commercially reasonable efforts to promote, market and sell the strip and grid electrodes. We
believe, due to physician feedback, that our technology represents a major improvement over existing cortical electrodes for the recording
of brain activity. We are initially targeting epilepsy as we believe this is a clinical area of great need and a market that is underserved
with a quick path to commercialization. We believe the largest and quickest-to-market geography for our cortical strip and grid technology
under development is the United States for a number of reasons, including the following: (i) many industry sources believe there is a
large underserved U.S. market, (ii) healthy procedural reimbursement exist for centers and physicians, (iii) average selling prices are
robust, and (iv) there is substantial physician enthusiasm for our technology under development.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Launch
depth electrodes for sEEG recording:</b> In September 2021, we announced that we received FDA 510(k) clearance to market our Evo sEEG
electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation equipment for recording, monitoring,
and stimulation of electrical signals at the subsurface level of the brain. We filed for 510(k) clearance to expand the duration of use
up to less than 30 days in November 2021. This submission is pending FDA review. Given the reluctance of patients to undergo epilepsy
surgery due to its invasiveness, a number of epilepsy centers have adopted the use of depth electrodes, which are placed by drilling
small holes into the patient&#8217;s cranium, thereby avoiding a craniotomy. We believe our technology offers advantages compared to
current depth electrode technology and will enable us to offer a therapeutic solution using this technology in the future. As we continue
to develop our technology, we plan to release further information about the expected advantages of our technology over currently available
therapies.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Utilize
these core technologies to develop all-in-one diagnostic and therapeutic solutions with the initial focus on a combination diagnostic
and ablation electrode:</b> Patients currently undergo one surgical procedure for diagnosis (either
to have a cortical electrode placed via a craniotomy or depth electrodes placed via holes drilled into the skull) and, hopefully after
the brain recordings successfully indicate where the affected brain tissue is located, a second procedure or surgery is then required
to treat the patient. There is strong physician interest in being able to perform both the diagnostic and therapeutic procedure concurrently.
We are developing our technology with the goal of being able to offer this benefit although there can be no assurance that we will be
able to do so. We are pursuing cortical grid, strip and depth electrode technology that can record brain activity (diagnose) and also
provide both acute and long term stimulation as well as depth electrode technology that can ablate brain tissue. The technology has demonstrated
these functions in acute and short term animal models; however, additional development is required to offer a device that has long term
therapeutic application. These therapeutic technologies are expected to require more robust regulatory approvals for the United States,
ranging from a 510(k) to pre-market approvals (&#8220;PMAs&#8221;) with human clinical data. We will engage the FDA at the proper time
to determine the most efficient regulatory path.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Develop
percutaneous placed electrodes for spinal cord stimulation with scalable contact configurations: </b>Given that many surgically placed
technologies have become less invasive due to patient and physician demands, we believe that our flexible thin film technology will allow
for percutaneous placement, thus potentially eliminating the need to make a surgical incision. By leveraging our existing FDA cleared
cortical electrode and sEEG technology, we may be able to offer the ability to improve precision of where the stimulation is delivered.
NeuroOne&#8217;s platform thin film technology has the capability to increase the number of contacts in a similar footprint that has
fewer contacts.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Gain
approval for other brain or motor related disorders such as Parkinson&#8217;s with the therapeutic technologies developed for epilepsy:
</b>While we are developing our technology for the diagnosis and treatment of epilepsy, we believe that our technology has strong application
and utilization for other brain or motor related disorders such as Parkinson&#8217;s disease, dystonia, essential tremors and facial
pain as these diseases are currently treated with DBS if medications are not effective. As previously mentioned, we are planning to offer
electrodes that can be implanted for long term stimulation applications, but such use will require that we pursue additional approvals
from the FDA and any international regulatory bodies where we seek to commercialize our technology.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Explore
partnerships with other companies that leverage our core technology: </b>Given that our technology enables, complements and/or competes
with a number of companies that are in the market or attempting to enter the market with diagnostic or therapeutic technologies to treat
brain related disorders, we believe there may be opportunities to establish mutually beneficial relationships. In addition, our technology
may have application in cardiovascular, orthopedic and pain related indications that could benefit from a high fidelity thin film electrode
product that can provide stimulation and/or ablation therapies.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Investigate
the potential applications associated with Artificial Intelligence:</b> We have been informed by some of our corporate advisors that
the ability to offer scale-able electrode technology that can provide thousands of electrodes in the brain may be helpful in treating
medical conditions that may benefit from using artificial intelligence. The Company has formed an advisory board that will provide guidance
to the Company as we continue to explore the opportunities in this exciting field.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Our
Technology</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Epilepsy Mapping and Monitoring</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Epileptic seizures occur when the neurons in the
brain miscommunicate. This miscommunication typically results in involuntary muscle seizure activities and/or periods of perceptual disconnect
where the individual appears frozen. Modern medical science has advanced the treatment of epileptic seizures by mapping the electrical
communication activity of neurons and understanding their special orientation in the brain. This mapping is accomplished by access to
the cranium (through a craniotomy) and placing conductive contacts on the brain directly. The craniotomy procedure is very invasive, traumatic
to the surrounding tissue, results in high patient down time, and increases the risk of infection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to leverage scale-able technology and
produce ultra-thin, or paper-thin electrodes that allow for high-resolution and high-definition recordings, which would improve mapping
resolution and signal acquisition. If the Company is able to leverage scale-able technology, it would mean that our technology would be
able to incorporate smaller electrodes and thereby increase the number of electrodes on a given surface area. We expect that this would
increase the imaging resolution so that brain activity is displayed in greater definition. We also believe that the electrodes&#8217;
unique thinness and flexibility will provide a less invasive approach to electrode placement. The electrodes would be able to be placed
through a small quarter size hole instead of by an invasive full craniotomy procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The images under &#8220;Cortical Electrode,&#8221;
from bottom to top, are images of our cortical electrode strip, our grid electrode, and the placement of the grid electrode on the brain,
respectively. The images under &#8220;High Density Interconnect&#8221; are both images of our product that connects our electrodes to
the head box, which is a piece of hardware that connects to electrodes to acquire, amplify, display, store and archive electrophysiological
signals, and is integrated as part of our manufactured electrode product. The images under &#8220;Head Box&#8221; and &#8220;Signal Monitoring
and Mapping&#8221; are images of the device which processes information received through the high density interconnect, and a sample output
of data acquisition, respectively, neither of which is one of the Company&#8217;s products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our technology consists of three primary types
of cortical electrodes: grid electrodes, strip electrodes and dual-sided electrodes. These electrodes have a patented design that utilizes
proprietary processing and materials technology, which we believe will allow the electrodes to have improved features over the current
industry standard recording electrodes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">What sets our technology apart from others is
the integration of state of the art design leveraging the latest in flexible printed circuit technology. We believe our patented designs
will provide the surgeon a higher tactile perspective on electrode placement allowing for ultra-precise neuron recording. We expect the
benefits of our electrode designs to include the ability to detect better defined margins between healthy tissue and resect-able tissue,
less immune-response from the brain and surrounding tissue, better signal acquisition due to superior conformability of the electrode
over the brain, improved flexibility that physicians have requested, which we expect will enable a minimally invasive approach and the
electrodes unique thinness that is unmatched by current products being used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Future of Neurology Mapping with NeuroOne</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We seek to develop superior &#8220;scale-able&#8221;
technology for future product system iterations in higher density contact placement. This will open the doors to other brain related
disease recording procedures by providing high fidelity, more accurate diagnostic capabilities and also the ability to provide an all-in-one
therapy capable of diagnosis, ablation and/or stimulation. Beyond the brain, we believe our technology under development has applications
in other neurological signal recording disease states related to voluntary or involuntary motor neuron abnormalities, understanding sensory
neuro behavior (pain), limb prosthetics and degenerative muscle disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Development and Regulatory Pathway</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Experience, Future Development
and Clinical Trial Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Evo cortical electrode technology has received
510(k) clearance from the FDA for recording, monitoring, and stimulating brain tissue for up to 30 days. Our Evo sEEG electrode technology
has received FDA 510(k) clearance from the FDA for use (less than 24 hours) with recording, monitoring, and stimulation equipment for
the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Our other products have not received
any clearance for commercialization by any U.S. or foreign regulatory body. To date, the Company has performed a number of bench top (which
includes feasibility testing) and pre-clinical tests (which include animal testing of device placement, ergonomics, performance, ease
of use, and other tests required by FDA regulations). As described in &#8220;&#8212;Government Regulation&#8221; below, the Company will
be required to perform additional testing of its technology in connection with seeking additional regulatory clearances or approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to expand our product offerings to include
less invasive means and all-in-one solutions, thus providing both patients and physicians better options to treat epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. While we expect
to make modifications to our initial system, we believe that most of our future product development initiatives will involve unique and
transformational next generation technology that should drive further appeal of our products with both physicians and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are utilizing a number of resources to develop
these technologies. We license three critical patents from WARF that are the foundation of the technology and we are developing and intend
to commercialize and benefit from the thin film technology know-how of Mayo Clinic doctors through our license and development agreement.
WARF, Mayo Clinic (cortical electrodes) and Cleveland Clinic (sEEG electrodes) have been responsible for all pre-clinical studies of our
technology under development to date. See &#8220;&#8212;WARF License&#8221; and &#8220;&#8212;Mayo Foundation for Medical Education and
Research License and Development Agreement&#8221; below. Further, as we announced in December 2020, Mayo Clinic doctors used our technology
in the first human commercial application of our Evo cortical electrode technology to perform recording, functional mapping and stimulation
of the brain on a human patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below we have summarized, for each component of
our technology, the current stage of development or commercial production, the pre-clinical testing done to date by WARF, the Cleveland
Clinic or Mayo Clinic on such component, if any, our plans for further testing or clinical trials and our expectations regarding the requirements
for regulatory clearance or approval and timing of regulatory submissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 17%; text-align: justify"><b>Technology</b></td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 33%; text-align: center"><b>Stage of Development and Pre-Clinical Testing to Date</b></td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 46%; text-align: center"><b>Additional Expected Steps for Regulatory <br/>
Clearance or Approval</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: left"><b>Cortical strip and grid electrodes for the diagnosis of epilepsy</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has finalized the design for the product
    and there are no further expected changes to the device (&#8220;design freeze&#8221;).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical testing and clinical testing
on the final design has been conducted by Mayo Clinic and WARF (as described in &#8220;Mayo Clinic Studies&#8221; below). The product
is in commercial production.</p></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received FDA 510(k) clearance in the
    fourth calendar quarter of 2019.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commercial launch commenced utilizing Zimmer,
    our distribution partner.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: left"><b>Depth electrodes for recording (diagnostic) purposes</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have frozen this design and the product is
    in commercial production.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No clinical testing was required in order
to obtain FDA clearance.</p></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">The Company filed for FDA 510(k) marketing clearance for sEEG electrodes in May 2021 and received a 510(k) clearance from FDA for recording, monitoring and stimulation of brain tissue for less than 24 hours in September 2021. The Company filed for 510(k) clearance to expand the duration of use up to less than 30 days in November 2021. This submission is pending FDA review. Zimmer has indicated its desire to distribute this product once we receive FDA 510(k) clearance to market for less than 30 days use and has placed initial stocking orders. </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 17%"><b>Depth electrode diagnostic and ablation devices</b></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No design freeze.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical testing, including benchtop and animal
    testing, has been conducted on early designs. Additional pre-clinical testing at the Cleveland Clinic was completed in the second calendar
    quarter of 2020.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical (animal) testing was conducted in
    September 2021 with representatives from Emory University in Atlanta Georgia.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company announced a partnership
    with RBC Medical Systems in August 2021 to develop an RF generator that will be used with the Company&#8217;s diagnostic and ablation
    electrode.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">No clinical testing planned
prior to FDA clearance because predicates did not perform clinical testing.</p></td>
    <td style="text-align: justify; width: 2%">&#160;</td>
    <td style="width: 46%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the design is finalized, we will be required
    to conduct additional pre-clinical testing, which may include additional benchtop or animal testing for safety and performance.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are planning a Pre-Submission (Q-Sub)
to the FDA for the RF Ablation System, to review the feasibility of &#8220;Breakthrough&#8221; designation and to complete animal studies
in  the first calendar quarter of 2022. We anticipate filing a 510(k) submission in the fourth calendar quarter of 2022. We expect
that we will need to demonstrate design verification, which we estimate will cost us $200,000 to complete, biocompatibility, which we
estimate will require an investment of $100,000 to complete, and sterilization validation and adoption, which we estimate will require
$25,000 to complete. We may also need to demonstrate electrical safety, which we estimate will cost us $60,000. It is estimated the RF
generator will cost approximately $1.5 million to complete.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future testing requirements for regulatory clearance
    will continue to be evaluated as we develop the design and regulatory strategy for this product.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 17%; text-align: left"><b>Spinal cord stim electrodes</b></td>
    <td style="width: 2%; border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="width: 33%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No design freeze.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We performed pre-clinical in-house bench top testing
    in August 2020 and are currently performing bench top testing at Carnegie Mellon University in Pittsburgh, Pennsylvania.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In June 2021 we started bench
    top testing of prototypes to demonstrate chronic performance and longevity.&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></td>
    <td style="width: 2%; border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="width: 46%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This device is in early stages of development.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the design is finalized, we will be required
    to conduct additional pre-clinical testing, which may include additional benchtop or animal testing for safety and performance. Additionally,
    the FDA may require that we conduct human clinical studies.&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No FDA feedback has been sought or received by
    us to date on the regulatory/clinical process that may be required for spinal cord stimulation indication, but we expect regulatory PMA
    approval will require a more robust clinical process, human clinical data for a PMA (implanted system), depending on proposed indications
    for use.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future pre-clinical and clinical testing requirements
    for regulatory submission will continue to be evaluated as we develop the design of this product.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: left"><b>Depth electrode chronic stimulation devices</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No design freeze.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Bench top testing remains in progress and we expect
    to announce results of these studies in the first quarter of 2022.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While this device remains in early development,
    we began conducting bench top durability testing in the second calendar quarter of 2021 and expect to announce results in the first quarter
    of 2022.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a design freeze, we will be required
    to conduct additional pre-clinical testing, which may include additional benchtop or animal testing for safety and performance. Additionally,
    FDA-approved human clinical studies will most likely be required.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No FDA feedback has been sought or received by
    us to date on the clinical process that will be required for chronic stimulation, but we expect regulatory approval for chronic stimulation
    may require a more robust clinical process, which could a PMA with human clinical data. Because we have not yet met with the FDA, we cannot
    yet determine what clinical data and testing we will need to complete or what the testing will need to demonstrate. However, we believe,
    based on the experience of competitors for similar technology, that we will need to conduct clinical trials, which we estimate will require
    an investment of approximately $2,000,000, as well as demonstrate biocompatibility, which we estimate will cost $150,000 to complete,
    and demonstrate sterilization validation and adoption, which we estimate will cost $35,000 to complete.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mayo Clinic and University of Wisconsin-Madison
Studies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical technology for the diagnosis of epilepsy
has been tested by doctors at Mayo Clinic in multiple pre-clinical tests conducted from 2012 to 2017. In pre-clinical models, doctors
examined the biological impact on mammalian brains. Polyimide substrate electrodes (NeuroOne technology) were implanted on the pig&#8217;s
brain for one week alongside standard competitive electrodes. The tissue underneath the two types of electrodes was removed, fixed, stained,
and examined for immunological responses. The results of a histological (evaluation of brain tissue under a microscope) analysis showed
reduced immunological reaction to prolonged polyimide substrate implants (NeuroOne technology) compared to standard silicone substrate
clinical electrodes. Electrophysiological recordings showed data obtained from polyimide electrodes which showed the feasibility of high
fidelity multi-scale electrophysiology while also displaying easier deployment of polyimide electrodes (NeuroOne technology) through minimally
invasive burr holes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, doctors implanted our polyimide
thin film electrodes on five human patients who were undergoing surgery to remove brain tissue for drug resistant epilepsy. Electrophysiological
recordings from the polyimide thin film technology displayed in each of these patients demonstrated micro-seizure activity due to the
high fidelity multi-scale electrophysiology. In December 2020, we announced the first human commercial use of our Evo cortical electrode
to perform recording, functional mapping and stimulation of the brain. In the procedure, performed at the Mayo Clinic, our electrodes
were used to record evidence of pre-seizure activity which may be critical in developing treatments to prevent the onset of seizures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conclusions reached by the physicians at Mayo
Clinic were that thin, flexible polyimide electrodes (NeuroOne technology) provided recordings similar to standard clinical electrodes
with reduced immunological response. In addition, Mayo Clinic physicians observed that the flexibility of polyimide electrodes may reduce
pain and swelling associated with implantation of the device, and the single wire exiting the skull may reduce infection risk. The ability
to record micro-seizure and single neuron brain activity may also provide additional useful clinical data. Combined, these properties
suggest that the replacement of current competitive silicone electrodes with polyimide substrate electrodes (NeuroOne technology) for
recording brain activity for epilepsy could provide enhanced clinical value with reduced cost, reduced infection risk, and improved patient
comfort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our thin film cortical implant technology
has been tested by researchers at the University of Wisconsin-Madison in multiple pre-clinical animal studies conducted from 2006 to 2016,
which included mice, rats and primates. In these studies, our technology was able to record brain activity from different areas of the
brain, was implanted in a minimally invasive fashion, electrically provided brain stimulation and tissue ablation, and had increased flexibility
compared to existing commercially available technology, which allowed the grids to conform more easily to the brain surface (and may have
reduced pain and swelling, compared to less flexible devices).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Zimmer Development Agreement </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the size and maturity of the U.S. market,
our initial commercial focus, on July 20, 2020, we entered into an exclusive development and distribution agreement (the &#8220;Development
Agreement&#8221;) with Zimmer, pursuant to which we granted Zimmer exclusive global rights to distribute NeuroOne&#8217;s strip and grid
cortical electrodes (the &#8220;Strip/Grid Products&#8221;) and electrode cable assembly products (the &#8220;Electrode Cable Assembly
Products&#8221;), including to approximately 188 Level 4 epilepsy centers. Additionally, we granted Zimmer the exclusive right and license
to distribute certain depth electrodes developed by the Company (&#8220;SEEG Products&#8221;, and together with the Strip/Grid Products
and Electrode Cable Assembly Products, the &#8220;Products&#8221;). The parties have agreed to collaborate with respect to development
activities under the Development Agreement through a joint development committee composed of an equal number of representatives of Zimmer
and the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Development Agreement,
we are responsible for all costs and expenses related to developing the Products, and Zimmer is responsible for all costs and expenses
related to the commercialization of the Products. In addition to the Development Agreement, Zimmer and the Company have entered into a
manufacturing and supply agreement (the &#8220;MS Agreement&#8221;) and a supplier quality agreement (the &#8220;Quality Agreement&#8221;)
with respect to the manufacturing and supply of the Products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the Development
Agreement, we are responsible for performing all development activities, including non-clinical and clinical studies directed at obtaining
regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts to promote, market and sell each Product
following the &#8220;Product Availability Date&#8221; (as defined in the Development Agreement) for such Product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Development Agreement, Zimmer
made an upfront payment of $2.0 million to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Development Agreement will expire on the tenth
anniversary of the date of the first commercial sale of the last of the Products to achieve a first commercial sale, unless terminated
earlier pursuant to its terms. Either party may terminate the Development Agreement (x) with written notice for the other party&#8217;s
material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In addition, Zimmer
may terminate the Development Agreement for any reason with 90 days&#8217; written notice, and we may terminate the Development Agreement
if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will investigate markets outside of the U.S.
with the assistance of Zimmer and formulate a plan to enter those markets with the support of Zimmer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information regarding the Development
Agreement, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Financial Overview&#8212;Collaborations
Revenue&#8221; and &#8220;Note 7 &#8211; Zimmer Development Agreement&#8221; included in &#8220;Item 8 &#8212; Financial Statements and
Supplementary Data&#8221; in this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage in the United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursement from private third-party healthcare
payors and, to a lesser extent, Medicare will be an important element of our success. Although the Centers for Medicare and Medicaid Services
(&#8220;CMS&#8221;) and third-party payors have adopted coverage policies for our targeted indications, there is no guarantee this will
continue at the same levels or at all in the future. Current Procedural Terminology, or CPT, is a medical code set that is used to report
medical, surgical and diagnostic procedures and services to entities such as physicians, health insurance companies and accreditation
organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applicable diagnostic CPT codes for mapping (diagnosing)
the brain for diagnostic procedures are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">61531
Subdural implantation of strip electrodes through one or more burr or trephine (saw) hole(s) for long-term seizure monitoring;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">61533
Craniotomy with elevation of bone flap: for subdural implantation of an electrode array, for long term seizure monitoring;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">61535
Craniotomy with elevation of bone flap; for removal of epidural or subdural electrode array, without excision of cerebral tissue (separate
procedure); and</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">61760
Stereotactic implantation of depth electrodes into the cerebrum for long term seizure monitoring.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Regar</span>ding
ICD-10 codes, the International Classification of Diseases, Tenth Edition (ICD-10) is a clinical cataloging system that went into effect
for the U.S. healthcare industry on October 1, 2015, after a series of lengthy delays. Accounting for modern advances in clinical treatment
and medical devices, ICD-10 codes offer many more classification options compared to those found in its predecessor, ICD-9. Within the
healthcare industry, providers, coders, IT professionals, insurance carriers, government agencies and others use ICD codes to properly
note diseases on health records, to track epidemiological trends and to assist in medical reimbursement decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ICD-10 codes for epilepsy are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.0
Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.1
Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.2
Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.3
Generalized idiopathic epilepsy and epileptic syndromes;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.A
Absence epileptic syndrome;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.4
Other generalized epilepsy and epileptic syndromes;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.50
Epileptic seizures related to external causes, not intractable;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.80
Other epilepsy; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G40.82
Epileptic spasms.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that many of the indications we are
pursuing with our technologies are currently reimbursed on a widespread basis by Medicare, Medicaid and private insurance companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medicare, Medicaid, health maintenance organizations
and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement
of new medical devices, and, as a result, their coverage policies may be restrictive, or they may not cover or provide adequate payment
for our products. In order to obtain reimbursement arrangements, we may have to agree to a net sales price lower than the net sales price
we might charge in other sales channels. Our revenue may be limited by the continuing efforts of government and third-party payors to
contain or reduce the costs of healthcare through various increasingly sophisticated means, such as requiring prospective reimbursement
and second opinions, purchasing in groups, or redesigning benefits. Our future dependence on the commercial success of our technologies
makes us particularly susceptible to any cost containment or reduction efforts. Accordingly, if government and other third-party payors
do not provide adequate coverage and reimbursement for our products and the related insertion and removal procedures, our financial performance
will be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing, Supply and Quality Assurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently outsource the supply and manufacture
of all components of our prototypes of our technology under development. We plan to continue with an outsourced manufacturing arrangement
for the foreseeable future. Our third-party manufacturers are recognized in their field for their competency to manufacture the respective
portions of our system and have quality systems established that meet FDA requirements. We believe the manufacturers we currently utilize
have sufficient capacity to meet our requirements; however, see &#8220;Risk Factors&#8212;Risks Related to Our Business&#8212;The COVID-19
pandemic has adversely impacted, and may continue to impact, our business&#8221;. We believe that as we increase our demand in the future,
our per-unit costs will decrease materially. We have also identified capable second source manufacturers and suppliers in the event of
disruption from any of our primary vendors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our suppliers meet the latest ISO 13485 certification,
which includes design control requirements. As a medical device developer, the facilities of our sterilization and other critical suppliers
are subject to periodic inspection by the FDA and corresponding state and foreign agencies. We believe that our quality systems and those
of our suppliers are robust and achieve high product quality. We plan to audit our suppliers periodically to ensure conformity with the
specifications, policies and procedures for our devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development team, which includes
our Director of Electrode Development, utilizes advice from leading experts in the neurotech field on our scientific advisory board and
is focused on the development of thin film cortical grid and strip electrodes and depth electrodes for recording, ablation and chronic
stimulation for brain related disorders as well as stimulation for spinal cord stimulation for back related pain. Our research and development
expenses were $3.9 million and $2.1 million for the years ended September 30, 2021 and 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the market for Epilepsy diagnosis, our cortical
strip, sheet and depth electrode technology will likely compete with Integra Life Science&#8217;s Integra Epilepsy Strip, Grid and depth
electrodes, which provide a similar function to our diagnostic technologies. These products are well established in the marketplace and
Integra has greater resources than us, which could allow them to innovate faster. Ad-Tech Medical Instrument Corporation&#8217;s Epilepsy/LTM
(subdural grid, strip and depth) electrodes, which have become the market leaders for diagnostic mapping in epilepsy, and PMT&#8217;s
Cortac Strips and grid electrodes and Depthalon depth electrodes are used for recording brain activity similar to other competitive technologies.
In addition, Dixie Medical has launched a product line of depth electrodes and CorTec has launched a cortical electrode product line called
AirRay. Today&#8217;s success rates for seizure free post-operative conditions remain at 50%, which has limited patients&#8217; willingness
to undergo the currently highly invasive surgical procedure. We will also compete against other companies in early stages of development
of thin film technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the neuro-ablation market, we expect to compete
with Medtronic&#8217;s Visualase guided-laser ablation technology and Monteris Medical&#8217;s NeuroBlate technology, which use MRI guided
laser surgical ablation for use to ablate, necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy in medicine
and surgery in the discipline of neurosurgery with 1064 nm lasers. Their website claims it is used for ablation in the brain for soft
tissue and tumors. We believe there are other laser-based systems in development that will compete with these technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the neurostimulation market, we expect to compete
with NeuroPace&#8217;s RNS system approved for epilepsy, Medtronic&#8217;s Activa system approved for Parkinson&#8217;s disease, Boston
Scientific Vercise (indicated for Parkinson&#8217;s, dystonia and essential tremors), Abbott/St. Jude Medical&#8217;s Infinity DBS system
(approved for Parkinson&#8217;s disease and essential tremors), Liva Nova/Cyberonic&#8217;s VNS therapy intended for patients suffering
with epilepsy. We believe there are additional companies pursuing thin film electrode technology for use in the brain although none are
expected to be commercially available in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we will face potential competition from
many different sources, we believe that our technology, knowledge, experience and scientific resources will provide us with competitive
advantages. For a discussion of the key competitive factors that we believe will impact the success of our cortical strip and sheet electrodes
under development, if successfully developed and approved, see &#8220;&#8212;Our Solution&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of the companies against which we may compete
in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the
pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of
our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WARF License</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2020, we entered into the Amended and
Restated Exclusive Start-Up Company License Agreement, dated as of January 21, 2020, as amended on June 15, 2020 (the &#8220;WARF License&#8221;)
with WARF, which amended and restated in full the Original WARF License. Pursuant to the WARF License, WARF has granted to us an exclusive
license to make, use and sell, in the United States only, products that employ certain licensed patents for a neural probe array or thin-film
micro electrode array and method. We have agreed to pay WARF a royalty equal to a single-digit percentage of our product sales pursuant
to the WARF License, with a minimum annual royalty payment of $50,000 for calendar year 2020, $100,000 for calendar year 2021 and $150,000
for calendar year 2022 and each calendar year thereafter that the WARF License is in effect. The minimum annual royalty payment for calendar
year 2020 in the amount of $50,000 was paid in January 2021. If we or any of our sublicensees contest the validity of any licensed patent,
the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed
by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WARF may terminate this license on 30 days&#8217;
written notice, if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our
development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain
bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90 days&#8217; notice if we had failed to have commercial
sales of one or more FDA-approved products under the WARF License by June 30, 2021 or (ii) if, after royalties earned on sales begin to
be paid, such earned royalties cease for more than four calendar quarters. The first commercial sale occurred on December 7, 2020, prior
to the June 30, 2021 deadline. The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed
thereunder remain. We expect the latest expiration of a licensed patent to occur in 2030.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, WARF reserves the right to grant
non-profit research institutions and government agencies non-exclusive licenses to practice and use the inventions of the licensed patents
for non-commercial research purposes, and we grant WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial
research purposes to use improvements to the licensed patents. In the event that we discontinue use or commercialization of the licensed
patents or improvements thereon, we must grant WARF an option to obtain a non-exclusive, sub-licensable, royalty-bearing license to use
the improvements for commercial purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Risk Factors&#8212; Risks Related
to Our Business&#8212;We depend on intellectual property licensed from WARF for our technology, including our technology under development,
and the termination of this license would harm our business&#8221; for additional information regarding the WARF License.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mayo Foundation for Medical Education and Research
License and Development Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, we entered into the Amended and Restated
License and Development Agreement, dated as of May 25, 2017 (the &#8220;Mayo Development Agreement&#8221;), with Mayo Foundation for Medical
Education and Research (&#8220;Mayo&#8221;) to license worldwide (i) certain know how for the development and commercialization of products,
methods and processes related to flexible circuit thin film technology for the recording of tissue and (ii) the products developed therefrom,
and to partner with Mayo to assist the Company in the investigation, research application, development and improvement of such technology.
Mayo has agreed to assist us by providing access to certain individuals at Mayo (the &#8220;Mayo Principal Investigators&#8221;), in developing
our cortical thin film flexible circuit technology, including prototype development, animal testing, protocol development for human and
animal use, abstract development and presentation and access to and license of any intellectual property that the Mayo Principal Investigators
develop relating to the procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to pay Mayo a royalty equal to
a single-digit percentage of our product sales pursuant to the Mayo Development Agreement. Mayo may purchase any developed products licensed
under the Mayo Development Agreement at the best price offered by us to the end user in the prior year. The Mayo Development Agreement
generally will expire in October 2034, unless the Mayo know-how and improvements under the Mayo Development Agreement remain in use, and
the Mayo Development Agreement may be terminated by Mayo for cause or under certain circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information regarding the Mayo
Development Agreement, see &#8220;Risk Factors&#8212; Risks Related to Our Business&#8212;We depend on our partnership with Mayo to license
certain know how for the development and commercialization of our technology. Termination of this partnership would harm our business,
and even if this partnership continues, it may not be successful.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protection of our intellectual property is a strategic
priority for our business. We rely on a combination of patents, trademarks, copyrights, and trade secrets as well as nondisclosure and
assignment of invention agreements, material transfer agreements, confidentiality agreements and other measures to protect our intellectual
property and other proprietary rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, our patent estate consists
of three issued United States patents licensed from WARF covering a neural probe array and thin-film micro electrode array and method,
a pending U.S. patent application filed by us and published in 2018 covering our applications and additional devices used during the diagnostic
and therapeutic ablation and stimulation procedures, pending U.S. and European patent applications filed by us and published in 2020 relating
to improved neural depth electrodes, a pending U.S. patent application filed by us and published in 2020 relating to agent-delivering
neural electrodes, three pending U.S. applications (and corresponding PCT applications) filed in 2020 and 2021 relating to minimally invasive
electrodes, spinal cord stimulation devices, and additional electrode improvements and one additional pending U.S. application relating
to devices with temperature sensors. The licensed issued patents expire between 2025 and 2030, subject to any patent extensions that may
be available for such patents. If a patent or patents are issued on our pending patent applications, the resulting patents are projected
to expire between 2038 and 2042.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our patent applications may not result in issued
patents, and any patents that have been issued or may be issued in the future may not protect the commercially important aspects of our
technology. Furthermore, the validity and enforceability of our issued patents may be challenged by third parties and our patents could
be invalidated or modified by the issuing governmental authority. Third parties may independently develop technology that is not covered
by our patents that is similar to, or competes with, our technology. In addition, our intellectual property may be infringed or misappropriated
by third parties, particularly in foreign countries where the laws and governmental authorities may not protect our proprietary rights
as effectively as those in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The medical device industry in general, and the
recording, ablation and neurostimulation sector of this industry in particular, are characterized by the existence of a large number of
patents and frequent litigation based on assertions of patent infringement. We are aware of numerous patents issued to third parties that
may relate to the technology used in our business, including the design and manufacture of electrodes and pulse generators, as well as
methods for device placement. Each of these patents contains multiple claims, any one of which may be independently asserted against us.
The owners of these patents may assert that the manufacture, use, sale or offer for sale of our cortical strip and sheet electrodes infringe
one or more claims of their patents. Furthermore, there may be additional patents issued to third parties of which we are presently unaware
that may relate to aspects of our technology that such third parties could assert against us and materially and adversely affect our business.
In addition, because patent applications can take many years to issue, there may be patent applications that are currently pending and
unknown to us, which may later result in issued patents that third parties could assert against us and materially and adversely affect
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any adverse determination in litigations, post
grant trial proceedings, at the Patent Office relating to intellectual property to which we are or may become a party could subject us
to significant liabilities to third parties or require us to seek licenses from third parties, and result in the cancellation and/or invalidation
of our intellectual property. Furthermore, if a court finds that we have willfully infringed a third party&#8217;s intellectual property,
we could be required to pay treble damages and/or attorney fees for the prevailing party, in addition to other penalties. Although intellectual
property disputes in the medical device area are often settled through licensing or similar arrangements, costs associated with such arrangements
can be substantial and often require ongoing royalty payments. We may be unable to obtain necessary licenses on satisfactory terms, if
at all. If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement; if we are able to redesign
our products to avoid infringement, we may not receive FDA approval in a timely manner. Adverse determinations in a judicial or administrative
proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our products, which could have a significant
adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trademarks</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a registered U.S. trademark for the &#8220;EVO&#8221;
trademark. The document(s) updating the owner&#8217;s name were filed with the U.S. Trademark Office on November 30, 2021, with an effective
date of December 30, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trade Secrets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets, technical know-how
and continuing innovation to develop and maintain our competitive position. We seek to protect such intellectual property and proprietary
information by generally requiring our employees, consultants, contractors, scientific collaborators and other advisors to execute non-disclosure
and assignment of invention agreements upon the commencement of their employment or engagement as the case may be. Our agreements with
our employees prohibit them from providing us with any intellectual property or proprietary information of third parties. We also generally
require confidentiality agreements or material transfer agreements with third parties that receive or have access to our confidential
information, data or other materials. Notwithstanding the foregoing, there can be no assurance that our employees and third parties that
have access to our confidential proprietary information will abide by the terms of their agreements. Despite the measures that we take
to protect our intellectual property and confidential information, unauthorized third parties may copy aspects of our products or obtain
and use our proprietary information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cortical strip, grid and depth electrodes
are medical devices subject to extensive and ongoing regulation by the FDA and the U.S. CMS. Regulations cover virtually every critical
aspect of a medical device company&#8217;s business operations, including research activities, product development, quality, manufacturing,
supplier management and risk management, contracting, reimbursement, medical communications, and sales and marketing. In the United States,
the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), and the implementing regulations of the FDA (specifically, 21 Code of Regulations
(21 CFR Parts 801- labeling, 803 &#8211; medical device reporting, 807 &#8211; registration and listing, subpart E premarket notification
510k, 812 - investigational device exemption, 814 &#8211; premarket approval and 820 &#8211; quality system regulation) and applicable
FDA guidance) govern product design and development, pre-clinical and clinical testing, premarket clearance or approval, product manufacturing,
quality systems, import and export, product labeling, product storage, recalls and field safety corrective actions, advertising and promotion,
product sales and distribution, and post-market clinical surveillance. Our business is subject to federal, state and local quality regulations,
such as ISO 13485, ISO 14971, and FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) contained in 21 CFR Part 820.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulatory Framework in the United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Device classification</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA characterizes medical devices into one
of three classes, <span>Class I, II, and III. Regulatory control increases from Class I to Class III.
The device classification regulation defines the regulatory requirements for a general device type. Most Class I devices are exempt from
Premarket Notification under 510(k); most Class II devices require Premarket Notification under 510(k); and most Class III devices require
Premarket Approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Class I devices are subject to controls for labeling.
However, most such devices are exempt from pre-market notification and adherence to the FDA&#8217;s QSR. This pertains to manufacturers&#8217;
methods and documentation of the design, testing, production, control quality assurance, labeling, packaging, sterilization, storage and
shipping of products. Class II devices are subject to the same general controls but may be subject to special controls such as performance
standards, post-market surveillance, FDA guidance, or particularized labeling, and may also require clinical testing prior to clearance
or approval. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general
or special controls, including devices that support or sustain human life, are of substantial importance in preventing impairment of human
health, or which present a potential, unreasonable risk of illness or injury. <span>Premarket Approval
is required for </span>most Class III devices<span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some Class I and Class II devices are exempted
by regulation from the pre-market notification requirement under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, but
must meet the requirement of compliance with substantially all of the QSR. However, a pre-market approval (&#8220;PMA application&#8221;)
is required for devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or certain implantable devices,
or those that are &#8220;not substantially equivalent&#8221; either to a device previously cleared through the 510(k) process or to a
&#8220;preamendment&#8221; Class III device in commercial distribution before May 28, 1976 when PMA applications were not required. The
PMA approval process is more comprehensive than the 510(k) clearance process and typically takes multiple years to complete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on FDA classifications, we believe our diagnostic
strip, grid depth electrode and RF ablation technology will be categorized by the FDA as Class II devices that do not require clinical
testing and can be filed as a 510(k), similar to existing competitive technology. The Company expects that indications for treating epilepsy,
Parkinson&#8217;s and other patients suffering from motor related neurological deficiencies via a permanent implant for chronic treatment
will require a PMA process to commercially distribute in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The 510(k) clearance process</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 510(k) clearance process, the manufacturer
must submit to the FDA a premarket notification, demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally
marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally
marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class
III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#8220;substantially
equivalent,&#8221; the proposed device must have the same intended use, indications for use as the predicate device, and either have the
same technological characteristics as the predicate device or have different technological characteristics and not raise different questions
of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a 510(k) premarket notification is submitted,
the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will
refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required
to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance
often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the
FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly
prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market
the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA determines that the device is not &#8220;substantially
equivalent&#8221; to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill
the more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the De Novo process.
<span>The De Novo request provides a marketing pathway to classify novel medical devices for which general
controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for
which there is no legally marketed predicate device. De Novo classification is a risk-based classification process. </span>The De Novo
classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which
are low to moderate risk. A manufacturer can submit a Pre-submission (Q-Sub) for De Novo review if the manufacturer is unable to identify
an appropriate predicate device and the new device or new use of the device presents a moderate or low risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a device receives 510(k) clearance, any
modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended
use, will require a new 510(k) clearance or, depending on the modification, could require a De Novo device application and potentially
a PMA application. The FDA requires each manufacturer to determine whether the proposed change requires a new submission in the first
instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are
accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file based on adherence to FDA
guidance on changes to an existing 510(k) device. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such
change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination
regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require
the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a De Novo or PMA application
is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the
requisite application(s).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The PMA approval process</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following receipt of a PMA application, the FDA
conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it
is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin its review. The FDA
has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period
of time. During this review period, the FDA may request additional information or clarification of information already provided, and the
FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the
FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving or denying a PMA, an FDA advisory
committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should
approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of
the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but
may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
device may not be safe, effective, reliable or accurate to the FDA&#8217;s satisfaction;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
data from pre-clinical studies and clinical trials may be insufficient to support approval;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
manufacturing process or facilities may not meet applicable requirements; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in FDA approval policies or adoption of new regulations may require additional data.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an FDA evaluation of a PMA application is favorable, the FDA will either issue an approval letter, or approvable letter, which usually
contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been
fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of a device, subject
to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application
or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may
determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or
years while the trials are conducted and data is submitted in an amendment to the PMA. The PMA process can be expensive, uncertain and
lengthy and a number of devices for which FDA approval has been sought by other companies have never been approved by the FDA for marketing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
PMA applications or PMA supplements may be required for modifications to the manufacturing process, labeling, device specifications,
materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same
type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes
from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening
of an advisory panel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are typically required to support a PMA application and are sometimes required for a 510(k) clearance. These trials generally
require submission of an application for an Investigational Device Exemption (&#8220;IDE&#8221;), to the FDA. The IDE application must
be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number
of patients, unless the product is deemed a non-significant risk device and eligible for abbreviated IDE requirements. Generally, clinical
trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent
are approved by appropriate institutional review boards at the clinical trial sites. The FDA&#8217;s approval of an IDE allows clinical
testing to go forward, but it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety
and efficacy, even if the trial meets its intended success criteria. All clinical trials must be conducted in accordance with the FDA&#8217;s
IDE regulations that govern investigational device labeling, prohibit promotion, and specify an array of recordkeeping, reporting and
monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA&#8217;s regulations
for institutional review board approval and for informed consent and other human subject protections. Required records and reports are
subject to inspection by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and efficacy success
criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a product. Clinical trials must
be entered into the clinical trials registry at clinicaltrials.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application,
for numerous reasons, including, but not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
do not enroll in clinical trials at the rate expected;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients,
sponsor (NeuroOne) or study sites do not comply with trial protocols;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
follow-up is not at the rate expected;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
experience adverse side effects;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
die during a clinical trial, even though their death may not be related to the products that are part of our trial;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">institutional
review boards and third-party clinical investigators may delay or reject the trial protocol;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the
clinical trial protocol, good clinical practices or other FDA requirements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
sponsor (NeuroOne) or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner
or consistent with the clinical trial protocol or investigational or statistical plans;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
clinical investigators have significant financial interests related to the sponsor (NeuroOne) or the study that the FDA deems to make
the study results unreliable, or the company or investigators fail to disclose such interests;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action
or suspend or terminate our clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in governmental regulations or administrative actions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA concludes that our trial design is inadequate to demonstrate safety and efficacy.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Regulatory Requirements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after a device receives clearance or approval and is placed in commercial distribution, numerous regulatory requirements apply. These
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
registration and device listing;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR,
which requires manufacturers, including third party manufacturers, to follow stringent design, testing, risk management, production,
control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of
the manufacturing process;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
regulations that prohibit the promotion of products for uncleared, unapproved or &#8220;off-label&#8221; uses, and impose other restrictions
on labeling, advertising and promotion;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDR
regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious
injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
and mandatory device recalls to address problems when a device is defective and could be a risk to health; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrections
and removals reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals
if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the FDA may require us to conduct post-market surveillance studies or establish and maintain a system for tracking our products through
the chain of distribution to the patient level. The FDA enforces regulatory requirements by conducting periodic, unannounced inspections
and market surveillance. Inspections may include the manufacturing facilities of our subcontractors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable regulatory requirements can result in enforcement actions by the FDA and other regulatory agencies. These may
include any of the following sanctions or consequences:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
letters or untitled letters that require corrective action;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines
and civil penalties;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
expenditures;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in approving or refusal to approve future products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
refusal to issue certificates to foreign governments needed to export products for sale in other countries;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
or withdrawal of FDA clearance or approval;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
recall or seizure; interruption of production;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
restrictions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;
and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
prosecution.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers, specification developers and some suppliers of components or device accessories, also are required to manufacture
our products in compliance with current good manufacturing practice requirements set forth in the QSR. The QSR requires a quality system
for the design, manufacture, packaging, labeling, storage, installation and servicing of marketed devices, and it includes extensive
requirements with respect to quality management and organization, device design, buildings, equipment, purchase and handling of components
or services, production and process controls, packaging and labeling controls, device evaluation, distribution, installation, complaint
handling, servicing, and record keeping. The FDA evaluates compliance with the QSR through periodic unannounced inspections that may
include the manufacturing facilities of our subcontractors. If the FDA believes that any of our contract manufacturers or regulated suppliers
are not in compliance with these requirements, it can shut down such manufacturing operations, require a recall of our products, refuse
to approve new marketing applications, institute legal proceedings to detain or seize products, enjoin future violations or assess civil
and criminal penalties against us or our officers or other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and Similar Foreign and State Laws and Regulations
Affecting the Transmission, Security and Privacy of Health Information</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing
regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information.
Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as service providers
of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for
or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties and gave state attorneys general new
authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health
information in certain circumstances, many of which differ from HIPAA and each other in significant ways and may not have the same effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fraud
and Abuse Laws</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to FDA restrictions, there are numerous U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback
laws and physician self-referral laws. Our relationships with healthcare providers and other third parties are subject to scrutiny under
these laws. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion
from participation in federal and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Anti-Kickback and Self-Referral Laws</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute (the &#8220;Anti-Kickback Statute&#8221;) prohibits persons from knowingly and willfully soliciting, receiving,
offering or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce
either the referral of an individual, or the furnishing, recommending, or arranging of a good or service, for which payment may be made
under a federal healthcare program such as Medicare and Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221;
has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment,
credit arrangements, waiver of payments and providing anything at less than its fair market value. Although there are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn
narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations
may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular
applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead,
the legality of the arrangement will be evaluated on a case-by-case basis based on a review of all its relevant facts and circumstances.
Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration
is to induce referrals of (or purchases, or recommendations related to) federal healthcare covered business, the Anti-Kickback Statute
has been implicated and potentially violated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
penalties for violating the Anti-Kickback Statute include imprisonment for up to five years, fines of up to $25,000 per violation and
possible exclusion from federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the
Anti-Kickback Statute, some of which do not have the same exceptions and apply to the referral of patients for healthcare services reimbursed
by any source, not only by the Medicare and Medicaid programs. Further, the Anti-Kickback Statute was amended by the Patient Protection
and Affordable Care Act (&#8220;ACA&#8221;). Specifically, as noted above, under the Anti-Kickback Statute, the government must prove
the defendant acted &#8220;knowingly&#8221; to prove a violation occurred. The ACA added a provision to clarify that with respect to
violations of the Anti-Kickback Statute, &#8220;a person need not have actual knowledge&#8221; of the statute or specific intent to commit
a violation of the statute. This change effectively overturns case law interpretations that set a higher standard under which prosecutors
had to prove the specific intent to violate the law. In addition, the ACA codified case law that a claim including items or services
resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False
Claims Act (the &#8220;False Claims Act&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to provide the initial training to providers and patients necessary for appropriate use of our technology either through our own
educators or by contracting with outside educators that have completed an appropriate training course. Outside educators are reimbursed
for their services at fair market value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncompliance
with the Anti-Kickback Statute could result in our exclusion from Medicare, Medicaid or other governmental programs, restrictions on
our ability to operate in certain jurisdictions, and civil and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Physician Self-Referral Prohibition, commonly known as the &#8220;Stark Law,&#8221; prohibits a physician from ordering &#8220;designated
health services,&#8221; including durable medical equipment, for Medicare and Medicaid patients from entities with which the physician
(or an immediate family member) has a &#8220;financial relationship.&#8221; Financial relationships include both compensation arrangements
and investment and ownership interests. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements
received under a noncompliant arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental programs. We
believe that we have structured our provider arrangements to comply with current Stark Law requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
a determination of liability under such laws could result in fines and penalties and restrictions on our ability to operate in these
jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
as some of these laws are still evolving, we lack definitive guidance as to the application of certain key aspects of these laws as they
relate to our arrangements with providers with respect to patient training. We cannot predict the final form that these regulations will
take or the effect that the final regulations will have on us. As a result, our provider and training arrangements may ultimately be
found to be not in compliance with applicable federal law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>False
Claims Act</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly
presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false
statement or used a false record to get a claim approved. In addition, amendments in 1986 to the False Claims Act have made it easier
for private parties to bring &#8220;qui tam&#8221; whistleblower lawsuits against companies under the False Claims Act. Penalties include
fines ranging from $5,500 to $11,000 for each false claim, plus three times the amount of damages that the federal government sustained
because of the act of that person. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare
companies to have to defend a false claim action, pay fines or be excluded from Medicare, Medicaid or other federal or state healthcare
programs as a result of an investigation arising out of such action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are other federal anti-fraud laws that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a
scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing
from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection
with the delivery of or payment for healthcare benefits, items or services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
HIPAA established two federal crimes related to making false statements in relation to healthcare matters. The healthcare fraud statute
prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation
of this statute is a felony and may result in fines, imprisonment or exclusion from government sponsored programs. The false statements
statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious
or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this
statute is a felony and may result in fines or imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Civil
Monetary Penalties Law</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Anti-Kickback Statute and the False Claims Act, the federal government has the authority to seek civil monetary penalties,
or CMPs, assessments, and exclusion against an individual or entity based on a wide variety of prohibited conduct. For example, the Civil
Monetary Penalties Law authorizes the imposition of substantial CMPs against an entity that engages in activities including, but not
limited to: (1) knowingly presenting or causing to be presented, a claim for services not provided as claimed or which is otherwise false
or fraudulent in any way; (2) knowingly giving or causing to be given false or misleading information reasonably expected to influence
the decision to discharge a patient; (3) offering or giving remuneration to any beneficiary of a federal health care program likely to
influence the receipt of reimbursable items or services; (4) arranging for reimbursable services with an entity which is excluded from
participation from a federal health care program; (5) knowingly or willfully soliciting or receiving remuneration for a referral of a
federal health care program beneficiary; or (6) using a payment intended for a federal health care program beneficiary for another use.
The government is authorized to seek different amounts of CMPs and assessments based on underlying violation. For false or fraudulent
claims, the government may seek a penalty of up to $10,000 for each item or service improperly claimed, and an assessment of up to three
times the amount improperly claimed. For kickback violations, the government may seek a penalty of up to $50,000 for each improper act
and damages of up to three times the amount of remuneration at issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>State
Fraud and Abuse Provisions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have also adopted some form of anti-kickback and anti-referral laws and a false claims act. We believe that we are in conformance
to such laws. Nevertheless, a determination of liability under such laws could result in fines and penalties and restrictions on our
ability to operate in these jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Physician
Payment Sunshine Act</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transparency
laws regarding payments or other items of value provided to healthcare providers and teaching hospitals may also impact our business
practices. The federal Physician Payment Sunshine Act requires most medical device manufacturers to report annually to the Secretary
of Human Health Services financial arrangements, payments, or other transfers of value made by that entity to physicians and teaching
hospitals. The payment information is made publicly available in a searchable format on a CMS website. Over the next several years, we
will need to dedicate significant resources to establish and maintain systems and processes in order to comply with these regulations.
Failure to comply with the reporting requirements can result in significant civil monetary penalties. Similar laws have been enacted
or are under consideration in foreign jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, we had 11 employees, all of whom are full-time, 6 of whom are engaged in research and development activities,
and all of whom are located in the United States. As of September 30, 2021, we also retained the services of approximately 11 regular
consultants. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our
relationship with our employees to be good. During our 2021 fiscal year, we did not experience any turnover among our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 7599 Anagram Drive, Eden Prairie, Minnesota 55344, and our telephone number is 952-426-1383.
Our website address is www.n1mtc.com. Information on our website is not part of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 1A. RISK FACTORS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors summarized and detailed below could materially harm our business, operating results and financial condition, impair our
future prospects and cause the price of our common stock to decline. These are not all of the risks we face and other factors not presently
known to us or that we currently believe are immaterial may also affect our business if they occur. Material risks that may affect our
business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
have incurred significant operating losses since inception and cannot assure you that we will ever achieve or sustain profitability;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to continue our operations requires that we raise additional capital and our operations could be curtailed if we are unable to
obtain the additional funding as or when needed;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
COVID-19 pandemic has adversely impacted and will likely continue to adversely impact our business, including through component shortages,
including of our primary component, polyimide film, due to supply chain shortages attributed to COVID related issues, supply chain disruptions,
including related to staffing availability, and delays in product availability and delivery, impacts on pre-clinical and clinical trials
and regulatory clearances/approvals;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
will need to raise substantial additional funds in the future, and these funds may not be available on acceptable terms or at all. A
failure to obtain this necessary capital when needed could force us to delay, limit, scale back or cease some or all operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical
device development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays
in completing, or ultimately be unable to complete, the development and commercialization of any product;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in the configuration of our cortical strip, grid electrode and depth electrode technology under development may result in additional
costs or delay;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we are unable to successfully develop, receive regulatory clearance/approval for and commercialize our technology and other products
under development, or if we experience significant delays in doing so, our business will be harmed;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
to secure or retain coverage or adequate reimbursement for our cortical strip, grid electrode and depth electrode technology or future
versions thereof, including the implantation procedures, by third-party payors could adversely affect our business, financial condition
and operating results;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
our competitors are better able to develop and market products for the diagnosis and treatment of epilepsy, Parkinson&#8217;s disease,
dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that are safer, more
effective, less costly, easier to use or otherwise more attractive than our cortical strip, grid electrode and depth electrode technology,
our business will be adversely impacted;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
size and future growth in the market for our cortical strip, grid electrode and depth electrode technology under development has not
been established with precision and may be smaller than we estimate, possibly materially;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
depend on intellectual property licensed from WARF for our technology under development, and the termination of this license would harm
our business;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
depend on our partnership with Mayo to license certain know how for the development and commercialization of our technology. Termination
of this partnership would harm our business, and even if this partnership continues, it may not be successful;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
if we have our cortical strip, grid electrode and depth electrode technology approved for commercial sale, if we are unable to expand
our sales and marketing infrastructure, we may not be successful in commercializing our cortical strip, grid electrode and depth electrode
technology in the United States;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
contract with third parties for the manufacture of our cortical strip, grid electrode and depth electrode technology under development
and expect to continue to do so for clinical trials and commercialization. Risks associated with the manufacturing of our products could
reduce our gross margins and negatively affect our operating results;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we or our third-party suppliers or manufacturers fail to comply with the FDA&#8217;s good manufacturing practice regulations, this could
impair our ability to market our products in a cost-effective and timely manner;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
complications from our cortical strip, grid electrode and depth electrode technology that are currently unknown may come to light;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
there are significant disruptions in our information technology systems, our business, financial condition and operating results could
be adversely affected;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
have entered into, and may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships
with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to protect our intellectual property and proprietary technology is uncertain;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed alleged trade secrets of
our competitors or are in breach of non-competition or non-solicitation agreements with our competitors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
products and operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause
our business to suffer;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
price of our Common Stock might fluctuate significantly, and you could lose all or part of your investment; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
intend to issue more shares to raise capital, which will result in substantial dilution.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant operating losses since inception and cannot assure you that we will ever achieve or sustain profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred losses since inception, and
as of September 30, 2021, we had an accumulated deficit of $40.8 million primarily as a result of expenses incurred in connection with
our operations and from our research and development programs. We expect to continue to incur significant expenses and increasing operating
costs resulting in net losses for the foreseeable future, and management has raised substantial doubt about our ability to continue as
a going concern. There was also substantial doubt about the Company&#8217;s ability to continue as a going concern as of and for the year ended September 30, 2020. To date, we have financed our operations primarily through debt and equity
financings, and our primary activities have been limited to, and our limited resources have been dedicated to, performing business and
financial planning, raising capital, recruiting personnel, negotiating with business partners and the licensors of our intellectual property
and conducting development activities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
implement our business strategy we need to, among other things, successfully complete all required steps for regulatory clearance to
expand the use of our depth electrodes for sEEG recording in the U.S. for up to 30 days, develop an all-in-one diagnostic and therapeutic
solution, successfully complete the necessary testing and clinical trials required for regulatory approval of our technology for ablation
and stimulation therapies, gain approval for other brain or motor related disorders such as Parkinson&#8217;s with the therapeutic technologies
developed for epilepsy, convince physicians and patients that our technology, if approved, represents an improvement over existing diagnostic
or treatment options, hire direct experienced sales representatives to market our technology, and engage in beneficial partnerships that
can leverage our core technology. We have never been profitable and do not expect to be profitable in the foreseeable future. We expect
our expenses to increase significantly as we pursue our objectives. The extent of our future operating losses and the timing of profitability
are highly uncertain, and we expect to continue incurring significant expenses and operating losses over the next several years. Our
prior losses have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. Any additional
operating losses may have an adverse effect on our stockholders&#8217; equity, and we cannot assure you that we will ever be able to
achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. Our failure to become and remain profitable would depress the value of our Company and could impair our ability to raise capital,
expand our business, maintain our development efforts, obtain regulatory approvals or continue our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history, making it difficult for you to evaluate our business and your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain
stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain
due to failed back surgeries and other related neurological disorders. Our operations are subject to all of the risks inherent in the
establishment of a new business enterprise, including but not limited to the absence of an operating history, lack of fully-developed
or commercialized products, insufficient capital, expected substantial and continual losses for the foreseeable future, limited experience
in dealing with regulatory issues, lack of manufacturing and marketing experience, need to rely on third parties for the development
and commercialization of our proposed products, a competitive environment characterized by well-established and well-capitalized competitors
and reliance on key personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From our inception through September 30, 2021,
we have generated limited in revenue from the commercial sales of our products. Because we have generated very limited revenues from commercialization,
our operations to date have been principally financed through public and private offerings of our Common Stock and convertible debt and
exercises of options and warrants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors are subject to all the risks incident
to the creation and development of a new business and each investor should be prepared to withstand a complete loss of his, her or its
investment. Furthermore, the accompanying financial statements have been prepared assuming that we will continue as a going concern.
However, the factors included above raise substantial doubt about our ability to continue as a going concern. Our financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company has limited experience in medical device development and may not be able to successfully develop any device or therapy. Our ability
to become profitable depends primarily on: our ability to further develop our cortical strip, grid electrode and depth electrode technology,
our successful completion of all necessary pre-clinical testing and clinical trials on such technology, our ability to obtain clearance
or approval for such technology and successfully commercialize such technology, our ongoing research and development efforts, the timing
and cost of clinical trials, our ability to identify personnel with the necessary skill sets or enter into favorable alliances with third-parties
who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing and distribution and our ability
to obtain and maintain necessary intellectual property rights to such technology. Our limited experience in medical device development
may make it more difficult for us to complete these tasks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully develop and market such technology, we may not generate sufficient or sustainable revenue to achieve or sustain profitability,
which could cause us to cease operations and cause you to lose all of your investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to continue our operations requires that we raise additional capital and our operations could be curtailed if we are unable to
obtain the additional funding as or when needed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our independent registered public accounting
firm and our former independent registered public accounting firm included explanatory paragraphs in the reports on our financial
statements as of and for the years ended September 30, 2021 and 2020, respectively, noting the existence of substantial doubt about
our ability to continue as a going concern. At September 30, 2021, we had $6.9 million in cash deposits. Our existing cash and cash
equivalents will not be sufficient to fund our operating expenses. To continue to fund operations, we will need to secure additional
funding. We may obtain additional financing in the future through the issuance of our Common Stock, through other equity or debt
financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms
acceptable to us, or at all.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
COVID-19 pandemic has adversely impacted, and may continue to impact, our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the beginning of the COVID-19 pandemic, governments, public institutions, and other organizations have taken and are continuing to take
certain preventative or protective measures to combat the transmission of the virus, including implementation of travel restrictions
or bans, vaccination mandates, closures of non-essential businesses, limitations of public gatherings, other social distancing and shelter-in-place
measures, and delays or cancellations of elective surgeries. The Company, our employees, contractors, suppliers, and other partners may
be prevented from conducting business activities for an indefinite period of time due to shutdowns or other regulatory requirements that
may be requested or mandated by state and federal governmental authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced, and will likely continue to experience, disruptions that could negatively or severely impact our business and planned
clinical trials, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
or difficulties in conducting pre-clinical and clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
in global manufacturing and shipping, including testing equipment and personal protective equipment used at our facilities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">material
shortages for manufacturing, including those the Company is currently experiencing related to its primary component, polyimide film,
due to supply chain shortages attributed to COVID related issues;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in timelines for product availability and delivery from vendors, including related to staffing shortages, both generally and due to employee
illness, and due to increases in demand from other larger or more longstanding customers of our suppliers placing large orders due to
concerns with supply chain disruption and the impact of COVID-19;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the way in which clinical trials
are conducted and may result in unexpected costs; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention
to approval of other therapeutics or other activities related to COVID-19.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, COVID-19 could disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism
by members of management and other employees who elect not to come to work due to the illness affecting others in our office or laboratory
facilities, or due to quarantines. COVID-19 illness could also impact members of our Board and its ability to hold meetings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the COVID-19 pandemic continues to adversely affect our operating and financial results, it may also have the effect of heightening many
of the other risks described in the risk factors in this Report. Further, the COVID-19 pandemic may also affect our operating and financial
results in a manner that is not presently known to us or that we currently do not expect to present significant risks to our operations
or financial results, particularly if the COVID-19 pandemic and its associated impacts reoccur in successive waves in the coming months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to raise substantial additional funds in the future, and these funds may not be available on acceptable terms or at all. A
failure to obtain this necessary capital when needed could force us to delay, limit, scale back or cease some or all operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued growth of our business, including the development, regulatory approval and commercialization of our cortical strip, grid electrode
and depth electrode technology, will significantly increase our expenses going forward. As a result, we will be required to seek substantial
additional funds in the future. Our future capital requirements will depend on many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of further developing our cortical strip, grid electrode and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and maintaining regulatory clearance or approval for our cortical strip, grid electrode and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs associated with commercializing our cortical strip, grid electrode and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
change in our development priorities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the revenue generated by sales of our cortical strip, grid electrode and depth electrode technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs associated with expanding our sales and marketing infrastructure for commercialization of our cortical strip grid electrode and depth electrode technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
change in our plans regarding the manner in which we choose to commercialize any approved product in the United States;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of ongoing compliance with regulatory requirements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
we incur in connection with potential litigation or governmental investigations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
and costs we incur in connection with changes in the economy and regulatory process in connection with the COVID-19 pandemic;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs to develop additional intellectual property;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipated
or unanticipated capital expenditures; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
general and administrative expenses.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these and other factors, we do not know whether and the extent to which we may be required to raise additional capital. We
may in the future seek additional capital from public or private offerings of our capital stock, borrowings under credit lines or other
sources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise additional capital could compromise
our ability to execute on our business plan, and we may be forced to liquidate our assets. In such a scenario, the values we receive
for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we issue additional equity or debt securities to raise additional funds, our existing stockholders may experience dilution, and the new
equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we
raise additional funds through collaborations, licensing, joint ventures, strategic alliances, partnership arrangements or other similar
arrangements, it may be necessary to relinquish valuable rights to our potential future products or proprietary technologies or grant
licenses on terms that are not favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in the configuration of our cortical strip, grid electrode and depth electrode technology under development may result in additional
costs or delay.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
products are developed through pre-clinical testing and clinical trials towards approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods and configuration, are altered along the way in an effort to optimize
processes and results. Any changes we make carry the risk that they will not achieve the intended objectives. Any of these changes could
cause our products to perform differently and affect the results of planned clinical trials or other future clinical trials conducted
with the altered device. Such changes may also require additional testing, regulatory notification or regulatory approval. This could
delay completion of pre-clinical testing or clinical trials, increase costs, delay approval of our future products and jeopardize our
ability to commence sales and generate revenue.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have two products, our cortical strip and grid electrodes and our sEEG electrode technology for less than 24 hours use, which have each
received 510(k) clearance from the FDA. If we are unable to successfully develop, and receive regulatory approval for our sEEG electrode
for use up to 30 days or our other products under development, or if we experience significant delays in doing so, our business will
be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two of our products have received 510(k) clearance
from the FDA. Our Evo cortical electrode technology has received 510(k) clearance from the FDA for recording, monitoring, and stimulating
brain tissue for up to 30 days, and our Evo sEEG electrode technology has received 510(k) clearance from the FDA for use (less than 24
hours) with recording, monitoring, and stimulation equipment for recording, monitoring, and stimulation of electrical signals at the subsurface
level of the brain. Our submission to the FDA seeking 510(k) for use of our Evo sEEG electrode technology for up to 30 days is pending.
None of our other products have received clearance or approval for commercial sale. Our ability to generate revenue from our developed
products, if any, will depend heavily on their successful development and regulatory approval.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining marketing clearance or approval from regulatory authorities for the sale of our cortical strip, grid electrode and depth electrode
technology under development in the United States for certain indications, we must complete all pre-clinical testing, clinical trials
and other regulatory requirements necessitated by the FDA and demonstrate the performance and safety of our technology. Clinical testing
is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. A failure
of one or more clinical trials can occur at any stage of testing. Further, the outcomes of completed clinical trials may not be predictive
of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Clinical data
is often susceptible to varying interpretations and analyses, and many companies that have believed their products performed satisfactorily
in clinical trials have nonetheless failed to obtain marketing clearance or approval. We have limited resources to complete the expensive
process of medical device development, pre-clinical testing and clinical trials, putting us at a disadvantage, particularly compared
to some of our larger and established competitors, and we may not have sufficient resources to commercialize our products under development
in a timely fashion, if ever.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during or as a result of clinical trials that could delay or prevent our ability to receive
marketing approval or commercialize our products, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
failure to successfully complete pre-clinical testing requirements required by the FDA;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts with third parties or clinical
trial protocols with prospective trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among
different trial sites;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
trials of our cortical strip, grid electrode and depth electrode technology may produce negative or inconclusive results, including failure
to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon
our development programs;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number of people with brain related disorders required for clinical trials may be larger than we anticipate, enrollment in these clinical
trials may be slower than we anticipate or people may drop out of these clinical trials or fail to return for post-treatment follow-up
at a higher rate than we anticipate;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
products may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional
review boards to suspend or terminate the trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
third-party contractors conducting the clinical trials may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
may require that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with
regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of clinical trials of our products may be greater than we anticipate;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
supply or quality of our products or other materials necessary to conduct clinical trials of our products may be insufficient or inadequate;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
COVID-19 pandemic may cause delays and disruptions in the supply chain, clinical trials, clinical development, and regulatory approval
process; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
from our suppliers and manufacturers could impact clinical trial completion and impact revenue.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to conduct additional clinical trials or other testing of our cortical strip, grid electrode and depth electrode technology
under development beyond those that we contemplate, if we are unable to successfully complete clinical trials, if the results of these
trials or tests are not favorable or if there are safety concerns, we may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
obtain marketing approval at all;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
delayed in obtaining marketing approval for our cortical strip, grid electrode and depth electrode technology under development in a
jurisdiction;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
subject to additional post-marketing testing requirements; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
our cortical strip, grid electrode and depth electrode technology removed from the market after obtaining marketing approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development costs will also increase if we experience delays in testing or marketing approvals, including, but not limited to, the COVID-19
pandemic. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed
on schedule, or at all. Significant clinical trial delays also could allow our competitors to bring innovative products to market before
we do and impair our ability to successfully commercialize our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for our products, we will remain subject to extensive regulatory scrutiny and compliance obligations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
before and after a product is commercially released, we will have ongoing responsibilities under FDA regulations. We will also be subject
to periodic inspections by the FDA and comparable foreign authorities to determine compliance with regulatory requirements, such as the
Quality System Regulation, or QSR, of the FDA, medical device reporting regulations and regulations regarding notification, corrections,
and recalls. These inspections can result in observations or reports, warning letters or other similar notices or forms of enforcement
action. If the FDA concludes that we are not in compliance with applicable laws or regulations, or that any of our products are ineffective
or pose an unreasonable health risk, it could ban these products, suspend or cancel our marketing authorizations, impose &#8220;stop-sale&#8221;
and &#8220;stop-import&#8221; orders, detain or seize adulterated or misbranded products, order a recall, repair, replacement, correction
or refund of such products, or require us to notify health providers and others that the products present unreasonable risks of substantial
harm to the public health. Discovery of previously unknown problems with our product&#8217;s design or manufacture may result in restrictions
on use, restrictions placed on us or our suppliers, or withdrawal of an existing regulatory clearance. The FDA may also impose operating
restrictions, enjoin and restrain certain violations of applicable law pertaining to medical devices, assess civil or criminal penalties
against our officers, employees or us, or recommend criminal prosecution of our Company. Adverse regulatory action may restrict us from
effectively marketing and selling our products. In addition, negative publicity and product liability claims resulting from any adverse
regulatory action could have a material adverse effect on our business, financial condition, and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even though we have obtained FDA clearance to market two of our products, and even if we obtain the proper regulatory approval
or clearance to market any additional products under development, the FDA has the power to require us to conduct post-market surveillance
studies, which are designed to identify adverse events, device malfunctions or complaints from patients implanted with the device during
a specified period after the commencement of commercial use in the U.S. The FDA may also require us to conduct post-approval studies
to further monitor the safety and/or effectiveness of our products. Failure to conduct required surveillance or studies in a timely manner
could result in the revocation of the approved PMA product that is subject to such a requirement and could also result in the recall
or withdrawal of the product, which would prevent us from generating sales from that product in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to expand our sales and marketing infrastructure, and execute other steps necessary to penetrate market opportunities and
produce our products, we may not be successful in commercializing our cortical strip, grid electrode and depth electrode technology in
the United States.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early stage development company with limited resources, and have not generated significant revenues to date. To achieve commercial
success and generate sufficient revenue in the United States for our cortical strip, grid electrode and depth electrode technology, we
will need to further expand our sales and marketing infrastructure to drive adoption of our products, which will include a team of educators
that will train healthcare providers and people with brain related disorders on the benefits and use of our cortical strip, grid electrode
and depth electrode technology. There is significant competition for sales personnel experienced in relevant medical device sales. We
expect that we will face significant challenges as we recruit and subsequently grow our sales and marketing infrastructure. If we are
unable to attract and retain sufficient, and skilled, sales and marketing representatives, our sales could be adversely affected. If
one of our sales or marketing representatives were to depart and be retained by one of our competitors, they could help competitors solicit
business from customers, which could further harm our sales. In addition, if our sales and marketing representatives or educators fail
to achieve their objectives or if we are not able to recruit and retain a network of educators, we may not be able to successfully train
healthcare providers on the use of our cortical strip, grid electrode and depth electrode technology, which could delay new sales and
harm our reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we increase our sales and marketing expenditures with respect to our cortical strip, grid electrode and depth electrode technology under
development, if approved, or future versions thereof, we will need to hire, train, retain and motivate skilled sales and marketing representatives
with significant industry-specific knowledge in various areas. Our success will depend largely on the competitive landscape for our products
and the ability of our sales personnel to obtain access to healthcare providers and persuade those healthcare providers to recommend
our cortical strip, grid electrode and depth electrode technology. Recently hired sales representatives require training and take time
to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future,
we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. In addition, the
expansion of our sales and marketing personnel will place significant burdens on our management team.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will derive nearly all of our U.S. revenue from the sales of our cortical strip, grid electrode and depth electrode
technology or future versions thereof. As a result, our financial condition and operating results will be highly dependent on the ability
of our sales representatives to adequately promote, market and sell our cortical strip, grid electrode and depth electrode technology
and the ability of our educators to train healthcare providers on the use of our cortical strip, grid electrode and depth electrode technology.
If we are unable to expand our sales and marketing capabilities, we may not be able to effectively commercialize our existing or planned
products, or enhance the strength of our brand, either of which could impair our projected sales growth and have an adverse impact on
our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we expect the revenue opportunity for additional uses of our technology to be greater than the technology and uses that have currently
been cleared by the FDA, and so we believe our ability to generate significant revenue in the future will be dependent upon the receipt
of additional FDA clearances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue will be dependent, in part, upon the size of the markets in which we gain regulatory approval, the accepted price for the product,
the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of people
we target is not as significant as we estimate or the treatment population is narrowed by competition, physician choice or treatment
guidelines, we may not generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of any products that we develop will depend on several factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
of timely commercialization approvals from applicable regulatory authorities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to procure and maintain suppliers and manufacturers of the components of our current cortical strip, grid electrode and depth
electrode technology and future versions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
commercial sales of our cortical strip, grid electrode and depth electrode technology, if approved for marketing;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
acceptance of our cortical strip, grid electrode and depth electrode technology, if approved, by people with epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders, the medical
community and third-party payors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
success in educating healthcare providers and people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain
due to failed back surgeries and other related neurological disorders about the benefits, administration and use of our cortical strip,
grid electrode and depth electrode technology and future versions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of adverse events, including, but not limited to, events related to the COVID-19 pandemic;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
perceived advantages, cost, safety, convenience and accuracy of alternative therapies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our cortical strip, grid electrode and depth
electrode technology and otherwise protecting our rights in our intellectual property portfolio;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
compliance with regulatory requirements, including current good manufacturing practices; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and maintaining a continued acceptable performance and safety profile of our cortical strip, grid electrode and depth electrode technology
following approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
continuing development and commercialization of our products depends upon us maintaining strong relationships with academic and healthcare
institutions and professionals.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to maintain our strong working relationships with healthcare and academic institutions and their professionals such as the Mayo
Clinic, the Cleveland Clinic and Emory University, many of our products may not be developed and marketed in line with the needs and
expectations of the professionals who use and support our products, which could cause a decline in our earnings and profitability. The
development, marketing and sales of many of our products depends on our maintaining working relationships with healthcare institutions
and professionals. We rely on these professionals to provide us with considerable knowledge and experience regarding the development,
marketing and sale of our products. In addition, as a result of the COVID-19 pandemic, our access to these professionals has been limited
at times, and travel restrictions, shutdowns and similar measures have impacted our ability to maintain these relationships, thereby
affecting our ability to develop, gain regulatory clearance or approval and market our products. If we are unable to maintain strong
relationships with these institutions and professionals, the development and marketing of our products could suffer, which could have
a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to continue to develop, commercialize and gain market acceptance for our cortical strip, grid electrode
and depth electrode technology.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current business strategy is highly dependent on developing and commercially launching our cortical strip, grid electrode and depth electrode
technology, and achieving and maintaining market acceptance. In order for us to sell cortical strip, grid electrode and depth electrode
technology to people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries
and other related neurological disorders, we must convince them, their caregivers and healthcare providers that cortical strip, grid
electrode and depth electrode technology is an attractive alternative to competitive products for neuromodulation cEEG and sEEG recording,
ablation, and brain stimulation. Market acceptance and adoption of our cortical strip, grid electrode and depth electrode technology
depend on educating people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries
and other related neurological disorders, as well as their caregivers and healthcare providers, and other perceived benefits of our cortical
strip, grid electrode and depth electrode technology as compared to competitive products. We may face challenges convincing physicians,
many of whom have extensive experience with competitors&#8217; products and established relationships with other companies, to appreciate
the benefits of our cortical strip, grid electrode and depth electrode technology and, in particular, our ability to successfully diagnose
and treat epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related
neurological disordersin a way that is superior to and differentiated from currently available technology, and adopt it for treatment
of their patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Achieving
and maintaining market acceptance of cortical strip, grid electrode and depth electrode technology could be negatively impacted by many
factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
failure of our cortical strip, grid electrode and depth electrode technology to achieve wide acceptance among people with epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders, their caregivers,
healthcare providers, third-party payors and key opinion leaders in the community;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
of evidence supporting the performance criteria or other perceived benefits of our cortical strip, grid electrode and depth electrode
technology over competitive products or other currently available technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
risks associated with the use of our cortical strip, grid electrode and depth electrode technology or similar products or technologies
generally;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
introduction of competitive products and the rate of acceptance of those products as compared to our cortical strip, grid electrode and
depth electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
results of clinical trials relating to our cortical strip, grid electrode and depth electrode technology or similar competitive products;
and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of regulatory clearance or approval for our cortical strip, grid electrode and depth electrode technology, adverse publicity or other
adverse events including any product liability lawsuits.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our cortical strip, grid electrode and depth electrode technology may be perceived by people with epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders, their caregivers
or healthcare providers to be more complicated or less effective than current technology, and people may be unwilling to change their
current regimens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we believe that healthcare providers tend to be slow to change their medical treatment practices because of perceived liability risks
arising from the use of new products and the uncertainty of third-party reimbursement. Accordingly, healthcare providers may not recommend
our cortical strip, grid electrode and depth electrode technology until, if ever, there is sufficient evidence to convince them to alter
the treatment methods they typically recommend, such as receiving recommendations from prominent healthcare providers or other key opinion
leaders in the community.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not successful in convincing people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to
failed back surgeries and other related neurological disordersof the benefits of our cortical strip, grid electrode and depth electrode
technology, or if we are unable to achieve the support of caregivers and healthcare providers or widespread market acceptance for our
cortical strip, grid electrode and depth electrode technology, then our sales potential, strategic objectives and profitability could
be negatively impacted, which would adversely affect our business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Failure
to secure or retain coverage or adequate reimbursement for our cortical strip, grid electrode and depth electrode technology or future
versions thereof, including the implantation procedures, by third-party payors could adversely affect our business, financial condition
and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to derive nearly all of our revenue from sales of our cortical strip, grid electrode and depth electrode technology under development,
if approved, in the United States and expect to do so for the next several years. We anticipate a substantial portion of the purchase
price of our cortical strip, grid electrode and depth electrode technology will be paid for by third-party payors, including private
insurance companies, preferred provider organizations and other managed care providers. Patients who receive treatment for their medical
conditions and their healthcare providers generally rely on third-party payors to reimburse all or part of the costs associated with
their medical treatment, including healthcare providers&#8217; services. Coverage and adequate reimbursement from third-party payors,
including governmental healthcare programs, such as Medicare and Medicaid, and commercial payors, is critical to new product acceptance.
Future sales of our cortical strip, grid electrode and depth electrode technology will be limited unless people with epilepsy, Parkinson&#8217;s
disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorderscan rely on third-party
payors to pay for all or part of the cost to purchase our cortical strip, grid electrode and depth electrode technology. Access to adequate
coverage and reimbursement for our cortical strip, grid electrode and depth electrode technology by third-party payors is essential to
the acceptance of our products by people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed
back surgeries and other related neurological disorders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, a third-party payor&#8217;s decision to provide coverage for our products does not imply that an adequate reimbursement
rate will be obtained. Further, one third-party payor&#8217;s decision to cover our products does not assure that other payors will also
provide coverage for the products or will provide coverage at an adequate reimbursement rate. Healthcare providers may choose not to
order a product unless third-party payors pay a substantial portion of the product. Within and outside the United States, reimbursement
is obtained from a variety of sources, including government-sponsored and private health insurance plans. These third-party payors determine
whether to provide coverage and reimbursement for specific products and procedures. Coverage determinations and reimbursement levels
of both our products and the healthcare provider&#8217;s performance of the insertion and removal procedures are critical to the commercial
success of our product, and if we are not able to secure positive coverage determinations and reimbursement levels for our products or
the insertion and removal procedures, our business would be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there may be significant delays in obtaining reimbursement, and coverage may be more limited than the purposes for which the
product is cleared by the FDA or other foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any
product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.
Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed
for lower cost products that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for
products may be reduced by mandatory discounts or rebates required by government healthcare programs or third-party payors and by any
future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the
United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
there is generally no separate reimbursement for medical devices and other supplies used in such procedures, including our cortical strip,
grid electrode and depth electrode technology, and because we believe that our cortical strip, grid electrode and depth electrode technology,
if approved, would be adequately described by existing DRG and ICD-9 codes for epilepsy surgery, some of our target customers may be
unwilling to adopt our cortical strip, grid electrode and depth electrode technology over more established or lower cost therapeutic
alternatives already available or subsequently become available. Further, any decline in the amount payors are willing to reimburse our
customers for procedures using our cortical strip, grid electrode and depth electrode technology could make it difficult for new customers
to adopt our cortical strip, grid electrode and depth electrode technology and could create additional pricing pressure for us, which
could adversely affect our ability to invest in and grow our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition,
in the United States, no uniform policy of coverage and reimbursement for medical device products and services exists among third-party
payors. Therefore, coverage and reimbursement for medical device products and services can differ significantly from payor to payor.
In addition, payors continually review new technologies for possible coverage and can, without notice, deny coverage for these new products
and procedures. As a result, the coverage determination process is often a time-consuming and costly process that will require us to
provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate
reimbursement will be obtained, or maintained if obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sufficient coverage and reimbursement is not available for our any product we develop, in the United States, the demand for our products
and our revenues will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reimbursement
by Medicare is highly regulated and subject to change.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare program is administered by the Centers for Medicare and Medicaid Services, or CMS, which imposes extensive and detailed requirements
on medical services providers, including, but not limited to, rules that govern how we structure our relationships with physicians, and
how and where we provide our solutions. Our failure to comply with applicable Medicare rules could result in discontinuing the ability
for physicians to receive reimbursement as they will likely utilize our cortical strip, grid electrode and depth electrode technology
under the Medicare payment program, civil monetary penalties, and/or criminal penalties, any of which could have a material adverse effect
on our business and revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our competitors are better able to develop and market products for the diagnosis and treatment of epilepsy, Parkinson&#8217;s disease,
dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disordersthat are safer, more effective,
less costly, easier to use or otherwise more attractive than our cortical strip, grid electrode and depth electrode technology, our business
will be adversely impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry is highly competitive and subject to technological change. Our success depends, in part, upon our ability to
establish a competitive position in the market for the diagnosis and treatment of epilepsy, Parkinson&#8217;s disease, dystonia, essential
tremors, chronic pain due to failed back surgeries and other related neurological disorders by securing broad market acceptance of our
cortical strip, grid electrode and depth electrode technology. Any product we develop that achieves regulatory clearance or approval
will have to compete for market acceptance and market share. We believe that the primary competitive factors of our cortical strip, grid
electrode and depth electrode technology will be: reduced infections, ability to record additional brain activity, minimally invasive
surgical procedure, ease of use and cost effectiveness. We face significant competition in the United States and internationally, which
we believe will intensify. For example, our major competitors are: (i) in the market for diagnosis, PMT, Ad-Tec Medical and Integra Lifesciences,
(ii) in the market for neuro-ablation, Medtronic and Monteris Medical and (iii) in the market for neurostimulation, Medtronic, Boston
Scientific, NeuroPace Biotronik and Abbott. Each of the foregoing competitors has systems approved in the United States and certain foreign
jurisdictions and has been established for several years. We face a particular challenge overcoming the long-standing practices by some
physicians of using the existing technology of our larger, more established competitors. Physicians may be reluctant to try new products
from a source with which they are less familiar. If these physicians do not try to subsequently adopt our product, then we may never
achieve profitability and such failure to adopt our product could have a material adverse effect on our business, financial condition
and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Mayo Clinic is conducting testing of its own minimally invasive cortical electrode delivery device. In the event the Mayo Clinic
completes development of its own device prior to us, we may forego completing development of our device and we may be unable to enter
into any arrangement with Mayo Clinic relating to its device. If we are unable to pursue the development of a minimally invasive cortical
electrode device, this may delay our ability to become profitable and we could be forced to terminate our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to facing competition from major competitors and potentially our development partner, we may also face competition from other
emerging competitors or smaller companies with active development programs that may emerge in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies developing or marketing competing products enjoy several advantages over us, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
experienced sales forces;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
name recognition;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
established sales and marketing programs and distribution networks;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">earlier
regulatory clearance or approval in the United States or foreign jurisdictions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">long
established relationships with physicians and hospitals;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
patent portfolios, including issued U.S. and foreign patents and pending patent applications, as well as the resources to enforce patents
against us or any of our third-party suppliers and distributors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability to acquire and integrate our competitors and/or their technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrated
ability to develop product enhancements and new product offerings;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established
history of product reliability, safety and durability;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability to offer rebates or bundle multiple product offerings to offer greater discounts or incentives;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
financial and human resources for product development, sales, and marketing; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
experience in and resources for conducting research and development, clinical studies, manufacturing, preparing regulatory submissions,
obtaining regulatory clearance or approval for products and marketing approved products.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may develop and patent processes or products earlier than us, obtain patents that may apply to us at any time, obtain regulatory
clearance or approvals for competing products more rapidly than us or develop more effective or less expensive products or technologies
that render our technology or products obsolete or less competitive. Furthermore, the frequent introduction by competitors of products
that are, or claim to be, superior to our products may create market confusion that may make it difficult to differentiate the benefits
of our products over competitive products. In addition, the entry of multiple new products may lead some of our competitors to employ
pricing strategies that could adversely affect the pricing of any product we may develop and commercialize. We also face fierce competition
in recruiting and retaining qualified sales, scientific, and management personnel, establishing clinical trial sites and enrolling patients
in clinical studies. If our competitors are more successful than us in these matters, our business may be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
size and future growth in the market for our cortical strip, grid electrode and depth electrode technology under development has not
been established with precision and may be smaller than we estimate, possibly materially. If our estimates and projections overestimate
the size of this market, our sales growth may be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimates of the size and future growth in the market for our cortical strip, grid electrode and depth electrode technology under development,
including the number of people with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back
surgeries and other related neurological disorderswho may benefit from and be amenable to using cortical strip, grid electrode and depth
electrode technology for diagnosis and treatment, is based on a number of internal and third-party studies, reports and estimates. In
addition, our internal estimates are based in large part on current treatment patterns by healthcare providers using current generation
technology and our belief is that the incidence of epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders in the United States and worldwide is increasing. While we believe
these factors have historically provided and may continue to provide us with effective tools in estimating the total market for cortical
strip, grid electrode and depth electrode technology, these estimates may not be correct and the conditions supporting our estimates
may change at any time, thereby reducing the predictive accuracy of these underlying factors. The actual incidence of brain related disorders,
and the actual demand for our products or competitive products, could differ materially from our projections if our assumptions are incorrect.
As a result, our estimates of the size and future growth in the market for cortical strip, grid electrode and depth electrode technology
may prove to be incorrect. If the actual number of people with brain related disorders who would benefit from cortical strip, grid electrode
and depth electrode technology and the size and future growth in the market for cortical strip, grid electrode and depth electrode technology
is smaller than we have estimated, it may impair our projected sales growth and have an adverse impact on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on intellectual property licensed from WARF for our technology, including our technology under development, and the termination
of this license would harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARF
has granted us the WARF License, to make, use and sell, in the United States only, products that employ certain licensed patents for
a neural probe array or thin-film micro electrode array and method. See &#8220;Business &#8212; WARF License&#8221; for additional information
regarding our license agreement with WARF.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARF
may terminate this license in the event that we default on the payments of amounts due to WARF or fail to timely submit development reports,
actively pursue our development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in
the event of certain bankruptcy events involving us. WARF may also terminate this license if, after royalties earned on sales begin to
be paid, such earned royalties cease for more than four calendar quarters. The WARF License otherwise expires by its terms on the date
that no valid claims on the patents licensed thereunder remain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise between us and WARF regarding intellectual property subject to this agreement, including with respect to: the scope of rights
granted under the WARF License and other interpretation-related issues; whether and the extent to which our technology and processes
infringe on intellectual property of WARF that is not subject to the WARF License; the amount and timing of milestones and royalty payments;
the rights of WARF under the license; our right to sublicense; and the ownership of inventions and know-how resulting from the WARF License.
For example, if we or any of our sublicenses for any reason contest the validity of any patent licensed under the WARF License, the royalty
rate will be doubled during the pendency of such contest and, if the contested patent is found to be valid and would be infringed by
us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF License.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
disputes with WARF may prevent or impair our ability to maintain our current licensing arrangement. We depend on the intellectual property
licensed from WARF to develop our cortical strip, grid electrode and depth electrode technology. The original license agreement entered
into with WARF in 2014 required that we meet certain milestones and make certain payments to WARF. We failed to do so and were in default
under the original license agreement. Furthermore, the LLC was not able to transfer the rights and obligations under the 2014 WARF Agreement
to us at the time of the Merger without the consent of WARF. As a result, in February 2017, we signed an amendment to the WARF License
which, among other things, modified and removed certain previous milestones and provided WARF&#8217;s consent to such transfer. Because
of this past breach, WARF may be less likely to waive future defaults or breaches or further amend the WARF License in the future, to
the extent we request any waiver or amendment. See &#8220;Note 4&#8212;Commitments and Contingencies&#8221; included in &#8220;Item 8
&#8212; Financial Statements and Supplementary Data&#8221; in this Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of our license could result in the loss of significant rights and would harm our ability to further develop our cortical strip, grid
electrode and depth electrode technology. In addition, WARF reserves the right to grant non-profit research institutions and government
agencies non-exclusive licenses to practice and use the inventions of the licensed patents for non-commercial research purposes, and
we grant WARF a non-exclusive, sub licensable, royalty-free right and license for non-commercial research purposes to use improvements
to the licensed patents. In the event that we discontinue use or commercialization of the licensed patents or improvements thereon, we
must grant WARF an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial purposes.
Such rights, if exercised by WARF, could harm our ability to develop and commercialize our cortical strip, grid electrode and depth electrode
technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our partnership with Mayo to license certain know how for the development and commercialization of our technology. Termination
of this partnership would harm our business, and even if this partnership continues, it may not be successful.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into the Mayo Development Agreement to (i) exclusively license worldwide certain Mayo improvements for the development and
commercialization of products, methods and processes related to flexible circuit technology for the recording and stimulation of tissue
and (ii) license, on a non-exclusive basis, worldwide Mayo thin film electrode technology know-how for the development and commercialization
of products, methods and processes related to flexible circuit technology for the recording and stimulation of tissue. Mayo has agreed
to assist the Company by providing access to the Mayo Principal Investigators in developing a minimally invasive device/delivery system
and procedure for a minimally invasive approach for the implantation of any flexible circuit technology developed by the Company, including
prototype development, animal testing, protocol development for human and animal use, abstract development and presentation and access
to and license of any intellectual property that the Mayo Principal Investigators develop relating to the procedure. See &#8220;Business&#8212;Mayo
Foundation for Medical Education and Research License and Development Agreement&#8221; for additional information regarding our agreement
with Mayo.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Mayo Development Agreement generally will expire in October 2034, unless the Mayo know-how and improvements under the Mayo Development
Agreement remain in use, and the Mayo Development Agreement may be terminated by Mayo for cause or under certain circumstances. Mayo
and the Company may not be successful in their efforts to develop any product, method, process, device, delivery system or minimally
invasive approach by such expiration date or termination, if at all. If no such minimally invasive device or delivery system and procedure
for minimally invasive approach is developed, the Company may never receive regulatory approval of its cortical strip, grid electrode
and depth electrode technology under development or the market may never accept such technology, if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise between us and Mayo regarding intellectual property subject to the Mayo Development Agreement or other matters, including with
respect to: the scope of rights granted under the agreement and other interpretation-related issues; the amount and timing of payments;
the rights and obligations of Mayo under the license agreement; and the ownership of inventions and know-how resulting from the joint
creation or use of intellectual property by Mayo and us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
disputes with Mayo may prevent or impair our ability to maintain our current arrangement. We depend on the intellectual property licensed
from and development assistance from Mayo to develop our cortical strip, grid electrode and depth electrode technology. We cannot assure
you that we will be able to continue to comply with the Mayo Development Agreement. In fact, the original license and development agreement
entered into with Mayo in 2014 required that, upon the Merger with the LLC, we make certain payments and issue shares of Common Stock
to Mayo, which we failed to do at such time. We signed the Mayo Development Agreement in May 2017, which, among other things, modified
or removed certain provisions of the original agreement, including those we breached. In addition, pursuant to the Mayo Development Agreement
signed in May 2017, we agreed to pay Mayo a cash payment of approximately $92,000 on the earlier of September 30, 2017 or the date we
raise a minimum amount of financing. We did not make this payment by September 30, 2017 and breached this provision of the Mayo Development
Agreement. Mayo granted us an extension of this deadline to December 31, 2017, and we made this payment within such extended deadline.
Because of our past breach, Mayo may be less likely to waive future defaults or breaches or further amend the Mayo Development Agreement
in the future, to the extent we request any waiver or amendment. Termination of the Mayo Development Agreement could result in the loss
of significant rights and would harm our ability to further develop our technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on a limited number of third-party suppliers for the components of our cortical strip, grid electrode and depth electrode technology,
and the loss of any of these suppliers, or their inability to provide us with an adequate supply of materials, could harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third-party suppliers to supply and manufacture the components of our cortical strip, grid electrode and depth electrode technology.
For our business strategy to be successful, our suppliers must be able to provide us with components in sufficient quantities, in compliance
with regulatory requirements and quality control standards, in accordance with agreed upon specifications, at acceptable costs and on
a timely basis. Future increases in sales of our cortical strip and sheet electrode technology, if approved, whether expected or unanticipated,
could strain the ability of our suppliers to deliver an increasingly large supply of components and our cortical strip, grid electrode
and depth electrode technology in a manner that meets these various requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use a small number of suppliers of components for our products. Depending on a limited number of suppliers exposes us to risks, including
limited control over pricing, availability, quality and delivery schedules. We may not have long-term supply agreements with our suppliers
and, in many cases, we may make our purchases on a purchase order basis. Our ability to purchase adequate quantities of components or
our products may be limited and we may not be able to convince suppliers to make components and products available to us. Additionally,
our suppliers may encounter problems that limit their ability to supply components or manufacture products for us, including financial
difficulties, damage to their manufacturing equipment or facilities, product discontinuations, or complications arising in connection
with the COVID-19 pandemic. As a result, there is a risk that certain components could be discontinued and no longer available to us.
We may be required to make significant &#8220;last time&#8221; purchases of component inventory that is being discontinued by the supplier
to ensure supply continuity. If we fail to obtain sufficient quantities of high quality components to meet demand for our products in
a timely manner or on terms acceptable to us, we would have to seek alternative sources of supply. Because of factors such as the proprietary
nature of our products, our quality control standards and regulatory requirements, we may not be able to quickly engage additional or
replacement suppliers for some of our critical components. Failure of any supplier to deliver components at the level our business requires
could disrupt the manufacturing of our products and, if approved, limit our ability to meet our sales commitments, which could harm our
reputation and adversely affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
vandalism, terrorism or a natural or other disaster, such as an earthquake, fire or flood, could damage or destroy equipment, our inventory
of component supplies or finished products, cause substantial delays in development or our operations, result in the loss of key information,
and cause us to incur additional expenses. We do not currently have insurance to cover such losses or expenses and, once we obtain such
insurance, it may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to
our or our suppliers&#8217; facilities could harm our business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA or other regulatory agencies,
and the failure of any supplier to comply with strictly enforced regulatory requirements could expose us to regulatory action including
warning letters, product recalls, and termination of distribution, product seizures or civil penalties. It could also require us to cease
using the components, seek alternative components or technologies and modify our products to incorporate alternative components or technologies,
which could result in a requirement to seek additional regulatory approvals. Any disruption of this nature or increased expenses could
harm our development, approval or commercialization efforts and adversely affect our operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;&#8212;The COVID-19 pandemic has adversely impacted, and may continue to impact, our business&#8221; above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
contract with third parties for the manufacture of our cortical strip, grid electrode and depth electrode technology, including our under
development and expect to continue to do so for clinical trials and commercialization. Risks associated with the manufacturing of our
products could reduce our gross margins and negatively affect our operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely, and expect to continue to rely, on third parties for the manufacture of our cortical strip, grid electrode and depth
electrode technology. Therefore, our business strategy depends on our third-party manufacturers&#8217; ability to manufacture our cortical
strip, grid electrode and depth electrode technology and future generations thereof in sufficient quantities and on a timely basis so
as to meet consumer demand, while adhering to product quality standards, complying with regulatory requirements and managing manufacturing
costs. To date, we have only manufactured small quantities of our cortical electrodes. As a result, we currently have limited data and
experience regarding the quality, reliability and timeliness of our third-party manufacturers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous risks relating to the manufacturing capabilities of our third-party manufacturers, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality
or reliability defects;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to secure product components in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
to increase production to meet demand;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to
regulatory requirements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
identifying and qualifying alternative manufacturers in a timely manner;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to manufacture product components cost-effectively;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to establish agreements with future third-party manufacturers or to do so on acceptable terms;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">potential damage to or destruction of our manufacturers&#8217; equipment or facilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
to complete sterilization on time or in compliance with the required regulatory standards;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transportation
and import and export risk;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in analytical results or failure of analytical techniques that we will depend on for quality control and release of products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
disasters, labor disputes, financial distress, raw material availability, issues with facilities and equipment or other forms of disruption
to business operations affecting our manufacturers or suppliers; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">latent
defects that may become apparent after products have been released and that may result in a recall of such products.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
risks are likely to be exacerbated by our limited experience with our cortical strip, grid electrode and depth electrode technology and
its manufacturing process. As demand for our products increases, our third-party suppliers will need to invest additional resources to
purchase components, hire and train employees, and enhance their manufacturing processes. If our manufacturers fail to increase production
capacity efficiently, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline.
In addition, manufacturing any future versions of our cortical strip, grid electrode and depth electrode technology may require the modification
of production lines, the identification of new manufacturers for specific components, or the development of new manufacturing technologies.
It may not be possible for us to manufacture these products at a cost or in quantities sufficient to make any future versions of our
cortical strip, grid electrode and depth electrode technology commercially viable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
complications from our cortical strip, grid electrode and depth electrode technology that are currently unknown may come to light.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our industry experience and the experience of the physicians that use products similar to our cortical strip, grid electrode and depth
electrode technology, complications from use of our cortical strip, grid electrode and depth electrode technology may include post-operative
hemorrhage, infection, brain inflammation, brain tissue necrosis, inability to accurately localize the epileptogenic focus (the area
of the cerebral cortex responsible for causing epileptic seizures), neurologic deficit (abnormal function of a body area due to weaker
function of the brain, spinal cord, muscles or nerves, such as abnormal reflexes, inability to speak and decreased sensation) and extra
axial fluid collections (fluid that occurs in the brain after surgery). If these or unanticipated complications or side-effects result
from the use of our cortical strip, grid electrode and depth electrode technology, our product development may be delayed, we may not
be able to obtain regulatory clearance or approval for certain products, we could be subject to liability and, even for cleared/approved
products, our technology would not be widely adopted. We cannot assure you that use, even for a limited time, would not result in unanticipated
complications, even after the device is removed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Undetected
errors or defects in our cortical strip, grid electrode and depth electrode technology under development or future versions thereof could
harm our reputation, decrease the market acceptance of our cortical strip, grid electrode and depth electrode technology or expose us
to product liability claims adversely affecting our financial condition and results of operations or liquidity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cortical strip, grid electrode and depth electrode technology may contain undetected errors or defects. As a result, we may be subject
to warranty and liability claims for damages related to errors or defects in such products. A material liability claim or other occurrence
that harms our reputation or decreases market acceptance of our cortical strip, grid electrode and depth electrode technology could harm
our business and operating results. This risk exists even if a device is cleared or approved for commercial sale and manufactured in
facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products are designed to affect, and
any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse
or abuse associated with our cortical strip, grid electrode and depth electrode technology or future versions thereof could result in
patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims,
and we cannot offer any assurance that we will not face product liability lawsuits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sale and use of our cortical strip, grid electrode and depth electrode technology or future versions thereof could lead to the filing
of product liability claims if someone were to allege that our cortical strip, grid electrode and depth electrode technology or one of
our products contained a design or manufacturing defect. A product liability claim could result in substantial damages and be costly
and time consuming to defend, either of which could materially harm our business or financial condition. Product liability claims may
be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our products, among others.
If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm.
In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction
of management&#8217;s attention from our primary business;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
inability to commercialize our cortical strip, grid electrode and depth electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
demand;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage
to our business reputation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
recalls or withdrawals from the market;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
of clinical trial participants;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
monetary awards or settlements to patients or other claimants; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of revenue.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability lawsuits and claims, safety alerts or product recalls, with or without merit, could cause us to incur substantial costs, delay
our product development efforts, place a significant strain on our financial resources, divert the attention of management from our core
business, harm our reputation, increase our product liability insurance rates, once we obtain such insurance, or prevent us from securing
such insurance coverage in the future and adversely affect our ability to attract and retain customers, if approved, any of which could
harm our business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently maintain commercial product liability insurance with an aggregate limit of $5,000,000. We cannot be assured that such insurance
would adequately protect our assets from the financial impact of defending a product liability claim because these policies typically
have substantial deductibles. Product liability claims in excess of applicable insurance coverage would negatively impact our business,
financial condition and operating results. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee
that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on sophisticated information technology systems, and any breach or disruption affecting these systems could adversely affect our
business, financial condition and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
efficient operation of our business depends on our information technology systems, which we use to manage product development tasks,
research and development data and accounting and financial functions. In the future, we may rely on our information technology systems
for inventory management and technical support functions. Our information technology systems are vulnerable to damage or interruption
from earthquakes, fires, floods, other natural disasters, terrorist attacks, attacks by computer viruses or hackers, power losses, and
computer system or data network failures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our data management application and a variety of our software systems are hosted by third-party service providers whose security
and information technology systems are subject to similar risks. If our, or our third-party service provider&#8217;s, security systems
are breached or fail, unauthorized persons may be able to obtain access to sensitive data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur liability. The failure of our or our service providers&#8217; information
technology systems or our transmitter&#8217;s software to perform as we anticipate or our failure to effectively implement new information
technology systems could disrupt our entire operation, adversely affect our products, or result in delays in our product development,
clinical trial or commercialization efforts, increased overhead costs and damage our reputation. Any of these results could negatively
affect our business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Zimmer
has exclusive global rights to distribute our strip and grid cortical electrodes and electrode cable assembly products. Zimmer&#8217;s
failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results.
Further, our inability to agree with Zimmer on dates of completion for product development, regulatory clearance and commercialization
milestones on which various fee payments to the Company are based under the Zimmer Development Agreement could have a material adverse
impact on our financial and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company granted Zimmer an exclusive global right to distribute our strip and grid cortical electrodes and electrode cable assembly products.
Additionally, we granted Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company. The
collaboration with Zimmer may not be successful due to several factors, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zimmer
may not be able to obtain from us or manufacture our products in a timely or cost-effective manner;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zimmer
may not timely perform its obligations under the Zimmer Development Agreement;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zimmer
may fail to effectively commercialize our products; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual
disputes or other disagreements between us and Zimmer, including those regarding the development, manufacture, and commercialization
of our products, interpretation of the Zimmer Development Agreement, and ownership of proprietary rights.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could adversely impact the likelihood and timing of any payments we are eligible to receive under the Zimmer Development
Agreement. Neither the Product Availability Date nor the Acceptance of all Deliverables for SEEG Products under the Development Plan
(which are key milestones for payments under the Development Agreement) has occurred. In September 2021, the Company received 510(k)
clearance from the FDA to market its Evo sEEG Electrode technology for temporary (less than 24 hours) use with recording, monitoring,
and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
FDA clearance is one condition of the Product Availability Date. However, the Company does not intend to deliver saleable product to
Zimmer if and until it receives regulatory clearance to expand the use of its Evo sEEG Electrode technology for up to 30 days, at which
point the Company and Zimmer intend to commence negotiations regarding payments by Zimmer under the Development Agreement notwithstanding
the deadlines under the Development Agreement for the Product Availability Date and the Acceptance of all Deliverables for SEEG Products.
Accordingly, the amount of the SEEG Exclusivity Maintenance Fee and the Interim Fee Bonus that we may receive under the Development Agreement
will depend on the outcome of such negotiations, and we cannot guarantee any particular outcome.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the Company is reliant on Zimmer to drive the commercialization and sales of our products. If Zimmer does not perform its obligations
under the Zimmer Development Agreement, we may be forced to incur material expenses to build a sales organization and infrastructure
to market our products which sales would be substantially delayed and could result in a material adverse effect on our business, results
of operations and prospects and would likely cause our stock price to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have entered into, and may enter into additional collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships
with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances,
partnerships or other arrangements to develop products and to pursue new markets. Proposing, negotiating and implementing collaborations,
in-licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies,
including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for
these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner,
on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these
business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular,
these collaborations may not result in the development of products that achieve commercial success or result in significant revenues
and could be terminated prior to developing any products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may not be in a position to exercise sole decision making authority regarding the transaction or arrangement, which could create the
potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that
are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators,
such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement,
such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration.
If any conflicts arise with any future collaborators, they may act in their self-interest, which may be adverse to our best interest,
and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any
future collaborators devote to our or their future products. Disputes between us and our collaborators may result in litigation or arbitration
which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual
in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have
rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property
rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed
to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection
for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue
such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization,
royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly
seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to protect our intellectual property and proprietary technology is uncertain.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device market in which we operate is largely technology driven. We rely primarily on patent, trademark and trade secret laws,
as well as confidentiality and non-disclosure agreements, to protect our intellectual property and proprietary technologies. We continue
to review new technological developments in order to make decisions about what additional filings would be the most appropriate for us.
We also plan to seek patent protection for our proprietary technology in select countries internationally. If we fail to timely file
a patent application in any jurisdiction, we may be precluded from doing so at a later date. Furthermore, we cannot assure you that any
patent application will be approved in a timely manner or at all. The rights granted to us under our patents, and the rights we are seeking
to have granted in our pending patent applications, may not be meaningful or provide us with any commercial advantage. In addition, those
rights could be opposed, contested or circumvented by our competitors, or be declared invalid or unenforceable in judicial or administrative
proceedings. The failure of our patents to adequately protect our technology might make it easier for our competitors to offer the same
or similar products or technologies. Even if we are successful in receiving patent protection for certain products and processes, our
competitors may be able to design around our patents or develop products that provide outcomes which are comparable to ours without infringing
on our intellectual property rights. Due to differences between foreign and U.S. patent laws, our patented intellectual property rights
may not receive the same degree of protection in foreign countries as they would in the United States. Even if patents are granted outside
the United States, effective enforcement in those countries may not be available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on our trademarks and trade names to
distinguish our products from the products of our competitors, and have registered or applied to register many of these trademarks. For
example, we have a registered U.S. trademark for the &#8220;EVO&#8221; trademark. We cannot assure you that our trademark applications
will be approved in a timely manner or at all. Third parties also may oppose our trademark applications, or otherwise challenge our use
of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could
result in loss of brand recognition, and could require us to devote additional resources to marketing new brands. Further, we cannot
assure you that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets, know-how and technology, which are not protectable by patents, to maintain our competitive position. We try
to protect this information by entering into confidentiality agreements and intellectual property assignment agreements with our officers,
employees, temporary employees and consultants regarding our intellectual property and proprietary technology. In the event of unauthorized
use or disclosure or other breaches of those agreements, we may not be provided with meaningful protection for our trade secrets or other
proprietary information. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To
the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their
work for us, disputes may arise as to the rights in the related or resulting know-how and inventions. If any of our trade secrets, know-how
or other technologies not protected by a patent were to be disclosed to or independently developed by a competitor, our business, financial
condition and results of operations could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a competitor infringes upon one of our patents, trademarks or other intellectual property rights, enforcing those patents, trademarks
and other rights may be difficult and time-consuming. Patent law relating to the scope of claims in the industry in which we operate
is subject to rapid change and constant evolution and, consequently, patent positions in our industry can be uncertain. Even if successful,
litigation to defend our patents and trademarks against challenges or to enforce our intellectual property rights could be expensive
and time consuming and could divert management&#8217;s attention from managing our business. Moreover, we may not have sufficient resources
or desire to defend our patents or trademarks against challenges or to enforce our intellectual property rights. Litigation also puts
our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing. Additionally, we
may provoke third-parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded, if any, may not be commercially valuable. The occurrence of any of these events may harm our business, financial condition and
operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is limited market awareness of our technology, and we may not be able to establish or strengthen our brand.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently limited market awareness of our technology. We believe that establishing and strengthening our brand is critical to achieving
widespread acceptance of our cortical strip, grid electrode and depth electrode technology. Promoting and positioning our brand, and
increasing market awareness of our technology, will depend largely on the success of our marketing efforts and our ability to provide
physicians with a reliable product for successful treatment of brain-related disorders. Additionally, we believe the quality and reliability
of our product is critical to building physician support in the United States, and any negative publicity regarding the quality or reliability
of our cortical strip, grid electrode and depth electrode technology could significantly damage our reputation in the market. Further,
given the established nature of our competitors, it is likely that our future marketing efforts will require us to incur significant
additional expenses. These brand promotion activities may not yield increased sales and, even if they do, any sales increases may not
offset the expenses we incur to promote our brand. If we fail to successfully promote and maintain our brand, or if we incur substantial
expenses in an unsuccessful attempt to promote and maintain our brand, our cortical strip, grid electrode and depth electrode technology
may not be accepted by physicians, which would adversely affect our business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could become subject to patent litigation that could be costly, result in the diversion of management&#8217;s time and efforts, stop
our development and commercialization measures or require us to pay damages.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on not infringing the patents or violating the other proprietary rights of third-parties. Significant litigation
regarding patent rights exists in our industry. Our competitors in both the United States and abroad, many of which have substantially
greater resources and have made substantial investments in competing technologies, may have applied for or obtained or may in the future
apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make and sell our products. The large
number of patents, the rapid rate of new patent issuances, and the complexities of the technology involved increase the risk of patent
litigation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we could receive communications from various industry participants alleging our infringement of their intellectual property
rights. Any potential intellectual property litigation could force us to do one or more of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stop
selling our products or using technology that contains the allegedly infringing intellectual property;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
significant legal expenses;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
substantial damages to the party whose intellectual property rights we are allegedly infringing;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redesign
those products that contain the allegedly infringing intellectual property; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attempt
to obtain a license to the relevant intellectual property from third-parties, which may not be available on reasonable terms or at all,
and if available, may be non-exclusive, thereby giving our competitors access to the same technology.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
litigation can involve complex factual and legal questions, and its outcome is uncertain. Any litigation or claim against us, even those
without merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention
of management from our core business and harm our reputation. Further, as the number of participants in the neurostimulation market increases,
the possibility of intellectual property infringement claims against us increases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed alleged trade secrets of
our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our current or future employees may have previously been employed at other medical device companies, including those that are our
direct competitors or could potentially be our direct competitors. We may be subject to claims that we, or our employees, have inadvertently
or otherwise used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition,
we may in the future be subject to allegations that we caused an employee to breach the terms of his or her non-competition or non-solicitation
agreement. Litigation may be necessary to defend against these claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently subject to litigation with the former employer of a current employee of NeuroOne, which is described in more detail under
&#8220;Note 4&#8212;Commitments and Contingencies&#8221; included in &#8220;Item 8 &#8212; Financial Statements and Supplementary Data&#8221;
in this Annual Report<i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we successfully defend against these claims, litigation could result in substantial costs place a significant strain on our financial
resources, divert the attention of management from our core business and harm our reputation. If our defense to those claims fails, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There can be no assurance that this
type of litigation will not occur, and any future litigation or the threat thereof may adversely affect our ability to hire additional
employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our cortical strip, grid
electrode and depth electrode technology or future versions thereof, which could have an adverse effect on our business, financial condition
and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may be able to make devices that are the same as or similar to our cortical strip, grid electrode and depth electrode technology but
that are not covered by the claims of the patents that we own;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
or any collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications
that we own;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
might not have been the first to file patent applications covering certain of our inventions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
is possible that our pending patent applications will not lead to issued patents;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal
challenges;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
might enforce our patent rights or defend a challenge to our issued patents or pending application, putting the patents and patent applications
at risk of being invalidated or interpreted narrowly;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights,
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not develop additional proprietary technologies that are patentable.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Legal and Regulatory Environment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products and operations are subject to extensive governmental regulation, and any adverse regulatory action may materially adversely
affect our financial condition and business operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
medical devices and technologies and business activities, including marketing, manufacturing, sales and development processes, are subject
to regulation by the FDA, U.S. Department of Justice, Health and Human Services &#8211; Office of Inspector General, and other federal
and state, governmental authorities. These governmental authorities enforce laws and regulations that are meant to assure product safety
and effectiveness, including the regulation of, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
design and development;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-clinical
studies and clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
safety;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment
registration and product listing;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling,
content and language of instructions for use and storage;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">marketing,
manufacturing, sales and distribution;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-market
clearance or approval;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">servicing
and post-market surveillance;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">record-keeping
procedures;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
import and export;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advertising
and promotion; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls
and field safety corrective actions.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in
restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as fines,
civil penalties, injunctions, warning letters, recalls of products, delays in the introduction of products into the market, refusal of
the regulatory agency or other regulators to grant future clearances or approvals, and the suspension or withdrawal of existing approvals
by such regulatory agencies. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and
harm our reputation, business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
recall of our products, or the discovery of serious safety issues with our products, could have a significant negative impact on us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or
manufacture or in the event that a product poses an unacceptable risk to health. Our third-party suppliers may, under their own initiative,
recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our third-party
distributors, if any, could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or
labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and
have an adverse effect on our reputation, financial condition and operating results, which could impair our ability to produce our products
in a cost-effective and timely manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
under the FDA&#8217;s medical device reporting regulations, we are required to report to the FDA any incident in which our product may
have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur,
would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product
recall, which could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and
timely manner and have an adverse effect on our reputation, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications,
or regulatory agency action, which could include inspection, mandatory recall or other enforcement action. Any corrective action, whether
voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business and may
harm our reputation and financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply
with those laws could have an adverse impact on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we will not provide healthcare services, submit claims for third-party reimbursement, or receive payments directly from government health
insurance programs or other third-party payors for our cortical strip, grid electrode and depth electrode technology, we are subject
to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could adversely impact our
business. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our operations include,
but are not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Anti-Kickback Statute, which will apply to our marketing practices, educational programs, pricing policies and relationships with healthcare
providers, by prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase
or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare or Medicaid programs. A
person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or qui tam actions that prohibit,
among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are
false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal
government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property
to the federal government. The government may assert that a claim including items or services resulting from a violation of the Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
and its implementing regulations, which created federal criminal laws that prohibit, among other things, executing a scheme to defraud
any healthcare benefit program or making false statements relating to healthcare matters. A person or entity does not need to have actual
knowledge of these statutes or specific intent to violate them;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations, also
imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of individually identifiable
health information;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
&#8220;sunshine&#8221; requirements imposed by the ACA on device manufacturers regarding any &#8220;transfer of value&#8221; made or
distributed to physicians and teaching hospitals. Failure to submit required information may result in civil monetary penalties of up
to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &#8220;knowing failures&#8221;), for all payments,
transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission.
Manufacturers must submit reports by the 90th day of each subsequent calendar year;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed
by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments
that may be made to healthcare providers; state laws that require device manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy
and security of certain health information, many of which differ from each other in significant ways and often are not preempted by HIPAA;
and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of our being found in violation of these laws and regulations is increased by the fact that the scope and enforcement of these laws
is uncertain, many of them have not been fully interpreted by the regulatory authorities or the courts, their provisions are open to
a variety of interpretations, or they vary country by country. We are unable to predict what additional federal, state or foreign legislation
or regulatory initiatives may be enacted in the future regarding our business or the healthcare industry in general, or what effect such
legislation or regulations may have on us. Federal, state or foreign governments may (i) impose additional restrictions or adopt interpretations
of existing laws that could have a material adverse effect on us or (ii) challenge our current or future activities under these laws.
Any of these challenges could impact our reputation, business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us
now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement of profits,
exclusion from governmental health care programs, and the curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and our financial results. Any federal, state or foreign regulatory review to which we may
become subject, regardless of the outcome, would be costly and time-consuming.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, to enforce compliance with the federal laws, the U.S. Department of Justice, or DOJ, has recently increased its scrutiny of
interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions
and settlements in the healthcare industry. Dealing with investigations can be time and resource consuming and can divert management&#8217;s
attention from our core business. Additionally, if we settle an investigation with law enforcement or other regulatory agencies, we may
be forced to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement.
Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be liable if the FDA or another regulatory agency concludes that we have engaged in the off-label promotion of our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition
of the promotion of the off-label use of our products. Healthcare providers may use our products, if approved, off-label, as the FDA
does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. However, if the FDA determines
that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or
promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter,
injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or foreign enforcement authorities
might take action if they consider our promotional or training materials to constitute promotion of an unapproved use, which could result
in significant fines or penalties. Although we intend to train our marketing and direct sales force to not promote our products for uses
outside of their cleared uses and our policy will be to refrain from statements that could be considered off-label promotion of our products,
the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. In addition, the off-label
use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could result
in substantial damage awards against us and harm our reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative
or regulatory healthcare reforms may have a material adverse effect on our business, financial condition, results or operations and cash
flows.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
political, economic and regulatory influences are subjecting the healthcare industry to fundamental changes. The sales of our products
depend in part on the availability of coverage and reimbursement from third-party payors such as government health administration authorities,
private health insurers, health maintenance organizations and other healthcare-related organizations. Both the federal and state governments
in the United States continue to propose and pass new legislation and regulations designed to contain or reduce the cost of healthcare.
This legislation and regulation may result in decreased reimbursement for medical devices, which may further exacerbate industry-wide
pressure to reduce the prices charged for medical devices. This could harm our ability to market our products and generate sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business
and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen
review times of our products. Delays in receipt of or failure to receive regulatory clearances or approvals for our products would harm
our business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
one often stated goal of healthcare reform is to expand coverage to more individuals, it also involves increased government price controls,
additional regulatory mandates and other measures designed to constrain medical costs. For example, the ACA and Health Care and Education
Affordability Reconciliation Act of 2010 were enacted into law in the U.S. in March 2010. Certain provisions of this law, including comparative
effectiveness research, pilot programs to evaluate alternative payment methodologies and other changes to the payment systems, have started
changing the way healthcare is delivered, reimbursed and funded. While the extent to which it has affected our business is not clear,
these changes, over the long-term, may adversely affect our business and results of operations. The current U.S. administration may attempt
to reverse some of the previous administration&#8217;s changes to the ACA, particularly related to healthcare coverage for the uninsured,
and is further expected to introduce more ambitious healthcare legislation, which could include what is commonly referred to as a &#8220;public
option&#8221; or changes to Medicare age requirements. If passed, this legislation would lead to increased coverage levels and utilization
of services; however, at this point, the impact of any such changes is unclear because specific changes have not been enacted or implemented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict whether any additional healthcare reform proposals will be adopted or how such proposals may impact our business and operations.
However, any changes that lower reimbursements for either our products or procedures using our products, reduce medical procedure volumes,
increase cost containment pressures on us or others in the healthcare sector, or impose additional or heightened regulatory requirements
could adversely affect our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our Common Stock might fluctuate significantly, and you could lose all or part of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility
in the market price of our Common Stock may prevent you from being able to sell your shares of our Common Stock at or above the price
you paid for your shares. The trading price of our Common Stock may be volatile and subject to wide price fluctuations in response to
various factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
or anticipated fluctuations in our quarterly financial and operating results;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
progress toward developing our cortical strip and sheet electrode technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
commencement, enrollment and results of our future clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
results from, delays in or termination of our clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
regulatory decisions, including failure to receive regulatory approval;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities
analysts, if any;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceptions
about the market acceptance of our products and the recognition of our brand;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
publicity about our products or industry in general;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
performance of the equity markets;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
of products, or announcements of significant contracts, licenses or acquisitions, by us or our competitors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislative,
political or regulatory developments;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
or departures of key personnel;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">threatened
or actual litigation and government investigations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
promotional activities, which are subject to ongoing regulatory obligations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
of shares of our Common Stock by us or members of our management; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
economic conditions.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other factors might cause the market price of our Common Stock to fluctuate substantially, which may negatively affect the liquidity
of our Common Stock. In addition, in recent years, the stock market has experienced significant price and volume fluctuations. This volatility
has had a significant impact on the market price of securities issued by many companies across many industries. The changes frequently
appear to occur without regard to the operating performance of the affected companies. Accordingly, the price of our Common Stock could
fluctuate based upon factors that have little or nothing to do with our Company, and these fluctuations could materially reduce our share
price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
class action litigation has often been instituted against companies following periods of volatility in the overall market and in the
market price of a company&#8217;s securities. This litigation, if instituted against us, could result in substantial costs, divert our
management&#8217;s attention and resources, and harm our business, operating results and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to maintain an effective system of internal controls could result in material misstatements of our financial statements or cause
us to fail to meet our reporting obligations or fail to prevent fraud in which case, our stockholders could lose confidence in our financial
reporting, which would harm our business and could negatively impact the price of our stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to comply with the internal control
evaluation and certification requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and management is required
to report annually on our internal control over financial reporting. Our independent registered public accounting firm will not be required
to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404(b) of SOX until the date
we have a public float of $75 million or greater.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to maintain effective internal controls
and procedures for financial reporting, it could result in material misstatements in the annual or interim financial statements that would
not be prevented or detected in a timely manner. We identified material weaknesses in our internal control over financial reporting in
2018, and we cannot assure you that material weaknesses or significant deficiencies will not occur in the future and that we will be able
to remediate such weaknesses or deficiencies in a timely manner, which could impair our ability to accurately and timely report our financial
position, results of operations or cash flows.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to issue more shares to raise capital, which will result in substantial dilution.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes the issuance of a maximum of 100,000,000 shares of Common Stock and 10,000,000 shares of preferred
stock. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of
equity, debt financings, or other capital sources. Any additional financings effected by us may result in the issuance of additional
securities without stockholder approval and the substantial dilution in the percentage of Common Stock held by our then existing stockholders.
Moreover, the Common Stock issued in any such transaction may be valued on an arbitrary or non-arm&#8217;s-length basis by our management,
resulting in an additional reduction in the percentage of Common Stock held by our current stockholders. Our Board has the power to issue
any or all of such authorized but unissued shares without stockholder approval. To the extent that additional shares of Common Stock
are issued, dilution to the interests of our stockholders will occur and the rights of the holder of Common Stock might be materially
and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, we had outstanding warrants to purchase an aggregate of 7,503,808 shares of Common Stock at a weighted average
exercise price of $6.06 per share, and options to purchase an aggregate of 1,122,560 shares of Common Stock at a weighted average exercise
price of $5.89 per share. For a description of our outstanding warrants and information about the number of shares of Common Stock for
which they are exercisable, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity
and Capital Resources&#8212;Historical Capital Resources.&#8221; To the extent these outstanding options or warrants are exercised, there
will be further dilution to holders of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in the Company&#8217;s certificate of incorporation and bylaws may prevent or frustrate attempts by stockholders to change
the Board or current management and could make a third-party acquisition of the Company difficult.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s certificate of incorporation and bylaws contain provisions that may discourage, delay or prevent a merger, acquisition
or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive
a premium for their shares. For example, our certificate of incorporation permits the Board without stockholder approval to issue up
to 10,000,000 shares of preferred stock and to fix the designation, power, preferences, and rights of those shares. Furthermore, our
Board has the ability to increase the size of the Board and fill the newly created vacancies without stockholder approval. These provisions
could limit the price that investors might be willing to pay in the future for shares of the Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our Common
Stock less attractive to investors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in Section 12 of the Exchange Act. For as long as we continue to be a smaller
reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies
that are not smaller reporting companies such as, reduced disclosure obligations regarding executive compensation in our annual and periodic
reports and proxy statements and stockholder approval of any golden parachute payments not previously approved. We will remain a &#8220;smaller
reporting company&#8221; as long as (i) our public float remains less than $250 million or (ii) our annual revenues are less than $100
million and we either have no public float, or our public float is less than $700 million. Public float is measured as of the last business
day of our most recently-completed second fiscal quarter, and annual revenues are as of the most recently completed fiscal year for which
audited financial statements are available. We cannot predict if investors will find our Common Stock less attractive because we may
rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market
for our Common Stock and our stock price may be more volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Common Stock has been, and may in the future be subject to the &#8220;penny stock&#8221; rules of the SEC, which makes transactions in
our stock cumbersome and may reduce the value of an investment in our stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted regulations which generally define a &#8220;penny stock&#8221; as an equity security that has a market price of less
than $5.00 per share, subject to specific exemptions. The SEC&#8217;s penny stock rules require a broker-dealer, before a transaction
in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about
penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations
for the penny stock, the compensation of the broker-dealer and the salesperson in the transaction, and monthly account statements showing
the market value of each penny stock held in the customer&#8217;s account. In addition, the penny stock rules generally require that
before a transaction in a penny stock occurs, the broker-dealer must make a special written determination that the penny stock is a suitable
investment for the purchaser and receive the purchaser&#8217;s agreement to the transaction. If our Common Stock is subject to the &#8220;penny
stock&#8221; rules, these rules may restrict the ability of brokers-dealers to sell our Common Stock and may affect the ability of investors
to sell their shares, until our Common Stock no longer is considered a penny stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to
the value of our stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings
for use in the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Accordingly,
you may have to sell some or all of your shares of our Common Stock in order to generate cash flow from your investment. You may not
receive a gain on your investment when you sell shares and you may lose the entire amount of the investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business
or our market, our stock price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Common Stock will be influenced by the research and reports that securities or industry analysts publish about
us and our business. Securities or industry analysts may elect not to provide coverage of our Common Stock, and such lack of coverage
may adversely affect the market price of our Common Stock. In the event we do not secure additional securities or industry analyst coverage,
we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline
if one or more securities or industry analysts downgrade our stock or issue other unfavorable commentary or research. If one or more
securities or industry analysts ceases coverage of our Company or fails to publish reports on us regularly, demand for our stock could
decrease, which in turn could cause our stock price or trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing standards of the Nasdaq Capital Market, our Common Stock could be delisted. If it is delisted,
our Common Stock and the liquidity of our Common Stock would be impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued listing of our Common Stock on Nasdaq is contingent on NeuroOne&#8217;s continued compliance with a number of listing standards.
There is no assurance that NeuroOne will remain in compliance with these standards. Delisting from Nasdaq would adversely affect our
ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors
to trade our securities and negatively affect the value and liquidity of our Common Stock. Delisting also could limit our strategic alternatives
and attractiveness to potential counterparties and have other negative results, including the potential loss of employee confidence,
the loss of institutional investors or interest in business development opportunities. Moreover, NeuroOne committed in connection with
the sale of securities to use commercially reasonable efforts to maintain the listing of its Common Stock during such time that certain
warrants are outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Acquisition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to unknown risks as a result of our completed Acquisition by Original Source Entertainment, Inc.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Original
Source Entertainment, Inc., which was renamed NeuroOne Medical Technologies Corporation in connection with the Acquisition, was formed
to license songs to the television and movie industry and has generated very little revenues. Prior to the Acquisition, its operations
have been primarily limited to organizational, start-up, and capital formation activities, with no employees other than the former officers.
In connection with the Acquisition, the liabilities existing in Original Source Entertainment, Inc. at the time of the Acquisition were
cancelled or paid by a related party, as required by the Merger Agreement with NeuroOne, Inc. and OSOK Acquisition Company (the &#8220;Merger
Agreement&#8221;). Despite this requirement and the representations and warranties of Original Source Entertainment, Inc. in the Merger
Agreement, there may be unknown liabilities, or liabilities that were known but believed to be immaterial, related to the business of
Original Source Entertainment, Inc. that may become material liabilities we are subject to in the future. If we are subject to material
liabilities as a result of the conduct of Original Source Entertainment, Inc., we may have limited recourse for such liabilities, which
could have a material impact on our business and stock price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
risks may exist since we were engaged in a transaction that can be generally characterized as a &#8220;reverse merger&#8221; with a shell
company. Securities analysts of major brokerage firms may not provide coverage of the Company since there is little incentive to brokerage
firms to recommend the purchase of the Common Stock. No assurance can be given that brokerage firms will want to conduct any secondary
offerings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial
condition and cash flows.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to income and other non-income-based taxes and tariffs in the U.S., and our operations, plans and results are affected by
tax and other initiatives. The tax laws in the U.S. and any other countries in which we and our affiliates do business could change on
a prospective or retroactive basis, and any such changes could materially adversely affect our business, our results of operations, and
our effective tax rate. For example, on December 22, 2017, the U.S. enacted the Tax Act, which contains significant changes to corporate
taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, and the recent change
in administration and control of Congress in the U.S. may result in additional U.S. tax law changes that could have a material impact
on our future effective tax rate. Notwithstanding the reduction in the corporate income tax rate under the Tax Act, guidance on tax reform
continues to be released and such guidance may adversely affect our business and financial condition. It is also unknown if and to what
extent various states will conform to the Tax Act or any future tax reform legislation. The impact of the tax reform implemented under
the Tax Act and any future tax reform legislation on holders of our Common Stock is likewise uncertain and could be adverse. We urge
you to consult with your legal and tax advisors with respect to this legislation and the potential tax consequences of investing in our
Common Stock. The decrease in the corporate tax rate resulted in changes in the valuation of our deferred tax assets and liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to regular reviews, examinations, and audits by the Internal Revenue Service and other taxing authorities with respect
to our taxes. Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken,
we could face additional tax liability, including interest and penalties. There can be no assurance that payment of such additional amounts
upon final adjudication of any disputes will not have a material impact on our results of operations and financial position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may seek to grow our business through acquisitions of complementary products or technologies, and the failure to complete acquisitions,
or the failure to integrate them with our existing business, could harm our business, financial condition and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider opportunities to acquire other companies, products or technologies that may enhance our product platform
or technology, expand the breadth of our markets or customer base, or advance our business strategies. The success of our strategy relating
to future acquisitions, investments or alliances will depend on a number of factors, including our ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">identify suitable opportunities for acquisition, investment or alliance, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">manage acquisition, investment or alliance opportunities within our capital capacity and prioritize those investments to execute on our strategy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">manage our due diligence process to uncover potential issues and liabilities with targets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">finance any future acquisition, investment or alliance on terms acceptable to us, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">complete acquisitions, investments or alliances in a timely manner on terms that are satisfactory to us, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">successfully integrate and operate acquired businesses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">successfully identify and retain key target employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">comply with applicable laws and regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">protect intellectual property and to prevail in litigation related to newly acquired technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilate
the acquired products or technologies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
uniform standards, procedures, controls and policies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">anticipate
costs associated with acquisitions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid
the diversion of management&#8217;s attention from our existing business;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
risks associated with entering new markets in which we have limited or no experience; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
legal and accounting costs relating to the acquisitions or compliance with regulatory matters.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable,
whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully
integrate any acquired products or technologies. Our potential inability to integrate any acquired products or technologies effectively
may adversely affect our business, operating results and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the management, research and development, clinical, financial and business development expertise of our officers
and advisory board members. Although we have an employment agreement with David Rosa, he (and each of our other key employees) may terminate
his employment with us at any time and will continue to be able to do so. We do not maintain &#8220;key person&#8221; insurance for any
of our executives or employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruiting
and retaining qualified scientific and clinical personnel will also be critical to our success. The loss of the services of our executive
officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously
harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be
difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills
and experience required to successfully develop, gain regulatory approval of and commercialize our products. Competition to hire from
this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous medical device companies for similar personnel, many of which have greater financial and other resources dedicated
to attracting and retaining personnel. We also experience competition for the hiring of scientific and clinical personnel from universities
and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us
in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers
other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to
us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prolonged
negative economic conditions could adversely affect us, our customers and third-party partners, manufactures or suppliers, if any, which
could harm our financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the risks arising from adverse changes in general economic and market conditions, including, but not limited to, changes
related to the COVID-19 pandemic. Uncertainty about future economic conditions could negatively impact our existing and potential customers,
adversely affect the financial ability of health insurers to pay claims, adversely impact our expenses and ability to obtain financing
of our operations, and cause delays or other problems with key suppliers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
spending in the United States has been, and is expected to continue to be, under significant pressure and there are many initiatives
to reduce healthcare costs. As a result, we believe that some insurers are scrutinizing insurance claims more rigorously and delaying
or denying coverage and reimbursement more often. Because the sale, if approved, of our cortical strip, grid electrode and depth electrode
technology under development will generally depend on the availability of third-party coverage and reimbursement, any delay or decline
in coverage and reimbursement will adversely affect our sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred, and may continue to incur increased costs and demands upon management as a result of being a public company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company in the United States, we incur significant legal, accounting and other costs. These additional costs could negatively
affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure,
including regulations implemented by the SEC and the stock exchange on which we may list our Common Stock, may increase legal and financial
compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations
and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.
We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general
and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance
activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities
may initiate legal proceedings against us and our business may be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer
liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain
the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons
to serve on our Board, on committees of our Board or as members of senior management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 2. PROPERTIES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently lease office space in Eden Prairie,
Minnesota, and Los Gatos, California to accommodate our finance and administrative functions as well as laboratory space accommodating
our research and development operations. We believe that our existing facilities are adequate for our immediate needs and can accommodate
our anticipated growth. We believe that, should it be needed, additional space can be leased to accommodate any future growth.&#160;&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 3. LEGAL PROCEEDINGS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is subject to litigation and claims arising in the ordinary course of business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2018, the Company was served with a complaint filed by PMT Corporation (&#8220;PMT&#8221;), the former employer of Mark Christianson,
a current Company employee and Wade Fredrickson, a now former Company employee. The complaint added the Company, NeuroOne, Inc. and Mr.
Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. In the
lawsuit, PMT claims by virtue of their work for the Company and their prior work during employment with PMT, Mr. Fredrickson and Mr.
Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations,
were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT&#8217;s contracts
and prospective economic advantage, and breached a covenant of good faith and fair dealing. The complaint purported to attach Mr. Fredrickson&#8217;s
noncompete agreement as Exhibit A. Against Mr. Fredrickson, PMT also alleged that he intentionally or negligently spoliated evidence,
made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort
of conversion and statutory civil theft. Against the Company and NeuroOne, Inc., PMT alleged that the Company and NeuroOne, Inc. were
unjustly enriched and engaged in unfair competition. PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson
and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys&#8217; fees, costs and interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October
11, 2018. The motion for dismissal stated that: the contract claims against Mr. Christianson fail because his agreement was not supported
by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff&#8217;s claims for unfair competition, civil conspiracy
and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing;
plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff
has not stated a claim for unfair competition. On January 7, 2019, the judge granted the motion for dismissal with respect to PMT&#8217;s
claim for breach of the duty of good faith and fair dealing, and denied the motion for dismissal with respect to the other claims presented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2019, PMT served the Company, NeuroOne, Inc. and Christianson with a proposed Second Amended Complaint, which included new claims
against the Company and NeuroOne, Inc for tortious interference with contract and tortious interference with prospective business advantage
and punitive damages against the Company, NeuroOne Inc. and Christianson. On June 28, 2019, the Company presented evidence indicating
that PMT had participated in a fraud on the Court and sought an Order that PMT had waived the attorney client privilege.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2019, the defendants served PMT with a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct
including, but not limited to, dismissal of the case and an award of attorneys&#8217; fees. The Company, NeuroOne Inc and Mr. Christianson
further moved for summary judgment on all remaining claims asserted against them as well as for leave to assert counterclaims against
PMT for abuse of process. Following hearings on the dispositive motions and defendants&#8217; sanctions motion, the district court granted
the Company&#8217;s motion for sanctions on April 29, 2020. Additionally, the district court granted the Company&#8217;s motion for summary
judgment in part with respect to the counts for Christianson&#8217;s breach of non-confidentiality agreement, and denied the Company&#8217;s
motion for summary judgment on all other counts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2020, defendants moved the Court
to amend their counterclaims for abuse of process against PMT to add a claim for punitive damages with respect to its conduct pertaining
to the Fredrickson noncompete. On October 12, 2020 the Court awarded NeuroOne, Inc. $185,000&#160;in Rule 11 sanctions and Fredrickson
$145,000&#160;in Rule 11 sanctions with respect to PMT&#8217;s misconduct relating to the Fredrickson noncompete. PMT and its former litigation
counsel, Barnes &amp; Thornburg, were jointly and severally liable for these awards, which were paid on December 11, 2020 and have been
recognized in other income in the statements of operations. The Court granted NeuroOne, Inc.&#8217;s motion to amend to permit its assertion
of the right to assert a punitive damages claim against PMT associated with fighting the allegations relating to the Fredrickson noncompete.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 27, 2021 PMT moved for summary judgment on defendants&#8217; claims for abuse of process and punitive damages, and on August 5, 2021,
the district court granted PMT&#8217;s motion to dismiss the abuse of process and punitive damage claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trial
has been postponed from December 2021 to August of 2022. The Company intends to continue to defend itself vigorously and to continue
to aggressively prosecute its affirmative counterclaim against PMT. The outcome of any claim against the Company by PMT was not estimable
as of the issuance of the financial statements included herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock commenced trading on the Nasdaq Capital Market on May 26, 2021 under the ticker symbol &#8220;NMTC.&#8221; Previously, our
Common Stock was traded on the OTC Markets quotation system on the OTCQB administered by the Financial Industry Regulatory Authority
under the symbol &#8220;NMTC&#8221; since December 19, 2017. Prior to December 19, 2017, our Common Stock had been quoted on the OTC
Pink Sheets under the symbol &#8220;OSOK&#8221; from November 2012 to August 4, 2017 and under the symbol &#8220;NMTC&#8221; from August
4, 2017 to December 19, 2017.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2021, there were 119 record holders of our Common Stock. The transfer agent and registrar for our Common Stock is Action
Stock Transfer Corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Equity Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
sales of unregistered equity securities have previously been disclosed in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 6. [RESERVED]</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_011"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of financial condition and results of operations of NeuroOne together with our financial
statements and the related notes included elsewhere in this Report. References in this discussion to &#8220;series&#8221; or &#8220;notes&#8221;
refer to all of our outstanding notes as of the relevant date of the item being discussed. References in this discussion to &#8220;convertible
promissory notes&#8221; refer to all of our outstanding convertible promissory notes as of the relevant date of the item being discussed.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical technology company focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram
(cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients
suffering from epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other
related neurological disorders. Additionally, we are investigating the potential applications of our technology associated with artificial
intelligence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to FDA approval or clearance of certain of our products, our primary activities were limited to, and our limited resources were dedicated
to, performing business and financial planning, raising capital, recruiting personnel, negotiating with business partners and the licensors
of our intellectual property and conducting research and development activities. In November 2019, our Evo cortical technology (&#8220;cEEG&#8221;)
received 510(k) clearance from the FDA for recording, monitoring, and stimulating brain tissue for up to 30 days, and in September 2021,
we received FDA clearance for our Evo sEEG electrode technology for temporary (less than 24 hours) use with recording, monitoring, and
stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. Our
submission to the FDA seeking 510(k) for use of our Evo sEEG electrode technology for up to 30 days is pending.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed feasibility bench top testing with a new design of our diagnostic and ablation depth electrode in the first calendar quarter
of 2021, and signed a contract with RBC Medical Innovations to develop hardware for the system in the third calendar quarter of 2021.
We are targeting the third calendar quarter of 2022 for completion of such hardware. We also completed an animal feasibility study at
Emory University in September 2021. Next, we plan to submit a Pre-Submission(Q-Sub) to the FDA for the RF ablation system and to review
the feasibility of &#8220;Breakthrough&#8221; designation, complete additional animal studies through the first half of calendar 2022,
and submit an application for FDA 510(k) clearance in the fourth calendar quarter of 2022. Our other products are still under development<span>.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception. As of September 30, 2021, we had an accumulated deficit of $40.8 million, primarily as a result
of expenses incurred in connection with our research and development, selling, general and administrative expenses associated with our
operations and interest expense, fair value adjustments and loss on extinguishments related to our debt, offset in part by collaborations
and product revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to FDA approval of certain of our products, our main source of cash was proceeds from the issuances of notes, common stock, warrants
and unsecured loans. See &#8220;&#8212;Liquidity and Capital Resources&#8212;Historical Capital Resources&#8221; below. <span>While
we </span>have begun to generate revenue from the sale of products based on our cEEG technology beginning in the first quarter of fiscal
2021 and through milestone payments from our current collaboration with Zimmer<span>, </span>we expect
to continue to incur significant expenses and increasing operating and net losses for the foreseeable future until and unless we generate
a higher level of revenue from commercial sales, <span>and we </span>will need to obtain substantial
additional funding in connection with our continuing operations through public or private equity or debt financings, through collaborations
or partnerships with other companies or other sources<span>.&#160;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise additional funds when needed on favorable terms or at all. Our failure to raise such capital as and when needed
would have a negative impact on our financial condition and our ability to develop and commercialize our cortical strip, grid electrode
and depth electrode technology and future products and our ability to pursue our business strategy. See &#8220;&#8212;Liquidity and Capital
Resources&#8212;Funding Requirements and Outlook&#8221; below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>October
2021 Underwritten Public Offering </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2021, we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Craig-Hallum Capital Group
LLC, as underwriter (the &#8220;Underwriter&#8221;), relating to the issuance and sale of 3,750,000 shares of our common stock, par value
$0.001 per share, at a price to the public of $3.20 per share. In addition, under the terms of the Underwriting Agreement, we granted
the Underwriter an option, exercisable for 30 days, to purchase up to an additional 562,500 shares of common stock on the same terms.
The base offering closed on October 15, 2021, and the sale of 422,057 shares of common stock subject to the Underwriter&#8217;s overallotment
option closed on November 15, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds from this offering were approximately $13.4 million prior to deducting underwriting discounts and other offering expenses
payable by us. We intend to use the net proceeds from this offering for working capital and general corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
of Independent Registered Public Accounting Firm for Fiscal 2021</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2021, the Audit Committee of the Board (i) engaged Baker Tilly US, LLP (&#8220;Baker Tilly&#8221;) to serve as the Company&#8217;s
independent registered public accounting firm for the Company&#8217;s fiscal year ending September 30, 2021, and (ii)&#160;determined
to dismiss BDO USA, LLP (&#8220;BDO&#8221;), the Company&#8217;s independent registered public accounting firm for the year ending September
30, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Shelf Registration</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2021, NeuroOne filed a Form S-3 shelf registration statement under the Securities Act, which was declared effective by the SEC
on June 14, 2021 (the &#8220;2021 Shelf&#8221;). Under the 2021 Shelf, the Company may offer and sell, from time to time in its sole
discretion, securities having an aggregate offering price of up to $150 million, subject to the limitations of Form S-3.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Capital Market</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s common stock commenced trading on The Nasdaq Capital Market on May 26, 2021 under the ticker symbol &#8220;NMTC.&#8221;
Previously, the Company&#8217;s common stock was traded on the OTC Markets quotation system on the OTCQB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
after the close of business on March 31, 2021, the Company completed a 1-for-3 reverse stock split of its common stock. All share and
per share amounts in this Report have been reflected on a post-split basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic. As a result of the COVID-19 pandemic,
the Company has experienced, and will likely continue to experience, delays and disruptions in our pre-clinical and clinical trials,
as well as interruptions in our manufacturing, supply chain, shipping and research and development operations. <span>For
example:</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
of our technology was delayed in fiscal year 2021 due to interruptions in global manufacturing and shipping as a result of the COVID-19
pandemic<span>, including as one of our key manufacturing partners and one of the Company&#8217;s suppliers
had staffing issues leading to delays in the Company&#8217;s development builds and delays in shipping product;</span></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">the
Company&#8217;s own staff has been impacted by infections and mandatory quarantines;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company is currently experiencing product shortages of its primary component, polyimide film, due to supply chain shortages attributed
to COVID related issues;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company is experiencing delays in timelines for product availability and delivery from vendors, including related to staffing shortages,
both generally and due to employee illness, and due to increases in demand from other larger or more longstanding customers of our suppliers
placing large orders due to concerns with supply chain disruption and the impact of COVID-19.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><span>The Company&#8217;s plans for
further testing or clinical trials may be further impacted by the continuing effects of COVID-19. </span>The global outbreak of COVID-19
continues to rapidly evolve. In April 2020, given the impact of COVID-19 on the Company, the Company applied for and received loan funding
of $83,333 under the Paycheck Protection Program, which was forgiven by the U.S. Small Business Administration on June 9, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which the COVID-19 pandemic may further impact our business and pre-clinical and clinical trials will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, such as the effect of the pandemic on our suppliers and distributors
and the global supply chain, the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social
distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S.
and other countries to contain and treat the disease. The COVID-19 pandemic may also continue to impact our business as a result of employee
illness, school closures, and other community response measures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic may also impact our ability to secure additional financing. Although the Company cannot estimate the length or gravity
of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company&#8217;s
results of future operations, financial position, and liquidity in for fiscal year 2022 and beyond.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Risk Factors&#8212;Risks Related to Our Business&#8212;The COVID-19 pandemic has adversely impacted, and may continue to impact,
our business.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product revenue was derived from the sale of our strip and grid cortical electrodes (&#8220;Strip/Grid Products&#8221;) and electrode
cable assembly products (&#8220;Electrode Cable Assembly Products&#8221;) based on Evo cortical technology. We anticipate that we will
generate additional revenue from the sale of products based on Evo cortical technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received FDA 510(k) clearance for our cortical strip electrode <span>for temporary (less than 30
days) recording, monitoring, and stimulation on the surface of the brain </span>and our Evo sEEG electrode technology for temporary (less
than 24 hours) use <span>with recording, monitoring, and stimulation equipment for the recording, monitoring,
and stimulation of electrical signals at the subsurface level of the brain</span>, but we do not expect to generate any revenue from
the sale of our other products until we develop and obtain all required regulatory approvals or clearances for and commercialize depth
electrode technology. If we fail to complete the development of the depth electrode technology, or any other product candidate we may
pursue in the future, in a timely manner, or fail to obtain regulatory approvals or clearances, we may never be able to generate revenue
from product sales sufficient to sustain operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Gross Loss</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
gross loss represents our product revenue less our cost of product revenue. Our cost of product revenue consists of the manufacturing
and materials costs incurred by our third-party contract manufacturer in connection with our Strip/Grid Products and outside supplier
materials costs of producing the Electrode Cable Assembly Products. In addition, cost of product revenue includes royalty fees incurred
in connection with our license agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Collaborations
Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On
July 20, 2020, the Company entered into the Development Agreement with Zimmer, pursuant to which the Company granted Zimmer exclusive
global rights to distribute the Strip/Grid Products and electrode cable assembly products (the &#8220;Electrode Cable Assembly Products&#8221;).
Additionally, the Company granted Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company
(&#8220;SEEG Products&#8221;, and together with the Strip/Grid Products and Electrode Cable Assembly Products, the &#8220;Products&#8221;).
The parties have agreed to collaborate with respect to development activities under the Development Agreement through a joint development
committee composed of an equal number of representatives of Zimmer and the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Under
the terms of the Development Agreement, the Company is responsible for all costs and expenses related to developing the Products, and
Zimmer is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Development Agreement,
Zimmer and the Company have entered into a Manufacturing and Supply Agreement (the &#8220;MS Agreement&#8221;) and a supplier quality
agreement (the &#8220;Quality Agreement&#8221;) with respect to the manufacturing and supply of the Products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Except
as otherwise provided in the Development Agreement, the Company is responsible for performing all development activities, including non-clinical
and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts
to promote, market and sell each Product following the &#8220;Product Availability Date&#8221; (as defined in the Development Agreement)
for such Product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Pursuant
to the Development Agreement, Zimmer made an upfront initial exclusivity fee payment of $2.0&#160;million (the &#8220;Initial Exclusivity
Fee&#8221;) to the Company. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Except
where Zimmer timely delivers a Design Modification Notice under the Development Agreement, if one or more of the events set forth below
occurs on or before the deadline indicated for such event and the Product Availability Date (as defined in the Development Agreement)
for the SEEG Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event
as part of the SEEG Exclusivity Maintenance Fee:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Design
freeze for the SEEG Products by December 15, 2020 - $500,000</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan (as defined in the Development Agreement) by April 30, 2021 - $500,000</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">If
Zimmer timely delivers a Design Modification Notice to the Company under the Development Agreement, and one or more of the events set
forth below occurs on or before the deadline indicated for such event and the Product Availability Date for the SEEG Products occurs
on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the SEEG Exclusivity
Maintenance Fee:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan other than the Modified Connector by April 30, 2021 - $500,000</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan, including the Modified Connector by September 30, 2021 - $500,000</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">For
purposes of the Development Agreement, each of the foregoing events shall have occurred only if the Company has demonstrated the achievement
of the event to Zimmer&#8217;s reasonable satisfaction. Notwithstanding the foregoing, the events in Sections 6.1(c)(ii), (iii) and (iv)
of the Development Agreement shall not be deemed to be met if FDA Approval for the SEEG Products is not received prior to the applicable
deadline. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Zimmer
has delivered a Design Modification Notice. The design freeze for the SEEG Products occurred by December 15, 2020. In September 2021,
the Company received 510(k) clearance from the FDA to market its Evo sEEG Electrode technology for temporary (less than 24 hours) use
with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface
level of the brain. FDA clearance is one condition of the Product Availability Date under the Development Agreement. However, the Company
does not intend to deliver saleable product to Zimmer unless and until it receives regulatory clearance to expand the use of its Evo
sEEG Electrode technology for up to 30 days, at which point the Company and Zimmer intend to commence negotiations regarding payments
of applicable amounts above, notwithstanding the deadlines for the Product Availability Date and the Acceptance of all Deliverables for
SEEG Products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Initial Exclusivity Fee and Interim Fee Bonus, in order to maintain the exclusivity of the SEEG Distribution License,
Zimmer must pay the SEEG Exclusivity Maintenance Fee to the Company, on or prior to the SEEG Exclusivity Confirmation Date, in immediately
available funds as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
the Product Availability Date for the SEEG Products occurs on or before June 30, 2021, then $3,000,000, plus the amount of any Interim
Fee Bonuses earned pursuant to Section 6.1(c), including any such Interim Fee Bonus earned after June 30, 2021 pursuant to Section 6.1(c)(iv)
following the delivery of a Design Modification Notice;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
the Product Availability Date for the SEEG Products occurs after June 30, 2021, but on or before September 30, 2021, then $3,000,000,
plus if Zimmer timely issues a Design A-9 Modification Notice, any Interim Fee Bonus earned pursuant to Section 6.1(c)(iv);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
the Product Availability Date for the SEEG Products occurs after September 30, 2021, but on or before December 31, 2021, then $2,500,000;
and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
the Product Availability Date for the SEEG Products occurs after December 31, 2021, then $1,500,000.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, upon receipt (if any) of regulatory clearance to expand the use of its Evo sEEG Electrode technology for up to 30 days,
the Company and Zimmer intend to commence negotiations regarding the applicable SEEG Exclusivity Maintenance Fee amount, notwithstanding
the above deadlines for the Product Availability Date. <span>Notwithstanding any other provision of the
Development Agreement, if the Product Availability Date for the SEEG Products has not occurred on or before June 30, 2022, Zimmer shall
have the right to terminate the SEEG Distribution License by delivering written notice to the Company to that effect and, upon delivery
of such notice, Zimmer shall be relieved of all of its obligations hereunder with respect to SEEG Products, including any obligation
to pay the SEEG Exclusivity Maintenance Fee or to purchase, market, distribute or sell any SEEG Products. The Initial Exclusivity Fee
and the SEEG Exclusivity Maintenance Fee (including any Interim Fee Bonus(es)), once paid, are non-refundable.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Development Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last of the Products to achieve
a first commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Development Agreement (x) with
written notice for the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain
insolvency proceedings. In addition, Zimmer may terminate the Development Agreement for any reason with 90 days&#8217; written notice,
and the Company may terminate the Development Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain
competitors of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">At
inception of the Zimmer Development Agreement through September 30, 2021, the Company has identified the following three performance
obligations under the Zimmer Development Agreement: (1) the Company obligation to grant Zimmer access to its intellectual property; (2)
complete SEEG Product development; and (3) complete Strip/Grid Product development. Accordingly, the Company recognized revenue in the
amount of $64,812&#160;and $1,926,566&#160;during the years ended September 30, 2021 and 2020, respectively, related to the development
of the Products completed during the periods in connection with the Initial Exclusivity Fee payment. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2021, we received initial stocking orders from Zimmer for SEEG electrodes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
achievement of future milestones or level of sales required to earn royalty payments from Zimmer is uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Selling,
General and Administrative</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation for personnel in
functions not directly associated with research and development activities. Other significant costs include legal fees relating to corporate
matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial
matters, and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of our Strip/Grid
Products and Electrode Cable Assembly Products. We anticipate that our general and administrative expenses will significantly increase
in the future to support our continued research and development activities, further commercialization of our cortical strip technology,
commercial sales of our sEEG electrode technology, and the increased costs of operating as a public company. These expense increases
will include increased costs related to the hiring of additional personnel and fees for legal and professional services, as well as other
public-company related costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist of expenses incurred in developing our cortical strip, grid electrode and depth electrode technology,
compensation and benefits for research and development employees, including stock-based compensation, overhead expenses, cost of laboratory
supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants
and other outside expenses. Research and development costs are expensed as incurred and costs incurred by third parties are expensed
as the contracted work is performed. Lastly, de minimis income from the sale of prototype products and related materials are offset against
research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase over the next several years as we continue to develop our cortical
strip, grid electrode and depth electrode technology and conduct preclinical testing and clinical trials and will depend on the duration,
costs and timing to complete our preclinical programs and clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Expense</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense primarily consists of interest costs related to our 2019 Paulson Notes and 2020 Paulson Notes, as defined below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
valuation change of instruments measured at fair value</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net valuation change of instruments measured at fair value includes the change in fair value of the 2019 Paulson Notes and 2020 Paulson
Notes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loss
on notes extinguishment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
on note extinguishment includes the loss associated with debt instrument modifications and conversions accounted for as debt extinguishments.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income consists of proceeds derived from activity outside of normal operating activity, including legal settlements, the forgiveness
of the paycheck protection program loan and interest income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Fiscal Years Ended September 30, 2021 and 2020</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our results of operations for the fiscal years ended September 30, 2021 and 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period to<br/> Period<br/> Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Product revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">178,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">178,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cost of product revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Product gross loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,749</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Collaborations revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,812</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,926,566</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,861,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,260,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,753,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,507,230</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,925,008</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,075,791</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,849,217</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,185,274</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,828,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,356,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,218,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,902,261</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,315,950</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,053</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,524,581</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,521,528</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net valuation change of instruments measured at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(802,555</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Loss on note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,017,847</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">271,122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">271,122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(9,948,168</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(13,640,160</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,691,992</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Revenue and Product Gross Loss</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
revenue and product gross loss were $0.2 million and $(0.1) million, respectively, during the year ended September 30, 2021. The product
revenue consisted of the sale of Strip/Grid Products and Electrode Cable Assembly Products. Cost of product revenue consisted of the
manufacturing and materials costs incurred by our third-party contract manufacturer in connection with our Strip/Grid Products and outside
supplier materials costs in connection with the Electrode Cable Assembly Products. In addition, cost of product revenue included royalty
fees incurred, including the royalty fees to WARF and Mayo of $0.1 million in connection with our license agreements. There was no product
revenue or product gross loss recognized during the comparable prior year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collaborations
Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
revenue was $65,000 and $1.9 million for the years ended September 30, 2021 and 2020, respectively. Revenue during the period was derived
from the Development Agreement and represented the portion of the upfront initial development fee payment eligible for revenue recognition
during the respective periods ended September 30, 2021 and 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling,
general and administrative expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative expenses were $6.3 million for the year ended September 30, 2021, compared to $4.8 million for the year ended
September 30, 2020. The increase of $1.5 million was primarily due to an increase in sales and marketing costs of $0.8 million, payroll
related costs of $0.3 million, board and public company costs of $0.3 million, insurance costs of $0.2 million and outside professional
support and other costs of $0.2 million, offset partially by a reduction in litigation support costs of $0.2 million and stock-based
compensation of $0.1 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and development expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $3.9 million for the year ended September 30, 2021, compared to $2.1 million for the year ended September
30, 2020. The increase during fiscal 2021 over the comparable prior year period was due to an increase in supporting development activities
largely attributed to our Evo sEEG electrode technology, which primarily included salary-related expenses and other costs of consulting
services, materials and supplies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for the year ended September 30, 2021 and 2020 was $3,000 and $7.5 million, respectively. The decrease year over year is attributed
to the full conversion of the 2019 Paulson Notes and 2020 Paulson Notes by early fiscal year 2021. Interest expense during the year ended
September 30, 2021 was $3,000 and consisted of issuance costs in connection with our 2019 Paulson Notes described further below. Interest
expense in fiscal year 2020 related to the 2019 Paulson Notes and 2020 Paulson Notes and was comprised of issuance costs of $1.9 million
and day-one interest at issuance of $5.6 million representing the amount by which fair value exceeded note proceeds. Interest on principal
in connection with the 2019 Paulson Notes and 2020 Paulson Notes is included in the <i>net valuation change of instruments measured at
fair value</i> line item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
valuation change of instruments measured at fair value</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net valuation change of instruments measured at fair value for the years ended September 30, 2021 and 2020 was a benefit of $(2,000)
and $(0.8) million, respectively. The change was due to accrued interest on the 2019 Paulson Notes and 2020 Paulson Notes, while outstanding,
and due to fluctuations in our common stock fair value, the number of potential shares of common stock issuable upon conversion of the
2019 Paulson Notes and 2020 Paulson Notes during the respective periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss
on note extinguishment</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
loss on note extinguishment for the year ended September 30, 2020 was $2.0 million. The 2019 Paulson notes as described further below
were amended on April 24, 2020 to principally add a 40% discount to the optional conversion feature and to extend the maturity date by
six months. The April 2020 amendment was accounted for as a note extinguishment given the significant modification made to the optional
conversion feature. There were no note extinguishments during the year ended September 30, 2021.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income during the year ended September 30, 2021 consisted principally of proceeds received in connection with the PMT Corporation litigation
in the amount of $0.2 million and from the forgiveness of the paycheck protection program loan in the amount of $0.1 million. We did
not have other income during the comparable prior year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Historical
Capital Resources</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, our principal source of liquidity consisted of cash deposits of $6.9 million. Subsequent to September 30, 2021,
we received gross proceeds of $13.4 million in the aggregate from the issuance and sale of common stock in the October 2021 underwritten
public offering described below. While we began to generate revenue from commercial sales during the first quarter of fiscal year 2021
and through milestone payments from our current collaboration with Zimmer, we expect to continue to incur significant expenses and increasing
operating and net losses for the foreseeable future until and unless we generate an adequate level of revenue from commercial sales to
cover expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses will increase substantially as we develop and commercialize our cortical strip, grid electrode and depth
electrode technology and pursue pre-clinical and clinical trials, seek regulatory approvals, manufacture products, establish our own
sales, marketing and distribution infrastructure to commercialize our cortical strip, grid electrode and depth electrode technology,
hire additional staff, add operational, financial and management systems and continue to operate as a public company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
source of cash, outside of collaboration and product revenues, to date has been proceeds from the issuances of notes with warrants, common
stock with and without warrants and unsecured loans, the terms of which are further described below. See also &#8220;&#8212;Funding Requirements
and Outlook&#8221; below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">October
2021 Underwritten Public Offering </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2021, we entered into Underwriting Agreement relating to the issuance and sale of 3,750,000 shares of our common stock at
a price to the public of $3.20 per share. In addition, under the terms of the Underwriting Agreement, we granted the Underwriter an option,
exercisable for 30 days, to purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on
October 15, 2021, and the sale of 422,057 shares of common stock subject to the Underwriter&#8217;s overallotment option closed on November
15, 2021. The gross proceeds from this offering were approximately $13.4 million prior to deducting underwriting discounts and other
offering expenses payable by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">2021
Private Placement</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2021, we entered into a purchase agreement with certain accredited investors, pursuant to which the Company, in a private
placement (the &#8220;2021 Private Placement&#8221;), agreed to issue and sell an aggregate of 4,166,682 shares (the &#8220;Shares&#8221;)
of the common stock of the Company, and warrants to purchase an aggregate of 4,166,682 shares of common stock (the &#8220;2021 Warrants&#8221;)
at an aggregate purchase price of $3.00 per share of common stock and corresponding warrant, resulting in total gross proceeds of $12.5
million before deducting placement agent fees and estimated offering expenses. The 2021 Warrants have an initial exercise price of $5.25
per share. The 2021 Warrants became immediately exercisable beginning on the date of issuance and will expire on the fifth anniversary
of such date. Prior to expiration, subject to the terms and conditions set forth in the 2021 Warrants, the holders of such 2021 Warrants
may exercise the 2021 Warrants for shares of common stock by providing notice to the Company and paying the exercise price per share
for each share so exercised or by utilizing the &#8220;cashless exercise&#8221; feature contained in each 2021 Warrant. The 2021 Private
Placement closed on January 14, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2021 Private Placement, the Company agreed to file a registration statement with the SEC covering the resale of the
Shares, the 2021 Warrants and the shares of common stock issuable upon exercise of the 2021 Warrants. The Company agreed to file such
registration statement within 30 days of the execution of the 2021 Purchase Agreement on January 12, 2021 and filed such registration
statement on February 10, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Other
Common Stock Offerings</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2020, we entered into a Securities Purchase Agreement (&#8220;2020 Purchase Agreement&#8221;) with an accredited investor pursuant
to which we, in a private placement, issued and sold 25,000 shares of the Company&#8217;s common stock for gross proceeds in the amount
of $135,000. Under the 2020 Purchase Agreement, we agreed to use the net proceeds from the private placement for funding operations or
working capital and general corporate purposes. We granted the investor indemnification rights with respect to representations, warranties
and agreements under the 2020 Purchase Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2019, we entered into securities purchase agreements with certain accredited investors, pursuant to which the Company, in
a private placement, issued and sold 47,223 shares of the Company&#8217;s common stock to the accredited investors at a price of $5.40
per share, for gross proceeds amounting to $0.3 million before deducting offering expenses. We filed a registration statement with the
SEC covering the resale of the shares of common stock sold in the private placement on August 11, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">2020
Paulson Convertible Notes</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2020, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in
a private placement (the &#8220;2020 Paulson Private Placement&#8221;), agreed to issue and sell to the investors 13% convertible promissory
notes (each, a &#8220;2020 Paulson Note&#8221; and collectively, the &#8220;2020 Paulson Notes&#8221;) and warrants (each, a &#8220;2020
Paulson Warrant&#8221; and collectively, the &#8220;2020 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
April 30, 2020 and June 30, 2020, the Company issued 2020 Paulson Notes in an aggregate principal amount of $5.1 million to the accredited
investors. The final closing under the 2020 Paulson Private Placement occurred on June 30, 2020. In July 2020, all remaining 2020 Paulson
Notes outstanding were automatically converted into Common Stock following the announcement of a Strategic Transaction (as defined in
the 2020 Paulson Notes) with Zimmer, Inc. The terms of the 2020 Paulson Notes are summarized below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Paulson Notes had interest at a fixed rate of 13% per annum and required the Company to repay the principal and accrued and unpaid
interest thereon on the earlier of (i) December 31, 2020 or (ii) a change of control transaction. If the Company had raised more than
$5,000,000 in an equity financing before the maturity date (the &#8220;2020 Qualified Financing&#8221;), without any action on the part
of the subscribers, all of the outstanding principal and accrued and unpaid interest of the 2020 Paulson Notes (the &#8220;Outstanding
Balance&#8221;) would have been converted into that number of shares of the securities issued by the Company in the closing on the date
a 2020 Qualified Financing occurred equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual
per share price of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume
weighted average price (&#8220;VWAP&#8221;) of the common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as was the case in July 2020, if the Company announced a transaction between the Company and any other company (or an affiliate
of any such company) that was included in the S&amp;P 500 Health Care Index as published from time to time by S&amp;P Dow Jones Indices
LLC that included an investment or upfront payments resulting in gross proceeds to the Company of at least $2,000,000 upon the execution
of such transaction or definitive agreement, and provided for terms of collaboration, manufacturing, distribution, licensing or supply
of the Company&#8217;s products (a &#8220;Strategic Transaction&#8221;) before the maturity date, without any action on the part of the
subscribers, the Outstanding Balance would convert into that number of shares of common stock equal to: (i) the Outstanding Balance divided
by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten (10) trading days immediately preceding the first
announcement of the Strategic Transaction or (B) closing price of the common stock on the day preceding the first announcement by the
Company of a Strategic Transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
any time, at the sole election of the holder of such 2020 Paulson Note prior to a 2020 Qualified Financing, Strategic Transaction or
change of control transaction, all or a portion of the Outstanding Balance could be converted into that number of shares of common stock
equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by the
volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a change of control transaction had occurred prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson
Notes would have become payable on demand as of the closing date of such transaction. Change of control meant a merger or consolidation
with another entity in which the Company&#8217;s stockholders did not own more than 50% of the outstanding voting power of the surviving
entity or the disposition of all or substantially all of the Company&#8217;s assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2020 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii)
the principal amount of such subscriber&#8217;s 2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.
As of the final closing on June 30, 2020, the Company issued 2020 Paulson Warrants exercisable for 456,564 shares of Common Stock in
connection with all closings of the private placement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2020 Paulson Warrants are immediately exercisable and expire on April 30, 2023. The exercise price is subject to adjustment in the event
of any stock dividends or splits, reverse stock split, recapitalization, reorganization, or similar transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2020 Paulson Private Placement, Paulson Investment Company (&#8220;Paulson&#8221;), received a cash commission equal
to 12% of the gross proceeds from the sale of the 2020 Paulson Notes, and at the final closing of the 2020 Paulson Private Placement,
Paulson received 7-year warrants to purchase an amount of Common Stock equal to 136,971 (&#8220;Broker Warrants&#8221;). The Broker Warrants
have an exercise price equal to $5.61.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Paulson Note Conversions</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
May 4, 2020 and July 22, 2020, certain subscribers elected to convert $3,590,353 of the outstanding principal and interest of such subscribers&#8217;
2020 Paulson Notes into 1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance
of the 2020 Paulson Notes in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the
Zimmer Development Agreement that qualified as a Strategic Transaction as discussed above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">2019
Paulson Convertible Notes</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2019, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company,
in a private placement (the &#8220;2019 Paulson Private Placement&#8221;), agreed to issue and sell to the investors 13% convertible
promissory notes (each, a &#8220;2019 Paulson Note&#8221; and collectively, the &#8220;2019 Paulson Notes&#8221;) and warrants (each,
a &#8220;2019 Paulson Warrant&#8221; and collectively, the &#8220;2019 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s
common stock.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial closing of the private placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company
issued 2019 Paulson Notes in an aggregate principal amount of $3,234,800 to the Subscribers for gross proceeds equaling the principal
amount. The private placement terminated on December 3, 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Paulson Notes had a fixed interest rate of 13% per annum and required the Company to repay the principal and accrued and unpaid interest
thereon on May 1, 2020 (the &#8220;Maturity Date&#8221;). If the Company had raised more than $3,000,000 in an equity financing before
the Maturity Date (the &#8220;Qualified Financing&#8221;), each subscriber would have had the option to convert the outstanding principal
and accrued and unpaid interest of such subscriber&#8217;s 2019 Paulson Note (the &#8220;Outstanding Balance&#8221;) into the securities
issued by the Company in such Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6
multiplied by (A) the actual per share price of securities issued by the Company in the Qualified Financing and (B) the ten day volume
weighted average closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction
had occurred prior to the earlier of a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on
demand as of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the
Company&#8217;s stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of
all or substantially all of the Company&#8217;s assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
2019 Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii)
the principal amount of such subscriber&#8217;s 2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.
As of the final closing on December 3, 2019, the Company issued 2019 Paulson Warrants exercisable for 288,305 shares of Common Stock
in connection with all closings of the private placement. The 2019 Paulson Warrants are immediately exercisable and expire on November
1, 2022. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization,
reorganization or similar transaction, as described therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the private placement, Paulson received a cash commission equal to 12% of the gross proceeds from the sale of the 2019
Paulson Notes, and 10-year warrants to purchase an amount of Common Stock equal to 86,498 shares of common stock at an exercise price
equal to $5.61 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Second
Amendment of 2019 Paulson Notes</span></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2020, the Company and holders of a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment
to the 2019 Paulson Notes (the &#8220;Second Paulson Amendment&#8221;) to, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Extended
the Maturity Date</i></b><i> &#8211; </i>The Second Paulson Amendment extended the maturity date of the 2019 Paulson Notes from May 1,
2020 to November 1, 2020 (in either case, unless a change of control transaction happens prior to such date);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revised
Optional Conversion Terms</i></b><i> &#8211; </i>The Second Paulson Amendment provided that the amount of shares to be received upon
the a subscriber&#8217;s optional conversion of the 2019 Paulson Notes prior to a Qualified Financing (as defined in the 2019 Paulson
Notes) would have been equal to: (1) the outstanding balance of such subscriber&#8217;s 2019 Paulson Note elected by the subscriber to
be converted divided by (2) an amount equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10)
trading days immediately preceding the date of conversion; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revised
the Registration Date &#8211;</i></b> The Second Paulson Amendment provided that promptly following the earlier of (1) May 1, 2020, if
the applicable subscriber had converted all or a majority of the outstanding balance of such subscriber&#8217;s 2019 Paulson Note prior
to such date; (2) the final closing a Qualified Financing; and (3) the maturity date, the Company would enter into a registration rights
agreement with the applicable subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and
file with the SEC a registration statement on or prior to the 90th calendar day following the registration date, covering the resale
of any common stock received on conversion of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no other significant changes to terms under the Second Paulson Amendment.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">2019
Paulson Note Conversions</span></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended September 30, 2021 and 2020, the 2019 Paulson Notes were converted into 292,754 and 725,394 shares of common stock, respectively.
All of the 2019 Paulson notes were converted shares of common stock by December 31, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Paycheck
Protection Program Loan</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2020 Coronavirus Aid, Relief, and Economic Security (&#8220;CARES Act&#8221;), the Company received loan funding
of approximately $83,000 under the Paycheck Protection Program (&#8220;PPP&#8221;), which was forgiven by the U.S. Small Business Administration
on June 9, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Funding
Requirements and Outlook</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2021, we had approximately $6.9 million in cash deposits. Subsequent to September 30, 2021, we received gross proceeds
of approximately $13.4 million in the aggregate from the issuance and sale of common stock in the October 2021 underwritten public offering
described below. To date, we have generated limited revenues from commercialization and through milestone payments from our current collaboration
with Zimmer, and we expect to continue to incur significant expenses and increasing operating and net losses for the foreseeable future
until and unless we generate a higher level of revenue from commercial sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has noted the existence of
substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public accounting firm
and our former independent registered public accounting firm included explanatory paragraphs in the reports on our financial
statements as of and for the years ended September 30, 2021 and 2020, respectively, noting the existence of substantial doubt about
our ability to continue as a going concern. Our existing cash may not be sufficient to fund our operating expenses through at least
twelve months from the date of this filing. To continue to fund operations, we will need to secure additional funding through public
or private equity or debt financings, through collaborations or partnerships with other companies or other sources. We may not be
able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital when needed could compromise our
ability to execute on our business plan. If we are unable to raise additional funds, or if our anticipated operating results are not
achieved, we believe planned expenditures may need to be reduced in order to extend the time period that existing resources can fund
our operations. If we are unable to obtain the necessary capital, it may have a material adverse effect on our operations and the
development of our technology, or we may have to cease operations altogether.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a discussion of potential fee payments under
the Zimmer Development Agreement, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;
Financial Overview&#8212;Collaborations Revenue,&#8221; &#8220;Note 7 &#8212; Zimmer Development Agreement&#8221; included in &#8220;Item
8 &#8212; Financial Statements and Supplementary Data&#8221; in this Report and &#8220;Risk Factors&#8212;Risks Related to Our Business&#8212;Zimmer
has exclusive global rights to distribute our strip and grid cortical electrodes and electrode cable assembly products. Zimmer&#8217;s
failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results.
Further, our inability to agree with Zimmer on dates of completion for product development, regulatory clearance and commercialization
milestones on which various fee payments to the Company are based under the Zimmer Development Agreement could have a material adverse
impact on our financial and operating results.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our material cash requirements relate to the funding
of our ongoing product development and commercialization operations and our royalty obligations under our intellectual property licenses
with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) and the Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;).
&#160;See &#8220;Item 1&#8212;Business&#8212;Clinical Development and Regulatory Pathway&#8212;Clinical Experience, Future Development
and Clinical Trial Plans&#8221; in this Report for a discussion of design, development, pre-clinical and clinical activities that we may
conduct in the future, including expected cash expenditures required for some of those activities, to the extent we are able to estimate
such costs. In addition, we have agreements with the WARF Mayo that require us to make certain milestone and royalty payments.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2020, we entered into an Amended and Restated License Agreement (the &#8220;WARF License&#8221;) with WARF, which amended
and restated in full our prior license agreement with WARF, dated October 1, 2014 (the &#8220;Original WARF License&#8221;). Under the
WARF License, we have agreed to pay WARF a royalty equal to a single-digit percentage of our product sales pursuant to the WARF License,
with a minimum annual royalty payment of $50,000 for 2020, $100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter
that the WARF License is in effect. The minimum annual royalty payment for calendar year 2020 in the amount of $50,000 was paid in January
2021. If we or any of our sublicensees contest the validity of any licensed patent, the royalty rate will be doubled during the pendency
of such contest and, if the contested patent is found to be valid and would be infringed by us if not for the WARF License, the royalty
rate will be tripled for the remaining term of the WARF License.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Amended and Restated License and Development Agreement with Mayo (the &#8220;Mayo Development Agreement&#8221;), we have agreed to
pay Mayo a royalty equal to a single-digit percentage of our product sales pursuant to the Mayo Development Agreement. Nothing further
was due until we started selling our products. As of September 30, 2021, $4,000 in royalty payments were earned by Mayo based on the
commencement of commercial sales in fiscal year 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to &#8220;Item 1&#8212;Business&#8212;WARF License&#8221;, &#8220;Item 1&#8212;Business&#8212;Mayo Foundation for Medical Education and
Research License and Development Agreement&#8221;, &#8220;Item 1A&#8212;Risk Factors&#8212;Risks Related to Our Business&#8212;We depend
on intellectual property licensed from WARF for our technology under development, and the termination of this license would harm our
business&#8221; and &#8220;Item 1A&#8212;Risk Factors&#8212;Risks Related to Our Business&#8212;We depend on our partnership with Mayo
to license certain know how for the development and commercialization of our technology&#8221; of this Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of our cortical strip, grid electrode and depth electrode technology is subject to numerous uncertainties,
and we could use our cash resources sooner than we expect. Additionally, the process of developing medical devices is costly, and the
timing of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will
be dependent upon achieving further regulatory approvals and achieving a level of product sales adequate to support our cost structure.
We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash flows for each of the periods set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(8,602,826</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(3,425,302</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67,079</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122,427</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,534,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,323,377</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net increase in cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,864,949</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,775,648</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $8.6 million for the year ended September 30, 2021, which consisted of a net loss of $9.9 million
partially offset primarily by stock-based compensation, depreciation, amortization related to intangible assets, revaluation of convertible
notes, non-cash lease expense and Paycheck Protection Program loan forgiveness, totaling approximately $1.9 million in the aggregate.
The net change in our net operating assets and liabilities associated with fluctuations in our operating activities resulted in a cash
use of approximately $0.5 million. The year on year change in operating assets and liabilities was primarily attributable to a net decrease
in accounts payable and accrued expenses, and by an increase in our prepaid expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3.4 million for the year ended September 30, 2020, which consisted of a net loss of $13.6 million
partially offset primarily by non-cash interest, stock-based compensation, depreciation, amortization related to intangible assets, revaluation
of convertible notes and loss on notes extinguishment, totaling approximately $10.6 million in the aggregate. The net change in our net
operating assets and liabilities associated with fluctuations in our operating activities resulted in a cash use of approximately $0.4
million. The year on year change in operating assets and liabilities was primarily attributable to a decrease in accounts payable and
accrued expenses, largely in connection with the payment of legal expenses, and by an increase in our prepaid expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in investing activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used by investing activities for the year ended September 30, 2021 was $0.1 million and consisted of outlays for research and development
equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used by investing activities for the year ended September 30, 2020 was $0.1 million and consisted of outlays for furniture and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by financing activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $11.5 million for the year ended September 30, 2021, which consisted primarily of net proceeds
received upon the issuance of the 2021 Private Placement in the amount of $11.3 million in the aggregate. There were also exercises of
stock options and warrants during the year ended September 30, 2021 resulting in additional cash proceeds of $0.3 million, offset in
part by deferred offering costs of $49,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $7.3 million for the year ended September 30, 2020, which consisted primarily of net proceeds
received upon the issuance of the 2020 and 2019 Paulson Notes and the common stock offerings totaling $7.2 million in the aggregate,
and $0.1 million in proceeds received from the Paycheck Protection Program.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Critical
Accounting Policies</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue
and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other
assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially
from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes
in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively
from the date of the change in estimate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Report,
we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant
estimates and judgments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product
Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from product sales are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects
the consideration we expect to be entitled to in exchange for those goods or services. At the inception of each contract, performance
obligations are identified and the total transaction price is allocated to the performance obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Product Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of product revenue consists of the manufacturing and materials costs incurred by our third-party contract manufacturer in connection
with our strip and grid cortical electrodes (the &#8220;Strip/Grid Products&#8221;) and outside supplier materials costs in connection
with the Electrode Cable Assembly Products. In addition, cost of product revenue includes royalty fees incurred in connection with our
license agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collaborations
Revenue</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in
Account Standards Codification (&#8220;ASC&#8221;) Topic 606. Performance obligations may include license rights, development services,
and services associated with regulatory submission and approval processes. Significant management judgment is required to determine the
level of effort required under an arrangement and the period over which we expect to complete our performance obligations under the arrangement.
If we cannot reasonably estimate when our performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. We use key assumptions to determine the stand-alone selling price, which
may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of
technical and regulatory success. We allocate the total transaction price to each performance obligation based on the estimated relative
standalone selling prices of the promised goods or service underlying each performance obligation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Licenses
of intellectual property</i>: If the license to our intellectual property is determined to be distinct from the other performance obligations
identified in the arrangement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is
transferred to the customer, and the customer can use and benefit from the license. For licenses that are bundled with other promises,
we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from non-refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure
of performance and related revenue recognition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Milestone
payments</i>: At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered
probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not
considered probable of being achieved until those approvals are received. When our assessment of probability of achievement changes and
variable consideration becomes probable, any additional estimated consideration is allocated to each performance obligation based on
the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recorded
in license, collaboration, and other revenues based upon when the customer obtains control of each element.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalties</i>:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements
on a recurring or nonrecurring basis adhering to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that
prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted
prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving
significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
date.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
for substantially the full term of the asset or liability.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021 and 2020, the fair values of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and
accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. We elected to account
for the convertible notes while they were outstanding on a fair value basis under ASC 825 to comprehensively value and streamline the
accounting for the embedded conversion options. The fair value of these convertible notes were based on both the fair value of our common
stock, discount associated with the embedded redemption features, and cash flow models discounted at current implied market rates evidenced
in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level
3 inputs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Note 3 &#8212; Summary of Significant Accounting Policies&#8221; included in &#8220;Item 8 &#8212;  Financial Statements and
Supplementary Data&#8221; in this Report regarding the impact of certain recent accounting pronouncements on our financial
statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: justify"><a href="#f_001">Report of Independent Registered Public Accounting Firm &#8211; Baker Tilly US, LLP</a></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 9%; text-align: center">77</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#l_001">Report of Independent Registered Public Accounting Firm &#8211; BDO USA, LLP</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">79</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_002">Balance Sheets</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">80</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#f_003">Statements of Operations</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">81</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_004">Statements of Changes in Stockholders&#8217; Equity </a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">82</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><a href="#f_005">Statements of Cash Flows</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">83</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><a href="#f_006">Notes to Financial Statements</a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"> 84 to 107</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Report of Independent
Registered Public Accounting Firm</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the shareholders and the board of directors of NeuroOne Medical
Technologies Corporation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheet of NeuroOne Medical
Technologies Corporation (the "Company") as of September 30, 2021, the related statements of operations, shareholders&#8217;
equity and cash flows, for the year then ended, and the related notes (collectively referred to as the "financial statements").
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September
30, 2021, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally
accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. As discussed in Note 2 of the financial statements, the Company has recurring losses from operations,
an accumulated deficit, expects to incur losses for the foreseeable future and needs additional working capital. These are the reasons
that raise substantial doubt about their ability to continue as a going concern. Management&#8217;s plans in regard to these matters are
also described in Note 2. The financial statements do not contain any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting
firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matter</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The critical audit matter communicated below is a matter arising from
the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that:
(1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective,
or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements,
taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit
matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matter Description</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Classification of warrants issued as permanent equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As described in Note 10 to the financial statements, the Company completed
an equity offering during the year which included the issuance of warrants. Management determined the proper classification of the warrants
by reviewing the terms and conditions of the issued warrants and applying the applicable accounting guidance, including Accounting Standards
Codification (ASC) 480 Distinguishing Liabilities from Equity and ASC 815 Derivatives and Hedging. Management concluded the warrants met
the criteria for the classification as permanent equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounting guidance for determining the proper classification of
warrants is highly complex and subject to interpretation. A slight variation in the terms and conditions of the warrants could result
in the warrants being classified as a liability, which would also impact the statement of operations, as the subsequent accounting for
warrants treated as liabilities is significantly different from those classified as permanent equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to the complexity in the accounting guidance, the need for management
judgment in applying the accounting guidance, and the fact that a slight change in terms can result in significant changes in both the
initial accounting and subsequent accounting for the warrants, we identified the evaluation of the classification of the warrants issued
during the year as a critical audit matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>How We Addressed the Matter in Our Audit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary procedures we performed to address this critical audit
matter included:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">As part of our risk assessment procedures, we evaluated the
design and implementation of the Company&#8217;s controls over the evaluation and application of the relevant accounting guidance to
the specific terms and conditions within the warrant agreements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We obtained the Company&#8217;s accounting analysis for the
equity offering during the year. We compared the terms described in the Company&#8217;s analysis to the terms of the respective agreements
to determine the completeness and accuracy of the analysis performed.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">With the assistance of firm personnel having expertise in
the accounting for complex equity instruments, we performed a detailed examination of the warrant agreement for the equity offering,
with a primary focus on the key terms and conditions regarding the treatment of the warrants upon the occurrence of a fundamental transaction.
As warrant holders can obtain cash from the Company only when a fundamental transaction is deemed to be within the Company&#8217;s control,
we agreed with the conclusion to classify the warrants within permanent equity. We also focused on the subsequent rights offering provision
and its impact within the indexation guidance, noting the provision was appropriately evaluated when applying the indexation guidance.
Therefore, it was determined this would not preclude the Company from classifying the warrants within permanent equity.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We discussed with the Company&#8217;s legal counsel the impact
of these terms and conditions within the warrant agreements to support the Company&#8217;s conclusion.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">/s/
Baker Tilly US, LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Minneapolis, Minnesota</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">December 15, 2021</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="l_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Report of Independent Registered Public Accounting
Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders and Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Eden Prairie, Minnesota</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Opinion on the Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have audited the accompanying
balance sheet of NeuroOne Medical Technologies Corporation (the &#8220;Company&#8221;) as of September 30, 2020, the related statements
of operations, changes in stockholders&#8217; equity (deficit), and cash flows for the year ended September 30, 2020, and the related
notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in
all material respects, the financial position of the Company at September 30, 2020, and the results of its operations and its cash flows
for the year ended September 30, 2020<b>,</b> in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Going Concern Uncertainty</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The accompanying financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the
Company has suffered recurring losses from operations, negative cash flows from operations and an accumulated deficit that raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note
2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">These financial statements are
the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we were required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ BDO USA, LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor from 2016
to 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Minneapolis, Minnesota</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">December 8, 2020</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>




</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,901,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">4,036,397</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">48,336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">98,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid and other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">244,043</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">118,611</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.125in">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">7,292,012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">4,155,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">134,207</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">156,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">288,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">282,211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">223,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">166,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">7,938,496</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">4,759,773</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">528,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">762,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">644,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">512,762</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Convertible promissory notes (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">8,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">73,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">1,181,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">2,355,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Operating lease liability, long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">202,895</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">254,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="0" unitRef="usd">83,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">1,384,595</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">2,693,601</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies (Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September 30, 2021 and 2020; <span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9"><span style="-sec-ix-hidden: hidden-fact-10"><span style="-sec-ix-hidden: hidden-fact-11">no</span></span></span></span> shares issued or outstanding as of September 30, 2021 and 2020.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September 30, 2021 and 2020; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">12,010,019</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">7,393,637</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and 2020, respectively.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">35,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">22,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Additional paid&#8211;in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">47,345,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">32,923,022</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">40,827,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">30,879,031</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,553,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,066,172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">7,938,496</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">4,759,773</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><i>See accompanying notes to financial statements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Product revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">178,146</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of product revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">275,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Product gross loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd">97,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Collaborations revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RevenueFromCollaboration" scale="0" unitRef="usd">64,812</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RevenueFromCollaboration" scale="0" unitRef="usd">1,926,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">6,260,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">4,753,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">3,925,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">2,075,791</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">10,185,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">6,828,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">10,218,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">4,902,261</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" sign="-" unitRef="usd">3,053</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" sign="-" unitRef="usd">7,524,581</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net valuation change of instruments measured at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue" scale="0" unitRef="usd">1,974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue" scale="0" unitRef="usd">804,529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Loss on note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">2,017,847</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">271,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">9,948,168</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,640,160</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:EarningsPerSharesBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.93</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="nmtc:EarningsPerSharesBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">2.52</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Number of shares used in per share calculations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" scale="0" unitRef="shares">10,696,799</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" scale="0" unitRef="shares">5,415,424</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>See accompanying notes to financial statements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Statement of Changes
in Stockholders&#8217; Equity (Deficit)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional<br/> Paid&#8211;In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total<br/> Stockholders&#8217;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Equity</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">4,497,930</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">13,494</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">15,987,799</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">17,238,871</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">1,237,578</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock under securities purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">72,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">389,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">390,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of warrants in connection with convertible notes offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" scale="0" unitRef="usd">696,672</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" scale="0" unitRef="usd">696,672</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Conversion of convertible notes into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">2,598,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">7,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">14,172,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">14,180,470</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance costs in connection with conversion of convertible notes into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" scale="0" sign="-" unitRef="usd">161,881</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" scale="0" sign="-" unitRef="usd">161,881</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">798,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">798,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock for consulting services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">142,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">641,289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">641,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock upon vesting of restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" scale="0" unitRef="shares">57,744</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" scale="0" unitRef="usd">173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" scale="0" unitRef="usd">395,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" scale="0" unitRef="usd">396,012</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodExerciseOfStockOptions" scale="0" unitRef="shares">25,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">2,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">2,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">13,640,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">13,640,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Balance at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">7,393,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">22,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">32,923,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">30,879,031</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,066,172</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock and warrants under securities
    purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" unitRef="shares">4,166,682</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">12,487,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" unitRef="usd">12,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Conversion of convertible notes into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">292,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,004,354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,005,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance costs in connection with securities issuances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacement" scale="0" sign="-" unitRef="usd">1,198,080</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacement" scale="0" sign="-" unitRef="usd">1,198,080</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance cost adjustment related to private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement" scale="0" unitRef="usd">50,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement" scale="0" unitRef="usd">50,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,793,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,793,199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock for consulting services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">74,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" sign="-" unitRef="usd">74</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Issuance of common stock upon vesting of restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" scale="0" unitRef="shares">30,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" scale="0" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" scale="0" sign="-" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodExerciseOfStockOptions" scale="0" unitRef="shares">1,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">10,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">10,146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodSharesStockWarrantsExercised" scale="0" unitRef="shares">51,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="0" unitRef="usd">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="0" unitRef="usd">274,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised" scale="0" unitRef="usd">275,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">9,948,168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">9,948,168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">12,010,019</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">35,834</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">47,345,266</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">40,827,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,553,901</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>See accompanying notes to financial statements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Statements of Cash Flows&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">9,948,168</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">13,640,160</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Amortization and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">80,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd">47,609</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AllocatedShareBasedCompensation" scale="0" unitRef="usd">1,793,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AllocatedShareBasedCompensation" scale="0" unitRef="usd">1,835,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Non-cash interest on convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NoncashInterestOnConvertiblePromissoryNotes" scale="0" unitRef="usd">5,616,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Payroll protection program loan forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:PayrollProtectionProgramLoanForgiveness" scale="0" unitRef="usd">83,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Fair value change of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FairValueChangeOfConvertibleNotes" scale="0" sign="-" unitRef="usd">1,974</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FairValueChangeOfConvertibleNotes" scale="0" sign="-" unitRef="usd">804,529</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Issuance costs attributed to financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsAttributedToFinancingActivities" scale="0" unitRef="usd">3,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsAttributedToFinancingActivities" scale="0" unitRef="usd">1,907,723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">66,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">22,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Loss on notes extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">2,017,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Change in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 27pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">48,336</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 27pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">98,287</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 27pt">Prepaid and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">8,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">77,609</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 27pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">350,313</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">269,601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Accrued expenses, deferred revenue, operating lease and other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" sign="-" unitRef="usd">7,477</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" sign="-" unitRef="usd">82,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">8,602,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">3,425,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">67,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">122,427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">67,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">122,427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -9pt; padding-left: 9pt">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Proceeds from issuance of convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd">8,357,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Proceeds from issuance of common stock in connection with private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" scale="0" unitRef="usd">8,829,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" scale="0" unitRef="usd">390,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Proceeds from issuance of warrants in connection with private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" scale="0" unitRef="usd">3,670,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Issuance costs in connection with convertible promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes" scale="0" unitRef="usd">3,053</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes" scale="0" unitRef="usd">1,125,241</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Issuance costs in connection with private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacements" scale="0" unitRef="usd">1,198,080</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacements" scale="0" unitRef="usd">384,894</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">275,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercise of stock-options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">10,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">2,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Proceeds from paycheck protection program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProceedsFromPaycheckProtectionProgram" scale="0" unitRef="usd">83,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deferred offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:DeferredsOfferingCosts" scale="0" sign="-" unitRef="usd">49,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">11,534,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">7,323,377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">2,864,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">3,775,648</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,036,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">260,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">6,901,346</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">4,036,397</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: justify; text-indent: -9pt; padding-left: 9pt">Supplemental non-cash financing and investing transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConversionOfConvertiblePromissoryNotesToEquity" scale="0" unitRef="usd">1,005,232</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConversionOfConvertiblePromissoryNotesToEquity" scale="0" unitRef="usd">14,180,470</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" scale="0" unitRef="usd">50,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" scale="0" unitRef="usd">95,735</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Non-cash issuance of broker warrants in connection with convertible notes and private placements</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:BrokerWarrantsIssuedInConnectionWithConvertibleNotes" scale="0" unitRef="usd">696,672</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Operating lease right of use asset obtained in exchange for operating lease</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" scale="0" unitRef="usd">73,118</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" scale="0" unitRef="usd">335,119</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Payroll protection program loan forgiveness</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ValueOfPayrollProtectionProgramLoanForgiveness" scale="0" unitRef="usd">83,333</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unpaid deferred offering costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UnpaidDeferredOfferingCosts" scale="0" unitRef="usd">67,954</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Unpaid purchases of property and equipment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UnpaidPurchasesOfPropertyAndEquipment" scale="0" unitRef="usd">48,651</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UnpaidPurchasesOfPropertyAndEquipment" scale="0" unitRef="usd">16,872</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>See accompanying notes to financial statements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - Organization and Nature of Operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>NeuroOne
Medical Technologies Corporation (the &#8220;Company&#8221; or &#8220;NeuroOne&#8221;), a Delaware corporation, is an early-stage medical
technology company developing comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions
to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back
surgeries and other related neurological disorders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_3" id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
received 510(k) clearance from the FDA for its Evo cortical technology in November 2019, and in September 2021 received 510(k) clearance
from the FDA for its Evo sEEG electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation
equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. To date, the Company
has had limited commercial sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_4" id="_NatureOfOperations-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company&#8217;s
common stock commenced trading on The Nasdaq Capital Market on May 26, 2021 under the ticker symbol &#8220;NMTC.&#8221; Previously, the
Company&#8217;s common stock was traded on the OTC Markets quotation system on the OTCQB.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_5" id="_NatureOfOperations-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
is based in Eden Prairie, Minnesota.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_6" id="_NatureOfOperations-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID-19</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_7" id="_NatureOfOperations-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#8220;COVID-19&#8221;) as a global pandemic. As
a result of the COVID-19 pandemic, the Company has experienced, and will likely continue to experience, delays and disruptions in its
pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, shipping, and research and development
operations. In April 2020, given the impact of COVID-19 on the Company and in connection with the enactment of the CARES Act, the Company
applied for and received loan funding of $<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProceedsFromPayrollProtectionProgramLoan" scale="0" unitRef="usd">83,333</ix:nonFraction>&#160;under the Paycheck Protection Program, which was forgiven by the U.S. Small Business
Administration in June 2021. </span>The development of the Company&#8217;s technology was delayed in fiscal year 2021 due to interruptions
in global manufacturing and shipping as a result of the COVID-19 pandemic. Additionally, the Company&#8217;s own staff has been impacted
by infections and mandatory quarantines. Further testing and clinical trials, <span>manufacturing, component
supply, shipping and research and development operations</span> may be further impacted by the continuing effects of COVID-19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_8" id="_NatureOfOperations-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The extent
to which the COVID-19 pandemic may further impact the Company&#8217;s business will depend on future developments, which are highly uncertain
and cannot be predicted with confidence, such as the effect of the pandemic on its suppliers and distributors and the global supply chain,
the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business
disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic
may also impact the Company&#8217;s business because of employee illness, school closures, and other community response measures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_NatureOfOperations-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Although
the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may
have a material adverse effect on the Company&#8217;s results of future operations, financial position, and liquidity for fiscal year
2022 and beyond.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubstantialDoubtAboutGoingConcernTextBlock-c0_cont_1" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 - Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_SubstantialDoubtAboutGoingConcernTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The accompanying
financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses
since inception, negative cash flows from operations, and an accumulated deficit of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CumulativeEarningsDeficit" scale="6" unitRef="usd">40.8</ix:nonFraction> million as of September 30, 2021. To date,
the Company&#8217;s revenues have not been sufficient to cover its full operating costs, and as such, has been dependent on funding operations
through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without
raising additional funds and such actions are not solely within the control of the Company. These factors raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome
of this condition. If the Company is unable to raise additional funds, or the Company&#8217;s anticipated operating results are not achieved,
management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the
Company&#8217;s operations. The Company intends to fund ongoing activities by utilizing its current cash on hand, from product and collaborations
revenue and by raising additional capital through equity or debt financings. If management is unable to obtain the necessary capital,
it may have a material adverse effect on the operations of the Company and the development of its technology, or the Company may have
to cease operations altogether.&#160; There was also substantial doubt about the Company&#8217;s ability to continue as a going concern
for the financial statements as of and for the year ended September 30, 2020.</span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - Summary of Significant Accounting
Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting standards generally accepted in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the Company merged its wholly-owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the
Company&#8217;s wholly-owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company
did not have any remaining entities that required consolidation for financial statement reporting purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segment Information</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise
for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker
in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive
Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure">one</ix:nonFraction> operating segment,
which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording,
monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ReverseStockSplitPolicyTextBlock-c0_cont_1" escape="true" name="nmtc:ReverseStockSplitPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Reverse
Stock Split</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_ReverseStockSplitPolicyTextBlock-c0_cont_2" id="_ReverseStockSplitPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
11, 2021, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved a one-for-three reverse stock split of the Company&#8217;s
issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;) effective end-of-day March 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_ReverseStockSplitPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>All issued
and outstanding common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this
Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of
common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#8217;s equity
incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result
of the Reverse Stock Split was rounded up to the next whole share. The authorized shares and par value of the common stock and preferred
stock were not adjusted as a result of the Reverse Stock Split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes, and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United
States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since
inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2021,
the Company had $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="nmtc:DepositsExcessOfFederallyInsured" scale="6" unitRef="usd">6.7</ix:nonFraction> million of deposits in excess of federally insured amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
entered into a development and distribution agreement which has current and future revenue recognition implications. See &#8220;Note 7
&#8211; Zimmer Development Agreement.&#8221;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Product
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues
from product sales are recognized when control of the promised goods or services is transferred to the Company&#8217;s customers, in an
amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception
of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations.
The Company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Cost
of Product Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of
product revenue consists of the manufacturing and materials costs incurred by the Company&#8217;s third-party contract manufacturer in
connection with the Company&#8217;s strip and grid cortical electrodes (the &#8220;Strip/Grid Products&#8221;) and outside supplier materials
costs in connection with the </span>electrode cable assembly products (&#8220;Electrode Cable Assembly Products&#8221;)<span>.
In addition, cost of product revenue includes royalty fees incurred in connection with the Company&#8217;s license agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Collaborations
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In determining
the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards
Codification (&#8220;ASC&#8221;) Topic 606. Performance obligations may include license rights, development services, and services associated
with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required
under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the
Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As part
of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling
price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities
of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated
relative standalone selling prices of the promised goods or service underlying each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Licenses
of intellectual property</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to
the license when the license is transferred to the customer, and the customer can use and benefit from the license. For licenses that
are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress
each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_12" id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Milestone
payments</i>: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are
considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators,
are not considered probable of being achieved until those approvals are received. When the Company&#8217;s assessment of probability of
achievement changes and variable consideration becomes probable, any additional estimated consideration is allocated to each performance
obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation
and recorded in license, collaboration, and other revenues based upon when the customer obtains control of each element.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Royalties</i>:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur,
or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounting for fair value
measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring
basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active markets
for identical assets or liabilities accessible to the Company at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 2 Inputs: Other than quoted prices included in Level
1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset
or liability.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or liability
used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the fair values
of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values
because of the short-term nature of these assets or liabilities. The fair value of the convertible notes while outstanding were based
on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted
at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for
similar instruments and are based on Level 3 inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between fair value hierarchy
levels during the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no financial instruments measured on
a recurring basis outstanding as of September 30, 2021. The fair value of financial instruments measured on a recurring basis was as follows
as of September 30, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Total liabilities at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward of
the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level 3 inputs for the years ended September 30 as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock" scale="0" sign="-" unitRef="usd">1,005,232</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ChangeInFairValueIncludingAccruedInterest" scale="0" sign="-" unitRef="usd">1,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation id="_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-c0_cont_1"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FairValueAttributedToConvertibleNotesUponIssuance" scale="0" unitRef="usd">13,974,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FairValueAttributedToNoteExtinguishment" scale="0" unitRef="usd">2,017,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock" scale="0" sign="-" unitRef="usd">14,180,470</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ChangeInFairValueIncludingAccruedInterest" scale="0" sign="-" unitRef="usd">804,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" continuedAt="_IntellectualPropertyPolicyTextBlock-c0_cont_1" escape="true" name="nmtc:IntellectualPropertyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Intellectual
Property</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_IntellectualPropertyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has entered into&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="nmtc:NumberOfLicencingAgreements" scale="0" unitRef="pure">two</ix:nonFraction>&#160;licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful
life of the acquired technology.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property
and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful
lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to&#160;<ix:nonNumeric contextRef="c24" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">seven
years</ix:nonNumeric>&#160;and&#160;<ix:nonNumeric contextRef="c25" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"><ix:nonNumeric contextRef="c23" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">three years</ix:nonNumeric></ix:nonNumeric>&#160;for software. Tangible assets acquired for research and development activities and that have alternative
use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate,
changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party
software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and
an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly
to expense as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company evaluates its long-lived
assets, which consist of licensed intellectual property, property and equipment and right of use assets for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability
of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying
value and the fair value of the impaired asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Allowances
for Doubtful Accounts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation id="_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability
of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of
the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances
are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual
write-offs may be in excess of the Company&#8217;s estimated allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventories
are stated at the lower of cost (using the first-in, first-out &#8220;FIFO&#8221; method) or net realizable value. The Company calculates
inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected
useful lives, and estimated future demand of the products and spare parts. The Company&#8217;s inventory is currently comprised of cEEG
strip/grid and electrode cable assembly finished good product. The Strip/Grid Products are produced by a third-party contract manufacturer
and the Electrode Cable Assembly Products are obtained from outside suppliers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Research
and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as
other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather
than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Selling,
General and Administrative</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Selling,
general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters,
and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of cEEG strip/grid
and electrode cable assembly products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the
Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred
tax asset will not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share of common
stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of common stock
is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional
shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s convertible notes, warrants, stock
options and restricted stock units, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible
promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share
because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares were not considered in the computation
of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:Warrantshares" scale="0" unitRef="shares">7,503,808</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:Warrantshares" scale="0" unitRef="shares">3,390,320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:StockOptions" scale="0" unitRef="shares">1,122,560</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:StockOptions" scale="0" unitRef="shares">492,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:RestrictedStockUnit" scale="0" unitRef="shares">11,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:RestrictedStockUnit" scale="0" unitRef="shares">26,698</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Unissued vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:UnissuedVestedRestrictedStockUnits" scale="0" unitRef="shares">1,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:UnissuedVestedRestrictedStockUnits" scale="0" unitRef="shares">2,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ConvertibleNotes" scale="0" unitRef="shares">277,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<i>Financial Instruments &#8211; Credit Losses&#8221;</i>.
The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model which requires the Company to measure all expected
credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued
the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of
the adoption of this ASU on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2018, the FASB issued ASU 2018-13,&#160;<i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement&#160;</i>(ASU 2018-13)<i>.</i>&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Removals: the amount
of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels;
and the valuation processes for Level 3 fair value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Modifications: for investments
in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#8217;s
assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty
in measurement as of the reporting date.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Additions: the changes
in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held
at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair
value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>This guidance
is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop
Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only
the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively
to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or
modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
adopted the new guidance on October 1, 2020 and it did not have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income
taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting
for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption
of this new guidance will have a material impact on the Company&#8217;s financial statements and plans to adopt this guidance on a prospective
basis for the provisions applicable to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2020, FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,
which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This ASU eliminates the
beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition,
this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted
earnings per share computation. The amendments in this ASU are effective for smaller reporting companies as defined by the SEC for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>WARF
License Agreement</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) for
WARF&#8217;s neural probe array and thin film micro electrode technology (the &#8220;WARF Agreement&#8221;). The Company entered into
an Amended and Restated Exclusive Start-up Company License Agreement (the &#8220;WARF License&#8221;) with WARF on January 21, 2020, which
amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1,
2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The WARF
License grants to the Company an exclusive license to </span>make, use and sell, in the United States only, products that employ certain
licensed patents for a neural probe array or thin-film micro electrode array and method. We have agreed to pay WARF a royalty equal to
a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RoyaltyMinimumPaymentsYearOne" scale="0" unitRef="usd">50,000</ix:nonFraction> for 2020,
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RoyaltyMinimumPaymentsYearTwo" scale="0" unitRef="usd">100,000</ix:nonFraction> for 2021 and $<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RoyaltyMinimumPaymentsYearThree" scale="0" unitRef="usd">150,000</ix:nonFraction> for 2022 and each calendar year thereafter that the WARF License is in effect. The minimum annual royalty
payment for calendar year 2020 in the amount of $<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd">50,000</ix:nonFraction> was paid in January 2021. If we or any of our sublicensees contest the validity
of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to
be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF
License.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WARF may terminate the WARF License on 30 days&#8217;
written notice if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our
development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain
bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90 days&#8217; notice if we had failed to have commercial
sales of one or more FDA-approved products under the WARF License by June 30, 2021 or (ii) if, after royalties earned on sales begin to
be paid, such earned royalties cease for more than four calendar quarters. The first commercial sale occurred on December 7, 2020, prior
to the June 30, 2021 deadline.<span>&#160;</span>The WARF License otherwise expires by its terms on the
date that no valid claims on the patents licensed thereunder remain. We expect the latest expiration of a licensed patent to occur in
2030.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Mayo
Agreement</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;) related
to certain intellectual property and development services for thin film micro electrode technology (&#8220;Mayo Agreement&#8221;). If
the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales
of products of the licensed technology through the term of the Mayo Agreement, set to expire&#160;May 25, 2037. As of September 30, 2021,
$<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="0" unitRef="usd">3,894</ix:nonFraction> in royalty fees were incurred given the commencement of commercial sales and were reflected as a component of cost of product revenue
during the year ended September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Legal</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>PMT
Litigation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to litigation
and claims arising in the ordinary course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, the Company was served with
a complaint filed by PMT Corporation (&#8220;PMT&#8221;), the former employer of Mark Christianson, a current Company employee, and Wade
Fredrickson, a now former Company employee. The complaint added the Company, NeuroOne, Inc. and Mr. Christianson to its existing lawsuit
against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. In the lawsuit, PMT claims that Mr. Fredrickson
and Mr. Christianson, by virtue of their work for the Company and their prior work during employment with PMT, breached their non-competition,
non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair
competition, engaged in a civil conspiracy, tortiously interfered with PMT&#8217;s contracts and prospective economic advantage, and breached
a covenant of good faith and fair dealing. The complaint purported to attach Mr. Fredrickson&#8217;s noncompete agreement as Exhibit A.
Against Mr. Fredrickson, PMT also alleged that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations,
misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the
Company and NeuroOne, Inc., PMT alleged that the Company and NeuroOne, Inc. were unjustly enriched and engaged in unfair competition.
PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory
damages, equitable relief, punitive damages, attorneys&#8217; fees, costs and interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the Company
and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal stated that:
the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade
Secrets Act preempts plaintiff&#8217;s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state
a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive
trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.
On January 7, 2019, the judge granted the motion for dismissal with respect to PMT&#8217;s claim for breach of the duty of good faith
and fair dealing, and denied the motion for dismissal with respect to the other claims presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, PMT served the Company, NeuroOne,
Inc. and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious
interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne
Inc. and Christianson. On June 28, 2019, the Company presented evidence indicating that PMT had participated in a fraud on the Court and
sought an Order that PMT had waived the attorney client privilege.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2019, the defendants served PMT with
a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal
of the case and an award of attorneys&#8217; fees. The Company, NeuroOne Inc and Mr. Christianson further moved for summary judgment on
all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process. Following hearings
on the dispositive motions and defendants&#8217; sanctions motion, the district court granted the Company&#8217;s motion for sanctions
on April 29, 2020. Additionally, the district court granted the Company&#8217;s motion for summary judgment in part with respect to the
counts for Christianson&#8217;s breach of non-confidentiality agreement, and denied the Company&#8217;s motion for summary judgment on
all other counts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2020, defendants moved the Court
to amend their counterclaims for abuse of process against PMT to add a claim for punitive damages with respect to its conduct pertaining
to the Fredrickson noncompete. On October 12, 2020 the Court awarded NeuroOne, Inc. $<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="0" unitRef="usd">185,000</ix:nonFraction>&#160;in Rule 11 sanctions and Fredrickson
$<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="0" unitRef="usd">145,000</ix:nonFraction>&#160;in Rule 11 sanctions with respect to PMT&#8217;s misconduct relating to the Fredrickson noncompete. PMT and its former litigation
counsel, Barnes &amp; Thornburg, were jointly and severally liable for these awards, which were paid on December 11, 2020 and have been
recognized in other income in the statements of operations. The Court granted NeuroOne, Inc.&#8217;s motion to amend to permit its assertion
of the right to assert a punitive damages claim against PMT associated with fighting the allegations relating to the Fredrickson noncompete.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2021 PMT moved for summary judgment
on defendants&#8217; claims for abuse of process and punitive damages, and on August 5, 2021, the district court granted PMT&#8217;s motion
to dismiss the abuse of process and punitive damage claims.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Trial has been postponed from December 2021 to August of 2022. The
Company intends to continue to defend itself vigorously and to continue to aggressively prosecute its affirmative counterclaim against
PMT. The outcome of any claim against the Company by PMT was not estimable as of the issuance of these financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Facility Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Headquarters Lease</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="nmtc:LeaseAgreementDescription"><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2019, the Company entered into a
non-cancellable lease agreement (the &#8220;Lease&#8221;) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together,
the &#8220;Landlord&#8221;) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie,
Minnesota (the &#8220;Premises&#8221;). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending
65 months after such date, unless terminated earlier (the &#8220;Term&#8221;). The initial base rent for the Premises is $6,410 per month
for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default
under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will
pay its pro rata share of the Landlord&#8217;s annual operating expenses associated with the premises, calculated as set forth in the
Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Los Gatos Lease</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 1, 2021, the Company entered into a non-cancellable
facility lease (the &#8220;New Lease&#8221;), pursuant to which the Company agreed to rent office space for its research and development
operations located at 718 University Avenue, Suite #111, Los Gatos, California. The term of the New Lease is eighteen months. The facility
space under the New Lease is approximately <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseSpace" scale="0" unitRef="sqm">1,162</ix:nonFraction> square feet. The Company took possession of the office space on July 2, 2021. The initial
monthly rent under the New Lease is approximately $<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseRentalExpense" scale="0" unitRef="usd">4,241</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">San Jose Lease</span>:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2020, the Company entered into
a non-cancellable lease agreement for short term office space in San Jose, California (the &#8220;San Jose Lease&#8221;) for a three month
initial term. After March 31, 2021, the San Jose Lease was cancellable upon a 30-day notice to the landlord. The Company took possession
of the office space on January 1, 2021 and the San Jose Lease was terminated upon the commencement of the New Lease discussed above. The
base rent under the San Jose Lease was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:MonthlyLeaseRent" scale="0" unitRef="usd">504</ix:nonFraction> per month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, rent expense associated with the facility leases amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RentExpense" scale="0" unitRef="usd">136,826</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RentExpense" scale="0" unitRef="usd">103,189</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information related to
the operating lease was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" escape="true" name="nmtc:SupplementalCashFlowTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Year Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingCashFlowsFromOperatingLeases" scale="0" unitRef="usd">70,897</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingCashFlowsFromOperatingLeases" scale="0" unitRef="usd">38,462</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingLeases" scale="0" unitRef="usd">73,118</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OperatingLeases" scale="0" unitRef="usd">335,119</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental balance sheet information related
to the operating lease was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_29" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" escape="true" name="nmtc:SupplementalBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">288,948</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">282,211</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseLiability" scale="0" unitRef="usd">315,673</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseLiability" scale="0" unitRef="usd">312,176</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average remaining lease term (years)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.1</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.5</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average discount rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">6.7</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">7.0</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_30" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maturity of the lease liability was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Calendar Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: 0pt; padding-left: 0pt">2021 (period from October 1, 2021 to December 31, 2021)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LesseeOperatingLeaseLiabilityPaymentsDueOneYear" scale="0" unitRef="usd">32,435</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" scale="0" unitRef="usd">131,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" scale="0" unitRef="usd">82,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFourYear" scale="0" unitRef="usd">84,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" scale="0" unitRef="usd">21,227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">351,606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ImputedInterest" scale="0" sign="-" unitRef="usd">35,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseLiabilityNet" scale="0" unitRef="usd">315,673</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in">Short-term portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCommitmentAmount" scale="0" unitRef="usd">112,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Long-term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd">202,895</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_1" escape="true" name="nmtc:SupplementalBalanceSheetInformationTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span style="font-family: Times New Roman, Times, Serif">Supplemental
Balance Sheet Information</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_2" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid and Other Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_3" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid and other assets consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_4" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="pf0:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:PrepaidExpenses" scale="0" unitRef="usd">151,109</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:PrepaidExpenses" scale="0" unitRef="usd">118,010</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">92,934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd">601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">244,043</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">118,611</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_5" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intangibles</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_6" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets roll forward is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_7" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Useful Life</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c36" format="ixt-sec:duryear" name="nmtc:NetIntangiblesUsefulLives">12</ix:nonNumeric>-<ix:nonNumeric contextRef="c37" format="ixt-sec:duryear" name="nmtc:NetIntangiblesUsefulLives">13</ix:nonNumeric> years</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">178,838</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">22,315</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">156,523</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">22,316</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">134,207</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_8" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company anticipates amortization expense of
approximately $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="0" unitRef="usd">21,000</ix:nonFraction> per year for fiscal year 2022 through 2026 based upon the two current license agreements.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_9" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_10" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment held for use by category
are presented in the following table:</p></ix:continuation><div>

</div><ix:continuation continuedAt="_SupplementalBalanceSheetInformationTextBlock-c0_cont_11" id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Equipment and furniture</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="0" unitRef="usd">311,486</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FurnitureAndFixturesGross" scale="0" unitRef="usd">195,756</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="0" unitRef="usd">1,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedComputerSoftwareGross" scale="0" unitRef="usd">1,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">313,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">197,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LessAccumulatedDepreciations" scale="0" sign="-" unitRef="usd">90,052</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LessAccumulatedDepreciations" scale="0" sign="-" unitRef="usd">31,620</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">223,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">166,031</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SupplementalBalanceSheetInformationTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">58,432</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">25,294</ix:nonFraction> for
the years ended September 30, 2021 and 2020, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 - Accrued Expenses and Other Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following at
September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_3" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued payroll</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AccruedPayroll" scale="0" unitRef="usd">376,236</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AccruedPayroll" scale="0" unitRef="usd">238,212</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating lease liability, short term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseLiabilityShortterms" scale="0" unitRef="usd">112,778</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LeaseLiabilityShortterms" scale="0" unitRef="usd">57,848</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">50,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Royalty Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:RoyaltyPayments" scale="0" unitRef="usd">72,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">83,152</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">166,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">644,249</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">512,762</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_4" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &#8220;other&#8221; category is primarily
comprised of board fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_5" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paycheck Protection Program</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CARES Act, signed into law in March 2020,
established the Paycheck Protection Program (&#8220;PPP&#8221;).&#160;<ix:nonNumeric contextRef="c0" name="nmtc:PaycheckProtectionProgramDescription">The PPP authorizes over $600 billion in forgivable loans to small
businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility
costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments
may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term
liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the
accompanying statements of operations. Interest was nominal during the years ended September 30, 2021 and 2020.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_1" escape="true" name="nmtc:ZimmerDevelopmentAgreementTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; Zimmer Development Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_2" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July
20, 2020, the Company entered into an exclusive development and distribution agreement (the &#8220;Development Agreement&#8221;) with
Zimmer, Inc. (&#8220;Zimmer&#8221;), pursuant to which the Company granted Zimmer exclusive global rights to distribute the Strip/Grid
Products and electrode cable assembly products (the &#8220;Electrode Cable Assembly Products&#8221;). Additionally, the Company granted
Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company (&#8220;SEEG Products&#8221;, and
together with the Strip/Grid Products and Electrode Cable Assembly Products, the &#8220;Products&#8221;). The parties have agreed to collaborate
with respect to development activities under the Development Agreement through a joint development committee composed of an equal number
of representatives of Zimmer and the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_3" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Under the
terms of the Development Agreement, the Company is responsible for all costs and expenses related to developing the Products, and Zimmer
is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Development Agreement,
Zimmer and the Company have entered into a Manufacturing and Supply Agreement (the &#8220;MS Agreement&#8221;) and a supplier quality
agreement (the &#8220;Quality Agreement&#8221;) with respect to the manufacturing and supply of the Products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_4" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Except as
otherwise provided in the Development Agreement, the Company is responsible for performing all development activities, including non-clinical
and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts
to promote, market and sell each Product following the &#8220;Product Availability Date&#8221; (as defined in the Development Agreement)
for such Product.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_5" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant
to the Development Agreement, Zimmer made an upfront initial exclusivity fee payment of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="nmtc:IntialFeePayment" scale="6" unitRef="usd">2.0</ix:nonFraction>&#160;million (the &#8220;Initial Exclusivity
Fee&#8221;) to the Company. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_6" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Except where
Zimmer timely delivers a Design Modification Notice pursuant to Section 1.2, if one or more of the events set forth below occurs on or
before the deadline indicated for such event and the Product Availability Date (as defined in the Development Agreement) for the SEEG
Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the
SEEG Exclusivity Maintenance Fee:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_7" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Design
freeze for the SEEG Products by December 15, 2020 - $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">500,000</ix:nonFraction></span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_8" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan (as defined in the Development Agreement) by April 30, 2021 - $<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">500,000</ix:nonFraction></span></td>
</tr></table><p style="text-align: justify; margin: 0">&#160;</p></ix:continuation><div>



</div><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_9" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_8"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif; ">If Zimmer timely delivers a Design Modification Notice to the Company under the Development Agreement, and one or more of the events set forth below occurs on or before the deadline indicated for such event and the Product Availability Date for the SEEG Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the SEEG Exclusivity Maintenance Fee:</span></p><p style="text-align: justify; margin: 0">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_10" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan other than the Modified Connector by April 30, 2021 - $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">500,000</ix:nonFraction></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif; ">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_11" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan, including the Modified Connector by September 30, 2021 - $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">500,000</ix:nonFraction></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_12" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For purposes
of the Development Agreement, each of the foregoing events shall have occurred only if the Company has demonstrated the achievement of
the event to Zimmer&#8217;s reasonable satisfaction. Notwithstanding the foregoing, the events in Sections 6.1(c)(ii), (iii) and (iv)
of the Development Agreement shall not be deemed to be met if FDA Approval for the SEEG Products is not received prior to the applicable
deadline. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_13" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maintain the exclusivity of the SEEG
Distribution License, Zimmer must pay the SEEG Exclusivity Maintenance Fee to the Company, on or prior to the SEEG Exclusivity Confirmation
Date, in immediately available funds as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_14" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
on or before June 30, 2021, then $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">3,000,000</ix:nonFraction>, plus the amount of any Interim Fee Bonuses earned pursuant to Section 6.1(c), including
any such Interim Fee Bonus earned after June 30, 2021 pursuant to Section 6.1(c)(iv) following the delivery of a Design Modification
Notice;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_15" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after June 30, 2021, but on or before September 30, 2021, then $<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">3,000,000</ix:nonFraction>, plus if Zimmer timely issues a Design A-9 Modification Notice,
any Interim Fee Bonus earned pursuant to Section 6.1(c)(iv);</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_16" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after September 30, 2021, but on or before December 31, 2021, then $<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">2,500,000</ix:nonFraction>; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_17" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after December 31, 2021, then $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FuturePotentialMilestonePaymentsToNeuroone" scale="0" unitRef="usd">1,500,000</ix:nonFraction>.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_18" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Product Availability Date for the SEEG Products
has not yet occurred. <span>Notwithstanding any other provision of the Development Agreement, if the Product
Availability Date for the SEEG Products has not occurred on or before June 30, 2022, Zimmer shall have the right to terminate the SEEG
Distribution License by delivering written notice to the Company to that effect and, upon delivery of such notice, Zimmer shall be relieved
of all of its obligations hereunder with respect to SEEG Products, including any obligation to pay the SEEG Exclusivity Maintenance Fee
or to purchase, market, distribute or sell any SEEG Products. The Initial Exclusivity Fee and the SEEG Exclusivity Maintenance Fee (including
any Interim Fee Bonus(es)), once paid, are non-refundable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_19" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Development
Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last of the Products to achieve a first
commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Development Agreement (x) with written
notice for the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency
proceedings. In addition, Zimmer may terminate the Development Agreement for any reason with 90 days&#8217; written notice, and the Company
may terminate the Development Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors
of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_20" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At inception
of the Zimmer Development Agreement through September 30, 2021, the Company had identified the following three performance obligations
under the Zimmer Development Agreement: (1) the Company obligation to license Zimmer rights to certain of its intellectual property; (2)
complete SEEG Product development; and (3) complete Strip/Grid Product development. Accordingly, the Company recognized revenue in the
amount of $<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProductRevenueRecognized" scale="0" unitRef="usd">64,812</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ProductRevenueRecognized" scale="0" unitRef="usd">1,926,566</ix:nonFraction>&#160;during the years ended September 30, 2021 and 2020, respectively, related to the development
of the Products completed during the periods in connection with the Initial Exclusivity Fee payment. The Zimmer Development Agreement
was accounted for under the provisions of ASC 606,&#160;<i>Revenue from Contracts with Customers.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_21" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the closing balance of deferred
revenue related to the Zimmer Development Agreement is as follows as of September 30, 2021 and 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_22" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Deferred Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Balance as of&#160;&#160;September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Upfront initial exclusivity payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:UpfrontInitialExclusivityPayments" scale="0" unitRef="usd">2,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd">1,926,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of&#160;&#160;September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">73,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="0" unitRef="usd">64,812</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">8,622</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_23" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining performance obligations reflected
in deferred revenue as of September 30, 2021 are expected to be completed in first half of fiscal year 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_24" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_25" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, the Company commenced commercial
sales of its Strip/Grid Products and Electrode Cable Assembly Products in connection with the Development Agreement. Product revenue recognized
during the year ended September 30, 2021 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">178,146</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ZimmerDevelopmentAgreementTextBlock-c0_cont_26" id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advertising Expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ZimmerDevelopmentAgreementTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expense is charged to selling, general
and administrative expenses during the period that it is incurred. Total advertising expense amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">338,837</ix:nonFraction> for the year ended September
30, 2021. Advertising expense during the prior year period was negligible.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - Convertible Promissory Notes and Warrant
Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Paulson convertible notes, principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConvertibleNotesOutstandingPrincipal" scale="0" unitRef="usd">546,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" scale="0" unitRef="usd">63,458</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Fair value adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" scale="0" unitRef="usd">397,748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConvertiblePromissoryNotesPayable" scale="0" unitRef="usd">1,007,206</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paulson Convertible Note Offerings</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2019 Paulson Convertible Note Offering</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2019, the Company entered into
a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#8220;2019 Paulson
Private Placement&#8221;), agreed to issue and sell to the investors <ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">13</ix:nonFraction>% convertible promissory notes (each, a &#8220;2019 Paulson Note&#8221;
and collectively, the &#8220;2019 Paulson Notes&#8221;) and warrants (each, a &#8220;2019 Paulson Warrant&#8221; and collectively, the
&#8220;2019 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the 2019 Paulson Private
Placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued the 2019 Paulson Notes
in an aggregate principal amount of $<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">3,234,800</ix:nonFraction> to the subscribers for gross proceeds equaling the principal amount. The 2019 Paulson Private
Placement terminated on December 3, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2019 Paulson Notes had a fixed interest rate
of <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">13</ix:nonFraction>% per annum and required the Company to repay the principal and accrued and unpaid interest thereon on November 1, 2020 (the &#8220;Maturity
Date&#8221;). Interest on principal amounted to $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="nmtc:InterestOnPrincipalAmount" scale="0" unitRef="usd">5,701</ix:nonFraction> and $<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="nmtc:InterestOnPrincipalAmount" scale="0" unitRef="usd">213,383</ix:nonFraction> during the years ended September 30, 2021 and 2020, respectively,
and was recorded under the net valuation change of instruments measured at fair value in the statements of operations. The subscriber,
prior to the Second 2019 Paulson Notes Amendment, had the option to convert the outstanding principal and accrued and unpaid interest
of such subscriber&#8217;s 2019 Paulson Note (the &#8220;Outstanding Balance&#8221;) into common stock in an amount equal to the Outstanding
Balance divided by the ten day volume weighted average closing price of the common stock prior to conversion. In addition, both before
and after the Second 2019 Paulson Note Amendment, if the Company raised more than $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="nmtc:EquityFinancingAmount" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in an equity financing (the &#8220;Qualified
Financing&#8221;) before the Maturity Date, each subscriber had the option to convert the Outstanding Balance into the securities issued
by the Company in such Qualified Financing in an amount equal to <ix:nonNumeric contextRef="c53" name="nmtc:EquityQualifiedFinancingDescriptiononConvertibleNoteOffering">(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied
by (A) the actual per share price of securities issued by the Company in the Qualified Financing or (B) the ten day volume weighted average
closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction had occurred
prior to a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on demand as of the closing date
of such transaction.</ix:nonNumeric> Change of control meant a merger or consolidation with another entity in which the Company&#8217;s stockholders did
not own more than <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="nmtc:OutstandingVotingPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#8217;s
assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elected to account for the 2019 Paulson
Notes on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options.
The fair value of the 2019 Paulson Notes was significantly higher than the proceeds received as of each of the respective issuance dates
given the significant redemption discount associated with the Qualified Financing provision. The excess of fair value over proceeds at
issuance amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfFairValueAmount" scale="0" unitRef="usd">1,831,940</ix:nonFraction> and was recorded to interest expense in the statements of operations during the year ended September 30,
2020. Subsequent to issuance, the fair value change of the 2019 Paulson Notes amounted to a benefit of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ChangesOfFairValueBenefit" scale="0" unitRef="usd">1,974</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ChangesOfFairValueBenefit" scale="0" unitRef="usd">1,221,480</ix:nonFraction> during the
years ended September 30, 2021 and 2020, respectively, and was recorded under the net valuation change of instruments measured at fair
value in the statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c54" name="nmtc:WarrantsDescription">Each 2019 Paulson Warrant granted the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.</ix:nonNumeric> As of the final closing on December 3, 2019, the
Company issued 2019 Paulson Warrants exercisable for <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="nmtc:WarrantsExercisableForSharesOfCommonStockConnection" scale="0" unitRef="shares">288,305</ix:nonFraction> shares of common stock in connection with all closings of the 2019 Paulson
Private Placement. The 2019 Paulson Warrants are immediately exercisable and expire on <ix:nonNumeric contextRef="c54" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">November 1, 2022</ix:nonNumeric>. The exercise price is subject
to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction,
as described therein. The 2019 Paulson warrants were deemed to be a free-standing instrument and were accounted for as equity. Given that
the fair value of the 2019 Paulson Notes exceeded the proceeds received at issuance, there was no value attributed to the 2019 Paulson
Warrants in the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" continuedAt="_IssuanceCostsDescription-c0_cont_1" name="nmtc:IssuanceCostsDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2019 Private Placement,
Paulson Investment Company, LLC (&#8220;Paulson&#8221;) received a cash commission equal to 12% of the gross proceeds from the sale of
the 2019 Paulson Notes, and 10-year warrants to purchase an amount of common stock equal to 86,498 shares of common stock at an exercise
price equal to $5.61 per share (the &#8220;Broker Warrants&#8221;). The issuance costs incurred during the year ended September 30, 2021
and 2020 in connection with the 2019 Paulson Private Placement were $3,053 and $865,567, respectively. Issuance costs in 2021 related
to legal costs. Issuance costs in 2020 included cash commissions equal to $388,176 and legal and third-party fees in the amount of $57,756.
In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_2" id="_IssuanceCostsDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2020, the Company and holders of
a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the &#8220;Second
2019 Paulson Notes Amendment&#8221;) to, among other things:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_3" id="_IssuanceCostsDescription-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">i.</td><td style="text-align: justify"><ix:nonNumeric contextRef="c56" name="nmtc:ExtendedMaturityDateDescription"><b><i>Extended the Maturity Date</i></b><i> &#8211; </i>The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);</ix:nonNumeric></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_4" id="_IssuanceCostsDescription-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">ii.</td><td style="text-align: justify"><ix:nonNumeric contextRef="c56" name="nmtc:RevisedOptionalConversionTermsDescription"><b><i>Revised Optional Conversion Terms</i></b><i> &#8211;
</i>The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#8217;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#8217;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and</ix:nonNumeric></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_5" id="_IssuanceCostsDescription-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">iii.</td><td style="text-align: justify"><ix:nonNumeric contextRef="c56" name="nmtc:ReviseTheRegistrationDateDescription"><b><i>Revised the Registration Date &#8211;</i></b> The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#8217;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.</ix:nonNumeric></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_6" id="_IssuanceCostsDescription-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Second 2019 Paulson Notes Amendment was accounted
for as a note extinguishment for accounting purposes given the substantive change in the optional redemption feature&#8217;s conversion
formula. The fair value change in the 2019 Paulson Notes associated with the extinguishment was recorded as a loss on notes extinguishment
in the accompanying statements of operations in the amount of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">2,017,847</ix:nonFraction> during the year ended September 30, 2020. Lastly, in connection
with the Second 2019 Paulson Notes Amendment, legal costs in the amount of $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd">1,943</ix:nonFraction> were incurred and recorded as a component of interest
in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_16" id="_DebtDisclosureTextBlock-c0_cont_15"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_7" id="_IssuanceCostsDescription-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, the 2019 Paulson Notes were converted into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConvertedNotesCommonStock" scale="0" unitRef="shares">292,754</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ConvertedNotesCommonStock" scale="0" unitRef="shares">725,394</ix:nonFraction> shares of common stock, respectively. All of the 2019 Paulson notes
were converted into shares of common stock by December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_17" id="_DebtDisclosureTextBlock-c0_cont_16"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_8" id="_IssuanceCostsDescription-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paulson 2020 Convertible Note Financing&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_18" id="_DebtDisclosureTextBlock-c0_cont_17"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_9" id="_IssuanceCostsDescription-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2020, the Company entered into a
subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#8220;2020 Paulson
Private Placement&#8221;), agreed to issue and sell to the investors <ix:nonNumeric contextRef="c58" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">13%</ix:nonNumeric> convertible promissory notes (each, a &#8220;2020 Paulson Note&#8221;
and collectively, the &#8220;2020 Paulson Notes&#8221;) and warrants (each, a &#8220;2020 Paulson Warrant&#8221; and collectively, the
&#8220;2020 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_19" id="_DebtDisclosureTextBlock-c0_cont_18"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_10" id="_IssuanceCostsDescription-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between May 1, 2020 and June 30, 2020, the Company
issued 2020 Paulson Notes in an aggregate principal amount of $<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="nmtc:aggregatePrincipalAmount" scale="0" unitRef="usd">5,122,700</ix:nonFraction> to the Subscribers. The 2020 Paulson Private Placement was terminated
on June 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_20" id="_DebtDisclosureTextBlock-c0_cont_19"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_11" id="_IssuanceCostsDescription-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Paulson Notes had a fixed interest rate
of <ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">13</ix:nonFraction>% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of December 31,
2020 or a change of control transaction. Interest on principal amounted to $<ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NoncashInterest" scale="0" unitRef="usd">81,613</ix:nonFraction> during the year ended September 30, 2020 and was recorded
under the net valuation change of instruments measured at fair value in the statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_21" id="_DebtDisclosureTextBlock-c0_cont_20"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_12" id="_IssuanceCostsDescription-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company had raised more than $5,000,000
in an equity financing before the maturity date (the &#8220;2020 Qualified Financing&#8221;), without any action on the part of the Subscribers,
all of the outstanding principal and accrued and unpaid interest of the Notes (the &#8220;Outstanding Balance&#8221;) would have been
converted into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred
equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities
issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume weighted average price of the
common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_22" id="_DebtDisclosureTextBlock-c0_cont_21"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_13" id="_IssuanceCostsDescription-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company had announced a transaction between
the Company and any other company (or an affiliate of any such company) that was included in the S&amp;P 500 Health Care Index as published
from time to time by S&amp;P Dow Jones Indices LLC that included an investment or upfront payments resulting in gross proceeds to the
Company of at least $<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="nmtc:GrossProceeds" scale="0" unitRef="usd">2,000,000</ix:nonFraction> upon the execution of such transaction or definitive agreement, and provides for terms of collaboration,
manufacturing, distribution, licensing or supply of the Company&#8217;s products (a &#8220;Strategic Transaction&#8221;) before the maturity
date, without any action on the part of the subscribers, the Outstanding Balance would be converted into that number of shares of common
stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten
(10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on
the day preceding the first announcement by the Company of a Strategic Transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_23" id="_DebtDisclosureTextBlock-c0_cont_22"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_14" id="_IssuanceCostsDescription-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time, at the sole election of the holder
of such 2020 Paulson Note, all or a portion of the Outstanding Balance could have been converted into that number of shares of common
stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by
the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_24" id="_DebtDisclosureTextBlock-c0_cont_23"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_15" id="_IssuanceCostsDescription-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a change of control transaction had occurred
prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would have become payable on demand as
of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#8217;s
stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially
all of the Company&#8217;s assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_25" id="_DebtDisclosureTextBlock-c0_cont_24"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_16" id="_IssuanceCostsDescription-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elected to account for the 2020 Paulson
Notes on a fair value basis under ASC 825&#160;<span>to comprehensively value and streamline the accounting
for the embedded conversion options</span>. The fair value of the 2020 Paulson Notes was significantly higher than the proceeds received
as of each of the respective issuance dates given the significant redemption discount associated with the redemption provisions. The excess
of fair value over proceeds at issuance amounted to $<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="nmtc:InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" scale="0" unitRef="usd">3,784,918</ix:nonFraction> and was recorded to interest expense in the statements of operations during
the year ended September 30, 2020. Subsequent to issuance, the fair value change of the 2020 Paulson Notes amounted to an expense of $<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IncreaseDecreaseInFairValue" scale="0" unitRef="usd">416,951</ix:nonFraction>
during the year ended September 30, 2020 and was recorded under the net valuation change of instruments measured at fair value in the
statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_26" id="_DebtDisclosureTextBlock-c0_cont_25"><ix:continuation continuedAt="_IssuanceCostsDescription-c0_cont_17" id="_IssuanceCostsDescription-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each 2020 Paulson Warrant grants the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">5.61</ix:nonFraction>. The 2020 Paulson Warrants are immediately exercisable
and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock
split, recapitalization, reorganization or similar transaction. The Company issued 2020 Paulson Warrants exercisable for <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="nmtc:WarrantsToPurchaseOfCommonStockShares" scale="0" unitRef="shares">456,564</ix:nonFraction> shares
of common stock in connection with all closings of the 2020 Paulson Private Placement through June 30, 2020. The 2020 Paulson warrants
were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2020 Paulson Notes exceeded
the proceeds received at issuance, there was no value attributed to the 2020 Paulson Warrants in the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_27" id="_DebtDisclosureTextBlock-c0_cont_26"><ix:continuation id="_IssuanceCostsDescription-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2020 Paulson Private Placement,&#160;Paulson&#160;received
a cash commission equal to <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="nmtc:CashCommissionPercentageRateOnProceeds" scale="-2" unitRef="pure">12</ix:nonFraction>% of the gross proceeds from the sale of the 2020 Paulson Notes and received <ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">7</ix:nonNumeric>-year warrants to purchase
an amount of common stock equal to <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="nmtc:WarrantsToPurchaseOfCommonStockShares" scale="0" unitRef="shares">136,971</ix:nonFraction> (&#8220;Broker Warrants&#8221;). The Broker Warrants have an exercise price equal to $<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">5.61</ix:nonFraction>
per share. The issuance costs incurred during the year ended September 30, 2020 in connection with the 2020 Paulson Private Placement
were $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceOfCostsIncurred" scale="0" unitRef="usd">1,040,213</ix:nonFraction>. Issuance costs included cash commissions equal to $<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="nmtc:CashCommissions" scale="0" unitRef="usd">614,725</ix:nonFraction> and legal and third-party fees in the amount of $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="nmtc:LegalAndThirdPartyFee" scale="0" unitRef="usd">148,451</ix:nonFraction>.
In addition, issuance costs included the value of the Broker Warrants in the amount of $<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="nmtc:IssuanceCosts" scale="0" unitRef="usd">277,037</ix:nonFraction>. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c73" name="nmtc:ConvertibleNoteFinancingDescription"><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between May 4, 2020 and July 22, 2020, certain
Subscribers elected to convert $3,590,353 of the outstanding principal and interest of such Subscribers&#8217; 2020 Paulson Notes into
1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance of the 2020 Paulson Notes
in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the Zimmer Development Agreement
that qualified as a Strategic Transaction.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 - Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, stock-based expense related to the stock options, restricted stock units and stock awards was included in selling, general and administrative
and research and development costs as follows in the accompanying statements of operations:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Selling, general and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,550,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,623,629</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">242,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">212,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total stock-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,793,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">1,835,970</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s 2016 and 2017 Equity Incentive
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company
initially reserved <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">764,089</ix:nonFraction> shares of common stock for issuance under the 2016 and 2017 Equity Incentive Plans on a combined basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Evergreen provision</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2017 Plan, <ix:nonNumeric contextRef="c75" name="nmtc:SharesReservedDescription">the shares reserved automatically
increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders
of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted
shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January
1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the
share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence.
&#8220;Fully Diluted Shares&#8221; as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii)
issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants
or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common
stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2021 and 2020,
484,622 and 428,930 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision.</ix:nonNumeric><span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">703,117</ix:nonFraction> and <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">334,731</ix:nonFraction> stock options were granted to employees, directors and consultants, respectively, with a weighted average grant
date fair value of $<ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">3.01</ix:nonFraction> and $<ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">3.03</ix:nonFraction> per share, respectively. The options granted have vesting periods ranging from being immediate to <ix:nonNumeric contextRef="c76" format="ixt-sec:durwordsen" name="nmtc:StockOptionVestedOverAPeriodTerm">four
years</ix:nonNumeric>. All options expire <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="nmtc:StockOptionVestedOverAPeriodTerm">ten years</ix:nonNumeric> from the date of grant. The total expense for the years ended September 30, 2021 and 2020 related
to the stock options was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:TotalExpenseOfStockOption" scale="0" unitRef="usd">983,301</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:TotalExpenseOfStockOption" scale="0" unitRef="usd">798,242</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the Company&#8217;s
stock option plan activity for the years ended September 30, 2021 and 2020 as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">281,956</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.46</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c95" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.0</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">343,406</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">334,731</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">25,515</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">98,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.91</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">492,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.8</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" scale="0" unitRef="usd">96,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">703,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">1,538</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">71,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,122,560</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.89</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.8</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" scale="0" unitRef="usd">127,339</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">481,047</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.89</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">8.2</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" unitRef="usd">311,388</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The aggregate intrinsic value is
calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September
30, 2021 and 2020 of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePriceOfUnderlyingOptions" scale="0" unitRef="usdPershares">3.95</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePriceOfUnderlyingOptions" scale="0" unitRef="usdPershares">3.86</ix:nonFraction> per share, respectively. As of September 30, 2021 and 2020, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OutstandingStockOptionsShares" scale="0" unitRef="shares">1,055,376</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:OutstandingStockOptionsShares" scale="0" unitRef="shares">467,327</ix:nonFraction> outstanding options,
respectively, had no intrinsic value.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average assumptions used in the Black-Scholes
option-pricing model are as follows for the stock options granted during the years ended September 30:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">55.9</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">53.1</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended September 30, 2021 and 2020,
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">280,557</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">198,191</ix:nonFraction> stock options vested, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of restricted stock unit (&#8220;RSU&#8221;)
activity is as follows for the years ended September 30, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-left: 0">Non-vested at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">10,503</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">78,323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares">2,335</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">59,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Non-vested at September 30, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">26,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares">13,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">29,090</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0">Non-vested at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">11,384</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">13,776</ix:nonFraction> and <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">78,323</ix:nonFraction> RSUs were granted to members of the Company&#8217;s board of directors and consultants that vest over a period
ranging from an immediate to a <ix:nonNumeric contextRef="c79" format="ixt-sec:durwordsen" name="nmtc:StockOptionVestedOverAPeriodTerm"><ix:nonNumeric contextRef="c78" format="ixt-sec:durwordsen" name="nmtc:StockOptionVestedOverAPeriodTerm">two year</ix:nonNumeric></ix:nonNumeric> period, with a grant date fair value of $<ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="nmtc:GrantDateFairValueOfPerUnit" scale="0" unitRef="usdPershares">7.26</ix:nonFraction> and $<ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="nmtc:GrantDateFairValueOfPerUnit" scale="0" unitRef="usdPershares">6.27</ix:nonFraction> per unit, respectively. During the years
ended September 30, 2021 and 2020, <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">29,090</ix:nonFraction> and <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">59,793</ix:nonFraction> RSUs vested, respectively. The total expense for the years ended September 30, 2021
and 2020 related to the RSU&#8217;s was $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="nmtc:TotalExpenseOfStockOption" scale="0" unitRef="usd">163,988</ix:nonFraction> and $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="nmtc:TotalExpenseOfStockOption" scale="0" unitRef="usd">396,012</ix:nonFraction>, respectively. The number of RSUs forfeited during the years ended September
30, 2021 and 2020 was <ix:nonFraction contextRef="c80" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares">zero</ix:nonFraction> and <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares">2,335</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Stock-Based Awards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2021 Activity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, two consulting agreements were
executed whereby a total of <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">62,659</ix:nonFraction> shares of common stock were issued and vested as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2021, two consulting agreements were executed
whereby a total of <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">11,668</ix:nonFraction> shares of common stock were issued and vested as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2020 Activity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2019, <ix:nonNumeric contextRef="c84" name="nmtc:ConsultingAgreementsDescription">two consulting agreements were
executed whereby up to 38,334 shares of common stock were issued and vested as of September 30, 2020. On April 22, 2020, the Company entered
into an amendment (the &#8220;Amendment&#8221;) to one of the consulting agreements. Pursuant to the Amendment, the Company issued an
additional 11,667 shares in exchange for consulting services of which 11,667 shares of common stock were vested as of September 30, 2020
under the Amendment. Vesting was based on a time-based vesting condition ranging over a three to nine-month period commencing upon the
execution of the consulting agreements.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, <ix:nonNumeric contextRef="c85" name="nmtc:ConsultingAgreementsDescription">an additional consulting agreement
was executed whereby up to 30,000 shares of common stock were issued and vested as of September 30, 2020 under this agreement. In addition,
on May 21, 2020, 22,195 shares of common stock were issued as compensation to a former 2019 Paulson Note holder related to a prior 2019
Paulson Note conversion and release of liability.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, <ix:nonNumeric contextRef="c86" name="nmtc:ConsultingAgreementsDescription">an additional consulting agreement
was executed whereby 40,000 shares of common stock were issued, subject to Company repurchase. The stock award under the agreement vests
over a six-month period. As of September 30, 2021 and 2020, 33,333 and 6,667 shares vested under this agreement, respectively.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation expense related to the stock awards
granted under the consulting agreements and to the former 2019 Paulson Note holder referenced above amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="0" unitRef="usd">645,910</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="0" unitRef="usd">641,716</ix:nonFraction>
for the years ended September 30, 2021 and 2020, respectively, and was included in stock-based compensation expense. The expense recognition
related to the grants was based on the fair value of the underlying common stock at the point of vesting which ranged from $<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="nmtc:FairValueOfTheUnderlyingCommonStock" scale="0" unitRef="usdPershares">4.53</ix:nonFraction> to $<ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="nmtc:FairValueOfTheUnderlyingCommonStock" scale="0" unitRef="usdPershares">7.95</ix:nonFraction>
per share.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="nmtc:FutureIssuanceOnACombinedBasis" scale="0" unitRef="shares">389,709</ix:nonFraction> shares were
available for future issuance on a combined basis under the 2016 and 2017 Equity Incentive Plans. Unrecognized stock-based compensation
was $<ix:nonFraction contextRef="c3" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd">1.7</ix:nonFraction> million as of September 30, 2021. The unrecognized share-based expense is expected to be recognized over a weighted average period
of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.9</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - Stockholders&#8217; Deficit</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Private Placement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, the Company entered into
a Common Stock and Warrant Purchase Agreement with certain accredited investors, pursuant to which the Company, in the 2021 Private Placement,
agreed to issue and sell an aggregate of <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="nmtc:AggregateShareIssued" scale="0" unitRef="shares">4,166,682</ix:nonFraction> shares of the common stock of the Company and warrants to purchase an aggregate of
<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="nmtc:PurchaseOfWarrants" scale="0" unitRef="shares">4,166,682</ix:nonFraction> shares of common stock (the &#8220;2021 Warrants&#8221;) at an aggregate purchase price of $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="nmtc:PurchasePriceOfCommonStock" scale="0" unitRef="usdPershares">3.00</ix:nonFraction> per share of common stock and
corresponding warrant, resulting in total gross proceeds of $<ix:nonFraction contextRef="c96" decimals="-5" format="ixt:num-dot-decimal" name="nmtc:TotalGrossProceeds" scale="6" unitRef="usd">12.5</ix:nonFraction> million before deducting placement agent fees and estimated offering
expenses. The 2021 Warrants have an initial exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">5.25</ix:nonFraction> per share. The 2021 Warrants are immediately exercisable and will
expire on the fifth anniversary of issuance. Prior to expiration, subject to the terms and conditions set forth in the 2021 Warrants,
the holders of such 2021 Warrants may exercise the 2021 Warrants for shares of common stock by providing notice to the Company and paying
the exercise price per share for each share so exercised or by utilizing the &#8220;cashless exercise&#8221; feature contained in each
2021 Warrant. The fair value of the 2021 Warrants was $<ix:nonFraction contextRef="c96" decimals="-5" format="ixt:num-dot-decimal" name="nmtc:FairValueOfWarrants" scale="6" unitRef="usd">7.3</ix:nonFraction> million and was based on the Black-Scholes pricing model. Input assumptions
used were as follows: a risk-free interest rate of <ix:nonFraction contextRef="c96" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.5</ix:nonFraction>%; expected volatility of <ix:nonFraction contextRef="c96" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">56.0</ix:nonFraction>%; expected life of <ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric> years; expected dividend yield
of <ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction>%; and the underlying traded stock price.&#160;$<ix:nonFraction contextRef="c96" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd">3.7</ix:nonFraction> million of the total proceeds was allocated to the 2021 Warrants based on the
relative fair value allocation method, which has been reflected in stockholders&#8217; equity. The 2021 Warrants were classified in stockholders&#8217;
equity as the number of shares were fixed and determinable, and no other provisions precluded equity treatment. The private placement
closed on January 14, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Common Stock Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2020, the Company entered into securities
purchase agreements with an accredited investor in a private placement, pursuant to which the Company has issued and sold <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="nmtc:SharesIssuedUnderPrivatePlacement" scale="0" unitRef="shares">25,000</ix:nonFraction> shares
to such investor, at $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.40</ix:nonFraction> per share for gross proceeds amounting to $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="nmtc:GrossProceedsFromPrivatePlacement" scale="0" unitRef="usd">135,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2019 Common Stock Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2019, the Company entered into
Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and
sold <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="nmtc:SharesIssuedUnderPrivatePlacement" scale="0" unitRef="shares">47,223</ix:nonFraction> shares of the Company&#8217;s common stock to the accredited investors at a price of $<ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.40</ix:nonFraction> per share, for gross proceeds amounting
to $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="nmtc:GrossProceedsFromPrivatePlacement" scale="0" unitRef="usd">255,000</ix:nonFraction>. The Company filed a registration statement with the SEC covering the resale of the shares of common stock sold in the private
placement on August 11, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrant Activity and Summary</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes warrant activity
during the years ended September 30, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="nmtc:SummaryOfWarrantActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Warrants</b> &#160; &#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise <br/>
Price Per <br/>
Warrant</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted<br/>
Average Exercise <br/>
Price</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted <br/>
Average Term <br/>
(years)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" scale="0" unitRef="shares">2,421,940</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1" scale="0" unitRef="usdPershares">5.40</ix:nonFraction> - <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1" scale="0" unitRef="usdPershares">9.00</ix:nonFraction>&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.65</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"><span style="font-size: 10pt">3.60</span></ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" scale="0" unitRef="shares">968,380</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantIssued" scale="0" unitRef="usdPershares">5.61</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.61</ix:nonFraction></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-77">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-81">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" scale="0" unitRef="shares">3,390,320</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">5.40</ix:nonFraction> - <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">9.00</ix:nonFraction>&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">7.05</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"><span style="font-size: 10pt">2.89</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" scale="0" unitRef="shares">4,166,682</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantIssued" scale="0" unitRef="usdPershares">5.25</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">4.29</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" scale="0" sign="-" unitRef="shares">53,194</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageExercisePriceExercised" scale="0" unitRef="usdPershares">5.61</ix:nonFraction>-<ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageExercisePriceExercised" scale="0" unitRef="usdPershares">8.25</ix:nonFraction> </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">5.61</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-87">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" scale="0" unitRef="shares">7,503,808</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">5.25</ix:nonFraction>-<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">9.00</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding" scale="0" unitRef="usdPershares">6.06</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"><span style="font-size: 10pt">3.23</span></ix:nonNumeric></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information about
warrants outstanding at September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercise Price</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Outstanding</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average <br/>
Remaining Contractual<br/>
life (Years)</b></td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Exercisable at <br/>
September 30,<br/>
2021</b></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; text-align: justify">$</td>
    <td style="width: 21%; text-align: right"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">5.25</ix:nonFraction></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">4,166,682</ix:nonFraction></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 24%; text-align: center"><ix:nonNumeric contextRef="c106" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">4.29</ix:nonNumeric></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">4,166,682</ix:nonFraction></td>
    <td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">5.40</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">750,364</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c107" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">0.14</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">750,364</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">5.61</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">916,753</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c108" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">2.68</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">916,753</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">6.00</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">45,173</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c109" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">2.75</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">45,173</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">279,733</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c110" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">2.41</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">279,733</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">8.25</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">62,911</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c111" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">2.75</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">62,911</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ExercisePrice" scale="0" unitRef="usdPershares">9.00</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">1,282,192</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c112" format="ixt-sec:duryear" name="nmtc:WeightedAverageRemainingContractualLifeYears">2.18</ix:nonNumeric></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">1,282,192</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: justify">Total</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberOutstandingsTotal" scale="0" unitRef="shares">7,503,808</ix:nonFraction></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="nmtc:NumberExercisable1" scale="0" unitRef="shares">7,503,808</ix:nonFraction></td>
    <td style="padding-bottom: 4.5pt">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rate for the Company for the
years ended September 30, 2021 and 2020 was <ix:nonFraction contextRef="c0" decimals="2" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">zero</ix:nonFraction></ix:nonFraction> percent. A reconciliation of income tax computed at the statutory federal income tax
rate to the provision (benefit) for income taxes included in the accompanying statements of operations for the years ended September 30
is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Income tax benefit at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="nmtc:IncomeTaxBenefitAtFederalStatutoryRate" scale="-2" sign="-" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:IncomeTaxBenefitAtFederalStatutoryRate" scale="-2" sign="-" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">State income tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="nmtc:StateIncomeTaxNetOfFederalBenefit" scale="-2" sign="-" unitRef="pure">7.7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:StateIncomeTaxNetOfFederalBenefit" scale="-2" sign="-" unitRef="pure">7.7</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Disqualified interest and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:DisqualifiedInterestAndOther" scale="-2" unitRef="pure">17.0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="nmtc:ResearchCredits" scale="-2" sign="-" unitRef="pure">3.7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:ResearchCredits" scale="-2" sign="-" unitRef="pure">1.3</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="nmtc:StockbasedCompensation" scale="-2" unitRef="pure">1.0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:StockbasedCompensation" scale="-2" unitRef="pure">0.2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="nmtc:ValuationAllowance" scale="-2" unitRef="pure">31.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="nmtc:ValuationAllowance" scale="-2" unitRef="pure">12.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are summarized in the tables below as of September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Federal and state operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd">7,575,069</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd">4,936,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Acquired intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" unitRef="usd">24,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" unitRef="usd">22,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd">8,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd">30,406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research and development credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" unitRef="usd">812,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" unitRef="usd">450,081</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd">451,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd">255,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">8,872,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">5,694,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" unitRef="usd">64,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" unitRef="usd">64,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">8,808,329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd">5,694,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company
had gross deferred tax assets of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:DeferredTaxAssetGrossCurrent" scale="0" unitRef="usd">8,873,000</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:DeferredTaxAssetGrossCurrent" scale="0" unitRef="usd">5,695,000</ix:nonFraction>, respectively. Realization of the deferred assets is primarily
dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses
since its inception. The Company has not yet generated revenues from sales and faces significant challenges to becoming profitable. Accordingly,
the net deferred tax assets have been fully offset by a valuation allowance of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">8,808,000</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd">5,695,000</ix:nonFraction> as of September
30, 2021 and 2020, respectively. The U.S. net deferred tax assets will continue to require a valuation allowance until the Company can
demonstrate their realizability through sustained profitability or another source of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company&#8217;s
federal net operating loss carryforwards were approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" unitRef="usd">26,355,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" unitRef="usd">17,175,000</ix:nonFraction>, respectively. The Company had federal research
credit carryforwards as of September 30, 2021 and 2020 of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="0" unitRef="usd">506,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="0" unitRef="usd">272,000</ix:nonFraction>, respectively. The federal net operating
loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating
losses incurred after December 31, 2017 will not expire. As of September 30, 2021 and 2020, the Company had state net operating loss carryforwards
of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd">26,355,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd">17,175,000</ix:nonFraction>, respectively. The Company had state research credit carryforwards of approximately $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StateTaxCreditCarryForward" scale="0" unitRef="usd">307,000</ix:nonFraction>
and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nmtc:StateTaxCreditCarryForward" scale="0" unitRef="usd">178,000</ix:nonFraction> as of September 30, 2021 and 2020, respectively. The state net operating loss carryforwards will begin to expire in 2031,
if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the net operating loss carryforwards
and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal
Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation
applies when one or more &#8220;5-percent shareholders&#8221; increase their ownership, in the aggregate, by more than 50 percentage points
over a 36-month testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result
in the expiration of net operating losses and credits before utilization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute
for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company believes
its income tax filing positions and deductions will be sustained upon examination, and accordingly, no reserves or related accruals for
interest and penalties have been recorded at September 30, 2021 and 2020.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with this guidance, the Company
has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will
be classified as a component of interest expense and any related penalties will be classified in operating expenses in the statements
of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has tax filing obligations in the
following jurisdictions: U.S. federal, Minnesota and California. The income tax returns since inception as a corporation in 2016 are subject
to examination by the federal and Minnesota taxing authorities.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DefinedContributionPlanTextBlock-c0_cont_1" escape="true" name="us-gaap:DefinedContributionPlanTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 - Defined Contribution Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DefinedContributionPlanTextBlock-c0_cont_2" id="_DefinedContributionPlanTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a 401(k) defined contribution
plan (the &#8220;401K Plan&#8221;) for all employees over age 21. Employees can defer up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:EmployeesCompensationPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of their compensation through payroll
withholdings into the 401K Plan subject to federal law limits. The Company may match <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:DeferralsPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of deferrals up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:ContributionsPercentage" scale="-2" unitRef="pure">3</ix:nonFraction>% of one&#8217;s contributions.
The Company&#8217;s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing
contributions under the 401K Plan in the future, but it has not done so through September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NeuroOne Medical Technologies Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DefinedContributionPlanTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee contributions and any employer matching
contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nmtc:InternalRevenuePercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% vested upon contribution.
Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee&#8217;s
date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee&#8217;s
date of hire. The amount of contributions made by the Company under the 401K Plan during the years ended September 30, 2021 and 2020 was
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ContributionsAmount" scale="0" unitRef="usd"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nmtc:ContributionsAmount" scale="0" unitRef="usd">14,803</ix:nonFraction></ix:nonFraction> and zero, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 - Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Inducement Plan </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">On October 4, 2021, the Company
adopted the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the &#8220;Plan&#8221;), pursuant to which the Company reserved
<ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="nmtc:SharesAreAuthorizedForFutureIssuance" scale="0" unitRef="shares">420,350</ix:nonFraction> shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors
of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule
5635(c)(4) of the Nasdaq Listing Rules. The Plan was approved by the Company&#8217;s Board of Directors without stockholder approval in
accordance with such rule.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Public Offering</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_5" id="_SubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2021, <ix:nonNumeric contextRef="c115" name="nmtc:UnderwritingAgreementDescription">the Company, entered into
an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Craig-Hallum Capital Group LLC, as underwriter (the &#8220;Underwriter&#8221;),
relating to the issuance and sale of 3,750,000 shares of the Company&#8217;s common stock at a price to the public of $3.20 per share.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to
purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale
of 422,057 shares of common stock subject to the Underwriter&#8217;s overallotment option closed on November 15, 2021. Deferred offering
costs in connection with the offering amounted to $92,934 and are reflected in the prepaid and other assets line item in the accompanying
balance sheets as of September 30, 2021.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from this offering
were approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="nmtc:GrossProceeds" scale="6" unitRef="usd">13.4</ix:nonFraction> million prior to deducting underwriting discounts and other offering expenses payable by the Company.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>ITEM 9A. CONTROLS AND PROCEDURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain disclosure controls and procedures
(as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) which are controls and other procedures that are designed to provide
reasonable assurance that that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is
accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, our management, with
the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation
of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and
procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports
we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief
Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level
as of September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control Over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that,
in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting
principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and Board;
and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our
assets that could have a material effect on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, including our Chief Executive
Officer and Chief Financial Officer, recognizes that our internal control over financial reporting cannot prevent or detect all errors
and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the
control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints,
and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues
and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about
the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management, with the participation of the Chief
Executive Officer and Chief Financial Officer, assessed our internal control over financial reporting as of September 30, 2021, the end
of our fiscal year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework (2013) issued
by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management has concluded that the Company&#8217;s
internal control over financial reporting was effective as of September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control Over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No change in our system of internal control over
financial reporting occurred during the quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>ITEM 9B. OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>ITEM 9C. DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of the Company (the &#8220;Board&#8221;)
is divided into three classes. Members of each class serve staggered three-year terms. The following table provides information as to
each person who is, as of the filing hereof, a director and/or executive officer of the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: justify"><b>Name</b></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="width: 60%; border-bottom: black 1.5pt solid; text-align: center"><b>Position(s)</b></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><b>Age</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify">David Rosa </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Class II Director, Chief Executive Officer, and President </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">57 </td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">Mark Christianson </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Business Development Director, Medical Sales Liaison </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">54 </td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify">Steve Mertens </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Chief Technology Officer </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">59 </td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">Ronald McClurg </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Chief Financial Officer </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">63 </td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify">Jeffrey Mathiesen </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Class III Director </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">61 </td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">Paul Buckman </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Class I Director and Chairman of the Board </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">66 </td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify">Edward Andrle </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Class III Director </td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">64 </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no family relationship
between any director and executive officer or among any directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Experience and Background of Directors
and Executive Officers&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Rosa</i></b> has
served as the Chief Executive Officer, President and a director of the Company since July 2017 and served as Chief Executive Officer and
a director of NeuroOne, Inc., formerly our wholly-owned subsidiary, from October 2016 until December 2019, when NeuroOne, Inc. merged
with and into the Company. From November 2009 to November 2015, Mr. Rosa served as the chief executive officer and president of Sunshine
Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company. From 2008 to November 2009, Mr.
Rosa served as chief executive officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008,
Mr. Rosa served as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical, Inc. Currently, he serves
as a director on the board of directors of Biotricity Inc. (Nasdaq: BTCY) Biorestorative Therapies (Nasdaq: BRTX) and Healthcare Triangle,
Inc. (Nasdaq: HCTI). Mr. Rosa holds an MBA from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa&#8217;s qualifications
to serve on the Board include his senior leadership experience in the medical device industry. In addition, his day-to-day leadership
of the Company gives him critical insights into the Company&#8217;s operations, strategy and competition, and he facilitates the Board&#8217;s
ability to perform its oversight function. Throughout his career at the Company and his former positions, he has demonstrated strong technical,
strategic, and operational expertise, and he possesses in-depth knowledge of the medical device industry on a global basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mark Christianson </i></b>is
a co-founder of the Company and has served as Business Development Director and Medical Sales Liaison of the Company since February 2019.
Previously, he served as Vice President of Business Development and Marketing of the Company from July 2017 until February 2019 and served
as vice president of sales and marketing of our wholly-owned subsidiary, NeuroOne, Inc., since December 2016. From May 2013 to December
2016 Mr. Christianson served as North American sales manager for Cortec Corporation. From February 2012 to May 2013 Mr. Christianson held
the position of business development executive for Robert Half International. From May 2009 to February 2012, Mr. Christianson held the
position of regional sales manager for PMT Corporation. Mr. Christianson studied accounting at Augsburg College in Minneapolis. Mr. Christianson
brings 15 years of high performing sales, sales management, and project management experience to the NeuroOne team. In addition, he has
contributed to the development and corporate strategy of the Company given his experience in the neurological field and his close relationships
with key epilepsy opinion leaders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Steve Mertens </i></b>has
served as Chief Technology Officer of the Company since April 2019. From September 2018 through April 2019, Mr. Mertens was a consultant
at Steve Mertens Consulting, L.L.C., of which he was the principal and owner. From November 2012 through September 2018, Mr. Mertens served
as the senior vice president of research and development and operations at Nuvaira Inc., a privately held lung denervation company developing
minimally invasive product for obstructive lung diseases. Prior to Nuvaira<b>,</b> Mr. Mertens served as a senior vice president of research
and development for Boston Scientific Corporation (NYSE: BSX), guiding a wide range of technologies through product development for the
cardiology, electrophysiology and peripheral vascular markets. He holds a bachelor&#8217;s degree in chemical engineering from the University
of Minnesota and a Master&#8217;s degree in business administration from the University of St. Thomas. Currently, he serves on the board
of directors of the University Enterprise Laboratories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ronald McClurg </i></b>has served as Chief
Financial Officer of the Company since January 2021. Prior to joining the Company, from October 2003 to June 2019, Mr. McClurg served
as vice president - finance &amp; administration and chief financial officer of Incisive Surgical, Inc., a privately-held medical device
manufacturer. From 1997 to 2002, Mr. McClurg served as chief financial officer and treasurer of Wavecrest Corporation, a privately-held
manufacturer of electronic test instruments for the semiconductor industry. Prior to 1997, Mr. McClurg served as chief financial officer
for several publicly-held companies, including Video Sentry Corporation, Insignia Systems, Inc. (Nasdaq: ISIG), and Orthomet, Inc. Currently,
he serves on the board of governors of Biomagnetic Sciences, LLC. Mr. McClurg holds a Bachelor of Business Administration degree in accounting
from the University of Wisconsin &#8211; Eau Claire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paul Buckman </i></b>has served as Chairman
of the Board of the Company since August 2017, and served as Chairman of the board of NeuroOne, Inc., from October 2016 until December
2019. Mr. Buckman has served as the president of North America for LivaNova PLC (Nasdaq: LIVN) since April 2019 and previously served
as the general manager of Structural Heart for LivaNova PLC from April 2017 to December 2019. Prior to joining LivaNova PLC, Mr. Buckman
served as chief executive officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation,
from September 2013 until March of 2017. Mr. Buckman was chief executive officer of Sentreheart, Inc., a medical technology company focused
on closure of various anatomic structures, from February 2012 to September 2013. Previously, Mr. Buckman served as chief executive officer
and chairman of Pathway Medical Technologies, Inc., a medical device company focused on treatment of peripheral arterial disease, from
September 2008 to February 2012; as chief executive officer of Devax, Inc., a developer and manufacturer of drug eluting stents, from
December 2006 to September 2008; as president of the cardiology division of St. Jude Medical, Inc., a publicly traded diversified medical
products company, from August 2004 to December 2006; and as chairman of the board of directors and chief executive officer of ev3, LLC,
a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman co-founded from January 2001 to January 2004.
Mr. Buckman has worked in the medical device industry for over 40 years, including 10 years at Scimed Life Systems, Inc. and Boston Scientific
Corporation (NYSE: BSX), a publicly traded medical device manufacturer, where he held several executive positions before becoming president
of the cardiology division in January 2000. Mr. Buckman also currently serves as a director for Helius Medical Technologies Corporation
(Nasdaq: HSDT), Ablative Solutions, Inc., ActivOrtho, Inc., a privately held company, Shoulder Innovations, Inc., a privately held company,
MDMA, and as chairman of Miromatrix, Inc. He previously served as a director of Aortica, Inc., DyaMX, Inc., Conventus Orthopaedics, Caisson
Interventional LLC, Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc., Sunshine Heart, Inc., n/k/a Nuwellis,
Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, NexGen Medical, and Micro Therapeutics, Inc. Mr. Buckman received
a Master&#8217;s degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University.
We believe that Mr. Buckman&#8217;s strong executive experience in medical device companies provides the Company with valuable guidance
on product development and operational matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Jeffrey Mathiesen </i></b>has
served as a member of the Board of the Company since August 2017, and served as a director of NeuroOne, Inc., from April 2017 until December
2019. He has served as chief financial officer of Helius Medical Technologies, Inc. (Nasdaq: HSDT), a publicly traded medical device company,
developing noninvasive platform technologies focused on neurological wellness since June 2021, where he previously served as a director
and audit committee chair from June 2020 until June 2021. Additionally, Mr. Mathiesen has served as vice chair and lead independent director
since March 2020 and as director and audit committee chair, since 2015, of Panbela Therapeutics, Inc. (Nasdaq: PBLA), a publicly traded
biopharmaceutical company developing therapies for pancreatic diseases, and from 2018 to 2020 he served as a member of the board of directors
of eNeura, Inc., a privately-held medical technology company providing therapy for both acute treatment and prevention of migraine. Mr.
Mathiesen served as advisor to the CEO of Teewinot Life Sciences Corporation, a privately held global leader in the biosynthetic development
and production of cannabinoids and their derivatives for consumer and pharmaceutical products from October 2019 to December 2019, and
served as chief financial officer from March 2019 to October 2019. In August 2020, Teewinot Life Insurance Sciences filed a voluntary
petition under Chapter 11 of the United States Bankruptcy Code. Mr. Mathiesen previously served as chief financial officer of Gemphire
Therapeutics Inc., which was acquired by NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) in January 2020, a publicly-held clinical-stage
biopharmaceutical company developing therapies for patients with cardiometabolic disorders, from 2015 to 2018, and as chief financial
officer of Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company, from 2011 to
2015. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is a Certified Public Accountant. We believe
that Mr. Mathiesen brings financial insight and leadership and a wealth of experience in capital markets to the Board, as well as knowledge
of public company accounting and financial reporting requirements and familiarity with the life sciences industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Edward Andrle </i></b>has
served as a member of the Board of the Company since February 2020. He is also a member of the Board of Rainbow Medical, a medical device
incubator in Israel, since August 2020. Mr. Andrle most recently served as the general manager of Neuromodulation of LivaNova PLC (Nasdaq:
LIVN), a publicly-traded medical device company, from January 2018 to January 2020, and as senior vice president of strategy and business
development of LivaNova PLC from September 2015 to January 2018. Prior to these roles, Mr. Andrle served as vice president of business
development and strategy of Sorin S.p.A from 2010 to September 2015, when Sorin S.p.A. was merged with Cyberonics, Inc. to become LivaNova
PLC. Prior to joining Sorin, he co-founded three medical device companies, Myocor Inc., TERAMED Inc. and StarFire Medical Inc. All three
companies were eventually acquired. He also held executive positions with Boston Scientific, Inc. (NYSE: BSX) and Baxter International,
Inc. (NYSE: BAX), leading large product portfolios in cardiovascular and dialysis. Mr. Andrle received his MBA from Stanford Graduate
School of Business and his B.S. in Chemical Engineering from the University of Notre Dame. We believe that Mr. Andrle&#8217;s substantial
experience in medical device companies and business development experience provides the Company with valuable insight on product development
and strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Board and Committee Information</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the Company&#8217;s
fiscal year ended September 30, 2021, the Board held a total of eleven meetings, and each director attended at least 75% of such meetings.
Under the policies of the Board, Directors are expected to attend regular Board meetings, Board committee meetings, as applicable, and
the Annual Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Board Leadership Structure</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board is currently chaired
by Paul Buckman, who has authority, among other things, to call and preside over meetings of our Board, to set meeting agendas and to
determine materials to be distributed to the Board and, accordingly, has substantial ability to shape the work of the Board. The positions
of our chairman of the Board and Chief Executive Officer are presently separated. Separating these positions allows our Chief Executive
Officer, Mr. Rosa, to focus on our day-to-day business, while allowing Mr. Buckman to lead the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Role of the Board in Risk Oversight</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board does not have a
standing risk management committee, but rather administers its risk oversight function directly through the Board as a whole. The Board&#8217;s
risk oversight is administered primarily through the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review and approval of an annual business plan;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review of a summary of risks and opportunities at meetings
of the Board;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review of business developments, business plan implementation
and financial results;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">oversight of internal controls over financial reporting; and</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">review of employee compensation and its relationship to our
business plans.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Structure and Operation of the Board</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our Common Stock is
listed on Nasdaq, the Company is subject to the Nasdaq listing requirements regarding committee matters. The Company currently has the
following committees: an audit committee, a compensation committee and a nominating and corporate governance committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nominating and Corporate Governance Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nominating and corporate
governance committee reviews, evaluates and seeks out candidates qualified to become Board members. The Board includes individuals with
a diversity of experience, including scientific, business, financial and academic backgrounds. Nominations may be submitted by directors,
officers, employees, stockholders and others for recommendation to the Board. In fulfilling this responsibility, the Company&#8217;s nominating
and corporate governance committee also consults with the Board and the Chief Executive Officer concerning director candidates. The nominating
and corporate governance committee&#8217;s charter is available on our website, <i>www.n1mtc.com</i>, under <i>Investors &#8212;Governance</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The responsibilities of the
Company&#8217;s nominating and corporate governance committee include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reviewing, evaluating and seeking out candidates qualified
to become members of the Board;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reviewing committee structure and recommending directors for
appointment to committees;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">developing, reevaluating (not less frequently than every three
years) and recommending the selection criteria for board and committee membership;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">establishing procedures to oversee evaluation of the board,
its committees, individual directors and management; and</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">developing and recommending guidelines on corporate governance.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current members of our
nominating and corporate governance committee are Mr. Buckman, Mr. Andrle, and Mr. Mathiesen, each of whom has been determined by the
Board to be independent under the rules and regulations of the Nasdaq Stock Market LLC. Mr. Andrle is the chair of the nominating and
corporate governance committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The compensation committee&#8217;s
charter is available on our website, <i>www.n1mtc.com</i>, under <i>Investors &#8212;Governance</i>. The responsibilities of the compensation
committee include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">fixing salaries of executive officers and reviewing salary
plans for other executives in senior management positions;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reviewing and making recommendations with respect to the compensation
and benefits for the Company&#8217;s non-employee directors, including through equity-based plans;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">evaluating the performance of the Company&#8217;s chief executive
officer and other senior executives and assisting the Board in developing and evaluating potential candidates for executive positions;
and</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">administering the Company&#8217;s incentive compensation,
deferred compensation and equity-based plans pursuant to the terms of the respective plans.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current members of the
compensation committee include Mr. Buckman, Mr. Andrle, and Mr. Mathiesen. Mr. Buckman is the chair of the compensation committee. The
compensation committee may form and delegate authorities to subcommittees as appropriate, including, but not limited to, a subcommittee
composed of one or more members of the Board or officers of the Company to grant stock awards under the Company&#8217;s equity incentive
plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To qualify as independent
to serve on the Company&#8217;s compensation committee, the listing standards of Nasdaq require a director not to accept any consulting,
advisory, or other compensatory fee from the Company, other than for service on the Board, and that the Board consider whether a director
is affiliated with the Company and, if so, whether such affiliation would impair the director&#8217;s judgment as a member of the Company&#8217;s
compensation committee. The Board has concluded that the members of the compensation committee meet the requirements for independence
under the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee reviews
with management and the Company&#8217;s independent public accountants the Company&#8217;s financial statements, the accounting principles
applied in their preparation, the scope of the audit, any comments made by the independent accountants upon the financial condition of
the Company and its accounting controls and procedures and such other matters as the audit committee deems appropriate. The audit committee&#8217;s
charter is available on our website, <i>www.n1mtc.com</i>, under <i>Investors &#8212;Governance</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee currently
consists of three directors: Mr. Buckman, Mr. Mathiesen and Mr. Andrle. The Board has determined that each of Mr. Buckman, Mr. Mathiesen
and Mr. Andrle is &#8220;independent&#8221; under Nasdaq independence standards. Additionally, the Board has determined that each of Mr.
Mathiesen and Mr. Buckman qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined in rules promulgated
by the SEC. The designation of an &#8220;audit committee financial expert&#8221; does not impose upon such persons any duties, obligations
or liabilities that are greater than those generally imposed on each of them as a member of the audit committee and the Board, and such
designation does not affect the duties, obligations or liabilities of any other member of the audit committee or the Board. Mr. Mathiesen
is the chair of the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functions of the audit
committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Selecting our independent auditors;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reviewing the results and scope of the audit and other services
provided by our independent auditors; and</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reviewing and evaluating our audit and control functions.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Code of Business Conduct and Ethics</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted a code
of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief
Financial Officer and other executive officers. We intend to disclose future amendments to certain provisions of our code of business
conduct and ethics, or waivers of these provisions, in public filings. A copy of the code of business conduct and ethics is available
on our website, <i>www.n1mtc.com</i>, under <i>Investors &#8212; Governance</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hedging Policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of its insider trading
policy, the Board has implemented an anti-hedging policy that applies to the Board, executive officers and employees. Under this policy,
these persons are prohibited from engaging in various trading practices which would suggest speculation in Company securities, including
financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds or other hedging transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Corporate Governance Guidelines</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted Corporate
Governance Guidelines that set forth expectations for directors, director independence standards, Board structure and functions and other
policies for the governance of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
11. EXECUTIVE COMPENSATION</b>.</p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Compensation Table for Fiscal Year
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows
the compensation earned or received during the fiscal year ended September 30, 2021 and the fiscal year ended September 30, 2020 by each
of our named executive officers (as determined pursuant to the SEC&#8217;s disclosure requirements for executive compensation in Item
402 of Regulation S-K).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 3pt; margin-bottom: 0pt; text-align: left"><b>Name
and Principal Position</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Year</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> Incentive Plan <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Dave Rosa,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">410,844</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,285,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">192,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,889,351</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-style: italic; text-align: left; padding-left: 0.25in">Chief Executive Officer and President</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">403,914</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">547,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,886</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,122,891</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Ron McClurg,</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">522,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-style: italic; text-align: justify; padding-left: 0.25in">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Steve Mertens,</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,138</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-style: italic; text-align: justify; padding-left: 0.25in">Chief Technology Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,247</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Amounts reported reflect the aggregate
grant date fair value of option awards, calculated in accordance with FASB Topic 718, excluding the impact of potential forfeitures.
The weighted-average assumptions used in the valuation of option awards under the Black-Scholes option-pricing model are set forth under
&#8220;Stock Options&#8221; in Note 9 to the Company&#8217;s financial statements in this Report on Form 10-K.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative to Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The compensation program for
the Company&#8217;s named executive officers for fiscal 2021 had three components: base salary, annual cash bonus and stock option grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Base Salary</i>. There
was a 1.3% increase for cost of living adjustments for the Company&#8217;s named executive officers for calendar year 2021, as compared
to calendar year 2020, except for Mr. McClurg, who joined the Company in January 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Equity Incentive Plan</i>.
In fiscal 2021, each of the Company&#8217;s named executive officers had a target bonus, set forth as a percentage of annual base salary.
In fiscal 2021, target bonuses for the Company&#8217;s named executive officers other than Mr. Rosa&#8217;s were 25% of base salary. Mr.
Rosa&#8217;s target bonus was set at 50% of base salary pursuant to his employment agreement, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2021, the Board
established weighted performance targets for fiscal 2021 that it would consider in approving bonus payments for fiscal 2021. These targets
included various corporate objectives related to uplisting the Company&#8217;s Common Stock, regulatory submissions, certain research
and development, and commercialization milestones, and cash burn targets. In October 2021, the Compensation Committee determined that
95% of the performance targets had been met, and approved the bonus payments to Messrs. Rosa, McClurg and Mertens at 95% each of their
respective targets, which targets were 50%, 25% and 25% of each of their base salaries, respectively, as discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equity Grants</i>. In connection
with Mr. McClurg&#8217;s appointment as Chief Financial Officer, the Board granted Mr. McClurg an option exercisable for 60,000 shares
of the Company&#8217;s Common Stock, with an exercise price of $4.71. Twenty-five percent of the shares underlying the option vest on
January 1, 2022 and the remaining 75% vest in 36 equal monthly installments thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, the Board
granted Mr. Rosa, Mr. McClurg and Mr. Mertens options exercisable for 416,667, 46,667, and 23,334 shares, respectively, each with an exercise
price of $5.97. Twenty-five percent of the shares underlying the option vest on January 27, 2022 and the remaining 75% vest in 36 equal
monthly installments thereafter, except that Mr. Rosa&#8217;s options are subject to acceleration upon achieving certain performance milestones.
On May 6, 2021, the Compensation Committee determined that the performance criteria on 83,333 of Mr. Rosa&#8217;s options were met resulting
in the accelerated vesting of those options on such date. As of September 30, 2021, 20% of the shares underlying Mr. Rosa&#8217;s options
had vested upon the achievement of performance milestones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreement and Arrangements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an employment agreement
with our Chief Executive Officer, Mr. Rosa, and an offer letter for each of Mr. McClurg and Mr. Mertens. Each of our named executive officers
has also executed our standard form of proprietary information, inventions assignment and non-competition agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mr. Rosa</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Rosa&#8217;s employment
agreement (&#8220;Amended Employment Agreement&#8221;) was effective on August 4, 2017, continues through the third anniversary and automatically
renews for an additional one-year period at the end of the initial term and each anniversary thereafter, provided that Mr. Rosa notifies
the Board of such renewal at least 30 days prior to the expiration of the initial term or any renewal terms and the Board does not notify
Mr. Rosa of its intention not to renew the Amended Employment Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amended Employment Agreement
also entitles Mr. Rosa to, among other benefits, the following compensation: (i) an opportunity to participate in any stock option, performance
share, performance unit or other equity based long-term incentive compensation plan commensurate with the terms and conditions applicable
to other senior executive officers; and (ii) participation in welfare benefit plans, practices, policies and programs provided by the
Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life,
accidental death and travel accident insurance plans and programs) to the extent available generally or to our other senior executive
officers. Mr. Rosa is entitled to receive a target award value, determined in accordance with the policies and practices generally available
to other senior executive officers, for an annual cash bonus and if determined by the Board or a committee of the Board, a long-term incentive
bonus. Mr. Rosa is entitled to retain all shares of Common Stock he held as of the commencement date. Mr. Rosa is also entitled to certain
severance benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Amended Employment
Agreement, regardless of the manner in which Mr. Rosa&#8217;s service terminates, Mr. Rosa is entitled to receive amounts earned during
his term of service, including salary and other benefits. The Company is permitted to terminate Mr. Rosa&#8217;s employment for the following
reasons: (i) death or disability, (ii) Termination for Cause (as defined below) or (iii) for any other reason or no reason. Mr. Rosa is
permitted Termination for Good Reason (as defined below) of his employment. In addition, he may terminate his employment upon written
notice to the Company 30 days prior to the effective date of such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of Mr. Rosa&#8217;s
death during the employment period or a termination due to his disability, his beneficiaries or legal representatives shall be provided
the sum of (i) any annual base salary earned, but unpaid, for services rendered to the Company on or prior to the date on which the employment
period ends and (ii) certain other benefits provided for in the employment agreement (the &#8220;Unconditional Entitlements&#8221;). In
the event of Mr. Rosa&#8217;s Termination for Cause by the Company or the termination of Mr. Rosa&#8217;s employment as a result of his
resignation other than a Termination for Good Reason, Mr. Rosa shall be provided the Unconditional Entitlements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a Termination
for Good Reason by Mr. Rosa or the exercise by the Company of its termination rights to terminate Mr. Rosa other than by Termination for
Cause, death or disability, Mr. Rosa shall be provided the Unconditional Entitlements and, subject to his signing and delivering to the
Company and not revoking a general release of claims in favor of the Company and certain related parties, the Company shall provide Mr.
Rosa: (a) a severance amount equal to the aggregate annual base salary he would have earned from the day after his termination date through
the end of the employment period and a prorated portion of his cash bonus for the year in which the termination date occurs, provided,
however, in no event would the severance amount be less than 12 months or more than 18 months of his annual base salary; (b) continued
health insurance coverage for 12 months following his termination date, provided that such coverage shall cease if Mr. Rosa becomes eligible
to receive health insurance coverage from another employer group health plan; (c) vesting of all stock options in accordance with the
stock option award documents, subject to the same conditions that would be applicable to Mr. Rosa if he remained employed through the
end of the employment period; and (d) continued vesting of equity awards in accordance with the terms of the award agreements, provided,
however, Mr. Rosa would have 90 days from the termination date to exercise any vested options (the &#8220;Conditional Benefits&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a change in
control during the employment period or within two years after a change in control, if the Company terminates Mr. Rosa other than due
to Mr. Rosa&#8217;s death or disability or a Termination for Cause, or Mr. Rosa effects a Termination for Good Reason, the Company will
pay to Mr. Rosa, in a lump sum in cash within 30 days after the termination date, the aggregate of: (i) the Unconditional Entitlements;
and (ii) the amount equal to the product of 1.5 times the sum of (y) Mr. Rosa&#8217;s annual base salary, and (z) the greater of the target
bonus for the then current fiscal year under the 2016 Equity Incentive Plan and 2017 Equity Incentive Plan or any successor annual bonus
plan and the average annual bonus paid to or for the benefit of Mr. Rosa for the prior three full years (or any shorter period during
which Mr. Rosa had been employed by the Company). In addition, the Company shall provide Mr. Rosa the Conditional Benefits minus Mr. Rosa&#8217;s
severance amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Amended Employment
Agreement, &#8220;Termination for Cause&#8221; means a termination of Mr. Rosa&#8217;s employment by the Company due to (A) an act or
acts of dishonesty undertaken by Mr. Rosa and intended to result in substantial gain or personal enrichment to Mr. Rosa at the expense
of the Company, (B) unlawful conduct or gross misconduct that is willful and deliberate on Mr. Rosa&#8217;s part and that, in either event,
is materially injurious to the Company, (C) the conviction of Mr. Rosa of, or Mr. Rosa&#8217;s entry of a no contest or nolo contendere
plea to, a felony, (D) breach by Mr. Rosa of his fiduciary obligations as an officer or director of the Company, (E) a persistent failure
by Mr. Rosa to perform his duties and responsibilities of his employment under the Amended Employment Agreement, which failure is not
remedied by Mr. Rosa within 30 days after his receipt of written notice from the Company of such failure, provided, however, the Company
is not obligated to provide written notice and opportunity to cure if the action or conduct is not reasonably susceptible to cure, or
(F) material breach of any terms and conditions of the Amended Employment Agreement, any contract or agreement between Mr. Rosa and the
Company, or of any Company policy, or of any statutory duty he owes to the Company, which breach has not been cured by Mr. Rosa within
ten days after written notice thereof to Mr. Rosa from the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Amended Employment
Agreement, &#8220;Termination for Good Reason&#8221; means a termination of Mr. Rosa&#8217;s employment by Mr. Rosa within 30 days of
the Company&#8217;s failure to cure, in accordance with the procedures set forth below, any of the following events: (A) a reduction in
his annual base salary as in effect immediately prior to such reduction by more than 10% without his written consent, unless such reduction
is made pursuant to an across the board reduction applicable to all senior executives of the Company; (B) a material reduction in his
duties, position and responsibilities as in effect immediately prior to such reduction without his written consent; provided, however,
that a mere change in title or reporting relationship following a Change in Control by itself will not constitute &#8220;Good Reason&#8221;
for Mr. Rosa&#8217;s resignation, and further provided that the acquisition of the Company and subsequent conversion of the Company to
a division or unit of the acquiring entity will not by itself result in a &#8220;reduction&#8221; of duties, position or responsibility;
or (C) a material breach of any material provision of the Amended Employment Agreement by the Company. A termination by Mr. Rosa shall
not be treated as a Termination for Good Reason if Mr. Rosa consented in writing to the occurrence of the event giving rise to the claim
of Termination for Good Reason or unless Mr. Rosa shall have delivered a written notice to the Board within 45 days of Mr. Rosa&#8217;s
having actual knowledge of the occurrence of one of such events stating that Mr. Rosa intends to terminate his employment by Termination
for Good Reason and specifying the factual basis for such termination, and such event, if capable of being cured, shall not have been
cured within 21 days of the receipt of such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mr. McClurg</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2021, the Company
and Mr. McClurg executed an employment offer letter (the &#8220;McClurg Offer Letter&#8221;) under which, effective January 1, 2021, Mr.
McClurg was appointed Chief Financial Officer of the Company. The McClurg Offer Letter provides that Mr. McClurg is an at-will employee
of the Company meaning that either Mr. McClurg or the Company may end the employment relationship at any time, for any reason, and with
or without notice or cause. Under the McClurg Offer Letter, the Company agreed to provide Mr. McClurg: (a) an annual base salary in the
amount of $250,000, subject to review and adjustment based upon the Company&#8217;s normal performance review practices; (b) an annual
performance bonus of up to 25% of Mr. McClurg&#8217;s then effective base salary for the applicable bonus year based upon his performance
and the Company&#8217;s performance, all as determined in the sole discretion of the Board or committee thereof; (c) the right to participate
in the benefit programs and arrangements that the Company makes available to its employees, including paid vacation and sick leave, contributory
and non-contributory welfare and benefit plans, disability plans, and medical, death benefit and life insurance plans for which Mr. McClurg
is eligible under the terms of those plans; and (d) subject to the terms of Company&#8217;s 2017 Equity Incentive Plan, a stock option
award to purchase 60,000 shares of the Company&#8217;s Common Stock with an exercise price of $4.71 per share, 25% of which will vest
on January 1, 2022, with the balance vesting in equal monthly installments on the last day of each month over the next thirty-six (36)
months following January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mr. Mertens</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2019, the Company
and Mr. Mertens executed an employment offer letter (the &#8220;Mertens Offer Letter&#8221;) under which, effective April 1, 2019, Mr.
Mertens was appointed Chief Technology Officer of the Company. The Mertens Offer letter provides that Mr. Mertens is an at-will employee
of the Company meaning that either Mr. Mertens or the Company may end the employment relationship at any time, for any reason, and with
or without notice or cause. Under the Mertens Offer Letter, the Company agreed to provide Mr. Mertens: (a) an annual base salary in the
amount of $235,000, subject to applicable deductions and adjustment; (b) an annual discretionary bonus of up to 25% percent of Mr. Merten&#8217;s
base salary based on his performance and the Company&#8217;s performance, all as determined in the sole discretion of the Board or committee
thereof; (c) subject to the terms of Company&#8217;s 2017 Equity Incentive Plan, a stock option award to purchase 43,149 shares of the
Company&#8217;s common stock with an exercise price of $7.14 per share, 25% of which vested on May 13, 2019, and 75% of which vest in
36 equal monthly installments beginning on April 1, 2020; and (d) the right to participate in the benefit programs and arrangements that
the Company makes available to its employees, including paid vacation and sick leave, contributory and non&#172;contributory welfare and
benefit plans, disability plans, and medical, death benefit and life insurance plans for which Mr. Mertens is eligible under the terms
of those plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Potential Payments Upon Termination or Change
in Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Rosa</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a discussion of payments
to Mr. Rosa upon termination or change in control under his Amended Employment Agreement, see &#8220;<i>Employment Agreement and Arrangements&#8212;
Mr. Rosa</i>&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2017 Equity Incentive Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2017, the Board adopted
and the stockholders approved the 2017 Equity Incentive Plan. The 2017 Equity Incentive Plan is designed to provide a vehicle under which
a variety of stock-based and other awards can be granted to the Company&#8217;s employees, consultants and directors, which align the
interests of award recipients with those of our stockholders, reinforce key goals and objectives that help drive stockholder value, and
attract, motivate and retain experienced and highly qualified individuals who contribute to the Company&#8217;s financial success. The
Board believes that the 2017 Equity Incentive Plan serves a critical role in attracting and retaining high caliber employees, consultants
and directors essential to our success and in motivating these individuals to strive to meet our goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporate Transactions.
</i>The 2017 Equity Incentive Plan provides that in the event of certain specified significant corporate transactions, including: (1)
a sale of all or substantially all of our assets, (2) the sale or disposition of more than 90% of our outstanding securities, (3) the
consummation of a merger or consolidation where we do not survive the transaction, and (4) the consummation of a merger or consolidation
where we do survive the transaction but the shares of our Common Stock outstanding before such transaction are converted or exchanged
into other property by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement between us
and the award holder, the plan administrator may take one or more of the following actions with respect to such stock awards:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">arrange for the assumption, continuation, or substitution
of a stock award by a successor corporation;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">arrange for the assignment of any reacquisition or repurchase
rights held by us to a successor corporation;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">accelerate the vesting, in whole or in part, of the stock
award and provide for its termination before the transaction;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">arrange for the lapse, in whole or in part, of any reacquisition
or repurchase rights held by us;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">cancel or arrange for the cancellation of the stock award
before the transaction in exchange for a cash payment, or no payment, as determined by the Board; or</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">make a payment, in the form determined by our Board, equal
to the excess, if any, of the value of the property the participant would have received on exercise of the awards before the transaction
over any exercise price payable by the participant in connection with the exercise.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator is
not obligated to treat all stock awards or portions of stock awards, even those that are of the same type, in the same manner and is not
obligated to treat all participants in the same manner. In the event of a change in control, awards granted under the 2017 Equity Incentive
Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement.
Under the 2017 Equity Incentive Plan, a change in control is defined to include (1) the acquisition by any person or company of more than
50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation, or similar transaction in which our stockholders
immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity
(or the parent of the surviving entity), (3) a sale, lease, exclusive license, or other disposition of all or substantially all of our
assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders, and (4) an unapproved
change in the majority of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021,
our named executive officers had no outstanding stock awards. The following table sets forth information regarding outstanding option
awards held by our named executive officers as of September 30, 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-align: justify"><b>NAME</b></p></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><b>GRANT DATE</b></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><b>NUMBER OF <br/>
SECURITIES <br/>
UNDERLYING <br/>
UNEXERCISED <br/>
OPTIONS <br/>
EXERCISABLE <br/>
(#)</b></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><b>NUMBER OF <br/>
SECURITIES <br/>
UNDERLYING <br/>
UNEXERCISED <br/>
OPTIONS <br/>
UNEXERCISABLE <br/>
(#)</b></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><b>OPTION <br/>
EXERCISE <br/>
PRICE <br/>
($)</b></td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><b>OPTION <br/>
EXPIRATION <br/>
DATE</b></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 18%; padding-left: 10pt; text-align: justify; text-indent: -10pt">Steven Mertens</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 18%; text-align: center">May 13, 2019</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 16%; text-align: right">26,968</td>
    <td style="vertical-align: top; width: 2%; text-align: justify"><span style="font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 16%; text-align: right">16,181</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: right">7.14</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 13%; text-align: center">May 13, 2029</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: justify; text-indent: -10pt">Steven Mertens</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2021</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">0</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">23,334</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">5.97</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2031</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: justify; text-indent: -10pt">David Rosa</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">November 5, 2019</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">143,797</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">2,870</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">6.42</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">November 5, 2029</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: justify; text-indent: -10pt">David Rosa</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2021</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">83,333</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">333,334</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">5.97</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2031</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: justify; text-indent: -10pt">Ronald McClurg</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 1, 2021</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">0</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">60,000</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">4.71</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 1, 2031</td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 10pt; text-align: justify; text-indent: -10pt">Ronald McClurg</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2021</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">0</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">46,667</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">5.97</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">January 27, 2031</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(1)</td>
    <td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">25%
of the shares underlying the option vested immediately upon grant; the remaining vest monthly in equal increments over a 36 month period
beginning April 1, 2020.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(2)</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">25% of the shares underlying the option vest on
    January 27, 2022; the remaining vest monthly in equal increments over a 36 month period thereafter.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(3) </td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">25% of the shares underlying the option vested
    on November 5, 2020 and the remaining 75% vest in 36 equal monthly installments beginning on December 1, 2020, subject to acceleration
    upon achieving certain performance milestones. As of September 30, 2021, 20% of the shares underlying the options had vested upon the
    achievement of performance milestones.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(4) </td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">25% of the shares underlying the option vest on
    January 27, 2022; the remaining vest monthly in equal increments over a 36 month period thereafter, subject to acceleration upon achieving
    certain performance milestones. As of September 30, 2021, 20% of the shares underlying the options had vested upon the achievement of
    performance milestones.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(5)</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">25% of the shares underlying the option vest on
    January 1, 2022; the remaining vest monthly in equal increments over a 36 month period thereafter.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(6)</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">25% of the shares underlying the option vest
on January 27, 2022; the remaining vest monthly in equal increments over a 36 month period thereafter.&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chief Executive Officer Pay Ratio</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a &#8220;smaller reporting
company&#8221;, we are not required to provide information relating to the ratio of total compensation of our Chief Executive Officer
to the median of the annual total compensation of all of our employees, as required by the Investor Protection and Securities Reform Act
of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-Employee Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, our Board
approved a Non-Employee Director Compensation Policy effective as of January 1, 2018 whereby our non-employee directors receive a mix
of cash and share-based compensation intended to encourage non-employee directors to continue to serve on our Board, further align the
interests of the directors and stockholders, and attract new non-employee directors with outstanding qualifications. Directors who are
employees or officers of the Company do not receive any additional compensation for Board service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this policy, each
of our non-employee directors receive an annual retainer of $50,000, except that our non-executive chairman receives an annual retainer
of $100,000. Additionally, the chairman and members of our Audit Committee receive an additional annual payment of $12,500 and $5,000,
respectively, and the chairmen and members of each of our Compensation and Nominating and Corporate Governance Committees receive an additional
annual payment of $10,000 and $4,000, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, on the date
of each annual stockholder meeting of the Company, each director automatically receives an equity award with an aggregate value on the
date of grant equal to $50,000. Two-thirds of the equity award is issued in the form of restricted stock units, and one-third is issued
in the form of stock options, each of which vest in twelve monthly installments, subject to such director&#8217;s continued service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides
compensation information for the fiscal year ended September 30, 2021 for each non-employee member of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Fees Earned or <br/> Paid&#160;in&#160;Cash <br/> ($)<span style="font-size: 10pt"><sup>(1)</sup></span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Stock Awards <br/> ($)<span style="font-size: 10pt"><sup>(2)</sup></span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Option <br/> Awards <br/> ($)<span style="font-size: 10pt"><sup>(2)</sup></span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -10pt; padding-left: 10pt">Paul Buckman</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">112,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,338</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,666</td><td style="width: 1%; text-align: left">(4)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">162,004</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Edward Andrle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,338</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,666</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Jeffrey Mathiesen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,338</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,666</td><td style="text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,504</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">These represent amounts earned in fiscal year 2021.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; text-align: justify">(2)</td>
    <td style="width: 97%; text-align: justify">Stock option and RSU awards were granted under the 2017 Equity Incentive Plan. The amounts reported reflect the aggregate grant date fair value of each equity award granted to the Company&#8217;s non-employee directors during the fiscal year ended September 30, 2021, as computed in accordance with ASC 718. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(3)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Buckman had 3,446 outstanding stock awards.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style=" text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(4)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Buckman had 77,466 outstanding stock options.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style=" text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(5)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Andrle had 3,446 outstanding stock awards.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style=" text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(6)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Andrle had 12,591 outstanding stock options.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style=" text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(7)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Mathiesen had 3,446 outstanding stock awards.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style=" text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(8)</td>
    <td style=" text-align: justify">At the end of fiscal year 2021, Mr. Mathiesen had 66,126 outstanding stock options.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a named executive officer
of the Company, compensation paid to Mr. Rosa for fiscal 2021 is fully reflected under &#8220;<i>Executive Compensation &#8212; Summary
Compensation Table.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth
the beneficial ownership of our Common Stock as of December 6, 2021 for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each person, or group of affiliated persons, who is known
by us to beneficially own more than 5% of our Common Stock;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each of our named executive officers;</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">each of our directors; and</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">all of our current executive officers and directors as a group.</td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table lists applicable
percentage ownership based on 16,187,722 shares of Common Stock outstanding as of December 6, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have determined beneficial
ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess
sole or shared voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities
identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject
to applicable community property laws. In addition, the rules include shares of our Common Stock issuable pursuant to the exercise of
stock options and warrants that are either immediately exercisable or exercisable within 60 days of December 6, 2021. These shares are
deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership
of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise noted
below, the address for persons listed in the table is c/o NeuroOne Medical Technologies Corporation, 7599 Anagram Dr., Eden Prairie, MN
55344.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name and address of beneficial owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> shares of <br/> Common&#160;Stock <br/> beneficially <br/> owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage&#160;of<br/> Common&#160;Stock beneficially<br/> owned<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Greater than 5% Stockholders:</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James E. Besser<sup>(2)</sup><br/> 2 Calle Candina, #1701 <br/> San Juan, Puerto Rico, 00907 <br/> United States of America</span></td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">1,747,651</p></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">10.8</p></td><td style="text-align: left; width: 1%">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">David Rosa</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">606,669</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Paul Buckman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,804</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Jeffrey Mathiesen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,852</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Edward Andrle</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,906</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Steve Mertens</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,296</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Ronald McClurg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,917</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">All Current Directors and Officers as a Group (7 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,252,614</td><td style="text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.5</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(1)</td>
    <td style="text-align: justify">Based on 16,187,722 shares of Common Stock outstanding as of December 6, 2021.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(2) </span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Based on Form 3 filed by James E. Besser, Morgan C. Frank, Manchester Management Co LLC, Manchester Management PR, LLC, and Manchester Explorer, L.P.on January 21, 2021 (the &#8220;Form 3&#8221;) and Form 13G filed by Manchester Explorer, L.P., Manchester Management Company, LLC, Manchester Management PR, LLC, JEB Partners, L.P., Messrs. Frank and Besser on January 21, 2021. The Form 3 also reported ownership of 1,666,669 shares of Common Stock issuable upon the exercise of outstanding warrants. The reported securities and warrants are directly owned by Manchester Explorer, L.P., JEB Partners, L.P. and by Mr. Frank in his personal capacity. The reported securities and warrants are indirectly beneficially owned by Manchester Management PR, LLC and Manchester Management Company, LLC as a result of having investment discretion over Manchester Explorer, L.P. and JEB Partners, L.P. The reported securities and warrants may also be deemed to be indirectly beneficially owned by Mr. Besser, as the Managing Member of Manchester Management PR, LLC and Manchester Management Company, LLC and by Mr. Frank, who serves as a portfolio manager and as a consultant for Manchester Management Company, LLC. Manchester Explorer, L.P. reports shared voting power over 1,181,930&#160;shares and shared investment power over 1,333,334&#160;shares; Manchester Management Company, LLC and Manchester Management PR, LLC report shared voting power over 1,181,930&#160;shares and shared investment power over 1,500,000&#160;shares; JEB Partners, L.P. reports shared voting and investment powers over 166,667&#160;shares; Mr.&#160;Besser reports sole voting power over 164,317&#160;shares, shared voting power over 1,181,930&#160;shares, sole investment power over 164,317, and shared investment power over 1,664,317 shares; and Mr. Frank reports sole voting and investment powers over 83,334 shares, shared voting power over 1,181,930 shares, and shared investment power over 1,583,334 shares.&#160;The reporting persons disclaim beneficial ownership of the reported securities and warrants except to the extent of their pecuniary interest therein. The percentage in this table reflects that the reporting persons may not exercise the warrants to the extent such exercise would cause the reporting persons to beneficially own a number of shares of common stock that would exceed 9.99% of our then outstanding common stock following such exercise. </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Includes 342,061 shares of Common Stock issuable upon exercise of outstanding options that have vested or vest within 60 days of December 6, 2021.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Includes 765 restricted stock units that vest within 60 days of December 6, 2021, and 75,905 shares of Common Stock issuable upon exercise of outstanding options.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(5)</td>
    <td style="text-align: justify">Includes 765 restricted stock units that vest within 60 days of December 6, 2021, and 64,565 shares
    of Common Stock issuable upon exercise of outstanding options.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Includes 765 restricted stock units that vest within
    60 days of December 6, 2021, and 11,030 shares of Common Stock issuable upon exercise of outstanding options.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(7)</td>
    <td style="text-align: justify">Includes 37,296 shares of Common Stock issuable upon exercise of outstanding options that have vested or vest within 60 days of December 6, 2021.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(8)</td>
    <td style="text-align: justify">Includes 27,917 shares of Common Stock issuable upon exercise of outstanding options that have vested or vest within 60 days of December 6, 2021.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(9)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Includes 2,296 restricted stock units that vest within 60 days of December 6, 2021, and 558,774 shares of Common Stock issuable upon exercise of outstanding options.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">*</td>
    <td style="text-align: justify">Less than 1%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Delinquent Section 16(a) Reports</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 16(a) of the Exchange
Act requires our officers and directors, and greater than 10% stockholders, to file reports of ownership and changes in ownership of our
securities with the SEC. Based on our review of these reports and written representations from reporting persons, we believe that all
reporting persons complied with all filing requirements during the fiscal year ended September 30, 2021, except for David A. Rosa who
had one late Form 4 filing related to the vesting of a portion of a stock option grant from the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Securities Authorized for Issuance Under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents
information as of September 30, 2021 with respect to compensation plans under which shares of our Common Stock may be issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Plan Category</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/>
Securities<br/> to be issued<br/>
upon<br/> exercise of<br/> outstanding<br/>
options,<br/>
warrants and<br/>
rights<br/> (a)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-average<br/>
exercise<br/>
price of<br/> outstanding<br/>
options,<br/>
warrants and<br/>
rights<br/> (b)</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> securities<br/> remaining<br/> available<br/> for future<br/> issuance<br/> under equity<br/> compensation<br/> plans<br/> (excluding<br/> securities<br/> reflected in<br/> column(a))(1)(2)<br/> (c)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: justify">Equity compensation plans not approved by security holders(3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt">Equity compensation plan approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,122,560</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.89</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">389,709</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,122,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.89</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">389,709</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(1)</td>
    <td style="text-align: justify">The number of shares of common stock reserved for issuance under our 2017 Equity Incentive Plan automatically increases on January 1st of each calendar year, starting on January 1, 2018 through January 1, 2027, to an amount equal to 13% of the total number of fully-diluted shares of our common stock as of December 31 of the preceding calendar year, or a lesser number of shares determined by our Board.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">(2)</td>
    <td style="text-align: justify">Consists of 241,338 shares remaining available for issuance under the 2017 Equity Incentive Plan and 148,371 shares remaining available for issuance under the 2016 Equity Incentive Plan.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">(3)</td>
    <td style="text-align: justify">There are no other securities available for future issuance under Company Plans as of September 30, 2021.&#160;&#160;The Company adopted an Inducement Plan subsequent to September 30, 2021. </td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Relationships and Related Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following includes a summary
of transactions since October 1, 2019 to which NeuroOne, Inc. or the Company has been a participant in which the amount involved exceeded
or will exceed the lesser of $120,000 or 1% of the average of the Company&#8217;s total assets at year end for the last two completed
fiscal years, and in which any of our directors, executive officers or holders of more than five percent of our capital stock, or any
members of their immediate family, had or will have a direct or indirect material interest.. Other than described below, there have not
been, nor are there currently any proposed, transactions or series of similar transactions to which we have been or will be a party other
than compensation arrangements, which include equity and other compensation, termination, change in control and other arrangements, which
are described under &#8220;Item 11 - Executive Compensation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Lock-Up Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 21, 2019, Wade
Fredrickson, a holder of over 5% of our Common Stock, entered into a lock-up agreement with the Company in which he agreed, subject to
certain exceptions, not to offer, sell, transfer or otherwise dispose of the Company&#8217;s securities for a period of 18 months following
the effective date of the agreement. On January 12, 2021, all of our directors, officers, and certain stockholders (including Wade Fredrickson)
entered into lock-up agreements in which they agreed, subject to certain exceptions, not to offer, sell, transfer or otherwise dispose
of the Company&#8217;s securities for a period of 90 days following the effectiveness of a resale registration statement to be filed in
connection with the Company&#8217;s January 2021 private placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation
contains provisions limiting the liability of directors, and our bylaws provides that we indemnify each of our directors to the fullest
extent permitted under Delaware law. Our Certificate of Incorporation and bylaws also provide our Board with discretion to indemnify our
officers and employees when determined appropriate by the Board. In addition, we have entered into an indemnification agreement with our
directors and our executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policies and Procedures for Transactions with
Related Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To assist the Company in complying
with its disclosure obligations and to enhance the Company&#8217;s disclosure controls, the Board approved a formal policy in January
2018 regarding related person transactions. A &#8220;related person&#8221; is a director, officer, nominee for director or a more than
5% stockholder (of any class of the Company&#8217;s voting stock) since the beginning of the Company&#8217;s last completed fiscal year,
and their immediate family members. A related person transaction is any transaction or any series of transactions in which the Company
was or is to be a participant, the amount involved exceeds $120,000, and in which any related person had or will have a direct or indirect
material interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, the policy establishes
a process for identifying related persons and procedures for reviewing and approving such related person transactions. In addition, directors
and executive officers are required to complete an annual questionnaire in connection with the Company&#8217;s proxy statement for its
annual meeting of stockholders, which includes questions regarding related person transactions, and such persons also are required to
provide written notice to the Company or outside legal counsel of any updates to such information prior to the annual meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee and/or
the independent directors of the Board review such proposed business transactions to ensure that the Company&#8217;s involvement in such
transactions is on terms comparable to those that could be obtained in arm&#8217;s length dealings with an unrelated third party and is
in the best interests of the Company and its stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq listing standards require
that the Company&#8217;s Board consist of a majority of independent directors, as determined under the applicable rules and regulations
of Nasdaq. Based upon information requested from and provided by each proposed director concerning his or her background, employment and
affiliations, including family relationships, the Company believes that each current member of the Board qualifies as an &#8220;independent
director&#8221; as defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq, except
Mr. Rosa, the Company&#8217;s President and Chief Executive Officer. In making such independence determinations, the Board considers the
current and prior relationships that each non-employee director has with the Company and all other facts and circumstances that the Board
deems relevant in determining each non-employee director&#8217;s independence, including the participation by the Company&#8217;s non-employee
directors, or their affiliates, in certain financing transactions and the beneficial ownership of the Company&#8217;s Common Stock by
each non-employee director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows
the fees for professional services rendered to us by Baker Tilly US, LLP (&#8220;Baker Tilly&#8221;) or BDO USA, LLP (&#8220;BDO&#8221;)
for services in respect of the fiscal years ended September 30, 2021 and 2020, which were approved by the Audit Committee in accordance
with its established policies and procedures.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FISCAL<br/> YEAR 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FISCAL<br/> YEAR 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">FEE CATEGORY</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Baker Tilly</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">BDO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Baker Tilly</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">BDO</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Audit fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">126,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#8212;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">251,799</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Audit-related fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total fees</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">126,745</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">159,633</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">251,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policy on Audit Committee Pre-Approval of Audit
and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Audit Committee generally
pre-approves all audit and permitted non-audit and tax services provided by the independent registered public accounting firm. Pre-approval
is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered
public accounting firm and management are required to periodically report to the Audit Committee regarding the extent of services provided
by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to
date. Our Audit Committee may also pre-approve particular services on a case-by-case basis. All of the services relating to the fees described
in the table above were approved by our Audit Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The following documents are filed as part
of this Annual Report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Financial
Statements: The financial statements filed as part of this Annual Report are listed in Part II, Item 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Financial
Statement Schedules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No financial statement schedules are provided
because the information called for is not required or is shown either in the financial statements or notes thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Exhibits:
The exhibits incorporated by reference or filed as part of this Annual Report are listed in the Index to Exhibits below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; padding-right: 0.8pt; text-align: justify"><b>Exhibit&#160;No.</b></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><b>Document</b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2.1 *</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex2-1.htm">Agreement and Plan of Merger and Reorganization by and among NeuroOne Medical Technologies Corporation,&#160;OSOK Acquisition Company&#160;and NeuroOne, Inc. dated as of July 20, 2017 (incorporated by reference to Exhibit 2.1 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex2-1.htm">Plan of Conversion of NeuroOne Medical Technologies Corporation dated June 20, 2017 (incorporated by reference to Exhibit 2.1 on the Registrant&#8217;s Current Report on Form 8-K filed on June 29, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">3.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm">Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant&#8217;s Current Report on Form 8-K filed on June, 29, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">3.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690ex3-1_neuroone.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant&#8217;s Current Report on Form 8-K filed on March 31, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">3.3</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-5.htm">Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant&#8217;s Current Report on Form 8-K filed on June 29, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex4-1.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">4.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019026720/f10k2019ex4-2_neuroonemedi.htm">Description of Securities (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Annual Report on Form 10-K filed on December 20, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.1 #</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390020001745/f8k0120ex10-1_neuroone.htm">Amended and Restated Exclusive Start-up Company License Agreement effective January 21, 2020 by and between NeuroOne Medical Technologies Corporation and Wisconsin Alumni Research Foundation (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on January 24, 2020)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.2 ##</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-3.htm">Mayo Foundation for Medical Education and Research Amended and Restated License and Development Agreement by and between Mayo Foundation for Medical Education and Research, and NeuroOne LLC dated as of May 25, 2017 (incorporated by reference to Exhibit 10.3 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.3 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-11.htm">2016 Equity Incentive Plan of NeuroOne, Inc.&#160;(incorporated by reference to Exhibit 10.11 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.4 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-12.htm">Form of Stock Option Award Agreement pursuant to 2016 Equity Incentive Plan of NeuroOne, Inc.&#160;(incorporated by reference to Exhibit 10.12 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%">10.5 +</td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-13.htm">Restricted Stock Purchase Agreement by and between NeuroOne, Inc. and Thomas Bachinski, dated as of April 10, 2017&#160;(incorporated by reference to Exhibit 10.13 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.6 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">2017 Equity Incentive Plan of the Company (incorporated by reference to Appendix G to Schedule 14C filed on April&#160;20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">10.7 +</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-15.htm">NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan Option Agreement (incorporated by reference to Exhibit 10.15 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.8 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-16.htm">NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.16 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.9 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="background-color: #CCEEFF"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000101376221000094/ea148325ex10-1_neuroone.htm">NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on October 4, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.10 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000101376221000094/ea148325ex10-2_neuroone.htm">NeuroOne Medical Technologies Corporation 2021 Inducement Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.2 on the Registrant&#8217;s Current Report on Form 8-K filed on October 4, 2021)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.11 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-18.htm">Offer Letter to Mark Christianson from NeuroOne, Inc. dated December 1, 2016 (incorporated by reference to Exhibit 10.18 on the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.12 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">Form of Indemnification Agreement with the Company&#8217;s Officers and Directors (incorporated by reference to Exhibit E to Appendix B to Schedule 14C filed on April 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.13 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417040898/v472061_ex10-1.htm">Employment Agreement by and between NeuroOne Medical Technologies Corporation and David A. Rosa dated August 4, 2017 (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on August 7, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.14</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex4-2.htm">Form of Capital Stock Purchase Warrant pursuant to August 2017 Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on August 23, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.15</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390017010361/f8k100417ex4-2_neuroone.htm">Form of Capital Stock Purchase Warrant issued pursuant to October 2017 Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on October 6, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.16</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390017013472/f8k121417ex4-2_neuroone.htm">Form of Amended and Restated Capital Stock Purchase Warrant issued pursuant to Amended and Restated Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on December 20, 2017)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.17</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-2_neuroone.htm">Form of Replacement Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on March 16, 2018)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.18</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-3_neuroone.htm">Form of Additional Warrant issued pursuant to August 2017 Subscription Agreement, as amended (incorporated by reference to Exhibit 4.3 on the Registrant&#8217;s Current Report on Form 8-K filed on March 16, 2018)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.19 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-40_neuroone.htm">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.40 to 10-K filed April 16, 2018)</a></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%">10.20</td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009196/f8k070918ex4-1_neuroone.htm">Form of Warrant (incorporated by reference to Exhibit 4.1 to 8-K filed July 13, 2018)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.21</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018009196/f8k070918ex10-2_neuroone.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to 8-K filed July 13, 2018)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.22 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018017239/f10kt2018ex10-52_neuroone.htm">Employee Proprietary Information, Inventions, Assignment and Non-Competition Agreement. (incorporated by reference to Exhibit 10.52 on the Registrant&#8217;s Annual Report on Form 10-KT filed on December 12, 2018)&#160;</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.23</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019000211/f8k122818ex4-1_neuroone.htm">Form of Warrant (incorporated by reference to Exhibit 4.1 on the Registrant&#8217;s Current Report on Form 8-K filed on January 4, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.24</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019000211/f8k122818ex10-2_neuroone.htm">Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 on the Registrant&#8217;s Current Report on Form 8-K filed on January 4, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.25 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019008306/f10q0319ex10-2_neuroone.htm">Offer Letter between Steve Mertens and NeuroOne Medical Technologies Corporation, effective April 1, 2019 (incorporated by reference to Exhibit 10.2 on the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.26</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019003689/f8k022819ex4-2_neuroonemed.htm">Form of Conversion Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on March 6, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.27</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019012136/f8k0719ex4-2_neuroone.htm">Form of Paulson Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed on July 5, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.28</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019012136/f8k0719ex4-3_neuroone.htm">Form of HRA Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed on July 5, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.29</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019020209/f8k100719ex10-1_neuroone.htm">Lease Agreement dated October 7, 2019, by and among NeuroOne Medical Technologies Corporation and Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on October 11, 2019)</a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%">10.30</td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019021393/f8k1019ex10-1_neuroone.htm">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on October 29, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.31</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390019022367/f8k1119ex4-2_neuroonemed.htm">Form of Common Stock Purchase Warrant issued pursuant to November 2019 Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on November 7, 2019)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.32</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390020001745/f8k0120ex4-1_neuroone.htm">Form of Broker Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 24, 2020)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.33</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390020010775/ea121253ex4-2_neuroone.htm">Form of Warrant (incorporated by reference to Exhibit 4.2 on the Registrant&#8217;s Current Report on Form 8-K filed on May 1, 2020)</a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%">10.34</td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390020018233/ea124403ex10-1_neuroone.htm">Exclusive Development and Distribution Agreement dated as of July 20, 2020 by and between the Company and Zimmer, Inc. (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on July 22, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.35 +</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021000810/ea132820ex10-1_neuroone.htm">Employment Offer Letter, dated as of January 1, 2021, by and between Ron McClurg and the Company (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on January 7, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.36</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021002402/ea133294ex4-1_neuroone.htm">Form of Warrant (incorporated by reference to Exhibit 4.1 on the Registrant&#8217;s Current Report on Form 8-K filed on January 15, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.37</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021002402/ea133294ex10-1_neuroone.htm">Form of Common Stock and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 on the Registrant&#8217;s Current Report on Form 8-K filed on January 15, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.38</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021052752/ea148799ex1-1_neuroone.htm">Underwriting Agreement, dated October 13, 2021, between NeuroOne Medical Technologies Corporation and Craig-Hallum Capital Group LLC (incorporated by reference to Exhibit 1.1 on the Registrant&#8217;s Current Report on Form 8-K filed on October 14, 2021).</a></td></tr>
<tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.39</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390021065463/f10k2021ex10-39_neuroonemed.htm" style="-sec-extract: exhibit">Amendment to Exclusive Development and Distribution Agreement by and between the Company and Zimmer, Inc. dated January 6, 2021 (incorporated by reference to Exhibit 10.39 on the Registrant&#8217;s Annual Report on Form 10-K filed on December 15, 2021).</a></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%">16.1</td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%">&#160;<a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390021033970/ea143230ex-16_neuroone.htm">Letter from BDO USA, LLP (incorporated by reference to Exhibit 16 on the Registrant&#8217;s Current Report on Form 8-K filed on June 24, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">21.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left"><a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390021065463/f10k2021ex21-1_neuroonemed.htm" style="-sec-extract: exhibit">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 on the Registrant&#8217;s Annual Report on Form 10-K filed on December 15, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">23.1</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="f10k2021a1ex23-1_neuroone.htm" style="-sec-extract: exhibit">Consent of Baker Tilly US, LLP</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">23.2</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><a href="f10k2021a1ex23-2_neuroone.htm">Consent of BDO USA, LLP</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">31.1</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="f10k2021a1ex31-1_neuroone.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">31.2</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="f10k2021a1ex31-2_neuroone.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">32.1</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="f10k2021a1ex32-1_neuroone.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">32.2</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify"><a href="f10k2021a1ex32-2_neuroone.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.INS</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Instance Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.SCH</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.CAL</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.DEF</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.LAB</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">101.PRE</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">104.1</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K, the Registrant
agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Agreement and Plan of Merger to the Securities and
Exchange Commission upon request.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">#</td><td style="text-align: justify">Certain schedules and exhibits have been omitted pursuant to Item
601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions
of the exhibits that are not material and would be competitively harmful if publicly disclosed have been redacted pursuant to Item 601(b)(10)(iv)
of Regulation S-K. Copies of the unredacted exhibits will be furnished to the SEC upon request.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">##</td><td style="text-align: justify">Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been separately filed with the Securities and Exchange Commission.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Indicates management contract or compensatory plan.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(b)</td><td style="text-align: justify">The exhibits listed in Item 15(a)(3) are hereby filed with this
Annual Report.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(c)</td><td style="text-align: justify">None.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>ITEM
16. FORM 10-K SUMMARY</b></p><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left">Date: May 31, 2022</td>
    <td colspan="2" style="text-align: left"><b>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: left">&#160;</td>
    <td style="width: 36%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">By:</td>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ DAVID ROSA</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">David Rosa</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><i>Chief Executive Officer</i></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: left"><b>SIGNATURE</b></td>
    <td style="vertical-align: top; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 41%; text-align: center"><b>TITLE</b></td>
    <td style="vertical-align: top; width: 1%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 18%; text-align: center"><b>DATE</b></td></tr>
  <tr>
    <td style="text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ DAVID ROSA</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">Chief Executive Officer and Director</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">May 31, 2022</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: left">David Rosa</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">(Principal Executive Officer)</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ RONALD MCCLURG</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">Chief Financial Officer </td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">May 31, 2022</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: left">Ronald McClurg</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: left">(Principal Financial Officer and Principal Accounting Officer)</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ PAUL BUCKMAN</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">Chairman of the Board of Directors</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">May 31, 2022</td></tr>
  <tr>
    <td style="text-align: left">Paul Buckman</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ EDWARD ANDRLE</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">Member of the Board of Directors</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">May 31, 2022</td></tr>
  <tr>
    <td style="text-align: left">Edward Andrle</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left">/s/ JEFFREY MATHIESEN</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">Member of the Board of Directors</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">May 31, 2022</td></tr>
  <tr>
    <td style="text-align: left">Jeffrey Mathiesen</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">128</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>





</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:LocalPhoneNumber">426-1383</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-1" name="dei:CityAreaCode">952</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:OtherLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-11" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-12" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-13" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-14" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-15" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-16" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-18" name="nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-22" name="nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-28" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-29" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-32" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-33" name="nmtc:IssuanceCostsInConnectionWithPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-34" name="nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-35" name="nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-40" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-43" name="nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-44" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-45" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="nmtc:NoncashInterestOnConvertiblePromissoryNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-47" name="nmtc:PayrollProtectionProgramLoanForgiveness" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-49" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-50" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-52" name="nmtc:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-53" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="nmtc:ProceedsFromPaycheckProtectionProgram" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-55" name="nmtc:DeferredsOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="nmtc:BrokerWarrantsIssuedInConnectionWithConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="nmtc:ValueOfPayrollProtectionProgramLoanForgiveness" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-58" name="nmtc:UnpaidDeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-59" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-60" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-61" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-62" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-63" name="us-gaap:ConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-64" name="us-gaap:ConvertibleNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="nmtc:ConvertibleNotes" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-66" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-67" name="us-gaap:OtherPrepaidExpenseCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-68" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-69" name="nmtc:RoyaltyPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-70" name="us-gaap:DeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-71" name="nmtc:ConvertibleNotesOutstandingPrincipal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-72" name="nmtc:AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-73" name="nmtc:FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-74" name="nmtc:ConvertiblePromissoryNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September 30, 2021 and 2020 of $3.95 and $3.86 per share, respectively. As of September 30, 2021 and 2020, 1,055,376 and 467,327 outstanding options, respectively, had no intrinsic value.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of stock option plan activity-->
<ix:nonNumeric contextRef="c5" id="hidden-fact-75" name="nmtc:WeightedAverageTermyearsIssuedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c5" id="hidden-fact-76" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-77" name="nmtc:WeightedAverageExercisePriceExercised" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c5" id="hidden-fact-79" name="nmtc:WeightedAverageTermyearsExercisedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="nmtc:WarrantsForfeitedinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-81" name="nmtc:WeightedAverageExercisePriceForfeited" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c5" id="hidden-fact-83" name="nmtc:WeightedAverageTermyearsForfeitedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-84" name="nmtc:WeightedAverageTermyearsIssuedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-85" name="nmtc:WeightedAverageTermyearsExercisedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="nmtc:WarrantsForfeitedinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="nmtc:WeightedAverageExercisePriceForfeited" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-89" name="nmtc:WeightedAverageTermyearsForfeitedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-90" name="nmtc:DisqualifiedInterestAndOther" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-91" name="nmtc:EffectiveTaxRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-92" name="nmtc:EffectiveTaxRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-93" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-94" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-95" name="nmtc:DeferredIncomeTaxAssetNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-96" name="nmtc:DeferredIncomeTaxAssetNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001500198</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="nmtc-20210930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-03</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:MayoAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nmtc:WadeFredricksonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-28</xbrli:startDate>
    <xbrli:endDate>2021-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:November302020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:April302021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:ModifiedConnectorbyApril302021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:ModifiedConnectorbySeptember302021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:OnOrBeforeJune302021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterJune302021ButOnOrBeforeSeptember302021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterSeptember302021ButOnOrBeforeDecember312021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterDecember312021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-11-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandNineteenQualifiedFinancingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3lqQ+eJmZU++LNv2ItnPhOfKxPj+16td6Q=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-02</xbrli:startDate>
    <xbrli:endDate>2020-04-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:Second2019PaulsonNotesAmendmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-03</xbrli:startDate>
    <xbrli:endDate>2020-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-11-25</xbrli:startDate>
    <xbrli:endDate>2019-12-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmtc:BrokerWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmtc:BrokerWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:EquityIncentivePlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoZeroOneSevenPlanEvergreenProvisionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">pf0:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">pf0:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:TwoconsultingAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:ActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:TwoconsultingAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:ActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-02</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2019-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-30</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-02</xbrli:startDate>
    <xbrli:endDate>2021-01-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:TwoZeroTwoZeroCommonStockOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:TwoZeroTwoZeroCommonStockOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmtc:TwoThousandNineteenCommonStockOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-03</xbrli:startDate>
    <xbrli:endDate>2019-10-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmtc:TwoThousandNineteenCommonStockOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-10-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceSixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>f10k2021a1ex23-1_neuroone.htm
<DESCRIPTION>CONSENT OF BAKER TILLY US, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">We consent to the incorporation by reference in the Registration
Statements on Form S-1 (No. 333-232656, No. 333-244487 and No. 333-252951), Form S-3 (No. 333-256830) and Form S-8 (No. 333-224572 and
No. 333-261302) of NeuroOne Medical Technologies Corporation of our report dated December 15, 2021, relating to the financial statements,
which report expresses an unqualified opinion on the financial statements for the year ended September 30, 2021 and includes an explanatory
paragraph relating to the Company&rsquo;s ability to continue as a going concern as described in Note 2 to the financial statements, appearing
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Baker Tilly US, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Minneapolis, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 31, 2022</P>
<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>f10k2021a1ex23-2_neuroone.htm
<DESCRIPTION>CONSENT OF BDO USA, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Consent of Independent Registered Public Accounting
Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Eden Prairie, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We hereby consent to the incorporation by reference
in the Registration Statements on Form S-1 (No. 333-232656, No. 333-244487 and No. 333-252951), Form S-3 (No. 333-256830) and Form S-8
(No. 333-224572 and No. 333-261302) of NeuroOne Medical Technologies Corporation of our report dated December 8, 2020, relating to the
financial statements, which appears in the Annual Report on Form 10-K/A. Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Minneapolis, Minnesota</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">May 31, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10k2021a1ex31-1_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a),
AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, David Rosa, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Amendment No. 1 to the Annual Report on
Form 10-K for the year ended September 30, 2021 (the &ldquo;report&rdquo;) of NeuroOne Medical Technologies Corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations, and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Date: May 31, 2022</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 1.8pt; text-align: justify">/s/ David Rosa</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; text-align: justify">David Rosa</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">(Principal&nbsp;Executive&nbsp;Officer) &nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10k2021a1ex31-2_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a),
AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Ronald McClurg, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Amendment No. 1 to the Annual Report on
Form 10-K for the year ended September 30, 2021 (the &ldquo;report&rdquo;) of NeuroOne Medical Technologies Corporation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations, and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Date: May 31, 2022</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 1.8pt; text-align: justify">/s/ Ronald McClurg</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="width: 35%; padding-right: 0.8pt; text-align: justify">Ronald McClurg</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Title:</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">(Principal&nbsp;Financial&nbsp;Officer) &nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10k2021a1ex32-1_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002*</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement
set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and
Section 1350 of Chapter 63 of Title 18 of the United States Code, David Rosa, Chief Executive Officer of NeuroOne Medical Technologies
Corporation (the &ldquo;Company&rdquo;) hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Amendment No. 1 to the Annual Report on
Form 10-K for the year ended September 30, 2021 (the &ldquo;Report&rdquo;) to which this Certification is attached as Exhibit 32.1 fully
complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in
all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations
of the Company for the period covered by the Report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; padding-right: 0.8pt; text-align: left; font-size: 10pt">/s/ David Rosa</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-size: 10pt">David Rosa</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-size: 10pt">Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-size: 10pt">(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Dated: May 31, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">*</FONT></TD><TD STYLE="text-align: justify">This certification accompanies the report to which it relates, is not deemed filed with the Securities
and Exchange Commission and is not to be incorporated by reference into any filing of NeuroOne Medical Technologies Corporation under
the Securities Act of 1933, as amended, or the Exchange Act made before or after the date of the report, irrespective of any general incorporation
language contained in such filing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>f10k2021a1ex32-2_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002*</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirement
set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and
Section 1350 of Chapter 63 of Title 18 of the United States Code, Ronald McClurg, Chief Financial Officer of NeuroOne Medical Technologies
Corporation (the &ldquo;Company&rdquo;) hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Amendment No. 1 to the Annual Report
on Form 10-K for the year ended September 30, 2021 (the &ldquo;Report&rdquo;) to which this Certification is attached as Exhibit 32.2
fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in
all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations
of the Company for the period covered by the Report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt">/s/ Ronald McClurg</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ronald McClurg</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">Dated: May 31, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">*</FONT></TD><TD STYLE="text-align: justify">This certification accompanies the report to which it relates, is not deemed filed with the Securities
and Exchange Commission and is not to be incorporated by reference into any filing of NeuroOne Medical Technologies Corporation under
the Securities Act of 1933, as amended, or the Exchange Act made before or after the date of the report, irrespective of any general incorporation
language contained in such filing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- G # 2(  A$! Q$!_\0
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M7GGN'T^T\ZX7;+)Y"[I!W#'&2/K5FTM+:R@6"UMHX(EX\N) JC\!0!;HHHH
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M33#(C1<3F945I1 )B-K?,J;6P&(QGBNUFTK3Y[:.UGT^UEMH^(X7@5E7Z C
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MGI4W5T(;=) SRQQ<MR0 I(S^&<UZ%&@BC6-1M50 !4B):*** "BBB@ HHHH
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M9E)]<'%+9V&M=3O/!*O>VES).!+AE7+*..&_^O\ YS7MWP>4KX8OT88/]I7
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MWT>K^&]1U*-'CCNM3N)5C8Y*@[>#7(J4XUG/HS>=5.FH]CT>BBBNPYPHHHH
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MN(GIRU/&J6+<"ZC.?4T6 NT56%]:GD3H?QIZ2Q2AMA#>N.] $U%%% !1110
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MPK 1>XSQZUHVVH:S';36</D6EO*=SC)<L1P">WI6*G.6VA3C!;F\O]HSZ?\
M;((8_L_F>7O9QNSC/W>N/_KUGZLY$-MG5V::0$RVT2\QG/'W22V?I6>;4S%G
MO+F>Z.W=M=RB_P#?*XJY%Y=NH6WC6,-VC3\JKDF]V+FBMBM<K--J45S8VXM(
M8@N/-).6'5@#D_-Z&HELH$F\QW+2[]WR?* ?O=.]7-Y^;"G\.,5&6()SN/4'
MG!-7&DEJ2YO8](^$C;KC5QR>(\Y_&O4J\K^$1S<:QCGB,@^O6O5*V("BBB@
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MBVK@(JR%0?4<4[]!'G*+;"WN/M,+QW3X1)$53#RN2/8]#Z5R,Z?Z0%0ELX
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>nmtc-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:38 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:nmtc="http://originalsourcemusic.com/20210930" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://originalsourcemusic.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20210930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20210930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20210930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20210930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet" id="nmtc_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nmtc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement" id="nmtc_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ShareholdersEquityType2or3" id="nmtc_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Statement of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConsolidatedCashFlow" id="nmtc_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperations" id="nmtc_r_OrganizationandNatureofOperations">
        <link:definition>006 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/GoingConcern" id="nmtc_r_GoingConcern">
        <link:definition>007 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies" id="nmtc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/CommitmentsandContingencies" id="nmtc_r_CommitmentsandContingencies">
        <link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation" id="nmtc_r_SupplementalBalanceSheetInformation">
        <link:definition>010 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities" id="nmtc_r_AccruedExpensesandOtherLiabilities">
        <link:definition>011 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement" id="nmtc_r_ZimmerDevelopmentAgreement">
        <link:definition>012 - Disclosure - Zimmer Development Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements" id="nmtc_r_ConvertiblePromissoryNotesandWarrantAgreements">
        <link:definition>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockBasedCompensation" id="nmtc_r_StockBasedCompensation">
        <link:definition>014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockholdersDeficit" id="nmtc_r_StockholdersDeficit">
        <link:definition>015 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/IncomeTaxes" id="nmtc_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/DefinedContributionPlan" id="nmtc_r_DefinedContributionPlan">
        <link:definition>017 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SubsequentEvents" id="nmtc_r_SubsequentEvents">
        <link:definition>018 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/AccountingPoliciesByPolicy" id="nmtc_r_AccountingPoliciesByPolicy">
        <link:definition>019 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables" id="nmtc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesTables" id="nmtc_r_CommitmentsandContingenciesTables">
        <link:definition>021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables" id="nmtc_r_SupplementalBalanceSheetInformationTables">
        <link:definition>022 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables" id="nmtc_r_AccruedExpensesandOtherLiabilitiesTables">
        <link:definition>023 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables" id="nmtc_r_ZimmerDevelopmentAgreementTables">
        <link:definition>024 - Disclosure - Zimmer Development Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables" id="nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsTables">
        <link:definition>025 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockBasedCompensationTables" id="nmtc_r_StockBasedCompensationTables">
        <link:definition>026 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockholdersDeficitTables" id="nmtc_r_StockholdersDeficitTables">
        <link:definition>027 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/IncomeTaxesTables" id="nmtc_r_IncomeTaxesTables">
        <link:definition>028 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails" id="nmtc_r_OrganizationandNatureofOperationsDetails">
        <link:definition>029 - Disclosure - Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/GoingConcernDetails" id="nmtc_r_GoingConcernDetails">
        <link:definition>030 - Disclosure - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails" id="nmtc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>031 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable" id="nmtc_r_ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable">
        <link:definition>032 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable" id="nmtc_r_Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable">
        <link:definition>033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable" id="nmtc_r_ScheduleofcomputationofdilutednetlosspershareTable">
        <link:definition>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails" id="nmtc_r_CommitmentsandContingenciesDetails">
        <link:definition>035 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable" id="nmtc_r_ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable">
        <link:definition>036 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable" id="nmtc_r_ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable">
        <link:definition>037 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable" id="nmtc_r_ScheduleofmaturityoftheleaseliabilityTable">
        <link:definition>038 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of the lease liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails" id="nmtc_r_SupplementalBalanceSheetInformationDetails">
        <link:definition>039 - Disclosure - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable" id="nmtc_r_ScheduleofPrepaidandotherassetsTable">
        <link:definition>040 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable" id="nmtc_r_ScheduleofintangibleassetsTable">
        <link:definition>041 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable" id="nmtc_r_ScheduleofpropertyandequipmentTable">
        <link:definition>042 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails" id="nmtc_r_AccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>043 - Disclosure - Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable" id="nmtc_r_ScheduleofaccruedexpensesTable">
        <link:definition>044 - Disclosure - Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails" id="nmtc_r_ZimmerDevelopmentAgreementDetails">
        <link:definition>045 - Disclosure - Zimmer Development Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable" id="nmtc_r_ScheduleofdeferredrevenueTable">
        <link:definition>046 - Disclosure - Zimmer Development Agreement (Details) - Schedule of deferred revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails" id="nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsDetails">
        <link:definition>047 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable" id="nmtc_r_ScheduleofconvertiblepromissorynotesandwarrantagreementsTable">
        <link:definition>048 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockBasedCompensationDetails" id="nmtc_r_StockBasedCompensationDetails">
        <link:definition>049 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable" id="nmtc_r_ScheduleofstockbasedcompensationexpenseTable">
        <link:definition>050 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable" id="nmtc_r_ScheduleofstockoptionplanactivityTable">
        <link:definition>051 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option plan activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3kwhSuLFx8WOMhM4bnaHIIg/6f6yZ8ORvI=] CSR-->
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable" id="nmtc_r_ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable">
        <link:definition>052 - Disclosure - Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable" id="nmtc_r_ScheduleofrestrictedstockunitactivityTable">
        <link:definition>053 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/StockholdersDeficitDetails" id="nmtc_r_StockholdersDeficitDetails">
        <link:definition>054 - Disclosure - Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable" id="nmtc_r_ScheduleofwarrantactivityTable">
        <link:definition>055 - Disclosure - Stockholders' Deficit (Details) - Schedule of warrant activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable" id="nmtc_r_ScheduleofsummarizesinformationaboutwarrantsoutstandingTable">
        <link:definition>056 - Disclosure - Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/IncomeTaxesDetails" id="nmtc_r_IncomeTaxesDetails">
        <link:definition>057 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable" id="nmtc_r_ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable">
        <link:definition>058 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="nmtc_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/DefinedContributionPlanDetails" id="nmtc_r_DefinedContributionPlanDetails">
        <link:definition>060 - Disclosure - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/SubsequentEventsDetails" id="nmtc_r_SubsequentEventsDetails">
        <link:definition>061 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://originalsourcemusic.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract"/>
  <xs:element name="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract"/>
  <xs:element name="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract"/>
  <xs:element name="SupplementalBalanceSheetInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SupplementalBalanceSheetInformationAbstract"/>
  <xs:element name="ScheduleOfPrepaidAndOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfAccruedExpensesAbstract"/>
  <xs:element name="ZimmerDevelopmentAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ZimmerDevelopmentAgreementAbstract"/>
  <xs:element name="ScheduleOfDeferredRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfDeferredRevenueAbstract"/>
  <xs:element name="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfStockOptionPlanActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfStockOptionPlanActivityAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ConvertibleNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertibleNotesAbstract"/>
  <xs:element name="ConvertibleNotesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertibleNotesAbstract0"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferredTaxAssetsAbstract"/>
  <xs:element name="RevenueFromCollaboration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RevenueFromCollaboration"/>
  <xs:element name="NetValuationChangeOfInstrumentsMeasuredAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue"/>
  <xs:element name="EarningsPerSharesBasicAndDiluted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EarningsPerSharesBasicAndDiluted"/>
  <xs:element name="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted"/>
  <xs:element name="IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering"/>
  <xs:element name="IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock"/>
  <xs:element name="IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits"/>
  <xs:element name="IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares"/>
  <xs:element name="StockIssuedDuringPeriodExerciseOfStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions"/>
  <xs:element name="IssuanceCostsInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostsInConnectionWithPrivatePlacement"/>
  <xs:element name="IssuanceCostSettlementInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement"/>
  <xs:element name="StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
  <xs:element name="AllocatedShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AllocatedShareBasedCompensation"/>
  <xs:element name="NoncashInterestOnConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NoncashInterestOnConvertiblePromissoryNotes"/>
  <xs:element name="PayrollProtectionProgramLoanForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PayrollProtectionProgramLoanForgiveness"/>
  <xs:element name="FairValueChangeOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueChangeOfConvertibleNotes"/>
  <xs:element name="IssuanceCostsAttributedToFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostsAttributedToFinancingActivities"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement"/>
  <xs:element name="ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement"/>
  <xs:element name="IssuanceCostsInConnectionWithConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes"/>
  <xs:element name="IssuanceCostsInConnectionWithPrivatePlacements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostsInConnectionWithPrivatePlacements"/>
  <xs:element name="ProceedsFromPaycheckProtectionProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ProceedsFromPaycheckProtectionProgram"/>
  <xs:element name="DeferredsOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferredsOfferingCosts"/>
  <xs:element name="ConversionOfConvertiblePromissoryNotesToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConversionOfConvertiblePromissoryNotesToEquity"/>
  <xs:element name="UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement"/>
  <xs:element name="BrokerWarrantsIssuedInConnectionWithConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes"/>
  <xs:element name="OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease"/>
  <xs:element name="ValueOfPayrollProtectionProgramLoanForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness"/>
  <xs:element name="UnpaidDeferredOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UnpaidDeferredOfferingCosts"/>
  <xs:element name="UnpaidPurchasesOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UnpaidPurchasesOfPropertyAndEquipment"/>
  <xs:element name="SupplementalBalanceSheetInformationTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SupplementalBalanceSheetInformationTextBlock"/>
  <xs:element name="ZimmerDevelopmentAgreementTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ZimmerDevelopmentAgreementTextBlock"/>
  <xs:element name="ReverseStockSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ReverseStockSplitPolicyTextBlock"/>
  <xs:element name="IntellectualPropertyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IntellectualPropertyPolicyTextBlock"/>
  <xs:element name="SupplementalCashFlowTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SupplementalCashFlowTableTextBlock"/>
  <xs:element name="SupplementalBalanceSheetTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SupplementalBalanceSheetTableTextBlock"/>
  <xs:element name="SummaryOfWarrantActivityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SummaryOfWarrantActivityTableTextBlock"/>
  <xs:element name="ConversionOfConvertiblePromissoryNotesToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
  <xs:element name="ChangeInFairValueIncludingAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ChangeInFairValueIncludingAccruedInterest"/>
  <xs:element name="FairValueAttributedToConvertibleNotesUponIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueAttributedToConvertibleNotesUponIssuance"/>
  <xs:element name="FairValueAttributedToNoteExtinguishment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueAttributedToNoteExtinguishment"/>
  <xs:element name="Warrantshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_Warrantshares"/>
  <xs:element name="StockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockOptions"/>
  <xs:element name="RestrictedStockUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RestrictedStockUnit"/>
  <xs:element name="UnissuedVestedRestrictedStockUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UnissuedVestedRestrictedStockUnits"/>
  <xs:element name="ConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertibleNotes"/>
  <xs:element name="OperatingCashFlowsFromOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OperatingCashFlowsFromOperatingLeases"/>
  <xs:element name="OperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OperatingLeases"/>
  <xs:element name="LeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseLiability"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueOneYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueFourYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear"/>
  <xs:element name="ImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ImputedInterest"/>
  <xs:element name="LeaseLiabilityNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseLiabilityNet"/>
  <xs:element name="PrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PrepaidExpenses"/>
  <xs:element name="NetIntangiblesUsefulLives" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NetIntangiblesUsefulLives"/>
  <xs:element name="LessAccumulatedDepreciations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LessAccumulatedDepreciations"/>
  <xs:element name="AccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AccruedPayroll"/>
  <xs:element name="LeaseLiabilityShortterms" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseLiabilityShortterms"/>
  <xs:element name="RoyaltyPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RoyaltyPayments"/>
  <xs:element name="UpfrontInitialExclusivityPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UpfrontInitialExclusivityPayments"/>
  <xs:element name="ConvertibleNotesOutstandingPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertibleNotesOutstandingPrincipal"/>
  <xs:element name="AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables"/>
  <xs:element name="FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable"/>
  <xs:element name="ConvertiblePromissoryNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertiblePromissoryNotesPayable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1"/>
  <xs:element name="StockholdersDeficitDetailsScheduleofwarrantactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable"/>
  <xs:element name="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber"/>
  <xs:element name="ExercisePricePerWarrantOutstandingAndExercisableBeginning1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
  <xs:element name="ExercisePricePerWarrantIssued" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePricePerWarrantIssued"/>
  <xs:element name="WeightedAverageTermyearsIssuedinShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageTermyearsIssuedinShares"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
  <xs:element name="WeightedAverageExercisePriceExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageExercisePriceExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1"/>
  <xs:element name="WeightedAverageTermyearsExercisedinShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageTermyearsExercisedinShares"/>
  <xs:element name="WarrantsForfeitedinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WarrantsForfeitedinShares"/>
  <xs:element name="WeightedAverageExercisePriceForfeited" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageExercisePriceForfeited"/>
  <xs:element name="WeightedAverageTermyearsForfeitedinShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageTermyearsForfeitedinShares"/>
  <xs:element name="ExercisePricePerWarrantOutstandingAndExercisableEnding" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding"/>
  <xs:element name="WeightedAverageExercisePriceOutstandingAndExercisableEnding" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePrice"/>
  <xs:element name="NumberOutstandingsTotal" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NumberOutstandingsTotal"/>
  <xs:element name="WeightedAverageRemainingContractualLifeYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WeightedAverageRemainingContractualLifeYears"/>
  <xs:element name="NumberExercisable1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NumberExercisable1"/>
  <xs:element name="IncomeTaxBenefitAtFederalStatutoryRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IncomeTaxBenefitAtFederalStatutoryRate"/>
  <xs:element name="StateIncomeTaxNetOfFederalBenefit" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StateIncomeTaxNetOfFederalBenefit"/>
  <xs:element name="DisqualifiedInterestAndOther" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DisqualifiedInterestAndOther"/>
  <xs:element name="ResearchCredits" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ResearchCredits"/>
  <xs:element name="StockbasedCompensation" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockbasedCompensation"/>
  <xs:element name="ValuationAllowance" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ValuationAllowance"/>
  <xs:element name="EffectiveTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EffectiveTaxRate"/>
  <xs:element name="DeferredIncomeTaxAssetNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferredIncomeTaxAssetNet"/>
  <xs:element name="ProceedsFromPayrollProtectionProgramLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ProceedsFromPayrollProtectionProgramLoan"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="DepositsExcessOfFederallyInsured" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DepositsExcessOfFederallyInsured"/>
  <xs:element name="NumberOfLicencingAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NumberOfLicencingAgreements"/>
  <xs:element name="TypeOfAgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TypeOfAgreementDomain"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RoyaltyMinimumPaymentsYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RoyaltyMinimumPaymentsYearOne"/>
  <xs:element name="RoyaltyMinimumPaymentsYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RoyaltyMinimumPaymentsYearTwo"/>
  <xs:element name="RoyaltyMinimumPaymentsYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RoyaltyMinimumPaymentsYearThree"/>
  <xs:element name="LeaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseAgreementDescription"/>
  <xs:element name="LeaseSpace" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseSpace"/>
  <xs:element name="LeaseRentalExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LeaseRentalExpense"/>
  <xs:element name="MonthlyLeaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_MonthlyLeaseRent"/>
  <xs:element name="RentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RentExpense"/>
  <xs:element name="PaycheckProtectionProgramDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PaycheckProtectionProgramDescription"/>
  <xs:element name="ZimmerDevelopmentAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_ZimmerDevelopmentAgreementDetailsTable"/>
  <xs:element name="ZimmerDevelopmentAgreementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ZimmerDevelopmentAgreementDetailsLineItems"/>
  <xs:element name="IntialFeePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IntialFeePayment"/>
  <xs:element name="FuturePotentialMilestonePaymentsToNeuroone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FuturePotentialMilestonePaymentsToNeuroone"/>
  <xs:element name="ProductRevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ProductRevenueRecognized"/>
  <xs:element name="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable"/>
  <xs:element name="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems"/>
  <xs:element name="InterestOnPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_InterestOnPrincipalAmount"/>
  <xs:element name="EquityFinancingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EquityFinancingAmount"/>
  <xs:element name="EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering"/>
  <xs:element name="OutstandingVotingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OutstandingVotingPercentage"/>
  <xs:element name="IssuanceOfFairValueAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceOfFairValueAmount"/>
  <xs:element name="ChangesOfFairValueBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ChangesOfFairValueBenefit"/>
  <xs:element name="WarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WarrantsDescription"/>
  <xs:element name="WarrantsExercisableForSharesOfCommonStockConnection" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WarrantsExercisableForSharesOfCommonStockConnection"/>
  <xs:element name="IssuanceCostsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCostsDescription"/>
  <xs:element name="ExtendedMaturityDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExtendedMaturityDateDescription"/>
  <xs:element name="RevisedOptionalConversionTermsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_RevisedOptionalConversionTermsDescription"/>
  <xs:element name="ReviseTheRegistrationDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ReviseTheRegistrationDateDescription"/>
  <xs:element name="ConvertedNotesCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertedNotesCommonStock"/>
  <xs:element name="aggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_aggregatePrincipalAmount"/>
  <xs:element name="NoncashInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_NoncashInterest"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_GrossProceeds"/>
  <xs:element name="InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance"/>
  <xs:element name="IncreaseDecreaseInFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IncreaseDecreaseInFairValue"/>
  <xs:element name="WarrantsToPurchaseOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WarrantsToPurchaseOfCommonStockShares"/>
  <xs:element name="CashCommissionPercentageRateOnProceeds" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_CashCommissionPercentageRateOnProceeds"/>
  <xs:element name="IssuanceOfCostsIncurred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceOfCostsIncurred"/>
  <xs:element name="CashCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_CashCommissions"/>
  <xs:element name="LegalAndThirdPartyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_LegalAndThirdPartyFee"/>
  <xs:element name="IssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_IssuanceCosts"/>
  <xs:element name="ConvertibleNoteFinancingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConvertibleNoteFinancingDescription"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_StockBasedCompensationDetailsTable"/>
  <xs:element name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockBasedCompensationDetailsLineItems"/>
  <xs:element name="SharesReservedDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SharesReservedDescription"/>
  <xs:element name="StockOptionVestedOverAPeriodTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockOptionVestedOverAPeriodTerm"/>
  <xs:element name="TotalExpenseOfStockOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TotalExpenseOfStockOption"/>
  <xs:element name="ExercisePriceOfUnderlyingOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePriceOfUnderlyingOptions"/>
  <xs:element name="OutstandingStockOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OutstandingStockOptionsShares"/>
  <xs:element name="GrantDateFairValueOfPerUnit" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_GrantDateFairValueOfPerUnit"/>
  <xs:element name="VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
  <xs:element name="ConsultingAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ConsultingAgreementsDescription"/>
  <xs:element name="FairValueOfTheUnderlyingCommonStock" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueOfTheUnderlyingCommonStock"/>
  <xs:element name="FutureIssuanceOnACombinedBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FutureIssuanceOnACombinedBasis"/>
  <xs:element name="StockholdersDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nmtc_StockholdersDeficitDetailsTable"/>
  <xs:element name="StockholdersDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StockholdersDeficitDetailsLineItems"/>
  <xs:element name="AggregateShareIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AggregateShareIssued"/>
  <xs:element name="PurchaseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PurchaseOfWarrants"/>
  <xs:element name="PurchasePriceOfCommonStock" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PurchasePriceOfCommonStock"/>
  <xs:element name="TotalGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TotalGrossProceeds"/>
  <xs:element name="FairValueOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_FairValueOfWarrants"/>
  <xs:element name="SharesIssuedUnderPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SharesIssuedUnderPrivatePlacement"/>
  <xs:element name="GrossProceedsFromPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_GrossProceedsFromPrivatePlacement"/>
  <xs:element name="DeferredTaxAssetGrossCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferredTaxAssetGrossCurrent"/>
  <xs:element name="DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal"/>
  <xs:element name="StateTaxCreditCarryForward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_StateTaxCreditCarryForward"/>
  <xs:element name="EmployeesCompensationPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EmployeesCompensationPercentage"/>
  <xs:element name="DeferralsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DeferralsPercentage"/>
  <xs:element name="ContributionsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ContributionsPercentage"/>
  <xs:element name="InternalRevenuePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_InternalRevenuePercentage"/>
  <xs:element name="ContributionsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ContributionsAmount"/>
  <xs:element name="SharesAreAuthorizedForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_SharesAreAuthorizedForFutureIssuance"/>
  <xs:element name="UnderwritingAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nmtc_UnderwritingAgreementDescription"/>
  <xs:element name="TypeOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="nmtc_TypeOfAgreementAxis"/>
  <xs:element name="ActivityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ActivityMember"/>
  <xs:element name="AfterDecember312021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AfterDecember312021Member"/>
  <xs:element name="AfterJune302021ButOnOrBeforeSeptember302021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member"/>
  <xs:element name="AfterSeptember302021ButOnOrBeforeDecember312021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member"/>
  <xs:element name="April302021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_April302021Member"/>
  <xs:element name="BrokerWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_BrokerWarrantsMember"/>
  <xs:element name="DevelopmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DevelopmentAgreementMember"/>
  <xs:element name="EquityIncentivePlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_EquityIncentivePlansMember"/>
  <xs:element name="ExercisePriceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePriceMember"/>
  <xs:element name="ExercisePriceOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePriceOneMember"/>
  <xs:element name="ExercisePriceThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePriceThreeMember"/>
  <xs:element name="ExercisePriceTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ExercisePriceTwoMember"/>
  <xs:element name="MayoAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_MayoAgreementMember"/>
  <xs:element name="ModifiedConnectorbyApril302021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ModifiedConnectorbyApril302021Member"/>
  <xs:element name="ModifiedConnectorbySeptember302021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ModifiedConnectorbySeptember302021Member"/>
  <xs:element name="November302020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_November302020Member"/>
  <xs:element name="OnOrBeforeJune302021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_OnOrBeforeJune302021Member"/>
  <xs:element name="PaulsonPrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PaulsonPrivatePlacementMember"/>
  <xs:element name="PaulsonPrivatePlacementTwoThousandNineteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember"/>
  <xs:element name="PurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_PurchaseAgreementMember"/>
  <xs:element name="ScenarioOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScenarioOneMember"/>
  <xs:element name="ScenarioTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_ScenarioTwoMember"/>
  <xs:element name="Second2019PaulsonNotesAmendmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_Second2019PaulsonNotesAmendmentMember"/>
  <xs:element name="TwentyTwentyActivityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwentyTwentyActivityMember"/>
  <xs:element name="TwoThousandNineteenCommonStockOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoThousandNineteenCommonStockOfferingMember"/>
  <xs:element name="TwoThousandNineteenQualifiedFinancingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoThousandNineteenQualifiedFinancingMember"/>
  <xs:element name="TwoThousandSixteenAndSeventeenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
  <xs:element name="TwoZeroOneNinePaulsonNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoZeroOneNinePaulsonNotesMember"/>
  <xs:element name="TwoZeroOneSevenPlanEvergreenProvisionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember"/>
  <xs:element name="TwoZeroTwoZeroCommonStockOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoZeroTwoZeroCommonStockOfferingMember"/>
  <xs:element name="TwoZeroTwoZeroPaulsonNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoZeroTwoZeroPaulsonNotesMember"/>
  <xs:element name="TwoZeroTwoZeroPaulsonPrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember"/>
  <xs:element name="TwoconsultingAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_TwoconsultingAgreementsMember"/>
  <xs:element name="WadeFredricksonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_WadeFredricksonMember"/>
  <xs:element name="newExercisePriceFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_newExercisePriceFiveMember"/>
  <xs:element name="newExercisePriceFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_newExercisePriceFourMember"/>
  <xs:element name="newExercisePriceSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_newExercisePriceSixMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nmtc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>nmtc-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:38 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedBalanceSheet" roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedIncomeStatement" roleURI="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedCashFlow" roleURI="http://originalsourcemusic.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofPrepaidandotherassetsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenue" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_RevenueFromCollaboration" xlink:href="nmtc-20210930.xsd#nmtc_RevenueFromCollaboration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="nmtc_RevenueFromCollaboration" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3lZKp1ttJfdriVnGZSX4A7UX+EOpLkhkfY=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:href="nmtc-20210930.xsd#nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_AllocatedShareBasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_AllocatedShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmtc_AllocatedShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterestOnConvertiblePromissoryNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmtc_NoncashInterestOnConvertiblePromissoryNotes" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueChangeOfConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_FairValueChangeOfConvertibleNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmtc_FairValueChangeOfConvertibleNotes" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsAttributedToFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmtc_IssuanceCostsAttributedToFinancingActivities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_PayrollProtectionProgramLoanForgiveness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nmtc_PayrollProtectionProgramLoanForgiveness" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPaycheckProtectionProgram"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_ProceedsFromPaycheckProtectionProgram" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredsOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_DeferredsOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_DeferredsOfferingCosts" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:label="nmtc_PrepaidExpenses" xlink:href="nmtc-20210930.xsd#nmtc_PrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="nmtc_PrepaidExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_DeferredOfferingCosts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>nmtc-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:38 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedBalanceSheet" roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedIncomeStatement" roleURI="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ShareholdersEquityType2or3" roleURI="http://originalsourcemusic.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedCashFlow" roleURI="http://originalsourcemusic.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_OrganizationandNatureofOperations" roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_GoingConcern" roleURI="http://originalsourcemusic.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPolicies" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingencies" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformation" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilities" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreement" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreements" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensation" roleURI="http://originalsourcemusic.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficit" roleURI="http://originalsourcemusic.com/role/StockholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxes" roleURI="http://originalsourcemusic.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_DefinedContributionPlan" roleURI="http://originalsourcemusic.com/role/DefinedContributionPlan"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SubsequentEvents" roleURI="http://originalsourcemusic.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccountingPoliciesByPolicy" roleURI="http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingenciesTables" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformationTables" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilitiesTables" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreementTables" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsTables" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensationTables" roleURI="http://originalsourcemusic.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficitTables" roleURI="http://originalsourcemusic.com/role/StockholdersDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxesTables" roleURI="http://originalsourcemusic.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable" roleURI="http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable" roleURI="http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofcomputationofdilutednetlosspershareTable" roleURI="http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofmaturityoftheleaseliabilityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofPrepaidandotherassetsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofintangibleassetsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofpropertyandequipmentTable" roleURI="http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofaccruedexpensesTable" roleURI="http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofdeferredrevenueTable" roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofconvertiblepromissorynotesandwarrantagreementsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofstockoptionplanactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable" roleURI="http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofrestrictedstockunitactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofwarrantactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsummarizesinformationaboutwarrantsoutstandingTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable" roleURI="http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_OrganizationandNatureofOperationsDetails" roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_GoingConcernDetails" roleURI="http://originalsourcemusic.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingenciesDetails" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformationDetails" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilitiesDetails" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreementDetails" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsDetails" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensationDetails" roleURI="http://originalsourcemusic.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficitDetails" roleURI="http://originalsourcemusic.com/role/StockholdersDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxesDetails" roleURI="http://originalsourcemusic.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_DefinedContributionPlanDetails" roleURI="http://originalsourcemusic.com/role/DefinedContributionPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SubsequentEventsDetails" roleURI="http://originalsourcemusic.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#DocumentAndEntityInformation" roleURI="http://originalsourcemusic.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RevenueFromCollaboration" xlink:href="nmtc-20210930.xsd#nmtc_RevenueFromCollaboration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="nmtc_RevenueFromCollaboration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:href="nmtc-20210930.xsd#nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_EarningsPerSharesBasicAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_EarningsPerSharesBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="nmtc_EarningsPerSharesBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodExerciseOfStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AllocatedShareBasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_AllocatedShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmtc_AllocatedShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterestOnConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmtc_NoncashInterestOnConvertiblePromissoryNotes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_PayrollProtectionProgramLoanForgiveness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmtc_PayrollProtectionProgramLoanForgiveness" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueChangeOfConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_FairValueChangeOfConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmtc_FairValueChangeOfConvertibleNotes" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsAttributedToFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nmtc_IssuanceCostsAttributedToFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPaycheckProtectionProgram"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_ProceedsFromPaycheckProtectionProgram" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredsOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_DeferredsOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nmtc_DeferredsOfferingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_ValueOfPayrollProtectionProgramLoanForgiveness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidDeferredOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidDeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_UnpaidDeferredOfferingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidPurchasesOfPropertyAndEquipment" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidPurchasesOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="nmtc_UnpaidPurchasesOfPropertyAndEquipment" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/OrganizationandNatureofOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/GoingConcern">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation">
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="nmtc_SupplementalBalanceSheetInformationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement">
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:to="nmtc_ZimmerDevelopmentAgreementTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DefinedContributionPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ReverseStockSplitPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ReverseStockSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmtc_ReverseStockSplitPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IntellectualPropertyPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_IntellectualPropertyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmtc_IntellectualPropertyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalCashFlowTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalCashFlowTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nmtc_SupplementalCashFlowTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nmtc_SupplementalBalanceSheetTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables">
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables">
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SummaryOfWarrantActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="nmtc_SummaryOfWarrantActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:to="nmtc_ConvertibleNotesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToConvertibleNotesUponIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueAttributedToNoteExtinguishment" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToNoteExtinguishment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_FairValueAttributedToNoteExtinguishment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ChangeInFairValueIncludingAccruedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ChangeInFairValueIncludingAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_ChangeInFairValueIncludingAccruedInterest" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_Warrantshares" xlink:href="nmtc-20210930.xsd#nmtc_Warrantshares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_Warrantshares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_StockOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RestrictedStockUnit" xlink:href="nmtc-20210930.xsd#nmtc_RestrictedStockUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_RestrictedStockUnit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnissuedVestedRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_UnissuedVestedRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_UnissuedVestedRestrictedStockUnits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_ConvertibleNotes" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:to="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingCashFlowsFromOperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingCashFlowsFromOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:to="nmtc_OperatingCashFlowsFromOperatingLeases" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:to="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="nmtc_OperatingLeases" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiability" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="nmtc_LeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ImputedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ImputedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="nmtc_ImputedInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiabilityNet" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ImputedInterest" xlink:to="nmtc_LeaseLiabilityNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ImputedInterest" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ImputedInterest" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_PrepaidExpenses" xlink:href="nmtc-20210930.xsd#nmtc_PrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="nmtc_PrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NetIntangiblesUsefulLives" xlink:href="nmtc-20210930.xsd#nmtc_NetIntangiblesUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="nmtc_NetIntangiblesUsefulLives" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LessAccumulatedDepreciations" xlink:href="nmtc-20210930.xsd#nmtc_LessAccumulatedDepreciations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="nmtc_LessAccumulatedDepreciations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_AccruedPayroll" xlink:href="nmtc-20210930.xsd#nmtc_AccruedPayroll"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="nmtc_AccruedPayroll" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiabilityShortterms" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityShortterms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="nmtc_LeaseLiabilityShortterms" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyPayments" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="nmtc_RoyaltyPayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfDeferredRevenueAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfDeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UpfrontInitialExclusivityPayments" xlink:href="nmtc-20210930.xsd#nmtc_UpfrontInitialExclusivityPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="nmtc_UpfrontInitialExclusivityPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotesOutstandingPrincipal" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesOutstandingPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="nmtc_ConvertibleNotesOutstandingPrincipal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:href="nmtc-20210930.xsd#nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:href="nmtc-20210930.xsd#nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesPayable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="nmtc_ConvertiblePromissoryNotesPayable" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfStockOptionPlanActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3nsq9Oq0rdWOjfMDT5CRlms] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="nmtc-20210930.xsd#nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable">
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantIssued" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ExercisePricePerWarrantIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsIssuedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsIssuedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageTermyearsIssuedinShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceExercised" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageExercisePriceExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsExercisedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsExercisedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageTermyearsExercisedinShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsForfeitedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WarrantsForfeitedinShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceForfeited" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageExercisePriceForfeited" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsForfeitedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageTermyearsForfeitedinShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_ExercisePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_ExercisePriceOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_ExercisePriceTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceThreeMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_ExercisePriceThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceFourMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_newExercisePriceFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceFiveMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_newExercisePriceFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceSixMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nmtc_newExercisePriceSixMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePrice" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nmtc_ExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberOutstandingsTotal" xlink:href="nmtc-20210930.xsd#nmtc_NumberOutstandingsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nmtc_NumberOutstandingsTotal" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageRemainingContractualLifeYears" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageRemainingContractualLifeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nmtc_WeightedAverageRemainingContractualLifeYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberExercisable1" xlink:href="nmtc-20210930.xsd#nmtc_NumberExercisable1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nmtc_NumberExercisable1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" xlink:href="nmtc-20210930.xsd#nmtc_IncomeTaxBenefitAtFederalStatutoryRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StateIncomeTaxNetOfFederalBenefit" xlink:href="nmtc-20210930.xsd#nmtc_StateIncomeTaxNetOfFederalBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_StateIncomeTaxNetOfFederalBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DisqualifiedInterestAndOther" xlink:href="nmtc-20210930.xsd#nmtc_DisqualifiedInterestAndOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_DisqualifiedInterestAndOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ResearchCredits" xlink:href="nmtc-20210930.xsd#nmtc_ResearchCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_ResearchCredits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockbasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_StockbasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_StockbasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ValuationAllowance" xlink:href="nmtc-20210930.xsd#nmtc_ValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_ValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_EffectiveTaxRate" xlink:href="nmtc-20210930.xsd#nmtc_EffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_EffectiveTaxRate" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nmtc_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredIncomeTaxAssetNet" xlink:href="nmtc-20210930.xsd#nmtc_DeferredIncomeTaxAssetNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nmtc_DeferredIncomeTaxAssetNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromPayrollProtectionProgramLoan" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPayrollProtectionProgramLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nmtc_ProceedsFromPayrollProtectionProgramLoan" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/GoingConcernDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DepositsExcessOfFederallyInsured" xlink:href="nmtc-20210930.xsd#nmtc_DepositsExcessOfFederallyInsured"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nmtc_DepositsExcessOfFederallyInsured" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberOfLicencingAgreements" xlink:href="nmtc-20210930.xsd#nmtc_NumberOfLicencingAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nmtc_NumberOfLicencingAgreements" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_CommitmentsandContingenciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_CommitmentsandContingenciesDetailsTable" xlink:to="nmtc_TypeOfAgreementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain_0" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_MayoAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_MayoAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_TypeOfAgreementDomain" xlink:to="nmtc_MayoAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WadeFredricksonMember" xlink:href="nmtc-20210930.xsd#nmtc_WadeFredricksonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nmtc_WadeFredricksonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearOne" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_RoyaltyMinimumPaymentsYearOne" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearTwo" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_RoyaltyMinimumPaymentsYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearThree" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_RoyaltyMinimumPaymentsYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_LeaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_LeaseAgreementDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseSpace" xlink:href="nmtc-20210930.xsd#nmtc_LeaseSpace"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_LeaseSpace" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseRentalExpense" xlink:href="nmtc-20210930.xsd#nmtc_LeaseRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_LeaseRentalExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_MonthlyLeaseRent" xlink:href="nmtc-20210930.xsd#nmtc_MonthlyLeaseRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_MonthlyLeaseRent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RentExpense" xlink:href="nmtc-20210930.xsd#nmtc_RentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_RentExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaycheckProtectionProgramDescription" xlink:href="nmtc-20210930.xsd#nmtc_PaycheckProtectionProgramDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="nmtc_PaycheckProtectionProgramDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails">
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="nmtc_ZimmerDevelopmentAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:to="nmtc_TypeOfAgreementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain_0" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScenarioOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nmtc_ScenarioOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScenarioTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nmtc_ScenarioTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DevelopmentAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_DevelopmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_TypeOfAgreementDomain" xlink:to="nmtc_DevelopmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_November302020Member" xlink:href="nmtc-20210930.xsd#nmtc_November302020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_November302020Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_April302021Member" xlink:href="nmtc-20210930.xsd#nmtc_April302021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_April302021Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ModifiedConnectorbyApril302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbyApril302021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_ModifiedConnectorbyApril302021Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ModifiedConnectorbySeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbySeptember302021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_ModifiedConnectorbySeptember302021Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OnOrBeforeJune302021Member" xlink:href="nmtc-20210930.xsd#nmtc_OnOrBeforeJune302021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_OnOrBeforeJune302021Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterDecember312021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_AfterDecember312021Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IntialFeePayment" xlink:href="nmtc-20210930.xsd#nmtc_IntialFeePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="nmtc_IntialFeePayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FuturePotentialMilestonePaymentsToNeuroone" xlink:href="nmtc-20210930.xsd#nmtc_FuturePotentialMilestonePaymentsToNeuroone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="nmtc_FuturePotentialMilestonePaymentsToNeuroone" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProductRevenueRecognized" xlink:href="nmtc-20210930.xsd#nmtc_ProductRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="nmtc_ProductRevenueRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="us-gaap_Revenues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_BrokerWarrantsMember" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="nmtc_BrokerWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandNineteenQualifiedFinancingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenQualifiedFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_TwoThousandNineteenQualifiedFinancingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroOneNinePaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneNinePaulsonNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_TwoZeroOneNinePaulsonNotesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_Second2019PaulsonNotesAmendmentMember" xlink:href="nmtc-20210930.xsd#nmtc_Second2019PaulsonNotesAmendmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_Second2019PaulsonNotesAmendmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroPaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_TwoZeroTwoZeroPaulsonNotesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="nmtc_PaulsonPrivatePlacementMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_InterestOnPrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_InterestOnPrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_InterestOnPrincipalAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityFinancingAmount" xlink:href="nmtc-20210930.xsd#nmtc_EquityFinancingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_EquityFinancingAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:href="nmtc-20210930.xsd#nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OutstandingVotingPercentage" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingVotingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_OutstandingVotingPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfFairValueAmount" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfFairValueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_IssuanceOfFairValueAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ChangesOfFairValueBenefit" xlink:href="nmtc-20210930.xsd#nmtc_ChangesOfFairValueBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ChangesOfFairValueBenefit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsDescription" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_WarrantsDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsExercisableForSharesOfCommonStockConnection" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsExercisableForSharesOfCommonStockConnection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_WarrantsExercisableForSharesOfCommonStockConnection" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsDescription" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_IssuanceCostsDescription" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExtendedMaturityDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ExtendedMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ExtendedMaturityDateDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_RevisedOptionalConversionTermsDescription" xlink:href="nmtc-20210930.xsd#nmtc_RevisedOptionalConversionTermsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_RevisedOptionalConversionTermsDescription" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ReviseTheRegistrationDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ReviseTheRegistrationDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ReviseTheRegistrationDateDescription" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_LegalFees" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertedNotesCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConvertedNotesCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ConvertedNotesCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_aggregatePrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_aggregatePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_aggregatePrincipalAmount" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_NoncashInterest" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_NoncashInterest" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_GrossProceeds" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:href="nmtc-20210930.xsd#nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IncreaseDecreaseInFairValue" xlink:href="nmtc-20210930.xsd#nmtc_IncreaseDecreaseInFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_IncreaseDecreaseInFairValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsToPurchaseOfCommonStockShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsToPurchaseOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_WarrantsToPurchaseOfCommonStockShares" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashCommissionPercentageRateOnProceeds" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissionPercentageRateOnProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_CashCommissionPercentageRateOnProceeds" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCostsIncurred" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCostsIncurred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_IssuanceOfCostsIncurred" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashCommissions" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_CashCommissions" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_LegalAndThirdPartyFee" xlink:href="nmtc-20210930.xsd#nmtc_LegalAndThirdPartyFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_LegalAndThirdPartyFee" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCosts" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_IssuanceCosts" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNoteFinancingDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNoteFinancingDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ConvertibleNoteFinancingDescription" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="nmtc_TypeOfAgreementAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain_0" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityIncentivePlansMember" xlink:href="nmtc-20210930.xsd#nmtc_EquityIncentivePlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_EquityIncentivePlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nmtc_TwoThousandSixteenAndSeventeenPlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoconsultingAgreementsMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoconsultingAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_TypeOfAgreementDomain" xlink:to="nmtc_TwoconsultingAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_ActivityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="nmtc_ActivityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwentyTwentyActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_TwentyTwentyActivityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="nmtc_TwentyTwentyActivityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesReservedDescription" xlink:href="nmtc-20210930.xsd#nmtc_SharesReservedDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_SharesReservedDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockOptionVestedOverAPeriodTerm" xlink:href="nmtc-20210930.xsd#nmtc_StockOptionVestedOverAPeriodTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_StockOptionVestedOverAPeriodTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TotalExpenseOfStockOption" xlink:href="nmtc-20210930.xsd#nmtc_TotalExpenseOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_TotalExpenseOfStockOption" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceOfUnderlyingOptions" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOfUnderlyingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_ExercisePriceOfUnderlyingOptions" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_OutstandingStockOptionsShares" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingStockOptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_OutstandingStockOptionsShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrantDateFairValueOfPerUnit" xlink:href="nmtc-20210930.xsd#nmtc_GrantDateFairValueOfPerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_GrantDateFairValueOfPerUnit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConsultingAgreementsDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConsultingAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_ConsultingAgreementsDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueOfTheUnderlyingCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfTheUnderlyingCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_FairValueOfTheUnderlyingCommonStock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FutureIssuanceOnACombinedBasis" xlink:href="nmtc-20210930.xsd#nmtc_FutureIssuanceOnACombinedBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_FutureIssuanceOnACombinedBasis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficitDetails">
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_StockholdersDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockholdersDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nmtc_StockholdersDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchaseAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmtc_PurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroCommonStockOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nmtc_TwoZeroTwoZeroCommonStockOfferingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandNineteenCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenCommonStockOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nmtc_TwoThousandNineteenCommonStockOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_AggregateShareIssued" xlink:href="nmtc-20210930.xsd#nmtc_AggregateShareIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_AggregateShareIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchaseOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_PurchaseOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchasePriceOfCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_PurchasePriceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_PurchasePriceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_TotalGrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_TotalGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_TotalGrossProceeds" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_FairValueOfWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesIssuedUnderPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_SharesIssuedUnderPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_SharesIssuedUnderPrivatePlacement" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrossProceedsFromPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceedsFromPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_GrossProceedsFromPrivatePlacement" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetGrossCurrent" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmtc_DeferredTaxAssetGrossCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_StateTaxCreditCarryForward" xlink:href="nmtc-20210930.xsd#nmtc_StateTaxCreditCarryForward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nmtc_StateTaxCreditCarryForward" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DefinedContributionPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_EmployeesCompensationPercentage" xlink:href="nmtc-20210930.xsd#nmtc_EmployeesCompensationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="nmtc_EmployeesCompensationPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferralsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_DeferralsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="nmtc_DeferralsPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ContributionsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="nmtc_ContributionsPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_InternalRevenuePercentage" xlink:href="nmtc-20210930.xsd#nmtc_InternalRevenuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="nmtc_InternalRevenuePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_ContributionsAmount" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="nmtc_ContributionsAmount" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesAreAuthorizedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_SharesAreAuthorizedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="nmtc_SharesAreAuthorizedForFutureIssuance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnderwritingAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_UnderwritingAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="nmtc_UnderwritingAgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="nmtc_GrossProceeds" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>nmtc-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:38 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Product gross loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule of fair value of financial instruments measured on a recurring basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:to="nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract_lbl" xml:lang="en-US">Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:to="nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Balance as of beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Balance as of end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of computation of diluted net loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to the operating lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:to="nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information related to the operating lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract_lbl" xml:lang="en-US">Schedule of maturity of the lease liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SupplementalBalanceSheetInformationAbstract_lbl" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalBalanceSheetInformationAbstract" xlink:to="nmtc_SupplementalBalanceSheetInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule of Prepaid and other assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfIntangibleAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfIntangibleAssetsAbstract" xlink:to="nmtc_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Net Intangibles, beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Net Intangibles, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="nmtc_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule of accrued expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfAccruedExpensesAbstract" xlink:to="nmtc_ScheduleOfAccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ZimmerDevelopmentAgreementAbstract_lbl" xml:lang="en-US">Zimmer Development Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ZimmerDevelopmentAgreementAbstract" xlink:to="nmtc_ZimmerDevelopmentAgreementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfDeferredRevenueAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfDeferredRevenueAbstract_lbl" xml:lang="en-US">Schedule of deferred revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfDeferredRevenueAbstract" xlink:to="nmtc_ScheduleOfDeferredRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl1" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract_lbl" xml:lang="en-US">Schedule of convertible promissory notes and warrant agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule of stock-based compensation expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="nmtc_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfStockOptionPlanActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfStockOptionPlanActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option plan activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfStockOptionPlanActivityAbstract" xlink:to="nmtc_ScheduleOfStockOptionPlanActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested and exercisable at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and exercisable at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule of restricted stock unit activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="nmtc_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non-vested, Number of Shares beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Non-vested, Number of Shares ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfWarrantActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule of warrant activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfWarrantActivityAbstract" xlink:to="nmtc_ScheduleOfWarrantActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl" xml:lang="en-US">Warrants, Outstanding and exercisable, Beginning (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl0" xml:lang="en-US">Warrants, Outstanding and exercisable, Ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of summarizes information about warrants outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract" xlink:to="nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of income tax computed at the statutory federal income tax rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAbstract_lbl" xml:lang="en-US">Defined Contribution Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible promissory notes (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 4)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2021 and 2020; no shares issued or outstanding as of September 30, 2021 and 2020.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2021 and 2020; 12,010,019 and 7,393,637 shares issued and outstanding as of September 30, 2021 and 2020, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid&#8211;in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Product revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of product revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RevenueFromCollaboration" xlink:href="nmtc-20210930.xsd#nmtc_RevenueFromCollaboration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RevenueFromCollaboration_lbl" xml:lang="en-US">Collaborations revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RevenueFromCollaboration" xlink:to="nmtc_RevenueFromCollaboration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:href="nmtc-20210930.xsd#nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl" xml:lang="en-US">Net valuation change of instruments measured at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:to="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on note extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on notes extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Loss on notes extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EarningsPerSharesBasicAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_EarningsPerSharesBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EarningsPerSharesBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EarningsPerSharesBasicAndDiluted" xlink:to="nmtc_EarningsPerSharesBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Number of shares used in per share calculations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock under securities purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock under securities purchase agreement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl" xml:lang="en-US">Issuance of warrants in connection with convertible notes offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:to="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes into common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl" xml:lang="en-US">Issuance costs in connection with conversion of convertible notes into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:to="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for consulting services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for consulting services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" xlink:to="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl" xml:lang="en-US">Issuance costs in connection with securities issuances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl" xml:lang="en-US">Issuance cost adjustment related to private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Amortization and depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AllocatedShareBasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_AllocatedShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AllocatedShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AllocatedShareBasedCompensation" xlink:to="nmtc_AllocatedShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterestOnConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl" xml:lang="en-US">Non-cash interest on convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:to="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueChangeOfConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_FairValueChangeOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueChangeOfConvertibleNotes_lbl" xml:lang="en-US">Fair value change of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueChangeOfConvertibleNotes" xlink:to="nmtc_FairValueChangeOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsAttributedToFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl" xml:lang="en-US">Issuance costs attributed to financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:to="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses, deferred revenue, operating lease and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of common stock in connection with private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of warrants in connection with private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock-options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPaycheckProtectionProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram_lbl" xml:lang="en-US">Proceeds from paycheck protection program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:to="nmtc_ProceedsFromPaycheckProtectionProgram_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredsOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_DeferredsOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferredsOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredsOfferingCosts" xlink:to="nmtc_DeferredsOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash financing and investing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl" xml:lang="en-US">Conversion of convertible promissory notes to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl" xml:lang="en-US">Unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:to="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes_lbl" xml:lang="en-US">Non-cash issuance of broker warrants in connection with convertible notes and private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes" xlink:to="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease_lbl" xml:lang="en-US">Operating lease right of use asset obtained in exchange for operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" xlink:to="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_ValueOfPayrollProtectionProgramLoanForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl" xml:lang="en-US">Payroll protection program loan forgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidDeferredOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidDeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UnpaidDeferredOfferingCosts_lbl" xml:lang="en-US">Unpaid deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidDeferredOfferingCosts" xlink:to="nmtc_UnpaidDeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnpaidPurchasesOfPropertyAndEquipment" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidPurchasesOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl" xml:lang="en-US">Unpaid purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidPurchasesOfPropertyAndEquipment" xlink:to="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_PayrollProtectionProgramLoanForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness_lbl" xml:lang="en-US">Payroll protection program loan forgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_PayrollProtectionProgramLoanForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl" xml:lang="en-US">Issuance costs in connection with convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:to="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl" xml:lang="en-US">Issuance costs in connection with private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid&#8211;In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of financial instruments measured on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertibleNotesAbstract_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_ConvertibleNotesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl" xml:lang="en-US">Conversion of convertible promissory notes to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ChangeInFairValueIncludingAccruedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ChangeInFairValueIncludingAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl" xml:lang="en-US">Change in fair value including accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ChangeInFairValueIncludingAccruedInterest" xlink:to="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotesAbstract0" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertibleNotesAbstract0_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesAbstract0" xlink:to="nmtc_ConvertibleNotesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToConvertibleNotesUponIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl" xml:lang="en-US">Fair value attributed to convertible promissory notes upon issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" xlink:to="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueAttributedToNoteExtinguishment" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToNoteExtinguishment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueAttributedToNoteExtinguishment_lbl" xml:lang="en-US">Fair value attributed to note extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToNoteExtinguishment" xlink:to="nmtc_FairValueAttributedToNoteExtinguishment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of computation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_Warrantshares" xlink:href="nmtc-20210930.xsd#nmtc_Warrantshares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_Warrantshares_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_Warrantshares" xlink:to="nmtc_Warrantshares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockOptions_lbl" xml:lang="en-US">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptions" xlink:to="nmtc_StockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RestrictedStockUnit" xlink:href="nmtc-20210930.xsd#nmtc_RestrictedStockUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RestrictedStockUnit_lbl" xml:lang="en-US">Restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RestrictedStockUnit" xlink:to="nmtc_RestrictedStockUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnissuedVestedRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_UnissuedVestedRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UnissuedVestedRestrictedStockUnits_lbl" xml:lang="en-US">Unissued vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnissuedVestedRestrictedStockUnits" xlink:to="nmtc_UnissuedVestedRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertibleNotes_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotes" xlink:to="nmtc_ConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalCashFlowTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalCashFlowTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SupplementalCashFlowTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to the operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalCashFlowTableTextBlock" xlink:to="nmtc_SupplementalCashFlowTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:to="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingCashFlowsFromOperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingCashFlowsFromOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OperatingCashFlowsFromOperatingLeases_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingCashFlowsFromOperatingLeases" xlink:to="nmtc_OperatingCashFlowsFromOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OperatingLeases_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingLeases" xlink:to="nmtc_OperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SupplementalBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information related to the operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalBalanceSheetTableTextBlock" xlink:to="nmtc_SupplementalBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiability" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiability" xlink:to="nmtc_LeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturity of the lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl" xml:lang="en-US">2021 (period from October 1, 2021 to December 31, 2021)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ImputedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ImputedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ImputedInterest_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ImputedInterest" xlink:to="nmtc_ImputedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiabilityNet" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseLiabilityNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiabilityNet" xlink:to="nmtc_LeaseLiabilityNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SupplementalBalanceSheetInformationTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SupplementalBalanceSheetInformationTextBlock_lbl" xml:lang="en-US">Supplemental Balance Sheet Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalBalanceSheetInformationTextBlock" xlink:to="nmtc_SupplementalBalanceSheetInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PrepaidExpenses" xlink:href="nmtc-20210930.xsd#nmtc_PrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PrepaidExpenses" xlink:to="nmtc_PrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NetIntangiblesUsefulLives" xlink:href="nmtc-20210930.xsd#nmtc_NetIntangiblesUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NetIntangiblesUsefulLives_lbl" xml:lang="en-US">Net Intangibles, useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetIntangiblesUsefulLives" xlink:to="nmtc_NetIntangiblesUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Equipment and furniture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LessAccumulatedDepreciations" xlink:href="nmtc-20210930.xsd#nmtc_LessAccumulatedDepreciations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LessAccumulatedDepreciations_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LessAccumulatedDepreciations" xlink:to="nmtc_LessAccumulatedDepreciations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AccruedPayroll" xlink:href="nmtc-20210930.xsd#nmtc_AccruedPayroll"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AccruedPayroll_lbl" xml:lang="en-US">Accrued payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AccruedPayroll" xlink:to="nmtc_AccruedPayroll_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseLiabilityShortterms" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityShortterms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseLiabilityShortterms_lbl" xml:lang="en-US">Operating lease liability, short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiabilityShortterms" xlink:to="nmtc_LeaseLiabilityShortterms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Accrued issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyPayments" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RoyaltyPayments_lbl" xml:lang="en-US">Royalty Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyPayments" xlink:to="nmtc_RoyaltyPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ZimmerDevelopmentAgreementTextBlock_lbl" xml:lang="en-US">Zimmer Development Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ZimmerDevelopmentAgreementTextBlock" xlink:to="nmtc_ZimmerDevelopmentAgreementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueAbstract_lbl" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UpfrontInitialExclusivityPayments" xlink:href="nmtc-20210930.xsd#nmtc_UpfrontInitialExclusivityPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UpfrontInitialExclusivityPayments_lbl" xml:lang="en-US">Upfront initial exclusivity payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UpfrontInitialExclusivityPayments" xlink:to="nmtc_UpfrontInitialExclusivityPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of convertible promissory notes and warrant agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNotesOutstandingPrincipal" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesOutstandingPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertibleNotesOutstandingPrincipal_lbl" xml:lang="en-US">Paulson convertible notes, principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesOutstandingPrincipal" xlink:to="nmtc_ConvertibleNotesOutstandingPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:href="nmtc-20210930.xsd#nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:to="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:href="nmtc-20210930.xsd#nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl" xml:lang="en-US">Fair value adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:to="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesPayable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertiblePromissoryNotesPayable_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertiblePromissoryNotesPayable" xlink:to="nmtc_ConvertiblePromissoryNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Term (years), Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Stock options, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="nmtc-20210930.xsd#nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Term (years), Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Term (years), Vested and exercisable at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock unit activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SummaryOfWarrantActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:to="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1_lbl" xml:lang="en-US">Exercise Price Per Warrant, Outstanding and exercisable, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding and exercisable, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Term (years), Outstanding and exercisable, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xml:lang="en-US">Warrants, Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantIssued" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePricePerWarrantIssued_lbl" xml:lang="en-US">Exercise Price Per Warrant, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantIssued" xlink:to="nmtc_ExercisePricePerWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsIssuedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsIssuedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageTermyearsIssuedinShares_lbl" xml:lang="en-US">Weighted Average Term (years), Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsIssuedinShares" xlink:to="nmtc_WeightedAverageTermyearsIssuedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Warrants, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceExercised" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceExercised" xlink:to="nmtc_WeightedAverageExercisePriceExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsExercisedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsExercisedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageTermyearsExercisedinShares_lbl" xml:lang="en-US">Weighted Average Term (years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsExercisedinShares" xlink:to="nmtc_WeightedAverageTermyearsExercisedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsForfeitedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WarrantsForfeitedinShares_lbl" xml:lang="en-US">Warrants, Forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsForfeitedinShares" xlink:to="nmtc_WarrantsForfeitedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceForfeited" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageExercisePriceForfeited_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceForfeited" xlink:to="nmtc_WeightedAverageExercisePriceForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageTermyearsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsForfeitedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageTermyearsForfeitedinShares_lbl" xml:lang="en-US">Weighted Average Term (years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsForfeitedinShares" xlink:to="nmtc_WeightedAverageTermyearsForfeitedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding_lbl" xml:lang="en-US">Exercise Price Per Warrant, Outstanding and exercisable, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding and exercisable, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding" xlink:to="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Term (years), Outstanding and exercisable, Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of summarizes information about warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePrice" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePrice_lbl" xml:lang="en-US">Exercise Price, Total (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePrice" xlink:to="nmtc_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberOutstandingsTotal" xlink:href="nmtc-20210930.xsd#nmtc_NumberOutstandingsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NumberOutstandingsTotal_lbl" xml:lang="en-US">Number Outstanding, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOutstandingsTotal" xlink:to="nmtc_NumberOutstandingsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WeightedAverageRemainingContractualLifeYears" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageRemainingContractualLifeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WeightedAverageRemainingContractualLifeYears_lbl" xml:lang="en-US">Weighted Average Remaining Contractual life (Years), Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageRemainingContractualLifeYears" xlink:to="nmtc_WeightedAverageRemainingContractualLifeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberExercisable1" xlink:href="nmtc-20210930.xsd#nmtc_NumberExercisable1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NumberExercisable1_lbl" xml:lang="en-US">Number Exercisable , Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberExercisable1" xlink:to="nmtc_NumberExercisable1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax computed at the statutory federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" xlink:href="nmtc-20210930.xsd#nmtc_IncomeTaxBenefitAtFederalStatutoryRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl" xml:lang="en-US">Income tax benefit at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" xlink:to="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StateIncomeTaxNetOfFederalBenefit" xlink:href="nmtc-20210930.xsd#nmtc_StateIncomeTaxNetOfFederalBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl" xml:lang="en-US">State income tax, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateIncomeTaxNetOfFederalBenefit" xlink:to="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DisqualifiedInterestAndOther" xlink:href="nmtc-20210930.xsd#nmtc_DisqualifiedInterestAndOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DisqualifiedInterestAndOther_lbl" xml:lang="en-US">Disqualified interest and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DisqualifiedInterestAndOther" xlink:to="nmtc_DisqualifiedInterestAndOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ResearchCredits" xlink:href="nmtc-20210930.xsd#nmtc_ResearchCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ResearchCredits_lbl" xml:lang="en-US">Research credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ResearchCredits" xlink:to="nmtc_ResearchCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockbasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_StockbasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockbasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockbasedCompensation" xlink:to="nmtc_StockbasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ValuationAllowance" xlink:href="nmtc-20210930.xsd#nmtc_ValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValuationAllowance" xlink:to="nmtc_ValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EffectiveTaxRate" xlink:href="nmtc-20210930.xsd#nmtc_EffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EffectiveTaxRate_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EffectiveTaxRate" xlink:to="nmtc_EffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="nmtc_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Federal and state operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Acquired intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Accruals and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredIncomeTaxAssetNet" xlink:href="nmtc-20210930.xsd#nmtc_DeferredIncomeTaxAssetNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferredIncomeTaxAssetNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredIncomeTaxAssetNet" xlink:to="nmtc_DeferredIncomeTaxAssetNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xml:lang="en-US">Defined Contribution Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xml:lang="en-US">Short-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Less: amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePriceMember_lbl" xml:lang="en-US">5.25	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceMember" xlink:to="nmtc_ExercisePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePriceOneMember_lbl" xml:lang="en-US">5.40 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceOneMember" xlink:to="nmtc_ExercisePriceOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePriceTwoMember_lbl" xml:lang="en-US">5.61	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceTwoMember" xlink:to="nmtc_ExercisePriceTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceThreeMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePriceThreeMember_lbl" xml:lang="en-US">6.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceThreeMember" xlink:to="nmtc_ExercisePriceThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceFourMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_newExercisePriceFourMember_lbl" xml:lang="en-US">7.50	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceFourMember" xlink:to="nmtc_newExercisePriceFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceFiveMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_newExercisePriceFiveMember_lbl" xml:lang="en-US">8.25 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceFiveMember" xlink:to="nmtc_newExercisePriceFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_newExercisePriceSixMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_newExercisePriceSixMember_lbl" xml:lang="en-US">9.00	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceSixMember" xlink:to="nmtc_newExercisePriceSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TypeOfAgreementAxis_lbl" xml:lang="en-US">Type Of Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProceedsFromPayrollProtectionProgramLoan" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPayrollProtectionProgramLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl" xml:lang="en-US">Funding loan received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPayrollProtectionProgramLoan" xlink:to="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DepositsExcessOfFederallyInsured" xlink:href="nmtc-20210930.xsd#nmtc_DepositsExcessOfFederallyInsured"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DepositsExcessOfFederallyInsured_lbl" xml:lang="en-US">Deposits in excess of federally insured amounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DepositsExcessOfFederallyInsured" xlink:to="nmtc_DepositsExcessOfFederallyInsured_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NumberOfLicencingAgreements" xlink:href="nmtc-20210930.xsd#nmtc_NumberOfLicencingAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NumberOfLicencingAgreements_lbl" xml:lang="en-US">Number of licensing agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOfLicencingAgreements" xlink:to="nmtc_NumberOfLicencingAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearOne" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RoyaltyMinimumPaymentsYearOne_lbl" xml:lang="en-US">Royalty payments - 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearOne" xlink:to="nmtc_RoyaltyMinimumPaymentsYearOne_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearTwo" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl" xml:lang="en-US">Royalty payments - 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearTwo" xlink:to="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RoyaltyMinimumPaymentsYearThree" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RoyaltyMinimumPaymentsYearThree_lbl" xml:lang="en-US">Royalty payments - 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearThree" xlink:to="nmtc_RoyaltyMinimumPaymentsYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Court awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_LeaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseAgreementDescription_lbl" xml:lang="en-US">Facility Lease agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseAgreementDescription" xlink:to="nmtc_LeaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseSpace" xlink:href="nmtc-20210930.xsd#nmtc_LeaseSpace"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseSpace_lbl" xml:lang="en-US">Lease space (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseSpace" xlink:to="nmtc_LeaseSpace_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LeaseRentalExpense" xlink:href="nmtc-20210930.xsd#nmtc_LeaseRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LeaseRentalExpense_lbl" xml:lang="en-US">Lease rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseRentalExpense" xlink:to="nmtc_LeaseRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_MonthlyLeaseRent" xlink:href="nmtc-20210930.xsd#nmtc_MonthlyLeaseRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_MonthlyLeaseRent_lbl" xml:lang="en-US">Monthly lease rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_MonthlyLeaseRent" xlink:to="nmtc_MonthlyLeaseRent_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RentExpense" xlink:href="nmtc-20210930.xsd#nmtc_RentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RentExpense_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RentExpense" xlink:to="nmtc_RentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaycheckProtectionProgramDescription" xlink:href="nmtc-20210930.xsd#nmtc_PaycheckProtectionProgramDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PaycheckProtectionProgramDescription_lbl" xml:lang="en-US">Paycheck protection program, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaycheckProtectionProgramDescription" xlink:to="nmtc_PaycheckProtectionProgramDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IntialFeePayment" xlink:href="nmtc-20210930.xsd#nmtc_IntialFeePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IntialFeePayment_lbl" xml:lang="en-US">Initial fee payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntialFeePayment" xlink:to="nmtc_IntialFeePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FuturePotentialMilestonePaymentsToNeuroone" xlink:href="nmtc-20210930.xsd#nmtc_FuturePotentialMilestonePaymentsToNeuroone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl" xml:lang="en-US">Future potential milestone payments to Neuroone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FuturePotentialMilestonePaymentsToNeuroone" xlink:to="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ProductRevenueRecognized" xlink:href="nmtc-20210930.xsd#nmtc_ProductRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ProductRevenueRecognized_lbl" xml:lang="en-US">Product revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProductRevenueRecognized" xlink:to="nmtc_ProductRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Total advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Convertible notes bear interest at fixed rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_InterestOnPrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_InterestOnPrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_InterestOnPrincipalAmount_lbl" xml:lang="en-US">Interest on principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InterestOnPrincipalAmount" xlink:to="nmtc_InterestOnPrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityFinancingAmount" xlink:href="nmtc-20210930.xsd#nmtc_EquityFinancingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EquityFinancingAmount_lbl" xml:lang="en-US">Equity financing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityFinancingAmount" xlink:to="nmtc_EquityFinancingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:href="nmtc-20210930.xsd#nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl" xml:lang="en-US">Equity qualified financing, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:to="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OutstandingVotingPercentage" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingVotingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OutstandingVotingPercentage_lbl" xml:lang="en-US">Outstanding voting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OutstandingVotingPercentage" xlink:to="nmtc_OutstandingVotingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfFairValueAmount" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfFairValueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceOfFairValueAmount_lbl" xml:lang="en-US">Issuance of fair value amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfFairValueAmount" xlink:to="nmtc_IssuanceOfFairValueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ChangesOfFairValueBenefit" xlink:href="nmtc-20210930.xsd#nmtc_ChangesOfFairValueBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ChangesOfFairValueBenefit_lbl" xml:lang="en-US">Changes of fair value benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ChangesOfFairValueBenefit" xlink:to="nmtc_ChangesOfFairValueBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsDescription" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WarrantsDescription_lbl" xml:lang="en-US">Warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsDescription" xlink:to="nmtc_WarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsExercisableForSharesOfCommonStockConnection" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsExercisableForSharesOfCommonStockConnection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WarrantsExercisableForSharesOfCommonStockConnection_lbl" xml:lang="en-US">Warrants exercisable for shares of common stock connection (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsExercisableForSharesOfCommonStockConnection" xlink:to="nmtc_WarrantsExercisableForSharesOfCommonStockConnection_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrants exercisable date of issuance and expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCostsDescription" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCostsDescription_lbl" xml:lang="en-US">Issuance costs, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsDescription" xlink:to="nmtc_IssuanceCostsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExtendedMaturityDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ExtendedMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExtendedMaturityDateDescription_lbl" xml:lang="en-US">Extended maturity date, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExtendedMaturityDateDescription" xlink:to="nmtc_ExtendedMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_RevisedOptionalConversionTermsDescription" xlink:href="nmtc-20210930.xsd#nmtc_RevisedOptionalConversionTermsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_RevisedOptionalConversionTermsDescription_lbl" xml:lang="en-US">Revised optional conversion terms, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RevisedOptionalConversionTermsDescription" xlink:to="nmtc_RevisedOptionalConversionTermsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ReviseTheRegistrationDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ReviseTheRegistrationDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ReviseTheRegistrationDateDescription_lbl" xml:lang="en-US">Revise the registration date description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ReviseTheRegistrationDateDescription" xlink:to="nmtc_ReviseTheRegistrationDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertedNotesCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConvertedNotesCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertedNotesCommonStock_lbl" xml:lang="en-US">Converted notes common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertedNotesCommonStock" xlink:to="nmtc_ConvertedNotesCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_aggregatePrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_aggregatePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_aggregatePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_aggregatePrincipalAmount" xlink:to="nmtc_aggregatePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_NoncashInterest" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_NoncashInterest_lbl" xml:lang="en-US">Non-cash interest on principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterest" xlink:to="nmtc_NoncashInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceeds" xlink:to="nmtc_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:href="nmtc-20210930.xsd#nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl" xml:lang="en-US">Interest expense related to excess of fair value over proceeds at issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:to="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IncreaseDecreaseInFairValue" xlink:href="nmtc-20210930.xsd#nmtc_IncreaseDecreaseInFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IncreaseDecreaseInFairValue_lbl" xml:lang="en-US">Increase decrease in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncreaseDecreaseInFairValue" xlink:to="nmtc_IncreaseDecreaseInFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Initial exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="nmtc_WarrantsToPurchaseOfCommonStockShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsToPurchaseOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US">Warrants to purchase of common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsToPurchaseOfCommonStockShares" xlink:to="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashCommissionPercentageRateOnProceeds" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissionPercentageRateOnProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_CashCommissionPercentageRateOnProceeds_lbl" xml:lang="en-US">Cash commission percentage rate on proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashCommissionPercentageRateOnProceeds" xlink:to="nmtc_CashCommissionPercentageRateOnProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceOfCostsIncurred" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCostsIncurred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceOfCostsIncurred_lbl" xml:lang="en-US">Issuance costs incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCostsIncurred" xlink:to="nmtc_IssuanceOfCostsIncurred_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_CashCommissions" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_CashCommissions_lbl" xml:lang="en-US">Cash commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashCommissions" xlink:to="nmtc_CashCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_LegalAndThirdPartyFee" xlink:href="nmtc-20210930.xsd#nmtc_LegalAndThirdPartyFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_LegalAndThirdPartyFee_lbl" xml:lang="en-US">Legal and third party fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LegalAndThirdPartyFee" xlink:to="nmtc_LegalAndThirdPartyFee_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IssuanceCosts" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCosts" xlink:to="nmtc_IssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertibleNoteFinancingDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNoteFinancingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConvertibleNoteFinancingDescription_lbl" xml:lang="en-US">Convertible Note financing, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNoteFinancingDescription" xlink:to="nmtc_ConvertibleNoteFinancingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesReservedDescription" xlink:href="nmtc-20210930.xsd#nmtc_SharesReservedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SharesReservedDescription_lbl" xml:lang="en-US">Shares reserved, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesReservedDescription" xlink:to="nmtc_SharesReservedDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockOptionVestedOverAPeriodTerm" xlink:href="nmtc-20210930.xsd#nmtc_StockOptionVestedOverAPeriodTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StockOptionVestedOverAPeriodTerm_lbl" xml:lang="en-US">Vested over a period term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptionVestedOverAPeriodTerm" xlink:to="nmtc_StockOptionVestedOverAPeriodTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TotalExpenseOfStockOption" xlink:href="nmtc-20210930.xsd#nmtc_TotalExpenseOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TotalExpenseOfStockOption_lbl" xml:lang="en-US">Total expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalExpenseOfStockOption" xlink:to="nmtc_TotalExpenseOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ExercisePriceOfUnderlyingOptions" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOfUnderlyingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ExercisePriceOfUnderlyingOptions_lbl" xml:lang="en-US">Exercise price of the underlying option (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceOfUnderlyingOptions" xlink:to="nmtc_ExercisePriceOfUnderlyingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OutstandingStockOptionsShares" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingStockOptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OutstandingStockOptionsShares_lbl" xml:lang="en-US">Outstanding stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OutstandingStockOptionsShares" xlink:to="nmtc_OutstandingStockOptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Stock options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrantDateFairValueOfPerUnit" xlink:href="nmtc-20210930.xsd#nmtc_GrantDateFairValueOfPerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_GrantDateFairValueOfPerUnit_lbl" xml:lang="en-US">Grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrantDateFairValueOfPerUnit" xlink:to="nmtc_GrantDateFairValueOfPerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Restricted stock units vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">RSUs forfeited shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConsultingAgreementsDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConsultingAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ConsultingAgreementsDescription_lbl" xml:lang="en-US">Consulting agreements description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConsultingAgreementsDescription" xlink:to="nmtc_ConsultingAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xml:lang="en-US">Compensation expense related to the stock awards (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueOfTheUnderlyingCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfTheUnderlyingCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueOfTheUnderlyingCommonStock_lbl" xml:lang="en-US">Vesting points (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfTheUnderlyingCommonStock" xlink:to="nmtc_FairValueOfTheUnderlyingCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FutureIssuanceOnACombinedBasis" xlink:href="nmtc-20210930.xsd#nmtc_FutureIssuanceOnACombinedBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FutureIssuanceOnACombinedBasis_lbl" xml:lang="en-US">Future issuance shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FutureIssuanceOnACombinedBasis" xlink:to="nmtc_FutureIssuanceOnACombinedBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AggregateShareIssued" xlink:href="nmtc-20210930.xsd#nmtc_AggregateShareIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AggregateShareIssued_lbl" xml:lang="en-US">Aggregate share issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AggregateShareIssued" xlink:to="nmtc_AggregateShareIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchaseOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PurchaseOfWarrants_lbl" xml:lang="en-US">Purchase of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchaseOfWarrants" xlink:to="nmtc_PurchaseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchasePriceOfCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_PurchasePriceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PurchasePriceOfCommonStock_lbl" xml:lang="en-US">Purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchasePriceOfCommonStock" xlink:to="nmtc_PurchasePriceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TotalGrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_TotalGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TotalGrossProceeds_lbl" xml:lang="en-US">Total gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalGrossProceeds" xlink:to="nmtc_TotalGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_FairValueOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_FairValueOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfWarrants" xlink:to="nmtc_FairValueOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Total proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesIssuedUnderPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_SharesIssuedUnderPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SharesIssuedUnderPrivatePlacement_lbl" xml:lang="en-US">Shares issue and sell under private placement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesIssuedUnderPrivatePlacement" xlink:to="nmtc_SharesIssuedUnderPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_GrossProceedsFromPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceedsFromPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_GrossProceedsFromPrivatePlacement_lbl" xml:lang="en-US">Gross proceeds from private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceedsFromPrivatePlacement" xlink:to="nmtc_GrossProceedsFromPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetGrossCurrent" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferredTaxAssetGrossCurrent_lbl" xml:lang="en-US">Gross deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetGrossCurrent" xlink:to="nmtc_DeferredTaxAssetGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Federal research credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:to="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StateTaxCreditCarryForward" xlink:href="nmtc-20210930.xsd#nmtc_StateTaxCreditCarryForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_StateTaxCreditCarryForward_lbl" xml:lang="en-US">State tax credit carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateTaxCreditCarryForward" xlink:to="nmtc_StateTaxCreditCarryForward_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EmployeesCompensationPercentage" xlink:href="nmtc-20210930.xsd#nmtc_EmployeesCompensationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EmployeesCompensationPercentage_lbl" xml:lang="en-US">Employees compensation percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EmployeesCompensationPercentage" xlink:to="nmtc_EmployeesCompensationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DeferralsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_DeferralsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DeferralsPercentage_lbl" xml:lang="en-US">Deferrals percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferralsPercentage" xlink:to="nmtc_DeferralsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ContributionsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ContributionsPercentage_lbl" xml:lang="en-US">Contributions percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsPercentage" xlink:to="nmtc_ContributionsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_InternalRevenuePercentage" xlink:href="nmtc-20210930.xsd#nmtc_InternalRevenuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_InternalRevenuePercentage_lbl" xml:lang="en-US">Internal Revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InternalRevenuePercentage" xlink:to="nmtc_InternalRevenuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ContributionsAmount" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ContributionsAmount_lbl" xml:lang="en-US">Contributions amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsAmount" xlink:to="nmtc_ContributionsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SharesAreAuthorizedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_SharesAreAuthorizedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_SharesAreAuthorizedForFutureIssuance_lbl" xml:lang="en-US">Shares are authorized for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesAreAuthorizedForFutureIssuance" xlink:to="nmtc_SharesAreAuthorizedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_UnderwritingAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_UnderwritingAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_UnderwritingAgreementDescription_lbl" xml:lang="en-US">Underwriting agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnderwritingAgreementDescription" xlink:to="nmtc_UnderwritingAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ReverseStockSplitPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ReverseStockSplitPolicyTextBlock" xlink:to="nmtc_ReverseStockSplitPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3nGLHBx5QwPrpWWAqC9V9bdFR44mQ+I1oU=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Management&#8217;s Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_IntellectualPropertyPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_IntellectualPropertyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_IntellectualPropertyPolicyTextBlock_lbl" xml:lang="en-US">Intellectual Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="nmtc_IntellectualPropertyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Allowances for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">Selling, General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment and Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_MayoAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_MayoAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_MayoAgreementMember_lbl" xml:lang="en-US">Mayo Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_MayoAgreementMember" xlink:to="nmtc_MayoAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_WadeFredricksonMember" xlink:href="nmtc-20210930.xsd#nmtc_WadeFredricksonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_WadeFredricksonMember_lbl" xml:lang="en-US">Wade Fredrickson [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WadeFredricksonMember" xlink:to="nmtc_WadeFredricksonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_DevelopmentAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_DevelopmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_DevelopmentAgreementMember_lbl" xml:lang="en-US">Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DevelopmentAgreementMember" xlink:to="nmtc_DevelopmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_November302020Member" xlink:href="nmtc-20210930.xsd#nmtc_November302020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_November302020Member_lbl" xml:lang="en-US">November 30, 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_November302020Member" xlink:to="nmtc_November302020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScenarioOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScenarioOneMember" xlink:to="nmtc_ScenarioOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_April302021Member" xlink:href="nmtc-20210930.xsd#nmtc_April302021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_April302021Member_lbl" xml:lang="en-US">April 30, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_April302021Member" xlink:to="nmtc_April302021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ScenarioTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScenarioTwoMember" xlink:to="nmtc_ScenarioTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ModifiedConnectorbyApril302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbyApril302021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ModifiedConnectorbyApril302021Member_lbl" xml:lang="en-US">Modified Connector by April 30, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ModifiedConnectorbyApril302021Member" xlink:to="nmtc_ModifiedConnectorbyApril302021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ModifiedConnectorbySeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbySeptember302021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ModifiedConnectorbySeptember302021Member_lbl" xml:lang="en-US">Modified Connector by September 30, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ModifiedConnectorbySeptember302021Member" xlink:to="nmtc_ModifiedConnectorbySeptember302021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_OnOrBeforeJune302021Member" xlink:href="nmtc-20210930.xsd#nmtc_OnOrBeforeJune302021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_OnOrBeforeJune302021Member_lbl" xml:lang="en-US">On or before June 30, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OnOrBeforeJune302021Member" xlink:to="nmtc_OnOrBeforeJune302021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member_lbl" xml:lang="en-US">After June 30, 2021, but on or before September 30, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member" xlink:to="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member_lbl" xml:lang="en-US">After September 30, 2021, but on or before December 31, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member" xlink:to="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_AfterDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterDecember312021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_AfterDecember312021Member_lbl" xml:lang="en-US">After December 31, 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterDecember312021Member" xlink:to="nmtc_AfterDecember312021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember_lbl" xml:lang="en-US">2019 Paulson Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember" xlink:to="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Paulson Convertible Note Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroOneNinePaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneNinePaulsonNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoZeroOneNinePaulsonNotesMember_lbl" xml:lang="en-US">2019 Paulson Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroOneNinePaulsonNotesMember" xlink:to="nmtc_TwoZeroOneNinePaulsonNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandNineteenQualifiedFinancingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenQualifiedFinancingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoThousandNineteenQualifiedFinancingMember_lbl" xml:lang="en-US">2019 Qualified Financing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandNineteenQualifiedFinancingMember" xlink:to="nmtc_TwoThousandNineteenQualifiedFinancingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_Second2019PaulsonNotesAmendmentMember" xlink:href="nmtc-20210930.xsd#nmtc_Second2019PaulsonNotesAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_Second2019PaulsonNotesAmendmentMember_lbl" xml:lang="en-US">Second 2019 Paulson Notes Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_Second2019PaulsonNotesAmendmentMember" xlink:to="nmtc_Second2019PaulsonNotesAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember_lbl" xml:lang="en-US">2020 Paulson Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember" xlink:to="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroPaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoZeroTwoZeroPaulsonNotesMember_lbl" xml:lang="en-US">2020 Paulson Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroPaulsonNotesMember" xlink:to="nmtc_TwoZeroTwoZeroPaulsonNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PaulsonPrivatePlacementMember_lbl" xml:lang="en-US">Paulson Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaulsonPrivatePlacementMember" xlink:to="nmtc_PaulsonPrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_BrokerWarrantsMember" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_BrokerWarrantsMember_lbl" xml:lang="en-US">Broker Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_BrokerWarrantsMember" xlink:to="nmtc_BrokerWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_EquityIncentivePlansMember" xlink:href="nmtc-20210930.xsd#nmtc_EquityIncentivePlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_EquityIncentivePlansMember_lbl" xml:lang="en-US">2016 and 2017 Equity Incentive Plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityIncentivePlansMember" xlink:to="nmtc_EquityIncentivePlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember" xlink:to="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoconsultingAgreementsMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoconsultingAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoconsultingAgreementsMember_lbl" xml:lang="en-US">Two consulting agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoconsultingAgreementsMember" xlink:to="nmtc_TwoconsultingAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_ActivityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_ActivityMember_lbl" xml:lang="en-US">2021 Activity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ActivityMember" xlink:to="nmtc_ActivityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwentyTwentyActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_TwentyTwentyActivityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwentyTwentyActivityMember_lbl" xml:lang="en-US">2020 Activity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwentyTwentyActivityMember" xlink:to="nmtc_TwentyTwentyActivityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoThousandSixteenAndSeventeenPlanMember_lbl" xml:lang="en-US">2016 and 2017 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:to="nmtc_TwoThousandSixteenAndSeventeenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_PurchaseAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_PurchaseAgreementMember_lbl" xml:lang="en-US">2021 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchaseAgreementMember" xlink:to="nmtc_PurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoZeroTwoZeroCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroCommonStockOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoZeroTwoZeroCommonStockOfferingMember_lbl" xml:lang="en-US">2020 Common Stock Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroCommonStockOfferingMember" xlink:to="nmtc_TwoZeroTwoZeroCommonStockOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TwoThousandNineteenCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenCommonStockOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nmtc_TwoThousandNineteenCommonStockOfferingMember_lbl" xml:lang="en-US">2019 Common Stock Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandNineteenCommonStockOfferingMember" xlink:to="nmtc_TwoThousandNineteenCommonStockOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable_lbl" xml:lang="en-US">Stockholders&apos; Deficit (Details) - Schedule of warrant activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:to="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems_lbl" xml:lang="en-US">Stockholders&apos; Deficit (Details) - Schedule of warrant activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="nmtc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TypeOfAgreementDomain_lbl" xml:lang="en-US">TypeOfAgreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TypeOfAgreementDomain" xlink:to="nmtc_TypeOfAgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_CommitmentsandContingenciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CommitmentsandContingenciesDetailsTable" xlink:to="nmtc_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CommitmentsandContingenciesDetailsLineItems" xlink:to="nmtc_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsTable_lbl" xml:lang="en-US">Zimmer Development Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsTable" xlink:to="nmtc_ZimmerDevelopmentAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ZimmerDevelopmentAgreementDetailsLineItems_lbl" xml:lang="en-US">Zimmer Development Agreement (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="nmtc_ZimmerDevelopmentAgreementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable_lbl" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems_lbl" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockBasedCompensationDetailsTable" xlink:to="nmtc_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockBasedCompensationDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockBasedCompensationDetailsLineItems" xlink:to="nmtc_StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockholdersDeficitDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Deficit (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockholdersDeficitDetailsTable" xlink:to="nmtc_StockholdersDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nmtc_StockholdersDeficitDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockholdersDeficitDetailsLineItems_lbl" xml:lang="en-US">Stockholders&apos; Deficit (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockholdersDeficitDetailsLineItems" xlink:to="nmtc_StockholdersDeficitDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_AccruedPayroll_lbl0" xml:lang="en-US">Accrued payroll.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AccruedPayroll" xlink:to="nmtc_AccruedPayroll_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_AllocatedShareBasedCompensation_lbl0" xml:lang="en-US">Amount of expense for share based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AllocatedShareBasedCompensation" xlink:to="nmtc_AllocatedShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl0" xml:lang="en-US">Amount of interest payable on debt, including, but not limited to, trade payables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:to="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_CashCommissionPercentageRateOnProceeds_lbl0" xml:lang="en-US">Cash commission percentage rate on proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashCommissionPercentageRateOnProceeds" xlink:to="nmtc_CashCommissionPercentageRateOnProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl0" xml:lang="en-US">Change in fair value including accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ChangeInFairValueIncludingAccruedInterest" xlink:to="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConsultingAgreementsDescription_lbl0" xml:lang="en-US">Consulting agreements description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConsultingAgreementsDescription" xlink:to="nmtc_ConsultingAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ContributionsAmount_lbl0" xml:lang="en-US">Contributions amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsAmount" xlink:to="nmtc_ContributionsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ContributionsPercentage_lbl0" xml:lang="en-US">Contributions percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsPercentage" xlink:to="nmtc_ContributionsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl0" xml:lang="en-US">Conversion of convertible promissory notes to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl0" xml:lang="en-US">It represent supplemental activity related to non-cash impact related to conversion of promissory notes to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConvertibleNotes_lbl0" xml:lang="en-US">It represent conversion of convertible notes not included in basic EPS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotes" xlink:to="nmtc_ConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConvertibleNotesOutstandingPrincipal_lbl0" xml:lang="en-US">Convertible notes outstanding principal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesOutstandingPrincipal" xlink:to="nmtc_ConvertibleNotesOutstandingPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ConvertiblePromissoryNotesPayable_lbl0" xml:lang="en-US">Including the current and noncurrent portions, at fair value value as of the balance sheet date of a written promise to pay a note, initially due within one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertiblePromissoryNotesPayable" xlink:to="nmtc_ConvertiblePromissoryNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DeferralsPercentage_lbl0" xml:lang="en-US">Deferrals percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferralsPercentage" xlink:to="nmtc_DeferralsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DeferredIncomeTaxAssetNet_lbl0" xml:lang="en-US">Amount of net deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredIncomeTaxAssetNet" xlink:to="nmtc_DeferredIncomeTaxAssetNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DeferredTaxAssetGrossCurrent_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetGrossCurrent" xlink:to="nmtc_DeferredTaxAssetGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:to="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DeferredsOfferingCosts_lbl0" xml:lang="en-US">Deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredsOfferingCosts" xlink:to="nmtc_DeferredsOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DepositsExcessOfFederallyInsured_lbl0" xml:lang="en-US">It represents the amount by which the cash balance exceeds the amount insured.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DepositsExcessOfFederallyInsured" xlink:to="nmtc_DepositsExcessOfFederallyInsured_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_DisqualifiedInterestAndOther_lbl0" xml:lang="en-US">Disqualified interest and other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DisqualifiedInterestAndOther" xlink:to="nmtc_DisqualifiedInterestAndOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_EarningsPerSharesBasicAndDiluted_lbl0" xml:lang="en-US">The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EarningsPerSharesBasicAndDiluted" xlink:to="nmtc_EarningsPerSharesBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_EffectiveTaxRate_lbl0" xml:lang="en-US">Effective tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EffectiveTaxRate" xlink:to="nmtc_EffectiveTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_EmployeesCompensationPercentage_lbl0" xml:lang="en-US">Employees compensation percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EmployeesCompensationPercentage" xlink:to="nmtc_EmployeesCompensationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl0" xml:lang="en-US">Equity qualified financing, description on Convertible Note Offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:to="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ExercisePriceOfUnderlyingOptions_lbl0" xml:lang="en-US">Exercise price of the underlying options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceOfUnderlyingOptions" xlink:to="nmtc_ExercisePriceOfUnderlyingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl0" xml:lang="en-US">Fair value attributed to convertible notes upon issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" xlink:to="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueAttributedToNoteExtinguishment_lbl0" xml:lang="en-US">Fair value attributed to note extinguishment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToNoteExtinguishment" xlink:to="nmtc_FairValueAttributedToNoteExtinguishment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueChangeOfConvertibleNotes_lbl0" xml:lang="en-US">Fair value change of convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueChangeOfConvertibleNotes" xlink:to="nmtc_FairValueChangeOfConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl0" xml:lang="en-US">Fair value in excess of principal and accrued interest related to debt instrument payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:to="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueOfTheUnderlyingCommonStock_lbl0" xml:lang="en-US">Fair value of the underlying common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfTheUnderlyingCommonStock" xlink:to="nmtc_FairValueOfTheUnderlyingCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FairValueOfWarrants_lbl0" xml:lang="en-US">Fair value of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfWarrants" xlink:to="nmtc_FairValueOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FutureIssuanceOnACombinedBasis_lbl0" xml:lang="en-US">Number of shares for future issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FutureIssuanceOnACombinedBasis" xlink:to="nmtc_FutureIssuanceOnACombinedBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl0" xml:lang="en-US">It represent future potential milestone payments to Neuroone.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FuturePotentialMilestonePaymentsToNeuroone" xlink:to="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_GrantDateFairValueOfPerUnit_lbl0" xml:lang="en-US">Grant date fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrantDateFairValueOfPerUnit" xlink:to="nmtc_GrantDateFairValueOfPerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_GrossProceeds_lbl0" xml:lang="en-US">The value of gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceeds" xlink:to="nmtc_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_GrossProceedsFromPrivatePlacement_lbl0" xml:lang="en-US">It represents the amount of gross proceeds from private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceedsFromPrivatePlacement" xlink:to="nmtc_GrossProceedsFromPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ImputedInterest_lbl0" xml:lang="en-US">Imputed interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ImputedInterest" xlink:to="nmtc_ImputedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl0" xml:lang="en-US">Income tax benefit at federal statutory rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" xlink:to="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IncreaseDecreaseInFairValue_lbl0" xml:lang="en-US">The amount of increase decrease in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncreaseDecreaseInFairValue" xlink:to="nmtc_IncreaseDecreaseInFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IntellectualPropertyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy fori ntellectual property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="nmtc_IntellectualPropertyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl0" xml:lang="en-US">Interest expense related to excess of fair value over proceeds at issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:to="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_InternalRevenuePercentage_lbl0" xml:lang="en-US">Internal Revenue percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InternalRevenuePercentage" xlink:to="nmtc_InternalRevenuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IntialFeePayment_lbl0" xml:lang="en-US">Intial fee payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntialFeePayment" xlink:to="nmtc_IntialFeePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl0" xml:lang="en-US">Issuance costs in connection with conversion of convertible notes into common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:to="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl0" xml:lang="en-US">Issuance cost adjustment related to private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl0" xml:lang="en-US">Issuance costs attributed to financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:to="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl0" xml:lang="en-US">Amount of issuance costs in connection with convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:to="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl0" xml:lang="en-US">Issuance costs in connection with private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl0" xml:lang="en-US">Amount of issuance costs in connection with private placements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl0" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl0" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceOfCostsIncurred_lbl0" xml:lang="en-US">The cash outflow for cost incurred directly with the issuance of an equity security.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCostsIncurred" xlink:to="nmtc_IssuanceOfCostsIncurred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceOfFairValueAmount_lbl0" xml:lang="en-US">The amount of fair value issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfFairValueAmount" xlink:to="nmtc_IssuanceOfFairValueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl0" xml:lang="en-US">Issuance of warrants in connection with convertible notes offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:to="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LeaseAgreementDescription_lbl0" xml:lang="en-US">It represent lease agreement, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseAgreementDescription" xlink:to="nmtc_LeaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LeaseLiabilityShortterms_lbl0" xml:lang="en-US">Amount of short-term lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiabilityShortterms" xlink:to="nmtc_LeaseLiabilityShortterms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LeaseRentalExpense_lbl0" xml:lang="en-US">Amount of lease rental expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseRentalExpense" xlink:to="nmtc_LeaseRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LeaseSpace_lbl0" xml:lang="en-US">Facility space square feet.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseSpace" xlink:to="nmtc_LeaseSpace_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LegalAndThirdPartyFee_lbl0" xml:lang="en-US">The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to issuance of financial instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LegalAndThirdPartyFee" xlink:to="nmtc_LegalAndThirdPartyFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LessAccumulatedDepreciations_lbl0" xml:lang="en-US">The amount of less accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LessAccumulatedDepreciations" xlink:to="nmtc_LessAccumulatedDepreciations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in fifth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in fourth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in remaining in current calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in third calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in second calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_MonthlyLeaseRent_lbl0" xml:lang="en-US">Monthly lease rent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_MonthlyLeaseRent" xlink:to="nmtc_MonthlyLeaseRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NetIntangiblesUsefulLives_lbl0" xml:lang="en-US">Net Intangibles, useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetIntangiblesUsefulLives" xlink:to="nmtc_NetIntangiblesUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl0" xml:lang="en-US">Net valuation change of instruments measured at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:to="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NoncashInterest_lbl0" xml:lang="en-US">Amount of the required periodic payments non-cash interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterest" xlink:to="nmtc_NoncashInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl0" xml:lang="en-US">Amount of noncash interest on convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:to="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NumberOfLicencingAgreements_lbl0" xml:lang="en-US">Number of agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOfLicencingAgreements" xlink:to="nmtc_NumberOfLicencingAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_NumberOutstandingsTotal_lbl0" xml:lang="en-US">Number Outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOutstandingsTotal" xlink:to="nmtc_NumberOutstandingsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_OperatingCashFlowsFromOperatingLeases_lbl0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingCashFlowsFromOperatingLeases" xlink:to="nmtc_OperatingCashFlowsFromOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_OperatingLeases_lbl0" xml:lang="en-US">Right-of-use assets obtained in exchange of lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingLeases" xlink:to="nmtc_OperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_OutstandingStockOptionsShares_lbl0" xml:lang="en-US">Number of shares option outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OutstandingStockOptionsShares" xlink:to="nmtc_OutstandingStockOptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_PaycheckProtectionProgramDescription_lbl0" xml:lang="en-US">Paycheck protection program, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaycheckProtectionProgramDescription" xlink:to="nmtc_PaycheckProtectionProgramDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness_lbl0" xml:lang="en-US">Payroll protection program loan forgiveness.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_PayrollProtectionProgramLoanForgiveness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_PrepaidExpenses_lbl0" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PrepaidExpenses" xlink:to="nmtc_PrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from issuance of common stock in connection with private placements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from issuance of warrants in connection with private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram_lbl0" xml:lang="en-US">Proceeds from paycheck protection program.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:to="nmtc_ProceedsFromPaycheckProtectionProgram_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl0" xml:lang="en-US">Cash proceeds associated with the PPP loan during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPayrollProtectionProgramLoan" xlink:to="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ProductRevenueRecognized_lbl0" xml:lang="en-US">Amount of product revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProductRevenueRecognized" xlink:to="nmtc_ProductRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_PurchasePriceOfCommonStock_lbl0" xml:lang="en-US">Purchase price of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchasePriceOfCommonStock" xlink:to="nmtc_PurchasePriceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RentExpense_lbl0" xml:lang="en-US">The amount of rent expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RentExpense" xlink:to="nmtc_RentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ResearchCredits_lbl0" xml:lang="en-US">Research credits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ResearchCredits" xlink:to="nmtc_ResearchCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RestrictedStockUnit_lbl0" xml:lang="en-US">This relates to restricted stock units not included in basic EPS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RestrictedStockUnit" xlink:to="nmtc_RestrictedStockUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RevenueFromCollaboration_lbl0" xml:lang="en-US">Revenue from collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RevenueFromCollaboration" xlink:to="nmtc_RevenueFromCollaboration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ReviseTheRegistrationDateDescription_lbl0" xml:lang="en-US">Revise the registration date description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ReviseTheRegistrationDateDescription" xlink:to="nmtc_ReviseTheRegistrationDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RoyaltyMinimumPaymentsYearOne_lbl0" xml:lang="en-US">Amount of royalty minimum payments year one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearOne" xlink:to="nmtc_RoyaltyMinimumPaymentsYearOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RoyaltyMinimumPaymentsYearThree_lbl0" xml:lang="en-US">Amount of royalty minimum payments year third year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearThree" xlink:to="nmtc_RoyaltyMinimumPaymentsYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl0" xml:lang="en-US">Amount of royalty minimum payments second year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearTwo" xlink:to="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_RoyaltyPayments_lbl0" xml:lang="en-US">Amount of royalty payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyPayments" xlink:to="nmtc_RoyaltyPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl1" xml:lang="en-US">The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_SharesAreAuthorizedForFutureIssuance_lbl0" xml:lang="en-US">These shares are authorized for future issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesAreAuthorizedForFutureIssuance" xlink:to="nmtc_SharesAreAuthorizedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_SharesIssuedUnderPrivatePlacement_lbl0" xml:lang="en-US">Shares issued under private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesIssuedUnderPrivatePlacement" xlink:to="nmtc_SharesIssuedUnderPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_SharesReservedDescription_lbl0" xml:lang="en-US">Description of shares reserved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesReservedDescription" xlink:to="nmtc_SharesReservedDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl0" xml:lang="en-US">State income tax, net of federal benefit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateIncomeTaxNetOfFederalBenefit" xlink:to="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StateTaxCreditCarryForward_lbl0" xml:lang="en-US">Amount of state tax credit carry forward.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateTaxCreditCarryForward" xlink:to="nmtc_StateTaxCreditCarryForward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl0" xml:lang="en-US">Number of shares exercise of stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" xlink:to="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl0" xml:lang="en-US">Number of exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl0" xml:lang="en-US">Amount of exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockOptionVestedOverAPeriodTerm_lbl0" xml:lang="en-US">Stock option vested over a period term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptionVestedOverAPeriodTerm" xlink:to="nmtc_StockOptionVestedOverAPeriodTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockOptions_lbl0" xml:lang="en-US">This relates to stock options not included in basic EPS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptions" xlink:to="nmtc_StockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_StockbasedCompensation_lbl0" xml:lang="en-US">Stock-based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockbasedCompensation" xlink:to="nmtc_StockbasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of warrant activity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:to="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_TotalExpenseOfStockOption_lbl0" xml:lang="en-US">Total expense of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalExpenseOfStockOption" xlink:to="nmtc_TotalExpenseOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_TotalGrossProceeds_lbl0" xml:lang="en-US">Amount of total gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalGrossProceeds" xlink:to="nmtc_TotalGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UnderwritingAgreementDescription_lbl0" xml:lang="en-US">Underwriting Agreement, Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnderwritingAgreementDescription" xlink:to="nmtc_UnderwritingAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UnissuedVestedRestrictedStockUnits_lbl0" xml:lang="en-US">This relates to restricted stock awards not included in basic EPS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnissuedVestedRestrictedStockUnits" xlink:to="nmtc_UnissuedVestedRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UnpaidDeferredOfferingCosts_lbl0" xml:lang="en-US">Amount of unpaid deferred offering costs related to future financings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidDeferredOfferingCosts" xlink:to="nmtc_UnpaidDeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl0" xml:lang="en-US">Amount of unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:to="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl0" xml:lang="en-US">The amount of unpaid purchases of property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidPurchasesOfPropertyAndEquipment" xlink:to="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_UpfrontInitialExclusivityPayments_lbl0" xml:lang="en-US">Upfront initial exclusivity payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UpfrontInitialExclusivityPayments" xlink:to="nmtc_UpfrontInitialExclusivityPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValuationAllowance" xlink:to="nmtc_ValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl0" xml:lang="en-US">Payroll protection program loan forgiveness.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_WarrantsDescription_lbl0" xml:lang="en-US">Warrants, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsDescription" xlink:to="nmtc_WarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl0" xml:lang="en-US">Number of warrants to be issued for the right to purchase common shares at stated exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsToPurchaseOfCommonStockShares" xlink:to="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_Warrantshares_lbl0" xml:lang="en-US">This relates to warrants not included in basic EPS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_Warrantshares" xlink:to="nmtc_Warrantshares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl0" xml:lang="en-US">Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nmtc_aggregatePrincipalAmount_lbl0" xml:lang="en-US">Aggregate principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_aggregatePrincipalAmount" xlink:to="nmtc_aggregatePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl1" xml:lang="en-US">IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:to="nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoZeroTwoZeroCommonStockOfferingMember_lbl0" xml:lang="en-US">TwoZeroTwoZeroCommonStockOfferingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroCommonStockOfferingMember" xlink:to="nmtc_TwoZeroTwoZeroCommonStockOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RoyaltyMinimumPaymentsYearOne_lbl1" xml:lang="en-US">RoyaltyMinimumPaymentsYearOne</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearOne" xlink:to="nmtc_RoyaltyMinimumPaymentsYearOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IntellectualPropertyPolicyTextBlock_lbl1" xml:lang="en-US">IntellectualPropertyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="nmtc_IntellectualPropertyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_BrokerWarrantsMember_lbl0" xml:lang="en-US">BrokerWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_BrokerWarrantsMember" xlink:to="nmtc_BrokerWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ProceedsFromPaycheckProtectionProgram_lbl1" xml:lang="en-US">ProceedsFromPaycheckProtectionProgram</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPaycheckProtectionProgram" xlink:to="nmtc_ProceedsFromPaycheckProtectionProgram_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_newExercisePriceFiveMember_lbl0" xml:lang="en-US">newExercisePriceFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceFiveMember" xlink:to="nmtc_newExercisePriceFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoThousandNineteenCommonStockOfferingMember_lbl0" xml:lang="en-US">TwoThousandNineteenCommonStockOfferingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandNineteenCommonStockOfferingMember" xlink:to="nmtc_TwoThousandNineteenCommonStockOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePriceMember_lbl0" xml:lang="en-US">ExercisePriceMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceMember" xlink:to="nmtc_ExercisePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl1" xml:lang="en-US">SummaryOfWarrantActivityTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SummaryOfWarrantActivityTableTextBlock" xlink:to="nmtc_SummaryOfWarrantActivityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl1" xml:lang="en-US">RoyaltyMinimumPaymentsYearTwo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearTwo" xlink:to="nmtc_RoyaltyMinimumPaymentsYearTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StateTaxCreditCarryForward_lbl1" xml:lang="en-US">StateTaxCreditCarryForward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateTaxCreditCarryForward" xlink:to="nmtc_StateTaxCreditCarryForward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl1" xml:lang="en-US">NetValuationChangeOfInstrumentsMeasuredAtFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:to="nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NumberOfLicencingAgreements_lbl1" xml:lang="en-US">NumberOfLicencingAgreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOfLicencingAgreements" xlink:to="nmtc_NumberOfLicencingAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScenarioOneMember_lbl0" xml:lang="en-US">ScenarioOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScenarioOneMember" xlink:to="nmtc_ScenarioOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DevelopmentAgreementMember_lbl0" xml:lang="en-US">DevelopmentAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DevelopmentAgreementMember" xlink:to="nmtc_DevelopmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseSpace_lbl1" xml:lang="en-US">LeaseSpace</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseSpace" xlink:to="nmtc_LeaseSpace_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl1" xml:lang="en-US">ConversionOfConvertiblePromissoryNotesToEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToEquity" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl1" xml:lang="en-US">IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:to="nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferredIncomeTaxAssetNet_lbl1" xml:lang="en-US">DeferredIncomeTaxAssetNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredIncomeTaxAssetNet" xlink:to="nmtc_DeferredIncomeTaxAssetNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember_lbl0" xml:lang="en-US">TwoZeroOneSevenPlanEvergreenProvisionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember" xlink:to="nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_newExercisePriceFourMember_lbl0" xml:lang="en-US">newExercisePriceFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceFourMember" xlink:to="nmtc_newExercisePriceFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DepositsExcessOfFederallyInsured_lbl1" xml:lang="en-US">DepositsExcessOfFederallyInsured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DepositsExcessOfFederallyInsured" xlink:to="nmtc_DepositsExcessOfFederallyInsured_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member_lbl0" xml:lang="en-US">AfterSeptember302021ButOnOrBeforeDecember312021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member" xlink:to="nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl1" xml:lang="en-US">StockIssuedDuringPeriodExerciseOfStockOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions" xlink:to="nmtc_StockIssuedDuringPeriodExerciseOfStockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes_lbl0" xml:lang="en-US">BrokerWarrantsIssuedInConnectionWithConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes" xlink:to="nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl1" xml:lang="en-US">IssuanceCostsInConnectionWithConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:to="nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePriceThreeMember_lbl0" xml:lang="en-US">ExercisePriceThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceThreeMember" xlink:to="nmtc_ExercisePriceThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseRentalExpense_lbl1" xml:lang="en-US">LeaseRentalExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseRentalExpense" xlink:to="nmtc_LeaseRentalExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_MonthlyLeaseRent_lbl1" xml:lang="en-US">MonthlyLeaseRent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_MonthlyLeaseRent" xlink:to="nmtc_MonthlyLeaseRent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PurchaseAgreementMember_lbl0" xml:lang="en-US">PurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchaseAgreementMember" xlink:to="nmtc_PurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_Warrantshares_lbl1" xml:lang="en-US">Warrantshares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_Warrantshares" xlink:to="nmtc_Warrantshares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AggregateShareIssued_lbl0" xml:lang="en-US">AggregateShareIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AggregateShareIssued" xlink:to="nmtc_AggregateShareIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RoyaltyMinimumPaymentsYearThree_lbl1" xml:lang="en-US">RoyaltyMinimumPaymentsYearThree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyMinimumPaymentsYearThree" xlink:to="nmtc_RoyaltyMinimumPaymentsYearThree_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePriceOfUnderlyingOptions_lbl1" xml:lang="en-US">ExercisePriceOfUnderlyingOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceOfUnderlyingOptions" xlink:to="nmtc_ExercisePriceOfUnderlyingOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ModifiedConnectorbySeptember302021Member_lbl0" xml:lang="en-US">ModifiedConnectorbySeptember302021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ModifiedConnectorbySeptember302021Member" xlink:to="nmtc_ModifiedConnectorbySeptember302021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_MayoAgreementMember_lbl0" xml:lang="en-US">MayoAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_MayoAgreementMember" xlink:to="nmtc_MayoAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UnpaidDeferredOfferingCosts_lbl1" xml:lang="en-US">UnpaidDeferredOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidDeferredOfferingCosts" xlink:to="nmtc_UnpaidDeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TypeOfAgreementAxis_lbl0" xml:lang="en-US">TypeOfAgreementAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TypeOfAgreementAxis" xlink:to="nmtc_TypeOfAgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueOfTheUnderlyingCommonStock_lbl1" xml:lang="en-US">FairValueOfTheUnderlyingCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfTheUnderlyingCommonStock" xlink:to="nmtc_FairValueOfTheUnderlyingCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertibleNotesAbstract0_lbl0" xml:lang="en-US">ConvertibleNotesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesAbstract0" xlink:to="nmtc_ConvertibleNotesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferredTaxAssetGrossCurrent_lbl1" xml:lang="en-US">DeferredTaxAssetGrossCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetGrossCurrent" xlink:to="nmtc_DeferredTaxAssetGrossCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl1" xml:lang="en-US">ChangeInFairValueIncludingAccruedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ChangeInFairValueIncludingAccruedInterest" xlink:to="nmtc_ChangeInFairValueIncludingAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl1" xml:lang="en-US">ConversionOfConvertiblePromissoryNotesToCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:to="nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl1" xml:lang="en-US">IssuanceCostsAttributedToFinancingActivities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsAttributedToFinancingActivities" xlink:to="nmtc_IssuanceCostsAttributedToFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_GrantDateFairValueOfPerUnit_lbl1" xml:lang="en-US">GrantDateFairValueOfPerUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrantDateFairValueOfPerUnit" xlink:to="nmtc_GrantDateFairValueOfPerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_GrossProceedsFromPrivatePlacement_lbl1" xml:lang="en-US">GrossProceedsFromPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceedsFromPrivatePlacement" xlink:to="nmtc_GrossProceedsFromPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl1" xml:lang="en-US">WeightedAverageNumberOfShareOutstandingBasicsAndDiluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ValuationAllowance_lbl1" xml:lang="en-US">ValuationAllowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValuationAllowance" xlink:to="nmtc_ValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueAttributedToNoteExtinguishment_lbl1" xml:lang="en-US">FairValueAttributedToNoteExtinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToNoteExtinguishment" xlink:to="nmtc_FairValueAttributedToNoteExtinguishment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract_lbl0" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:to="nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NoncashInterest_lbl1" xml:lang="en-US">NoncashInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterest" xlink:to="nmtc_NoncashInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwentyTwentyActivityMember_lbl0" xml:lang="en-US">TwentyTwentyActivityMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwentyTwentyActivityMember" xlink:to="nmtc_TwentyTwentyActivityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl1" xml:lang="en-US">WarrantsToPurchaseOfCommonStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsToPurchaseOfCommonStockShares" xlink:to="nmtc_WarrantsToPurchaseOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoconsultingAgreementsMember_lbl0" xml:lang="en-US">TwoconsultingAgreementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoconsultingAgreementsMember" xlink:to="nmtc_TwoconsultingAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl1" xml:lang="en-US">AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:to="nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceOfCostsIncurred_lbl1" xml:lang="en-US">IssuanceOfCostsIncurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCostsIncurred" xlink:to="nmtc_IssuanceOfCostsIncurred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseLiabilityShortterms_lbl1" xml:lang="en-US">LeaseLiabilityShortterms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiabilityShortterms" xlink:to="nmtc_LeaseLiabilityShortterms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl1" xml:lang="en-US">IncomeTaxBenefitAtFederalStatutoryRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncomeTaxBenefitAtFederalStatutoryRate" xlink:to="nmtc_IncomeTaxBenefitAtFederalStatutoryRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AccruedPayroll_lbl1" xml:lang="en-US">AccruedPayroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AccruedPayroll" xlink:to="nmtc_AccruedPayroll_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_InterestOnPrincipalAmount_lbl0" xml:lang="en-US">InterestOnPrincipalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InterestOnPrincipalAmount" xlink:to="nmtc_InterestOnPrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember_lbl0" xml:lang="en-US">PaulsonPrivatePlacementTwoThousandNineteenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember" xlink:to="nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AllocatedShareBasedCompensation_lbl1" xml:lang="en-US">AllocatedShareBasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AllocatedShareBasedCompensation" xlink:to="nmtc_AllocatedShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoZeroOneNinePaulsonNotesMember_lbl0" xml:lang="en-US">TwoZeroOneNinePaulsonNotesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroOneNinePaulsonNotesMember" xlink:to="nmtc_TwoZeroOneNinePaulsonNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertiblePromissoryNotesPayable_lbl1" xml:lang="en-US">ConvertiblePromissoryNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertiblePromissoryNotesPayable" xlink:to="nmtc_ConvertiblePromissoryNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NumberExercisable1_lbl0" xml:lang="en-US">NumberExercisable1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberExercisable1" xlink:to="nmtc_NumberExercisable1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ChangesOfFairValueBenefit_lbl0" xml:lang="en-US">ChangesOfFairValueBenefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ChangesOfFairValueBenefit" xlink:to="nmtc_ChangesOfFairValueBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ImputedInterest_lbl1" xml:lang="en-US">ImputedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ImputedInterest" xlink:to="nmtc_ImputedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ProductRevenueRecognized_lbl1" xml:lang="en-US">ProductRevenueRecognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProductRevenueRecognized" xlink:to="nmtc_ProductRevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_InternalRevenuePercentage_lbl1" xml:lang="en-US">InternalRevenuePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InternalRevenuePercentage" xlink:to="nmtc_InternalRevenuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockbasedCompensation_lbl1" xml:lang="en-US">StockbasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockbasedCompensation" xlink:to="nmtc_StockbasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EffectiveTaxRate_lbl1" xml:lang="en-US">EffectiveTaxRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EffectiveTaxRate" xlink:to="nmtc_EffectiveTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SharesReservedDescription_lbl1" xml:lang="en-US">SharesReservedDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesReservedDescription" xlink:to="nmtc_SharesReservedDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoThousandSixteenAndSeventeenPlanMember_lbl0" xml:lang="en-US">TwoThousandSixteenAndSeventeenPlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:to="nmtc_TwoThousandSixteenAndSeventeenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member_lbl0" xml:lang="en-US">AfterJune302021ButOnOrBeforeSeptember302021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member" xlink:to="nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageTermyearsForfeitedinShares_lbl0" xml:lang="en-US">WeightedAverageTermyearsForfeitedinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsForfeitedinShares" xlink:to="nmtc_WeightedAverageTermyearsForfeitedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ReviseTheRegistrationDateDescription_lbl1" xml:lang="en-US">ReviseTheRegistrationDateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ReviseTheRegistrationDateDescription" xlink:to="nmtc_ReviseTheRegistrationDateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoZeroTwoZeroPaulsonNotesMember_lbl0" xml:lang="en-US">TwoZeroTwoZeroPaulsonNotesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroPaulsonNotesMember" xlink:to="nmtc_TwoZeroTwoZeroPaulsonNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OperatingCashFlowsFromOperatingLeases_lbl1" xml:lang="en-US">OperatingCashFlowsFromOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingCashFlowsFromOperatingLeases" xlink:to="nmtc_OperatingCashFlowsFromOperatingLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LegalAndThirdPartyFee_lbl1" xml:lang="en-US">LegalAndThirdPartyFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LegalAndThirdPartyFee" xlink:to="nmtc_LegalAndThirdPartyFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferralsPercentage_lbl1" xml:lang="en-US">DeferralsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferralsPercentage" xlink:to="nmtc_DeferralsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NumberOutstandingsTotal_lbl1" xml:lang="en-US">NumberOutstandingsTotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NumberOutstandingsTotal" xlink:to="nmtc_NumberOutstandingsTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WarrantsForfeitedinShares_lbl0" xml:lang="en-US">WarrantsForfeitedinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsForfeitedinShares" xlink:to="nmtc_WarrantsForfeitedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePrice_lbl0" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePrice" xlink:to="nmtc_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_GrossProceeds_lbl1" xml:lang="en-US">GrossProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_GrossProceeds" xlink:to="nmtc_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_CashCommissionPercentageRateOnProceeds_lbl1" xml:lang="en-US">CashCommissionPercentageRateOnProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashCommissionPercentageRateOnProceeds" xlink:to="nmtc_CashCommissionPercentageRateOnProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SharesIssuedUnderPrivatePlacement_lbl1" xml:lang="en-US">SharesIssuedUnderPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesIssuedUnderPrivatePlacement" xlink:to="nmtc_SharesIssuedUnderPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl1" xml:lang="en-US">DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:to="nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredTaxAssetsAbstract" xlink:to="nmtc_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl1" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueFourYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesStockWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UnissuedVestedRestrictedStockUnits_lbl1" xml:lang="en-US">UnissuedVestedRestrictedStockUnits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnissuedVestedRestrictedStockUnits" xlink:to="nmtc_UnissuedVestedRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertibleNotesOutstandingPrincipal_lbl1" xml:lang="en-US">ConvertibleNotesOutstandingPrincipal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesOutstandingPrincipal" xlink:to="nmtc_ConvertibleNotesOutstandingPrincipal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PurchaseOfWarrants_lbl0" xml:lang="en-US">PurchaseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchaseOfWarrants" xlink:to="nmtc_PurchaseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OutstandingStockOptionsShares_lbl1" xml:lang="en-US">OutstandingStockOptionsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OutstandingStockOptionsShares" xlink:to="nmtc_OutstandingStockOptionsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IncreaseDecreaseInFairValue_lbl1" xml:lang="en-US">IncreaseDecreaseInFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IncreaseDecreaseInFairValue" xlink:to="nmtc_IncreaseDecreaseInFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueThreeYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ZimmerDevelopmentAgreementTextBlock_lbl0" xml:lang="en-US">ZimmerDevelopmentAgreementTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ZimmerDevelopmentAgreementTextBlock" xlink:to="nmtc_ZimmerDevelopmentAgreementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl1" xml:lang="en-US">ValueOfPayrollProtectionProgramLoanForgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_ValueOfPayrollProtectionProgramLoanForgiveness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePricePerWarrantIssued_lbl0" xml:lang="en-US">ExercisePricePerWarrantIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantIssued" xlink:to="nmtc_ExercisePricePerWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PayrollProtectionProgramLoanForgiveness_lbl1" xml:lang="en-US">PayrollProtectionProgramLoanForgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PayrollProtectionProgramLoanForgiveness" xlink:to="nmtc_PayrollProtectionProgramLoanForgiveness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePriceTwoMember_lbl0" xml:lang="en-US">ExercisePriceTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceTwoMember" xlink:to="nmtc_ExercisePriceTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RentExpense_lbl1" xml:lang="en-US">RentExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RentExpense" xlink:to="nmtc_RentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PurchasePriceOfCommonStock_lbl1" xml:lang="en-US">PurchasePriceOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PurchasePriceOfCommonStock" xlink:to="nmtc_PurchasePriceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OnOrBeforeJune302021Member_lbl0" xml:lang="en-US">OnOrBeforeJune302021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OnOrBeforeJune302021Member" xlink:to="nmtc_OnOrBeforeJune302021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ModifiedConnectorbyApril302021Member_lbl0" xml:lang="en-US">ModifiedConnectorbyApril302021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ModifiedConnectorbyApril302021Member" xlink:to="nmtc_ModifiedConnectorbyApril302021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl1" xml:lang="en-US">UnpaidPurchasesOfPropertyAndEquipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidPurchasesOfPropertyAndEquipment" xlink:to="nmtc_UnpaidPurchasesOfPropertyAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl1" xml:lang="en-US">IssuanceCostSettlementInConnectionWithPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseAgreementDescription_lbl1" xml:lang="en-US">LeaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseAgreementDescription" xlink:to="nmtc_LeaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_aggregatePrincipalAmount_lbl1" xml:lang="en-US">aggregatePrincipalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_aggregatePrincipalAmount" xlink:to="nmtc_aggregatePrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl1" xml:lang="en-US">FairValueAttributedToConvertibleNotesUponIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueAttributedToConvertibleNotesUponIssuance" xlink:to="nmtc_FairValueAttributedToConvertibleNotesUponIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WadeFredricksonMember_lbl0" xml:lang="en-US">WadeFredricksonMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WadeFredricksonMember" xlink:to="nmtc_WadeFredricksonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EquityIncentivePlansMember_lbl0" xml:lang="en-US">EquityIncentivePlansMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityIncentivePlansMember" xlink:to="nmtc_EquityIncentivePlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PaycheckProtectionProgramDescription_lbl1" xml:lang="en-US">PaycheckProtectionProgramDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaycheckProtectionProgramDescription" xlink:to="nmtc_PaycheckProtectionProgramDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NetIntangiblesUsefulLives_lbl1" xml:lang="en-US">NetIntangiblesUsefulLives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NetIntangiblesUsefulLives" xlink:to="nmtc_NetIntangiblesUsefulLives_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EarningsPerSharesBasicAndDiluted_lbl1" xml:lang="en-US">EarningsPerSharesBasicAndDiluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EarningsPerSharesBasicAndDiluted" xlink:to="nmtc_EarningsPerSharesBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding_lbl0" xml:lang="en-US">ExercisePricePerWarrantOutstandingAndExercisableEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding_lbl0" xml:lang="en-US">WeightedAverageExercisePriceOutstandingAndExercisableEnding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding" xlink:to="nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseLiability_lbl0" xml:lang="en-US">LeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiability" xlink:to="nmtc_LeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl1" xml:lang="en-US">InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:to="nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl1" xml:lang="en-US">UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:to="nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertibleNotes_lbl1" xml:lang="en-US">ConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotes" xlink:to="nmtc_ConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_newExercisePriceSixMember_lbl0" xml:lang="en-US">newExercisePriceSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_newExercisePriceSixMember" xlink:to="nmtc_newExercisePriceSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RestrictedStockUnit_lbl1" xml:lang="en-US">RestrictedStockUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RestrictedStockUnit" xlink:to="nmtc_RestrictedStockUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SupplementalBalanceSheetInformationTextBlock_lbl0" xml:lang="en-US">SupplementalBalanceSheetInformationTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalBalanceSheetInformationTextBlock" xlink:to="nmtc_SupplementalBalanceSheetInformationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageExercisePriceExercised_lbl0" xml:lang="en-US">WeightedAverageExercisePriceExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceExercised" xlink:to="nmtc_WeightedAverageExercisePriceExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl1" xml:lang="en-US">FuturePotentialMilestonePaymentsToNeuroone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FuturePotentialMilestonePaymentsToNeuroone" xlink:to="nmtc_FuturePotentialMilestonePaymentsToNeuroone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockOptionVestedOverAPeriodTerm_lbl1" xml:lang="en-US">StockOptionVestedOverAPeriodTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptionVestedOverAPeriodTerm" xlink:to="nmtc_StockOptionVestedOverAPeriodTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DeferredsOfferingCosts_lbl1" xml:lang="en-US">DeferredsOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DeferredsOfferingCosts" xlink:to="nmtc_DeferredsOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertibleNotesAbstract_lbl0" xml:lang="en-US">ConvertibleNotesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNotesAbstract" xlink:to="nmtc_ConvertibleNotesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UnderwritingAgreementDescription_lbl1" xml:lang="en-US">UnderwritingAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UnderwritingAgreementDescription" xlink:to="nmtc_UnderwritingAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageTermyearsExercisedinShares_lbl0" xml:lang="en-US">WeightedAverageTermyearsExercisedinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsExercisedinShares" xlink:to="nmtc_WeightedAverageTermyearsExercisedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OutstandingVotingPercentage_lbl0" xml:lang="en-US">OutstandingVotingPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OutstandingVotingPercentage" xlink:to="nmtc_OutstandingVotingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl1" xml:lang="en-US">IssuanceCostsInConnectionWithPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacement" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease_lbl0" xml:lang="en-US">OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" xlink:to="nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_AfterDecember312021Member_lbl0" xml:lang="en-US">AfterDecember312021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_AfterDecember312021Member" xlink:to="nmtc_AfterDecember312021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueOneYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl1" xml:lang="en-US">ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:to="nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_November302020Member_lbl0" xml:lang="en-US">November302020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_November302020Member" xlink:to="nmtc_November302020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueChangeOfConvertibleNotes_lbl1" xml:lang="en-US">FairValueChangeOfConvertibleNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueChangeOfConvertibleNotes" xlink:to="nmtc_FairValueChangeOfConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WarrantsDescription_lbl1" xml:lang="en-US">WarrantsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsDescription" xlink:to="nmtc_WarrantsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostsDescription_lbl0" xml:lang="en-US">IssuanceCostsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsDescription" xlink:to="nmtc_IssuanceCostsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertibleNoteFinancingDescription_lbl0" xml:lang="en-US">ConvertibleNoteFinancingDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertibleNoteFinancingDescription" xlink:to="nmtc_ConvertibleNoteFinancingDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageExercisePriceForfeited_lbl0" xml:lang="en-US">WeightedAverageExercisePriceForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageExercisePriceForfeited" xlink:to="nmtc_WeightedAverageExercisePriceForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RevisedOptionalConversionTermsDescription_lbl0" xml:lang="en-US">RevisedOptionalConversionTermsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RevisedOptionalConversionTermsDescription" xlink:to="nmtc_RevisedOptionalConversionTermsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePriceOneMember_lbl0" xml:lang="en-US">ExercisePriceOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePriceOneMember" xlink:to="nmtc_ExercisePriceOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FutureIssuanceOnACombinedBasis_lbl1" xml:lang="en-US">FutureIssuanceOnACombinedBasis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FutureIssuanceOnACombinedBasis" xlink:to="nmtc_FutureIssuanceOnACombinedBasis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConsultingAgreementsDescription_lbl1" xml:lang="en-US">ConsultingAgreementsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConsultingAgreementsDescription" xlink:to="nmtc_ConsultingAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SharesAreAuthorizedForFutureIssuance_lbl1" xml:lang="en-US">SharesAreAuthorizedForFutureIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SharesAreAuthorizedForFutureIssuance" xlink:to="nmtc_SharesAreAuthorizedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ReverseStockSplitPolicyTextBlock_lbl0" xml:lang="en-US">ReverseStockSplitPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ReverseStockSplitPolicyTextBlock" xlink:to="nmtc_ReverseStockSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ScenarioTwoMember_lbl0" xml:lang="en-US">ScenarioTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ScenarioTwoMember" xlink:to="nmtc_ScenarioTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LeaseLiabilityNet_lbl0" xml:lang="en-US">LeaseLiabilityNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LeaseLiabilityNet" xlink:to="nmtc_LeaseLiabilityNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl1" xml:lang="en-US">IssuanceOfCommonStockUponVestingOfRestrictedStockUnits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCosts_lbl0" xml:lang="en-US">IssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCosts" xlink:to="nmtc_IssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl1" xml:lang="en-US">IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:to="nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_Second2019PaulsonNotesAmendmentMember_lbl0" xml:lang="en-US">Second2019PaulsonNotesAmendmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_Second2019PaulsonNotesAmendmentMember" xlink:to="nmtc_Second2019PaulsonNotesAmendmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_CashCommissions_lbl0" xml:lang="en-US">CashCommissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_CashCommissions" xlink:to="nmtc_CashCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LessAccumulatedDepreciations_lbl1" xml:lang="en-US">LessAccumulatedDepreciations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LessAccumulatedDepreciations" xlink:to="nmtc_LessAccumulatedDepreciations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceOfFairValueAmount_lbl1" xml:lang="en-US">IssuanceOfFairValueAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceOfFairValueAmount" xlink:to="nmtc_IssuanceOfFairValueAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SupplementalCashFlowTableTextBlock_lbl0" xml:lang="en-US">SupplementalCashFlowTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalCashFlowTableTextBlock" xlink:to="nmtc_SupplementalCashFlowTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RoyaltyPayments_lbl1" xml:lang="en-US">RoyaltyPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RoyaltyPayments" xlink:to="nmtc_RoyaltyPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_April302021Member_lbl0" xml:lang="en-US">April302021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_April302021Member" xlink:to="nmtc_April302021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PrepaidExpenses_lbl1" xml:lang="en-US">PrepaidExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PrepaidExpenses" xlink:to="nmtc_PrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ResearchCredits_lbl1" xml:lang="en-US">ResearchCredits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ResearchCredits" xlink:to="nmtc_ResearchCredits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_PaulsonPrivatePlacementMember_lbl0" xml:lang="en-US">PaulsonPrivatePlacementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_PaulsonPrivatePlacementMember" xlink:to="nmtc_PaulsonPrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_RevenueFromCollaboration_lbl1" xml:lang="en-US">RevenueFromCollaboration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_RevenueFromCollaboration" xlink:to="nmtc_RevenueFromCollaboration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl1" xml:lang="en-US">IssuanceCostsInConnectionWithPrivatePlacements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IssuanceCostsInConnectionWithPrivatePlacements" xlink:to="nmtc_IssuanceCostsInConnectionWithPrivatePlacements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WarrantsExercisableForSharesOfCommonStockConnection_lbl0" xml:lang="en-US">WarrantsExercisableForSharesOfCommonStockConnection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WarrantsExercisableForSharesOfCommonStockConnection" xlink:to="nmtc_WarrantsExercisableForSharesOfCommonStockConnection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageTermyearsIssuedinShares_lbl0" xml:lang="en-US">WeightedAverageTermyearsIssuedinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageTermyearsIssuedinShares" xlink:to="nmtc_WeightedAverageTermyearsIssuedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EmployeesCompensationPercentage_lbl1" xml:lang="en-US">EmployeesCompensationPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EmployeesCompensationPercentage" xlink:to="nmtc_EmployeesCompensationPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueOfWarrants_lbl1" xml:lang="en-US">FairValueOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueOfWarrants" xlink:to="nmtc_FairValueOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoThousandNineteenQualifiedFinancingMember_lbl0" xml:lang="en-US">TwoThousandNineteenQualifiedFinancingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoThousandNineteenQualifiedFinancingMember" xlink:to="nmtc_TwoThousandNineteenQualifiedFinancingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl1" xml:lang="en-US">EquityQualifiedFinancingDescriptiononConvertibleNoteOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:to="nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ContributionsAmount_lbl1" xml:lang="en-US">ContributionsAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsAmount" xlink:to="nmtc_ContributionsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockOptions_lbl1" xml:lang="en-US">StockOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockOptions" xlink:to="nmtc_StockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ContributionsPercentage_lbl1" xml:lang="en-US">ContributionsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ContributionsPercentage" xlink:to="nmtc_ContributionsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember_lbl0" xml:lang="en-US">TwoZeroTwoZeroPaulsonPrivatePlacementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember" xlink:to="nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl1" xml:lang="en-US">ProceedsFromPayrollProtectionProgramLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ProceedsFromPayrollProtectionProgramLoan" xlink:to="nmtc_ProceedsFromPayrollProtectionProgramLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExtendedMaturityDateDescription_lbl0" xml:lang="en-US">ExtendedMaturityDateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExtendedMaturityDateDescription" xlink:to="nmtc_ExtendedMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueTwoYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_UpfrontInitialExclusivityPayments_lbl1" xml:lang="en-US">UpfrontInitialExclusivityPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_UpfrontInitialExclusivityPayments" xlink:to="nmtc_UpfrontInitialExclusivityPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TotalGrossProceeds_lbl1" xml:lang="en-US">TotalGrossProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalGrossProceeds" xlink:to="nmtc_TotalGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_EquityFinancingAmount_lbl0" xml:lang="en-US">EquityFinancingAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_EquityFinancingAmount" xlink:to="nmtc_EquityFinancingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl1" xml:lang="en-US">FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:to="nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_TotalExpenseOfStockOption_lbl1" xml:lang="en-US">TotalExpenseOfStockOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_TotalExpenseOfStockOption" xlink:to="nmtc_TotalExpenseOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl1" xml:lang="en-US">NoncashInterestOnConvertiblePromissoryNotes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_NoncashInterestOnConvertiblePromissoryNotes" xlink:to="nmtc_NoncashInterestOnConvertiblePromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueFiveYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_DisqualifiedInterestAndOther_lbl1" xml:lang="en-US">DisqualifiedInterestAndOther</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_DisqualifiedInterestAndOther" xlink:to="nmtc_DisqualifiedInterestAndOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_IntialFeePayment_lbl1" xml:lang="en-US">IntialFeePayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_IntialFeePayment" xlink:to="nmtc_IntialFeePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1_lbl0" xml:lang="en-US">ExercisePricePerWarrantOutstandingAndExercisableBeginning1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1" xlink:to="nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_OperatingLeases_lbl1" xml:lang="en-US">OperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_OperatingLeases" xlink:to="nmtc_OperatingLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueStockWarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_WeightedAverageRemainingContractualLifeYears_lbl0" xml:lang="en-US">WeightedAverageRemainingContractualLifeYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_WeightedAverageRemainingContractualLifeYears" xlink:to="nmtc_WeightedAverageRemainingContractualLifeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ConvertedNotesCommonStock_lbl0" xml:lang="en-US">ConvertedNotesCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ConvertedNotesCommonStock" xlink:to="nmtc_ConvertedNotesCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_ActivityMember_lbl0" xml:lang="en-US">ActivityMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_ActivityMember" xlink:to="nmtc_ActivityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_SupplementalBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">SupplementalBalanceSheetTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_SupplementalBalanceSheetTableTextBlock" xlink:to="nmtc_SupplementalBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl1" xml:lang="en-US">StateIncomeTaxNetOfFederalBenefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nmtc_StateIncomeTaxNetOfFederalBenefit" xlink:to="nmtc_StateIncomeTaxNetOfFederalBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueAbstract_lbl0" xml:lang="en-US">Deferred Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl1" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl0" xml:lang="en-US">Capitalized Computer Software, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl0" xml:lang="en-US">Defined Contribution Plan [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl0" xml:lang="en-US">Software Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl0" xml:lang="en-US">Short-Term Lease Commitment, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl0" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl0" xml:lang="en-US">Cost, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl0" xml:lang="en-US">Cumulative Earnings (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl0" xml:lang="en-US">Furniture and Fixtures, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl2" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl0" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>nmtc-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue May 31 20:12:38 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedBalanceSheet" roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedIncomeStatement" roleURI="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ShareholdersEquityType2or3" roleURI="http://originalsourcemusic.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConsolidatedCashFlow" roleURI="http://originalsourcemusic.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_OrganizationandNatureofOperations" roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_GoingConcern" roleURI="http://originalsourcemusic.com/role/GoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPolicies" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingencies" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformation" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilities" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreement" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreements" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensation" roleURI="http://originalsourcemusic.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficit" roleURI="http://originalsourcemusic.com/role/StockholdersDeficit"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxes" roleURI="http://originalsourcemusic.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_DefinedContributionPlan" roleURI="http://originalsourcemusic.com/role/DefinedContributionPlan"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SubsequentEvents" roleURI="http://originalsourcemusic.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccountingPoliciesByPolicy" roleURI="http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingenciesTables" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformationTables" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilitiesTables" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreementTables" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsTables" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensationTables" roleURI="http://originalsourcemusic.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficitTables" roleURI="http://originalsourcemusic.com/role/StockholdersDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxesTables" roleURI="http://originalsourcemusic.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable" roleURI="http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable" roleURI="http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofcomputationofdilutednetlosspershareTable" roleURI="http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofmaturityoftheleaseliabilityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofPrepaidandotherassetsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofintangibleassetsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofpropertyandequipmentTable" roleURI="http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofaccruedexpensesTable" roleURI="http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofdeferredrevenueTable" roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofconvertiblepromissorynotesandwarrantagreementsTable" roleURI="http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofstockoptionplanactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable" roleURI="http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofrestrictedstockunitactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofwarrantactivityTable" roleURI="http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofsummarizesinformationaboutwarrantsoutstandingTable" roleURI="http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable" roleURI="http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_OrganizationandNatureofOperationsDetails" roleURI="http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_GoingConcernDetails" roleURI="http://originalsourcemusic.com/role/GoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_CommitmentsandContingenciesDetails" roleURI="http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SupplementalBalanceSheetInformationDetails" roleURI="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_AccruedExpensesandOtherLiabilitiesDetails" roleURI="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ZimmerDevelopmentAgreementDetails" roleURI="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_ConvertiblePromissoryNotesandWarrantAgreementsDetails" roleURI="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockBasedCompensationDetails" roleURI="http://originalsourcemusic.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_StockholdersDeficitDetails" roleURI="http://originalsourcemusic.com/role/StockholdersDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_IncomeTaxesDetails" roleURI="http://originalsourcemusic.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_DefinedContributionPlanDetails" roleURI="http://originalsourcemusic.com/role/DefinedContributionPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#nmtc_r_SubsequentEventsDetails" roleURI="http://originalsourcemusic.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nmtc-20210930.xsd#DocumentAndEntityInformation" roleURI="http://originalsourcemusic.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueFromCollaboration" xlink:href="nmtc-20210930.xsd#nmtc_RevenueFromCollaboration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="RevenueFromCollaboration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetValuationChangeOfInstrumentsMeasuredAtFairValue" xlink:href="nmtc-20210930.xsd#nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="NetValuationChangeOfInstrumentsMeasuredAtFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_NetIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarningsPerSharesBasicAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_EarningsPerSharesBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="EarningsPerSharesBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostsInConnectionWithPrivatePlacement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostSettlementInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostSettlementInConnectionWithPrivatePlacement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodExerciseOfStockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodExerciseOfStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodExerciseOfStockOptions" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockWarrantsExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:href="nmtc-20210930.xsd#nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockWarrantsExercised" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocatedShareBasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_AllocatedShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AllocatedShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashInterestOnConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterestOnConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NoncashInterestOnConvertiblePromissoryNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_PayrollProtectionProgramLoanForgiveness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PayrollProtectionProgramLoanForgiveness" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueChangeOfConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_FairValueChangeOfConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueChangeOfConvertibleNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsAttributedToFinancingActivities" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsAttributedToFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceCostsAttributedToFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsInConnectionWithConvertiblePromissoryNotes" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceCostsInConnectionWithConvertiblePromissoryNotes" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsInConnectionWithPrivatePlacements" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsInConnectionWithPrivatePlacements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceCostsInConnectionWithPrivatePlacements" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromPaycheckProtectionProgram" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPaycheckProtectionProgram"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromPaycheckProtectionProgram" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredsOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_DeferredsOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="DeferredsOfferingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePromissoryNotesToEquity" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfConvertiblePromissoryNotesToEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BrokerWarrantsIssuedInConnectionWithConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="BrokerWarrantsIssuedInConnectionWithConvertibleNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueOfPayrollProtectionProgramLoanForgiveness" xlink:href="nmtc-20210930.xsd#nmtc_ValueOfPayrollProtectionProgramLoanForgiveness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ValueOfPayrollProtectionProgramLoanForgiveness" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidDeferredOfferingCosts" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidDeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidDeferredOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidPurchasesOfPropertyAndEquipment" xlink:href="nmtc-20210930.xsd#nmtc_UnpaidPurchasesOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidPurchasesOfPropertyAndEquipment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/OrganizationandNatureofOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/GoingConcern">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation">
    <loc xlink:type="locator" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="SupplementalBalanceSheetInformationTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="SupplementalBalanceSheetInformationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement">
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementAbstract" xlink:to="ZimmerDevelopmentAgreementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DefinedContributionPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_ReverseStockSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntellectualPropertyPolicyTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_IntellectualPropertyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="IntellectualPropertyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SupplementalCashFlowTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalCashFlowTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="SupplementalCashFlowTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalBalanceSheetTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="SupplementalBalanceSheetTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables">
    <loc xlink:type="locator" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables">
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryOfWarrantActivityTableTextBlock" xlink:href="nmtc-20210930.xsd#nmtc_SummaryOfWarrantActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="SummaryOfWarrantActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:to="ConvertibleNotesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAbstract" xlink:to="us-gaap_ConvertibleNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAttributedToConvertibleNotesUponIssuance" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToConvertibleNotesUponIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAbstract" xlink:to="FairValueAttributedToConvertibleNotesUponIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAttributedToNoteExtinguishment" xlink:href="nmtc-20210930.xsd#nmtc_FairValueAttributedToNoteExtinguishment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAbstract" xlink:to="FairValueAttributedToNoteExtinguishment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePromissoryNotesToCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAbstract" xlink:to="ConversionOfConvertiblePromissoryNotesToCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueIncludingAccruedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ChangeInFairValueIncludingAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesAbstract" xlink:to="ChangeInFairValueIncludingAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract" xlink:to="us-gaap_ConvertibleNotesPayable_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="Warrantshares" xlink:href="nmtc-20210930.xsd#nmtc_Warrantshares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="Warrantshares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptions" xlink:href="nmtc-20210930.xsd#nmtc_StockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="StockOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnit" xlink:href="nmtc-20210930.xsd#nmtc_RestrictedStockUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="RestrictedStockUnit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnissuedVestedRestrictedStockUnits" xlink:href="nmtc-20210930.xsd#nmtc_UnissuedVestedRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="UnissuedVestedRestrictedStockUnits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotes" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfDilutedNetLossPerShareAbstract" xlink:to="ConvertibleNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowsFromOperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingCashFlowsFromOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract" xlink:to="OperatingCashFlowsFromOperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract" xlink:to="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeases" xlink:href="nmtc-20210930.xsd#nmtc_OperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="OperatingLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiability" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="LeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueOneYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueOneYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueTwoYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueThreeYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueFourYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueFourYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:href="nmtc-20210930.xsd#nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfTheLeaseLiabilityAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImputedInterest" xlink:href="nmtc-20210930.xsd#nmtc_ImputedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueFiveYear" xlink:to="ImputedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilityNet" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImputedInterest" xlink:to="LeaseLiabilityNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImputedInterest" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ImputedInterest" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpenses" xlink:href="nmtc-20210930.xsd#nmtc_PrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="PrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NetIntangiblesUsefulLives" xlink:href="nmtc-20210930.xsd#nmtc_NetIntangiblesUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="NetIntangiblesUsefulLives" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessAccumulatedDepreciations" xlink:href="nmtc-20210930.xsd#nmtc_LessAccumulatedDepreciations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="LessAccumulatedDepreciations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedPayroll" xlink:href="nmtc-20210930.xsd#nmtc_AccruedPayroll"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="AccruedPayroll" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilityShortterms" xlink:href="nmtc-20210930.xsd#nmtc_LeaseLiabilityShortterms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="LeaseLiabilityShortterms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayments" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="RoyaltyPayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredRevenueAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontInitialExclusivityPayments" xlink:href="nmtc-20210930.xsd#nmtc_UpfrontInitialExclusivityPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="UpfrontInitialExclusivityPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesOutstandingPrincipal" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNotesOutstandingPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="ConvertibleNotesOutstandingPrincipal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" xlink:href="nmtc-20210930.xsd#nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" xlink:href="nmtc-20210930.xsd#nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesPayable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract" xlink:to="ConvertiblePromissoryNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionPlanActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfStockOptionPlanActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbj4xdQOK1oZVN/poQDJzv0cBhEcofUkm9RMHjH8L3uLdRS9C2Zx37ao8CbmJUFVfPO7kzacQyLd9rQNoD/meMeO3shMFt1+i/fm95ABxSmqLgPa3qdnCdy4AoGp9rP1DF4ffhSn8hLdt03fEVvPV8HJwXo/RWWlhUD0zTiUfG4Ekny/+RXFtQRZqrW5638Qu7YNj//evtW/wkC2JKDjLAg/PmFwLwnf3lW0Qqxfu2BqWz2dV4PyC7jiD6YM9BeIFI=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="nmtc-20210930.xsd#nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlanActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="StockholdersDeficitDetailsScheduleofwarrantactivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityTable" xlink:to="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerWarrantOutstandingAndExercisableBeginning1" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ExercisePricePerWarrantOutstandingAndExercisableBeginning1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerWarrantIssued" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ExercisePricePerWarrantIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTermyearsIssuedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsIssuedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageTermyearsIssuedinShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercised" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageExercisePriceExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTermyearsExercisedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsExercisedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageTermyearsExercisedinShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsForfeitedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WarrantsForfeitedinShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceForfeited" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageExercisePriceForfeited" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTermyearsForfeitedinShares" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageTermyearsForfeitedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageTermyearsForfeitedinShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_0" xlink:href="nmtc-20210930.xsd#nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerWarrantOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="ExercisePricePerWarrantOutstandingAndExercisableEnding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOutstandingAndExercisableEnding" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="WeightedAverageExercisePriceOutstandingAndExercisableEnding" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceThreeMember" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="newExercisePriceFourMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="newExercisePriceFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="newExercisePriceFiveMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="newExercisePriceFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="newExercisePriceSixMember" xlink:href="nmtc-20210930.xsd#nmtc_newExercisePriceSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="newExercisePriceSixMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOutstandingsTotal" xlink:href="nmtc-20210930.xsd#nmtc_NumberOutstandingsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOutstandingsTotal" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeYears" xlink:href="nmtc-20210930.xsd#nmtc_WeightedAverageRemainingContractualLifeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="WeightedAverageRemainingContractualLifeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberExercisable1" xlink:href="nmtc-20210930.xsd#nmtc_NumberExercisable1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberExercisable1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxBenefitAtFederalStatutoryRate" xlink:href="nmtc-20210930.xsd#nmtc_IncomeTaxBenefitAtFederalStatutoryRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="IncomeTaxBenefitAtFederalStatutoryRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateIncomeTaxNetOfFederalBenefit" xlink:href="nmtc-20210930.xsd#nmtc_StateIncomeTaxNetOfFederalBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="StateIncomeTaxNetOfFederalBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisqualifiedInterestAndOther" xlink:href="nmtc-20210930.xsd#nmtc_DisqualifiedInterestAndOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="DisqualifiedInterestAndOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchCredits" xlink:href="nmtc-20210930.xsd#nmtc_ResearchCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="ResearchCredits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockbasedCompensation" xlink:href="nmtc-20210930.xsd#nmtc_StockbasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="StockbasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowance" xlink:href="nmtc-20210930.xsd#nmtc_ValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="ValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveTaxRate" xlink:href="nmtc-20210930.xsd#nmtc_EffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract" xlink:to="EffectiveTaxRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxAssetNet" xlink:href="nmtc-20210930.xsd#nmtc_DeferredIncomeTaxAssetNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredIncomeTaxAssetNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromPayrollProtectionProgramLoan" xlink:href="nmtc-20210930.xsd#nmtc_ProceedsFromPayrollProtectionProgramLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ProceedsFromPayrollProtectionProgramLoan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/GoingConcernDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CumulativeEarningsDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsExcessOfFederallyInsured" xlink:href="nmtc-20210930.xsd#nmtc_DepositsExcessOfFederallyInsured"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="DepositsExcessOfFederallyInsured" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfLicencingAgreements" xlink:href="nmtc-20210930.xsd#nmtc_NumberOfLicencingAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="NumberOfLicencingAgreements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WadeFredricksonMember" xlink:href="nmtc-20210930.xsd#nmtc_WadeFredricksonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WadeFredricksonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="TypeOfAgreementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TypeOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MayoAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_MayoAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="MayoAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="RoyaltyMinimumPaymentsYearOne" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyMinimumPaymentsYearOne" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyMinimumPaymentsYearTwo" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyMinimumPaymentsYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyMinimumPaymentsYearThree" xlink:href="nmtc-20210930.xsd#nmtc_RoyaltyMinimumPaymentsYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RoyaltyMinimumPaymentsYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_LeaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LeaseAgreementDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseSpace" xlink:href="nmtc-20210930.xsd#nmtc_LeaseSpace"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LeaseSpace" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseRentalExpense" xlink:href="nmtc-20210930.xsd#nmtc_LeaseRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LeaseRentalExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyLeaseRent" xlink:href="nmtc-20210930.xsd#nmtc_MonthlyLeaseRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MonthlyLeaseRent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentExpense" xlink:href="nmtc-20210930.xsd#nmtc_RentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_SupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramDescription" xlink:href="nmtc-20210930.xsd#nmtc_PaycheckProtectionProgramDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="PaycheckProtectionProgramDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails">
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementAbstract" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ZimmerDevelopmentAgreementDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ZimmerDevelopmentAgreementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementAbstract" xlink:to="ZimmerDevelopmentAgreementDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScenarioOneMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="ScenarioOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScenarioTwoMember" xlink:href="nmtc-20210930.xsd#nmtc_ScenarioTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="ScenarioTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsTable" xlink:to="TypeOfAgreementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TypeOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DevelopmentAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_DevelopmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="DevelopmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="November302020Member" xlink:href="nmtc-20210930.xsd#nmtc_November302020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="November302020Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April302021Member" xlink:href="nmtc-20210930.xsd#nmtc_April302021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="April302021Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ModifiedConnectorbyApril302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbyApril302021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="ModifiedConnectorbyApril302021Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ModifiedConnectorbySeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_ModifiedConnectorbySeptember302021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="ModifiedConnectorbySeptember302021Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnOrBeforeJune302021Member" xlink:href="nmtc-20210930.xsd#nmtc_OnOrBeforeJune302021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="OnOrBeforeJune302021Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AfterJune302021ButOnOrBeforeSeptember302021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="AfterJune302021ButOnOrBeforeSeptember302021Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AfterSeptember302021ButOnOrBeforeDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="AfterSeptember302021ButOnOrBeforeDecember312021Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AfterDecember312021Member" xlink:href="nmtc-20210930.xsd#nmtc_AfterDecember312021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="AfterDecember312021Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsTable" xlink:to="ZimmerDevelopmentAgreementDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="IntialFeePayment" xlink:href="nmtc-20210930.xsd#nmtc_IntialFeePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="IntialFeePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FuturePotentialMilestonePaymentsToNeuroone" xlink:href="nmtc-20210930.xsd#nmtc_FuturePotentialMilestonePaymentsToNeuroone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="FuturePotentialMilestonePaymentsToNeuroone" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductRevenueRecognized" xlink:href="nmtc-20210930.xsd#nmtc_ProductRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="ProductRevenueRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="us-gaap_Revenues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ZimmerDevelopmentAgreementDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PaulsonPrivatePlacementTwoThousandNineteenMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="PaulsonPrivatePlacementTwoThousandNineteenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneNinePaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneNinePaulsonNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="TwoZeroOneNinePaulsonNotesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Second2019PaulsonNotesAmendmentMember" xlink:href="nmtc-20210930.xsd#nmtc_Second2019PaulsonNotesAmendmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="Second2019PaulsonNotesAmendmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroTwoZeroPaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="TwoZeroTwoZeroPaulsonPrivatePlacementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroTwoZeroPaulsonNotesMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroPaulsonNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="TwoZeroTwoZeroPaulsonNotesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaulsonPrivatePlacementMember" xlink:href="nmtc-20210930.xsd#nmtc_PaulsonPrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="PaulsonPrivatePlacementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenQualifiedFinancingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenQualifiedFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenQualifiedFinancingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BrokerWarrantsMember" xlink:href="nmtc-20210930.xsd#nmtc_BrokerWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="BrokerWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable" xlink:to="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestOnPrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_InterestOnPrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="InterestOnPrincipalAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingAmount" xlink:href="nmtc-20210930.xsd#nmtc_EquityFinancingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="EquityFinancingAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" xlink:href="nmtc-20210930.xsd#nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="EquityQualifiedFinancingDescriptiononConvertibleNoteOffering" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingVotingPercentage" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingVotingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="OutstandingVotingPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfFairValueAmount" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfFairValueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="IssuanceOfFairValueAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesOfFairValueBenefit" xlink:href="nmtc-20210930.xsd#nmtc_ChangesOfFairValueBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="ChangesOfFairValueBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDescription" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="WarrantsDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableForSharesOfCommonStockConnection" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsExercisableForSharesOfCommonStockConnection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="WarrantsExercisableForSharesOfCommonStockConnection" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsDescription" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCostsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="IssuanceCostsDescription" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExtendedMaturityDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ExtendedMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="ExtendedMaturityDateDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevisedOptionalConversionTermsDescription" xlink:href="nmtc-20210930.xsd#nmtc_RevisedOptionalConversionTermsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="RevisedOptionalConversionTermsDescription" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReviseTheRegistrationDateDescription" xlink:href="nmtc-20210930.xsd#nmtc_ReviseTheRegistrationDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="ReviseTheRegistrationDateDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_LegalFees" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertedNotesCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_ConvertedNotesCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="ConvertedNotesCommonStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="aggregatePrincipalAmount" xlink:href="nmtc-20210930.xsd#nmtc_aggregatePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="aggregatePrincipalAmount" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashInterest" xlink:href="nmtc-20210930.xsd#nmtc_NoncashInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="NoncashInterest" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="GrossProceeds" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" xlink:href="nmtc-20210930.xsd#nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInFairValue" xlink:href="nmtc-20210930.xsd#nmtc_IncreaseDecreaseInFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="IncreaseDecreaseInFairValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOfCommonStockShares" xlink:href="nmtc-20210930.xsd#nmtc_WarrantsToPurchaseOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="WarrantsToPurchaseOfCommonStockShares" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashCommissionPercentageRateOnProceeds" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissionPercentageRateOnProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="CashCommissionPercentageRateOnProceeds" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCostsIncurred" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceOfCostsIncurred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="IssuanceOfCostsIncurred" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashCommissions" xlink:href="nmtc-20210930.xsd#nmtc_CashCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="CashCommissions" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndThirdPartyFee" xlink:href="nmtc-20210930.xsd#nmtc_LegalAndThirdPartyFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="LegalAndThirdPartyFee" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCosts" xlink:href="nmtc-20210930.xsd#nmtc_IssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="IssuanceCosts" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteFinancingDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConvertibleNoteFinancingDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems" xlink:to="ConvertibleNoteFinancingDescription" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_ActivityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="ActivityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentyTwentyActivityMember" xlink:href="nmtc-20210930.xsd#nmtc_TwentyTwentyActivityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="TwentyTwentyActivityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementAxis" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="TypeOfAgreementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementDomain" xlink:href="nmtc-20210930.xsd#nmtc_TypeOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TypeOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoconsultingAgreementsMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoconsultingAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TwoconsultingAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EquityIncentivePlansMember" xlink:href="nmtc-20210930.xsd#nmtc_EquityIncentivePlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EquityIncentivePlansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneSevenPlanEvergreenProvisionMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoZeroOneSevenPlanEvergreenProvisionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenAndSeventeenPlanMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenAndSeventeenPlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="StockBasedCompensationDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesReservedDescription" xlink:href="nmtc-20210930.xsd#nmtc_SharesReservedDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharesReservedDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionVestedOverAPeriodTerm" xlink:href="nmtc-20210930.xsd#nmtc_StockOptionVestedOverAPeriodTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="StockOptionVestedOverAPeriodTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalExpenseOfStockOption" xlink:href="nmtc-20210930.xsd#nmtc_TotalExpenseOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="TotalExpenseOfStockOption" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOfUnderlyingOptions" xlink:href="nmtc-20210930.xsd#nmtc_ExercisePriceOfUnderlyingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="ExercisePriceOfUnderlyingOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingStockOptionsShares" xlink:href="nmtc-20210930.xsd#nmtc_OutstandingStockOptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="OutstandingStockOptionsShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateFairValueOfPerUnit" xlink:href="nmtc-20210930.xsd#nmtc_GrantDateFairValueOfPerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="GrantDateFairValueOfPerUnit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementsDescription" xlink:href="nmtc-20210930.xsd#nmtc_ConsultingAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="ConsultingAgreementsDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfTheUnderlyingCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfTheUnderlyingCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="FairValueOfTheUnderlyingCommonStock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FutureIssuanceOnACombinedBasis" xlink:href="nmtc-20210930.xsd#nmtc_FutureIssuanceOnACombinedBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="FutureIssuanceOnACombinedBasis" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/StockholdersDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersDeficitDetailsTable" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersDeficitDetailsLineItems" xlink:href="nmtc-20210930.xsd#nmtc_StockholdersDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersDeficitDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoThousandNineteenCommonStockOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="TwoThousandNineteenCommonStockOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementMember" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroTwoZeroCommonStockOfferingMember" xlink:href="nmtc-20210930.xsd#nmtc_TwoZeroTwoZeroCommonStockOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="TwoZeroTwoZeroCommonStockOfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsTable" xlink:to="StockholdersDeficitDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="AggregateShareIssued" xlink:href="nmtc-20210930.xsd#nmtc_AggregateShareIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="AggregateShareIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_PurchaseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="PurchaseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePriceOfCommonStock" xlink:href="nmtc-20210930.xsd#nmtc_PurchasePriceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="PurchasePriceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_TotalGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="TotalGrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfWarrants" xlink:href="nmtc-20210930.xsd#nmtc_FairValueOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="FairValueOfWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedUnderPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_SharesIssuedUnderPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="SharesIssuedUnderPrivatePlacement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceedsFromPrivatePlacement" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceedsFromPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersDeficitDetailsLineItems" xlink:to="GrossProceedsFromPrivatePlacement" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetGrossCurrent" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetGrossCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" xlink:href="nmtc-20210930.xsd#nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateTaxCreditCarryForward" xlink:href="nmtc-20210930.xsd#nmtc_StateTaxCreditCarryForward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="StateTaxCreditCarryForward" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DefinedContributionPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeesCompensationPercentage" xlink:href="nmtc-20210930.xsd#nmtc_EmployeesCompensationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="EmployeesCompensationPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferralsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_DeferralsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="DeferralsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContributionsPercentage" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="ContributionsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InternalRevenuePercentage" xlink:href="nmtc-20210930.xsd#nmtc_InternalRevenuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="InternalRevenuePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContributionsAmount" xlink:href="nmtc-20210930.xsd#nmtc_ContributionsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="ContributionsAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharesAreAuthorizedForFutureIssuance" xlink:href="nmtc-20210930.xsd#nmtc_SharesAreAuthorizedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SharesAreAuthorizedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwritingAgreementDescription" xlink:href="nmtc-20210930.xsd#nmtc_UnderwritingAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="UnderwritingAgreementDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="nmtc-20210930.xsd#nmtc_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="GrossProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://originalsourcemusic.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nmtc-20210930.xsd#nmtc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749752104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroOne Medical Technologies Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,187,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">We are filing this amendment to our Annual Report on Form 10-K for
the year ended September 30, 2021, as filed with the Securities and Exchange Commission on December 15, 2021 (the &#8220;Original Form
10-K&#8221;), solely to correct an error in the content of Baker Tilly US, LLP&#8217;s Report of Independent Registered Public Accounting
Firm.Beyond this correction, there have been no changes to the financial
or other information contained in the Original Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0863354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7599 Anagram Dr.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Eden Prairie<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">426-1383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749884456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 6,901,346<span></span>
</td>
<td class="nump">$ 4,036,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">48,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">98,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">244,043<span></span>
</td>
<td class="nump">118,611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,292,012<span></span>
</td>
<td class="nump">4,155,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">134,207<span></span>
</td>
<td class="nump">156,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">288,948<span></span>
</td>
<td class="nump">282,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">223,329<span></span>
</td>
<td class="nump">166,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,938,496<span></span>
</td>
<td class="nump">4,759,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">528,829<span></span>
</td>
<td class="nump">762,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">644,249<span></span>
</td>
<td class="nump">512,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,007,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">8,622<span></span>
</td>
<td class="nump">73,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,181,700<span></span>
</td>
<td class="nump">2,355,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long term</a></td>
<td class="nump">202,895<span></span>
</td>
<td class="nump">254,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,384,595<span></span>
</td>
<td class="nump">2,693,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2021 and 2020; no shares issued or outstanding as of September 30, 2021 and 2020.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2021 and 2020; 12,010,019 and 7,393,637 shares issued and outstanding as of September 30, 2021 and 2020, respectively.</a></td>
<td class="nump">35,834<span></span>
</td>
<td class="nump">22,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8211;in capital</a></td>
<td class="nump">47,345,266<span></span>
</td>
<td class="nump">32,923,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(40,827,199)<span></span>
</td>
<td class="num">(30,879,031)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">6,553,901<span></span>
</td>
<td class="nump">2,066,172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 7,938,496<span></span>
</td>
<td class="nump">$ 4,759,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486761642952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,010,019<span></span>
</td>
<td class="nump">7,393,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,010,019<span></span>
</td>
<td class="nump">7,393,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486851245864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenue</a></td>
<td class="nump">$ 178,146<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">275,895<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Product gross loss</a></td>
<td class="num">(97,749)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevenueFromCollaboration', window );">Collaborations revenue</a></td>
<td class="nump">64,812<span></span>
</td>
<td class="nump">1,926,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">6,260,266<span></span>
</td>
<td class="nump">4,753,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,925,008<span></span>
</td>
<td class="nump">2,075,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,185,274<span></span>
</td>
<td class="nump">6,828,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,218,211)<span></span>
</td>
<td class="num">(4,902,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(3,053)<span></span>
</td>
<td class="num">(7,524,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue', window );">Net valuation change of instruments measured at fair value</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">804,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on note extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,017,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">271,122<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,948,168)<span></span>
</td>
<td class="num">$ (13,640,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EarningsPerSharesBasicAndDiluted', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted', window );">Basic and diluted (in Shares)</a></td>
<td class="nump">10,696,799<span></span>
</td>
<td class="nump">5,415,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EarningsPerSharesBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EarningsPerSharesBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net valuation change of instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevenueFromCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevenueFromCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751487160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid&#8211;In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 13,494<span></span>
</td>
<td class="nump">$ 15,987,799<span></span>
</td>
<td class="num">$ (17,238,871)<span></span>
</td>
<td class="num">$ (1,237,578)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2019</a></td>
<td class="nump">4,497,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock under securities purchase agreement</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">389,783<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock under securities purchase agreement (in Shares)</a></td>
<td class="nump">72,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering', window );">Issuance of warrants in connection with convertible notes offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">696,672<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes into common stock</a></td>
<td class="nump">$ 7,794<span></span>
</td>
<td class="nump">14,172,676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,180,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes into common stock (in Shares)</a></td>
<td class="nump">2,598,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock', window );">Issuance costs in connection with conversion of convertible notes into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(161,881)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(161,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">798,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">798,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting services</a></td>
<td class="nump">$ 427<span></span>
</td>
<td class="nump">641,289<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">641,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting services (in Shares)</a></td>
<td class="nump">142,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">395,839<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">396,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares', window );">Issuance of common stock upon vesting of restricted stock units (in Shares)</a></td>
<td class="nump">57,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodExerciseOfStockOptions', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">25,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,640,160)<span></span>
</td>
<td class="num">(13,640,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 22,181<span></span>
</td>
<td class="nump">32,923,022<span></span>
</td>
<td class="num">(30,879,031)<span></span>
</td>
<td class="nump">2,066,172<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="nump">7,393,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock under securities purchase agreement</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">12,487,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock under securities purchase agreement (in Shares)</a></td>
<td class="nump">4,166,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes into common stock</a></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">1,004,354<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,005,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes into common stock (in Shares)</a></td>
<td class="nump">292,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsInConnectionWithPrivatePlacement', window );">Issuance costs in connection with securities issuances</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,198,080)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,198,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement', window );">Issuance cost adjustment related to private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,793,199<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,793,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting services</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting services (in Shares)</a></td>
<td class="nump">74,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares', window );">Issuance of common stock upon vesting of restricted stock units (in Shares)</a></td>
<td class="nump">30,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">10,143<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodExerciseOfStockOptions', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">274,865<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of warrants (in Shares)</a></td>
<td class="nump">51,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,948,168)<span></span>
</td>
<td class="num">(9,948,168)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 35,834<span></span>
</td>
<td class="nump">$ 47,345,266<span></span>
</td>
<td class="num">$ (40,827,199)<span></span>
</td>
<td class="nump">$ 6,553,901<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="nump">12,010,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs in connection with conversion of convertible notes into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance cost adjustment related to private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsInConnectionWithPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs in connection with private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsInConnectionWithPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon vesting of restricted stock units shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants in connection with convertible notes offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751341672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,948,168)<span></span>
</td>
<td class="num">$ (13,640,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Amortization and depreciation</a></td>
<td class="nump">80,748<span></span>
</td>
<td class="nump">47,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AllocatedShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,793,199<span></span>
</td>
<td class="nump">1,835,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NoncashInterestOnConvertiblePromissoryNotes', window );">Non-cash interest on convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,616,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PayrollProtectionProgramLoanForgiveness', window );">Payroll protection program loan forgiveness</a></td>
<td class="num">(83,333)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueChangeOfConvertibleNotes', window );">Fair value change of convertible promissory notes</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="num">(804,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsAttributedToFinancingActivities', window );">Issuance costs attributed to financing activities</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="nump">1,907,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash lease expense</a></td>
<td class="nump">66,382<span></span>
</td>
<td class="nump">22,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on notes extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,017,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(48,336)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(98,287)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(8,320)<span></span>
</td>
<td class="num">(77,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(350,313)<span></span>
</td>
<td class="num">(269,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses, deferred revenue, operating lease and other liabilities</a></td>
<td class="num">(7,477)<span></span>
</td>
<td class="num">(82,353)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,602,826)<span></span>
</td>
<td class="num">(3,425,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(67,079)<span></span>
</td>
<td class="num">(122,427)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(67,079)<span></span>
</td>
<td class="num">(122,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,357,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement', window );">Proceeds from issuance of common stock in connection with private placements</a></td>
<td class="nump">8,829,236<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement', window );">Proceeds from issuance of warrants in connection with private placements</a></td>
<td class="nump">3,670,764<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes', window );">Issuance costs in connection with convertible promissory notes</a></td>
<td class="num">(3,053)<span></span>
</td>
<td class="num">(1,125,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsInConnectionWithPrivatePlacements', window );">Issuance costs in connection with private placements</a></td>
<td class="num">(1,198,080)<span></span>
</td>
<td class="num">(384,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock-options</a></td>
<td class="nump">10,146<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromPaycheckProtectionProgram', window );">Proceeds from paycheck protection program</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredsOfferingCosts', window );">Deferred offering costs</a></td>
<td class="num">(49,159)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,534,854<span></span>
</td>
<td class="nump">7,323,377<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">2,864,949<span></span>
</td>
<td class="nump">3,775,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">4,036,397<span></span>
</td>
<td class="nump">260,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">6,901,346<span></span>
</td>
<td class="nump">4,036,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash financing and investing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionOfConvertiblePromissoryNotesToEquity', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">1,005,232<span></span>
</td>
<td class="nump">14,180,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement', window );">Unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement</a></td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">95,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes', window );">Non-cash issuance of broker warrants in connection with convertible notes and private placements</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">696,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease', window );">Operating lease right of use asset obtained in exchange for operating lease</a></td>
<td class="nump">73,118<span></span>
</td>
<td class="nump">335,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueOfPayrollProtectionProgramLoanForgiveness', window );">Payroll protection program loan forgiveness</a></td>
<td class="nump">83,333<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UnpaidDeferredOfferingCosts', window );">Unpaid deferred offering costs</a></td>
<td class="nump">67,954<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UnpaidPurchasesOfPropertyAndEquipment', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">$ 48,651<span></span>
</td>
<td class="nump">$ 16,872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AllocatedShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AllocatedShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionOfConvertiblePromissoryNotesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent supplemental activity related to non-cash impact related to conversion of promissory notes to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionOfConvertiblePromissoryNotesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueChangeOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value change of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueChangeOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsAttributedToFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs attributed to financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsAttributedToFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance costs in connection with convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsInConnectionWithPrivatePlacements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance costs in connection with private placements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsInConnectionWithPrivatePlacements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NoncashInterestOnConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash interest on convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NoncashInterestOnConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PayrollProtectionProgramLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll protection program loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PayrollProtectionProgramLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in connection with private placements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of warrants in connection with private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromPaycheckProtectionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromPaycheckProtectionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UnpaidDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unpaid deferred offering costs related to future financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UnpaidDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UnpaidPurchasesOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unpaid purchases of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UnpaidPurchasesOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueOfPayrollProtectionProgramLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll protection program loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueOfPayrollProtectionProgramLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755052328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - Organization and Nature of Operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>NeuroOne
Medical Technologies Corporation (the &#8220;Company&#8221; or &#8220;NeuroOne&#8221;), a Delaware corporation, is an early-stage medical
technology company developing comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions
to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back
surgeries and other related neurological disorders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
received 510(k) clearance from the FDA for its Evo cortical technology in November 2019, and in September 2021 received 510(k) clearance
from the FDA for its Evo sEEG electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation
equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. To date, the Company
has had limited commercial sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company&#8217;s
common stock commenced trading on The Nasdaq Capital Market on May 26, 2021 under the ticker symbol &#8220;NMTC.&#8221; Previously, the
Company&#8217;s common stock was traded on the OTC Markets quotation system on the OTCQB.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
is based in Eden Prairie, Minnesota.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID-19</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#8220;COVID-19&#8221;) as a global pandemic. As
a result of the COVID-19 pandemic, the Company has experienced, and will likely continue to experience, delays and disruptions in its
pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, shipping, and research and development
operations. In April 2020, given the impact of COVID-19 on the Company and in connection with the enactment of the CARES Act, the Company
applied for and received loan funding of $83,333&#160;under the Paycheck Protection Program, which was forgiven by the U.S. Small Business
Administration in June 2021. </span>The development of the Company&#8217;s technology was delayed in fiscal year 2021 due to interruptions
in global manufacturing and shipping as a result of the COVID-19 pandemic. Additionally, the Company&#8217;s own staff has been impacted
by infections and mandatory quarantines. Further testing and clinical trials, <span>manufacturing, component
supply, shipping and research and development operations</span> may be further impacted by the continuing effects of COVID-19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The extent
to which the COVID-19 pandemic may further impact the Company&#8217;s business will depend on future developments, which are highly uncertain
and cannot be predicted with confidence, such as the effect of the pandemic on its suppliers and distributors and the global supply chain,
the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business
disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic
may also impact the Company&#8217;s business because of employee illness, school closures, and other community response measures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Although
the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may
have a material adverse effect on the Company&#8217;s results of future operations, financial position, and liquidity for fiscal year
2022 and beyond.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762600728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 - Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The accompanying
financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses
since inception, negative cash flows from operations, and an accumulated deficit of $40.8 million as of September 30, 2021. To date,
the Company&#8217;s revenues have not been sufficient to cover its full operating costs, and as such, has been dependent on funding operations
through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without
raising additional funds and such actions are not solely within the control of the Company. These factors raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome
of this condition. If the Company is unable to raise additional funds, or the Company&#8217;s anticipated operating results are not achieved,
management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the
Company&#8217;s operations. The Company intends to fund ongoing activities by utilizing its current cash on hand, from product and collaborations
revenue and by raising additional capital through equity or debt financings. If management is unable to obtain the necessary capital,
it may have a material adverse effect on the operations of the Company and the development of its technology, or the Company may have
to cease operations altogether.&#160; There was also substantial doubt about the Company&#8217;s ability to continue as a going concern
for the financial statements as of and for the year ended September 30, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762571512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - Summary of Significant Accounting
Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting standards generally accepted in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the Company merged its wholly-owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the
Company&#8217;s wholly-owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company
did not have any remaining entities that required consolidation for financial statement reporting purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segment Information</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise
for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker
in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive
Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in one operating segment,
which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording,
monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Reverse
Stock Split</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
11, 2021, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved a one-for-three reverse stock split of the Company&#8217;s
issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;) effective end-of-day March 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>All issued
and outstanding common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this
Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of
common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#8217;s equity
incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result
of the Reverse Stock Split was rounded up to the next whole share. The authorized shares and par value of the common stock and preferred
stock were not adjusted as a result of the Reverse Stock Split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes, and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United
States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since
inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2021,
the Company had $6.7 million of deposits in excess of federally insured amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
entered into a development and distribution agreement which has current and future revenue recognition implications. See &#8220;Note 7
&#8211; Zimmer Development Agreement.&#8221;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Product
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues
from product sales are recognized when control of the promised goods or services is transferred to the Company&#8217;s customers, in an
amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception
of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations.
The Company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Cost
of Product Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of
product revenue consists of the manufacturing and materials costs incurred by the Company&#8217;s third-party contract manufacturer in
connection with the Company&#8217;s strip and grid cortical electrodes (the &#8220;Strip/Grid Products&#8221;) and outside supplier materials
costs in connection with the </span>electrode cable assembly products (&#8220;Electrode Cable Assembly Products&#8221;)<span>.
In addition, cost of product revenue includes royalty fees incurred in connection with the Company&#8217;s license agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Collaborations
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In determining
the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards
Codification (&#8220;ASC&#8221;) Topic 606. Performance obligations may include license rights, development services, and services associated
with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required
under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the
Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As part
of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling
price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities
of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated
relative standalone selling prices of the promised goods or service underlying each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Licenses
of intellectual property</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to
the license when the license is transferred to the customer, and the customer can use and benefit from the license. For licenses that
are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress
each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Milestone
payments</i>: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are
considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators,
are not considered probable of being achieved until those approvals are received. When the Company&#8217;s assessment of probability of
achievement changes and variable consideration becomes probable, any additional estimated consideration is allocated to each performance
obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation
and recorded in license, collaboration, and other revenues based upon when the customer obtains control of each element.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Royalties</i>:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur,
or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounting for fair value
measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring
basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active markets
for identical assets or liabilities accessible to the Company at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 2 Inputs: Other than quoted prices included in Level
1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset
or liability.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or liability
used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the fair values
of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values
because of the short-term nature of these assets or liabilities. The fair value of the convertible notes while outstanding were based
on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted
at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for
similar instruments and are based on Level 3 inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between fair value hierarchy
levels during the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no financial instruments measured on
a recurring basis outstanding as of September 30, 2021. The fair value of financial instruments measured on a recurring basis was as follows
as of September 30, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Total liabilities at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward of
the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level 3 inputs for the years ended September 30 as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,007,206</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,005,232</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,974,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,180,470</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(804,529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Intellectual
Property</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has entered into&#160;two&#160;licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful
life of the acquired technology.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property
and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful
lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to&#160;seven
years&#160;and&#160;three years&#160;for software. Tangible assets acquired for research and development activities and that have alternative
use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate,
changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party
software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and
an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly
to expense as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company evaluates its long-lived
assets, which consist of licensed intellectual property, property and equipment and right of use assets for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability
of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying
value and the fair value of the impaired asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Allowances
for Doubtful Accounts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability
of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of
the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances
are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual
write-offs may be in excess of the Company&#8217;s estimated allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventories
are stated at the lower of cost (using the first-in, first-out &#8220;FIFO&#8221; method) or net realizable value. The Company calculates
inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected
useful lives, and estimated future demand of the products and spare parts. The Company&#8217;s inventory is currently comprised of cEEG
strip/grid and electrode cable assembly finished good product. The Strip/Grid Products are produced by a third-party contract manufacturer
and the Electrode Cable Assembly Products are obtained from outside suppliers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Research
and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as
other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather
than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Selling,
General and Administrative</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Selling,
general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters,
and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of cEEG strip/grid
and electrode cable assembly products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the
Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred
tax asset will not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share of common
stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of common stock
is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional
shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s convertible notes, warrants, stock
options and restricted stock units, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible
promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share
because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares were not considered in the computation
of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,503,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,390,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,122,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,698</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Unissued vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,618</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<i>Financial Instruments &#8211; Credit Losses&#8221;</i>.
The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model which requires the Company to measure all expected
credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued
the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of
the adoption of this ASU on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2018, the FASB issued ASU 2018-13,&#160;<i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement&#160;</i>(ASU 2018-13)<i>.</i>&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Removals: the amount
of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels;
and the valuation processes for Level 3 fair value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Modifications: for investments
in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#8217;s
assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty
in measurement as of the reporting date.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Additions: the changes
in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held
at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair
value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>This guidance
is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop
Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only
the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively
to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or
modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
adopted the new guidance on October 1, 2020 and it did not have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income
taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting
for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption
of this new guidance will have a material impact on the Company&#8217;s financial statements and plans to adopt this guidance on a prospective
basis for the provisions applicable to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2020, FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,
which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This ASU eliminates the
beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition,
this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted
earnings per share computation. The amendments in this ASU are effective for smaller reporting companies as defined by the SEC for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762539032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>WARF
License Agreement</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) for
WARF&#8217;s neural probe array and thin film micro electrode technology (the &#8220;WARF Agreement&#8221;). The Company entered into
an Amended and Restated Exclusive Start-up Company License Agreement (the &#8220;WARF License&#8221;) with WARF on January 21, 2020, which
amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1,
2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The WARF
License grants to the Company an exclusive license to </span>make, use and sell, in the United States only, products that employ certain
licensed patents for a neural probe array or thin-film micro electrode array and method. We have agreed to pay WARF a royalty equal to
a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020,
$100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. The minimum annual royalty
payment for calendar year 2020 in the amount of $50,000 was paid in January 2021. If we or any of our sublicensees contest the validity
of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to
be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF
License.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WARF may terminate the WARF License on 30 days&#8217;
written notice if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our
development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain
bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90 days&#8217; notice if we had failed to have commercial
sales of one or more FDA-approved products under the WARF License by June 30, 2021 or (ii) if, after royalties earned on sales begin to
be paid, such earned royalties cease for more than four calendar quarters. The first commercial sale occurred on December 7, 2020, prior
to the June 30, 2021 deadline.<span>&#160;</span>The WARF License otherwise expires by its terms on the
date that no valid claims on the patents licensed thereunder remain. We expect the latest expiration of a licensed patent to occur in
2030.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Mayo
Agreement</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;) related
to certain intellectual property and development services for thin film micro electrode technology (&#8220;Mayo Agreement&#8221;). If
the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales
of products of the licensed technology through the term of the Mayo Agreement, set to expire&#160;May 25, 2037. As of September 30, 2021,
$3,894 in royalty fees were incurred given the commencement of commercial sales and were reflected as a component of cost of product revenue
during the year ended September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b>Legal</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>PMT
Litigation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to litigation
and claims arising in the ordinary course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 29, 2018, the Company was served with
a complaint filed by PMT Corporation (&#8220;PMT&#8221;), the former employer of Mark Christianson, a current Company employee, and Wade
Fredrickson, a now former Company employee. The complaint added the Company, NeuroOne, Inc. and Mr. Christianson to its existing lawsuit
against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. In the lawsuit, PMT claims that Mr. Fredrickson
and Mr. Christianson, by virtue of their work for the Company and their prior work during employment with PMT, breached their non-competition,
non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair
competition, engaged in a civil conspiracy, tortiously interfered with PMT&#8217;s contracts and prospective economic advantage, and breached
a covenant of good faith and fair dealing. The complaint purported to attach Mr. Fredrickson&#8217;s noncompete agreement as Exhibit A.
Against Mr. Fredrickson, PMT also alleged that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations,
misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the
Company and NeuroOne, Inc., PMT alleged that the Company and NeuroOne, Inc. were unjustly enriched and engaged in unfair competition.
PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory
damages, equitable relief, punitive damages, attorneys&#8217; fees, costs and interest.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2018, Mr. Christianson, the Company
and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal stated that:
the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade
Secrets Act preempts plaintiff&#8217;s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state
a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive
trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.
On January 7, 2019, the judge granted the motion for dismissal with respect to PMT&#8217;s claim for breach of the duty of good faith
and fair dealing, and denied the motion for dismissal with respect to the other claims presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, PMT served the Company, NeuroOne,
Inc. and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious
interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne
Inc. and Christianson. On June 28, 2019, the Company presented evidence indicating that PMT had participated in a fraud on the Court and
sought an Order that PMT had waived the attorney client privilege.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2019, the defendants served PMT with
a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal
of the case and an award of attorneys&#8217; fees. The Company, NeuroOne Inc and Mr. Christianson further moved for summary judgment on
all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process. Following hearings
on the dispositive motions and defendants&#8217; sanctions motion, the district court granted the Company&#8217;s motion for sanctions
on April 29, 2020. Additionally, the district court granted the Company&#8217;s motion for summary judgment in part with respect to the
counts for Christianson&#8217;s breach of non-confidentiality agreement, and denied the Company&#8217;s motion for summary judgment on
all other counts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2020, defendants moved the Court
to amend their counterclaims for abuse of process against PMT to add a claim for punitive damages with respect to its conduct pertaining
to the Fredrickson noncompete. On October 12, 2020 the Court awarded NeuroOne, Inc. $185,000&#160;in Rule 11 sanctions and Fredrickson
$145,000&#160;in Rule 11 sanctions with respect to PMT&#8217;s misconduct relating to the Fredrickson noncompete. PMT and its former litigation
counsel, Barnes &amp; Thornburg, were jointly and severally liable for these awards, which were paid on December 11, 2020 and have been
recognized in other income in the statements of operations. The Court granted NeuroOne, Inc.&#8217;s motion to amend to permit its assertion
of the right to assert a punitive damages claim against PMT associated with fighting the allegations relating to the Fredrickson noncompete.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2021 PMT moved for summary judgment
on defendants&#8217; claims for abuse of process and punitive damages, and on August 5, 2021, the district court granted PMT&#8217;s motion
to dismiss the abuse of process and punitive damage claims.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Trial has been postponed from December 2021 to August of 2022. The
Company intends to continue to defend itself vigorously and to continue to aggressively prosecute its affirmative counterclaim against
PMT. The outcome of any claim against the Company by PMT was not estimable as of the issuance of these financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Facility Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Headquarters Lease</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2019, the Company entered into a
non-cancellable lease agreement (the &#8220;Lease&#8221;) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together,
the &#8220;Landlord&#8221;) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie,
Minnesota (the &#8220;Premises&#8221;). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending
65 months after such date, unless terminated earlier (the &#8220;Term&#8221;). The initial base rent for the Premises is $6,410 per month
for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default
under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will
pay its pro rata share of the Landlord&#8217;s annual operating expenses associated with the premises, calculated as set forth in the
Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Los Gatos Lease</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 1, 2021, the Company entered into a non-cancellable
facility lease (the &#8220;New Lease&#8221;), pursuant to which the Company agreed to rent office space for its research and development
operations located at 718 University Avenue, Suite #111, Los Gatos, California. The term of the New Lease is eighteen months. The facility
space under the New Lease is approximately 1,162 square feet. The Company took possession of the office space on July 2, 2021. The initial
monthly rent under the New Lease is approximately $4,241.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">San Jose Lease</span>:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2020, the Company entered into
a non-cancellable lease agreement for short term office space in San Jose, California (the &#8220;San Jose Lease&#8221;) for a three month
initial term. After March 31, 2021, the San Jose Lease was cancellable upon a 30-day notice to the landlord. The Company took possession
of the office space on January 1, 2021 and the San Jose Lease was terminated upon the commencement of the New Lease discussed above. The
base rent under the San Jose Lease was $504 per month.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, rent expense associated with the facility leases amounted to $136,826 and $103,189, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information related to
the operating lease was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Year Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">70,897</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">38,462</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">335,119</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental balance sheet information related
to the operating lease was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">288,948</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">282,211</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315,673</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">312,176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average remaining lease term (years)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average discount rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.7</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maturity of the lease liability was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Calendar Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: 0pt; padding-left: 0pt">2021 (period from October 1, 2021 to December 31, 2021)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,435</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,391</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">351,606</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in">Short-term portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,778</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Long-term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">202,895</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762600728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalBalanceSheetInformationTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span style="font-family: Times New Roman, Times, Serif">Supplemental
Balance Sheet Information</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Prepaid and Other Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prepaid and other assets consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">151,109</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118,010</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">244,043</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,611</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intangibles</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets roll forward is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Useful Life</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt">12-13 years</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">178,838</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,315</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">156,523</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,316</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">134,207</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company anticipates amortization expense of
approximately $21,000 per year for fiscal year 2022 through 2026 based upon the two current license agreements.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment held for use by category
are presented in the following table:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Equipment and furniture</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">311,486</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195,756</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,052</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,620</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">223,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">166,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $58,432 and $25,294 for
the years ended September 30, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalBalanceSheetInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalBalanceSheetInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762663320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 - Accrued Expenses and Other Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses consisted of the following at
September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued payroll</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">376,236</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">238,212</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating lease liability, short term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,778</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,848</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Royalty Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">644,249</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">512,762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &#8220;other&#8221; category is primarily
comprised of board fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paycheck Protection Program</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CARES Act, signed into law in March 2020,
established the Paycheck Protection Program (&#8220;PPP&#8221;).&#160;The PPP authorizes over $600 billion in forgivable loans to small
businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility
costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments
may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term
liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the
accompanying statements of operations. Interest was nominal during the years ended September 30, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762643528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Zimmer Development Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementAbstract', window );"><strong>Zimmer Development Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementTextBlock', window );">Zimmer Development Agreement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; Zimmer Development Agreement</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On July
20, 2020, the Company entered into an exclusive development and distribution agreement (the &#8220;Development Agreement&#8221;) with
Zimmer, Inc. (&#8220;Zimmer&#8221;), pursuant to which the Company granted Zimmer exclusive global rights to distribute the Strip/Grid
Products and electrode cable assembly products (the &#8220;Electrode Cable Assembly Products&#8221;). Additionally, the Company granted
Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company (&#8220;SEEG Products&#8221;, and
together with the Strip/Grid Products and Electrode Cable Assembly Products, the &#8220;Products&#8221;). The parties have agreed to collaborate
with respect to development activities under the Development Agreement through a joint development committee composed of an equal number
of representatives of Zimmer and the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Under the
terms of the Development Agreement, the Company is responsible for all costs and expenses related to developing the Products, and Zimmer
is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Development Agreement,
Zimmer and the Company have entered into a Manufacturing and Supply Agreement (the &#8220;MS Agreement&#8221;) and a supplier quality
agreement (the &#8220;Quality Agreement&#8221;) with respect to the manufacturing and supply of the Products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Except as
otherwise provided in the Development Agreement, the Company is responsible for performing all development activities, including non-clinical
and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts
to promote, market and sell each Product following the &#8220;Product Availability Date&#8221; (as defined in the Development Agreement)
for such Product.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Pursuant
to the Development Agreement, Zimmer made an upfront initial exclusivity fee payment of $2.0&#160;million (the &#8220;Initial Exclusivity
Fee&#8221;) to the Company. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Except where
Zimmer timely delivers a Design Modification Notice pursuant to Section 1.2, if one or more of the events set forth below occurs on or
before the deadline indicated for such event and the Product Availability Date (as defined in the Development Agreement) for the SEEG
Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the
SEEG Exclusivity Maintenance Fee:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Design
freeze for the SEEG Products by December 15, 2020 - $500,000</span></td>
</tr></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160; &#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan (as defined in the Development Agreement) by April 30, 2021 - $500,000</span></td>
</tr></table><p style="text-align: justify; margin: 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif; ">If Zimmer timely delivers a Design Modification Notice to the Company under the Development Agreement, and one or more of the events set forth below occurs on or before the deadline indicated for such event and the Product Availability Date for the SEEG Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the SEEG Exclusivity Maintenance Fee:</span></p><p style="text-align: justify; margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan other than the Modified Connector by April 30, 2021 - $500,000</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif; ">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Acceptance
of all Deliverables for SEEG Products under the Development Plan, including the Modified Connector by September 30, 2021 - $500,000</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For purposes
of the Development Agreement, each of the foregoing events shall have occurred only if the Company has demonstrated the achievement of
the event to Zimmer&#8217;s reasonable satisfaction. Notwithstanding the foregoing, the events in Sections 6.1(c)(ii), (iii) and (iv)
of the Development Agreement shall not be deemed to be met if FDA Approval for the SEEG Products is not received prior to the applicable
deadline. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to maintain the exclusivity of the SEEG
Distribution License, Zimmer must pay the SEEG Exclusivity Maintenance Fee to the Company, on or prior to the SEEG Exclusivity Confirmation
Date, in immediately available funds as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
on or before June 30, 2021, then $3,000,000, plus the amount of any Interim Fee Bonuses earned pursuant to Section 6.1(c), including
any such Interim Fee Bonus earned after June 30, 2021 pursuant to Section 6.1(c)(iv) following the delivery of a Design Modification
Notice;</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after June 30, 2021, but on or before September 30, 2021, then $3,000,000, plus if Zimmer timely issues a Design A-9 Modification Notice,
any Interim Fee Bonus earned pursuant to Section 6.1(c)(iv);</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after September 30, 2021, but on or before December 31, 2021, then $2,500,000; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">if the Product Availability Date for the SEEG Products occurs
after December 31, 2021, then $1,500,000.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Product Availability Date for the SEEG Products
has not yet occurred. <span>Notwithstanding any other provision of the Development Agreement, if the Product
Availability Date for the SEEG Products has not occurred on or before June 30, 2022, Zimmer shall have the right to terminate the SEEG
Distribution License by delivering written notice to the Company to that effect and, upon delivery of such notice, Zimmer shall be relieved
of all of its obligations hereunder with respect to SEEG Products, including any obligation to pay the SEEG Exclusivity Maintenance Fee
or to purchase, market, distribute or sell any SEEG Products. The Initial Exclusivity Fee and the SEEG Exclusivity Maintenance Fee (including
any Interim Fee Bonus(es)), once paid, are non-refundable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Development
Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last of the Products to achieve a first
commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Development Agreement (x) with written
notice for the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency
proceedings. In addition, Zimmer may terminate the Development Agreement for any reason with 90 days&#8217; written notice, and the Company
may terminate the Development Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors
of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>At inception
of the Zimmer Development Agreement through September 30, 2021, the Company had identified the following three performance obligations
under the Zimmer Development Agreement: (1) the Company obligation to license Zimmer rights to certain of its intellectual property; (2)
complete SEEG Product development; and (3) complete Strip/Grid Product development. Accordingly, the Company recognized revenue in the
amount of $64,812&#160;and $1,926,566&#160;during the years ended September 30, 2021 and 2020, respectively, related to the development
of the Products completed during the periods in connection with the Initial Exclusivity Fee payment. The Zimmer Development Agreement
was accounted for under the provisions of ASC 606,&#160;<i>Revenue from Contracts with Customers.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the closing balance of deferred
revenue related to the Zimmer Development Agreement is as follows as of September 30, 2021 and 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Deferred Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Balance as of&#160;&#160;September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Upfront initial exclusivity payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,926,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of&#160;&#160;September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,434</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining performance obligations reflected
in deferred revenue as of September 30, 2021 are expected to be completed in first half of fiscal year 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, the Company commenced commercial
sales of its Strip/Grid Products and Electrode Cable Assembly Products in connection with the Development Agreement. Product revenue recognized
during the year ended September 30, 2021 was $178,146.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advertising Expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expense is charged to selling, general
and administrative expenses during the period that it is incurred. Total advertising expense amounted to $338,837 for the year ended September
30, 2021. Advertising expense during the prior year period was negligible.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ZimmerDevelopmentAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ZimmerDevelopmentAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ZimmerDevelopmentAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ZimmerDevelopmentAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762646904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Warrant Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 - Convertible Promissory Notes and Warrant
Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Paulson convertible notes, principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">546,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,458</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Fair value adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">397,748</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paulson Convertible Note Offerings</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2019 Paulson Convertible Note Offering</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2019, the Company entered into
a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#8220;2019 Paulson
Private Placement&#8221;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#8220;2019 Paulson Note&#8221;
and collectively, the &#8220;2019 Paulson Notes&#8221;) and warrants (each, a &#8220;2019 Paulson Warrant&#8221; and collectively, the
&#8220;2019 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the 2019 Paulson Private
Placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued the 2019 Paulson Notes
in an aggregate principal amount of $3,234,800 to the subscribers for gross proceeds equaling the principal amount. The 2019 Paulson Private
Placement terminated on December 3, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2019 Paulson Notes had a fixed interest rate
of 13% per annum and required the Company to repay the principal and accrued and unpaid interest thereon on November 1, 2020 (the &#8220;Maturity
Date&#8221;). Interest on principal amounted to $5,701 and $213,383 during the years ended September 30, 2021 and 2020, respectively,
and was recorded under the net valuation change of instruments measured at fair value in the statements of operations. The subscriber,
prior to the Second 2019 Paulson Notes Amendment, had the option to convert the outstanding principal and accrued and unpaid interest
of such subscriber&#8217;s 2019 Paulson Note (the &#8220;Outstanding Balance&#8221;) into common stock in an amount equal to the Outstanding
Balance divided by the ten day volume weighted average closing price of the common stock prior to conversion. In addition, both before
and after the Second 2019 Paulson Note Amendment, if the Company raised more than $3,000,000 in an equity financing (the &#8220;Qualified
Financing&#8221;) before the Maturity Date, each subscriber had the option to convert the Outstanding Balance into the securities issued
by the Company in such Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied
by (A) the actual per share price of securities issued by the Company in the Qualified Financing or (B) the ten day volume weighted average
closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction had occurred
prior to a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on demand as of the closing date
of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#8217;s stockholders did
not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#8217;s
assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elected to account for the 2019 Paulson
Notes on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options.
The fair value of the 2019 Paulson Notes was significantly higher than the proceeds received as of each of the respective issuance dates
given the significant redemption discount associated with the Qualified Financing provision. The excess of fair value over proceeds at
issuance amounted to $1,831,940 and was recorded to interest expense in the statements of operations during the year ended September 30,
2020. Subsequent to issuance, the fair value change of the 2019 Paulson Notes amounted to a benefit of $1,974 and $1,221,480 during the
years ended September 30, 2021 and 2020, respectively, and was recorded under the net valuation change of instruments measured at fair
value in the statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each 2019 Paulson Warrant granted the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. As of the final closing on December 3, 2019, the
Company issued 2019 Paulson Warrants exercisable for 288,305 shares of common stock in connection with all closings of the 2019 Paulson
Private Placement. The 2019 Paulson Warrants are immediately exercisable and expire on November 1, 2022. The exercise price is subject
to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction,
as described therein. The 2019 Paulson warrants were deemed to be a free-standing instrument and were accounted for as equity. Given that
the fair value of the 2019 Paulson Notes exceeded the proceeds received at issuance, there was no value attributed to the 2019 Paulson
Warrants in the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2019 Private Placement,
Paulson Investment Company, LLC (&#8220;Paulson&#8221;) received a cash commission equal to 12% of the gross proceeds from the sale of
the 2019 Paulson Notes, and 10-year warrants to purchase an amount of common stock equal to 86,498 shares of common stock at an exercise
price equal to $5.61 per share (the &#8220;Broker Warrants&#8221;). The issuance costs incurred during the year ended September 30, 2021
and 2020 in connection with the 2019 Paulson Private Placement were $3,053 and $865,567, respectively. Issuance costs in 2021 related
to legal costs. Issuance costs in 2020 included cash commissions equal to $388,176 and legal and third-party fees in the amount of $57,756.
In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2020, the Company and holders of
a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the &#8220;Second
2019 Paulson Notes Amendment&#8221;) to, among other things:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">i.</td><td style="text-align: justify"><b><i>Extended the Maturity Date</i></b><i> &#8211; </i>The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">ii.</td><td style="text-align: justify"><b><i>Revised Optional Conversion Terms</i></b><i> &#8211;
</i>The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#8217;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#8217;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">iii.</td><td style="text-align: justify"><b><i>Revised the Registration Date &#8211;</i></b> The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#8217;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Second 2019 Paulson Notes Amendment was accounted
for as a note extinguishment for accounting purposes given the substantive change in the optional redemption feature&#8217;s conversion
formula. The fair value change in the 2019 Paulson Notes associated with the extinguishment was recorded as a loss on notes extinguishment
in the accompanying statements of operations in the amount of $2,017,847 during the year ended September 30, 2020. Lastly, in connection
with the Second 2019 Paulson Notes Amendment, legal costs in the amount of $1,943 were incurred and recorded as a component of interest
in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, the 2019 Paulson Notes were converted into 292,754 and 725,394 shares of common stock, respectively. All of the 2019 Paulson notes
were converted into shares of common stock by December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Paulson 2020 Convertible Note Financing&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2020, the Company entered into a
subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#8220;2020 Paulson
Private Placement&#8221;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#8220;2020 Paulson Note&#8221;
and collectively, the &#8220;2020 Paulson Notes&#8221;) and warrants (each, a &#8220;2020 Paulson Warrant&#8221; and collectively, the
&#8220;2020 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between May 1, 2020 and June 30, 2020, the Company
issued 2020 Paulson Notes in an aggregate principal amount of $5,122,700 to the Subscribers. The 2020 Paulson Private Placement was terminated
on June 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Paulson Notes had a fixed interest rate
of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of December 31,
2020 or a change of control transaction. Interest on principal amounted to $81,613 during the year ended September 30, 2020 and was recorded
under the net valuation change of instruments measured at fair value in the statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company had raised more than $5,000,000
in an equity financing before the maturity date (the &#8220;2020 Qualified Financing&#8221;), without any action on the part of the Subscribers,
all of the outstanding principal and accrued and unpaid interest of the Notes (the &#8220;Outstanding Balance&#8221;) would have been
converted into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred
equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities
issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume weighted average price of the
common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company had announced a transaction between
the Company and any other company (or an affiliate of any such company) that was included in the S&amp;P 500 Health Care Index as published
from time to time by S&amp;P Dow Jones Indices LLC that included an investment or upfront payments resulting in gross proceeds to the
Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration,
manufacturing, distribution, licensing or supply of the Company&#8217;s products (a &#8220;Strategic Transaction&#8221;) before the maturity
date, without any action on the part of the subscribers, the Outstanding Balance would be converted into that number of shares of common
stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten
(10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on
the day preceding the first announcement by the Company of a Strategic Transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time, at the sole election of the holder
of such 2020 Paulson Note, all or a portion of the Outstanding Balance could have been converted into that number of shares of common
stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by
the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a change of control transaction had occurred
prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would have become payable on demand as
of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#8217;s
stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially
all of the Company&#8217;s assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elected to account for the 2020 Paulson
Notes on a fair value basis under ASC 825&#160;<span>to comprehensively value and streamline the accounting
for the embedded conversion options</span>. The fair value of the 2020 Paulson Notes was significantly higher than the proceeds received
as of each of the respective issuance dates given the significant redemption discount associated with the redemption provisions. The excess
of fair value over proceeds at issuance amounted to $3,784,918 and was recorded to interest expense in the statements of operations during
the year ended September 30, 2020. Subsequent to issuance, the fair value change of the 2020 Paulson Notes amounted to an expense of $416,951
during the year ended September 30, 2020 and was recorded under the net valuation change of instruments measured at fair value in the
statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each 2020 Paulson Warrant grants the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. The 2020 Paulson Warrants are immediately exercisable
and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock
split, recapitalization, reorganization or similar transaction. The Company issued 2020 Paulson Warrants exercisable for 456,564 shares
of common stock in connection with all closings of the 2020 Paulson Private Placement through June 30, 2020. The 2020 Paulson warrants
were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2020 Paulson Notes exceeded
the proceeds received at issuance, there was no value attributed to the 2020 Paulson Warrants in the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the 2020 Paulson Private Placement,&#160;Paulson&#160;received
a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes and received 7-year warrants to purchase
an amount of common stock equal to 136,971 (&#8220;Broker Warrants&#8221;). The Broker Warrants have an exercise price equal to $5.61
per share. The issuance costs incurred during the year ended September 30, 2020 in connection with the 2020 Paulson Private Placement
were $1,040,213. Issuance costs included cash commissions equal to $614,725 and legal and third-party fees in the amount of $148,451.
In addition, issuance costs included the value of the Broker Warrants in the amount of $277,037. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between May 4, 2020 and July 22, 2020, certain
Subscribers elected to convert $3,590,353 of the outstanding principal and interest of such Subscribers&#8217; 2020 Paulson Notes into
1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance of the 2020 Paulson Notes
in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the Zimmer Development Agreement
that qualified as a Strategic Transaction.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762541912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 - Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, stock-based expense related to the stock options, restricted stock units and stock awards was included in selling, general and administrative
and research and development costs as follows in the accompanying statements of operations:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Selling, general and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,550,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,623,629</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">242,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,341</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total stock-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,793,199</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,835,970</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s 2016 and 2017 Equity Incentive
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company
initially reserved 764,089 shares of common stock for issuance under the 2016 and 2017 Equity Incentive Plans on a combined basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Evergreen provision</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2017 Plan, the shares reserved automatically
increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders
of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted
shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January
1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the
share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence.
&#8220;Fully Diluted Shares&#8221; as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii)
issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants
or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common
stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2021 and 2020,
484,622 and 428,930 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, 703,117 and 334,731 stock options were granted to employees, directors and consultants, respectively, with a weighted average grant
date fair value of $3.01 and $3.03 per share, respectively. The options granted have vesting periods ranging from being immediate to four
years. All options expire ten years from the date of grant. The total expense for the years ended September 30, 2021 and 2020 related
to the stock options was $983,301 and $798,242, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the Company&#8217;s
stock option plan activity for the years ended September 30, 2021 and 2020 as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">281,956</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">343,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,330</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,861</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,122,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.89</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">127,339</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">481,047</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.89</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8.2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">311,388</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The aggregate intrinsic value is
calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September
30, 2021 and 2020 of $3.95 and $3.86 per share, respectively. As of September 30, 2021 and 2020, 1,055,376 and 467,327 outstanding options,
respectively, had no intrinsic value.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average assumptions used in the Black-Scholes
option-pricing model are as follows for the stock options granted during the years ended September 30:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">55.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">53.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended September 30, 2021 and 2020,
280,557 and 198,191 stock options vested, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of restricted stock unit (&#8220;RSU&#8221;)
activity is as follows for the years ended September 30, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-left: 0">Non-vested at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,503</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,323</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Non-vested at September 30, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,776</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,090</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0">Non-vested at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,384</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended September 30, 2021 and
2020, 13,776 and 78,323 RSUs were granted to members of the Company&#8217;s board of directors and consultants that vest over a period
ranging from an immediate to a two year period, with a grant date fair value of $7.26 and $6.27 per unit, respectively. During the years
ended September 30, 2021 and 2020, 29,090 and 59,793 RSUs vested, respectively. The total expense for the years ended September 30, 2021
and 2020 related to the RSU&#8217;s was $163,988 and $396,012, respectively. The number of RSUs forfeited during the years ended September
30, 2021 and 2020 was zero and 2,335, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Stock-Based Awards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2021 Activity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2021, two consulting agreements were
executed whereby a total of 62,659 shares of common stock were issued and vested as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2021, two consulting agreements were executed
whereby a total of 11,668 shares of common stock were issued and vested as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2020 Activity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2019, two consulting agreements were
executed whereby up to 38,334 shares of common stock were issued and vested as of September 30, 2020. On April 22, 2020, the Company entered
into an amendment (the &#8220;Amendment&#8221;) to one of the consulting agreements. Pursuant to the Amendment, the Company issued an
additional 11,667 shares in exchange for consulting services of which 11,667 shares of common stock were vested as of September 30, 2020
under the Amendment. Vesting was based on a time-based vesting condition ranging over a three to nine-month period commencing upon the
execution of the consulting agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, an additional consulting agreement
was executed whereby up to 30,000 shares of common stock were issued and vested as of September 30, 2020 under this agreement. In addition,
on May 21, 2020, 22,195 shares of common stock were issued as compensation to a former 2019 Paulson Note holder related to a prior 2019
Paulson Note conversion and release of liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, an additional consulting agreement
was executed whereby 40,000 shares of common stock were issued, subject to Company repurchase. The stock award under the agreement vests
over a six-month period. As of September 30, 2021 and 2020, 33,333 and 6,667 shares vested under this agreement, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation expense related to the stock awards
granted under the consulting agreements and to the former 2019 Paulson Note holder referenced above amounted to $645,910 and $641,716
for the years ended September 30, 2021 and 2020, respectively, and was included in stock-based compensation expense. The expense recognition
related to the grants was based on the fair value of the underlying common stock at the point of vesting which ranged from $4.53 to $7.95
per share.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, 389,709 shares were
available for future issuance on a combined basis under the 2016 and 2017 Equity Incentive Plans. Unrecognized stock-based compensation
was $1.7 million as of September 30, 2021. The unrecognized share-based expense is expected to be recognized over a weighted average period
of 2.9 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762646904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - Stockholders&#8217; Deficit</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2021 Private Placement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 12, 2021, the Company entered into
a Common Stock and Warrant Purchase Agreement with certain accredited investors, pursuant to which the Company, in the 2021 Private Placement,
agreed to issue and sell an aggregate of 4,166,682 shares of the common stock of the Company and warrants to purchase an aggregate of
4,166,682 shares of common stock (the &#8220;2021 Warrants&#8221;) at an aggregate purchase price of $3.00 per share of common stock and
corresponding warrant, resulting in total gross proceeds of $12.5 million before deducting placement agent fees and estimated offering
expenses. The 2021 Warrants have an initial exercise price of $5.25 per share. The 2021 Warrants are immediately exercisable and will
expire on the fifth anniversary of issuance. Prior to expiration, subject to the terms and conditions set forth in the 2021 Warrants,
the holders of such 2021 Warrants may exercise the 2021 Warrants for shares of common stock by providing notice to the Company and paying
the exercise price per share for each share so exercised or by utilizing the &#8220;cashless exercise&#8221; feature contained in each
2021 Warrant. The fair value of the 2021 Warrants was $7.3 million and was based on the Black-Scholes pricing model. Input assumptions
used were as follows: a risk-free interest rate of 0.5%; expected volatility of 56.0%; expected life of 5 years; expected dividend yield
of 0%; and the underlying traded stock price.&#160;$3.7 million of the total proceeds was allocated to the 2021 Warrants based on the
relative fair value allocation method, which has been reflected in stockholders&#8217; equity. The 2021 Warrants were classified in stockholders&#8217;
equity as the number of shares were fixed and determinable, and no other provisions precluded equity treatment. The private placement
closed on January 14, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2020 Common Stock Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 28, 2020, the Company entered into securities
purchase agreements with an accredited investor in a private placement, pursuant to which the Company has issued and sold 25,000 shares
to such investor, at $5.40 per share for gross proceeds amounting to $135,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2019 Common Stock Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2019, the Company entered into
Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and
sold 47,223 shares of the Company&#8217;s common stock to the accredited investors at a price of $5.40 per share, for gross proceeds amounting
to $255,000. The Company filed a registration statement with the SEC covering the resale of the shares of common stock sold in the private
placement on August 11, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrant Activity and Summary</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes warrant activity
during the years ended September 30, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Warrants</b> &#160; &#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise <br/>
Price Per <br/>
Warrant</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted<br/>
Average Exercise <br/>
Price</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted <br/>
Average Term <br/>
(years)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,421,940</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">5.40 - 9.00&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.65</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">3.60</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">968,380</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">5.61</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-77">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-81">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,390,320</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.40 - 9.00&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">7.05</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2.89</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,166,682</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">4.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(53,194</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61-8.25 </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-87">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">7,503,808</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">5.25-9.00</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">6.06</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">3.23</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information about
warrants outstanding at September 30, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercise Price</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Outstanding</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average <br/>
Remaining Contractual<br/>
life (Years)</b></td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Exercisable at <br/>
September 30,<br/>
2021</b></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; text-align: justify">$</td>
    <td style="width: 21%; text-align: right">5.25</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right">4,166,682</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 24%; text-align: center">4.29</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right">4,166,682</td>
    <td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">5.40</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">750,364</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">0.14</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">750,364</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">5.61</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">916,753</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.68</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">916,753</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">6.00</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">45,173</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.75</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">45,173</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">7.50</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">279,733</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.41</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">279,733</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">8.25</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">62,911</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.75</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">62,911</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">9.00</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,282,192</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.18</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,282,192</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: justify">Total</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">7,503,808</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">7,503,808</td>
    <td style="padding-bottom: 4.5pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762653848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rate for the Company for the
years ended September 30, 2021 and 2020 was zero percent. A reconciliation of income tax computed at the statutory federal income tax
rate to the provision (benefit) for income taxes included in the accompanying statements of operations for the years ended September 30
is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Income tax benefit at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">State income tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Disqualified interest and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are summarized in the tables below as of September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Federal and state operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,575,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,936,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Acquired intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,635</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research and development credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,081</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">451,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">255,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,872,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,694,574</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,808,329</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,694,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company
had gross deferred tax assets of approximately $8,873,000 and $5,695,000, respectively. Realization of the deferred assets is primarily
dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses
since its inception. The Company has not yet generated revenues from sales and faces significant challenges to becoming profitable. Accordingly,
the net deferred tax assets have been fully offset by a valuation allowance of approximately $8,808,000 and $5,695,000 as of September
30, 2021 and 2020, respectively. The U.S. net deferred tax assets will continue to require a valuation allowance until the Company can
demonstrate their realizability through sustained profitability or another source of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company&#8217;s
federal net operating loss carryforwards were approximately $26,355,000 and $17,175,000, respectively. The Company had federal research
credit carryforwards as of September 30, 2021 and 2020 of approximately $506,000 and $272,000, respectively. The federal net operating
loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating
losses incurred after December 31, 2017 will not expire. As of September 30, 2021 and 2020, the Company had state net operating loss carryforwards
of approximately $26,355,000 and $17,175,000, respectively. The Company had state research credit carryforwards of approximately $307,000
and $178,000 as of September 30, 2021 and 2020, respectively. The state net operating loss carryforwards will begin to expire in 2031,
if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the net operating loss carryforwards
and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal
Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation
applies when one or more &#8220;5-percent shareholders&#8221; increase their ownership, in the aggregate, by more than 50 percentage points
over a 36-month testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result
in the expiration of net operating losses and credits before utilization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes </i>(&#8220;ASC
740&#8221;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute
for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company believes
its income tax filing positions and deductions will be sustained upon examination, and accordingly, no reserves or related accruals for
interest and penalties have been recorded at September 30, 2021 and 2020.<span style="font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with this guidance, the Company
has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will
be classified as a component of interest expense and any related penalties will be classified in operating expenses in the statements
of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has tax filing obligations in the
following jurisdictions: U.S. federal, Minnesota and California. The income tax returns since inception as a corporation in 2016 are subject
to examination by the federal and Minnesota taxing authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762606008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 - Defined Contribution Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a 401(k) defined contribution
plan (the &#8220;401K Plan&#8221;) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll
withholdings into the 401K Plan subject to federal law limits. The Company may match 100% of deferrals up to 3% of one&#8217;s contributions.
The Company&#8217;s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing
contributions under the 401K Plan in the future, but it has not done so through September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee contributions and any employer matching
contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution.
Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee&#8217;s
date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee&#8217;s
date of hire. The amount of contributions made by the Company under the 401K Plan during the years ended September 30, 2021 and 2020 was
$14,803 and zero, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486845792760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 - Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>Inducement Plan </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">On October 4, 2021, the Company
adopted the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the &#8220;Plan&#8221;), pursuant to which the Company reserved
420,350 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors
of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within the meaning of Rule
5635(c)(4) of the Nasdaq Listing Rules. The Plan was approved by the Company&#8217;s Board of Directors without stockholder approval in
accordance with such rule.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Public Offering</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2021, the Company, entered into
an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Craig-Hallum Capital Group LLC, as underwriter (the &#8220;Underwriter&#8221;),
relating to the issuance and sale of 3,750,000 shares of the Company&#8217;s common stock at a price to the public of $3.20 per share.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to
purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale
of 422,057 shares of common stock subject to the Underwriter&#8217;s overallotment option closed on November 15, 2021. Deferred offering
costs in connection with the offering amounted to $92,934 and are reflected in the prepaid and other assets line item in the accompanying
balance sheets as of September 30, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds to the Company from this offering
were approximately $13.4 million prior to deducting underwriting discounts and other offering expenses payable by the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755097448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared in accordance with accounting standards generally accepted in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the Company merged its wholly-owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the
Company&#8217;s wholly-owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company
did not have any remaining entities that required consolidation for financial statement reporting purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Segment Information</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are components of an enterprise
for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker
in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive
Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in one operating segment,
which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording,
monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Reverse
Stock Split</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March
11, 2021, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved a one-for-three reverse stock split of the Company&#8217;s
issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;) effective end-of-day March 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>All issued
and outstanding common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this
Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of
common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#8217;s equity
incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result
of the Reverse Stock Split was rounded up to the next whole share. The authorized shares and par value of the common stock and preferred
stock were not adjusted as a result of the Reverse Stock Split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Management&#8217;s Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management&#8217;s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes, and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United
States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since
inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2021,
the Company had $6.7 million of deposits in excess of federally insured amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
entered into a development and distribution agreement which has current and future revenue recognition implications. See &#8220;Note 7
&#8211; Zimmer Development Agreement.&#8221;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Product
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Revenues
from product sales are recognized when control of the promised goods or services is transferred to the Company&#8217;s customers, in an
amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception
of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations.
The Company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Cost
of Product Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Cost of
product revenue consists of the manufacturing and materials costs incurred by the Company&#8217;s third-party contract manufacturer in
connection with the Company&#8217;s strip and grid cortical electrodes (the &#8220;Strip/Grid Products&#8221;) and outside supplier materials
costs in connection with the </span>electrode cable assembly products (&#8220;Electrode Cable Assembly Products&#8221;)<span>.
In addition, cost of product revenue includes royalty fees incurred in connection with the Company&#8217;s license agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Collaborations
Revenue</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In determining
the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards
Codification (&#8220;ASC&#8221;) Topic 606. Performance obligations may include license rights, development services, and services associated
with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required
under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the
Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>As part
of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling
price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities
of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated
relative standalone selling prices of the promised goods or service underlying each performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Licenses
of intellectual property</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to
the license when the license is transferred to the customer, and the customer can use and benefit from the license. For licenses that
are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress
each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Milestone
payments</i>: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are
considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators,
are not considered probable of being achieved until those approvals are received. When the Company&#8217;s assessment of probability of
achievement changes and variable consideration becomes probable, any additional estimated consideration is allocated to each performance
obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation
and recorded in license, collaboration, and other revenues based upon when the customer obtains control of each element.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><i>Royalties</i>:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur,
or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounting for fair value
measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring
basis adheres to the Financial Accounting Standards Board (&#8220;FASB&#8221;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 1 Inputs: Unadjusted quoted prices in active markets
for identical assets or liabilities accessible to the Company at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 2 Inputs: Other than quoted prices included in Level
1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset
or liability.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Level 3 Inputs: Unobservable inputs for the asset or liability
used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at the measurement date.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the fair values
of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values
because of the short-term nature of these assets or liabilities. The fair value of the convertible notes while outstanding were based
on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted
at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for
similar instruments and are based on Level 3 inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no transfers between fair value hierarchy
levels during the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no financial instruments measured on
a recurring basis outstanding as of September 30, 2021. The fair value of financial instruments measured on a recurring basis was as follows
as of September 30, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Total liabilities at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a roll-forward of
the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level 3 inputs for the years ended September 30 as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,007,206</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,005,232</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,974,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,180,470</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(804,529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IntellectualPropertyPolicyTextBlock', window );">Intellectual Property</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Intellectual
Property</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has entered into&#160;two&#160;licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful
life of the acquired technology.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Property
and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful
lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to&#160;seven
years&#160;and&#160;three years&#160;for software. Tangible assets acquired for research and development activities and that have alternative
use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate,
changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party
software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and
an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly
to expense as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Impairment
of Long-Lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company evaluates its long-lived
assets, which consist of licensed intellectual property, property and equipment and right of use assets for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability
of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying
value and the fair value of the impaired asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowances for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Allowances
for Doubtful Accounts</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability
of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of
the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances
are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual
write-offs may be in excess of the Company&#8217;s estimated allowance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Inventories</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Inventories
are stated at the lower of cost (using the first-in, first-out &#8220;FIFO&#8221; method) or net realizable value. The Company calculates
inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected
useful lives, and estimated future demand of the products and spare parts. The Company&#8217;s inventory is currently comprised of cEEG
strip/grid and electrode cable assembly finished good product. The Strip/Grid Products are produced by a third-party contract manufacturer
and the Electrode Cable Assembly Products are obtained from outside suppliers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Research
and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as
other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather
than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Selling,
General and Administrative</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Selling,
general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters,
and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of cEEG strip/grid
and electrode cable assembly products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>For the
Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred
tax asset will not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, basic loss per share of common
stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings or loss per share of common stock
is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional
shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s convertible notes, warrants, stock
options and restricted stock units, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible
promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share
because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following potential common shares were not considered in the computation
of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,503,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,390,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,122,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,698</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Unissued vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,618</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<i>Financial Instruments &#8211; Credit Losses&#8221;</i>.
The ASU sets forth a &#8220;current expected credit loss&#8221; (&#8220;CECL&#8221;) model which requires the Company to measure all expected
credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued
the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of
the adoption of this ASU on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2018, the FASB issued ASU 2018-13,&#160;<i>Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement&#160;</i>(ASU 2018-13)<i>.</i>&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Removals: the amount
of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels;
and the valuation processes for Level 3 fair value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Modifications: for investments
in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#8217;s
assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty
in measurement as of the reporting date.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>Additions: the changes
in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held
at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair
value measurements.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>This guidance
is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop
Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only
the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively
to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or
modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
adopted the new guidance on October 1, 2020 and it did not have a material impact on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income
taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting
for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption
of this new guidance will have a material impact on the Company&#8217;s financial statements and plans to adopt this guidance on a prospective
basis for the provisions applicable to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In August
2020, FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,
which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This ASU eliminates the
beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition,
this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted
earnings per share computation. The amendments in this ASU are effective for smaller reporting companies as defined by the SEC for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IntellectualPropertyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy fori ntellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IntellectualPropertyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486756412008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value of financial instruments measured on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> September 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,007,206</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Total liabilities at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,007,206</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,005,232</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,974</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Convertible notes</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of beginning of period &#8211; September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to convertible promissory notes upon issuance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,974,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Fair value attributed to note extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,017,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Conversion of convertible promissory notes to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,180,470</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in fair value including accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(804,529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Balance as of end of period &#8211; September 30, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of computation of diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,503,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,390,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,122,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,698</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Unissued vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,063</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,618</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486756509784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalCashFlowTableTextBlock', window );">Schedule of supplemental cash flow information related to the operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Year Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">70,897</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">38,462</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,118</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">335,119</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalBalanceSheetTableTextBlock', window );">Schedule of supplemental balance sheet information related to the operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">288,948</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">282,211</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">315,673</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">312,176</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average remaining lease term (years)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.5</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Weighted average discount rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.7</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of the lease liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Calendar Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: 0pt; padding-left: 0pt">2021 (period from October 1, 2021 to December 31, 2021)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,435</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,391</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">351,606</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0.125in">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in">Short-term portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,778</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in">Long-term portion</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">202,895</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalCashFlowTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalCashFlowTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749713592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pf0_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Prepaid and other assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">151,109</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118,010</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">244,043</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">118,611</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Useful Life</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><span style="font-size: 10pt">12-13 years</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">178,838</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,315</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">156,523</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Less: amortization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,316</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; text-align: justify"><span style="font-size: 10pt">Net Intangibles, September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">134,207</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt">Equipment and furniture</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">311,486</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195,756</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0pt; padding-left: 0pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">313,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,052</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,620</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">223,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">166,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pf0_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pf0_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pf0_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755311816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued payroll</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">376,236</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">238,212</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Operating lease liability, short term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,778</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,848</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Royalty Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83,152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">644,249</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">512,762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762536872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Zimmer Development Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementAbstract', window );"><strong>Zimmer Development Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of deferred revenue</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Deferred Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Balance as of&#160;&#160;September 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Upfront initial exclusivity payment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,926,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Balance as of&#160;&#160;September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,434</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,812</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,622</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ZimmerDevelopmentAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ZimmerDevelopmentAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755319016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible promissory notes and warrant agreements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Paulson convertible notes, principal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">546,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,458</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Fair value adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">397,748</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,007,206</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486761270392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in">Selling, general and administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,550,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,623,629</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">242,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,341</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total stock-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,793,199</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,835,970</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">281,956</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">343,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334,731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25,515</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,330</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,842</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">703,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(71,861</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,122,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.89</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8.8</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">127,339</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Vested and exercisable at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">481,047</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.89</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8.2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">311,388</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected stock price volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">55.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">53.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-left: 0">Non-vested at September 30, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,503</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,323</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Non-vested at September 30, 2020</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,776</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,090</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0">Non-vested at September 30, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,384</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486754292616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryOfWarrantActivityTableTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Warrants</b> &#160; &#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Exercise <br/>
Price Per <br/>
Warrant</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted<br/>
Average Exercise <br/>
Price</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted <br/>
Average Term <br/>
(years)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">2,421,940</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">5.40 - 9.00&#160;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">7.65</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">3.60</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">968,380</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">5.61</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-77">&#8212;</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-81">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2020</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,390,320</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.40 - 9.00&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">7.05</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2.89</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Issued</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">4,166,682</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">4.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Exercised</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(53,194</span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61-8.25 </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5.61</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-size: 10pt">&#8212;&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Forfeited</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-87">&#8212;</span></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Outstanding and exercisable at September 30, 2021</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">7,503,808</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">5.25-9.00</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">6.06</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">3.23</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of summarizes information about warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercise Price</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Outstanding</b></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average <br/>
Remaining Contractual<br/>
life (Years)</b></td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number Exercisable at <br/>
September 30,<br/>
2021</b></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; text-align: justify">$</td>
    <td style="width: 21%; text-align: right">5.25</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right">4,166,682</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 24%; text-align: center">4.29</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 23%; text-align: right">4,166,682</td>
    <td style="width: 1%; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">5.40</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">750,364</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">0.14</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">750,364</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">5.61</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">916,753</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.68</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">916,753</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">6.00</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">45,173</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.75</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">45,173</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">7.50</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">279,733</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.41</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">279,733</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">8.25</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">62,911</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.75</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: right">62,911</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">$</td>
    <td style="text-align: right">9.00</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,282,192</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">2.18</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,282,192</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: justify">Total</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">7,503,808</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: justify">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">7,503,808</td>
    <td style="padding-bottom: 4.5pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762533112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax computed at the statutory federal income tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Income tax benefit at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">State income tax, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.7</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Disqualified interest and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.7</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">31.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Federal and state operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,575,069</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,936,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Acquired intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,635</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Accruals and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Research and development credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,081</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">451,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">255,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,872,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,694,574</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(64,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,808,329</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,694,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755346376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProceedsFromPayrollProtectionProgramLoan', window );">Funding loan received</a></td>
<td class="nump">$ 83,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProceedsFromPayrollProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds associated with the PPP loan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProceedsFromPayrollProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762633480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Going Concern (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 40.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486761141592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DepositsExcessOfFederallyInsured', window );">Deposits in excess of federally insured amounts (in Dollars)</a></td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOfLicencingAgreements', window );">Number of licensing agreements</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DepositsExcessOfFederallyInsured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount by which the cash balance exceeds the amount insured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DepositsExcessOfFederallyInsured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NumberOfLicencingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NumberOfLicencingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749946392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible Notes</a></td>
<td class="nump">$ 1,007,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">1,007,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible Notes</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible Notes</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Convertible Notes</a></td>
<td class="nump">1,007,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 1,007,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749949064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesAbstract', window );"><strong>Convertible notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 1,007,206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAttributedToConvertibleNotesUponIssuance', window );">Fair value attributed to convertible promissory notes upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,974,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueAttributedToNoteExtinguishment', window );">Fair value attributed to note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock', window );">Conversion of convertible promissory notes to common stock</a></td>
<td class="num">(1,005,232)<span></span>
</td>
<td class="num">(14,180,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ChangeInFairValueIncludingAccruedInterest', window );">Change in fair value including accrued interest</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="num">(804,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Balance as of end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,007,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ChangeInFairValueIncludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value including accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ChangeInFairValueIncludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible promissory notes to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAttributedToConvertibleNotesUponIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value attributed to convertible notes upon issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAttributedToConvertibleNotesUponIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueAttributedToNoteExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value attributed to note extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueAttributedToNoteExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751657416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract', window );"><strong>Schedule of computation of diluted net loss per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_Warrantshares', window );">Warrants</a></td>
<td class="nump">7,503,808<span></span>
</td>
<td class="nump">3,390,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockOptions', window );">Stock options</a></td>
<td class="nump">1,122,560<span></span>
</td>
<td class="nump">492,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RestrictedStockUnit', window );">Restricted stock units</a></td>
<td class="nump">11,384<span></span>
</td>
<td class="nump">26,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UnissuedVestedRestrictedStockUnits', window );">Unissued vested restricted stock units</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotes', window );">Convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">277,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent conversion of convertible notes not included in basic EPS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This relates to restricted stock units not included in basic EPS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This relates to stock options not included in basic EPS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UnissuedVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This relates to restricted stock awards not included in basic EPS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UnissuedVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_Warrantshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This relates to warrants not included in basic EPS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_Warrantshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486746605080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Oct. 12, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RoyaltyMinimumPaymentsYearOne', window );">Royalty payments - 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RoyaltyMinimumPaymentsYearTwo', window );">Royalty payments - 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RoyaltyMinimumPaymentsYearThree', window );">Royalty payments - 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Court awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseAgreementDescription', window );">Facility Lease agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On October 7, 2019, the Company entered into a
non-cancellable lease agreement (the &#8220;Lease&#8221;) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together,
the &#8220;Landlord&#8221;) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie,
Minnesota (the &#8220;Premises&#8221;). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending
65 months after such date, unless terminated earlier (the &#8220;Term&#8221;). The initial base rent for the Premises is $6,410 per month
for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default
under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will
pay its pro rata share of the Landlord&#8217;s annual operating expenses associated with the premises, calculated as set forth in the
Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseSpace', window );">Lease space (in Square Meters) | m&#178;</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseRentalExpense', window );">Lease rental expense</a></td>
<td class="nump">$ 4,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_MonthlyLeaseRent', window );">Monthly lease rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,826<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TypeOfAgreementAxis=nmtc_MayoAgreementMember', window );">Mayo Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmtc_WadeFredricksonMember', window );">Wade Fredrickson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Court awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent lease agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease rental expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility space square feet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_MonthlyLeaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly lease rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_MonthlyLeaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RoyaltyMinimumPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty minimum payments year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RoyaltyMinimumPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RoyaltyMinimumPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty minimum payments year third year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RoyaltyMinimumPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RoyaltyMinimumPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty minimum payments second year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RoyaltyMinimumPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_TypeOfAgreementAxis=nmtc_MayoAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_TypeOfAgreementAxis=nmtc_MayoAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmtc_WadeFredricksonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmtc_WadeFredricksonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755747368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OperatingCashFlowsFromOperatingLeases', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 70,897<span></span>
</td>
<td class="nump">$ 38,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OperatingLeases', window );">Operating leases</a></td>
<td class="nump">$ 73,118<span></span>
</td>
<td class="nump">$ 335,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OperatingCashFlowsFromOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OperatingCashFlowsFromOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange of lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749761912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract', window );"><strong>Schedule of supplemental balance sheet information related to the operating lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 288,948<span></span>
</td>
<td class="nump">$ 282,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 315,673<span></span>
</td>
<td class="nump">$ 312,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486749725208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of maturity of the lease liability<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract', window );"><strong>Schedule of maturity of the lease liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear', window );">2021 (period from October 1, 2021 to December 31, 2021)</a></td>
<td class="nump">$ 32,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear', window );">2022</a></td>
<td class="nump">131,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear', window );">2023</a></td>
<td class="nump">82,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear', window );">2024</a></td>
<td class="nump">84,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear', window );">2025</a></td>
<td class="nump">21,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">351,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ImputedInterest', window );">Less imputed interest</a></td>
<td class="num">(35,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseLiabilityNet', window );">Total</a></td>
<td class="nump">315,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term portion</a></td>
<td class="num">(112,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term portion</a></td>
<td class="nump">$ 202,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Imputed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in remaining in current calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486756413352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 58,432<span></span>
</td>
<td class="nump">$ 25,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755091672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract', window );"><strong>Schedule of Prepaid and other assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 151,109<span></span>
</td>
<td class="nump">$ 118,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">92,934<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total</a></td>
<td class="nump">$ 244,043<span></span>
</td>
<td class="nump">$ 118,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486851234584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Details) - Schedule of intangible assets - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangibles, beginning</a></td>
<td class="nump">$ 156,523<span></span>
</td>
<td class="nump">$ 178,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Less: amortization</a></td>
<td class="num">(22,316)<span></span>
</td>
<td class="num">(22,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangibles, ending</a></td>
<td class="nump">$ 134,207<span></span>
</td>
<td class="nump">$ 156,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NetIntangiblesUsefulLives', window );">Net Intangibles, useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NetIntangiblesUsefulLives', window );">Net Intangibles, useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NetIntangiblesUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Intangibles, useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NetIntangiblesUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486851220744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPropertyAndEquipmentAbstract', window );"><strong>Schedule of property and equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Equipment and furniture</a></td>
<td class="nump">$ 311,486<span></span>
</td>
<td class="nump">$ 195,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software</a></td>
<td class="nump">1,895<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">313,381<span></span>
</td>
<td class="nump">197,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LessAccumulatedDepreciations', window );">Less accumulated depreciation</a></td>
<td class="num">(90,052)<span></span>
</td>
<td class="num">(31,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 223,329<span></span>
</td>
<td class="nump">$ 166,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LessAccumulatedDepreciations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of less accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LessAccumulatedDepreciations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfPropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfPropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486762536152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PaycheckProtectionProgramDescription', window );">Paycheck protection program, description</a></td>
<td class="text">The PPP authorizes over $600 billion in forgivable loans to small
businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility
costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments
may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term
liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the
accompanying statements of operations. Interest was nominal during the years ended September 30, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PaycheckProtectionProgramDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paycheck protection program, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PaycheckProtectionProgramDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486851228696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfAccruedExpensesAbstract', window );"><strong>Schedule of accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">$ 376,236<span></span>
</td>
<td class="nump">$ 238,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LeaseLiabilityShortterms', window );">Operating lease liability, short term</a></td>
<td class="nump">112,778<span></span>
</td>
<td class="nump">57,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Accrued issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RoyaltyPayments', window );">Royalty Fees</a></td>
<td class="nump">72,083<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">83,152<span></span>
</td>
<td class="nump">166,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 644,249<span></span>
</td>
<td class="nump">$ 512,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LeaseLiabilityShortterms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LeaseLiabilityShortterms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751049512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Zimmer Development Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IntialFeePayment', window );">Initial fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,146<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Total advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember', window );">Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ProductRevenueRecognized', window );">Product revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,812<span></span>
</td>
<td class="nump">$ 1,926,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember', window );">Development Agreement [Member] | November 30, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember', window );">Development Agreement [Member] | After September 30, 2021, but on or before December 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember', window );">Development Agreement [Member] | After December 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=nmtc_ScenarioOneMember', window );">Scenario One [Member] | Development Agreement [Member] | April 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=nmtc_ScenarioOneMember', window );">Scenario One [Member] | Development Agreement [Member] | On or before June 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=nmtc_ScenarioTwoMember', window );">Scenario Two [Member] | Development Agreement [Member] | Modified Connector by April 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=nmtc_ScenarioTwoMember', window );">Scenario Two [Member] | Development Agreement [Member] | Modified Connector by September 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=nmtc_ScenarioTwoMember', window );">Scenario Two [Member] | Development Agreement [Member] | After June 30, 2021, but on or before September 30, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems', window );"><strong>Zimmer Development Agreement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone', window );">Future potential milestone payments to Neuroone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FuturePotentialMilestonePaymentsToNeuroone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent future potential milestone payments to Neuroone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FuturePotentialMilestonePaymentsToNeuroone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IntialFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intial fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IntialFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ProductRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of product revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ProductRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ZimmerDevelopmentAgreementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ZimmerDevelopmentAgreementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_TypeOfAgreementAxis=nmtc_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_November302020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_November302020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_AfterDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_AfterDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nmtc_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nmtc_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_April302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_April302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_OnOrBeforeJune302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_OnOrBeforeJune302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nmtc_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nmtc_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_ModifiedConnectorbyApril302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_ModifiedConnectorbyApril302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_ModifiedConnectorbySeptember302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_ModifiedConnectorbySeptember302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751755784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Zimmer Development Agreement (Details) - Schedule of deferred revenue - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Balance</a></td>
<td class="nump">$ 73,434<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UpfrontInitialExclusivityPayments', window );">Upfront initial exclusivity payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="num">(64,812)<span></span>
</td>
<td class="num">(1,926,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Balance</a></td>
<td class="nump">$ 8,622<span></span>
</td>
<td class="nump">$ 73,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UpfrontInitialExclusivityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront initial exclusivity payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UpfrontInitialExclusivityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486745373480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OutstandingVotingPercentage', window );">Outstanding voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfFairValueAmount', window );">Issuance of fair value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,831,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ChangesOfFairValueBenefit', window );">Changes of fair value benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="nump">$ 1,221,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsDescription', window );">Issuance costs, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the 2019 Private Placement,
Paulson Investment Company, LLC (&#8220;Paulson&#8221;) received a cash commission equal to 12% of the gross proceeds from the sale of
the 2019 Paulson Notes, and 10-year warrants to purchase an amount of common stock equal to 86,498 shares of common stock at an exercise
price equal to $5.61 per share (the &#8220;Broker Warrants&#8221;). The issuance costs incurred during the year ended September 30, 2021
and 2020 in connection with the 2019 Paulson Private Placement were $3,053 and $865,567, respectively. Issuance costs in 2021 related
to legal costs. Issuance costs in 2020 included cash commissions equal to $388,176 and legal and third-party fees in the amount of $57,756.
In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&#160;On April 24, 2020, the Company and holders of
a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the &#8220;Second
2019 Paulson Notes Amendment&#8221;) to, among other things:&#160;
i.Extended the Maturity Date &#8211; The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);
&#160;
ii.Revised Optional Conversion Terms &#8211;
The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#8217;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#8217;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and
&#160;
iii.Revised the Registration Date &#8211; The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#8217;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.
&#160;The Second 2019 Paulson Notes Amendment was accounted
for as a note extinguishment for accounting purposes given the substantive change in the optional redemption feature&#8217;s conversion
formula. The fair value change in the 2019 Paulson Notes associated with the extinguishment was recorded as a loss on notes extinguishment
in the accompanying statements of operations in the amount of $2,017,847 during the year ended September 30, 2020. Lastly, in connection
with the Second 2019 Paulson Notes Amendment, legal costs in the amount of $1,943 were incurred and recorded as a component of interest
in the accompanying statements of operations.&#160;During the years ended September 30, 2021 and
2020, the 2019 Paulson Notes were converted into 292,754 and 725,394 shares of common stock, respectively. All of the 2019 Paulson notes
were converted into shares of common stock by December 31, 2020.&#160;Paulson 2020 Convertible Note Financing&#160;&#160;On April 30, 2020, the Company entered into a
subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#8220;2020 Paulson
Private Placement&#8221;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#8220;2020 Paulson Note&#8221;
and collectively, the &#8220;2020 Paulson Notes&#8221;) and warrants (each, a &#8220;2020 Paulson Warrant&#8221; and collectively, the
&#8220;2020 Paulson Warrants&#8221;) to purchase shares of the Company&#8217;s common stock.&#160;&#160;Between May 1, 2020 and June 30, 2020, the Company
issued 2020 Paulson Notes in an aggregate principal amount of $5,122,700 to the Subscribers. The 2020 Paulson Private Placement was terminated
on June 30, 2020.&#160;The 2020 Paulson Notes had a fixed interest rate
of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of December 31,
2020 or a change of control transaction. Interest on principal amounted to $81,613 during the year ended September 30, 2020 and was recorded
under the net valuation change of instruments measured at fair value in the statements of operations.&#160;If the Company had raised more than $5,000,000
in an equity financing before the maturity date (the &#8220;2020 Qualified Financing&#8221;), without any action on the part of the Subscribers,
all of the outstanding principal and accrued and unpaid interest of the Notes (the &#8220;Outstanding Balance&#8221;) would have been
converted into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred
equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities
issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume weighted average price of the
common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.&#160;If the Company had announced a transaction between
the Company and any other company (or an affiliate of any such company) that was included in the S&P 500 Health Care Index as published
from time to time by S&P Dow Jones Indices LLC that included an investment or upfront payments resulting in gross proceeds to the
Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration,
manufacturing, distribution, licensing or supply of the Company&#8217;s products (a &#8220;Strategic Transaction&#8221;) before the maturity
date, without any action on the part of the subscribers, the Outstanding Balance would be converted into that number of shares of common
stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten
(10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on
the day preceding the first announcement by the Company of a Strategic Transaction.&#160;At any time, at the sole election of the holder
of such 2020 Paulson Note, all or a portion of the Outstanding Balance could have been converted into that number of shares of common
stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by
the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.&#160;If a change of control transaction had occurred
prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would have become payable on demand as
of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#8217;s
stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially
all of the Company&#8217;s assets.&#160;The Company elected to account for the 2020 Paulson
Notes on a fair value basis under ASC 825&#160;to comprehensively value and streamline the accounting
for the embedded conversion options. The fair value of the 2020 Paulson Notes was significantly higher than the proceeds received
as of each of the respective issuance dates given the significant redemption discount associated with the redemption provisions. The excess
of fair value over proceeds at issuance amounted to $3,784,918 and was recorded to interest expense in the statements of operations during
the year ended September 30, 2020. Subsequent to issuance, the fair value change of the 2020 Paulson Notes amounted to an expense of $416,951
during the year ended September 30, 2020 and was recorded under the net valuation change of instruments measured at fair value in the
statements of operations.&#160;Each 2020 Paulson Warrant grants the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. The 2020 Paulson Warrants are immediately exercisable
and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock
split, recapitalization, reorganization or similar transaction. The Company issued 2020 Paulson Warrants exercisable for 456,564 shares
of common stock in connection with all closings of the 2020 Paulson Private Placement through June 30, 2020. The 2020 Paulson warrants
were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2020 Paulson Notes exceeded
the proceeds received at issuance, there was no value attributed to the 2020 Paulson Warrants in the financial statements.&#160;In connection with the 2020 Paulson Private Placement,&#160;Paulson&#160;received
a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes and received 7-year warrants to purchase
an amount of common stock equal to 136,971 (&#8220;Broker Warrants&#8221;). The Broker Warrants have an exercise price equal to $5.61
per share. The issuance costs incurred during the year ended September 30, 2020 in connection with the 2020 Paulson Private Placement
were $1,040,213. Issuance costs included cash commissions equal to $614,725 and legal and third-party fees in the amount of $148,451.
In addition, issuance costs included the value of the Broker Warrants in the amount of $277,037. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on notes extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,017,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertedNotesCommonStock', window );">Converted notes common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,754<span></span>
</td>
<td class="nump">725,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncreaseDecreaseInFairValue', window );">Increase decrease in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CashCommissions', window );">Cash commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNoteFinancingDescription', window );">Convertible Note financing, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Between May 4, 2020 and July 22, 2020, certain
Subscribers elected to convert $3,590,353 of the outstanding principal and interest of such Subscribers&#8217; 2020 Paulson Notes into
1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance of the 2020 Paulson Notes
in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the Zimmer Development Agreement
that qualified as a Strategic Transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=nmtc_BrokerWarrantsMember', window );">Broker Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember', window );">2019 Paulson Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsExercisableForSharesOfCommonStockConnection', window );">Warrants exercisable for shares of common stock connection (in Shares)</a></td>
<td class="nump">288,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CashCommissionPercentageRateOnProceeds', window );">Cash commission percentage rate on proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Paulson Convertible Note Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 3,234,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsDescription', window );">Warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each 2019 Paulson Warrant granted the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#8217;s
2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date of issuance and expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExtendedMaturityDateDescription', window );">Extended maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Extended the Maturity Date &#8211; The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevisedOptionalConversionTermsDescription', window );">Revised optional conversion terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revised Optional Conversion Terms &#8211;
The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#8217;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#8217;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ReviseTheRegistrationDateDescription', window );">Revise the registration date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revised the Registration Date &#8211; The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#8217;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NoncashInterest', window );">Non-cash interest on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance', window );">Interest expense related to excess of fair value over proceeds at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,784,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock shares (in Shares)</a></td>
<td class="nump">456,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Paulson Convertible Note Offering [Member] | 2019 Qualified Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering', window );">Equity qualified financing, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied
by (A) the actual per share price of securities issued by the Company in the Qualified Financing or (B) the ten day volume weighted average
closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction had occurred
prior to a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on demand as of the closing date
of such transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroOneNinePaulsonNotesMember', window );">2019 Paulson Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InterestOnPrincipalAmount', window );">Interest on principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,701<span></span>
</td>
<td class="nump">$ 213,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EquityFinancingAmount', window );">Equity financing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_Second2019PaulsonNotesAmendmentMember', window );">Second 2019 Paulson Notes Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember', window );">2020 Paulson Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceOfCostsIncurred', window );">Issuance costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,040,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonNotesMember', window );">2020 Paulson Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_aggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,122,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementMember', window );">Paulson Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_LegalAndThirdPartyFee', window );">Legal and third party fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CashCommissionPercentageRateOnProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash commission percentage rate on proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CashCommissionPercentageRateOnProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CashCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CashCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ChangesOfFairValueBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ChangesOfFairValueBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertedNotesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertedNotesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNoteFinancingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNoteFinancingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EquityFinancingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EquityFinancingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity qualified financing, description on Convertible Note Offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExtendedMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExtendedMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IncreaseDecreaseInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase decrease in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IncreaseDecreaseInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense related to excess of fair value over proceeds at issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InterestOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InterestOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceOfFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceOfFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_LegalAndThirdPartyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to issuance of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_LegalAndThirdPartyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NoncashInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments non-cash interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NoncashInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OutstandingVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OutstandingVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ReviseTheRegistrationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revise the registration date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ReviseTheRegistrationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevisedOptionalConversionTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevisedOptionalConversionTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsExercisableForSharesOfCommonStockConnection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsExercisableForSharesOfCommonStockConnection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to be issued for the right to purchase common shares at stated exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_aggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_aggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=nmtc_BrokerWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=nmtc_BrokerWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandNineteenQualifiedFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandNineteenQualifiedFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroOneNinePaulsonNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroOneNinePaulsonNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_Second2019PaulsonNotesAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_Second2019PaulsonNotesAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_TwoZeroTwoZeroPaulsonNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=nmtc_PaulsonPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755069544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract', window );"><strong>Schedule of convertible promissory notes and warrant agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesOutstandingPrincipal', window );">Paulson convertible notes, principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 546,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable', window );">Fair value adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">397,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesPayable', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,007,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes outstanding principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, at fair value value as of the balance sheet date of a written promise to pay a note, initially due within one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value in excess of principal and accrued interest related to debt instrument payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486747531192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,117<span></span>
</td>
<td class="nump">334,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockOptionVestedOverAPeriodTerm', window );">Vested over a period term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TotalExpenseOfStockOption', window );">Total expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 983,301<span></span>
</td>
<td class="nump">$ 798,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePriceOfUnderlyingOptions', window );">Exercise price of the underlying option (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 3.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OutstandingStockOptionsShares', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,055,376<span></span>
</td>
<td class="nump">467,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,557<span></span>
</td>
<td class="nump">198,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Compensation expense related to the stock awards (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,910<span></span>
</td>
<td class="nump">$ 641,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_EquityIncentivePlansMember', window );">2016 and 2017 Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FutureIssuanceOnACombinedBasis', window );">Future issuance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueOfTheUnderlyingCommonStock', window );">Vesting points (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueOfTheUnderlyingCommonStock', window );">Vesting points (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,117<span></span>
</td>
<td class="nump">334,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockOptionVestedOverAPeriodTerm', window );">Vested over a period term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member] | 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SharesReservedDescription', window );">Shares reserved, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the shares reserved automatically
increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders
of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted
shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January
1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the
share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence.
&#8220;Fully Diluted Shares&#8221; as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii)
issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants
or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common
stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2021 and 2020,
484,622 and 428,930 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmtc_ActivityMember', window );">2021 Activity [Member] | Two consulting agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock</a></td>
<td class="nump">11,668<span></span>
</td>
<td class="nump">62,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=nmtc_TwentyTwentyActivityMember', window );">2020 Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConsultingAgreementsDescription', window );">Consulting agreements description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an additional consulting agreement
was executed whereby 40,000 shares of common stock were issued, subject to Company repurchase. The stock award under the agreement vests
over a six-month period. As of September 30, 2021 and 2020, 33,333 and 6,667 shares vested under this agreement, respectively.<span></span>
</td>
<td class="text">an additional consulting agreement
was executed whereby up to 30,000 shares of common stock were issued and vested as of September 30, 2020 under this agreement. In addition,
on May 21, 2020, 22,195 shares of common stock were issued as compensation to a former 2019 Paulson Note holder related to a prior 2019
Paulson Note conversion and release of liability.<span></span>
</td>
<td class="text">two consulting agreements were
executed whereby up to 38,334 shares of common stock were issued and vested as of September 30, 2020. On April 22, 2020, the Company entered
into an amendment (the &#8220;Amendment&#8221;) to one of the consulting agreements. Pursuant to the Amendment, the Company issued an
additional 11,667 shares in exchange for consulting services of which 11,667 shares of common stock were vested as of September 30, 2020
under the Amendment. Vesting was based on a time-based vesting condition ranging over a three to nine-month period commencing upon the
execution of the consulting agreements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TotalExpenseOfStockOption', window );">Total expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,988<span></span>
</td>
<td class="nump">$ 396,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance', window );">Restricted stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,090<span></span>
</td>
<td class="nump">59,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">RSUs forfeited shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,776<span></span>
</td>
<td class="nump">78,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockOptionVestedOverAPeriodTerm', window );">Vested over a period term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GrantDateFairValueOfPerUnit', window );">Grant date fair value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConsultingAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting agreements description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConsultingAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExercisePriceOfUnderlyingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the underlying options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExercisePriceOfUnderlyingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueOfTheUnderlyingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the underlying common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueOfTheUnderlyingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FutureIssuanceOnACombinedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FutureIssuanceOnACombinedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GrantDateFairValueOfPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GrantDateFairValueOfPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OutstandingStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares option outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OutstandingStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SharesReservedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of shares reserved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SharesReservedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockOptionVestedOverAPeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option vested over a period term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockOptionVestedOverAPeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_TotalExpenseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense of stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_TotalExpenseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_EquityIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_EquityIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=nmtc_ActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=nmtc_ActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_TypeOfAgreementAxis=nmtc_TwoconsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_TypeOfAgreementAxis=nmtc_TwoconsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=nmtc_TwentyTwentyActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=nmtc_TwentyTwentyActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486851231432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 1,793,199<span></span>
</td>
<td class="nump">$ 1,835,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">1,550,841<span></span>
</td>
<td class="nump">1,623,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 242,358<span></span>
</td>
<td class="nump">$ 212,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486745302344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock option plan activity - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfStockOptionPlanActivityAbstract', window );"><strong>Schedule of stock option plan activity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">281,956<span></span>
</td>
<td class="nump">492,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (years), Outstanding at beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding at beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 343,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,117<span></span>
</td>
<td class="nump">334,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 6.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,538)<span></span>
</td>
<td class="num">(25,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,861)<span></span>
</td>
<td class="num">(98,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="nump">$ 5.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122,560<span></span>
</td>
<td class="nump">492,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (years), Outstanding at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,339<span></span>
</td>
<td class="nump">$ 96,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and exercisable at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (years), Vested and exercisable at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable at ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September 30, 2021 and 2020 of $3.95 and $3.86 per share, respectively. As of September 30, 2021 and 2020, 1,055,376 and 467,327 outstanding options, respectively, had no intrinsic value.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfStockOptionPlanActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfStockOptionPlanActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486761210856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract', window );"><strong>Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">55.90%<span></span>
</td>
<td class="nump">53.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755534088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of restricted stock unit activity - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfRestrictedStockUnitActivityAbstract', window );"><strong>Schedule of restricted stock unit activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Number of Shares beginning</a></td>
<td class="nump">26,698<span></span>
</td>
<td class="nump">10,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, Number of Shares</a></td>
<td class="nump">13,776<span></span>
</td>
<td class="nump">78,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, Number of Shares</a></td>
<td class="num">(29,090)<span></span>
</td>
<td class="num">(59,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, Number of Shares ending</a></td>
<td class="nump">11,384<span></span>
</td>
<td class="nump">26,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfRestrictedStockUnitActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfRestrictedStockUnitActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486745232568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jul. 28, 2020</div></th>
<th class="th"><div>Oct. 23, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsLineItems', window );"><strong>Stockholders' Deficit (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.90%<span></span>
</td>
<td class="nump">53.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_PurchaseAgreementMember', window );">2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsLineItems', window );"><strong>Stockholders' Deficit (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AggregateShareIssued', window );">Aggregate share issued (in Shares)</a></td>
<td class="nump">4,166,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PurchaseOfWarrants', window );">Purchase of warrants (in Shares)</a></td>
<td class="nump">4,166,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PurchasePriceOfCommonStock', window );">Purchase price (in Dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_TotalGrossProceeds', window );">Total gross proceeds</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Initial exercise price (in Dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Total proceeds</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_TwoZeroTwoZeroCommonStockOfferingMember', window );">2020 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsLineItems', window );"><strong>Stockholders' Deficit (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SharesIssuedUnderPrivatePlacement', window );">Shares issue and sell under private placement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GrossProceedsFromPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nmtc_TwoThousandNineteenCommonStockOfferingMember', window );">2019 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsLineItems', window );"><strong>Stockholders' Deficit (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SharesIssuedUnderPrivatePlacement', window );">Shares issue and sell under private placement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GrossProceedsFromPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AggregateShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AggregateShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GrossProceedsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of gross proceeds from private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GrossProceedsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PurchasePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PurchasePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SharesIssuedUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SharesIssuedUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockholdersDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockholdersDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_TotalGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_TotalGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmtc_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_TwoZeroTwoZeroCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmtc_TwoZeroTwoZeroCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nmtc_TwoThousandNineteenCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nmtc_TwoThousandNineteenCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486746520536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - Schedule of warrant activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems', window );"><strong>Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber', window );">Warrants, Outstanding and exercisable, Beginning (in Shares)</a></td>
<td class="nump">3,390,320<span></span>
</td>
<td class="nump">2,421,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding and exercisable, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Term (years), Outstanding and exercisable, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Warrants, Issued (in Shares)</a></td>
<td class="nump">4,166,682<span></span>
</td>
<td class="nump">968,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePricePerWarrantIssued', window );">Exercise Price Per Warrant, Issued</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageTermyearsIssuedinShares', window );">Weighted Average Term (years), Issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Warrants, Exercised (in Shares)</a></td>
<td class="num">(53,194)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageTermyearsExercisedinShares', window );">Weighted Average Term (years), Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsForfeitedinShares', window );">Warrants, Forfeited (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageExercisePriceForfeited', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageTermyearsForfeitedinShares', window );">Weighted Average Term (years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber', window );">Warrants, Outstanding and exercisable, Ending (in Shares)</a></td>
<td class="nump">7,503,808<span></span>
</td>
<td class="nump">3,390,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding', window );">Weighted Average Exercise Price, Outstanding and exercisable, Ending</a></td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Term (years), Outstanding and exercisable, Ending</a></td>
<td class="text">3 years 2 months 23 days<span></span>
</td>
<td class="text">2 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems', window );"><strong>Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1', window );">Exercise Price Per Warrant, Outstanding and exercisable, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding', window );">Exercise Price Per Warrant, Outstanding and exercisable, Ending</a></td>
<td class="nump">5.25<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems', window );"><strong>Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1', window );">Exercise Price Per Warrant, Outstanding and exercisable, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding', window );">Exercise Price Per Warrant, Outstanding and exercisable, Ending</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExercisePricePerWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExercisePricePerWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options issued in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsForfeitedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsForfeitedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageExercisePriceForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageExercisePriceForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageTermyearsExercisedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageTermyearsExercisedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageTermyearsForfeitedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageTermyearsForfeitedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageTermyearsIssuedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageTermyearsIssuedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486747433752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">7,503,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">7,503,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceMember', window );">5.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">4,166,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">4 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">4,166,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceOneMember', window );">5.40 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">750,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">750,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceTwoMember', window );">5.61 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">916,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">2 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">916,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceThreeMember', window );">6.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">45,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">45,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFourMember', window );">7.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">279,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">2 years 4 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">279,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFiveMember', window );">8.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">62,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">62,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceSixMember', window );">9.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ExercisePrice', window );">Exercise Price, Total (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberOutstandingsTotal', window );">Number Outstanding, Total</a></td>
<td class="nump">1,282,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WeightedAverageRemainingContractualLifeYears', window );">Weighted Average Remaining Contractual life (Years), Total</a></td>
<td class="text">2 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NumberExercisable1', window );">Number Exercisable , Total</a></td>
<td class="nump">1,282,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NumberExercisable1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NumberExercisable1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NumberOutstandingsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NumberOutstandingsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WeightedAverageRemainingContractualLifeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WeightedAverageRemainingContractualLifeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nmtc_newExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486761219208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredTaxAssetGrossCurrent', window );">Gross deferred tax assets</a></td>
<td class="nump">$ 8,873,000<span></span>
</td>
<td class="nump">$ 5,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">8,808,000<span></span>
</td>
<td class="nump">5,695,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">26,355,000<span></span>
</td>
<td class="nump">17,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Federal research credit carryforwards</a></td>
<td class="nump">506,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">26,355,000<span></span>
</td>
<td class="nump">17,175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StateTaxCreditCarryForward', window );">State tax credit carry forward</a></td>
<td class="nump">$ 307,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredTaxAssetGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredTaxAssetGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StateTaxCreditCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state tax credit carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StateTaxCreditCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486755486376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract', window );"><strong>Schedule of reconciliation of income tax computed at the statutory federal income tax rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxBenefitAtFederalStatutoryRate', window );">Income tax benefit at federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StateIncomeTaxNetOfFederalBenefit', window );">State income tax, net of federal benefit</a></td>
<td class="num">(7.70%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DisqualifiedInterestAndOther', window );">Disqualified interest and other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ResearchCredits', window );">Research credits</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockbasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">31.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DisqualifiedInterestAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disqualified interest and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DisqualifiedInterestAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IncomeTaxBenefitAtFederalStatutoryRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax benefit at federal statutory rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IncomeTaxBenefitAtFederalStatutoryRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ResearchCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ResearchCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StateIncomeTaxNetOfFederalBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State income tax, net of federal benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StateIncomeTaxNetOfFederalBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751405336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">$ 7,575,069<span></span>
</td>
<td class="nump">$ 4,936,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">24,541<span></span>
</td>
<td class="nump">22,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accruals and other</a></td>
<td class="nump">8,370<span></span>
</td>
<td class="nump">30,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">812,781<span></span>
</td>
<td class="nump">450,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">451,757<span></span>
</td>
<td class="nump">255,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">8,872,518<span></span>
</td>
<td class="nump">5,694,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(64,189)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(64,189)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(8,808,329)<span></span>
</td>
<td class="num">(5,694,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferredIncomeTaxAssetNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredIncomeTaxAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredIncomeTaxAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751755912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_EmployeesCompensationPercentage', window );">Employees compensation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DeferralsPercentage', window );">Deferrals percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ContributionsPercentage', window );">Contributions percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InternalRevenuePercentage', window );">Internal Revenue percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ContributionsAmount', window );">Contributions amount (in Dollars)</a></td>
<td class="nump">$ 14,803<span></span>
</td>
<td class="nump">$ 14,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ContributionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ContributionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ContributionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ContributionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DeferralsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferrals percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DeferralsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_EmployeesCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employees compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_EmployeesCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InternalRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Internal Revenue percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InternalRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140486751469288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SharesAreAuthorizedForFutureIssuance', window );">Shares are authorized for future issuance</a></td>
<td class="nump">420,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_UnderwritingAgreementDescription', window );">Underwriting agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company, entered into
an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Craig-Hallum Capital Group LLC, as underwriter (the &#8220;Underwriter&#8221;),
relating to the issuance and sale of 3,750,000 shares of the Company&#8217;s common stock at a price to the public of $3.20 per share.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to
purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale
of 422,057 shares of common stock subject to the Underwriter&#8217;s overallotment option closed on November 15, 2021. Deferred offering
costs in connection with the offering amounted to $92,934 and are reflected in the prepaid and other assets line item in the accompanying
balance sheets as of September 30, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SharesAreAuthorizedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>These shares are authorized for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SharesAreAuthorizedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_UnderwritingAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting Agreement, Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_UnderwritingAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>f10k2021a1_neuroone_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nmtc="http://originalsourcemusic.com/20210930"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nmtc-20210930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:MayoAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-12</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nmtc:WadeFredricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-12</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:November302020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:April302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:ModifiedConnectorbyApril302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:ModifiedConnectorbySeptember302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:OnOrBeforeJune302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">nmtc:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterJune302021ButOnOrBeforeSeptember302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterSeptember302021ButOnOrBeforeDecember312021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:AfterDecember312021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroOneNinePaulsonNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandNineteenQualifiedFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-02</startDate>
            <endDate>2020-04-24</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:Second2019PaulsonNotesAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-25</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmtc:BrokerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:TwoZeroTwoZeroPaulsonPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">nmtc:PaulsonPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">nmtc:BrokerWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoZeroOneSevenPlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">pf0:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">pf0:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:ActivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:TwoconsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:ActivityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nmtc:TypeOfAgreementAxis">nmtc:TwoconsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">nmtc:TwentyTwentyActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2019-09-29</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-12</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:TwoZeroTwoZeroCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-28</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:TwoZeroTwoZeroCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-28</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmtc:TwoThousandNineteenCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-03</startDate>
            <endDate>2019-10-23</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nmtc:TwoThousandNineteenCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-23</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:ExercisePriceThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nmtc:newExercisePriceSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-04</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-40439</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">NeuroOne Medical Technologies Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">27-0863354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">7599 Anagram Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Eden Prairie</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">55344</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">NMTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="-5" unitRef="usd">82500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">16187722</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="c0">We are filing this amendment to our Annual Report on Form 10-K for
the year ended September 30, 2021, as filed with the Securities and Exchange Commission on December 15, 2021 (the &#x201c;Original Form
10-K&#x201d;), solely to correct an error in the content of Baker Tilly US, LLP&#x2019;s Report of Independent Registered Public Accounting
Firm.Beyond this correction, there have been no changes to the financial
or other information contained in the Original Form 10-K.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">6901346</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">4036397</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">48336</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">98287</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">244043</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" unitRef="usd">118611</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">7292012</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" unitRef="usd">4155008</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">134207</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" unitRef="usd">156523</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">288948</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" unitRef="usd">282211</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">223329</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">166031</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">7938496</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" unitRef="usd">4759773</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">528829</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="0" unitRef="usd">762538</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">644249</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">512762</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c4" decimals="0" unitRef="usd">1007206</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="0" unitRef="usd">8622</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c4" decimals="0" unitRef="usd">73434</us-gaap:DeferredRevenue>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1181700</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">2355940</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">202895</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" unitRef="usd">254328</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities contextRef="c4" decimals="0" unitRef="usd">83333</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">1384595</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" unitRef="usd">2693601</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">12010019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">12010019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">7393637</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">7393637</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">35834</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" unitRef="usd">22181</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">47345266</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" unitRef="usd">32923022</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-40827199</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" unitRef="usd">-30879031</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">6553901</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">2066172</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">7938496</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" unitRef="usd">4759773</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">178146</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">275895</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">-97749</us-gaap:GrossProfit>
    <nmtc:RevenueFromCollaboration contextRef="c0" decimals="0" unitRef="usd">64812</nmtc:RevenueFromCollaboration>
    <nmtc:RevenueFromCollaboration contextRef="c5" decimals="0" unitRef="usd">1926566</nmtc:RevenueFromCollaboration>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">6260266</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">4753036</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">3925008</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">2075791</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">10185274</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">6828827</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-10218211</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-4902261</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">-3053</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="0" unitRef="usd">-7524581</us-gaap:InterestIncomeExpenseNet>
    <nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue contextRef="c0" decimals="0" unitRef="usd">1974</nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue>
    <nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue contextRef="c5" decimals="0" unitRef="usd">804529</nmtc:NetValuationChangeOfInstrumentsMeasuredAtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-2017847</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" unitRef="usd">271122</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-9948168</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-13640160</us-gaap:NetIncomeLoss>
    <nmtc:EarningsPerSharesBasicAndDiluted contextRef="c0" decimals="2" unitRef="usdPershares">-0.93</nmtc:EarningsPerSharesBasicAndDiluted>
    <nmtc:EarningsPerSharesBasicAndDiluted contextRef="c5" decimals="2" unitRef="usdPershares">-2.52</nmtc:EarningsPerSharesBasicAndDiluted>
    <nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted contextRef="c0" decimals="0" unitRef="shares">10696799</nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted contextRef="c5" decimals="0" unitRef="shares">5415424</nmtc:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">4497930</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">13494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">15987799</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">-17238871</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">-1237578</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c10" decimals="0" unitRef="shares">72223</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c10" decimals="0" unitRef="usd">217</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c11" decimals="0" unitRef="usd">389783</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c5" decimals="0" unitRef="usd">390000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering contextRef="c11" decimals="0" unitRef="usd">696672</nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering>
    <nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering contextRef="c5" decimals="0" unitRef="usd">696672</nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c10" decimals="0" unitRef="shares">2598025</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c10" decimals="0" unitRef="usd">7794</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c11" decimals="0" unitRef="usd">14172676</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c5" decimals="0" unitRef="usd">14180470</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock contextRef="c11" decimals="0" unitRef="usd">-161881</nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock>
    <nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock contextRef="c5" decimals="0" unitRef="usd">-161881</nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c11" decimals="0" unitRef="usd">798242</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" unitRef="usd">798242</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c10" decimals="0" unitRef="shares">142200</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c10" decimals="0" unitRef="usd">427</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c11" decimals="0" unitRef="usd">641289</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="0" unitRef="usd">641716</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares contextRef="c10" decimals="0" unitRef="shares">57744</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits contextRef="c10" decimals="0" unitRef="usd">173</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits contextRef="c11" decimals="0" unitRef="usd">395839</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits contextRef="c5" decimals="0" unitRef="usd">396012</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits>
    <nmtc:StockIssuedDuringPeriodExerciseOfStockOptions contextRef="c10" decimals="0" unitRef="shares">25515</nmtc:StockIssuedDuringPeriodExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c10" decimals="0" unitRef="usd">76</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c11" decimals="0" unitRef="usd">2603</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="0" unitRef="usd">2679</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProfitLoss contextRef="c12" decimals="0" unitRef="usd">-13640160</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">-13640160</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c13" decimals="0" unitRef="shares">7393637</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" unitRef="usd">22181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">32923022</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">-30879031</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">2066172</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c16" decimals="0" unitRef="shares">4166682</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c16" decimals="0" unitRef="usd">12500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c17" decimals="0" unitRef="usd">12487500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c0" decimals="0" unitRef="usd">12500000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c16" decimals="0" unitRef="shares">292754</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c16" decimals="0" unitRef="usd">878</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c17" decimals="0" unitRef="usd">1004354</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="0" unitRef="usd">1005232</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacement contextRef="c17" decimals="0" unitRef="usd">-1198080</nmtc:IssuanceCostsInConnectionWithPrivatePlacement>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">-1198080</nmtc:IssuanceCostsInConnectionWithPrivatePlacement>
    <nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement contextRef="c17" decimals="0" unitRef="usd">50400</nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement>
    <nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">50400</nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c17" decimals="0" unitRef="usd">1793199</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" unitRef="usd">1793199</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c16" decimals="0" unitRef="shares">74327</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c16" decimals="0" unitRef="usd">74</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c17" decimals="0" unitRef="usd">-74</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares contextRef="c16" decimals="0" unitRef="shares">30021</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits contextRef="c16" decimals="0" unitRef="usd">63</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits contextRef="c17" decimals="0" unitRef="usd">-63</nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits>
    <nmtc:StockIssuedDuringPeriodExerciseOfStockOptions contextRef="c16" decimals="0" unitRef="shares">1552</nmtc:StockIssuedDuringPeriodExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c16" decimals="0" unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c17" decimals="0" unitRef="usd">10143</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="0" unitRef="usd">10146</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <nmtc:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="c16" decimals="0" unitRef="shares">51046</nmtc:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="c16" decimals="0" unitRef="usd">135</nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="c17" decimals="0" unitRef="usd">274865</nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="c0" decimals="0" unitRef="usd">275000</nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" unitRef="usd">-9948168</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-9948168</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c19" decimals="0" unitRef="shares">12010019</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">35834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">47345266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">-40827199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">6553901</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-9948168</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-13640160</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" unitRef="usd">80748</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="0" unitRef="usd">47609</us-gaap:DepreciationDepletionAndAmortization>
    <nmtc:AllocatedShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">1793199</nmtc:AllocatedShareBasedCompensation>
    <nmtc:AllocatedShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">1835970</nmtc:AllocatedShareBasedCompensation>
    <nmtc:NoncashInterestOnConvertiblePromissoryNotes contextRef="c5" decimals="0" unitRef="usd">5616858</nmtc:NoncashInterestOnConvertiblePromissoryNotes>
    <nmtc:PayrollProtectionProgramLoanForgiveness contextRef="c0" decimals="0" unitRef="usd">83333</nmtc:PayrollProtectionProgramLoanForgiveness>
    <nmtc:FairValueChangeOfConvertibleNotes contextRef="c0" decimals="0" unitRef="usd">-1974</nmtc:FairValueChangeOfConvertibleNotes>
    <nmtc:FairValueChangeOfConvertibleNotes contextRef="c5" decimals="0" unitRef="usd">-804529</nmtc:FairValueChangeOfConvertibleNotes>
    <nmtc:IssuanceCostsAttributedToFinancingActivities contextRef="c0" decimals="0" unitRef="usd">3053</nmtc:IssuanceCostsAttributedToFinancingActivities>
    <nmtc:IssuanceCostsAttributedToFinancingActivities contextRef="c5" decimals="0" unitRef="usd">1907723</nmtc:IssuanceCostsAttributedToFinancingActivities>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-66382</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-22943</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-2017847</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">48336</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">98287</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" unitRef="usd">8320</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" unitRef="usd">77609</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">-350313</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c5" decimals="0" unitRef="usd">-269601</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">-7477</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">-82353</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-8602826</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-3425302</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">67079</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">122427</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-67079</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-122427</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c5" decimals="0" unitRef="usd">8357500</us-gaap:ProceedsFromConvertibleDebt>
    <nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">8829236</nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement>
    <nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement contextRef="c5" decimals="0" unitRef="usd">390000</nmtc:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement>
    <nmtc:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">3670764</nmtc:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement>
    <nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes contextRef="c0" decimals="0" unitRef="usd">3053</nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes>
    <nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes contextRef="c5" decimals="0" unitRef="usd">1125241</nmtc:IssuanceCostsInConnectionWithConvertiblePromissoryNotes>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacements contextRef="c0" decimals="0" unitRef="usd">1198080</nmtc:IssuanceCostsInConnectionWithPrivatePlacements>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacements contextRef="c5" decimals="0" unitRef="usd">384894</nmtc:IssuanceCostsInConnectionWithPrivatePlacements>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="0" unitRef="usd">275000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="0" unitRef="usd">10146</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c5" decimals="0" unitRef="usd">2679</us-gaap:ProceedsFromStockOptionsExercised>
    <nmtc:ProceedsFromPaycheckProtectionProgram contextRef="c5" decimals="0" unitRef="usd">83333</nmtc:ProceedsFromPaycheckProtectionProgram>
    <nmtc:DeferredsOfferingCosts contextRef="c0" decimals="0" unitRef="usd">-49159</nmtc:DeferredsOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">11534854</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">7323377</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">2864949</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">3775648</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">4036397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c9" decimals="0" unitRef="usd">260749</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">6901346</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">4036397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nmtc:ConversionOfConvertiblePromissoryNotesToEquity contextRef="c0" decimals="0" unitRef="usd">1005232</nmtc:ConversionOfConvertiblePromissoryNotesToEquity>
    <nmtc:ConversionOfConvertiblePromissoryNotesToEquity contextRef="c5" decimals="0" unitRef="usd">14180470</nmtc:ConversionOfConvertiblePromissoryNotesToEquity>
    <nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement contextRef="c0" decimals="0" unitRef="usd">50400</nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement>
    <nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement contextRef="c5" decimals="0" unitRef="usd">95735</nmtc:UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement>
    <nmtc:BrokerWarrantsIssuedInConnectionWithConvertibleNotes contextRef="c5" decimals="0" unitRef="usd">696672</nmtc:BrokerWarrantsIssuedInConnectionWithConvertibleNotes>
    <nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease contextRef="c0" decimals="0" unitRef="usd">73118</nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease>
    <nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease contextRef="c5" decimals="0" unitRef="usd">335119</nmtc:OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease>
    <nmtc:ValueOfPayrollProtectionProgramLoanForgiveness contextRef="c0" decimals="0" unitRef="usd">83333</nmtc:ValueOfPayrollProtectionProgramLoanForgiveness>
    <nmtc:UnpaidDeferredOfferingCosts contextRef="c0" decimals="0" unitRef="usd">67954</nmtc:UnpaidDeferredOfferingCosts>
    <nmtc:UnpaidPurchasesOfPropertyAndEquipment contextRef="c0" decimals="0" unitRef="usd">48651</nmtc:UnpaidPurchasesOfPropertyAndEquipment>
    <nmtc:UnpaidPurchasesOfPropertyAndEquipment contextRef="c5" decimals="0" unitRef="usd">16872</nmtc:UnpaidPurchasesOfPropertyAndEquipment>
    <us-gaap:NatureOfOperations contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 - Organization and Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;NeuroOne
Medical Technologies Corporation (the &#x201c;Company&#x201d; or &#x201c;NeuroOne&#x201d;), a Delaware corporation, is an early-stage medical
technology company developing comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions
to diagnose and treat patients with epilepsy, Parkinson&#x2019;s disease, dystonia, essential tremors, chronic pain due to failed back
surgeries and other related neurological disorders.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
received 510(k) clearance from the FDA for its Evo cortical technology in November 2019, and in September 2021 received 510(k) clearance
from the FDA for its Evo sEEG electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation
equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. To date, the Company
has had limited commercial sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company&#x2019;s
common stock commenced trading on The Nasdaq Capital Market on May 26, 2021 under the ticker symbol &#x201c;NMTC.&#x201d; Previously, the
Company&#x2019;s common stock was traded on the OTC Markets quotation system on the OTCQB.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
is based in Eden Prairie, Minnesota.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On March
11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#x201c;COVID-19&#x201d;) as a global pandemic. As
a result of the COVID-19 pandemic, the Company has experienced, and will likely continue to experience, delays and disruptions in its
pre-clinical and clinical trials, as well as interruptions in its manufacturing, supply chain, shipping, and research and development
operations. In April 2020, given the impact of COVID-19 on the Company and in connection with the enactment of the CARES Act, the Company
applied for and received loan funding of $83,333&#160;under the Paycheck Protection Program, which was forgiven by the U.S. Small Business
Administration in June 2021. &lt;/span&gt;The development of the Company&#x2019;s technology was delayed in fiscal year 2021 due to interruptions
in global manufacturing and shipping as a result of the COVID-19 pandemic. Additionally, the Company&#x2019;s own staff has been impacted
by infections and mandatory quarantines. Further testing and clinical trials, &lt;span&gt;manufacturing, component
supply, shipping and research and development operations&lt;/span&gt; may be further impacted by the continuing effects of COVID-19.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The extent
to which the COVID-19 pandemic may further impact the Company&#x2019;s business will depend on future developments, which are highly uncertain
and cannot be predicted with confidence, such as the effect of the pandemic on its suppliers and distributors and the global supply chain,
the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business
disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The COVID-19 pandemic
may also impact the Company&#x2019;s business because of employee illness, school closures, and other community response measures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Although
the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may
have a material adverse effect on the Company&#x2019;s results of future operations, financial position, and liquidity for fiscal year
2022 and beyond.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <nmtc:ProceedsFromPayrollProtectionProgramLoan contextRef="c22" decimals="0" unitRef="usd">83333</nmtc:ProceedsFromPayrollProtectionProgramLoan>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 - Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The accompanying
financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses
since inception, negative cash flows from operations, and an accumulated deficit of $40.8 million as of September 30, 2021. To date,
the Company&#x2019;s revenues have not been sufficient to cover its full operating costs, and as such, has been dependent on funding operations
through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without
raising additional funds and such actions are not solely within the control of the Company. These factors raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome
of this condition. If the Company is unable to raise additional funds, or the Company&#x2019;s anticipated operating results are not achieved,
management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the
Company&#x2019;s operations. The Company intends to fund ongoing activities by utilizing its current cash on hand, from product and collaborations
revenue and by raising additional capital through equity or debt financings. If management is unable to obtain the necessary capital,
it may have a material adverse effect on the operations of the Company and the development of its technology, or the Company may have
to cease operations altogether.&#160; There was also substantial doubt about the Company&#x2019;s ability to continue as a going concern
for the financial statements as of and for the year ended September 30, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CumulativeEarningsDeficit contextRef="c3" decimals="-5" unitRef="usd">40800000</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 - Summary of Significant Accounting
Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared in accordance with accounting standards generally accepted in the United States of America.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2019, the Company merged its wholly-owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the
Company&#x2019;s wholly-owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company
did not have any remaining entities that required consolidation for financial statement reporting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are components of an enterprise
for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker
in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive
Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment,
which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording,
monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On March
11, 2021, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) approved a one-for-three reverse stock split of the Company&#x2019;s
issued and outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;) effective end-of-day March 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;All issued
and outstanding common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this
Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of
common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#x2019;s equity
incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result
of the Reverse Stock Split was rounded up to the next whole share. The authorized shares and par value of the common stock and preferred
stock were not adjusted as a result of the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Management&#x2019;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes, and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to a concentration of credit risk consist of cash. The Company&#x2019;s cash is held by one financial institution in the United
States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since
inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2021,
the Company had $6.7 million of deposits in excess of federally insured amounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
entered into a development and distribution agreement which has current and future revenue recognition implications. See &#x201c;Note 7
&#x2013; Zimmer Development Agreement.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Product
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Revenues
from product sales are recognized when control of the promised goods or services is transferred to the Company&#x2019;s customers, in an
amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception
of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations.
The Company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Cost
of Product Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Cost of
product revenue consists of the manufacturing and materials costs incurred by the Company&#x2019;s third-party contract manufacturer in
connection with the Company&#x2019;s strip and grid cortical electrodes (the &#x201c;Strip/Grid Products&#x201d;) and outside supplier materials
costs in connection with the &lt;/span&gt;electrode cable assembly products (&#x201c;Electrode Cable Assembly Products&#x201d;)&lt;span&gt;.
In addition, cost of product revenue includes royalty fees incurred in connection with the Company&#x2019;s license agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Collaborations
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In determining
the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards
Codification (&#x201c;ASC&#x201d;) Topic 606. Performance obligations may include license rights, development services, and services associated
with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required
under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the
Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;As part
of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling
price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities
of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated
relative standalone selling prices of the promised goods or service underlying each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Licenses
of intellectual property&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to
the license when the license is transferred to the customer, and the customer can use and benefit from the license. For licenses that
are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress
each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Milestone
payments&lt;/i&gt;: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are
considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators,
are not considered probable of being achieved until those approvals are received. When the Company&#x2019;s assessment of probability of
achievement changes and variable consideration becomes probable, any additional estimated consideration is allocated to each performance
obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation
and recorded in license, collaboration, and other revenues based upon when the customer obtains control of each element.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Royalties&lt;/i&gt;:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur,
or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounting for fair value
measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring
basis adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets
for identical assets or liabilities accessible to the Company at the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 2 Inputs: Other than quoted prices included in Level
1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset
or liability.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability
used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the fair values
of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values
because of the short-term nature of these assets or liabilities. The fair value of the convertible notes while outstanding were based
on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted
at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for
similar instruments and are based on Level 3 inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no transfers between fair value hierarchy
levels during the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no financial instruments measured on
a recurring basis outstanding as of September 30, 2021. The fair value of financial instruments measured on a recurring basis was as follows
as of September 30, 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides a roll-forward of
the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level 3 inputs for the years ended September 30 as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,005,232&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to convertible promissory notes upon issuance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,974,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to note extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,017,847&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,180,470&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(804,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Intellectual
Property&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has entered into&#160;two&#160;licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful
life of the acquired technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Property
and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful
lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to&#160;seven
years&#160;and&#160;three years&#160;for software. Tangible assets acquired for research and development activities and that have alternative
use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate,
changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party
software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and
an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly
to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company evaluates its long-lived
assets, which consist of licensed intellectual property, property and equipment and right of use assets for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability
of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying
value and the fair value of the impaired asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Allowances
for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability
of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of
the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances
are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual
write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost (using the first-in, first-out &#x201c;FIFO&#x201d; method) or net realizable value. The Company calculates
inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected
useful lives, and estimated future demand of the products and spare parts. The Company&#x2019;s inventory is currently comprised of cEEG
strip/grid and electrode cable assembly finished good product. The Strip/Grid Products are produced by a third-party contract manufacturer
and the Electrode Cable Assembly Products are obtained from outside suppliers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Research
and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as
other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather
than when payment is made, in accordance with ASC 730,&#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Selling,
General and Administrative&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Selling,
general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters,
and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of cEEG strip/grid
and electrode cable assembly products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;For the
Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred
tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the Company, basic loss per share of common
stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted earnings or loss per share of common stock
is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional
shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#x2019;s convertible notes, warrants, stock
options and restricted stock units, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible
promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share
because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potential common shares were not considered in the computation
of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,503,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,390,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,122,560&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Unissued vested restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In June
2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &#x201c;&lt;i&gt;Financial Instruments &#x2013; Credit Losses&#x201d;&lt;/i&gt;.
The ASU sets forth a &#x201c;current expected credit loss&#x201d; (&#x201c;CECL&#x201d;) model which requires the Company to measure all expected
credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued
the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of
the adoption of this ASU on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In August
2018, the FASB issued ASU 2018-13,&#160;&lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement&#160;&lt;/i&gt;(ASU 2018-13)&lt;i&gt;.&lt;/i&gt;&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Removals: the amount
of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels;
and the valuation processes for Level 3 fair value measurements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Modifications: for investments
in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#x2019;s
assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty
in measurement as of the reporting date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Additions: the changes
in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held
at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair
value measurements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;This guidance
is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop
Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only
the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively
to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or
modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
adopted the new guidance on October 1, 2020 and it did not have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income
taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting
for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption
of this new guidance will have a material impact on the Company&#x2019;s financial statements and plans to adopt this guidance on a prospective
basis for the provisions applicable to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In August
2020, FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,
which, among other things, provides guidance on how to account for contracts on an entity&#x2019;s own equity. This ASU eliminates the
beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition,
this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted
earnings per share computation. The amendments in this ASU are effective for smaller reporting companies as defined by the SEC for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying financial statements have been
prepared in accordance with accounting standards generally accepted in the United States of America.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2019, the Company merged its wholly-owned subsidiary, NeuroOne Inc., into NeuroOne Medical Technologies Corporation. The merger of the
Company&#x2019;s wholly-owned subsidiary did not have a financial impact to the periods presented. Upon close of the merger, the Company
did not have any remaining entities that required consolidation for financial statement reporting purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are components of an enterprise
for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker
in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive
Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment,
which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording,
monitoring, ablation, and brain stimulation solutions. Accordingly, the Company has a single reporting segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <nmtc:ReverseStockSplitPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On March
11, 2021, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) approved a one-for-three reverse stock split of the Company&#x2019;s
issued and outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;) effective end-of-day March 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;All issued
and outstanding common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect this
Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of
common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#x2019;s equity
incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result
of the Reverse Stock Split was rounded up to the next whole share. The authorized shares and par value of the common stock and preferred
stock were not adjusted as a result of the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</nmtc:ReverseStockSplitPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Management&#x2019;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes, and disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to a concentration of credit risk consist of cash. The Company&#x2019;s cash is held by one financial institution in the United
States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since
inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2021,
the Company had $6.7 million of deposits in excess of federally insured amounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <nmtc:DepositsExcessOfFederallyInsured contextRef="c3" decimals="-5" unitRef="usd">6700000</nmtc:DepositsExcessOfFederallyInsured>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
entered into a development and distribution agreement which has current and future revenue recognition implications. See &#x201c;Note 7
&#x2013; Zimmer Development Agreement.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Product
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Revenues
from product sales are recognized when control of the promised goods or services is transferred to the Company&#x2019;s customers, in an
amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. At the inception
of each customer contract, performance obligations are identified and the total transaction price is allocated to the performance obligations.
The Company commenced commercial sales of cEEG strip/grid and electrode cable assembly products in the first quarter of fiscal year 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Cost
of Product Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Cost of
product revenue consists of the manufacturing and materials costs incurred by the Company&#x2019;s third-party contract manufacturer in
connection with the Company&#x2019;s strip and grid cortical electrodes (the &#x201c;Strip/Grid Products&#x201d;) and outside supplier materials
costs in connection with the &lt;/span&gt;electrode cable assembly products (&#x201c;Electrode Cable Assembly Products&#x201d;)&lt;span&gt;.
In addition, cost of product revenue includes royalty fees incurred in connection with the Company&#x2019;s license agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Collaborations
Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In determining
the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following
steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based
on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;A performance
obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Account Standards
Codification (&#x201c;ASC&#x201d;) Topic 606. Performance obligations may include license rights, development services, and services associated
with regulatory submission and approval processes. Significant management judgment is required to determine the level of effort required
under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the
Company cannot reasonably estimate when its performance obligations are either completed or become inconsequential, then revenue recognition
is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance
using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;As part
of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling
price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling
price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities
of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the estimated
relative standalone selling prices of the promised goods or service underlying each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Licenses
of intellectual property&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other
performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to
the license when the license is transferred to the customer, and the customer can use and benefit from the license. For licenses that
are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress
each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Milestone
payments&lt;/i&gt;: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are
considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission)
is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators,
are not considered probable of being achieved until those approvals are received. When the Company&#x2019;s assessment of probability of
achievement changes and variable consideration becomes probable, any additional estimated consideration is allocated to each performance
obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation
and recorded in license, collaboration, and other revenues based upon when the customer obtains control of each element.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;i&gt;Royalties&lt;/i&gt;:
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed
to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur,
or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounting for fair value
measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring
basis adheres to the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level
3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets
for identical assets or liabilities accessible to the Company at the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 2 Inputs: Other than quoted prices included in Level
1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset
or liability.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability
used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at the measurement date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the fair values
of cash, accounts receivable, inventory, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values
because of the short-term nature of these assets or liabilities. The fair value of the convertible notes while outstanding were based
on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted
at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for
similar instruments and are based on Level 3 inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no transfers between fair value hierarchy
levels during the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There were no financial instruments measured on
a recurring basis outstanding as of September 30, 2021. The fair value of financial instruments measured on a recurring basis was as follows
as of September 30, 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides a roll-forward of
the convertible notes, warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable
level 3 inputs for the years ended September 30 as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,005,232&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to convertible promissory notes upon issuance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,974,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to note extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,017,847&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,180,470&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(804,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c4" decimals="0" unitRef="usd">1007206</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c28" decimals="0" unitRef="usd">1007206</us-gaap:ShortTermBorrowings>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c4" decimals="0" unitRef="usd">1007206</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c28" decimals="0" unitRef="usd">1007206</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,005,232&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,974&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of beginning of period &#x2013; September 30, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to convertible promissory notes upon issuance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,974,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Fair value attributed to note extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,017,847&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Conversion of convertible promissory notes to common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,180,470&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in fair value including accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(804,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Balance as of end of period &#x2013; September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="c4" decimals="0" unitRef="usd">1007206</us-gaap:ConvertibleNotesPayable>
    <nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock contextRef="c0" decimals="0" unitRef="usd">-1005232</nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock>
    <nmtc:ChangeInFairValueIncludingAccruedInterest contextRef="c0" decimals="0" unitRef="usd">-1974</nmtc:ChangeInFairValueIncludingAccruedInterest>
    <nmtc:FairValueAttributedToConvertibleNotesUponIssuance contextRef="c5" decimals="0" unitRef="usd">13974358</nmtc:FairValueAttributedToConvertibleNotesUponIssuance>
    <nmtc:FairValueAttributedToNoteExtinguishment contextRef="c5" decimals="0" unitRef="usd">2017847</nmtc:FairValueAttributedToNoteExtinguishment>
    <nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock contextRef="c5" decimals="0" unitRef="usd">-14180470</nmtc:ConversionOfConvertiblePromissoryNotesToCommonStock>
    <nmtc:ChangeInFairValueIncludingAccruedInterest contextRef="c5" decimals="0" unitRef="usd">-804529</nmtc:ChangeInFairValueIncludingAccruedInterest>
    <us-gaap:ConvertibleNotesPayable contextRef="c4" decimals="0" unitRef="usd">1007206</us-gaap:ConvertibleNotesPayable>
    <nmtc:IntellectualPropertyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Intellectual
Property&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has entered into&#160;two&#160;licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful
life of the acquired technology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</nmtc:IntellectualPropertyPolicyTextBlock>
    <nmtc:NumberOfLicencingAgreements contextRef="c0" decimals="0" unitRef="pure">2</nmtc:NumberOfLicencingAgreements>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Property
and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful
lives of the assets using the straight-line method. The estimated useful life for equipment and furniture ranges from three to&#160;seven
years&#160;and&#160;three years&#160;for software. Tangible assets acquired for research and development activities and that have alternative
use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and, when appropriate,
changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party
software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and
an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly
to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c24">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c25">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c23">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company evaluates its long-lived
assets, which consist of licensed intellectual property, property and equipment and right of use assets for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability
of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying
value and the fair value of the impaired asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Allowances
for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
records a provision for doubtful accounts, when appropriate, based on historical experience and a detailed assessment of the collectability
of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of
the accounts receivable, its historical write-offs, the credit worthiness of each customer, and general economic conditions. Account balances
are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual
write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Inventories&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Inventories
are stated at the lower of cost (using the first-in, first-out &#x201c;FIFO&#x201d; method) or net realizable value. The Company calculates
inventory valuation adjustments for excess and obsolete inventory, when appropriate, based on current inventory levels, movement, expected
useful lives, and estimated future demand of the products and spare parts. The Company&#x2019;s inventory is currently comprised of cEEG
strip/grid and electrode cable assembly finished good product. The Strip/Grid Products are produced by a third-party contract manufacturer
and the Electrode Cable Assembly Products are obtained from outside suppliers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Research
and development costs are charged to expense as incurred. Research and development expenses may include costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as
other contracted services, license fees, and other external costs. Non-refundable advance payments for goods and services that will be
used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather
than when payment is made, in accordance with ASC 730,&#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Selling,
General and Administrative&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Selling,
general and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate matters,
intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development, financial matters,
and beginning in the first quarter of fiscal year 2021, sales and marketing in connection with the commercial sale of cEEG strip/grid
and electrode cable assembly products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;For the
Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred
tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the Company, basic loss per share of common
stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted earnings or loss per share of common stock
is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional
shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#x2019;s convertible notes, warrants, stock
options and restricted stock units, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed
utilizing the treasury method for the warrants, stock options and restricted stock units. Diluted earnings with respect to the convertible
promissory utilize the if-converted method. No incremental common stock equivalents were included in calculating diluted loss per share
because such inclusion would be anti-dilutive given the net loss reported for the years ended September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following potential common shares were not considered in the computation
of diluted net loss per share as their effect would have been anti-dilutive for the years ended September 30:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,503,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,390,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,122,560&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Unissued vested restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,503,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,390,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,122,560&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Unissued vested restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Convertible notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <nmtc:Warrantshares contextRef="c0" decimals="INF" unitRef="shares">7503808</nmtc:Warrantshares>
    <nmtc:Warrantshares contextRef="c5" decimals="INF" unitRef="shares">3390320</nmtc:Warrantshares>
    <nmtc:StockOptions contextRef="c0" decimals="INF" unitRef="shares">1122560</nmtc:StockOptions>
    <nmtc:StockOptions contextRef="c5" decimals="INF" unitRef="shares">492842</nmtc:StockOptions>
    <nmtc:RestrictedStockUnit contextRef="c0" decimals="INF" unitRef="shares">11384</nmtc:RestrictedStockUnit>
    <nmtc:RestrictedStockUnit contextRef="c5" decimals="INF" unitRef="shares">26698</nmtc:RestrictedStockUnit>
    <nmtc:UnissuedVestedRestrictedStockUnits contextRef="c0" decimals="INF" unitRef="shares">1148</nmtc:UnissuedVestedRestrictedStockUnits>
    <nmtc:UnissuedVestedRestrictedStockUnits contextRef="c5" decimals="INF" unitRef="shares">2063</nmtc:UnissuedVestedRestrictedStockUnits>
    <nmtc:ConvertibleNotes contextRef="c5" decimals="INF" unitRef="shares">277618</nmtc:ConvertibleNotes>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In June
2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &#x201c;&lt;i&gt;Financial Instruments &#x2013; Credit Losses&#x201d;&lt;/i&gt;.
The ASU sets forth a &#x201c;current expected credit loss&#x201d; (&#x201c;CECL&#x201d;) model which requires the Company to measure all expected
credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. Recently, the FASB issued
the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of
the adoption of this ASU on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In August
2018, the FASB issued ASU 2018-13,&#160;&lt;i&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements
for Fair Value Measurement&#160;&lt;/i&gt;(ASU 2018-13)&lt;i&gt;.&lt;/i&gt;&#160;The new guidance modifies the disclosure requirements in Topic 820 as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Removals: the amount
of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels;
and the valuation processes for Level 3 fair value measurements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Modifications: for investments
in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee&#x2019;s
assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced
the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty
in measurement as of the reporting date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Additions: the changes
in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held
at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair
value measurements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;This guidance
is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop
Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only
the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively
to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or
modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company
adopted the new guidance on October 1, 2020 and it did not have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) which amends the existing guidance relating to the accounting for income
taxes. This ASU is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting
for income taxes and to improve the consistent application of GAAP for other areas of accounting for income taxes by clarifying and amending
existing guidance. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption
of this new guidance will have a material impact on the Company&#x2019;s financial statements and plans to adopt this guidance on a prospective
basis for the provisions applicable to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In August
2020, FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,
which, among other things, provides guidance on how to account for contracts on an entity&#x2019;s own equity. This ASU eliminates the
beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts
in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition,
this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted
earnings per share computation. The amendments in this ASU are effective for smaller reporting companies as defined by the SEC for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier
than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;WARF
License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&#x201c;WARF&#x201d;) for
WARF&#x2019;s neural probe array and thin film micro electrode technology (the &#x201c;WARF Agreement&#x201d;). The Company entered into
an Amended and Restated Exclusive Start-up Company License Agreement (the &#x201c;WARF License&#x201d;) with WARF on January 21, 2020, which
amended and restated in full the prior license agreement between WARF and NeuroOne, LLC, a predecessor of the Company, dated October 1,
2014, as amended on February 22, 2017, March 30, 2019 and September 18, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The WARF
License grants to the Company an exclusive license to &lt;/span&gt;make, use and sell, in the United States only, products that employ certain
licensed patents for a neural probe array or thin-film micro electrode array and method. We have agreed to pay WARF a royalty equal to
a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000 for 2020,
$100,000 for 2021 and $150,000 for 2022 and each calendar year thereafter that the WARF License is in effect. The minimum annual royalty
payment for calendar year 2020 in the amount of $50,000 was paid in January 2021. If we or any of our sublicensees contest the validity
of any licensed patent, the royalty rate will be doubled during the pendency of such contest and, if the contested patent is found to
be valid and would be infringed by us if not for the WARF License, the royalty rate will be tripled for the remaining term of the WARF
License.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;WARF may terminate the WARF License on 30 days&#x2019;
written notice if we default on the payments of amounts due to WARF or fail to timely submit development reports, actively pursue our
development plan or breach any other covenant in the WARF License and fail to remedy such default in 90 days or in the event of certain
bankruptcy events involving us. WARF may also terminate the WARF License (i) on 90 days&#x2019; notice if we had failed to have commercial
sales of one or more FDA-approved products under the WARF License by June 30, 2021 or (ii) if, after royalties earned on sales begin to
be paid, such earned royalties cease for more than four calendar quarters. The first commercial sale occurred on December 7, 2020, prior
to the June 30, 2021 deadline.&lt;span&gt;&#160;&lt;/span&gt;The WARF License otherwise expires by its terms on the
date that no valid claims on the patents licensed thereunder remain. We expect the latest expiration of a licensed patent to occur in
2030.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;Mayo
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&#x201c;Mayo&#x201d;) related
to certain intellectual property and development services for thin film micro electrode technology (&#x201c;Mayo Agreement&#x201d;). If
the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales
of products of the licensed technology through the term of the Mayo Agreement, set to expire&#160;May 25, 2037. As of September 30, 2021,
$3,894 in royalty fees were incurred given the commencement of commercial sales and were reflected as a component of cost of product revenue
during the year ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;PMT
Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company is subject to litigation
and claims arising in the ordinary course of business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 29, 2018, the Company was served with
a complaint filed by PMT Corporation (&#x201c;PMT&#x201d;), the former employer of Mark Christianson, a current Company employee, and Wade
Fredrickson, a now former Company employee. The complaint added the Company, NeuroOne, Inc. and Mr. Christianson to its existing lawsuit
against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. In the lawsuit, PMT claims that Mr. Fredrickson
and Mr. Christianson, by virtue of their work for the Company and their prior work during employment with PMT, breached their non-competition,
non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair
competition, engaged in a civil conspiracy, tortiously interfered with PMT&#x2019;s contracts and prospective economic advantage, and breached
a covenant of good faith and fair dealing. The complaint purported to attach Mr. Fredrickson&#x2019;s noncompete agreement as Exhibit A.
Against Mr. Fredrickson, PMT also alleged that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations,
misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the
Company and NeuroOne, Inc., PMT alleged that the Company and NeuroOne, Inc. were unjustly enriched and engaged in unfair competition.
PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory
damages, equitable relief, punitive damages, attorneys&#x2019; fees, costs and interest.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 18, 2018, Mr. Christianson, the Company
and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal stated that:
the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade
Secrets Act preempts plaintiff&#x2019;s claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state
a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive
trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition.
On January 7, 2019, the judge granted the motion for dismissal with respect to PMT&#x2019;s claim for breach of the duty of good faith
and fair dealing, and denied the motion for dismissal with respect to the other claims presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2019, PMT served the Company, NeuroOne,
Inc. and Christianson with a proposed Second Amended Complaint, which included new claims against the Company and NeuroOne, Inc for tortious
interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne
Inc. and Christianson. On June 28, 2019, the Company presented evidence indicating that PMT had participated in a fraud on the Court and
sought an Order that PMT had waived the attorney client privilege.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 16, 2019, the defendants served PMT with
a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal
of the case and an award of attorneys&#x2019; fees. The Company, NeuroOne Inc and Mr. Christianson further moved for summary judgment on
all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process. Following hearings
on the dispositive motions and defendants&#x2019; sanctions motion, the district court granted the Company&#x2019;s motion for sanctions
on April 29, 2020. Additionally, the district court granted the Company&#x2019;s motion for summary judgment in part with respect to the
counts for Christianson&#x2019;s breach of non-confidentiality agreement, and denied the Company&#x2019;s motion for summary judgment on
all other counts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 24, 2020, defendants moved the Court
to amend their counterclaims for abuse of process against PMT to add a claim for punitive damages with respect to its conduct pertaining
to the Fredrickson noncompete. On October 12, 2020 the Court awarded NeuroOne, Inc. $185,000&#160;in Rule 11 sanctions and Fredrickson
$145,000&#160;in Rule 11 sanctions with respect to PMT&#x2019;s misconduct relating to the Fredrickson noncompete. PMT and its former litigation
counsel, Barnes &amp;amp; Thornburg, were jointly and severally liable for these awards, which were paid on December 11, 2020 and have been
recognized in other income in the statements of operations. The Court granted NeuroOne, Inc.&#x2019;s motion to amend to permit its assertion
of the right to assert a punitive damages claim against PMT associated with fighting the allegations relating to the Fredrickson noncompete.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2021 PMT moved for summary judgment
on defendants&#x2019; claims for abuse of process and punitive damages, and on August 5, 2021, the district court granted PMT&#x2019;s motion
to dismiss the abuse of process and punitive damage claims.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Trial has been postponed from December 2021 to August of 2022. The
Company intends to continue to defend itself vigorously and to continue to aggressively prosecute its affirmative counterclaim against
PMT. The outcome of any claim against the Company by PMT was not estimable as of the issuance of these financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Facility Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Headquarters Lease&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 7, 2019, the Company entered into a
non-cancellable lease agreement (the &#x201c;Lease&#x201d;) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together,
the &#x201c;Landlord&#x201d;) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie,
Minnesota (the &#x201c;Premises&#x201d;). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending
65 months after such date, unless terminated earlier (the &#x201c;Term&#x201d;). The initial base rent for the Premises is $6,410 per month
for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default
under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will
pay its pro rata share of the Landlord&#x2019;s annual operating expenses associated with the premises, calculated as set forth in the
Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Los Gatos Lease&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 1, 2021, the Company entered into a non-cancellable
facility lease (the &#x201c;New Lease&#x201d;), pursuant to which the Company agreed to rent office space for its research and development
operations located at 718 University Avenue, Suite #111, Los Gatos, California. The term of the New Lease is eighteen months. The facility
space under the New Lease is approximately 1,162 square feet. The Company took possession of the office space on July 2, 2021. The initial
monthly rent under the New Lease is approximately $4,241.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;San Jose Lease&lt;/span&gt;:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 30, 2020, the Company entered into
a non-cancellable lease agreement for short term office space in San Jose, California (the &#x201c;San Jose Lease&#x201d;) for a three month
initial term. After March 31, 2021, the San Jose Lease was cancellable upon a 30-day notice to the landlord. The Company took possession
of the office space on January 1, 2021 and the San Jose Lease was terminated upon the commencement of the New Lease discussed above. The
base rent under the San Jose Lease was $504 per month.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended September 30, 2021 and
2020, rent expense associated with the facility leases amounted to $136,826 and $103,189, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Supplemental cash flow information related to
the operating lease was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&lt;br/&gt; Year Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;70,897&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;38,462&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,118&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;335,119&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Supplemental balance sheet information related
to the operating lease was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;288,948&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;282,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315,673&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;312,176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Maturity of the lease liability was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Calendar Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2021 (period from October 1, 2021 to December 31, 2021)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;351,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in"&gt;Short-term portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(112,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Long-term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;202,895&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nmtc:RoyaltyMinimumPaymentsYearOne contextRef="c4" decimals="0" unitRef="usd">50000</nmtc:RoyaltyMinimumPaymentsYearOne>
    <nmtc:RoyaltyMinimumPaymentsYearTwo contextRef="c3" decimals="0" unitRef="usd">100000</nmtc:RoyaltyMinimumPaymentsYearTwo>
    <nmtc:RoyaltyMinimumPaymentsYearThree contextRef="c29" decimals="0" unitRef="usd">150000</nmtc:RoyaltyMinimumPaymentsYearThree>
    <us-gaap:RoyaltyExpense contextRef="c30" decimals="0" unitRef="usd">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c31" decimals="0" unitRef="usd">3894</us-gaap:RoyaltyExpense>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c32" decimals="0" unitRef="usd">185000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c33" decimals="0" unitRef="usd">145000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <nmtc:LeaseAgreementDescription contextRef="c0">On October 7, 2019, the Company entered into a
non-cancellable lease agreement (the &#x201c;Lease&#x201d;) with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together,
the &#x201c;Landlord&#x201d;) pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie,
Minnesota (the &#x201c;Premises&#x201d;). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending
65 months after such date, unless terminated earlier (the &#x201c;Term&#x201d;). The initial base rent for the Premises is $6,410 per month
for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default
under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will
pay its pro rata share of the Landlord&#x2019;s annual operating expenses associated with the premises, calculated as set forth in the
Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.&#160;</nmtc:LeaseAgreementDescription>
    <nmtc:LeaseSpace contextRef="c34" decimals="0" unitRef="sqm">1162</nmtc:LeaseSpace>
    <nmtc:LeaseRentalExpense contextRef="c35" decimals="0" unitRef="usd">4241</nmtc:LeaseRentalExpense>
    <nmtc:MonthlyLeaseRent contextRef="c0" decimals="0" unitRef="usd">504</nmtc:MonthlyLeaseRent>
    <nmtc:RentExpense contextRef="c0" decimals="0" unitRef="usd">136826</nmtc:RentExpense>
    <nmtc:RentExpense contextRef="c5" decimals="0" unitRef="usd">103189</nmtc:RentExpense>
    <nmtc:SupplementalCashFlowTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&lt;br/&gt; Year Ended&lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Cash paid for amounts included in the measurement of lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;70,897&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;38,462&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,118&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;335,119&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</nmtc:SupplementalCashFlowTableTextBlock>
    <nmtc:OperatingCashFlowsFromOperatingLeases contextRef="c0" decimals="0" unitRef="usd">70897</nmtc:OperatingCashFlowsFromOperatingLeases>
    <nmtc:OperatingCashFlowsFromOperatingLeases contextRef="c5" decimals="0" unitRef="usd">38462</nmtc:OperatingCashFlowsFromOperatingLeases>
    <nmtc:OperatingLeases contextRef="c0" decimals="0" unitRef="usd">73118</nmtc:OperatingLeases>
    <nmtc:OperatingLeases contextRef="c5" decimals="0" unitRef="usd">335119</nmtc:OperatingLeases>
    <nmtc:SupplementalBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;288,948&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;282,211&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;315,673&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;312,176&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</nmtc:SupplementalBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">288948</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" unitRef="usd">282211</us-gaap:OperatingLeaseRightOfUseAsset>
    <nmtc:LeaseLiability contextRef="c3" decimals="0" unitRef="usd">315673</nmtc:LeaseLiability>
    <nmtc:LeaseLiability contextRef="c4" decimals="0" unitRef="usd">312176</nmtc:LeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" unitRef="pure">0.067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="3" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Calendar Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2021 (period from October 1, 2021 to December 31, 2021)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,435&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,227&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;351,606&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in"&gt;Short-term portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(112,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0.125in"&gt;Long-term portion&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;202,895&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <nmtc:LesseeOperatingLeaseLiabilityPaymentsDueOneYear contextRef="c3" decimals="0" unitRef="usd">32435</nmtc:LesseeOperatingLeaseLiabilityPaymentsDueOneYear>
    <nmtc:LesseeOperatingLeaseLiabilityPaymentsDueTwoYear contextRef="c3" decimals="0" unitRef="usd">131220</nmtc:LesseeOperatingLeaseLiabilityPaymentsDueTwoYear>
    <nmtc:LesseeOperatingLeaseLiabilityPaymentsDueThreeYear contextRef="c3" decimals="0" unitRef="usd">82333</nmtc:LesseeOperatingLeaseLiabilityPaymentsDueThreeYear>
    <nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFourYear contextRef="c3" decimals="0" unitRef="usd">84391</nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFourYear>
    <nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFiveYear contextRef="c3" decimals="0" unitRef="usd">21227</nmtc:LesseeOperatingLeaseLiabilityPaymentsDueFiveYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" unitRef="usd">351606</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <nmtc:ImputedInterest contextRef="c3" decimals="0" unitRef="usd">-35933</nmtc:ImputedInterest>
    <nmtc:LeaseLiabilityNet contextRef="c3" decimals="0" unitRef="usd">315673</nmtc:LeaseLiabilityNet>
    <us-gaap:ShortTermLeaseCommitmentAmount contextRef="c3" decimals="0" unitRef="usd">112778</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c3" decimals="0" unitRef="usd">202895</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <nmtc:SupplementalBalanceSheetInformationTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;Supplemental
Balance Sheet Information&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Prepaid and Other Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Prepaid and other assets consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;151,109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118,010&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;244,043&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,611&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Intangibles&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets roll forward is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Useful Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;12-13 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,838&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;156,523&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,316&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;134,207&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company anticipates amortization expense of
approximately $21,000 per year for fiscal year 2022 through 2026 based upon the two current license agreements.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment held for use by category
are presented in the following table:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Equipment and furniture&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;311,486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,895&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,895&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(90,052&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31,620&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;223,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $58,432 and $25,294 for
the years ended September 30, 2021 and 2020, respectively.&lt;/p&gt;</nmtc:SupplementalBalanceSheetInformationTextBlock>
    <pf0:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;151,109&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118,010&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;244,043&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;118,611&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</pf0:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <nmtc:PrepaidExpenses contextRef="c3" decimals="0" unitRef="usd">151109</nmtc:PrepaidExpenses>
    <nmtc:PrepaidExpenses contextRef="c4" decimals="0" unitRef="usd">118010</nmtc:PrepaidExpenses>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" unitRef="usd">92934</us-gaap:DeferredOfferingCosts>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="0" unitRef="usd">601</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="0" unitRef="usd">244043</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c4" decimals="0" unitRef="usd">118611</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Useful Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;12-13 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;178,838&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,315&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;156,523&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less: amortization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,316&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Net Intangibles, September 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;134,207&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <nmtc:NetIntangiblesUsefulLives contextRef="c36">P12Y</nmtc:NetIntangiblesUsefulLives>
    <nmtc:NetIntangiblesUsefulLives contextRef="c37">P13Y</nmtc:NetIntangiblesUsefulLives>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c9" decimals="0" unitRef="usd">178838</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">22315</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="0" unitRef="usd">156523</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">22316</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">134207</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c5" decimals="0" unitRef="usd">21000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Equipment and furniture&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;311,486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,895&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,895&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;313,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(90,052&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(31,620&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;223,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;166,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FurnitureAndFixturesGross contextRef="c3" decimals="0" unitRef="usd">311486</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="c4" decimals="0" unitRef="usd">195756</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c3" decimals="0" unitRef="usd">1895</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="c4" decimals="0" unitRef="usd">1895</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">313381</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">197651</us-gaap:PropertyPlantAndEquipmentGross>
    <nmtc:LessAccumulatedDepreciations contextRef="c3" decimals="0" unitRef="usd">-90052</nmtc:LessAccumulatedDepreciations>
    <nmtc:LessAccumulatedDepreciations contextRef="c4" decimals="0" unitRef="usd">-31620</nmtc:LessAccumulatedDepreciations>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">223329</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">166031</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">58432</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">25294</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 - Accrued Expenses and Other Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued expenses consisted of the following at
September 30:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;376,236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;238,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease liability, short term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Royalty Fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;83,152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;166,302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;644,249&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;512,762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The &#x201c;other&#x201d; category is primarily
comprised of board fees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Paycheck Protection Program&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The CARES Act, signed into law in March 2020,
established the Paycheck Protection Program (&#x201c;PPP&#x201d;).&#160;The PPP authorizes over $600 billion in forgivable loans to small
businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility
costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments
may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term
liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the
accompanying statements of operations. Interest was nominal during the years ended September 30, 2021 and 2020.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued payroll&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;376,236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;238,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease liability, short term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Royalty Fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;83,152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;166,302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;644,249&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;512,762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nmtc:AccruedPayroll contextRef="c3" decimals="0" unitRef="usd">376236</nmtc:AccruedPayroll>
    <nmtc:AccruedPayroll contextRef="c4" decimals="0" unitRef="usd">238212</nmtc:AccruedPayroll>
    <nmtc:LeaseLiabilityShortterms contextRef="c3" decimals="0" unitRef="usd">112778</nmtc:LeaseLiabilityShortterms>
    <nmtc:LeaseLiabilityShortterms contextRef="c4" decimals="0" unitRef="usd">57848</nmtc:LeaseLiabilityShortterms>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c5" decimals="0" unitRef="usd">50400</us-gaap:PaymentsOfStockIssuanceCosts>
    <nmtc:RoyaltyPayments contextRef="c3" decimals="0" unitRef="usd">72083</nmtc:RoyaltyPayments>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">83152</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">166302</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">644249</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" unitRef="usd">512762</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <nmtc:PaycheckProtectionProgramDescription contextRef="c0">The PPP authorizes over $600 billion in forgivable loans to small
businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility
costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments
may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term
liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the
accompanying statements of operations. Interest was nominal during the years ended September 30, 2021 and 2020.</nmtc:PaycheckProtectionProgramDescription>
    <nmtc:ZimmerDevelopmentAgreementTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; Zimmer Development Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;On July
20, 2020, the Company entered into an exclusive development and distribution agreement (the &#x201c;Development Agreement&#x201d;) with
Zimmer, Inc. (&#x201c;Zimmer&#x201d;), pursuant to which the Company granted Zimmer exclusive global rights to distribute the Strip/Grid
Products and electrode cable assembly products (the &#x201c;Electrode Cable Assembly Products&#x201d;). Additionally, the Company granted
Zimmer the exclusive right and license to distribute certain depth electrodes developed by the Company (&#x201c;SEEG Products&#x201d;, and
together with the Strip/Grid Products and Electrode Cable Assembly Products, the &#x201c;Products&#x201d;). The parties have agreed to collaborate
with respect to development activities under the Development Agreement through a joint development committee composed of an equal number
of representatives of Zimmer and the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Under the
terms of the Development Agreement, the Company is responsible for all costs and expenses related to developing the Products, and Zimmer
is responsible for all costs and expenses related to the commercialization of the Products. In addition to the Development Agreement,
Zimmer and the Company have entered into a Manufacturing and Supply Agreement (the &#x201c;MS Agreement&#x201d;) and a supplier quality
agreement (the &#x201c;Quality Agreement&#x201d;) with respect to the manufacturing and supply of the Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Except as
otherwise provided in the Development Agreement, the Company is responsible for performing all development activities, including non-clinical
and clinical studies directed at obtaining regulatory approval of each Product. Zimmer has agreed to use commercially reasonable efforts
to promote, market and sell each Product following the &#x201c;Product Availability Date&#x201d; (as defined in the Development Agreement)
for such Product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Pursuant
to the Development Agreement, Zimmer made an upfront initial exclusivity fee payment of $2.0&#160;million (the &#x201c;Initial Exclusivity
Fee&#x201d;) to the Company. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Except where
Zimmer timely delivers a Design Modification Notice pursuant to Section 1.2, if one or more of the events set forth below occurs on or
before the deadline indicated for such event and the Product Availability Date (as defined in the Development Agreement) for the SEEG
Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the
SEEG Exclusivity Maintenance Fee:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;Design
freeze for the SEEG Products by December 15, 2020 - $500,000&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160; &#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;Acceptance
of all Deliverables for SEEG Products under the Development Plan (as defined in the Development Agreement) by April 30, 2021 - $500,000&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; "&gt;If Zimmer timely delivers a Design Modification Notice to the Company under the Development Agreement, and one or more of the events set forth below occurs on or before the deadline indicated for such event and the Product Availability Date for the SEEG Products occurs on or before June 30, 2021, then the Company shall receive the additional amount indicated for such event as part of the SEEG Exclusivity Maintenance Fee:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;Acceptance
of all Deliverables for SEEG Products under the Development Plan other than the Modified Connector by April 30, 2021 - $500,000&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "&gt;Acceptance
of all Deliverables for SEEG Products under the Development Plan, including the Modified Connector by September 30, 2021 - $500,000&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;For purposes
of the Development Agreement, each of the foregoing events shall have occurred only if the Company has demonstrated the achievement of
the event to Zimmer&#x2019;s reasonable satisfaction. Notwithstanding the foregoing, the events in Sections 6.1(c)(ii), (iii) and (iv)
of the Development Agreement shall not be deemed to be met if FDA Approval for the SEEG Products is not received prior to the applicable
deadline. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In order to maintain the exclusivity of the SEEG
Distribution License, Zimmer must pay the SEEG Exclusivity Maintenance Fee to the Company, on or prior to the SEEG Exclusivity Confirmation
Date, in immediately available funds as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if the Product Availability Date for the SEEG Products occurs
on or before June 30, 2021, then $3,000,000, plus the amount of any Interim Fee Bonuses earned pursuant to Section 6.1(c), including
any such Interim Fee Bonus earned after June 30, 2021 pursuant to Section 6.1(c)(iv) following the delivery of a Design Modification
Notice;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if the Product Availability Date for the SEEG Products occurs
after June 30, 2021, but on or before September 30, 2021, then $3,000,000, plus if Zimmer timely issues a Design A-9 Modification Notice,
any Interim Fee Bonus earned pursuant to Section 6.1(c)(iv);&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if the Product Availability Date for the SEEG Products occurs
after September 30, 2021, but on or before December 31, 2021, then $2,500,000; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;if the Product Availability Date for the SEEG Products occurs
after December 31, 2021, then $1,500,000.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Product Availability Date for the SEEG Products
has not yet occurred. &lt;span&gt;Notwithstanding any other provision of the Development Agreement, if the Product
Availability Date for the SEEG Products has not occurred on or before June 30, 2022, Zimmer shall have the right to terminate the SEEG
Distribution License by delivering written notice to the Company to that effect and, upon delivery of such notice, Zimmer shall be relieved
of all of its obligations hereunder with respect to SEEG Products, including any obligation to pay the SEEG Exclusivity Maintenance Fee
or to purchase, market, distribute or sell any SEEG Products. The Initial Exclusivity Fee and the SEEG Exclusivity Maintenance Fee (including
any Interim Fee Bonus(es)), once paid, are non-refundable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Development
Agreement will expire on the tenth anniversary of the date of the first commercial sale of the last of the Products to achieve a first
commercial sale, unless terminated earlier pursuant to its terms. Either party may terminate the Development Agreement (x) with written
notice for the other party&#x2019;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency
proceedings. In addition, Zimmer may terminate the Development Agreement for any reason with 90 days&#x2019; written notice, and the Company
may terminate the Development Agreement if Zimmer acquires or directly or indirectly owns a controlling interest in certain competitors
of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;At inception
of the Zimmer Development Agreement through September 30, 2021, the Company had identified the following three performance obligations
under the Zimmer Development Agreement: (1) the Company obligation to license Zimmer rights to certain of its intellectual property; (2)
complete SEEG Product development; and (3) complete Strip/Grid Product development. Accordingly, the Company recognized revenue in the
amount of $64,812&#160;and $1,926,566&#160;during the years ended September 30, 2021 and 2020, respectively, related to the development
of the Products completed during the periods in connection with the Initial Exclusivity Fee payment. The Zimmer Development Agreement
was accounted for under the provisions of ASC 606,&#160;&lt;i&gt;Revenue from Contracts with Customers.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the closing balance of deferred
revenue related to the Zimmer Development Agreement is as follows as of September 30, 2021 and 2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Deferred Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Balance as of&#160;&#160;September 30, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Upfront initial exclusivity payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,926,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of&#160;&#160;September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The remaining performance obligations reflected
in deferred revenue as of September 30, 2021 are expected to be completed in first half of fiscal year 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Product Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2020, the Company commenced commercial
sales of its Strip/Grid Products and Electrode Cable Assembly Products in connection with the Development Agreement. Product revenue recognized
during the year ended September 30, 2021 was $178,146.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advertising Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising expense is charged to selling, general
and administrative expenses during the period that it is incurred. Total advertising expense amounted to $338,837 for the year ended September
30, 2021. Advertising expense during the prior year period was negligible.&lt;/p&gt;</nmtc:ZimmerDevelopmentAgreementTextBlock>
    <nmtc:IntialFeePayment contextRef="c0" decimals="-5" unitRef="usd">2000000</nmtc:IntialFeePayment>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c38" decimals="0" unitRef="usd">500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c39" decimals="0" unitRef="usd">500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c40" decimals="0" unitRef="usd">500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c41" decimals="0" unitRef="usd">500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c42" decimals="0" unitRef="usd">3000000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c43" decimals="0" unitRef="usd">3000000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c44" decimals="0" unitRef="usd">2500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:FuturePotentialMilestonePaymentsToNeuroone contextRef="c45" decimals="0" unitRef="usd">1500000</nmtc:FuturePotentialMilestonePaymentsToNeuroone>
    <nmtc:ProductRevenueRecognized contextRef="c46" decimals="0" unitRef="usd">64812</nmtc:ProductRevenueRecognized>
    <nmtc:ProductRevenueRecognized contextRef="c47" decimals="0" unitRef="usd">1926566</nmtc:ProductRevenueRecognized>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Deferred Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Balance as of&#160;&#160;September 30, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Upfront initial exclusivity payment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,926,566&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of&#160;&#160;September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,434&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Revenue recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,812&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance as of September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,622&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <nmtc:UpfrontInitialExclusivityPayments contextRef="c5" decimals="0" unitRef="usd">2000000</nmtc:UpfrontInitialExclusivityPayments>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c5" decimals="0" unitRef="usd">1926566</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue contextRef="c4" decimals="0" unitRef="usd">73434</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="c0" decimals="0" unitRef="usd">64812</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="0" unitRef="usd">8622</us-gaap:DeferredRevenue>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">178146</us-gaap:Revenues>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" unitRef="usd">338837</us-gaap:AdvertisingExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 - Convertible Promissory Notes and Warrant
Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Paulson convertible notes, principal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;546,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Fair value adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;397,748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Paulson Convertible Note Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2019 Paulson Convertible Note Offering&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 1, 2019, the Company entered into
a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#x201c;2019 Paulson
Private Placement&#x201d;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#x201c;2019 Paulson Note&#x201d;
and collectively, the &#x201c;2019 Paulson Notes&#x201d;) and warrants (each, a &#x201c;2019 Paulson Warrant&#x201d; and collectively, the
&#x201c;2019 Paulson Warrants&#x201d;) to purchase shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The initial closing of the 2019 Paulson Private
Placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued the 2019 Paulson Notes
in an aggregate principal amount of $3,234,800 to the subscribers for gross proceeds equaling the principal amount. The 2019 Paulson Private
Placement terminated on December 3, 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2019 Paulson Notes had a fixed interest rate
of 13% per annum and required the Company to repay the principal and accrued and unpaid interest thereon on November 1, 2020 (the &#x201c;Maturity
Date&#x201d;). Interest on principal amounted to $5,701 and $213,383 during the years ended September 30, 2021 and 2020, respectively,
and was recorded under the net valuation change of instruments measured at fair value in the statements of operations. The subscriber,
prior to the Second 2019 Paulson Notes Amendment, had the option to convert the outstanding principal and accrued and unpaid interest
of such subscriber&#x2019;s 2019 Paulson Note (the &#x201c;Outstanding Balance&#x201d;) into common stock in an amount equal to the Outstanding
Balance divided by the ten day volume weighted average closing price of the common stock prior to conversion. In addition, both before
and after the Second 2019 Paulson Note Amendment, if the Company raised more than $3,000,000 in an equity financing (the &#x201c;Qualified
Financing&#x201d;) before the Maturity Date, each subscriber had the option to convert the Outstanding Balance into the securities issued
by the Company in such Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied
by (A) the actual per share price of securities issued by the Company in the Qualified Financing or (B) the ten day volume weighted average
closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction had occurred
prior to a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on demand as of the closing date
of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#x2019;s stockholders did
not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#x2019;s
assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company elected to account for the 2019 Paulson
Notes on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options.
The fair value of the 2019 Paulson Notes was significantly higher than the proceeds received as of each of the respective issuance dates
given the significant redemption discount associated with the Qualified Financing provision. The excess of fair value over proceeds at
issuance amounted to $1,831,940 and was recorded to interest expense in the statements of operations during the year ended September 30,
2020. Subsequent to issuance, the fair value change of the 2019 Paulson Notes amounted to a benefit of $1,974 and $1,221,480 during the
years ended September 30, 2021 and 2020, respectively, and was recorded under the net valuation change of instruments measured at fair
value in the statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each 2019 Paulson Warrant granted the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#x2019;s
2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. As of the final closing on December 3, 2019, the
Company issued 2019 Paulson Warrants exercisable for 288,305 shares of common stock in connection with all closings of the 2019 Paulson
Private Placement. The 2019 Paulson Warrants are immediately exercisable and expire on November 1, 2022. The exercise price is subject
to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction,
as described therein. The 2019 Paulson warrants were deemed to be a free-standing instrument and were accounted for as equity. Given that
the fair value of the 2019 Paulson Notes exceeded the proceeds received at issuance, there was no value attributed to the 2019 Paulson
Warrants in the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the 2019 Private Placement,
Paulson Investment Company, LLC (&#x201c;Paulson&#x201d;) received a cash commission equal to 12% of the gross proceeds from the sale of
the 2019 Paulson Notes, and 10-year warrants to purchase an amount of common stock equal to 86,498 shares of common stock at an exercise
price equal to $5.61 per share (the &#x201c;Broker Warrants&#x201d;). The issuance costs incurred during the year ended September 30, 2021
and 2020 in connection with the 2019 Paulson Private Placement were $3,053 and $865,567, respectively. Issuance costs in 2021 related
to legal costs. Issuance costs in 2020 included cash commissions equal to $388,176 and legal and third-party fees in the amount of $57,756.
In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 24, 2020, the Company and holders of
a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the &#x201c;Second
2019 Paulson Notes Amendment&#x201d;) to, among other things:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Extended the Maturity Date&lt;/i&gt;&lt;/b&gt;&lt;i&gt; &#x2013; &lt;/i&gt;The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;ii.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revised Optional Conversion Terms&lt;/i&gt;&lt;/b&gt;&lt;i&gt; &#x2013;
&lt;/i&gt;The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#x2019;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#x2019;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;iii.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revised the Registration Date &#x2013;&lt;/i&gt;&lt;/b&gt; The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#x2019;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Second 2019 Paulson Notes Amendment was accounted
for as a note extinguishment for accounting purposes given the substantive change in the optional redemption feature&#x2019;s conversion
formula. The fair value change in the 2019 Paulson Notes associated with the extinguishment was recorded as a loss on notes extinguishment
in the accompanying statements of operations in the amount of $2,017,847 during the year ended September 30, 2020. Lastly, in connection
with the Second 2019 Paulson Notes Amendment, legal costs in the amount of $1,943 were incurred and recorded as a component of interest
in the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended September 30, 2021 and
2020, the 2019 Paulson Notes were converted into 292,754 and 725,394 shares of common stock, respectively. All of the 2019 Paulson notes
were converted into shares of common stock by December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Paulson 2020 Convertible Note Financing&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 30, 2020, the Company entered into a
subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#x201c;2020 Paulson
Private Placement&#x201d;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#x201c;2020 Paulson Note&#x201d;
and collectively, the &#x201c;2020 Paulson Notes&#x201d;) and warrants (each, a &#x201c;2020 Paulson Warrant&#x201d; and collectively, the
&#x201c;2020 Paulson Warrants&#x201d;) to purchase shares of the Company&#x2019;s common stock.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Between May 1, 2020 and June 30, 2020, the Company
issued 2020 Paulson Notes in an aggregate principal amount of $5,122,700 to the Subscribers. The 2020 Paulson Private Placement was terminated
on June 30, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2020 Paulson Notes had a fixed interest rate
of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of December 31,
2020 or a change of control transaction. Interest on principal amounted to $81,613 during the year ended September 30, 2020 and was recorded
under the net valuation change of instruments measured at fair value in the statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company had raised more than $5,000,000
in an equity financing before the maturity date (the &#x201c;2020 Qualified Financing&#x201d;), without any action on the part of the Subscribers,
all of the outstanding principal and accrued and unpaid interest of the Notes (the &#x201c;Outstanding Balance&#x201d;) would have been
converted into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred
equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities
issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume weighted average price of the
common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company had announced a transaction between
the Company and any other company (or an affiliate of any such company) that was included in the S&amp;amp;P 500 Health Care Index as published
from time to time by S&amp;amp;P Dow Jones Indices LLC that included an investment or upfront payments resulting in gross proceeds to the
Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration,
manufacturing, distribution, licensing or supply of the Company&#x2019;s products (a &#x201c;Strategic Transaction&#x201d;) before the maturity
date, without any action on the part of the subscribers, the Outstanding Balance would be converted into that number of shares of common
stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten
(10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on
the day preceding the first announcement by the Company of a Strategic Transaction.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At any time, at the sole election of the holder
of such 2020 Paulson Note, all or a portion of the Outstanding Balance could have been converted into that number of shares of common
stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by
the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If a change of control transaction had occurred
prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would have become payable on demand as
of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#x2019;s
stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially
all of the Company&#x2019;s assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company elected to account for the 2020 Paulson
Notes on a fair value basis under ASC 825&#160;&lt;span&gt;to comprehensively value and streamline the accounting
for the embedded conversion options&lt;/span&gt;. The fair value of the 2020 Paulson Notes was significantly higher than the proceeds received
as of each of the respective issuance dates given the significant redemption discount associated with the redemption provisions. The excess
of fair value over proceeds at issuance amounted to $3,784,918 and was recorded to interest expense in the statements of operations during
the year ended September 30, 2020. Subsequent to issuance, the fair value change of the 2020 Paulson Notes amounted to an expense of $416,951
during the year ended September 30, 2020 and was recorded under the net valuation change of instruments measured at fair value in the
statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each 2020 Paulson Warrant grants the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#x2019;s
2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. The 2020 Paulson Warrants are immediately exercisable
and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock
split, recapitalization, reorganization or similar transaction. The Company issued 2020 Paulson Warrants exercisable for 456,564 shares
of common stock in connection with all closings of the 2020 Paulson Private Placement through June 30, 2020. The 2020 Paulson warrants
were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2020 Paulson Notes exceeded
the proceeds received at issuance, there was no value attributed to the 2020 Paulson Warrants in the financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the 2020 Paulson Private Placement,&#160;Paulson&#160;received
a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes and received 7-year warrants to purchase
an amount of common stock equal to 136,971 (&#x201c;Broker Warrants&#x201d;). The Broker Warrants have an exercise price equal to $5.61
per share. The issuance costs incurred during the year ended September 30, 2020 in connection with the 2020 Paulson Private Placement
were $1,040,213. Issuance costs included cash commissions equal to $614,725 and legal and third-party fees in the amount of $148,451.
In addition, issuance costs included the value of the Broker Warrants in the amount of $277,037. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Between May 4, 2020 and July 22, 2020, certain
Subscribers elected to convert $3,590,353 of the outstanding principal and interest of such Subscribers&#x2019; 2020 Paulson Notes into
1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance of the 2020 Paulson Notes
in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the Zimmer Development Agreement
that qualified as a Strategic Transaction.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Paulson convertible notes, principal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;546,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Fair value adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;397,748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,007,206&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <nmtc:ConvertibleNotesOutstandingPrincipal contextRef="c4" decimals="0" unitRef="usd">546000</nmtc:ConvertibleNotesOutstandingPrincipal>
    <nmtc:AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables contextRef="c4" decimals="0" unitRef="usd">63458</nmtc:AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables>
    <nmtc:FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable contextRef="c4" decimals="0" unitRef="usd">397748</nmtc:FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable>
    <nmtc:ConvertiblePromissoryNotesPayable contextRef="c4" decimals="0" unitRef="usd">1007206</nmtc:ConvertiblePromissoryNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c48" decimals="2" unitRef="pure">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c49" decimals="0" unitRef="usd">3234800</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c50" decimals="2" unitRef="pure">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nmtc:InterestOnPrincipalAmount contextRef="c51" decimals="0" unitRef="usd">5701</nmtc:InterestOnPrincipalAmount>
    <nmtc:InterestOnPrincipalAmount contextRef="c52" decimals="0" unitRef="usd">213383</nmtc:InterestOnPrincipalAmount>
    <nmtc:EquityFinancingAmount contextRef="c51" decimals="0" unitRef="usd">3000000</nmtc:EquityFinancingAmount>
    <nmtc:EquityQualifiedFinancingDescriptiononConvertibleNoteOffering contextRef="c53">(i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied
by (A) the actual per share price of securities issued by the Company in the Qualified Financing or (B) the ten day volume weighted average
closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction had occurred
prior to a Qualified Financing or the Maturity Date, the 2019 Paulson Notes would have become payable on demand as of the closing date
of such transaction.</nmtc:EquityQualifiedFinancingDescriptiononConvertibleNoteOffering>
    <nmtc:OutstandingVotingPercentage contextRef="c3" decimals="2" unitRef="pure">0.50</nmtc:OutstandingVotingPercentage>
    <nmtc:IssuanceOfFairValueAmount contextRef="c0" decimals="0" unitRef="usd">1831940</nmtc:IssuanceOfFairValueAmount>
    <nmtc:ChangesOfFairValueBenefit contextRef="c0" decimals="0" unitRef="usd">1974</nmtc:ChangesOfFairValueBenefit>
    <nmtc:ChangesOfFairValueBenefit contextRef="c5" decimals="0" unitRef="usd">1221480</nmtc:ChangesOfFairValueBenefit>
    <nmtc:WarrantsDescription contextRef="c54">Each 2019 Paulson Warrant granted the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#x2019;s
2019 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61.</nmtc:WarrantsDescription>
    <nmtc:WarrantsExercisableForSharesOfCommonStockConnection contextRef="c55" decimals="0" unitRef="shares">288305</nmtc:WarrantsExercisableForSharesOfCommonStockConnection>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c54">2022-11-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <nmtc:IssuanceCostsDescription contextRef="c0">In connection with the 2019 Private Placement,
Paulson Investment Company, LLC (&#x201c;Paulson&#x201d;) received a cash commission equal to 12% of the gross proceeds from the sale of
the 2019 Paulson Notes, and 10-year warrants to purchase an amount of common stock equal to 86,498 shares of common stock at an exercise
price equal to $5.61 per share (the &#x201c;Broker Warrants&#x201d;). The issuance costs incurred during the year ended September 30, 2021
and 2020 in connection with the 2019 Paulson Private Placement were $3,053 and $865,567, respectively. Issuance costs in 2021 related
to legal costs. Issuance costs in 2020 included cash commissions equal to $388,176 and legal and third-party fees in the amount of $57,756.
In addition, issuance costs included the value of the Broker Warrants in the amount of $419,635. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&#160;On April 24, 2020, the Company and holders of
a majority in aggregate principal amount of the 2019 Paulson Notes entered into an amendment to the 2019 Paulson Notes (the &#x201c;Second
2019 Paulson Notes Amendment&#x201d;) to, among other things:&#160;
i.Extended the Maturity Date &#x2013; The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);
&#160;
ii.Revised Optional Conversion Terms &#x2013;
The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#x2019;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#x2019;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and
&#160;
iii.Revised the Registration Date &#x2013; The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#x2019;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.
&#160;The Second 2019 Paulson Notes Amendment was accounted
for as a note extinguishment for accounting purposes given the substantive change in the optional redemption feature&#x2019;s conversion
formula. The fair value change in the 2019 Paulson Notes associated with the extinguishment was recorded as a loss on notes extinguishment
in the accompanying statements of operations in the amount of $2,017,847 during the year ended September 30, 2020. Lastly, in connection
with the Second 2019 Paulson Notes Amendment, legal costs in the amount of $1,943 were incurred and recorded as a component of interest
in the accompanying statements of operations.&#160;During the years ended September 30, 2021 and
2020, the 2019 Paulson Notes were converted into 292,754 and 725,394 shares of common stock, respectively. All of the 2019 Paulson notes
were converted into shares of common stock by December 31, 2020.&#160;Paulson 2020 Convertible Note Financing&#160;&#160;On April 30, 2020, the Company entered into a
subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement (the &#x201c;2020 Paulson
Private Placement&#x201d;), agreed to issue and sell to the investors 13% convertible promissory notes (each, a &#x201c;2020 Paulson Note&#x201d;
and collectively, the &#x201c;2020 Paulson Notes&#x201d;) and warrants (each, a &#x201c;2020 Paulson Warrant&#x201d; and collectively, the
&#x201c;2020 Paulson Warrants&#x201d;) to purchase shares of the Company&#x2019;s common stock.&#160;&#160;Between May 1, 2020 and June 30, 2020, the Company
issued 2020 Paulson Notes in an aggregate principal amount of $5,122,700 to the Subscribers. The 2020 Paulson Private Placement was terminated
on June 30, 2020.&#160;The 2020 Paulson Notes had a fixed interest rate
of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on the earlier of December 31,
2020 or a change of control transaction. Interest on principal amounted to $81,613 during the year ended September 30, 2020 and was recorded
under the net valuation change of instruments measured at fair value in the statements of operations.&#160;If the Company had raised more than $5,000,000
in an equity financing before the maturity date (the &#x201c;2020 Qualified Financing&#x201d;), without any action on the part of the Subscribers,
all of the outstanding principal and accrued and unpaid interest of the Notes (the &#x201c;Outstanding Balance&#x201d;) would have been
converted into that number of shares of the securities issued by the Company in the closing on the date a 2020 Qualified Financing occurred
equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of the securities
issued by the Company in the closing on the date a 2020 Qualified Financing occurred and (B) the volume weighted average price of the
common stock for ten (10) trading days immediately preceding the 2020 Qualified Financing.&#160;If the Company had announced a transaction between
the Company and any other company (or an affiliate of any such company) that was included in the S&amp;P 500 Health Care Index as published
from time to time by S&amp;P Dow Jones Indices LLC that included an investment or upfront payments resulting in gross proceeds to the
Company of at least $2,000,000 upon the execution of such transaction or definitive agreement, and provides for terms of collaboration,
manufacturing, distribution, licensing or supply of the Company&#x2019;s products (a &#x201c;Strategic Transaction&#x201d;) before the maturity
date, without any action on the part of the subscribers, the Outstanding Balance would be converted into that number of shares of common
stock equal to: (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the VWAP of the common stock for the ten
(10) trading days immediately preceding the first announcement of the Strategic Transaction or (B) closing price of the common stock on
the day preceding the first announcement by the Company of a Strategic Transaction.&#160;At any time, at the sole election of the holder
of such 2020 Paulson Note, all or a portion of the Outstanding Balance could have been converted into that number of shares of common
stock equal to: (i) the Outstanding Balance elected by the holder to be converted divided by (ii) an amount equal to 0.6 multiplied by
the volume weighted average price of the common stock for the ten (10) trading days immediately preceding the date of conversion.&#160;If a change of control transaction had occurred
prior to the conversion of the 2020 Paulson Notes or the maturity date, the 2020 Paulson Notes would have become payable on demand as
of the closing date of such transaction. Change of control meant a merger or consolidation with another entity in which the Company&#x2019;s
stockholders did not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially
all of the Company&#x2019;s assets.&#160;The Company elected to account for the 2020 Paulson
Notes on a fair value basis under ASC 825&#160;to comprehensively value and streamline the accounting
for the embedded conversion options. The fair value of the 2020 Paulson Notes was significantly higher than the proceeds received
as of each of the respective issuance dates given the significant redemption discount associated with the redemption provisions. The excess
of fair value over proceeds at issuance amounted to $3,784,918 and was recorded to interest expense in the statements of operations during
the year ended September 30, 2020. Subsequent to issuance, the fair value change of the 2020 Paulson Notes amounted to an expense of $416,951
during the year ended September 30, 2020 and was recorded under the net valuation change of instruments measured at fair value in the
statements of operations.&#160;Each 2020 Paulson Warrant grants the holder the
option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber&#x2019;s
2020 Paulson Notes divided by 5.61, with an exercise price per share equal to $5.61. The 2020 Paulson Warrants are immediately exercisable
and expire on April 30, 2023. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock
split, recapitalization, reorganization or similar transaction. The Company issued 2020 Paulson Warrants exercisable for 456,564 shares
of common stock in connection with all closings of the 2020 Paulson Private Placement through June 30, 2020. The 2020 Paulson warrants
were deemed to be a free-standing instrument and were accounted for as equity. Given that the fair value of the 2020 Paulson Notes exceeded
the proceeds received at issuance, there was no value attributed to the 2020 Paulson Warrants in the financial statements.&#160;In connection with the 2020 Paulson Private Placement,&#160;Paulson&#160;received
a cash commission equal to 12% of the gross proceeds from the sale of the 2020 Paulson Notes and received 7-year warrants to purchase
an amount of common stock equal to 136,971 (&#x201c;Broker Warrants&#x201d;). The Broker Warrants have an exercise price equal to $5.61
per share. The issuance costs incurred during the year ended September 30, 2020 in connection with the 2020 Paulson Private Placement
were $1,040,213. Issuance costs included cash commissions equal to $614,725 and legal and third-party fees in the amount of $148,451.
In addition, issuance costs included the value of the Broker Warrants in the amount of $277,037. The issuance costs were recorded as a
component of interest in the accompanying statements of operations.&#160;</nmtc:IssuanceCostsDescription>
    <nmtc:ExtendedMaturityDateDescription contextRef="c56">Extended the Maturity Date &#x2013; The
Second 2019 Paulson Notes Amendment extended the maturity date of the 2019 Paulson Notes from May 1, 2020 to November 1, 2020 (in either
case, unless a change of control transaction happens prior to such date);</nmtc:ExtendedMaturityDateDescription>
    <nmtc:RevisedOptionalConversionTermsDescription contextRef="c56">Revised Optional Conversion Terms &#x2013;
The Second 2019 Paulson Notes Amendment provided that the amount of shares to be received upon the subscriber&#x2019;s optional conversion
of the 2019 Paulson Notes prior to a 2019 Qualified Financing (as defined in the 2019 Paulson Notes) would have equaled: (1) the Outstanding
Balance as defined below of such subscriber&#x2019;s 2019 Paulson Note elected by the subscriber to be converted divided by (2) an amount
equal to 0.6 multiplied by the volume weighted average price of the common stock for the ten (10) trading days immediately preceding
the date of conversion; and</nmtc:RevisedOptionalConversionTermsDescription>
    <nmtc:ReviseTheRegistrationDateDescription contextRef="c56">Revised the Registration Date &#x2013; The Second
2019 Paulson Notes Amendment provided that promptly following the earlier of (1) May 1, 2020, if the applicable subscriber converted
all or a majority of the Outstanding Balance of such subscriber&#x2019;s 2019 Paulson Note prior to such date; (2) the final closing of
a 2019 Qualified Financing; and (3) the maturity date, the Company will enter into a registration rights agreement with the applicable
subscriber containing customary and usual terms pursuant to which the Company shall agree to prepare and file with the SEC a registration
statement on or prior to the 90th calendar day following the registration date, covering the resale of any common stock received on conversion
of such 2019 Paulson Notes, and shares of common stock underlying the Warrants.</nmtc:ReviseTheRegistrationDateDescription>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-2017847</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LegalFees contextRef="c57" decimals="0" unitRef="usd">1943</us-gaap:LegalFees>
    <nmtc:ConvertedNotesCommonStock contextRef="c0" decimals="0" unitRef="shares">292754</nmtc:ConvertedNotesCommonStock>
    <nmtc:ConvertedNotesCommonStock contextRef="c5" decimals="0" unitRef="shares">725394</nmtc:ConvertedNotesCommonStock>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="c58">13%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <nmtc:aggregatePrincipalAmount contextRef="c59" decimals="0" unitRef="usd">5122700</nmtc:aggregatePrincipalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c60" decimals="2" unitRef="pure">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nmtc:NoncashInterest contextRef="c61" decimals="0" unitRef="usd">81613</nmtc:NoncashInterest>
    <nmtc:GrossProceeds contextRef="c62" decimals="0" unitRef="usd">2000000</nmtc:GrossProceeds>
    <nmtc:InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance contextRef="c63" decimals="0" unitRef="usd">3784918</nmtc:InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance>
    <nmtc:IncreaseDecreaseInFairValue contextRef="c64" decimals="0" unitRef="usd">416951</nmtc:IncreaseDecreaseInFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c65" decimals="2" unitRef="usdPershares">5.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nmtc:WarrantsToPurchaseOfCommonStockShares contextRef="c66" decimals="0" unitRef="shares">456564</nmtc:WarrantsToPurchaseOfCommonStockShares>
    <nmtc:CashCommissionPercentageRateOnProceeds contextRef="c67" decimals="2" unitRef="pure">0.12</nmtc:CashCommissionPercentageRateOnProceeds>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c67">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <nmtc:WarrantsToPurchaseOfCommonStockShares contextRef="c68" decimals="0" unitRef="shares">136971</nmtc:WarrantsToPurchaseOfCommonStockShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c69" decimals="2" unitRef="usdPershares">5.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nmtc:IssuanceOfCostsIncurred contextRef="c70" decimals="0" unitRef="usd">1040213</nmtc:IssuanceOfCostsIncurred>
    <nmtc:CashCommissions contextRef="c62" decimals="0" unitRef="usd">614725</nmtc:CashCommissions>
    <nmtc:LegalAndThirdPartyFee contextRef="c71" decimals="0" unitRef="usd">148451</nmtc:LegalAndThirdPartyFee>
    <nmtc:IssuanceCosts contextRef="c72" decimals="0" unitRef="usd">277037</nmtc:IssuanceCosts>
    <nmtc:ConvertibleNoteFinancingDescription contextRef="c73">Between May 4, 2020 and July 22, 2020, certain
Subscribers elected to convert $3,590,353 of the outstanding principal and interest of such Subscribers&#x2019; 2020 Paulson Notes into
1,337,459 shares of common stock. On July 23, 2020, the remaining outstanding principal and interest balance of the 2020 Paulson Notes
in the amount of $1,613,961 was converted into 535,178 shares of common stock upon the announcement of the Zimmer Development Agreement
that qualified as a Strategic Transaction.</nmtc:ConvertibleNoteFinancingDescription>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 - Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended September 30, 2021 and
2020, stock-based expense related to the stock options, restricted stock units and stock awards was included in selling, general and administrative
and research and development costs as follows in the accompanying statements of operations:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,550,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,623,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;242,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,793,199&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,835,970&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s 2016 and 2017 Equity Incentive
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company
initially reserved 764,089 shares of common stock for issuance under the 2016 and 2017 Equity Incentive Plans on a combined basis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Evergreen provision&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the 2017 Plan, the shares reserved automatically
increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders
of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted
shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January
1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the
share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence.
&#x201c;Fully Diluted Shares&#x201d; as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii)
issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants
or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common
stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2021 and 2020,
484,622 and 428,930 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended September 30, 2021 and
2020, 703,117 and 334,731 stock options were granted to employees, directors and consultants, respectively, with a weighted average grant
date fair value of $3.01 and $3.03 per share, respectively. The options granted have vesting periods ranging from being immediate to four
years. All options expire ten years from the date of grant. The total expense for the years ended September 30, 2021 and 2020 related
to the stock options was $983,301 and $798,242, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
stock option plan activity for the years ended September 30, 2021 and 2020 as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value(1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;281,956&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;343,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(98,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(71,861&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,122,560&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8.8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,339&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Vested and exercisable at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;481,047&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;311,388&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The aggregate intrinsic value is
calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September
30, 2021 and 2020 of $3.95 and $3.86 per share, respectively. As of September 30, 2021 and 2020, 1,055,376 and 467,327 outstanding options,
respectively, had no intrinsic value.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted-average assumptions used in the Black-Scholes
option-pricing model are as follows for the stock options granted during the years ended September 30:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended September 30, 2021 and 2020,
280,557 and 198,191 stock options vested, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of restricted stock unit (&#x201c;RSU&#x201d;)
activity is as follows for the years ended September 30, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-left: 0"&gt;Non-vested at September 30, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Non-vested at September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 0"&gt;Non-vested at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended September 30, 2021 and
2020, 13,776 and 78,323 RSUs were granted to members of the Company&#x2019;s board of directors and consultants that vest over a period
ranging from an immediate to a two year period, with a grant date fair value of $7.26 and $6.27 per unit, respectively. During the years
ended September 30, 2021 and 2020, 29,090 and 59,793 RSUs vested, respectively. The total expense for the years ended September 30, 2021
and 2020 related to the RSU&#x2019;s was $163,988 and $396,012, respectively. The number of RSUs forfeited during the years ended September
30, 2021 and 2020 was zero and 2,335, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Other Stock-Based Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2021 Activity&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2021, two consulting agreements were
executed whereby a total of 62,659 shares of common stock were issued and vested as of September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2021, two consulting agreements were executed
whereby a total of 11,668 shares of common stock were issued and vested as of September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2020 Activity&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2019, two consulting agreements were
executed whereby up to 38,334 shares of common stock were issued and vested as of September 30, 2020. On April 22, 2020, the Company entered
into an amendment (the &#x201c;Amendment&#x201d;) to one of the consulting agreements. Pursuant to the Amendment, the Company issued an
additional 11,667 shares in exchange for consulting services of which 11,667 shares of common stock were vested as of September 30, 2020
under the Amendment. Vesting was based on a time-based vesting condition ranging over a three to nine-month period commencing upon the
execution of the consulting agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2020, an additional consulting agreement
was executed whereby up to 30,000 shares of common stock were issued and vested as of September 30, 2020 under this agreement. In addition,
on May 21, 2020, 22,195 shares of common stock were issued as compensation to a former 2019 Paulson Note holder related to a prior 2019
Paulson Note conversion and release of liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, an additional consulting agreement
was executed whereby 40,000 shares of common stock were issued, subject to Company repurchase. The stock award under the agreement vests
over a six-month period. As of September 30, 2021 and 2020, 33,333 and 6,667 shares vested under this agreement, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Compensation expense related to the stock awards
granted under the consulting agreements and to the former 2019 Paulson Note holder referenced above amounted to $645,910 and $641,716
for the years ended September 30, 2021 and 2020, respectively, and was included in stock-based compensation expense. The expense recognition
related to the grants was based on the fair value of the underlying common stock at the point of vesting which ranged from $4.53 to $7.95
per share.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;General&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, 389,709 shares were
available for future issuance on a combined basis under the 2016 and 2017 Equity Incentive Plans. Unrecognized stock-based compensation
was $1.7 million as of September 30, 2021. The unrecognized share-based expense is expected to be recognized over a weighted average period
of 2.9 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,550,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,623,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;242,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,793,199&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,835,970&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="0" unitRef="usd">1550841</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c91" decimals="0" unitRef="usd">1623629</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c92" decimals="0" unitRef="usd">242358</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c93" decimals="0" unitRef="usd">212341</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" unitRef="usd">1793199</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" unitRef="usd">1835970</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c74" decimals="0" unitRef="shares">764089</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nmtc:SharesReservedDescription contextRef="c75">the shares reserved automatically
increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders
of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted
shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January
1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the
share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence.
&#x201c;Fully Diluted Shares&#x201d; as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii)
issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants
or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common
stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2021 and 2020,
484,622 and 428,930 shares were added to the 2017 Plan, respectively, as a result of the evergreen provision.</nmtc:SharesReservedDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c76" decimals="0" unitRef="shares">703117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c77" decimals="0" unitRef="shares">334731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c76" decimals="2" unitRef="usdPershares">3.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c77" decimals="2" unitRef="usdPershares">3.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <nmtc:StockOptionVestedOverAPeriodTerm contextRef="c76">P4Y</nmtc:StockOptionVestedOverAPeriodTerm>
    <nmtc:StockOptionVestedOverAPeriodTerm contextRef="c0">P10Y</nmtc:StockOptionVestedOverAPeriodTerm>
    <nmtc:TotalExpenseOfStockOption contextRef="c0" decimals="0" unitRef="usd">983301</nmtc:TotalExpenseOfStockOption>
    <nmtc:TotalExpenseOfStockOption contextRef="c5" decimals="0" unitRef="usd">798242</nmtc:TotalExpenseOfStockOption>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value(1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;281,956&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;343,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334,731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,515&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(98,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5.91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;492,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;96,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(71,861&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,122,560&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8.8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,339&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Vested and exercisable at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;481,047&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;311,388&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c94" decimals="INF" unitRef="shares">281956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c94" decimals="2" unitRef="usdPershares">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c95">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c9" decimals="0" id="ix_0_fact" unitRef="usd">343406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c5" decimals="INF" unitRef="shares">334731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">6.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c5" decimals="INF" unitRef="shares">25515</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c5" decimals="INF" unitRef="shares">98330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c4" decimals="INF" unitRef="shares">492842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c5">P8Y9M18D</nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1 contextRef="c4" decimals="0" id="ix_1_fact" unitRef="usd">96088</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="INF" unitRef="shares">703117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c0" decimals="INF" unitRef="shares">1538</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c0" decimals="INF" unitRef="shares">71861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">1122560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P8Y9M18D</nmtc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1 contextRef="c3" decimals="0" id="ix_2_fact" unitRef="usd">127339</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">481047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" id="ix_3_fact" unitRef="usd">311388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <nmtc:ExercisePriceOfUnderlyingOptions contextRef="c0" decimals="2" unitRef="usdPershares">3.95</nmtc:ExercisePriceOfUnderlyingOptions>
    <nmtc:ExercisePriceOfUnderlyingOptions contextRef="c5" decimals="2" unitRef="usdPershares">3.86</nmtc:ExercisePriceOfUnderlyingOptions>
    <nmtc:OutstandingStockOptionsShares contextRef="c3" decimals="0" unitRef="shares">1055376</nmtc:OutstandingStockOptionsShares>
    <nmtc:OutstandingStockOptionsShares contextRef="c4" decimals="0" unitRef="shares">467327</nmtc:OutstandingStockOptionsShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="3" unitRef="pure">0.559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="3" unitRef="pure">0.531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="3" unitRef="pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="3" unitRef="pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c0" decimals="0" unitRef="shares">280557</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c5" decimals="0" unitRef="shares">198191</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-left: 0"&gt;Non-vested at September 30, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Non-vested at September 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 0"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,776&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 0"&gt;Non-vested at September 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c9" decimals="INF" unitRef="shares">10503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c5" decimals="INF" unitRef="shares">78323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c5" decimals="INF" unitRef="shares">2335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c5" decimals="INF" unitRef="shares">59793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c4" decimals="INF" unitRef="shares">26698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c0" decimals="INF" unitRef="shares">13776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c0" decimals="INF" unitRef="shares">29090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c3" decimals="INF" unitRef="shares">11384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c78" decimals="0" unitRef="shares">13776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c79" decimals="0" unitRef="shares">78323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <nmtc:StockOptionVestedOverAPeriodTerm contextRef="c79">P2Y</nmtc:StockOptionVestedOverAPeriodTerm>
    <nmtc:StockOptionVestedOverAPeriodTerm contextRef="c78">P2Y</nmtc:StockOptionVestedOverAPeriodTerm>
    <nmtc:GrantDateFairValueOfPerUnit contextRef="c78" decimals="2" unitRef="usdPershares">7.26</nmtc:GrantDateFairValueOfPerUnit>
    <nmtc:GrantDateFairValueOfPerUnit contextRef="c79" decimals="2" unitRef="usdPershares">6.27</nmtc:GrantDateFairValueOfPerUnit>
    <nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance contextRef="c80" decimals="0" unitRef="shares">29090</nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance>
    <nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance contextRef="c81" decimals="0" unitRef="shares">59793</nmtc:VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance>
    <nmtc:TotalExpenseOfStockOption contextRef="c80" decimals="0" unitRef="usd">163988</nmtc:TotalExpenseOfStockOption>
    <nmtc:TotalExpenseOfStockOption contextRef="c81" decimals="0" unitRef="usd">396012</nmtc:TotalExpenseOfStockOption>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c80" decimals="0" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c81" decimals="0" unitRef="shares">2335</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c82" decimals="0" unitRef="shares">62659</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c83" decimals="0" unitRef="shares">11668</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nmtc:ConsultingAgreementsDescription contextRef="c84">two consulting agreements were
executed whereby up to 38,334 shares of common stock were issued and vested as of September 30, 2020. On April 22, 2020, the Company entered
into an amendment (the &#x201c;Amendment&#x201d;) to one of the consulting agreements. Pursuant to the Amendment, the Company issued an
additional 11,667 shares in exchange for consulting services of which 11,667 shares of common stock were vested as of September 30, 2020
under the Amendment. Vesting was based on a time-based vesting condition ranging over a three to nine-month period commencing upon the
execution of the consulting agreements.</nmtc:ConsultingAgreementsDescription>
    <nmtc:ConsultingAgreementsDescription contextRef="c85">an additional consulting agreement
was executed whereby up to 30,000 shares of common stock were issued and vested as of September 30, 2020 under this agreement. In addition,
on May 21, 2020, 22,195 shares of common stock were issued as compensation to a former 2019 Paulson Note holder related to a prior 2019
Paulson Note conversion and release of liability.</nmtc:ConsultingAgreementsDescription>
    <nmtc:ConsultingAgreementsDescription contextRef="c86">an additional consulting agreement
was executed whereby 40,000 shares of common stock were issued, subject to Company repurchase. The stock award under the agreement vests
over a six-month period. As of September 30, 2021 and 2020, 33,333 and 6,667 shares vested under this agreement, respectively.</nmtc:ConsultingAgreementsDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c0" decimals="0" unitRef="usd">645910</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="c5" decimals="0" unitRef="usd">641716</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <nmtc:FairValueOfTheUnderlyingCommonStock contextRef="c87" decimals="2" unitRef="usdPershares">4.53</nmtc:FairValueOfTheUnderlyingCommonStock>
    <nmtc:FairValueOfTheUnderlyingCommonStock contextRef="c88" decimals="2" unitRef="usdPershares">7.95</nmtc:FairValueOfTheUnderlyingCommonStock>
    <nmtc:FutureIssuanceOnACombinedBasis contextRef="c89" decimals="0" unitRef="shares">389709</nmtc:FutureIssuanceOnACombinedBasis>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c3" decimals="1" unitRef="usd">1.7</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 - Stockholders&#x2019; Deficit&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2021 Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 12, 2021, the Company entered into
a Common Stock and Warrant Purchase Agreement with certain accredited investors, pursuant to which the Company, in the 2021 Private Placement,
agreed to issue and sell an aggregate of 4,166,682 shares of the common stock of the Company and warrants to purchase an aggregate of
4,166,682 shares of common stock (the &#x201c;2021 Warrants&#x201d;) at an aggregate purchase price of $3.00 per share of common stock and
corresponding warrant, resulting in total gross proceeds of $12.5 million before deducting placement agent fees and estimated offering
expenses. The 2021 Warrants have an initial exercise price of $5.25 per share. The 2021 Warrants are immediately exercisable and will
expire on the fifth anniversary of issuance. Prior to expiration, subject to the terms and conditions set forth in the 2021 Warrants,
the holders of such 2021 Warrants may exercise the 2021 Warrants for shares of common stock by providing notice to the Company and paying
the exercise price per share for each share so exercised or by utilizing the &#x201c;cashless exercise&#x201d; feature contained in each
2021 Warrant. The fair value of the 2021 Warrants was $7.3 million and was based on the Black-Scholes pricing model. Input assumptions
used were as follows: a risk-free interest rate of 0.5%; expected volatility of 56.0%; expected life of 5 years; expected dividend yield
of 0%; and the underlying traded stock price.&#160;$3.7 million of the total proceeds was allocated to the 2021 Warrants based on the
relative fair value allocation method, which has been reflected in stockholders&#x2019; equity. The 2021 Warrants were classified in stockholders&#x2019;
equity as the number of shares were fixed and determinable, and no other provisions precluded equity treatment. The private placement
closed on January 14, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2020 Common Stock Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 28, 2020, the Company entered into securities
purchase agreements with an accredited investor in a private placement, pursuant to which the Company has issued and sold 25,000 shares
to such investor, at $5.40 per share for gross proceeds amounting to $135,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Common Stock Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 23, 2019, the Company entered into
Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and
sold 47,223 shares of the Company&#x2019;s common stock to the accredited investors at a price of $5.40 per share, for gross proceeds amounting
to $255,000. The Company filed a registration statement with the SEC covering the resale of the shares of common stock sold in the private
placement on August 11, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrant Activity and Summary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes warrant activity
during the years ended September 30, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Warrants&lt;/b&gt; &#160; &#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise &lt;br/&gt;
Price Per &lt;br/&gt;
Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average Exercise &lt;br/&gt;
Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted &lt;br/&gt;
Average Term &lt;br/&gt;
(years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,421,940&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.40 - 9.00&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.65&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;968,380&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;5.61&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,390,320&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.40 - 9.00&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.05&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,166,682&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-size: 10pt"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(53,194&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61-8.25 &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-size: 10pt"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,503,808&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.25-9.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.06&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes information about
warrants outstanding at September 30, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average &lt;br/&gt;
Remaining Contractual&lt;br/&gt;
life (Years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number Exercisable at &lt;br/&gt;
September 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="width: 21%; text-align: right"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: right"&gt;4,166,682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;4.29&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: right"&gt;4,166,682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.40&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;750,364&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;0.14&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;750,364&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.61&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;916,753&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.68&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;916,753&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6.00&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,173&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.75&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,173&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7.50&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;279,733&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.41&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;279,733&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.25&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,911&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.75&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,911&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9.00&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,282,192&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.18&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,282,192&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;Total&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;7,503,808&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;7,503,808&lt;/td&gt;
    &lt;td style="padding-bottom: 4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <nmtc:AggregateShareIssued contextRef="c96" decimals="0" unitRef="shares">4166682</nmtc:AggregateShareIssued>
    <nmtc:PurchaseOfWarrants contextRef="c96" decimals="0" unitRef="shares">4166682</nmtc:PurchaseOfWarrants>
    <nmtc:PurchasePriceOfCommonStock contextRef="c96" decimals="2" unitRef="usdPershares">3</nmtc:PurchasePriceOfCommonStock>
    <nmtc:TotalGrossProceeds contextRef="c96" decimals="-5" unitRef="usd">12500000</nmtc:TotalGrossProceeds>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c97" decimals="2" unitRef="usdPershares">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nmtc:FairValueOfWarrants contextRef="c96" decimals="-5" unitRef="usd">7300000</nmtc:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c96" decimals="3" unitRef="pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c96" decimals="3" unitRef="pure">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c96">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c96" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c96" decimals="-5" unitRef="usd">3700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <nmtc:SharesIssuedUnderPrivatePlacement contextRef="c98" decimals="0" unitRef="shares">25000</nmtc:SharesIssuedUnderPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare contextRef="c99" decimals="2" unitRef="usdPershares">5.4</us-gaap:SaleOfStockPricePerShare>
    <nmtc:GrossProceedsFromPrivatePlacement contextRef="c98" decimals="0" unitRef="usd">135000</nmtc:GrossProceedsFromPrivatePlacement>
    <nmtc:SharesIssuedUnderPrivatePlacement contextRef="c100" decimals="0" unitRef="shares">47223</nmtc:SharesIssuedUnderPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare contextRef="c101" decimals="2" unitRef="usdPershares">5.4</us-gaap:SaleOfStockPricePerShare>
    <nmtc:GrossProceedsFromPrivatePlacement contextRef="c100" decimals="0" unitRef="usd">255000</nmtc:GrossProceedsFromPrivatePlacement>
    <nmtc:SummaryOfWarrantActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Warrants&lt;/b&gt; &#160; &#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise &lt;br/&gt;
Price Per &lt;br/&gt;
Warrant&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
Average Exercise &lt;br/&gt;
Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted &lt;br/&gt;
Average Term &lt;br/&gt;
(years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2,421,940&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.40 - 9.00&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.65&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.60&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;968,380&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;5.61&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,390,320&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.40 - 9.00&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.05&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4,166,682&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;4.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-size: 10pt"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(53,194&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61-8.25 &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.61&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-size: 10pt"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding and exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7,503,808&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.25-9.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6.06&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</nmtc:SummaryOfWarrantActivityTableTextBlock>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber contextRef="c9" decimals="INF" unitRef="shares">2421940</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1 contextRef="c102" decimals="2" unitRef="usdPershares">5.4</nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1 contextRef="c103" decimals="2" unitRef="usdPershares">9</nmtc:ExercisePricePerWarrantOutstandingAndExercisableBeginning1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">7.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c5">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod contextRef="c5" decimals="INF" unitRef="shares">968380</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <nmtc:ExercisePricePerWarrantIssued contextRef="c5" decimals="2" unitRef="usdPershares">5.61</nmtc:ExercisePricePerWarrantIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c5" decimals="2" unitRef="usdPershares">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber contextRef="c4" decimals="INF" unitRef="shares">3390320</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding contextRef="c102" decimals="2" unitRef="usdPershares">5.4</nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding contextRef="c103" decimals="2" unitRef="usdPershares">9</nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding>
    <nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding contextRef="c4" decimals="2" unitRef="usdPershares">7.05</nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c5">P2Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod contextRef="c0" decimals="INF" unitRef="shares">4166682</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <nmtc:ExercisePricePerWarrantIssued contextRef="c0" decimals="2" unitRef="usdPershares">5.25</nmtc:ExercisePricePerWarrantIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c0" decimals="2" unitRef="usdPershares">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod contextRef="c0" decimals="INF" unitRef="shares">-53194</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <nmtc:WeightedAverageExercisePriceExercised contextRef="c87" decimals="2" unitRef="usdPershares">5.61</nmtc:WeightedAverageExercisePriceExercised>
    <nmtc:WeightedAverageExercisePriceExercised contextRef="c88" decimals="2" unitRef="usdPershares">8.25</nmtc:WeightedAverageExercisePriceExercised>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1 contextRef="c0" decimals="2" unitRef="usdPershares">5.61</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber contextRef="c3" decimals="INF" unitRef="shares">7503808</nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding contextRef="c104" decimals="2" unitRef="usdPershares">5.25</nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding>
    <nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding contextRef="c105" decimals="2" unitRef="usdPershares">9</nmtc:ExercisePricePerWarrantOutstandingAndExercisableEnding>
    <nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding contextRef="c3" decimals="2" unitRef="usdPershares">6.06</nmtc:WeightedAverageExercisePriceOutstandingAndExercisableEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0">P3Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average &lt;br/&gt;
Remaining Contractual&lt;br/&gt;
life (Years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number Exercisable at &lt;br/&gt;
September 30,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="width: 21%; text-align: right"&gt;5.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: right"&gt;4,166,682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;4.29&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: right"&gt;4,166,682&lt;/td&gt;
    &lt;td style="width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.40&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;750,364&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;0.14&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;750,364&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.61&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;916,753&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.68&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;916,753&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;6.00&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,173&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.75&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;45,173&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7.50&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;279,733&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.41&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;279,733&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.25&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,911&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.75&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;62,911&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-align: justify"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9.00&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,282,192&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2.18&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,282,192&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;Total&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;7,503,808&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;7,503,808&lt;/td&gt;
    &lt;td style="padding-bottom: 4.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <nmtc:ExercisePrice contextRef="c106" decimals="2" unitRef="usdPershares">5.25</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c106" decimals="0" unitRef="shares">4166682</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c106">P4Y3M14D</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c106" decimals="0" unitRef="shares">4166682</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c107" decimals="2" unitRef="usdPershares">5.4</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c107" decimals="0" unitRef="shares">750364</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c107">P0Y1M20D</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c107" decimals="0" unitRef="shares">750364</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c108" decimals="2" unitRef="usdPershares">5.61</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c108" decimals="0" unitRef="shares">916753</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c108">P2Y8M4D</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c108" decimals="0" unitRef="shares">916753</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c109" decimals="2" unitRef="usdPershares">6</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c109" decimals="0" unitRef="shares">45173</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c109">P2Y9M</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c109" decimals="0" unitRef="shares">45173</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c110" decimals="2" unitRef="usdPershares">7.5</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c110" decimals="0" unitRef="shares">279733</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c110">P2Y4M28D</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c110" decimals="0" unitRef="shares">279733</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c111" decimals="2" unitRef="usdPershares">8.25</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c111" decimals="0" unitRef="shares">62911</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c111">P2Y9M</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c111" decimals="0" unitRef="shares">62911</nmtc:NumberExercisable1>
    <nmtc:ExercisePrice contextRef="c112" decimals="2" unitRef="usdPershares">9</nmtc:ExercisePrice>
    <nmtc:NumberOutstandingsTotal contextRef="c112" decimals="0" unitRef="shares">1282192</nmtc:NumberOutstandingsTotal>
    <nmtc:WeightedAverageRemainingContractualLifeYears contextRef="c112">P2Y2M4D</nmtc:WeightedAverageRemainingContractualLifeYears>
    <nmtc:NumberExercisable1 contextRef="c112" decimals="0" unitRef="shares">1282192</nmtc:NumberExercisable1>
    <nmtc:NumberOutstandingsTotal contextRef="c113" decimals="0" unitRef="shares">7503808</nmtc:NumberOutstandingsTotal>
    <nmtc:NumberExercisable1 contextRef="c113" decimals="0" unitRef="shares">7503808</nmtc:NumberExercisable1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 - Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effective tax rate for the Company for the
years ended September 30, 2021 and 2020 was zero percent. A reconciliation of income tax computed at the statutory federal income tax
rate to the provision (benefit) for income taxes included in the accompanying statements of operations for the years ended September 30
is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Income tax benefit at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;State income tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Disqualified interest and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Research credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities are summarized in the tables below as of September 30:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Federal and state operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,575,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,936,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Acquired intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Research and development credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;451,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;255,068&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,872,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,694,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,808,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,694,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the Company
had gross deferred tax assets of approximately $8,873,000 and $5,695,000, respectively. Realization of the deferred assets is primarily
dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses
since its inception. The Company has not yet generated revenues from sales and faces significant challenges to becoming profitable. Accordingly,
the net deferred tax assets have been fully offset by a valuation allowance of approximately $8,808,000 and $5,695,000 as of September
30, 2021 and 2020, respectively. The U.S. net deferred tax assets will continue to require a valuation allowance until the Company can
demonstrate their realizability through sustained profitability or another source of income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the Company&#x2019;s
federal net operating loss carryforwards were approximately $26,355,000 and $17,175,000, respectively. The Company had federal research
credit carryforwards as of September 30, 2021 and 2020 of approximately $506,000 and $272,000, respectively. The federal net operating
loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating
losses incurred after December 31, 2017 will not expire. As of September 30, 2021 and 2020, the Company had state net operating loss carryforwards
of approximately $26,355,000 and $17,175,000, respectively. The Company had state research credit carryforwards of approximately $307,000
and $178,000 as of September 30, 2021 and 2020, respectively. The state net operating loss carryforwards will begin to expire in 2031,
if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Utilization of the net operating loss carryforwards
and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal
Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation
applies when one or more &#x201c;5-percent shareholders&#x201d; increase their ownership, in the aggregate, by more than 50 percentage points
over a 36-month testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result
in the expiration of net operating losses and credits before utilization.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC
740&#x201d;), specifically related to uncertain tax positions, a Company is required to use a recognition threshold and a measurement attribute
for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits
to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company believes
its income tax filing positions and deductions will be sustained upon examination, and accordingly, no reserves or related accruals for
interest and penalties have been recorded at September 30, 2021 and 2020.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with this guidance, the Company
has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will
be classified as a component of interest expense and any related penalties will be classified in operating expenses in the statements
of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has tax filing obligations in the
following jurisdictions: U.S. federal, Minnesota and California. The income tax returns since inception as a corporation in 2016 are subject
to examination by the federal and Minnesota taxing authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Income tax benefit at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;State income tax, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Disqualified interest and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Research credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;31.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <nmtc:IncomeTaxBenefitAtFederalStatutoryRate contextRef="c3" decimals="3" unitRef="pure">-0.21</nmtc:IncomeTaxBenefitAtFederalStatutoryRate>
    <nmtc:IncomeTaxBenefitAtFederalStatutoryRate contextRef="c4" decimals="3" unitRef="pure">-0.21</nmtc:IncomeTaxBenefitAtFederalStatutoryRate>
    <nmtc:StateIncomeTaxNetOfFederalBenefit contextRef="c3" decimals="3" unitRef="pure">-0.077</nmtc:StateIncomeTaxNetOfFederalBenefit>
    <nmtc:StateIncomeTaxNetOfFederalBenefit contextRef="c4" decimals="3" unitRef="pure">-0.077</nmtc:StateIncomeTaxNetOfFederalBenefit>
    <nmtc:DisqualifiedInterestAndOther contextRef="c4" decimals="3" unitRef="pure">0.17</nmtc:DisqualifiedInterestAndOther>
    <nmtc:ResearchCredits contextRef="c3" decimals="3" unitRef="pure">-0.037</nmtc:ResearchCredits>
    <nmtc:ResearchCredits contextRef="c4" decimals="3" unitRef="pure">-0.013</nmtc:ResearchCredits>
    <nmtc:StockbasedCompensation contextRef="c3" decimals="3" unitRef="pure">0.01</nmtc:StockbasedCompensation>
    <nmtc:StockbasedCompensation contextRef="c4" decimals="3" unitRef="pure">0.002</nmtc:StockbasedCompensation>
    <nmtc:ValuationAllowance contextRef="c3" decimals="3" unitRef="pure">0.314</nmtc:ValuationAllowance>
    <nmtc:ValuationAllowance contextRef="c4" decimals="3" unitRef="pure">0.128</nmtc:ValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Federal and state operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,575,069&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,936,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Acquired intangibles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,541&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,635&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Accruals and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 9pt"&gt;Research and development credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;451,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;255,068&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -9pt; padding-left: 0.25in"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,872,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,694,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(64,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,808,329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,694,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c3" decimals="0" unitRef="usd">7575069</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c4" decimals="0" unitRef="usd">4936384</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c3" decimals="0" unitRef="usd">24541</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">22635</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="0" unitRef="usd">8370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c4" decimals="0" unitRef="usd">30406</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="0" unitRef="usd">812781</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="0" unitRef="usd">450081</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="0" unitRef="usd">451757</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c4" decimals="0" unitRef="usd">255068</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">8872518</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" unitRef="usd">5694574</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">64189</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c3" decimals="0" unitRef="usd">64189</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" unitRef="usd">8808329</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" unitRef="usd">5694574</us-gaap:DeferredTaxAssetsValuationAllowance>
    <nmtc:DeferredTaxAssetGrossCurrent contextRef="c0" decimals="0" unitRef="usd">8873000</nmtc:DeferredTaxAssetGrossCurrent>
    <nmtc:DeferredTaxAssetGrossCurrent contextRef="c5" decimals="0" unitRef="usd">5695000</nmtc:DeferredTaxAssetGrossCurrent>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="0" unitRef="usd">8808000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c5" decimals="0" unitRef="usd">5695000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c3" decimals="0" unitRef="usd">26355000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c4" decimals="0" unitRef="usd">17175000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c3" decimals="0" unitRef="usd">506000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c4" decimals="0" unitRef="usd">272000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal contextRef="c3" decimals="0" unitRef="usd">26355000</nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal>
    <nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal contextRef="c4" decimals="0" unitRef="usd">17175000</nmtc:DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal>
    <nmtc:StateTaxCreditCarryForward contextRef="c3" decimals="0" unitRef="usd">307000</nmtc:StateTaxCreditCarryForward>
    <nmtc:StateTaxCreditCarryForward contextRef="c4" decimals="0" unitRef="usd">178000</nmtc:StateTaxCreditCarryForward>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 - Defined Contribution Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a 401(k) defined contribution
plan (the &#x201c;401K Plan&#x201d;) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll
withholdings into the 401K Plan subject to federal law limits. The Company may match 100% of deferrals up to 3% of one&#x2019;s contributions.
The Company&#x2019;s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing
contributions under the 401K Plan in the future, but it has not done so through September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Employee contributions and any employer matching
contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution.
Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee&#x2019;s
date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee&#x2019;s
date of hire. The amount of contributions made by the Company under the 401K Plan during the years ended September 30, 2021 and 2020 was
$14,803 and zero, respectively.&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <nmtc:EmployeesCompensationPercentage contextRef="c0" decimals="2" unitRef="pure">1</nmtc:EmployeesCompensationPercentage>
    <nmtc:DeferralsPercentage contextRef="c0" decimals="2" unitRef="pure">1</nmtc:DeferralsPercentage>
    <nmtc:ContributionsPercentage contextRef="c0" decimals="2" unitRef="pure">0.03</nmtc:ContributionsPercentage>
    <nmtc:InternalRevenuePercentage contextRef="c0" decimals="2" unitRef="pure">1</nmtc:InternalRevenuePercentage>
    <nmtc:ContributionsAmount contextRef="c0" decimals="0" unitRef="usd">14803</nmtc:ContributionsAmount>
    <nmtc:ContributionsAmount contextRef="c5" decimals="0" unitRef="usd">14803</nmtc:ContributionsAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 - Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&lt;i&gt;Inducement Plan &lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;On October 4, 2021, the Company
adopted the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the &#x201c;Plan&#x201d;), pursuant to which the Company reserved
420,350 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors
of the Company, as an inducement material to the individual&#x2019;s entry into employment with the Company within the meaning of Rule
5635(c)(4) of the Nasdaq Listing Rules. The Plan was approved by the Company&#x2019;s Board of Directors without stockholder approval in
accordance with such rule.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Public Offering&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 13, 2021, the Company, entered into
an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Craig-Hallum Capital Group LLC, as underwriter (the &#x201c;Underwriter&#x201d;),
relating to the issuance and sale of 3,750,000 shares of the Company&#x2019;s common stock at a price to the public of $3.20 per share.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to
purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale
of 422,057 shares of common stock subject to the Underwriter&#x2019;s overallotment option closed on November 15, 2021. Deferred offering
costs in connection with the offering amounted to $92,934 and are reflected in the prepaid and other assets line item in the accompanying
balance sheets as of September 30, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The gross proceeds to the Company from this offering
were approximately $13.4 million prior to deducting underwriting discounts and other offering expenses payable by the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <nmtc:SharesAreAuthorizedForFutureIssuance contextRef="c114" decimals="0" unitRef="shares">420350</nmtc:SharesAreAuthorizedForFutureIssuance>
    <nmtc:UnderwritingAgreementDescription contextRef="c115">the Company, entered into
an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Craig-Hallum Capital Group LLC, as underwriter (the &#x201c;Underwriter&#x201d;),
relating to the issuance and sale of 3,750,000 shares of the Company&#x2019;s common stock at a price to the public of $3.20 per share.
In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to
purchase up to an additional 562,500 shares of common stock on the same terms. The base offering closed on October 15, 2021, and the sale
of 422,057 shares of common stock subject to the Underwriter&#x2019;s overallotment option closed on November 15, 2021. Deferred offering
costs in connection with the offering amounted to $92,934 and are reflected in the prepaid and other assets line item in the accompanying
balance sheets as of September 30, 2021.</nmtc:UnderwritingAgreementDescription>
    <nmtc:GrossProceeds contextRef="c0" decimals="-5" unitRef="usd">13400000</nmtc:GrossProceeds>
    <dei:LocalPhoneNumber contextRef="c0" id="hidden-fact-0">426-1383</dei:LocalPhoneNumber>
    <dei:CityAreaCode contextRef="c0" id="hidden-fact-1">952</dei:CityAreaCode>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      id="hidden-fact-11"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c5"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c5"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c5"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering
      contextRef="c10"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock
      contextRef="c12"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c10"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c12"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c12"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c10"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c11"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c18"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c18"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacement
      contextRef="c16"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostsInConnectionWithPrivatePlacement
      contextRef="c18"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement
      contextRef="c16"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceCostSettlementInConnectionWithPrivatePlacement
      contextRef="c18"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c18"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c18"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
      contextRef="c18"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:IssuanceOfCommonStockUponVestingOfRestrictedStockUnits
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c18"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="c18"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c16"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c17"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:NoncashInterestOnConvertiblePromissoryNotes
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:PayrollProtectionProgramLoanForgiveness
      contextRef="c5"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c5"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c5"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement
      contextRef="c5"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c5"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ProceedsFromPaycheckProtectionProgram
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:DeferredsOfferingCosts
      contextRef="c5"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:BrokerWarrantsIssuedInConnectionWithConvertibleNotes
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ValueOfPayrollProtectionProgramLoanForgiveness
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:UnpaidDeferredOfferingCosts
      contextRef="c5"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c26"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c27"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c26"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c27"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayable
      contextRef="c3"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayable
      contextRef="c9"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ConvertibleNotes
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c4"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="c3"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c0"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:RoyaltyPayments
      contextRef="c4"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="c9"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ConvertibleNotesOutstandingPrincipal
      contextRef="c3"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables
      contextRef="c3"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable
      contextRef="c3"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:ConvertiblePromissoryNotesPayable
      contextRef="c3"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsIssuedinShares contextRef="c5" id="hidden-fact-75" xsi:nil="true"/>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c5"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageExercisePriceExercised
      contextRef="c5"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsExercisedinShares contextRef="c5" id="hidden-fact-79" xsi:nil="true"/>
    <nmtc:WarrantsForfeitedinShares
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageExercisePriceForfeited
      contextRef="c5"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsForfeitedinShares contextRef="c5" id="hidden-fact-83" xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsIssuedinShares contextRef="c0" id="hidden-fact-84" xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsExercisedinShares contextRef="c0" id="hidden-fact-85" xsi:nil="true"/>
    <nmtc:WarrantsForfeitedinShares
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageExercisePriceForfeited
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nmtc:WeightedAverageTermyearsForfeitedinShares contextRef="c0" id="hidden-fact-89" xsi:nil="true"/>
    <nmtc:DisqualifiedInterestAndOther
      contextRef="c3"
      id="hidden-fact-90"
      unitRef="pure"
      xsi:nil="true"/>
    <nmtc:EffectiveTaxRate
      contextRef="c3"
      id="hidden-fact-91"
      unitRef="pure"
      xsi:nil="true"/>
    <nmtc:EffectiveTaxRate
      contextRef="c4"
      id="hidden-fact-92"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c4"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:DeferredIncomeTaxAssetNet
      contextRef="c3"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <nmtc:DeferredIncomeTaxAssetNet
      contextRef="c4"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001500198</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of September 30, 2021 and 2020 of $3.95 and $3.86 per share, respectively. As of September 30, 2021 and 2020, 1,055,376 and 467,327 outstanding options, respectively, had no intrinsic value.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 7H8+Z;COS%.I5;X9VH%[/FS3QIF(T /6]!*<CCBB1UGY^C(W[2&]M.).4$
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MVZ\?8->+6R=UVCS$@.\Y]QS,!:9[(1]5!J#1[YQQ-?,RK8MKWU=)!CE1/5$
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MY\CF,H.C/I<F '[?"NAOIQLS0/?GP>H_4$L#!!0    ( .6#OU1L"[(F,@<
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ML6D+)R ^E"+?-9UE!+LD._V-OC5"7'1 Q-(!-QVPT@$S2P?2="!J!UM(M.E
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MGLG#6R"'+UKL[(L42Z&UV-J/&\XJ+HT!_+X2,+6[+^8&QW=Q;O\'4$L#!!0
M   ( .6#OU0LIB2<3 <  &,0   8    >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULK5C;<MLV$'WG5^RHG4XRH^CJM&EC>T9VW#:=\:6QVSYT^@"1D(@1"#
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MZ"-4)K78H!];AU3AO4P?%-@540XJMX2\!%Q;-JXG$&W*?&X]/$;D%"&EPL2
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MHUQ:RTNUJ]K'V,T@R!X[TGJ8,LK9"V7_.'C.+=G:#>E#YP 5-$;,G\^%<59
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MX 'Z?555K?L#&_AKHG_Y7U!+ P04    " #E@[]41=D'^#,2  !$,   &0
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MY0'NUP:UV6U$0?^!=?DW4$L#!!0    ( .6#OU3/,^K<TPL  !TE   9
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M>\\<Q3/]8.-/'I(0F!.$K8%Y$?5WD9CLXY.GZQY-HQ7?DVG:,B=/E3FRTTA
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MRV='/L?%!ZN6[@<P4V4!=>[C0G!@)BW ^YE2-C[0 ?4OHE[_%U!+ P04
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M:Z!9_8!+2O.[^'HRNCX<H(+)_9P&76<T'2&GA?QD%$[=)/([?C<4+C++=E7
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M+I6$"6@!WL]+!):]H0/ZWZZ\^A]02P,$%     @ Y8._5&F@^4^E!P  0!,
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MQ^"2T")GLK8JX+A=0=:0),;KG'WC6G-@]-CJ; UYP&Y76CC>6VG7+!/:0A&
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ME#!P=W?NCTP+/-A[] GT?AEXO\TFX,;I& :8>-PM @_Y(IZ&LTD*WIS.NT5
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MB3 5]B6*66,9='@>N)B;&W#"6Q(!A L\!HE$KMF_F&'PT+:I\RZ#E1I3$)N
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M];JRATH5DT .![][D&-N*DHNR9"2K.XG*F"*(%)9LG"E:XAF.;J@1 <E(>O
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MW;&]<RME*K")#>SN+]$ 6VT[=CS<$D:3S1H%MMVAH2 7* 2+ +-:]=#7]D9
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MIL5Y$" +"P2+!XKZ8?P/<OU@@93T"?Z8)7NR35X'*]&)M[$8,&?&WO"V0+\
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M$0"V9)@W%SCGCP/@)J?8.N&R>-053!1WV_E-FI^$WVCNA*95C_6U4"-,:,H
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M1WY56'8OT^*:[K36]4?FYM-GYCX"^/?(T\\@Z]=X9GM4]W[@S-Q=R%X#==!
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M/WO$XZO^ Y@J^K<7EG7;UB7]N3$I* $^ +^OZKKU'W"!\*]Q_/)_4$L#!!0
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M:SR?!KMMR;S2 -XZ_L*6 LS)-+)(Y1*BO(===+#T!=B$DALE[<J0#[* XE^
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MF&!#@+^OC,&C$89E6O7\#U!+ P04    " #E@[]4>UQ_7@<#  !,"@  &0
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MPY4D&F87];?TS;LP< [>XB\.*[-S35PI4Z6^NIO;^*(>.$0@(+(N!,./)4Q
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M]^C]-3U_A7/<SLDE7TLV)Q,!2Q"XE1KD[F[2()>W#P?/W$:[CD$N&::YE4O
MV:]QMUGU!)A$-VJ[J=!:*!T7V=*%-@N&@!#U:LZC^5Y1<V8RS+%[G]6@9C,>
M ?$$$:$B9O$MLZ3?'0[)6XGF+"%7&H5"P^,B#YIQS:%1N^=2@E&6[57_H"'A
M!LP&4I-\W$%@48R05!DT\"I&S3S C1/!1W^J)21N7>AF73R%S@R7)-FX9#T"
M,L:)5.MU28+#:8[ES= (%156'F,I#;*0 G-Y5RY]<<"TX&BTB_HCOMY'S"6W
MG DO<%!L(:4H^/;!<D->]AH=&I 4PWD M8W1C&MC">WGN!H8+T*-:!"MX_YE
MOQ'T>UL_,EU[-ZQG4Z"#U,0.("R.N>M\[ V#*X0!\'-W61&'5!8S;,17;2%C
MT%N:]EO;S)G NEPRRZW(FH%AGBG2X[L9$7 <.X>E9U5MR'Z&;C?'B@M1P_GE
MXZ1:$8VJQ&764"S@3N_2_KD[8N0""4=YC<:.)_B.2ML1S8Q1$?>+5_1"FJ]"
M@T1,1 N1]:TA!CQ<M$(^T+!VE[=YR7Y XJHX0%/G^1S/,S;:&S90U?2"\XH#
M<%#,P4'E',P09SOR#*MX_+9PO-T#-C$>M_^0XP+J,HO<W9W,M!>6S^5A@6=X
M A[7"+@\.0EEN8<'IT(G[-#RW#38*M.@,ON]8U>L\W'E4)2*M:!$"G2.Y-Y1
MQ;3Z)':=<+SBZ]Q]C^YV;Q#VBL2Y"*0E0J%-!\,C +<*C8;5Y."82A8)^7+O
M9V:5_*);_47;OU+WT:WPHO]->95J^T/-5:%XZ%9ST6K1=<_6BKPM#O13"-W*
M*=K[I81N!16M5E0G$'J=A]@EM#T8'MLZVQE&JX?89Q8#N4$)I7GTU>"Y?@JC
MVXE$A[^2T7 [C<+J:?1#:1P>#B+:*='&K9TOZ^[7GGNFG[C$ QYFZ!@T^]BN
M.OL!);NQ*O7?WZ?*6I7XRSD@R=H9X/N94G9SXWX2*'[&&O\+4$L#!!0    (
M .6#OU0J-M?UOP(  +8&   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;(U5VT[;0!#]E975!Y *OB5.0$XD$EJU#ZB(B/9Y8X_C%7MQ=]<$_KZS:\<-
M@42\Q'N9<WSFS&2<;Y5^,C6 )2^"2S,+:FN;ZS T10V"FDO5@,2;2FE!+6[U
M)C2-!EIZD.!A$D59*"B3P3SW9_=ZGJO6<B;A7A/3"D'UZP*XVLZ".-@=/+!-
M;=U!.,\;NH$5V,?F7N,N'%A*)D :IB314,V"F_AZF;EX'_";P=;LK8G+9*W4
MD]O\+&=!Y 0!A\(Z!HJ/9U@"YXX(9?SM.8/AE0ZXO]ZQ?_>Y8RYK:F"I^!]6
MVGH63 -20D5;;A_4]@?T^8P=7Z&X\;]DV\=& 2E:8Y7HP:A ,-D]Z4OOPQX@
MSHX DAZ0' )&1P!I#TA]HITRG]8MM72>:[4EVD4CFUMX;SP:LV'257%E-=XR
MQ-GY4@G!+);%&D)E299*6B8W( L&AIS=@J6,FW-R05;80&7+@:@*:]XT'!R*
M<E)04Y,*VX$PV;555V%.+93$*F)K!#6@J6,F'-!UY'M<W9*S+^=Y:#$-)R8L
M>LF+3G)R1'*<D#M461OR3990OB4(,?_!A&1GPB(YR;B"YI*DT5>21$G\@:#E
MY^'1"3GI4)/4\Z7':N(,;2@K"=I)J%"MJPZ3!6\Q7UQX1P7ZV&I?!%>2SE;.
MZ)IQ9E^O3^@8#3I&7L?HB(Y?0\V&$AM2:24.JVD^*F+'/?'<;I8\SR?1]&J2
MA\_[SKZ/2J>C+!FBW@@?#\+')PWTL^A"51<M6D*- ;1/K;&396<?O!0UQ2;W
M_G;&J35G&]^YYI1UV: @^Z1UQPW*WAN4QO'TP*#W46DZCN.K X?"O1$@0&_\
M9#2D<+W3_1&&TV'XWOB9<W"^P*'<S=#_--U$OZ-ZPZ3!C"JDC"XG6 3=3<EN
M8U7C!\U:61Q;?EGCAP6T"\#[2BF[V[@7#)^J^3]02P,$%     @ Y8._5+&K
M+\BV @  7@<  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULK57O:]LP
M$/U7A-F@@S7^E3A920)MRMA@@]+0]</8!\6^)**RY$F7IOGO=Y)=+^T<L\&^
MV))][_F]N]-YNM?FP6X!D#V54ME9L$6L+L+0YELHN1WH"A2]66M3<J2MV82V
M,L +#RIEF$11%I9<J& ^]<]NS'RJ=RB%@AO#[*XLN3E<@=3[61 'SP]NQ6:+
M[D$XGU9\ TO N^K&T"YL60I1@K)"*V9@/0LNXXM%YN)]P#<!>WNT9L[)2NL'
MM_E<S(+("0().3H&3K='6("4CHAD_&PX@_:3#GB\?F;_Z+V3EQ6WL-#R7A2X
MG063@!6PYCN)MWK_"1H_(\>7:VG]E>V;V"A@^<ZB+ALP*2B%JN_\J<G#$2!)
M3P"2!I"\ L3C$X"T :3>:*W,V[KFR.=3H_?,N&AB<PN?&X\F-T*Y*B[1T%M!
M.)PO=%D*I+*@95P5;*$5"K4!E0NP[.P:D MIW[%SMJ0&*G82F%Y3S:M*@D-Q
M25F47.7 ZJX3JFZMNLJ2(Q0,-<,M 2LPW+$S"91YXKQ;7K.S-^^F(9(5)RC,
M&]E7M>SDA.PE5 .61N]9$B5Q!WSQ]_#H)3RD!+993-HL)IXO/<7WWW/S_7)E
MT5"3_^B1E[;R4B]O>$*>/YOG>GV^(V9N+:#M2GE-,O8D[O0_SI/)Y,-P,@T?
MCU/;%98D<=R&O= X;#4.>S5^\;:EX"LA!1ZZ] W_^' :C[)Q^DI?5U@2C[-N
M?:-6WZA7W[T?"%0P_DB5V@ 5T W)WQ5#,"4[.P WMK.A^^E3YI$L9B6=P"W+
M6,$/755:]/,,&YZLYK$]W9.USK-_<UX(F^N=0D8="UU6^_FRP3AZV^6L'S8>
M1*]AM9WP:/JY/\]7;C9"62K+FHBBP9@R9NII7F]05WX@KC32>/7++?T P;@
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M8\^RPQ+_*B!- 'XOA-"'B6E<_7\J_0]02P,$%     @ Y8._5%PL#BWW @
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MZ%Q$*EO>S>MN(UEM1MZ*235 S7*C?G' M8%Z7S FWS9ZB@X_S>0?4$L#!!0
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MLN8O( 9YP/<'STW<;X1@^*:N_@-02P,$%     @ Y8._5 WWF]H# P  F0@
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M;ECBM03*!N#^6DJSG]@7]!==]@=02P,$%     @ Y8._5+ZL)ZN+%   Z%P
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M8+D"<03H0?!&A+.1(NUXI0V*$KX$S8:5.R>H7CP"7-,'P+#=CJUC4*?D 6C
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M7[>,KEF.#\#?-QELH?R KSYN7F[^XO\ 4$L#!!0    ( .6#OU0M^ZJ9F0(
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M9#R*@P#K?.B@&C54HUZJ>9JJ/62$"0/X?--%T.OP#H+*9]PBB*/1^*(;8-P
MC'L!;BA3Y$#Y'@C-?N'7[5Y]%T:OSSLPQJ\PHH^3R>@(1]QPQ+T<WZ3IWC^]
MLG?$CE_MGV$03,(@_B>WW^I\]J_SA:HM$YIPV* R&$R07%6=O)H86;AFN)8&
M6ZL;[O#G!\HNP/L;B5])/;']M?F=)G\ 4$L#!!0    ( .6#OU08="'4@@H
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M]G//E[UOK9BU7RY1CX^#8/N-]>XZ/O8<NN>-J]N,^ZY]/F]YHPS;PGAC_VO
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MI['YN9 "VBLN@.>S%"!8=8$;U)^I7OP/4$L#!!0    ( .6#OU0$*PV<QP(
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MYUN8.LS2CL/Q6Y%X9RJFS[AHI_ ;W.1P3 +':91'4R[R[;"#BO".Z_'99/_
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ME>)9>;EB-&:B>$'_ON!<[6X*!\UQW/1_4$L#!!0    ( .6#OU3Y>. K_0(
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M(F73DC03+2I;U9="8X]@AVOLXD":#?@\%T+O)J91Z/K"V6]02P,$%     @
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ML/.J7W?8'(.R ?A](Z5Y&=CVJVNWE_\!4$L#!!0    ( .6#OU0:=B+ZAP(
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MC0'-KX70?<<4XN%EM_@74$L#!!0    ( .6#OU0X+OHM* ,   P3   -
M>&PO<W1Y;&5S+GAM;-U846_:,!#^*Y$[39TT-4!&2E9 VI J3=JF2NW#WBI#
M'+#DV)EC.NBOGR\."5 ?8GW88$$T]GVY[S[?76J+86G6@MTO&#/!*A>R')&%
M,<7',"QG"Y;3\DH53%HD4SJGQD[U/"P+S6A:@E,NPEZG$X<YY9*,AW*9W^:F
M#&9J*<V(]!M3X&Y?TA'IQA](X.@F*F4C\GCY]N=2F9LW@;M?O+^XZ%QU'M_=
M[".7-?2.A%[B_A'$*"U&&A^EMG-(;P<EOSZ._! W1CW8I6ZSNI/%L"[9>)@I
MV58N(LY@F6G.@B<J1F1"!9]J#EX9S;E8.W,/##,EE Z,;1D;J@N6\MG!73>#
M;JIY<BZ5KF*[".[OM'Y\#]C,0" 7HA'8(\XP'A;4&*;EK9U4#U?&%U!0CQ_6
MA54XUW3=[?5)ZU#=;)"ITBG339@NV9C&0\$RD*/Y? %WHXH00&-4;@<IIW,E
M::5AXU$/+.V,"7$/K]J/;(=[E6W5K ,5D\W0"JJ'CL9-@'^;S7%OT_9>Q1L4
M_$F9STN['%G-H<O8G6897U7S5=8(P-B[.#LM"K'^)/A<YLPM_NB XR'=^ 4+
MI?FSC0:M,K,&IDGPQ+3ALVW++TV+![8RFW9:9;CFWAEJ_KMYGC/)-!7;HFWO
MGW*67ZTXNOY7DJO_*ON"O1KK_?/41?;/061\#B+/H">CY/0UUB>BDQ,9UOOW
MUB%AYXC06 ,XBHW(=SC4B39H,%UR8;BL9PN>IDR^."E8>D.G]JB_PV^?3UE&
ME\(\-."(M.-O+.7+/&F>NH-$U$^UXZ^PO&[<G -M+"Y3MF+II)[J^;0:!G9@
MH]87..PCM]7E1S ?A_D1P+ XF +,QWEA<?ZG]0S0]3@,TS;P(@/49X#Z."\?
M,JD^6!R_3V(O_TJ3)(KB&,OH9.)5,,'R%L?P];-AVL #BP.1_BS7>+7Q#CG<
M!UA-#W4(ME*\$[&5XKD&Q)\W\$@2?[6Q.."!50'K'8COCP,]Y?>)(J@JI@U[
M@W$D23 $>M'?HW&,9">&C[\^V%L214GB1P#S*X@B#(&W$4<P!: !0Z*HV@?W
M]J-PLT^%[>]?X]]02P,$%     @ Y8._5)>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #E@[]4X\FG"\,$  !I*0
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MDBDJ.YD+Q^5/JSA(.3FQ<K 9\Q@3*2<G5P["+&),N"A&O2H&,<L8$RDGIY[
M0,Q)C(F4DY,K!PR'TA:.E),3*P=C)DT(*2<G5@[&3)H0<DY.[!R,F30A9)^<
MV#YX#!Q7>H'L4[SF&EI2Z06R4$%N(8095WJ!+%2\ZL0G[C<+9*'B52<^26["
M/1IB"V',)#>1A0IB"^'YV3S&1!8JB"T$,1-9%LA"!;F%T#0RR4UDH8+<0@@S
MR4UDH8+:0B_.=KMY1KS/B2Q44EL(82:Y62(+E=06@IAQ;I;(0B6UA2!FG)LE
MLE!)_H8 PHR=7B(+E<?8S'FZ$O/,/+V$[PJ\QI[. 3-M0LA"Y3&6WU[$3)H0
MLE!);*%T8>NYND;R*8^Z[':@8V_8TA>^;F-,))^26#X0,TG)"9+/A%@^+V[N
M]<PQ)I+/A'P*]-,6W[-Y.4'BF73B&78WV_.S=?_@E[YXZ\]7O*X6AH6/_F6$
MH@Q;AYNVKF?^W)7ZHOGZ\*;@X2W'\^]02P,$%     @ Y8._5'=+<84& @
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M&^IM!'K;;+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M3*5/?C_JIUU1]</L=+VOUB^'>00V/$Z_XX\S?J__RSX$2!\2I \%TH<&Z:,
MZ>,<I(\+D#XN0?K@$Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4
M606*K )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*
M%%DEBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR
M:A19-8JL&D56C2*K1I%5H\BJ460M4&0M4&0M_E/69VN7?QP_///6U-TAGPU_
M,IJ] 5!+ 0(4 Q0    ( .6#OU0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Y8._5!NZ #3N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ Y8._5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #E@[]4R!@$O_$&  # &@  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ Y8._5'S:Z 2J!0  &Q8  !@              ("!- \  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .6#OU10"TM%U (  /\)
M   8              " @105  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #E@[]4&M_39)@$  !($   &               @($>&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ Y8._5&P+LB8R
M!P  "R@  !@              ("![!P  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( .6#OU2[<U-$%@@  )<C   8              "
M@50D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #E@[]4
M+*8DG$P'  !C$   &               @(&@+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ Y8._5.-5M";K!   20L  !@
M     ("!(C0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M .6#OU0%1A"7>QX  #):   8              " @4,Y  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #E@[]41=D'^#,2  !$,   &0
M            @('T5P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( .6#OU2O>!*R$00   4)   9              " @5YJ  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ Y8._5*);!B""!
M; D  !D              ("!IFX  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #E@[]4SS/JW-,+   =)0  &0              @(%?
M<P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .6#OU3-
M%QG'T@\  /PZ   9              " @6E_  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ Y8._5)[XAIXI#   QR(  !D
M     ("!<H\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6#OU0SG_L>Q!\  )EC   9              "
M@;^U  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ Y8._
M5&Z3 X4%!   K0H  !D              ("!NM4  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #E@[]4D%_[R]<#   <"0  &0
M        @('VV0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( .6#OU2X$]%'9P,  #X(   9              " @03>  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ Y8._5.XJ[;R: @  ;04
M !D              ("!HN$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #E@[]4,C&"67X"  !W!0  &0              @(%SY
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .6#OU0Q4H10
MB@(  %(%   9              " @2CG  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ Y8._5'\I$-YO!   ;PL  !D
M ("!Z>D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #E
M@[]4L(EHN7<#  "0"   &0              @(&/[@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .6#OU1,J22,O0,  ),(   9
M          " @3WR  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @ Y8._5%D+OZ\6 @  7@0  !D              ("!,?8  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #E@[]4,J@II04"  #V
M P  &0              @(%^^   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    ( .6#OU1[7']>!P,  $P*   9              " @;KZ
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ Y8._5#^%
MJ?O, @  * H  !D              ("!^/T  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    " #E@[]4DO00"UD#  !!"0  &0
M    @('[  $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M .6#OU1+X/X-Z@(  !\(   9              " @8L$ 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ Y8._5)4R\)ZZ!0  TA(  !D
M             ("!K <! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #E@[]4*C;7];\"  "V!@  &0              @(&=#0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .6#OU2QJR_(M@(
M %X'   9              " @9,0 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ Y8._5+_2OX#= @  50@  !D              ("!
M@!,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #E@[]4
MSL%Z[T<"  "@!0  &0              @(&4%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( .6#OU1DW)<IA (  +,&   9
M      " @1(9 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ Y8._5%PL#BWW @  3@D  !D              ("!S1L! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #E@[]44[Z_I:4"  ! !P
M&0              @('['@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( .6#OU0KV\-4E ,  %\'   9              " @=<A 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ Y8._5 WWF]H#
M P  F0@  !D              ("!HB4! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " #E@[]4$ 9J^C<$   *%@  &0
M@('<* $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .6#
MOU3B# :ZK0(  /0&   9              " @4HM 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ Y8._5+ZL)ZN+%   Z%P  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( .6#OU1WPG1!SP(  #H(   9
M  " @<]: 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MY8._5,.$B="^ @  W@<  !D              ("!U5T! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " #E@[]46SN>)9,$  !B%   &0
M            @('*8 $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( .6#OU3&=1BGY 0  !(:   9              " @91E 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ Y8._5(>^&8_N!
MFAL  !D              ("!KVH! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " #E@[]4^7C@*_T"  !,"0  &0              @('4
M;P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .6#OU3>
M^E "] (  ",*   9              " @0AS 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ Y8._5*@C#"EO P  >@L  !D
M     ("!,W8! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M" #E@[]4&G8B^H<"  !L!P  &0              @('9>0$ >&PO=V]R:W-H
M965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .6#OU0!&<SX"@0  .4)   9
M              " @9=\ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L!
M A0#%     @ Y8._5#@N^BTH P  #!,   T              ( !V( ! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #E@[]4EXJ[',     3 @  "P
M        @ $KA $ 7W)E;',O+G)E;'-02P$"% ,4    " #E@[]4X\FG"\,$
M  !I*0  #P              @ $4A0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ Y8._5'=+<84& @  \20  !H              ( !!(H! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ Y8._5/\GIW7C 0
M;"0  !,              ( !0HP! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $8 1@ A$P  5HX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>116</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statement of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statement of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Zimmer Development Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement</Role>
      <ShortName>Zimmer Development Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Zimmer Development Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables</Role>
      <ShortName>Zimmer Development Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockholdersDeficit</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/OrganizationandNatureofOperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/GoingConcern</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of the lease liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of maturity of the lease liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable</Role>
      <ShortName>Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable</Role>
      <ShortName>Supplemental Balance Sheet Information (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Supplemental Balance Sheet Information (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Zimmer Development Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails</Role>
      <ShortName>Zimmer Development Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Zimmer Development Agreement (Details) - Schedule of deferred revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable</Role>
      <ShortName>Zimmer Development Agreement (Details) - Schedule of deferred revenue</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option plan activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock option plan activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/StockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Stockholders' Deficit (Details) - Schedule of warrant activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable</Role>
      <ShortName>Stockholders' Deficit (Details) - Schedule of warrant activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable</Role>
      <ShortName>Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/StockholdersDeficitTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/DefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/DefinedContributionPlan</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f10k2021a1_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://originalsourcemusic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://originalsourcemusic.com/role/SubsequentEvents</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" original="f10k2021a1_neuroone.htm">f10k2021a1_neuroone.htm</File>
    <File>f10k2021a1ex23-1_neuroone.htm</File>
    <File>f10k2021a1ex23-2_neuroone.htm</File>
    <File>f10k2021a1ex31-1_neuroone.htm</File>
    <File>f10k2021a1ex31-2_neuroone.htm</File>
    <File>f10k2021a1ex32-1_neuroone.htm</File>
    <File>f10k2021a1ex32-2_neuroone.htm</File>
    <File>nmtc-20210930.xsd</File>
    <File>nmtc-20210930_cal.xml</File>
    <File>nmtc-20210930_def.xml</File>
    <File>nmtc-20210930_lab.xml</File>
    <File>nmtc-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="413">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2021a1_neuroone.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 116,
   "dts": {
    "calculationLink": {
     "local": [
      "nmtc-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nmtc-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2021a1_neuroone.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nmtc-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nmtc-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nmtc-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 560,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 51,
    "http://originalsourcemusic.com/20210930": 44,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 100
   },
   "keyCustom": 163,
   "keyStandard": 229,
   "memberCustom": 37,
   "memberStandard": 17,
   "nsprefix": "nmtc",
   "nsuri": "http://originalsourcemusic.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://originalsourcemusic.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Commitments and Contingencies",
     "role": "http://originalsourcemusic.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SupplementalBalanceSheetInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SupplementalBalanceSheetInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Accrued Expenses and Other Liabilities",
     "role": "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:ZimmerDevelopmentAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Zimmer Development Agreement",
     "role": "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement",
     "shortName": "Zimmer Development Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:ZimmerDevelopmentAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Convertible Promissory Notes and Warrant Agreements",
     "role": "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements",
     "shortName": "Convertible Promissory Notes and Warrant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Stock-Based Compensation",
     "role": "http://originalsourcemusic.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Stockholders' Deficit",
     "role": "http://originalsourcemusic.com/role/StockholdersDeficit",
     "shortName": "Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Income Taxes",
     "role": "http://originalsourcemusic.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Defined Contribution Plan",
     "role": "http://originalsourcemusic.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Subsequent Events",
     "role": "http://originalsourcemusic.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Balance Sheets",
     "role": "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SupplementalCashFlowTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://originalsourcemusic.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SupplementalCashFlowTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "role": "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Zimmer Development Agreement (Tables)",
     "role": "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables",
     "shortName": "Zimmer Development Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Tables)",
     "role": "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables",
     "shortName": "Convertible Promissory Notes and Warrant Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://originalsourcemusic.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SummaryOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Stockholders' Deficit (Tables)",
     "role": "http://originalsourcemusic.com/role/StockholdersDeficitTables",
     "shortName": "Stockholders' Deficit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:SummaryOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Income Taxes (Tables)",
     "role": "http://originalsourcemusic.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Balance Sheets (Parentheticals)",
     "role": "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c22",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:ProceedsFromPayrollProtectionProgramLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Organization and Nature of Operations (Details)",
     "role": "http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails",
     "shortName": "Organization and Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c22",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:ProceedsFromPayrollProtectionProgramLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEarningsDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Going Concern (Details)",
     "role": "http://originalsourcemusic.com/role/GoingConcernDetails",
     "shortName": "Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEarningsDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis",
     "role": "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of fair value of financial instruments measured on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs",
     "role": "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c5",
      "decimals": "0",
      "lang": null,
      "name": "nmtc:FairValueAttributedToConvertibleNotesUponIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nmtc:Warrantshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share",
     "role": "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nmtc:Warrantshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:RoyaltyMinimumPaymentsYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:RoyaltyMinimumPaymentsYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nmtc:SupplementalCashFlowTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease",
     "role": "http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of supplemental cash flow information related to the operating lease",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nmtc:SupplementalCashFlowTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease",
     "role": "http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of supplemental balance sheet information related to the operating lease",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nmtc:SupplementalBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "nmtc:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:LesseeOperatingLeaseLiabilityPaymentsDueOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of the lease liability",
     "role": "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable",
     "shortName": "Commitments and Contingencies (Details) - Schedule of maturity of the lease liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:LesseeOperatingLeaseLiabilityPaymentsDueOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Statements of Operations",
     "role": "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c5",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Supplemental Balance Sheet Information (Details)",
     "role": "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails",
     "shortName": "Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c5",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:PrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets",
     "role": "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable",
     "shortName": "Supplemental Balance Sheet Information (Details) - Schedule of Prepaid and other assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:PrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of intangible assets",
     "role": "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable",
     "shortName": "Supplemental Balance Sheet Information (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c9",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Supplemental Balance Sheet Information (Details) - Schedule of property and equipment",
     "role": "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Supplemental Balance Sheet Information (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:PaycheckProtectionProgramDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Accrued Expenses and Other Liabilities (Details)",
     "role": "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nmtc:PaycheckProtectionProgramDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:AccruedPayroll",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses",
     "role": "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable",
     "shortName": "Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:AccruedPayroll",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nmtc:IntialFeePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Zimmer Development Agreement (Details)",
     "role": "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails",
     "shortName": "Zimmer Development Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nmtc:IntialFeePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Zimmer Development Agreement (Details) - Schedule of deferred revenue",
     "role": "http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable",
     "shortName": "Zimmer Development Agreement (Details) - Schedule of deferred revenue",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c5",
      "decimals": "0",
      "lang": null,
      "name": "nmtc:UpfrontInitialExclusivityPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nmtc:OutstandingVotingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)",
     "role": "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
     "shortName": "Convertible Promissory Notes and Warrant Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nmtc:OutstandingVotingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:ConvertibleNotesOutstandingPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements",
     "role": "http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable",
     "shortName": "Convertible Promissory Notes and Warrant Agreements (Details) - Schedule of convertible promissory notes and warrant agreements",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:ConvertibleNotesOutstandingPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Statement of Changes in Stockholders\u2019 Equity (Deficit)",
     "role": "http://originalsourcemusic.com/role/ShareholdersEquityType2or3",
     "shortName": "Statement of Changes in Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "lang": "en-US",
      "name": "nmtc:StockOptionVestedOverAPeriodTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "role": "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c94",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option plan activity",
     "role": "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock option plan activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c94",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model",
     "role": "http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity",
     "role": "http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of restricted stock unit activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Stockholders' Deficit (Details)",
     "role": "http://originalsourcemusic.com/role/StockholdersDeficitDetails",
     "shortName": "Stockholders' Deficit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c96",
      "decimals": "0",
      "lang": null,
      "name": "nmtc:AggregateShareIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nmtc:SummaryOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Stockholders' Deficit (Details) - Schedule of warrant activity",
     "role": "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable",
     "shortName": "Stockholders' Deficit (Details) - Schedule of warrant activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nmtc:SummaryOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c9",
      "decimals": "INF",
      "lang": null,
      "name": "nmtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c113",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:NumberOutstandingsTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding",
     "role": "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable",
     "shortName": "Stockholders' Deficit (Details) - Schedule of summarizes information about warrants outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c113",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:NumberOutstandingsTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Income Taxes (Details)",
     "role": "http://originalsourcemusic.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nmtc:IncomeTaxBenefitAtFederalStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate",
     "role": "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable",
     "shortName": "Income Taxes (Details) - Schedule of reconciliation of income tax computed at the statutory federal income tax rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nmtc:IncomeTaxBenefitAtFederalStatutoryRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Statements of Cash Flows",
     "role": "http://originalsourcemusic.com/role/ConsolidatedCashFlow",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "role": "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nmtc:EmployeesCompensationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Defined Contribution Plan (Details)",
     "role": "http://originalsourcemusic.com/role/DefinedContributionPlanDetails",
     "shortName": "Defined Contribution Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nmtc:EmployeesCompensationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c114",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:SharesAreAuthorizedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Subsequent Events (Details)",
     "role": "http://originalsourcemusic.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c114",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nmtc:SharesAreAuthorizedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Organization and Nature of Operations",
     "role": "http://originalsourcemusic.com/role/OrganizationandNatureofOperations",
     "shortName": "Organization and Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Going Concern",
     "role": "http://originalsourcemusic.com/role/GoingConcern",
     "shortName": "Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2021a1_neuroone.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nmtc_AccruedPayroll": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll.",
        "label": "AccruedPayroll",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedPayroll",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ActivityMember",
        "terseLabel": "2021 Activity [Member]"
       }
      }
     },
     "localname": "ActivityMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_AfterDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AfterDecember312021Member",
        "terseLabel": "After December 31, 2021 [Member]"
       }
      }
     },
     "localname": "AfterDecember312021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_AfterJune302021ButOnOrBeforeSeptember302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AfterJune302021ButOnOrBeforeSeptember302021Member",
        "terseLabel": "After June 30, 2021, but on or before September 30, 2021 [Member]"
       }
      }
     },
     "localname": "AfterJune302021ButOnOrBeforeSeptember302021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_AfterSeptember302021ButOnOrBeforeDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AfterSeptember302021ButOnOrBeforeDecember312021Member",
        "terseLabel": "After September 30, 2021, but on or before December 31, 2021 [Member]"
       }
      }
     },
     "localname": "AfterSeptember302021ButOnOrBeforeDecember312021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_AggregateShareIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AggregateShareIssued",
        "terseLabel": "Aggregate share issued (in Shares)"
       }
      }
     },
     "localname": "AggregateShareIssued",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_AllocatedShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for share based compensation.",
        "label": "AllocatedShareBasedCompensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensation",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AmountOfInterestPayableOnDebtIncludingButNotLimitedToTradePayables",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_April302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April302021Member",
        "terseLabel": "April 30, 2021 [Member]"
       }
      }
     },
     "localname": "April302021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_BrokerWarrantsIssuedInConnectionWithConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BrokerWarrantsIssuedInConnectionWithConvertibleNotes",
        "terseLabel": "Non-cash issuance of broker warrants in connection with convertible notes and private placements"
       }
      }
     },
     "localname": "BrokerWarrantsIssuedInConnectionWithConvertibleNotes",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_BrokerWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BrokerWarrantsMember",
        "terseLabel": "Broker Warrants [Member]"
       }
      }
     },
     "localname": "BrokerWarrantsMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_CashCommissionPercentageRateOnProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash commission percentage rate on proceeds.",
        "label": "CashCommissionPercentageRateOnProceeds",
        "terseLabel": "Cash commission percentage rate on proceeds"
       }
      }
     },
     "localname": "CashCommissionPercentageRateOnProceeds",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_CashCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CashCommissions",
        "terseLabel": "Cash commissions"
       }
      }
     },
     "localname": "CashCommissions",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liability:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilityAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ChangeInFairValueIncludingAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value including accrued interest.",
        "label": "ChangeInFairValueIncludingAccruedInterest",
        "terseLabel": "Change in fair value including accrued interest"
       }
      }
     },
     "localname": "ChangeInFairValueIncludingAccruedInterest",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ChangesOfFairValueBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangesOfFairValueBenefit",
        "terseLabel": "Changes of fair value benefit"
       }
      }
     },
     "localname": "ChangesOfFairValueBenefit",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ConsultingAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreements description.",
        "label": "ConsultingAgreementsDescription",
        "terseLabel": "Consulting agreements description"
       }
      }
     },
     "localname": "ConsultingAgreementsDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ContributionsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions amount.",
        "label": "ContributionsAmount",
        "terseLabel": "Contributions amount (in Dollars)"
       }
      }
     },
     "localname": "ContributionsAmount",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ContributionsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions percentage.",
        "label": "ContributionsPercentage",
        "terseLabel": "Contributions percentage"
       }
      }
     },
     "localname": "ContributionsPercentage",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_ConversionOfConvertiblePromissoryNotesToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible promissory notes to common stock.",
        "label": "ConversionOfConvertiblePromissoryNotesToCommonStock",
        "terseLabel": "Conversion of convertible promissory notes to common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePromissoryNotesToCommonStock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ConversionOfConvertiblePromissoryNotesToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent supplemental activity related to non-cash impact related to conversion of promissory notes to equity.",
        "label": "ConversionOfConvertiblePromissoryNotesToEquity",
        "terseLabel": "Conversion of convertible promissory notes to equity"
       }
      }
     },
     "localname": "ConversionOfConvertiblePromissoryNotesToEquity",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ConvertedNotesCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertedNotesCommonStock",
        "terseLabel": "Converted notes common stock (in Shares)"
       }
      }
     },
     "localname": "ConvertedNotesCommonStock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_ConvertibleNoteFinancingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleNoteFinancingDescription",
        "terseLabel": "Convertible Note financing, description"
       }
      }
     },
     "localname": "ConvertibleNoteFinancingDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent conversion of convertible notes not included in basic EPS.",
        "label": "ConvertibleNotes",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleNotes",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_ConvertibleNotesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleNotesAbstract",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleNotesAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ConvertibleNotesOutstandingPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes outstanding principal.",
        "label": "ConvertibleNotesOutstandingPrincipal",
        "terseLabel": "Paulson convertible notes, principal"
       }
      }
     },
     "localname": "ConvertibleNotesOutstandingPrincipal",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ConvertiblePromissoryNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, at fair value value as of the balance sheet date of a written promise to pay a note, initially due within one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "ConvertiblePromissoryNotesPayable",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesPayable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes and Warrant Agreements (Details) [Line Items]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesandWarrantAgreementsDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes and Warrant Agreements (Details) [Table]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotesandWarrantAgreementsDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_DeferralsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferrals percentage.",
        "label": "DeferralsPercentage",
        "terseLabel": "Deferrals percentage"
       }
      }
     },
     "localname": "DeferralsPercentage",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_DeferredIncomeTaxAssetNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net deferred tax assets.",
        "label": "DeferredIncomeTaxAssetNet",
        "terseLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetNet",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_DeferredTaxAssetGrossCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.",
        "label": "DeferredTaxAssetGrossCurrent",
        "terseLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetGrossCurrent",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal",
        "terseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxAssetsAbstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_DeferredsOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "DeferredsOfferingCosts",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredsOfferingCosts",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_DepositsExcessOfFederallyInsured": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount by which the cash balance exceeds the amount insured.",
        "label": "DepositsExcessOfFederallyInsured",
        "terseLabel": "Deposits in excess of federally insured amounts (in Dollars)"
       }
      }
     },
     "localname": "DepositsExcessOfFederallyInsured",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DevelopmentAgreementMember",
        "terseLabel": "Development Agreement [Member]"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_DisqualifiedInterestAndOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disqualified interest and other.",
        "label": "DisqualifiedInterestAndOther",
        "terseLabel": "Disqualified interest and other"
       }
      }
     },
     "localname": "DisqualifiedInterestAndOther",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_EarningsPerSharesBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "EarningsPerSharesBasicAndDiluted",
        "terseLabel": "Basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerSharesBasicAndDiluted",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_EffectiveTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective tax rate.",
        "label": "EffectiveTaxRate",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveTaxRate",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_EmployeesCompensationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees compensation percentage.",
        "label": "EmployeesCompensationPercentage",
        "terseLabel": "Employees compensation percentage"
       }
      }
     },
     "localname": "EmployeesCompensationPercentage",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_EquityFinancingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityFinancingAmount",
        "terseLabel": "Equity financing amount"
       }
      }
     },
     "localname": "EquityFinancingAmount",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_EquityIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityIncentivePlansMember",
        "terseLabel": "2016 and 2017 Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlansMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_EquityQualifiedFinancingDescriptiononConvertibleNoteOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity qualified financing, description on Convertible Note Offering.",
        "label": "EquityQualifiedFinancingDescriptiononConvertibleNoteOffering",
        "terseLabel": "Equity qualified financing, description"
       }
      }
     },
     "localname": "EquityQualifiedFinancingDescriptiononConvertibleNoteOffering",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePrice",
        "terseLabel": "Exercise Price, Total (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ExercisePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceMember",
        "terseLabel": "5.25\t[Member]"
       }
      }
     },
     "localname": "ExercisePriceMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ExercisePriceOfUnderlyingOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of the underlying options.",
        "label": "ExercisePriceOfUnderlyingOptions",
        "terseLabel": "Exercise price of the underlying option (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePriceOfUnderlyingOptions",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceOneMember",
        "terseLabel": "5.40 [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ExercisePricePerWarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePricePerWarrantIssued",
        "terseLabel": "Exercise Price Per Warrant, Issued"
       }
      }
     },
     "localname": "ExercisePricePerWarrantIssued",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ExercisePricePerWarrantOutstandingAndExercisableBeginning1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePricePerWarrantOutstandingAndExercisableBeginning1",
        "terseLabel": "Exercise Price Per Warrant, Outstanding and exercisable, Beginning"
       }
      }
     },
     "localname": "ExercisePricePerWarrantOutstandingAndExercisableBeginning1",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ExercisePricePerWarrantOutstandingAndExercisableEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePricePerWarrantOutstandingAndExercisableEnding",
        "terseLabel": "Exercise Price Per Warrant, Outstanding and exercisable, Ending"
       }
      }
     },
     "localname": "ExercisePricePerWarrantOutstandingAndExercisableEnding",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceThreeMember",
        "terseLabel": "6.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceTwoMember",
        "terseLabel": "5.61\t[Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ExtendedMaturityDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExtendedMaturityDateDescription",
        "terseLabel": "Extended maturity date, description"
       }
      }
     },
     "localname": "ExtendedMaturityDateDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_FairValueAttributedToConvertibleNotesUponIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value attributed to convertible notes upon issuance.",
        "label": "FairValueAttributedToConvertibleNotesUponIssuance",
        "terseLabel": "Fair value attributed to convertible promissory notes upon issuance"
       }
      }
     },
     "localname": "FairValueAttributedToConvertibleNotesUponIssuance",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_FairValueAttributedToNoteExtinguishment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value attributed to note extinguishment.",
        "label": "FairValueAttributedToNoteExtinguishment",
        "terseLabel": "Fair value attributed to note extinguishment"
       }
      }
     },
     "localname": "FairValueAttributedToNoteExtinguishment",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_FairValueChangeOfConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value change of convertible notes.",
        "label": "FairValueChangeOfConvertibleNotes",
        "terseLabel": "Fair value change of convertible promissory notes"
       }
      }
     },
     "localname": "FairValueChangeOfConvertibleNotes",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value in excess of principal and accrued interest related to debt instrument payable.",
        "label": "FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "FairValueInExcessOfPrincipalAndAccruedInterestRelatedToDebtInstrumentPayable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofconvertiblepromissorynotesandwarrantagreementsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_FairValueOfTheUnderlyingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the underlying common stock.",
        "label": "FairValueOfTheUnderlyingCommonStock",
        "terseLabel": "Vesting points (in Dollars per share)"
       }
      }
     },
     "localname": "FairValueOfTheUnderlyingCommonStock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants.",
        "label": "FairValueOfWarrants",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_FutureIssuanceOnACombinedBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares for future issuance.",
        "label": "FutureIssuanceOnACombinedBasis",
        "terseLabel": "Future issuance shares"
       }
      }
     },
     "localname": "FutureIssuanceOnACombinedBasis",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_FuturePotentialMilestonePaymentsToNeuroone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent future potential milestone payments to Neuroone.",
        "label": "FuturePotentialMilestonePaymentsToNeuroone",
        "terseLabel": "Future potential milestone payments to Neuroone"
       }
      }
     },
     "localname": "FuturePotentialMilestonePaymentsToNeuroone",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_GrantDateFairValueOfPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date fair value.",
        "label": "GrantDateFairValueOfPerUnit",
        "terseLabel": "Grant date fair value (in Dollars per share)"
       }
      }
     },
     "localname": "GrantDateFairValueOfPerUnit",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_GrossProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of gross proceeds.",
        "label": "GrossProceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_GrossProceedsFromPrivatePlacement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the amount of gross proceeds from private placement.",
        "label": "GrossProceedsFromPrivatePlacement",
        "terseLabel": "Gross proceeds from private placement"
       }
      }
     },
     "localname": "GrossProceedsFromPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ImputedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imputed interest.",
        "label": "ImputedInterest",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "ImputedInterest",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IncomeTaxBenefitAtFederalStatutoryRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax benefit at federal statutory rate.",
        "label": "IncomeTaxBenefitAtFederalStatutoryRate",
        "terseLabel": "Income tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxBenefitAtFederalStatutoryRate",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_IncreaseDecreaseInFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase decrease in fair value.",
        "label": "IncreaseDecreaseInFairValue",
        "terseLabel": "Increase decrease in fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValue",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IntellectualPropertyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy fori ntellectual property.",
        "label": "IntellectualPropertyPolicyTextBlock",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyPolicyTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense related to excess of fair value over proceeds at issuance.",
        "label": "InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance",
        "terseLabel": "Interest expense related to excess of fair value over proceeds at issuance"
       }
      }
     },
     "localname": "InterestExpenseRelatedToExcessOfFairValueOverProceedsAtIssuance",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_InterestOnPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "InterestOnPrincipalAmount",
        "terseLabel": "Interest on principal amount"
       }
      }
     },
     "localname": "InterestOnPrincipalAmount",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_InternalRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Revenue percentage.",
        "label": "InternalRevenuePercentage",
        "terseLabel": "Internal Revenue percentage"
       }
      }
     },
     "localname": "InternalRevenuePercentage",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_IntialFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intial fee payment.",
        "label": "IntialFeePayment",
        "terseLabel": "Initial fee payment"
       }
      }
     },
     "localname": "IntialFeePayment",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs in connection with conversion of convertible notes into common stock.",
        "label": "IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock",
        "terseLabel": "Issuance costs in connection with conversion of convertible notes into common stock"
       }
      }
     },
     "localname": "IssuanceCostInConnectionWithConversionOfConvertibleNotesIntoCommonStock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostSettlementInConnectionWithPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance cost adjustment related to private placement.",
        "label": "IssuanceCostSettlementInConnectionWithPrivatePlacement",
        "terseLabel": "Issuance cost adjustment related to private placement"
       }
      }
     },
     "localname": "IssuanceCostSettlementInConnectionWithPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceCosts",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "IssuanceCosts",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostsAttributedToFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs attributed to financing activities.",
        "label": "IssuanceCostsAttributedToFinancingActivities",
        "terseLabel": "Issuance costs attributed to financing activities"
       }
      }
     },
     "localname": "IssuanceCostsAttributedToFinancingActivities",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceCostsDescription",
        "terseLabel": "Issuance costs, description"
       }
      }
     },
     "localname": "IssuanceCostsDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_IssuanceCostsInConnectionWithConvertiblePromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuance costs in connection with convertible promissory notes.",
        "label": "IssuanceCostsInConnectionWithConvertiblePromissoryNotes",
        "negatedLabel": "Issuance costs in connection with convertible promissory notes"
       }
      }
     },
     "localname": "IssuanceCostsInConnectionWithConvertiblePromissoryNotes",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostsInConnectionWithPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs in connection with private placement.",
        "label": "IssuanceCostsInConnectionWithPrivatePlacement",
        "terseLabel": "Issuance costs in connection with securities issuances"
       }
      }
     },
     "localname": "IssuanceCostsInConnectionWithPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceCostsInConnectionWithPrivatePlacements": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuance costs in connection with private placements.",
        "label": "IssuanceCostsInConnectionWithPrivatePlacements",
        "negatedLabel": "Issuance costs in connection with private placements"
       }
      }
     },
     "localname": "IssuanceCostsInConnectionWithPrivatePlacements",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon vesting of restricted stock units.",
        "label": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnits",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnits",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock upon vesting of restricted stock units shares.",
        "label": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_IssuanceOfCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "IssuanceOfCostsIncurred",
        "terseLabel": "Issuance costs incurred"
       }
      }
     },
     "localname": "IssuanceOfCostsIncurred",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceOfFairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value issued.",
        "label": "IssuanceOfFairValueAmount",
        "terseLabel": "Issuance of fair value amount"
       }
      }
     },
     "localname": "IssuanceOfFairValueAmount",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants in connection with convertible notes offering.",
        "label": "IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering",
        "terseLabel": "Issuance of warrants in connection with convertible notes offering"
       }
      }
     },
     "localname": "IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LeaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent lease agreement, description.",
        "label": "LeaseAgreementDescription",
        "terseLabel": "Facility Lease agreement, description"
       }
      }
     },
     "localname": "LeaseAgreementDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LeaseLiability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LeaseLiabilityNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LeaseLiabilityNet",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiabilityNet",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LeaseLiabilityShortterms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease liability.",
        "label": "LeaseLiabilityShortterms",
        "terseLabel": "Operating lease liability, short term"
       }
      }
     },
     "localname": "LeaseLiabilityShortterms",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LeaseRentalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease rental expense.",
        "label": "LeaseRentalExpense",
        "terseLabel": "Lease rental expense"
       }
      }
     },
     "localname": "LeaseRentalExpense",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LeaseSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility space square feet.",
        "label": "LeaseSpace",
        "terseLabel": "Lease space (in Square Meters)"
       }
      }
     },
     "localname": "LeaseSpace",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "nmtc_LegalAndThirdPartyFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to issuance of financial instruments.",
        "label": "LegalAndThirdPartyFee",
        "terseLabel": "Legal and third party fee"
       }
      }
     },
     "localname": "LegalAndThirdPartyFee",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LessAccumulatedDepreciations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of less accumulated depreciation.",
        "label": "LessAccumulatedDepreciations",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "LessAccumulatedDepreciations",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFiveYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueFiveYear",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueFiveYear",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LesseeOperatingLeaseLiabilityPaymentsDueFourYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueFourYear",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueFourYear",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LesseeOperatingLeaseLiabilityPaymentsDueOneYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in remaining in current calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueOneYear",
        "terseLabel": "2021 (period from October 1, 2021 to December 31, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueOneYear",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LesseeOperatingLeaseLiabilityPaymentsDueThreeYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueThreeYear",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThreeYear",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_LesseeOperatingLeaseLiabilityPaymentsDueTwoYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second calendar year following calendar year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueTwoYear",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueTwoYear",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_MayoAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MayoAgreementMember",
        "terseLabel": "Mayo Agreement [Member]"
       }
      }
     },
     "localname": "MayoAgreementMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ModifiedConnectorbyApril302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ModifiedConnectorbyApril302021Member",
        "terseLabel": "Modified Connector by April 30, 2021 [Member]"
       }
      }
     },
     "localname": "ModifiedConnectorbyApril302021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ModifiedConnectorbySeptember302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ModifiedConnectorbySeptember302021Member",
        "terseLabel": "Modified Connector by September 30, 2021 [Member]"
       }
      }
     },
     "localname": "ModifiedConnectorbySeptember302021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_MonthlyLeaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly lease rent.",
        "label": "MonthlyLeaseRent",
        "terseLabel": "Monthly lease rent"
       }
      }
     },
     "localname": "MonthlyLeaseRent",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_NetIntangiblesUsefulLives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Intangibles, useful lives.",
        "label": "NetIntangiblesUsefulLives",
        "terseLabel": "Net Intangibles, useful lives"
       }
      }
     },
     "localname": "NetIntangiblesUsefulLives",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_NetValuationChangeOfInstrumentsMeasuredAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net valuation change of instruments measured at fair value.",
        "label": "NetValuationChangeOfInstrumentsMeasuredAtFairValue",
        "terseLabel": "Net valuation change of instruments measured at fair value"
       }
      }
     },
     "localname": "NetValuationChangeOfInstrumentsMeasuredAtFairValue",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_NoncashInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments non-cash interest.",
        "label": "NoncashInterest",
        "terseLabel": "Non-cash interest on principal amount"
       }
      }
     },
     "localname": "NoncashInterest",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_NoncashInterestOnConvertiblePromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash interest on convertible promissory notes.",
        "label": "NoncashInterestOnConvertiblePromissoryNotes",
        "terseLabel": "Non-cash interest on convertible promissory notes"
       }
      }
     },
     "localname": "NoncashInterestOnConvertiblePromissoryNotes",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_November302020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November302020Member",
        "terseLabel": "November 30, 2020 [Member]"
       }
      }
     },
     "localname": "November302020Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_NumberExercisable1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberExercisable1",
        "terseLabel": "Number Exercisable , Total"
       }
      }
     },
     "localname": "NumberExercisable1",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_NumberOfLicencingAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "NumberOfLicencingAgreements",
        "terseLabel": "Number of licensing agreements"
       }
      }
     },
     "localname": "NumberOfLicencingAgreements",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nmtc_NumberOutstandingsTotal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Outstanding.",
        "label": "NumberOutstandingsTotal",
        "terseLabel": "Number Outstanding, Total"
       }
      }
     },
     "localname": "NumberOutstandingsTotal",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_OnOrBeforeJune302021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OnOrBeforeJune302021Member",
        "terseLabel": "On or before June 30, 2021 [Member]"
       }
      }
     },
     "localname": "OnOrBeforeJune302021Member",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_OperatingCashFlowsFromOperatingLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liability.",
        "label": "OperatingCashFlowsFromOperatingLeases",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeases",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease",
        "terseLabel": "Operating lease right of use asset obtained in exchange for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_OperatingLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange of lease obligations.",
        "label": "OperatingLeases",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeases",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_OutstandingStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares option outstanding.",
        "label": "OutstandingStockOptionsShares",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "OutstandingStockOptionsShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_OutstandingVotingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OutstandingVotingPercentage",
        "terseLabel": "Outstanding voting percentage"
       }
      }
     },
     "localname": "OutstandingVotingPercentage",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_PaulsonPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PaulsonPrivatePlacementMember",
        "terseLabel": "Paulson Private Placement [Member]"
       }
      }
     },
     "localname": "PaulsonPrivatePlacementMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_PaulsonPrivatePlacementTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PaulsonPrivatePlacementTwoThousandNineteenMember",
        "terseLabel": "2019 Paulson Private Placement [Member]"
       }
      }
     },
     "localname": "PaulsonPrivatePlacementTwoThousandNineteenMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_PaycheckProtectionProgramDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program, description.",
        "label": "PaycheckProtectionProgramDescription",
        "terseLabel": "Paycheck protection program, description"
       }
      }
     },
     "localname": "PaycheckProtectionProgramDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_PayrollProtectionProgramLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll protection program loan forgiveness.",
        "label": "PayrollProtectionProgramLoanForgiveness",
        "negatedLabel": "Payroll protection program loan forgiveness"
       }
      }
     },
     "localname": "PayrollProtectionProgramLoanForgiveness",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_PrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "PrepaidExpenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenses",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in connection with private placements.",
        "label": "ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement",
        "terseLabel": "Proceeds from issuance of common stock in connection with private placements"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of warrants in connection with private placement.",
        "label": "ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement",
        "terseLabel": "Proceeds from issuance of warrants in connection with private placements"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ProceedsFromPaycheckProtectionProgram": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program.",
        "label": "ProceedsFromPaycheckProtectionProgram",
        "terseLabel": "Proceeds from paycheck protection program"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgram",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ProceedsFromPayrollProtectionProgramLoan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash proceeds associated with the PPP loan during the period.",
        "label": "ProceedsFromPayrollProtectionProgramLoan",
        "terseLabel": "Funding loan received"
       }
      }
     },
     "localname": "ProceedsFromPayrollProtectionProgramLoan",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ProductRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of product revenue recognized.",
        "label": "ProductRevenueRecognized",
        "terseLabel": "Product revenue recognized"
       }
      }
     },
     "localname": "ProductRevenueRecognized",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseAgreementMember",
        "terseLabel": "2021 Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_PurchaseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseOfWarrants",
        "terseLabel": "Purchase of warrants (in Shares)"
       }
      }
     },
     "localname": "PurchaseOfWarrants",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_PurchasePriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock.",
        "label": "PurchasePriceOfCommonStock",
        "terseLabel": "Purchase price (in Dollars per share)"
       }
      }
     },
     "localname": "PurchasePriceOfCommonStock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_RentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent expense.",
        "label": "RentExpense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "RentExpense",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ResearchCredits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research credits.",
        "label": "ResearchCredits",
        "terseLabel": "Research credits"
       }
      }
     },
     "localname": "ResearchCredits",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_RestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This relates to restricted stock units not included in basic EPS.",
        "label": "RestrictedStockUnit",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnit",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_RevenueFromCollaboration": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from collaboration.",
        "label": "RevenueFromCollaboration",
        "terseLabel": "Collaborations revenue"
       }
      }
     },
     "localname": "RevenueFromCollaboration",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ReverseStockSplitPolicyTextBlock",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_ReviseTheRegistrationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revise the registration date description.",
        "label": "ReviseTheRegistrationDateDescription",
        "terseLabel": "Revise the registration date description"
       }
      }
     },
     "localname": "ReviseTheRegistrationDateDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_RevisedOptionalConversionTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RevisedOptionalConversionTermsDescription",
        "terseLabel": "Revised optional conversion terms, description"
       }
      }
     },
     "localname": "RevisedOptionalConversionTermsDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_RoyaltyMinimumPaymentsYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty minimum payments year one.",
        "label": "RoyaltyMinimumPaymentsYearOne",
        "terseLabel": "Royalty payments - 2020"
       }
      }
     },
     "localname": "RoyaltyMinimumPaymentsYearOne",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_RoyaltyMinimumPaymentsYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty minimum payments year third year.",
        "label": "RoyaltyMinimumPaymentsYearThree",
        "terseLabel": "Royalty payments - 2022"
       }
      }
     },
     "localname": "RoyaltyMinimumPaymentsYearThree",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_RoyaltyMinimumPaymentsYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty minimum payments second year.",
        "label": "RoyaltyMinimumPaymentsYearTwo",
        "terseLabel": "Royalty payments - 2021"
       }
      }
     },
     "localname": "RoyaltyMinimumPaymentsYearTwo",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_RoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty payments.",
        "label": "RoyaltyPayments",
        "terseLabel": "Royalty Fees"
       }
      }
     },
     "localname": "RoyaltyPayments",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScenarioOneMember",
        "terseLabel": "Scenario One [Member]"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScenarioTwoMember",
        "terseLabel": "Scenario Two [Member]"
       }
      }
     },
     "localname": "ScenarioTwoMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ScheduleOfAccruedExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfComputationOfDilutedNetLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of diluted net loss per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComputationOfDilutedNetLossPerShareAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfConvertibleNotesAtFairValueOnARecurringBasisUsingUnobservableLevel3InputsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of convertible promissory notes and warrant agreements [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfConvertiblePromissoryNotesAndWarrantAgreementsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred revenue [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredRevenueAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of financial instruments measured on a recurring basis [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfFinancialInstrumentsMeasuredOnARecurringBasisAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfMaturityOfTheLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturity of the lease liability [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMaturityOfTheLeaseLiabilityAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfPrepaidAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid and other assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPrepaidAndOtherAssetsAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of income tax computed at the statutory federal income tax rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfIncomeTaxComputedAtTheStatutoryFederalIncomeTaxRateAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted stock unit activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfStockOptionPlanActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option plan activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionPlanActivityAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes information about warrants outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSummarizesInformationAboutWarrantsOutstandingAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental balance sheet information related to the operating lease [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToTheOperatingLeaseAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental cash flow information related to the operating lease [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToTheOperatingLeaseAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfWarrantActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_Second2019PaulsonNotesAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second2019PaulsonNotesAmendmentMember",
        "terseLabel": "Second 2019 Paulson Notes Amendment [Member]"
       }
      }
     },
     "localname": "Second2019PaulsonNotesAmendmentMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options exercised in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
        "terseLabel": "Warrants, Exercised (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options issued in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
        "terseLabel": "Warrants, Issued (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber",
        "periodEndLabel": "Warrants, Outstanding and exercisable, Ending (in Shares)",
        "periodStartLabel": "Warrants, Outstanding and exercisable, Beginning (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Weighted- Average Remaining Contractual Term (years), Outstanding at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_SharesAreAuthorizedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These shares are authorized for future issuance.",
        "label": "SharesAreAuthorizedForFutureIssuance",
        "terseLabel": "Shares are authorized for future issuance"
       }
      }
     },
     "localname": "SharesAreAuthorizedForFutureIssuance",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_SharesIssuedUnderPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued under private placement.",
        "label": "SharesIssuedUnderPrivatePlacement",
        "terseLabel": "Shares issue and sell under private placement (in Shares)"
       }
      }
     },
     "localname": "SharesIssuedUnderPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_SharesReservedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of shares reserved.",
        "label": "SharesReservedDescription",
        "terseLabel": "Shares reserved, description"
       }
      }
     },
     "localname": "SharesReservedDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StateIncomeTaxNetOfFederalBenefit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State income tax, net of federal benefit.",
        "label": "StateIncomeTaxNetOfFederalBenefit",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "StateIncomeTaxNetOfFederalBenefit",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_StateTaxCreditCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state tax credit carry forward.",
        "label": "StateTaxCreditCarryForward",
        "terseLabel": "State tax credit carry forward"
       }
      }
     },
     "localname": "StateTaxCreditCarryForward",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_StockBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockbasedcompensationexpenseTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockIssuedDuringPeriodExerciseOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares exercise of stock options.",
        "label": "StockIssuedDuringPeriodExerciseOfStockOptions",
        "terseLabel": "Exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfStockOptions",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of exercise of warrants.",
        "label": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
        "terseLabel": "Exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of exercise of warrants.",
        "label": "StockIssuedDuringPeriodValueStockWarrantsExercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_StockOptionVestedOverAPeriodTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option vested over a period term.",
        "label": "StockOptionVestedOverAPeriodTerm",
        "terseLabel": "Vested over a period term"
       }
      }
     },
     "localname": "StockOptionVestedOverAPeriodTerm",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_StockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This relates to stock options not included in basic EPS.",
        "label": "StockOptions",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptions",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_StockbasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation.",
        "label": "StockbasedCompensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockbasedCompensation",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_StockholdersDeficitDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Deficit (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersDeficitDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]"
       }
      }
     },
     "localname": "StockholdersDeficitDetailsScheduleofwarrantactivityLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockholdersDeficitDetailsScheduleofwarrantactivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Deficit (Details) - Schedule of warrant activity [Table]"
       }
      }
     },
     "localname": "StockholdersDeficitDetailsScheduleofwarrantactivityTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_StockholdersDeficitDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Deficit (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersDeficitDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_SummaryOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of warrant activity.",
        "label": "SummaryOfWarrantActivityTableTextBlock",
        "terseLabel": "Schedule of warrant activity"
       }
      }
     },
     "localname": "SummaryOfWarrantActivityTableTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_SupplementalBalanceSheetInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplementalBalanceSheetInformationTextBlock",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_SupplementalBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplementalBalanceSheetTableTextBlock",
        "terseLabel": "Schedule of supplemental balance sheet information related to the operating lease"
       }
      }
     },
     "localname": "SupplementalBalanceSheetTableTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_SupplementalCashFlowTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplementalCashFlowTableTextBlock",
        "terseLabel": "Schedule of supplemental cash flow information related to the operating lease"
       }
      }
     },
     "localname": "SupplementalCashFlowTableTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_TotalExpenseOfStockOption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense of stock option.",
        "label": "TotalExpenseOfStockOption",
        "terseLabel": "Total expense (in Dollars)"
       }
      }
     },
     "localname": "TotalExpenseOfStockOption",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_TotalGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total gross proceeds.",
        "label": "TotalGrossProceeds",
        "terseLabel": "Total gross proceeds"
       }
      }
     },
     "localname": "TotalGrossProceeds",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_TwentyTwentyActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwentyTwentyActivityMember",
        "terseLabel": "2020 Activity [Member]"
       }
      }
     },
     "localname": "TwentyTwentyActivityMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoThousandNineteenCommonStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandNineteenCommonStockOfferingMember",
        "terseLabel": "2019 Common Stock Offering [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenCommonStockOfferingMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoThousandNineteenQualifiedFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandNineteenQualifiedFinancingMember",
        "terseLabel": "2019 Qualified Financing [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenQualifiedFinancingMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoThousandSixteenAndSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenAndSeventeenPlanMember",
        "terseLabel": "2016 and 2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenAndSeventeenPlanMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoZeroOneNinePaulsonNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroOneNinePaulsonNotesMember",
        "terseLabel": "2019 Paulson Notes [Member]"
       }
      }
     },
     "localname": "TwoZeroOneNinePaulsonNotesMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoZeroOneSevenPlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroOneSevenPlanEvergreenProvisionMember",
        "terseLabel": "2017 Plan [Member]"
       }
      }
     },
     "localname": "TwoZeroOneSevenPlanEvergreenProvisionMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoZeroTwoZeroCommonStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroTwoZeroCommonStockOfferingMember",
        "terseLabel": "2020 Common Stock Offering [Member]"
       }
      }
     },
     "localname": "TwoZeroTwoZeroCommonStockOfferingMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoZeroTwoZeroPaulsonNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroTwoZeroPaulsonNotesMember",
        "terseLabel": "2020 Paulson Notes [Member]"
       }
      }
     },
     "localname": "TwoZeroTwoZeroPaulsonNotesMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoZeroTwoZeroPaulsonPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroTwoZeroPaulsonPrivatePlacementMember",
        "terseLabel": "2020 Paulson Private Placement [Member]"
       }
      }
     },
     "localname": "TwoZeroTwoZeroPaulsonPrivatePlacementMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TwoconsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoconsultingAgreementsMember",
        "terseLabel": "Two consulting agreements [Member]"
       }
      }
     },
     "localname": "TwoconsultingAgreementsMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_TypeOfAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfAgreementAxis",
        "terseLabel": "Type Of Agreement [Axis]"
       }
      }
     },
     "localname": "TypeOfAgreementAxis",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_TypeOfAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfAgreement [Domain]"
       }
      }
     },
     "localname": "TypeOfAgreementDomain",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_UnderwritingAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement, Description.",
        "label": "UnderwritingAgreementDescription",
        "terseLabel": "Underwriting agreement, description"
       }
      }
     },
     "localname": "UnderwritingAgreementDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_UnissuedVestedRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This relates to restricted stock awards not included in basic EPS.",
        "label": "UnissuedVestedRestrictedStockUnits",
        "terseLabel": "Unissued vested restricted stock units"
       }
      }
     },
     "localname": "UnissuedVestedRestrictedStockUnits",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_UnpaidDeferredOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unpaid deferred offering costs related to future financings.",
        "label": "UnpaidDeferredOfferingCosts",
        "terseLabel": "Unpaid deferred offering costs"
       }
      }
     },
     "localname": "UnpaidDeferredOfferingCosts",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement.",
        "label": "UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement",
        "terseLabel": "Unpaid issuance costs and non-cash adjustments attributed to convertible notes and private placement"
       }
      }
     },
     "localname": "UnpaidIssuanceCostsAttributedToConvertibleNotesAndPrivatePlacement",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_UnpaidPurchasesOfPropertyAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unpaid purchases of property and equipment.",
        "label": "UnpaidPurchasesOfPropertyAndEquipment",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "UnpaidPurchasesOfPropertyAndEquipment",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_UpfrontInitialExclusivityPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront initial exclusivity payment.",
        "label": "UpfrontInitialExclusivityPayments",
        "terseLabel": "Upfront initial exclusivity payment"
       }
      }
     },
     "localname": "UpfrontInitialExclusivityPayments",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_ValuationAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance.",
        "label": "ValuationAllowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowance",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofreconciliationofincometaxcomputedatthestatutoryfederalincometaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nmtc_ValueOfPayrollProtectionProgramLoanForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll protection program loan forgiveness.",
        "label": "ValueOfPayrollProtectionProgramLoanForgiveness",
        "terseLabel": "Payroll protection program loan forgiveness"
       }
      }
     },
     "localname": "ValueOfPayrollProtectionProgramLoanForgiveness",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Restricted stock units vested"
       }
      }
     },
     "localname": "VestedRestrictedCommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_WadeFredricksonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WadeFredricksonMember",
        "terseLabel": "Wade Fredrickson [Member]"
       }
      }
     },
     "localname": "WadeFredricksonMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_WarrantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, description.",
        "label": "WarrantsDescription",
        "terseLabel": "Warrants, description"
       }
      }
     },
     "localname": "WarrantsDescription",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_WarrantsExercisableForSharesOfCommonStockConnection": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsExercisableForSharesOfCommonStockConnection",
        "terseLabel": "Warrants exercisable for shares of common stock connection (in Shares)"
       }
      }
     },
     "localname": "WarrantsExercisableForSharesOfCommonStockConnection",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_WarrantsForfeitedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsForfeitedinShares",
        "terseLabel": "Warrants, Forfeited (in Shares)"
       }
      }
     },
     "localname": "WarrantsForfeitedinShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_WarrantsToPurchaseOfCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants to be issued for the right to purchase common shares at stated exercise price.",
        "label": "WarrantsToPurchaseOfCommonStockShares",
        "terseLabel": "Warrants to purchase of common stock shares (in Shares)"
       }
      }
     },
     "localname": "WarrantsToPurchaseOfCommonStockShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_Warrantshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This relates to warrants not included in basic EPS.",
        "label": "Warrantshares",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "Warrantshares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofcomputationofdilutednetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_WeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceExercised",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercised",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_WeightedAverageExercisePriceForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceForfeited",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceForfeited",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_WeightedAverageExercisePriceOutstandingAndExercisableEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceOutstandingAndExercisableEnding",
        "terseLabel": "Weighted Average Exercise Price, Outstanding and exercisable, Ending"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstandingAndExercisableEnding",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nmtc_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted",
        "terseLabel": "Basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "nmtc_WeightedAverageRemainingContractualLifeYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingContractualLifeYears",
        "terseLabel": "Weighted Average Remaining Contractual life (Years), Total"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYears",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_WeightedAverageTermyearsExercisedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageTermyearsExercisedinShares",
        "terseLabel": "Weighted Average Term (years), Exercised"
       }
      }
     },
     "localname": "WeightedAverageTermyearsExercisedinShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_WeightedAverageTermyearsForfeitedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageTermyearsForfeitedinShares",
        "terseLabel": "Weighted Average Term (years), Forfeited"
       }
      }
     },
     "localname": "WeightedAverageTermyearsForfeitedinShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_WeightedAverageTermyearsIssuedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageTermyearsIssuedinShares",
        "terseLabel": "Weighted Average Term (years), Issued"
       }
      }
     },
     "localname": "WeightedAverageTermyearsIssuedinShares",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "nmtc_ZimmerDevelopmentAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zimmer Development Agreement [Abstract]"
       }
      }
     },
     "localname": "ZimmerDevelopmentAgreementAbstract",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "xbrltype": "stringItemType"
    },
    "nmtc_ZimmerDevelopmentAgreementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zimmer Development Agreement (Details) [Line Items]"
       }
      }
     },
     "localname": "ZimmerDevelopmentAgreementDetailsLineItems",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ZimmerDevelopmentAgreementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zimmer Development Agreement (Details) [Table]"
       }
      }
     },
     "localname": "ZimmerDevelopmentAgreementDetailsTable",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nmtc_ZimmerDevelopmentAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZimmerDevelopmentAgreementTextBlock",
        "terseLabel": "Zimmer Development Agreement"
       }
      }
     },
     "localname": "ZimmerDevelopmentAgreementTextBlock",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nmtc_aggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount.",
        "label": "aggregatePrincipalAmount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "aggregatePrincipalAmount",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nmtc_newExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "newExercisePriceFiveMember",
        "terseLabel": "8.25 [Member]"
       }
      }
     },
     "localname": "newExercisePriceFiveMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_newExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "newExercisePriceFourMember",
        "terseLabel": "7.50\t[Member]"
       }
      }
     },
     "localname": "newExercisePriceFourMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nmtc_newExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "newExercisePriceSixMember",
        "terseLabel": "9.00\t[Member]"
       }
      }
     },
     "localname": "newExercisePriceSixMember",
     "nsuri": "http://originalsourcemusic.com/20210930",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r181",
      "r202",
      "r231",
      "r233",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r409",
      "r410",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable",
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r181",
      "r202",
      "r231",
      "r233",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r409",
      "r410",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable",
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r163",
      "r164",
      "r165",
      "r166",
      "r181",
      "r202",
      "r219",
      "r231",
      "r233",
      "r263",
      "r264",
      "r265",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r409",
      "r410",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable",
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r163",
      "r164",
      "r165",
      "r166",
      "r181",
      "r202",
      "r219",
      "r231",
      "r233",
      "r263",
      "r264",
      "r265",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r409",
      "r410",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails",
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable",
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r86",
      "r90",
      "r162",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r76",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Prepaid and other assets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r86",
      "r90",
      "r162",
      "r232",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r132",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r389",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid\u2013in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r276",
      "r277",
      "r278",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid\u2013In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Total advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r63",
      "r146",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Less: amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r74",
      "r118",
      "r121",
      "r127",
      "r137",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r307",
      "r311",
      "r329",
      "r352",
      "r354",
      "r384",
      "r399"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r29",
      "r74",
      "r137",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r307",
      "r311",
      "r329",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software, Gross",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r9",
      "r65"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r65",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r330"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r72",
      "r74",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r101",
      "r102",
      "r103",
      "r137",
      "r168",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r200",
      "r201",
      "r204",
      "r208",
      "r214",
      "r329",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants exercisable date of issuance and expire"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price (in Dollars per share)",
        "verboseLabel": "Initial exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r217",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r391",
      "r405"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r167",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2021 and 2020; 12,010,019 and 7,393,637 shares issued and outstanding as of September 30, 2021 and 2020, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible promissory notes and warrant agreements"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r14",
      "r387",
      "r401",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/Scheduleofconvertiblenotesatfairvalueonarecurringbasisusingunobservablelevel3inputsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible promissory notes (Note 8)"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r385",
      "r398",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Paulson Convertible Note Offering [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r52",
      "r74",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r329"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEarningsDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative earnings (deficits) for relevant time periods.",
        "label": "Cumulative Earnings (Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "CumulativeEarningsDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/GoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r192",
      "r193",
      "r194",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes and Warrant Agreements"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r179",
      "r195",
      "r196",
      "r337",
      "r338",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r36",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes bear interest at fixed rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r15",
      "r16",
      "r289",
      "r386",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
      "http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Abstract]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredrevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Federal and state operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r295",
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Federal research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r295",
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Abstract]"
       }
      }
     },
     "localname": "DefinedContributionPlanAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r117"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r40",
      "r315",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r270",
      "r271",
      "r273",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment and Furniture [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r44",
      "r45",
      "r46",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r100",
      "r138",
      "r214",
      "r216",
      "r276",
      "r277",
      "r278",
      "r299",
      "r300",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r347",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r322",
      "r323",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial instruments measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r189",
      "r195",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r323",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r189",
      "r220",
      "r221",
      "r226",
      "r228",
      "r323",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r189",
      "r195",
      "r196",
      "r220",
      "r221",
      "r226",
      "r228",
      "r323",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r189",
      "r195",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r323",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r326",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of convertible notes at fair value on a recurring basis using unobservable level 3 inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r189",
      "r195",
      "r196",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Equipment and furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r63",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on notes extinguishment",
        "terseLabel": "Loss on note extinguishment",
        "verboseLabel": "Loss on notes extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow",
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement",
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r51",
      "r74",
      "r118",
      "r120",
      "r123",
      "r126",
      "r128",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r329"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Product gross loss"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r286",
      "r287",
      "r294",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r283",
      "r284",
      "r287",
      "r288",
      "r293",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses, deferred revenue, operating lease and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r145",
      "r148"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Net Intangibles, ending",
        "periodStartLabel": "Net Intangibles, beginning",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r27",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r26",
      "r68",
      "r99",
      "r139",
      "r140",
      "r141",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal costs"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturity of the lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r74",
      "r122",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r308",
      "r311",
      "r312",
      "r329",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r74",
      "r137",
      "r329",
      "r354",
      "r388",
      "r403"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r74",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r308",
      "r311",
      "r312",
      "r329",
      "r352",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Court awarded"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/OrganizationandNatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r42",
      "r46",
      "r48",
      "r64",
      "r74",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r88",
      "r89",
      "r94",
      "r118",
      "r120",
      "r123",
      "r126",
      "r128",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r321",
      "r329",
      "r392",
      "r407"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow",
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental non-cash financing and investing transactions:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r120",
      "r123",
      "r126",
      "r128"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
      "http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r343",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r342",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsupplementalbalancesheetinformationrelatedtotheoperatingleaseTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r28",
      "r143"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Accrued issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails",
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2021 and 2020; no shares issued or outstanding as of September 30, 2021 and 2020."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofPrepaidandotherassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible promissory notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Total proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r275"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock-options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r42",
      "r46",
      "r59",
      "r74",
      "r81",
      "r88",
      "r89",
      "r118",
      "r120",
      "r123",
      "r126",
      "r128",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r306",
      "r309",
      "r310",
      "r313",
      "r314",
      "r321",
      "r329",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r154",
      "r354",
      "r395",
      "r404"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
      "http://originalsourcemusic.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowances for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r227",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r227",
      "r348",
      "r351",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r282",
      "r369",
      "r422"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r216",
      "r354",
      "r402",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r138",
      "r276",
      "r277",
      "r278",
      "r299",
      "r300",
      "r320",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r47",
      "r74",
      "r115",
      "r116",
      "r119",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r137",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r329",
      "r394"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement",
      "http://originalsourcemusic.com/role/ZimmerDevelopmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price, per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccruedExpensesandOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax computed at the statutory federal income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r147",
      "r149",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r147",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r239",
      "r254",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions used in the Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r217",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of summarizes information about warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, Number of Shares ending",
        "periodStartLabel": "Non-vested, Number of Shares beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable",
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable",
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable",
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Outstanding and exercisable, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Options, Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Stock options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable",
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Exercise Price, Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding at ending",
        "periodStartLabel": "Number of Options, Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of Options, Vested and exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Vested and exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r258",
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "terseLabel": "Compensation expense related to the stock awards (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofweightedaverageassumptionsusedintheBlackScholesoptionpricingmodelTable",
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Term (years), Outstanding and exercisable, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (years), Outstanding at beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Term (years), Outstanding and exercisable, Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofwarrantactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term (years), Vested and exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r12",
      "r354",
      "r385",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleoffairvalueoffinancialinstrumentsmeasuredonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "negatedLabel": "Short-term portion"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofmaturityoftheleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r72",
      "r74",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r101",
      "r102",
      "r103",
      "r137",
      "r168",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r200",
      "r201",
      "r204",
      "r208",
      "r214",
      "r329",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r44",
      "r45",
      "r46",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r100",
      "r138",
      "r214",
      "r216",
      "r276",
      "r277",
      "r278",
      "r299",
      "r300",
      "r320",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r347",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails",
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable",
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r100",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r19",
      "r20",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock under securities purchase agreement (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r191",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes into common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting services (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r19",
      "r20",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "RSUs forfeited shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r214",
      "r216",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofstockoptionplanactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r39",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock under securities purchase agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r23",
      "r24",
      "r74",
      "r136",
      "r137",
      "r329",
      "r354"
     ],
     "calculation": {
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet",
      "http://originalsourcemusic.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r218",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/GoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Management\u2019s Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ScheduleofsummarizesinformationaboutwarrantsoutstandingTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Number of shares used in per share calculations:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://originalsourcemusic.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918705-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r426": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r427": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r428": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r429": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r431": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r432": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r433": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001213900-22-030420-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-030420-xbrl.zip
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M\-]E'FM2 'R^9B/9W+&_;'QM/H[2^$_^>W-A)J\QZ:U#.CHE4VDZ2[*YRF4
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MT8<2""Z12H$TL,Q>4F@1W&ZA1>@*+>B(<%G59,Y6O*2PH-XYV&RL/M>JH95
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M-XF E8UL<IY]L8# I%I7/>..F/[2E_?+NQVQJB164:#,D%4==A=2P*T9WA"
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M.UPF$;@UF/8ABK4!T(K5&V/\4J[@KB3S3V;03GR1E^FG3CBR%=&I(L6(6+@
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MNM%*&+B%)P(&'B5Q3:=9N;LMI^])R3$%?J<B>L.]*R_"(CE"@4^8/_J)Y8N
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MFJZHWM2U]:75CH R'&<2\91I7" *#UUOJ8J*?)V"7-OEM^H%,Y-?P,B6&K!
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M)*LXC>ND*PX(+/QL-IED]&[0N(U@L?TNE=L@@/:M7VAJDZZZ_#T[X):0IZ*
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MO X9"&DS],U;+O?IOOUT>OST>Y].MZ2,;NDQ)]+3R24C8B])T?'Z/%5-L/A
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MO M6+T(]F5?52:A"F&+/,+HI<7EVQ/S)X$>MR':X1[?G "4?E!(O]MHS&I"
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M_B0G3LUX)3G<0D ?8'@:_\?R!DE,PQ=A!!&"T6X0.)E@4NP%<_F)ZZEQUE)
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MGRJY'K)W1'G9MEIV[9AB5<Y51]'+*H(U>8FX'7V#G[3,N_9 T=]!55\9]<P
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M-(;'Q G65I+%,>K3H>/>QK933)!'.G$0BM!]Z2B&J!7\Q Y'NJ!UD,L-L/:
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M,48SW$JY*&SVGK #C6J20F)G>XSQ/8+)76814<3HF_H^)=J/*"- +AX.F'C
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MUZZYWF\.VK\(@DN4(A6\5?@FKZ$QPK5VV),S[!AF &OF+%,2^;(6+'<L>HR
M^*69D8TY3ZZ1D).%X-<SC!?:L1V!/%AN=KMU'5*[U2^EIZP 6Y)XO;/!S@9[
M?@8KVAEL):I8M:ZNA\XO<"GMR/SF ,SOBORZJ\AN@0>BE>\TP-N1S8:_15H
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M+/5@U7-0DBSDH+N-%LZ9?'#;KBQ,62(^X]@%_T$!(Y DG'VPR$;\%XY5LCC
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M=7F8^SC?^_C)'??6#POV6MI!8_=-Q0_W+3HF^]>T<_*^!:Y"D8GAK>,&GLA
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M+8H\@FZ$FIFG"9O,IOM%M#-%KZ(,IFX[7R-PHSE. 9]7Q.&EBQTOP+H5>_:
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MM9#50GYK"]F5!SIJ( BPBTW%T)R&3"J;&TX]'/S!%5.BMMPQ3N]]/456&[E
M&XE2"XX9)#@9%ZB?.-M@$D0Y^B44[K<;._WU:A:K65R>64R<*QP"GJ"-*=;'
M9L=:;F,]5,QG/#LMPK>T\)ERO;&.50-JI=5^5ONY//NQ:G^ ;R,S/1[ I6ZA
MOA)ZP7(2QDE42_.T7/I%]ELH]Z[&LAK+8QE+ (09;5MJ*A&,WIA:M9\K,IU
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MR 3SLA[[E E$*)2 -6<LNK]L;NTN]"3. Q-]HCPD<CA=XI/1GD]F>].JQOK
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M/-GD?(.EO%CO$26)%:4#*D=VP"R>ZL4"/S189\HQ]8&JA/Q#G=) :U!W2,T
M=N[T_/3OSG>5PV#+2F?@T3P]F@)=0\VN@)U')<$ KND*-_:0+=&ED4K^#&?I
MLA(1<QAMD[T2O:4^CUH*J&*<UJF0I]<^)8%X@I?X6828N 3U%"[L5/+0XX5"
M90CT3LL%UJI=-O,VF;<NZKK$KND&[L&9TDU4;R#B!.#),&X^HX;R[*%JPD)L
M=H)VV6RG=:*](/,R_6$CZBHOI/J'?(?V%G/&\41@&BE^J1=JP(\;85S+1=1A
M];'KXNC0 .:PPD%N9>1E8#^2K1LQO43I57BE,>"L="\V$$($[K72Q"9S+#7
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M:4D96DM=0T'EN&:.BA9,N ;?Q_$E8; P42QQOF2U D'>296XT+R!^NHQG4@
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MRS!A& #W*)PJ6;@NB'$9E5Q.#1^88PGNC,IW"5E'UK3,,JP,X0Z>A?1XO;&
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M'GX\.CE\#V;SQ[=@Z\HS<#$^O[^@1Q!KXA#_T'DKN(86VU5^#\OX5U9Y@M6
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MS'^?L!ROX2+0*U&^H',.L952P@KGC)LOF?'(7A!O)ND7>.W-D-Z--'6_CL@
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M!!4/Y\.D_XXV!C[M<4\[ZY9Y9-S3>.9]>W3A[G2.%]OH::'_^4N@.;8J.9)
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M4939Y OW!J1.D93C)A)')_@;K+1>T7FT^:.]9.6\6XV38#S05+.4=5R=N,<
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M.4'C#MA)H7A:VQIITPP'K439P6A_T_W=6!#-9B;^9M.O W03[R;+OY #1A*
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M< (!Q3MY&9C)Q-'S>$&%"W$FX0A]FV$L/A38*5;Y/>OVPA&W+SB[I!IYJM\
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M.AS&[CK/_:S=6;=R5?QENW5-O($DKHNW!K^XS7_TLH6A><C0Z,WOS]#63VB
MV65S"O"P8\1#DI]6Z//%\-\-HJR$G 4&RBTCF^>6DX>Q;]H"P"]V%&Q<7;_@
M_#+@/BD3&TV/O1J,4$[(G9&%4%Z/)Y)< OT/?E9<K,OI(%VGH[-H%E&QP 96
M1(O<#S9Y;V.;Q],VSYWTV_[]0\O%^@U>U]\BGV.J'N4RW&(32K]>VA%<CAOO
M$,O2,6B4 :B@074!*H@WI9@I;VE.20;>I34[A;S[(,M57D0K+FCX(UX.-4%E
MA'Q)LQM_#O]3LG(#F[P>%%*K4IO %F+/"AX5&W7C<]3!!0HZ!!QQ,)$%?!?N
M%EPA\SN+/EPXL;2";Z#['#M;T 4C>]N3#!KV@U<<]%7.(Q4"+3(PA7,&.-39
M-O5<"T:ARC#HR0X'6B1*Q(6P(?@5MM7&B:'ICB^IR":8]0)<N<3T2!P#*,#Q
M3Z"^6KA>BA)=(32>7A0G)5AA"U"!<4IHI:T8/B+6<'MY-HM+]2QJJ%C-;1(^
MJ"$(AYXM#< .8U":UC7.@5%5U:.AR?MQ-8]PBCH+>^&PJ3:Z:_BD04&'4ZZP
M&W<T\'[#N%&*^G58%.@.6F65]L20+HT8;ZA0JT4D9&WH!"1&D+R.^"AG";(1
MRJLRF4[:Z=)A=O"_EYHC=#ES$I9Q!.?DO8-S*KJ]E.? H$W985P0TL6"RB11
MT5;4Q*F!Y)10R)&41@+,,B*C&+@R9TP^^E;\^'IN"9M13M2R@*U5_W+JLWGS
M-YN=Y_NW%'-SV.DG"2+=41JM%NI64=,]8/P-'"^9.@_J@6$AN$%__FGOI[5O
MM@7X.(L$K\F_T!X[1F/Z?E.@<M(?OPUO?#EO$]O#\.?&NW-7!%4H\.[]<TSH
M^K1;Y]@R='=W=/S]=Q2= M]G(SNRVN&/O39O_$N8[%6.-CGRPBS_V<^O+K?&
MPYU@O/TZ&._NOFQ>+6&0KY$_MEZSCR!?2 Q5A20VMJAT:Z J1G]JW_CZ4VU@
M%B_6C+E?>YHRIW[ZR];K8&\X#EZ/]];.I>TK+Y_ S+>#'2P6'8Z_9>:;WXX-
MV4KCO+G!4?MYW[9'S2FWTW#;ENSM!\/]@]N>K!W?0TUD-![#Z>QO/).')=;6
M+)(U#$^?HP9 N;3[A*RGW7LPT(V9YJ9'<+^1Y)!&HV 7V__L[FS(<#>=3>=V
M8C_8'F\'V_N-^_I-&_&=64OSINZH>RJE49&J;+MK^CO?<@SPDL0O-V+:]QI#
M]A_DS]Y.<+#3X%PM"_CV:_A45[\=[._O!GL[K[_#ZM7=Z_%L[C'_>R6O[O?)
MJ\WDU7&?O-IWJKW==1JCQ/(VL(AZH)_'F_]&1T3I5"]>(T*NE+K;M:]K2U]5
M@AXE#5-.$S4>4%7<E*]U8*KU/0S <A>M;#9#;^TRCV$W8%VHD5.=_"O.ML"B
MEB@M0DXMG48(I1O+3^$"@W,2K\M-"#A.RS"]BE7-C_3C <:N(WMV2]J4L>;2
M+'U%VY.0UB65L114N@U"A.%(!"@D*BA[%CO\X*[6  1<M ('/V#@75"YHH)%
MH^.I<OJ-=4RT&)I2$G/,#(\,?IWAGL#B*9@]2S"$);G?<5HK^;7.FHMF^#)P
M8QJ/HH\-[ /J;,53YQP^N@RP#OI_:\IW3962]?11AR57=:G48KXPTX@57X\;
M'6.^7Z'[TMF=$U7Q,H<P+Q%#T=&:.0LHHN1 ]>SCAP)Z_G,W_[&A-C;A/\--
M^,]HVW"U.QB0Y@6J(V?PP#S)<WF28)P1]=#T%>H9G!#L5Q47<TZV6<MKAA8'
M;S ;?RVS\7XDL_'7,9L=[X<P&\5H_#6,QFLRF@0H!B?9TLF.XH\FTSJ!K4[^
M:"SJ^>!;-IA5N\>WRZM\7O+D<M5Z1)NIKRQUAH.1YIF<$V8)DZPJ$VSK@./E
M*GN3L[],D1A6,]&_.DS#_;706L4]K\6LRE,JM.-BF6=P%YXA/[\[\M/EE3X;
MXKWKF)@T1R-CF'ZKH\)HB$#.*5D"@@'H=%QRP?TT+C'(CD^"4/5)M7UMJ56#
MB6[?KH_G$9><A$F1Z?ZJ!4&R$6H@]W5B)5>W=K5*SFZ7;ZQ\4S9=ZJ)8\5YS
MGUF<Z=!,-%"V4<SV$I[%%,LH<N)]C$[(%<#TZLX!5M-TF-W]P:AGW[J3WVAE
M_T[B&0ID7@-)7!61.,"9ZLH5QNR%-8S7TA4GUCORFQ+:Y;;K&6IPNUO\?-UO
M/?!\LK3SF +NWJ&!?OR4)8AS*/!5%MKHWZKIE0&V.A;L@H[G=S^?L]P4$/ZV
M,]<;T.6]Z#I[.:UR;]&$T9NZ,'JA!:/GHGE-'"B]W$#I61 W\)ZNP'7?-J"M
M@<<BRC2CE-Y(4^7ERZ<DA!@RP=PFZ8:-!4)<P(.^8<;T-,TO/Z<$KDQP>32[
MPP7LQR0DW,=?#P\_L<.2/ZD=NPP5US9;A7]2V  H"F %=OO?#O?",J2%J(%4
MAQ0RK)S!L\7J\ 7[,=&OJMVBGN46#>A0DHQ*FJ2M+V(*I.5ZEZ\2V1IJ#G]0
M/;N*>:3>6C<3 5XF>:PA9RWEE=^A8^ *#D:4J9T6;C"CCX92(Z>W"J_$'%22
M+&<@0(WEP[A(J0:N([!7K[&3%J0I8MV@?S9C0%&#83>)\TFU0,!>+* 3K OX
M?L00#V8N.,(BG()>?\A%M>HZ(RSH-$8M1F-$)2M/8VU;(\"DS=E+D2V]*,>D
M9T^XA$(Z#%[+.XC;D&#7!(2:K(T.ESG!["0Z?>["A+$V9WV!/PLG<JIF-_EZ
M,Y@'':R&NL(/%2H&X&Y%'LVD>6N\GFY1+3.0R5X+WG!DN?[5!WI;X]'F_]L\
MQCYO-7!WFZ%JE0S)(<LCG^L_#9J] NDEC1^!>]?=#6PR'A*SB)(BNB%CV<7;
M K9O*)C!XE7Y&'Z>;H^H$*US5%[^TN7>33EES<H!L+(VP5M#QQV^K(_K![Q7
M"M_K/H6OF<*WW:?P/7 *W_/QE'_B8GE/D*B[O9ZN2UDYA((5HAJ. >E6DPP$
MSW\Q&P.["* RGV>Z;YXT$9CZ5QF612/H(X*/"P $(3&(.U?$+_>CC?(B(',I
M53YLD76DR!6>H)<5\51L,[?_RR4A L9EHC)?$-J;=3=V,R+>9&-&H"VS2@UV
M6+14TI<AYW!5H(X&J-QB5Q!443T;X13W(D; ".[QJS%HT$_(ZPS9G0=FWH1
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M5=\GV,=K"=H/:]"Q'8DBN*O#W,2=F[0X/RNEPC7%)LO(':L./T$RIH/QG?!
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MVH:.0B%474^S4;\ZV-<1?";Y7)W\NUS+3:8A5M,?V^R!_,VBHK1Y\B--]\9
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MX,:D:N"/B#4?>>/$=525DI><G.Z92U)I#N&?L-__YNWB$'FY6?X;;I7UTFI
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M[$+0'^4$E]7'JK"OFE9CZY-]'C3,+D8Y$HK6SQ/%;*GJ5.R2>*U^QQKTCI>
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M[A(+Z^Y\82M?U][YZ_@0"NE03!<"MPTGR2-H8N ".$\*T,D!)5)K3G0S 7G
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MA%)9TB"9SZ588AIAZ1Q)AF^T)/=":0M#4^UX%-GLJA62P-K]S3/6" 9+7?@
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M==U*)P+<RC0!;48>@R<'76RC'G/E<F*Z\T*]G"Z@2AOM&ZN)^@K!I?+:]Z2
MTI5RW7.EW$*EW+!QKI0[ 1X_%^.=1C'>&A;9I'D(= >H(]K#5>!\H+^!\XFV
M>E;8M7'KT&9/K;5QZ,O-]VNS@V5KV9J40:M657?[T$KH7+V9J&I@JN(YRH++
MRFRP%R3VOZZ^?3)^%_//KNXBUY43O Z#R;Z;6&)%FK>W.[+:RU'U,#,64)"8
M);\ ?3P*=B%PX0--KXV2BW0FS/4G->+.ED><S8#X"[:$X2SPO/UT&GC9%,!/
MV-?,])4=4,@OJ@,*3 9#_H+<K@#4#L_-P(Q!%&%TG1(B.._#\Z?FU!M'H39.
M(I%J"7QH7(OVEHP;Y?OR)KF^>0,V?S7EB"&^$)O&J:KD6E'D5E)$?G^!Z1=7
M(#ZB]DLDH[\ 1?[+!MZ+GLR6".9;'!#E5)581R370?-.?%_$JCR$/ETX$%F4
M1R_ ;TLE;IF___[!HOB7Z[A8EA=&<V/.+4I$.%J" <.['0N=-+D@6/,G=Q3Q
MHEN47>M;YA]TTHQ+V1S2>S.4/ZQYIB3<"Q,$G>T$08UPD9D@R$GN.X)^F@MX
MYD6"9#CXC#C-J?T#>"L5DP=BU_<MF29$F 7$>TPHYH,Y1RN;YTRA"7<Z\\,G
M&;@PQ-,=<" 2A4EK%PD$QJH-+@KE028S).KK7ZZ(+^,]H3C\##[!=\2,PB?;
M3YXPU(.C0T$.F-C&YKL7CG?G)1@10%M4)'O#-%*S=WA&SBR-,#NHH&GU6R_Z
M]VP3YR--TZG,K,IWRI&9\."_K<09Z.@X XT-$&#X17_PZ[^*(:/_ Z(99$(A
MY$ :@\?:;5B-QB)*%!T(R2EC]7+;.U_N]\=P^7*;C=7KY<+GU4MN#7>_YGM@
MMQ6K7D/E%L\FMT&TYCLQ,63K<LA)I5ATKN/DEXC"L<(KYC]#\A]%1>>[/1OR
M(G.E^7HF;3<V)Z&:?LTK$O/--N?,1U!2,]LC+:FT*IS\I?EY8CZZ7-7P)&]P
M3'6?^":>4@8"*I'%ZY[C 64$I/><2!+E(.+VTM0O,9/7=$)X)A8/Z/#W6#(Y
MIK<2*+1\$YRK):M9Q>_4*TS*2*64+C1&8D5<>R++*+Q@@N_@F&D:XY,PZR;S
M6'D!M'3!.)W+U\"F(W<*0IC6[D93:1OH&N)P.--[5MW=[51WIS[536>+$7T\
M(\JF+-Y^H$*[ ;;<4RQL:N,QPI V#;3Q>.+-(TVNL5-?I5C5 &KD?#&-R$E)
MU;.U&F'!DD]:#I;M/^$EFGJY"70BQ(\E3++<B+0C0M)'AOY!S-/B(S%P2'/Y
MGE1AY8,;V%2.M+@SO 5R$5C^Y#SQO9);@>\,>><FI<>YHN!!P@<(,V-D!S^B
M=):,G_AO*"P?0I]2_FE\:2H:4QII!:%?>V^0>L,<L?-$OK=YQ6QUD!&2C<LS
MV(! F120A*()1)\^7EW8,RH3<#)[*1MOE5L"" !$R\@PX>$IKSU8ES>Q1%:"
M+S^&[#"KPS8\OYCR%T+,H.RTF)KB8]GWQC@<@>0$+9 3(2A&E<H0HP1C5C8\
M7G!A+.!8(#^$6?V(V9=^#SDTAC"A\EMR7-OQO0#$#UF<4E#DC-B,^9&+'G$H
M@_MS1F@:0"),HN YQH+9#8?/TZ8$#TO8L6][Z@/* E7RGW0N'P(+2K(J5:$#
MF,8VB79Z:]8,,:] D N($,!SX%VUZ\7N7PQ$'ERT]K83K=T]1+3^L)]"0PMC
MO;@05G^[,]I#<7$^A%7HHBZ,>ET,6N%!Z_$IE' RUW$-8E<T[7 LB*-9,H2%
M7U4A'3''%J67S,$7CX"=7Q-6"GMCU6]0)L"EO;\HN/69 5>TE#.(=(SV3%(:
MF!N.$F'D96-E3=8V.%5V[KO"4<XT ?R"WJR@@^PY]QB[R4BYH &ME)>P)3-A
MFFTHN8_"]([/0[<[\QNTL'R!RG=)J/-E@8^8+<JTM_N7YA6]9G%*REI7M5F_
MT]*V!L-%[%D\#VF9TR!@.72&U60V((8TJ:BMDI.2-,T:B\IT:K:?^ Q A=>"
M K=@6LAOQ?3_,GH1H?&3@B[,'!;R_):-F]G3",-C4UB#[81A[=6X0++?<3+U
MGO34!D,F]WQ0P^T.JO:J1*;<US^^@SN=>'<B<_XB<V3-QG9G-:QQLB(->?.F
MKG1T%Y0BN+W_%)/(?'60A'X@7 @[\F(O&[8>1@[XCQ&.AP-?F+3D"&?H@E)^
M,0&59G/+1':COA._"43^JC6D1-4@?^(86$0[#70B&HX&:U4?&Z[06N,@'-QJ
MO2!&F6GP>VF;\5/1N "=RHD/'JD)+_]A?KB/L$;?#N(PP"R=Q%Y4B4K^@LO-
M87_9CFM\ B,A\L8_Q#>"\%$^??Y+[)5GR[8=1_06J<Q?EB;\'(POZ25_1)>Y
M95'[0A)G'1J^_1BG7F+8U#27T!>T14G^!P,;L3+_*W6XVA?.F7K^X>7P!VGO
M49:(R.$%<#7"Q*;26/:LZ3T645G<,?+=YUYH%*W:PN-Y\*(D=<6KO,@DI"09
M]\P277*N-B=7Z4/".&)*9MX#K,02L2M7?@M,NPNDL9N(8E[\14R%]4GF2> O
M-;R <.0+"1(O/'#B@9WFT4#L%#$,](^2M9<&R,183!H ">ZQ9M4-[NP[SA6G
M ;7VZDO2_PP\YCUX5'P=8\ABC!B2-.(ZC1%K 3/C$TJ.RQWKPRI%@3&U7&0-
M%:8+?PK!?0$6>[#)*6"&E3NCVR,"?' :=V%(X3%,D7%H+\)HCP\DG^=9FDH9
MR?'B28)1P[GSSRH(PH!WK6?&X1I?_[SW1EYB7EV">U_(L\QC7#X.[ML=G05P
M&C4]TE0];.GS*0$9N'=P(%S-&R-6#B7/7:R?)_C4*5S2[$,4/XWL%&>PP;^F
M7ARYHL]1G*D!OR-/#-B/T2PB?$+LCB.7:ZP?O-!7H25U3_!^,)7')%P5$$88
M";L_5UV/Q00IN7U\_O#120+NDR (1L?T&Y$7#)(^&FGFK]"<)"EF5,YLS?.J
MJ?'JI4%OBG\H287"@CNHL([;)L9-HI09#WY [^9!Q$A%93N!W\+]GY=,A>)-
M=&C9CW;D\$J"F/QCP[&GL%"X==0-0%U!X/)[[L0"ML1>6.KA%)\!W@RCP,WB
MP>C:6>1]Q5ECLQLGQZC\CZ)"NW>NT%ZLT&Z>*[3/6*8OHWRZ&I9I5<]BVQ+;
M&FMLP3.Y F/ ER5T\-]%\U;3OT:!_F47Q3:GH0IQ@_F)\[(QWLOMU^CBW+NH
M]D0/EK#,-:R!)B] %),4/,L418IH$[PU9&$#6HG*+=9,KISBI8RN[)C#-C(M
M5&]S0[' F6=G:RS&%Q,7,%1A9@S]&7CH!9G?T7@R;H7Q=#7&ICL7D<5BDRU*
M;S+)#%I>(6YHT1*Q%@QE4N-LTPB+!A?[+GLP;8EAYI$J:/7B&S#F;D<\=EZ8
M4"+_+9P@L/,]3@C[(BZ,;\JLY%]T"UE_WQC1S1+3QT @6J<4Y9^SD0RRD?1O
M8>X$CB2=8!\F&[)4$4+I4N$*9(X JALF%$,2?<T]ATZ)64#NMIB<E\9-5J'3
ME]CXN/M_ILZ=J$(41E\AH\V/@\]Y)NK%"X1]RCL<QKS#88GL3.!M\G(*\'#A
M O.0PBXY1O.N'@FZ9<5[L\:2]\]2@C*7H4LA8CG%T0]#13]R$DH4<:)O%L:4
M'(&5.ZI:_(/T4J5 57AAB',P)_Y6^DL<E!!7S\A=/5J#DJGLK!1=4?J<[I/+
M8&/FD[/;/N>Y%"TPHTPQ82[-&Y[68K8&^DV6^\N ?*1;#&MU".B",D[@/N*1
M8)$,]SA[,UGI;K.WG % H$:"]QLQI@OQ1_,F<F0%I'S*H^W)PY5^&-#?XYYK
ME.(@=%_.Q=RR KU98PDZ\0WH&YSQD_&-XTZPGHA H_B:XL&*L.L_0XP#B>HJ
M!,'*Y',,%BOC,\2N^X/TJ_E@1Y[+4C_[\X2:)F30'J,P>)$Q&ZK:QV7?-VA3
M;^IQP,G*-( A-,K8%C4&P(@<,L!RGR+?/]=QDMTHNNZ%@8@)QDM=++9Z$.69
M<3J=HKI$#<E)X,! P*RL9%,*F1CH1CHXN\Q3#'T]NO!Q6Q# Q3(T#'70ITW&
M,8CFY!12GNKO1P+(0* Y7YJ?"+0=WXI&(\($&.*6 I5 0+)8X>.)A5:5YRH)
MDQT)?\Z2W^?0\)BNNVX*S"/ %)T^+D.(^Z%LP+]20%QR2$[%E\P? <@HE%E%
M%H$QYO))PNS03E8]-S-..&@<3% Z(J8:@DW86=7#G$FRR?H$B\BJRI0Q UZ(
MY-NR@+=98P7OC02G,5L=6?RHR3V^]$KE$30>FADB)Y"_JT7W,W>!"0@I;Y$O
MZ/UY!D;K7TK%&9<S(8B4,';U,&H69R=#0#F++8%,IRENE)#N@G.ZIC*G5;TR
M)TNQWRK8E2NJ:K[BI6">EZ!]OL(E?EK1I#'H%C8<,+N#$/B6^B[XQYI$PTNK
MIZ76[+)"K\SN=]G9>)>KW#!-K\ZCMRWC'XKV!^Q[BC2FEEU'MH]=WS)_P]KD
MV/R_[.GL'>A5T+:C-+H3^3"R$/PGT8F& )WH#/N>'$^'"T"MC;2)5? #OTF=
M(WI=<E-'5Z2R[9'K!D8$AO]=0$BA"@I8H+");*>&1X9UW3,1IE!6@*YR\K=A
M7JIG-S\4J#1$'%;:"DS-Y3&UFCJW%Z\XWWY=,,!GPS&GF>@@)_@0609&P0E>
M=MGS.ZQFV9]BV;)\N5EC_3+5,3R9K;XHF\=C7FY"HJVT:):MU"L%3B-;**%2
M:5U1<[G*T,H)"F)U@X<+H('-_%?BU6*I+\>DV;(HNYFKRBY$^9\C25E:OGK_
MG1 ;,0J(0M($%R#!LE.')SHHF4I<"4<M> 7.%YL<&9M9U5<19J<8HL!D8^AD
MY%24?ZX_,1^\NS#B,@61M-4_:]^!_1S'_S][[];5.):LB[[K5^CDJMH#QA N
M2[YG]LXQ*!*JZ9.5L"&K^ZS]LH:P95"7D=R2#$G]^A,1\Z(IZVK9,C;XI2H!
M6YHS9LRXQQ>\_2CP0V>\P#D,*#NG4Y=F,5 ;3FQ)"=&(.6<FJ/U%-&830JDW
M*2E U1 '+_X1@6H':/E(^B8>XZ"B!S,-E GHI7#;9OF90>=7+ZW=(E.O65QK
M-EE=>_?YPAZ[Y)%]Q0:HYD%HDG6U.R%UUBRJ-9NLJG5986U"IH&AS+.J'ZE9
M"_O&/GS^NV-/1(L:.TQ9<.ON:-%M 4*4TGM.>Y%=$E]BE/A2?.JZ\#1K5NZ:
M#9;N*B[H("L:G42ZH?*\,<KEV8P$]HRZ'.U,)!>B<Q+"Y5?WQ;,?]#,:?T8-
MW02P\NOE=>IWJ*3.)X[W9!-P*TXO\H$1CR+_WD$7PM#45\&G9WXPD6]3\268
MRZ)NBOJ?)*P%VX./"3UP1>8V_!?(S[)RD3[HC4;ZJ0<?MT$M!Z %#5J7?AW8
M;N ZAA;G4=7=7P<.V&9R'/H2AD[D^W^BSJ?QSS$"OO@26H??P Q]E)CU>"ZR
M!TOM^2$JZQRTNM\#Z]"+'D+>QLH:?6$K!OBN,[0*96?N1&!T)E;]'?Z<7+&8
M6X#=2WH@< \2BW5#_:>^T37;A'Q*"]#$AUA;JSG@ZR+(443FYM[13P.C/>C'
MWQ/)=&6V"RXIB?B*9L(,<7CMY-AWEYD3KB=ZF[6X 9C(E&3M\('/?" (6]YM
MC)'I.VY>X K0 DIOG>U*$'MI=8E":'<V0\ (>@[858@F8'-P6'& "N^2?<_A
M)K@;C(6TK%4J3#F@U'3+3\&(QY-1(Q/V?L%RHP?N9&M?.9MGW <W+*0!L[]2
MZUFB1D=0X[75?77XN9VHW!L<*O?2E7O6H7*O_I4X8*L>B@-789%FC-XUNY>L
M!KN75O""OOJA_IL=^?OB C5PD&L6>UH-%GM>BHH(-82:[;KH2ZZ+-A6!"F;_
MJU8PKBGAO1@E#D7L3 3,9E)\"1HZ$V%2@,,A+ $::'&^(^%WF$.LRZ0N%%CD
M*?6= W$6;N3H_V5BKD7RIJ&? 67@19YK,ZM=]1#D;LC.HU%LX+X(TY6P9S@I
M-+;BV&I.?)7Z;'ZX.&T&2%Z<GZL+O4<ON\559.;=PO\\?OAL&F;?2@,#A!BL
M<+!Z)*KD:R4.R>>,9/&V?=7UT8A4LQ=VMI6(4Y*][*U#G1OL?IJ5PB=T#:MK
MIJCTZL;YMH77NLC"34(+5]="M_"I?V 'EZJ$/KXK+;1F79[5;%V>S-=PX(]V
MOBK24JHH%46CW.,#MB)R.:Y(*O#F!3>H8C^AOY+LHJ)&@QZ,$&"31VE$<">B
M&,LIQ8PX+G%"I28?2(D;=?TT[]&&O9],[!=1;<ASWS,>WBB4R5J>3.8E[WPQ
M<LAGQGJ4P)88@)G"@$E*;>PH7H18FFS?^4^LX5N+8SVQH,]X6[& KP'I2?+]
M=Z9HI)@O0O3,@,:14;1WD^"UUJQ9LQJL6?N2A @*<S&"J$*;R0QB/!%>RXKV
M)8W6D(-.,M.S&9Y$/BPU-LQ.WQA:_31+ED,(U[6%JJVKW3',X2BU+D,485'"
M^_U<ES4K<:P&*W%N%_,Y*\;#X78X;&TZ\Y\1MI<8 FG (>,0?).4A0Q(SZ1<
MIFIMK+0./[Z;0UVSR,7B<WD+DJ=98W'H$JJ'=@9G=@&4_XXF@7P-/)LU_Z.Q
M,,<DB7=/%Q5_1CTO?A:!6Q:\'L,AVO/0^:B+?WT"(3B)'O ,VS^O4FBCZ?K?
MHD \GP8!@K001\JB=A]X*#>:%!3[Q,<>33XK'\6EG+ 9Y_B\V>23SC<:AY8Q
M^I[XOGP?[ ^M^?_]H?^AX(%9@<CR./\%2]#\[2[XY;..X.KZ.>H@]G-"$2WO
M*7,#C.J)E25I\DL4[ VYK<V3&Y7Y9@BY)[MM[R3;H"!BQ<GD\'!8;ME>R&N.
M'T%G+ +I&C 5@F7/9%]]%#NK2M:LE$7R1 M^W."#J](23AA.]#Y (%>4MG[P
M40_N[XZL=M>P.D/#ZO6.T_3F(GC0_SE3,:9YLRO3.2["^D<\92(^AE5V\*N6
M:?5<#QQIJ=&E 1"R>L@E71\N,Y[0#3]G+B'[<J2_FLGT\'T^IR"K0O"GG)6,
M5GT<5:1+3;Q9&U[25>CHD'H<Q&]9I5Z^%3UH&\/1(&5$KW8&6<3+%GGOXRSK
M^CUKGB5<[6Y&]'RS9UE="%42Z14D"/+%#5+]Q)^>+)CSC!@6#-2!27WGQ_C!
M!HM8]'.&"22Y8HF?L;@B%LY@AO(/9CUPAQ;3K&9I5)MDZXQ5A<LF),KNJ812
MX=\Q3'-8*C#6DOAOXB36%NBEHKO3@Z-(![,V<!3B;O]"OOJVPB9JD=[KAU'6
M;*NP&FRK2,3&[NP9-<:$#XX39<7'1-?Q(3[&#F;-=@QKN)GXV*_LW&[QV-Y>
MC"S;-=W]$%G&!(Q="FILA:R'4-C>A<)V*GR3XWR]3[]^#62*I"5(%+V:_A$Z
MITC.?+O0&@Z-4;?<1#_$9U8YQQH5C&N?HV589KIF;\=C,_5EQM=DS/U->H5U
MASH3;;X*TA0XA6;/Z \Z!_^\B0N]XDE8ACE(U\!LT#W?^= ;\L6_6(GY1+<1
M3.A>G9',_%"J:3RBFJCC5^"T;!9?@]TRO<).@L%.0F?\<;((<-/%VD)0[Y01
M[T;0COZ(K; F<%K+3,=/]NNZ;^<0N@T>0K?5:^ 0=D@[I^XQULO23'N<B/X6
M>*:"QNZL8?@M<=$73KX;H-XUF_\IE<F)I6B3^2)P/GSNM\HSKA49[.>W>UC=
MW3BL02L- [C>8>U71'XG&NF'AT;Z="-]Y]!(?QB!\SZZW+<Z J>S)J:3U2"F
MT^]VM A<!N-.+5C).,L>)@+7H72G72M_)^&"G3!TG*2Q(*,!@M)O(Y]7IN\R
MLA<YQWX&AI(WL0,J.F\\C[/VNH7TI63@4G4\6P.F!>GWFTML;275,QSFI7HJ
M^8#4GG8$O._Z')A4XI4;$IHT[GWEOTQ%=63$NFIR8+78__9BL@6BX-JF4;?A
MEX4#RON_*<:0&RJTC&ZGMTJ@?Q?K+1&(MN$ZQ5<]QN_/?O$QFL#PEE7N^>U<
M<+?J\7;>]/%B'WSQ 0\MH],ISZWLZ.7LON73PP'I)8?7-3JC\FSJSEW.'&NB
MZJGW*EDGJX?[$O;46O&^W"?M!%^Y3R5"P4*AOWIL5CW&'9,5WWVL*V5>XIR3
M8L]D1R5O33GF MNL9QK]=GD:]TW)#20;#HE?L$&";-;ZW@N2HT8DR24CTR6G
MDLI)(;S]?W\X2;.4,:I@1E26&,>O)2Q$9PT)C#V3$!FU'-^*JK&J%M:\&3D@
M#O<6@:=.J$AC3L-2O8,@R%,W1"LL""#&B@.4;)Y8@>=H6L9@L'I7U=9%PGH=
M>%]]^-TJG+27A67KF"M (&2?+\Y=A#%M>^Z"9"5FNHI;4PMLT;9E#$?ED:0-
MM(2MF![>?HZG(+Z?S/CD->5<QJU4Z2R"6:/+)^N!C<[>^7;U_5SO$0J@:7[2
M$^B2%(V>VH_N[.5C6?I W9#&=Z33EG1E3Q(+N>$)/YDSF*H!_!>G_FHQ@D!#
MKLE%39+I.G (]@1!UVB I7[*&S&:/:%&NOUJT;>SSN$T"/6JG@P;@,GQ">#%
MH1NBU\5SM5,Q)WH?TK(;.+'N.B?6J979G4_;'V_'#\YD,7.NIF<^&C*A,WG;
M_9E[BV&VXPV:VP8KVUBN^]"AN<-I^_P.S4KA/*%NQ."H-YJ/Y]OD*+ %;I+9
M,PVS78Z<43GAOK.DK-OD5)V4YM!HF^4Y[QVO7?CB3)T@(+,+_D&(<WZXMUD/
ML9LKOIDSW$O^&8XL8]1)XX>O%MELCDA*]3&V[)RX/TX>W F<YT>=_1_<V'%T
MTN_C0\'3M3YQ\_2M1F:18<F?V_M ;.6S'92<;:WLZCX3KJE6=62KI/ _6P1!
MX>R!?KN\JF(WLM_UF]\2&:Y#M)HQ2Y)/3KT)<0^+,17$J+M=H]T]=*@W>H_K
M'0T:<_T*B!/O'%&N5FRJMTY@J]MHG/@2UN+=NW N[R@TW%_G/!J<>Q$?AH@)
M!_YLAG?_V0XF-%INKUIU-G!4@W6.JMXT"YG0EW'A"YR-Y7QUGZC4AQ\1$ZAO
M+SJ< 3.W_/&U3>:[8D-7=D"FDI:A^Y?#"$'2ZX_0F2YF^E=WZC#IQ;.0ZZUY
M=>3]U5^VEL_Y7V=GY^<7%RN'#,LH^HV2NE(A&*D!58@XFT_BU>)?R^&@BH=>
MA+/2+\7XH #7-Q0;<I>,A_!RAV %6<NVPTGA&P?KO[&S_$8V(FQSA/ZYC*8_
M57A77@"RRF%E6[BC^A;NLA &\I[_P)$><.=^\_W)LSN;%5BZ@Z$Q[&057*U*
M\;6\U IN<<5KBQ6['W&X";SZKV0YQD:$]RHKW:K6V*#*J<3/Q;6#-4"_!4.?
M*F=W-5UF[P)_VC(Z9E;)U\K'7[SQ8_6)S:BN)M05YOG2E*@:JR[BZ:J_*XIM
MUQ>=:P0'UA2=O;[1L[+B-\5D/@C*@Z!,^%VO(BBS&GGV3U"6!N V)CW-5<A3
M%F6MONS5'K(Z:W>)M5E@=BW3N/3IFS:9UXC7KRGW.UW#:F<U.M9GD$-8>+A.
M;*O!$2/J<'8;=CEVYW;$!DQ+X2LG4_M3S9[/ _\'<%WDS%XV/^)9L#!6,EQ-
MD5D1\P?V\^2.G?#6GTU4K5#8K-MNIZM5:%0ZNMPT"VSJXM?9SPAJH4</();O
M'_"'OHX3X969\M&SKX]9BE2?P6)H4O=]X##$JU;Q31=\R6_0MHOF7Y'O1^OP
M_;#ALGF<E!.]4'7V^7\6[AR7]WXR(V9[G;-I$,<L<3"..!C]P9FQT:XX:N+N
M11^##+KW@Q?-#AQ]'C@A!A7EG%=94*^3ROE8A>)-$-E<JV]D/0PS0<AK>!WV
MF4DF?^M)C#VJ<-_QH=R'041[LMMW5.8NQ1@IB.DB --O$:2@R7>L1'L-A^Y"
M;!%D^ 5\'OX5_A;X8='02-,TNL-R.)-W6?J^!EW-4<\8]#9(U\:+'U>I-K[U
MI]&SG;Y*;ZMN=HV;R#OUP;6;H->\ /DL:%;&.+4:]@_US6_HG'85\9'A@,TS
MO:X][8S)]7Q*U6;'Z S710]\'7*M549<CUSF:&#T>]L#6]P6))H]'B\>%S15
M&6@Z#X!J]@$1J1!D\30FV1>%8@GFR<%)&[6-=L_:G,PMG2ZVY\=4?Z+=6L?4
M,8U^!=3CYK"K=F#(779HTM ]IQ0V<2];4YI0P87P>Y8%"M@J;]D^= TUH>X+
MC\;L]XUVY] UE#VEI&YVH+'-JN)=9G!Q!$QQTG:-@AWUC?ELU!L:W4Y:VY-$
M;2R?7&UI5L^P1ND&>7R1ACDE*M;6'= 1DXP*&MH!1F(-/7#"N0-??G)F+ZTJ
MF:>MI8-W;WS;Z#"^+3V^K7L8W[8'/'Z8$+<?$^)*6&05$%'PGQ#B-[RV7]!4
M >,)?A/ 7P6Z=,E4LAP\45GS6N_QS:.+]O43G2]%%VA!"N"DLKPM%]!L A!T
MW4,5V*#K,T=C5!-G)Z#!"A H=3O25.MF_[J/USV'SH;.T]I03W+ZK>^B%?E0
MQ7.HXCE4\>Q[%<_)*!U+'2%YA4J:VR\(?;'C929U<R-\E]=LDP69QT$?2'XH
MV%F?DL2X9GD^:4>@*G/OAYQFM3S(V=!#G#^BXX2-/<O/9TSCH5DJN)5"P*IJ
M<U/>2%J^)I5Z V/879=(KUVD4JHNW#!<T&"*K2"W5@6N'*X%2OHZG+E&/%V,
MU+N:WD;@@%SR,RD!H.VUC6Y&5]8K5XM48[\;_\6>12_ZA>/L&UPPB1.^?G%P
M^8<TL(SV<-WY9Z]_(4=O$24XWU9X&S#!#94B,%#,5!"E%/%VV#',318F'8IV
M&SDF+$SHM!LZIU< )\Z]Y0=TX@RNR6684V_RS??&I;#671#5W4/%4:-7>]U#
MZJ$#V%_]BK_YVJ/-)CZZ&TI\=)H%K$##SFI_HHEJ]&_SD^P&1^3<>0 \&+BS
M%VWL/\(/(<MRW?F(K#L% [[5, ;#WUQYWN[G!J 8UCV?WH;.N=MHXAFH" L;
M/S@@MZX#/W*83()_W@?V8X*TNYV=W BM&\2B)A"8TYOS6_UT'!E4_\WFP?OZ
MS'Y&1(7?[6#\P(K;-"=$2>F&#_ 93!P7G)%^Q*_J]?4UOZC'+4[4XL2H.J.(
M/S]^/'_Z%R<<!^Z<:OIH#_ 6W5Y$#W[@_@4T\<%2TW_JM]LZT'=&!^&ATKIW
MGRA;.O-MCRI40M!8,^UN$;J>$X8@'O2O\"?$P,$# Q*^Z'<._Z;CX3=PW[!<
M[$&>!_[8<2:ACC 4"Q0U\/<QO7OBCQ>/#)6")SD,'>%K[K$^RN6#Y+%:$$O(
ML9AB$5&P3Z/0%EN_K5O=DV?'^5-_=&SD#&I\G@/1_(F2L\>]Z%/P0N$'MOQ0
M?["?'/@^Z.A% $]%$6CQ&D9\F>W)->@!2$_\N_ES2Z>9 BQ*H/&M/]H31W]V
M@;(+?+>'D826?NGIIR!=9[SH,5*@A )G[""$=F)=^(*?P*?J=#J@WL$V8>R#
MAP;+P=)4^!H:+1/$/K?ANWR,M"9#WRU=G#,]^)DPTOFQP/G^8^$Y^HB78]Z]
MT//_:-VV]%L\8?U7?L+ZZ>31]=PP8N52RNNG,^ P]GXVK]/U0(4X'%1$L\=C
MMD'<32BKF7!C/HO6^UZ(A.%DQ8=Z/KS+GNF3!<V;6J&.M)6V%':UDG25$JK_
MZS["Q[XX3\[,IZKS4P&C5+E<BN1"A><T7Q<UD%.7V7)T93VZ7- >UD2M<DJB
M_FFUDVWN; AFZPK% 9B %H>'30HH2LH+)6=C@?QX!M(!!.9$.4"\B1.4$^[=
M@DD*L2']*(H-T<PS%_J.Y*;&2&. :!BWI%9DOQ0?-/3Y(L X>H0:Y/G!!8VK
M+AE4'JD2SFCQBN]G_AT(&'+A2)_))3OT@%OX8?[+;X$[T4!S3A;CB"D !X4=
M_,(!XUG,H7B\F[V@2F.?4C=Y+C]]1I\^%9\6SY0*'L3KQ$5R@<Q],;+VP,G!
MU:C8!VV 5B8 UI)[&3M!9(,DGH#(?(A7'XHC ]IPF2]>)PA]>W[^V_(Z2>-J
MD7_OD*#'4UJBEIZ@5NG^V4Z%P9,B"BJNN1V@F<<U,W(*MQ9F,_L.BW<=C=;!
M^P=H_RH[8DL!&8J*_LQD/@EE9^O_]H''$X\!'?;H1I&#*;3'N<^]([P$_UD
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MHI6&5TK,(NL5S:(.&D69AI&AS^$:,_G/HCY4<O_">L7<1Y()O_K> NNB'3O
M^'-6*IYI-<6HU"C*A#&CU)/$<^PI_"%)RH)GHX9<JL/DX3Z2A9D1/XU%_#XU
M8??MI\BI4]5D=@\BYU5$3L8%,730\LE0;]I'JR:0ZB)V;44@N<NA?837<Y3
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M7]!NNO+0IKH4+7F_+B+@TZ_NHPO^UG?_>V!/'/[)@K!(OV-T>\-WEJ"\L-U
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MD:M.F$*\2R5@<S4AD\Q:$GJA$97USW^=7I<5FFNKZ 2&LRKDPJ,3=S9F'H1
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M=###O9BD@_7G )(LO>1;*L+K:'?;AI51S)PQ^:%\XD,S-4))^590)=0WN\;
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M"\.WUM T1KW^>^@ Z:X9\-S,F2Q%/1/X-97 :KJ[>EAKW*-,&W+4JXSUM&Y
M.O]\I-Y2-!;J*NO#YU&KG2YNW86#V.BM624>B1Z&^^-_VO^#DZ\:O$-23Y:
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M%=;B%R?/D7<W]J+HV:<KE6E0*3]S AGZLQL] "7H-/0)4B8)NU",1I"\=RO
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M?P&C^=[QL 05=A4X3PY<M5"?!OZC'MK8,X.+ ],)_J6^;_P 'KCCW3-I<N?
MWG#YP)]3E\R@EGXZ'H-*AM_.7@P-=^ME&^BPEB<''N$@R6; V/YT"K_7[UYT
M6W]*>_Q;N G"+TN[8<L\=_9@ Q$NO5,ZR3)_>GL79/,[R+\WRPU56H:<2]XL
MY,0_6K>M7); :D\I^9'# H=*@W,X A;NSA+(I,"D<!\??2^,&(3E@^,&\!2Z
MT12&?('?@<=Z_Z"'(*_ADL$*!/NRO_L!;(!J*\&"7 2,\]@U;KW)AK'!*GJS
MORMZ4[8'"I@N0NTJZ.K0GQWDI!5$R'8:+;X T8$"XX**C[[1Z>5=PE(QLIVN
MA?)=F /#'%13P4F5-9%(; &OQ].R2CDS&CR7@8A75"'-%VB6E.'VVOU=./5:
M:[<&5N6SSKS"&EUA$+P+4A-@<"%:L*__PP99%[SH)IZN.61F% (<9_$$:90[
MYQX;@GW=^3%';0(_6.U.'VTR-(86H$6P:[BE7^2NPU%68D_!^=*_.&/.9FPA
M _8N?"![#9A"*PDT9MQ1<UJ9*-.:9^1,4WOMIJ6M2[)FMK&&*&,''"0QS):8
M=DNG2YM-WNT+MH2BQH!!YK:UYDZOSC+-09[577XET^=7[5(6R1K3T):$C<'D
MEGQZ,4<4/-I*B;'7-5*;LE*'JUBI@^:LU#^(S(GP0*FXQJ/F:(7PCA<X2? ^
M[OX-7(;':>,/. (G<JE%&8@TTV?N([@D]);)0F+Q^\\>SE9SY^B)@_^F?"QD
M0/T(H0\N]*W#;F!G:(E5$CJD9\^T&^;N@UB:D&]CCH9] V\&W#F$X&>L&<*3
M9W; V5,. 0A;^F\4. "7W4 6Q,0)O0J6R.,6N@-; 4\J</S@WO8XM4*F[>(5
M:R#D9A@N?7YP@):>@Z[7HP^<C;:]U?[4.^'##72:__+@ST ]A_1'\Q/J8W#L
M0N'D2=(8<@;!_7W@W,/J#:0(/3@"JNF]MAB:@('KN>]Z$6C4)Y &MM[IGX#W
M&#W V8=TFO!)UY_@RNCZX=PP%A*"8V2& /[TZ(<1CE_ M2Z?$<5^P@<_@ \S
M>9(^8F0*D "+6:3QQ=,=EUR6YC >HA%<Q6+_7 ;0U]ZH&!BM(@:&S8F!2X]F
M7 03BD0\N\ RI[=G^J +&N1OKD!UIZDU.M#H\Q'G:?B0!A_B3'QLZ*AL*+R&
M,;# F5%$#NZ2C *2<3OW0Y=?(EO:$VXH B3L&R$&2G (R+W'K^0#,!5>&^(5
M6W^$^P*$HFXX.XH"]VX1.9J8PC&5R0$YL"/Q-'R&^@24*^K2X*<_\2('R+P@
M?]BJ[AS^>Y05#-S+B1:!!]8VO=</'8&P'6KL\_RE3$LFWJ$_ OWQ(W2;9^Z?
M:!W1I48-R+X=QW4H'NO\L!]A8_1M$ /P-+Q"]@+>'%!56M)&NW- )#TYH<:C
MJ *;?PH7"\6!W"SK+IPLQNQ'KJ$+WL[$JJV$1V'1I/>Q-Q/))D[?%EV^<#):
M F9Y[H  )\"C.'J*U HF;+!+@6'3^AOB?*B7X20$$K,;$=]H_- V9RQM473@
MT.SJLF.T5=D1/<!EOE^X]*OE_! PV\2?$V<  \[<\0M(!U"%+&= ^D65 XD;
M))0A2TL8,6JW(FKP[_3 N?TB;G9BN@\RMP:/'<_L,&3HW[BH&+N+?8,_V6$M
M3XS=O5BHQ<PK+HOR/%AFK.#X$T*Q^'B D)88(+0'\=@5YGJUFQWLI>: %(GF
MW\%GN07)R*VQ>4OXQW\O C><N$S&?63!>QZL,?3?P1QR0C^RZ:3/X)T@KSS7
M9@)5D9U,X&,FB=)3(C4E>$CFRIE'8_8YFAL9R!KY.TD1KD2,\,WQ.C*$>Q5!
ML\-#_+Z 7O2P.]!CVAH6CWT0&=Q3C-16]IPM#/.S]!.=+T-7UZ'C0O9PLE_E
MHQ'3_58XRZT) EOOMLVC/X\Q'4<G,U96I\UA>?H1WC=NO<*'_U\Z+V&_T@@W
M,%UUYW$^\U\<-&3(DP+/RC);^KG\]1@>13D_,(Q0Z=0>"%@XGER\3FVGO9;.
M7B$0;T:XZ&?N.X-[J;:YRQ0BZ,L 9*6&*AS-;!QABWJ0J51)+-79%X)K9C\S
M!W#)_D1/$+8Z?FB&0"P4"M]:DR@3\9PF3U.]*147G)X 0,L%(T7D"Q,<'K:T
M[^F4(CL U"2)SU+HC3.80@!45A/0ZZ#EX%-V\)(^4/B8#__X<^F#//%,T0U,
M-"3?QDR\)",M&7/P41V^+ZHZ)AA#"7W)GFEO8!># KM1F&H>"E,S"E/[A\+4
M0V'JH3 UY="M8/LUMF!AZRPI*>%U<TT52&6VI%X>[0FE%="D":<O,G8/NO.$
MM)0K?2Z,A2NA1NZ"B7R"GL@GH#9LQ!@0K^-O6\=^>8+]B "=2I26]B6AGI,D
M=/(, 'P<MWK!Q?U!TXQ%WB!.&O@\E($S=O&$/!>^$>)K,-WKR0?'L.<$4SO5
M'ZB6X$N!X;#$ >IZICA1H7!!4S>@X.**Z_D>U['"[S)8BW.),(.RK)G)(A#I
ME!5&B6O-5$ GC,VRJLA&"IM76H'9-8;MK'E76645.$I\*;&]YW&1V\5=2-9(
M=/Z$NF+E@$CN [80">GH)WK\?ITM8 \C(.6'($(?58ZKH9TO]9&V$=R!$G23
MQ9CEL4@688ZN.?)G+:*11$@YH3N5CZ0QVR6+&E>>?C6.?)3Z72;TDUD0D0'!
MWU6V<9GR6#YJ-:"EQK(,'8R&<(%]#J#H63^&JL)XJFZB%4I_TZQ=Z(1%#N%I
MX)RR^/5?SN3"#R[(U[\,<6$Y_>!4'1%^^-RUVD:GEU'UQ#Y 29H( R"/CSYF
M N&P>;YH@4B.SH_Q;!&2>J"PWGU@\ZDL-JM"@L_"F;E/[H2RD\\//JNIQMC#
M/'">7'\1SE[44&"@3\!:@',-*'.C4),5G&!$0QX.%KL%Z +P^%G\+AF8@8^!
M@4(1-O86^B+/H,4GA;_@H9)'Q_9XA\W-8N9HO7ZG=S0^/NH>B[J8;W8XL?^C
M?W59P0=^BL?DB%N><9U8C?<4F[[+\:)??: //N^+V"TMP5]$C,JL<H4_!C;H
M>MIR C!< +<%\.X&0S0[)(6ZE:50@V.(0 U<+^YF8&Q<3<&8A]-O5@N\&K5[
ME:G=;8[:BH0W.T+$%QE]IME+R,<_T(5XQKR>=W]Z'S@D-;XXZ*I2/O'#YX1\
MH5 $FRK@:W"1U:_K\OL);9#]$9GKH(MZ%MCN_<G?[=EL\:B?V7,7<:)^"_S%
M7/_Z]8S$VD(\!K::^7@GD#I'H^PXN4%<ZG%)SXKP0-:C7.D8 P0:;K<549XE
MB!*BW8ZP7@#(*LL'YXS;X<L_=5H6E<&Q![:TR[B2SU"<-5CJHWQ;-GF21>RD
M-+B>5O:+HMZ?LZ<[/\!W=T-JCT0]TVEC-1V6!_H::.#Q Q;UL;2"':\*J-SK
M6T8O08/$?H6';3_R=3,ICC#%V%SH,%=YYJ.N\Q5F[ EFE!6Y0'545UW+,MJ]
M0=[[E*S.TF[E>: 7COUJ$2NK8&GO> G?X.^/ZAI:NH1]%"O6QGY(I4AX.3Q>
MUBDUGMP7\\59/<=/(\L8=;HL%!1@-<ATQNJQN%($93VWW4D\14 TX,U<#_M'
MG4=90SD>LX/%E=S9,^+,\,&A&6PYM=2M-%#%SDO4BN*QP:YQ9%76!@Y&PMAQ
MF+VE7BWJSJ5"(<D;*[>T):(C)[WJQBEU65_SE4DKM)\*2W0RQLSJC^YLADN1
M/3R\< [X=J'*%(P[(ALK\RUB#I=%07/[A61'TA@KC&CL6>A_HYDMZY#9RLAL
M#0Z9K779F_YCD^BT_Z=MHNGXB_UY0VFO]%G+WW"@3D3;7?9G\B-OE]_/?]=&
M+?WL[Z???CN_U2^_Z:??ONA?+F]/?[LY/__]_-OW6_U?E]__KI^>G5W]\>W[
M*?[BZIOX\?+;;_2%B\MOI]_.+D^_XE?/OE[=_G%S7I)*JY3.JSZ[<LO2YALX
M]]2H,29\AZV]MR+7]3;#=2M'$!E'Z:-38*FK;]]OKK[>$G]<WUR=G7\I9XHM
M^O5;T4EWG\]CB :*A(A*5U;LY_.A561"3.#7R^G=-Z6B_^7 QW"<'9C1DY@2
M8Y42<TD)[<@.90$>? -#4. CVR=F[\@YI@^;O0G_*?;-SG_P)K#3<72LX,<D
MWL*,J/A=V"T1L9HE!Y%=F,? 6\<T;*@"5PNM*_ (%@&9^_0-^H_K,7,1SWBI
MXISO,O8QP,7P@XB_[QGSC#-J\ *OZ=&-<K;!6EI8/X.AT:K!,9D8ZFQGW!5[
M./R@1/HB."6>Y0Q%5TV\G-OS,^F589B-(]S =D+A^,$Z*0JG[M(-,5*W>%SP
MS@R/!MX\@M$[%M7S_@(3Q!YH9.8-N]YXMIA0S!'^<O;@.E/8HS->T'3[J^D4
M'/* E4S3W^+2!_XW%AI%HQ[L96I?PP &EF33'L'&1P.=FO%T;'"C=I+X/&)^
M>WUAO66D$"-U&,@?A$(TMQ'"U)U+ 57[<+#:SF&RCL<Y''!1**_J ;?&F%%X
MO=@=% T+&G]ON4@@'E@2">&*,J&E"F'U/9HB#ABW.H8,6,==B4;>XA*B WRR
M1>#4E@_:*J*A["JN<0VU2M=0KW4-=9KPP^)3KF0>HG#&VK0*7(@G0^?&Y58U
MIF+9&LFM.HEU/(D,H3_#P7E:08CG;4H6L&-^ETPD%<8I:]B](9;%<Y2]U-RV
MT:^PW"8^)O9)2BB\72/G*B%KF>H.YW =7!'9=4($A7-#*C^C]E%N%%'$<@)7
M!6N*7%%(QMF6U2[%W:B!(*9BJ60S;7P-&5^+B0TO0N#+AVKQ0T74EX*B<<MU
M1C=LR#;U@R]WO@CF/N]26T[G4:?4O6B4QS\[<][:B0$N!IH'(LJ=8[91NZQ,
M BZO0]XY2^V KI.ZZ2@5/NI'[C%:1*R+F 43Z00<3R#J,6.+?=[ WG.%KA,'
MOC@S2.H&++C(4 '=@%J5*:C,3"\@?VB/E<98-XP[93GM68CY$RP*5U5PC!HS
M.!//#!RESS74/0<-0RQ60Y9P E0;5<ZOUDEI\4DIIB)N"3O^W3D/5U)\<N)&
M1']<\)V#!T;%<+XW>\EZ.>]4XP )@E+*I<('4W;Y$]T?H%T)\90[,"=<1T:/
M(-99$<\AP,L6GBU+#6!MH+E"D0$*'9:]E^?(%Z?Q3 '1 "@TF[!69#M.WS,%
M$]<7IL_AS:J/JU5\@2J*WHA;><.8[ZI+S+'MB>H,RD %G %8SU808&$&I8G@
MQVE@+R8M_50^-7P)X<"H31T.%[-X#V#\/#NS66P!QO8MNFG8Y"6XDW@^9E&#
MRD3LN]"?+="82OF7CI9\;YQ$HS2;^Z0T#C\Z$4ON<2L;:U26ELV@ E0IA4CP
M\F6!PX4*QW@<,\Q(Q (Q-*$2!"Z!+'%%FTI $. W8)\! :AB#O=)Y%FI72S$
MSJZ+18#O,A JU:8[->6E+;@"+TK@M[B$;;FT#5@-D-])Q%;D4E1R"\HN$_;1
M#14!R+%DZ.21&^C,8^0R'T4]20N*$BBKP;2TPWC%]1"L9LPRHO2 &-XVAB5@
M?(:H:DOGY+V($U*W M8#FR<+5$!?#<6'*$G''3W.N2:X R=%8T R?X*"?_!]
MJKSAL+O$YE),XRDCC>ZP1FF9,+@0OBS:/_C^F-QB8AINXQ.I6Z 9D6^BW_O4
M[D;."5)F[D<.0?9H_-U8V.TJ?>EO4+[]ON1:ZYFN-67ER*E:.>X14KQG12&7
MYZ6PR@10RIHT_S!O2<7F+3W>B^ \RFGC"EBV'AB0LOFN'1NRC#^DN<;-?SY:
M G]]SR"5+P+[T7GV@S_U(ZMM=H[9_9EH<<X2[GWDD$"X19O9IQSGE8J7)$CY
M'83HY-E^8=\*T>-,N)3 RZI+J5@/&*I8\A2S$%2K4QJ+X13_\1UZAPPW.<SB
M@B4G4'L73N W7T"1(8('W+%8MF>RE9;%5J1V*&@2=X2 ;XB(6?D](<3.R.'"
M\$3KG7@3+1'08>20<O/C18(%^<KG-?9Y8S5Y\_KLO90#Z[]R#NS7EG[U_>_G
M-_KEMXNKF]]/OU]>?7M?Z:]OOK<#T?8EMAB\,EN<M90<N7YS_MOIS9?+;[]I
MP"/GE[]]T__QQ\WE[9?+,V276_W[WT^_Z]<WY_\\__8=&.GV^IS_X;UQTFZE
MVS?[.C9%:\4"ILZA@"FC@&EX*&"JQ&P5A>6P06$IN"%35EZ?WH"\N[S<AIC+
M7TA%*HUVO\;+;*/:N0'M<75S:^CG_]_YV1_?+_]YKE]=7%R>G=^P,IVSJYOK
MJYO3[^?Z;U?_/+_!FJZW7<8%Y(F;D] )3[GF;[H@!V-0&5U:R3:*1+,&?5JT
M:6C@2TQ<AJ[,\9T"A^,78K?8[^2;T/,<&T&\\0\ZM0MB^.C^GL*$]*43ZL97
M^A-BM#V:H"0">F$BFXZ8?;Y&SY[#B[ %X,$'#\?@3CB+M!.@'T:]_"DBIXK>
M.SSO7RAS)8[<Y]&8Y/X_OOKI,PJ,G=F,#^2D1D?\.9S;8_'SRDMZ=B?1 WZT
M_;/4_F,@NST/0?>)?WTHF7H+-S\]SI8_VAK^G+(K[HJG"R?ZPD&]L^N7,5Q5
MK/[GXC':>33.?V*_O?*B%:29:YX8.@J/M[]T<ZVEG]['U*XP[A@./FO6\7^=
MG9V?7UQ4&G'\X?,7&VXUL&=HZYD;6Y40F9\_([ES>2E%G)%7^6+P:DP'<QA>
MM/DU"7+W!OI*=*Y(SM_MX$_86X!=N[:' K$YJOZZ"%TJ[?J"13'^G&*K,85%
M%_HM#<[[ZMIN(\N1!.VN1M!U&?<V@EW#)H/(\<(F>9<85;;RO\B407.4'#7"
MFC?8K#C1?Q^?S1;!?>,42Q>'-4:P?F>[K/</9SH-G!?]=SN"K89.DY=<B,Y8
M=C9(1[,1QKNV%S/]U\7X_V?O6[O31K)VO^M7:&6FSXK?(Q/NF*0G:Q%,TN[Q
M[;6=Z>GS998 8301$B.!'<^O/_M252K=,-A@8YL/TQ.#*-5EU[[O9_^8V$^P
M4_$^<4S/=D-\KU I6=G>W XVGY82>T.$P# [_C $!?654&%:D,A.]L/75S*)
M4(/F5WOB>G?F!65K!#[V:'GM1B^VB4)P6'/$:P^UM1M]9W:+J1J4":%?YAQ#
M,<0*<\J6C)^-S#RC\LFR']*NH5+C>0J?E'K8^XGE)XX$;_BB>$["Z6#D>U_D
MO%\O.<)6_>IJ=A"#K?0_8Q#78&@E\G/([)$\HR4V6+BCC2+;E">'6PW\/@>2
MI]Z,!*:A7K&@&L!(CBFAIBSSR!^4+"H8<C#]%2/&M^/ \^[VL>'3D'IXN4/7
M#N\LKM27^!+4T8!;%:N>D?!9V^*^5\DWF##ZM3,T.#O45]ZFN,S=_(J#*^2(
M:KG<QJ"V]@&"29R$);8UD_LZH(5GKS=G#\NMQ:2..;((WS%^<^QP)E?O?_CQ
MP39/YY@"B+XGFO%[!E#Z:)Y^_Z.WAWXGAAF!G1D[H ?# /#/B)IM382I-'1N
M7$JZT]<$2SE(+:7<IJ48J:44+0,F?N)Z/Z*)-F=;OD54>&%AF.U1/J7KIR;$
M"=ZV3_@(\:SJ."N<G644["NM)K&!UU[0AW%A)C\<RG' D0>8F6L/@%;@D$-.
MIZ;/V.#!!CZS$E#M4$&;B3T6[>VQ9Q!AB&+'((/@^V-BY73;OG1R#G4GYQ<W
MF(7N #/ADV?VY:K[YQY^C9U;"#4-MA/EACW%K/+XN8NK?W+5$1"$-QL/,'GR
M*@33^]IS+",YZ&_=JZ.]4DR#"']%8%\G7SI\-P[G_YD[D8^@*00[BA/C"_T%
MT['A8##7"2%>V5?M W-Q& :"?Q_"X7O:K]^4S)$;JS)D_S.'1["'&(EV;)G"
MKF=!$ZR+B\H!$TN0P)1") [/L8>B5YT3RRZ%G):XJPC4%LT0W3X!%82C#>V[
M_5FPCRWQXA%3>&_F-27PCMT)9=71R*X?N=?C691A<G'JKVKU8YG<TOWZ3E9^
M3>%>Q7VU.+\7BSUL@I26RU9);JK].Q4,(!^GA+^ " AF88[F/B7&HU>>\/.Q
M&@Z7A[2./#*1/,<O=2,A$?0&;?#0F*KW5!]Z5,-#U)YFZ-V@>VV(Y;@#*UDC
MB GT>!8S-W+4TJ8!9T;B5NT/G2D(AQ]^<.LYPVN54UQP7D@$MF1'?3MRWYQ^
M!DI'GK>0E0\L\ 5JVA\%G-F;HEK:?SO2V/U"9R#W(\KU!^8J*%^=?DC-K%$A
M*!GG"D0QYO/TTG_@B9[K\B5W&O1V)7%2;R3&&6M$K)$D)J!I22A<LD(MLF7A
M]$1_RT)=**U!\<)U3:@I).V)3=.HX165WQND/2'#2YQ>O#.G08BM%PEH"CNM
MT PY!38DF=O%0O&!C@HJ7J<OO8KO5._/O [U&*XBUHIA^O($AMH)Q#H)OOL"
M%<"9^9OMC62V*%_QQ(I9@4M,Q\J? U5)Z',(@8$0R\BN^_SD*KGH[";.YD,W
M69,&/*XSOX[ZZ+?LPH$ZG-=)';9LK#6+LN,8_9#ZWE0: L6;,,*OQY+-XK@T
M/2LQ2TXB%V5KA*.F)2YKTDA(!H7Y.G/L25H&$<.-\>WCKG;#U.60S<:<6)KD
MB"F?&'M6(OHX!T29Q=L]PDP6)06HMCEA74>LP_]P[DQGZGK.-()W35T?3TY(
MR3?$B/.GL&(B6'V7"):3"-;>)8*]F&L@]9%T3(UUD:0?I# >EJM)=*8AB'-2
M(UBVQ!GS\.&!Z@D5/\<R1L[A5C1C]+$)M>W/##)&]5EV^3M@YY9Y7#HN=4&8
MPU08=P;F<RML85$M*YHS4C?LK-,")6ZF2Q5.-#FK6!GAWAEDM63U$D3FML/!
M6#3E3?+\V(9 \78ZO['=T%;. 9CM#=<VDX#UY@A#B-7 -[9 3^1=%J-B.3!(
M-'004$7OC8V V2C"$-"0!&_0!]DRYPH9'@XT>9O2A,XE_J&8!1"#11ZP[)JY
M.>:]*S;2*\89? G EO?-RX&+!6I - E,]/>G?U[V@-E=_G//HI:S)/@Q1P8$
M&%5R(('IB.JJW9U89?I]5+NIW!B6Z6#)91A,QW>1]&Q0[^+0G8ZI^1WLVF".
MS>59C82=^<V17@(,U<!1!#&(ZM!!J%E"0!T[$Q*^3MHAP "LTAM@D"-([TYJ
M@ZX5Z<BL\:!*C[.'>+*D&. ^Y8Q+GC&J/(7K'^6[91*.&"/MB$F-UT/I "0(
MNL.QW<<3"D+5M?1-<<1,T%RQQ+3?-HO44N#\M7VA3R.NKKIZ_PX8?B*!%9UR
MV);)!OE]#NJFQBG%U H-I'U1+.28_\>>3#^EZ8GT3^+I<4V1YK@$AN02+[F$
ME\2NOP2/8H=JTM W8-OG6-H\#Q6CK;3;+>&SK.9-/O:A9J="E;,AMWFGB?UA
MWS@#:NRL<9'LM!+SH$1(Y@(^L!]L($5EP^$\QM%@C@[W.< 6 &@\QRXF=5JX
MDA570/WL(X>0EU.N:&;F+A)H7)G_#SB]  B66@LDEGB$_BG?M<U+48J=<IX>
M71Y]VV,;Y@RLT&#BS#+^6B.?,9"+&'U/?NRAG=C7/MC4 V;< YSE\7&WE%B]
M9))?!)-,N (Z28*+69R&95' U?Y Y%U8KD_IK]@-L6?/S:YGNZ\81HPY3RIK
M(I_O<'*#]&FJ3.(</6Q^C?@ Z&*Q,E&G9(J$(H1,D.F>\)'!:A[2A9QW<KX"
MSB96%Q)>$KI]QW!W01^SS?/C;DS1QT?_.-W+:)0R/"0;?"2U,H&=HIP/)"-1
M 9KCIQ0_RKZ1EJC>T-)=/D*)S3!L_?>6OG@CS1)R T.@OB(VP#SBNSJUD8MB
M_G2L*>QS';A4^52HB'%W2('9IUIWTEWZV&UU%#+' S;TD[D&W["$4EL3YW="
M.BK,!9></+_;Q9,G[N2,G41<2\J!66PBR*F/@@&V=#$$VCQ.$$:YL4,\03A.
MT#. \9J1.">\-Z-<GUAR'7@JL8=2G_^]1V"P^(MOP+D]&V-1>UX/G^P:DP%#
MN3YBJ2"K!+S^2-<QJ7H8Q8)0OWF%AKX@#C<FUOSI'BHZ=&[LG_'TA"8LQ&9:
M @[#^36(P3FYUJ(9(U/0+#1:+S?3^UP^H%DD+C %;^-((=8B1,('F!\RU..P
MB*4T)$@ZXO@$BRDVUA Z?22W5A""8F,<_$S,]Q-KU%'B. MBC['2D[N=SDV-
MA)QE9*_A_4?O^,- F1(S%;2D.*].G,J]/Q1.<*49EBNDZ,5_UTM&FJTBBD,,
M6U@492'+#PO&ZV5V@^HJ1D5\1A'> <BI(7"SD9/2*QCK*66Z&86F6_9\4W/3
MR9&2#8 +H*L4-2&I'\6G$N-UL2L((6N"B<"18D(T%A B;(^VC>4D=Z/^UP.I
M$TE]*!F_Q@W\S?%<X$_WM?4RXDCSY>$5;$6G+_!W+A$"AZ-P? DZ:(<3P\]1
MITU-*03"OQPCG!4<X9'O!S=V8IS"7QDGAR<=*^]&G+A :_8L= 6_0!LW(T13
MFP _ZP24OBA??'AGG_Q3_E$DP[JV&Z$GGF(, O,+]H_ZT?P#&!21G!Q$$8)T
M^<C8EP7FZ-#M8DH[/WGB#K#ME:\F([-"S$59(:ED@ =GA6#HZ.<WQX_Y&H6W
M<$XB0\&!LQ[(VZ/3&^&RD8I2;/87:<WXDJ_"CI,I"9W2$C\DUO('MI8-,6("
M7.^:N@ZI% 7C#[Q4GHM.M32/4A,4@>+X7B;#$+E;A==#58VE^Z"9! V#957H
MZR%\/>K$D77EI,/0C/GUEIP1:XE2-'91BFR4HE+>12E>S#60EG%>^45>I +5
M=-(.'V4>WY-XF3(8<RWBWYR4(;S W[9 UTC[>826<:_"I72".%B [=3C* %H
M*91XE/"N:PIM(L",XI3DC,QE)6\DHIHI"7Z/.L'(CJ""S@@IFP''2$61R2 \
M9%GLIGI%"62;[+HF+;V8"));S"NG0?%U&-I&K=A!,%24*FHRO RV@>FE0F=*
M9)[GSE8FC7!J*]F./@A2.T\-4(=V_N6XDW=H1M\-IF,;M+0!_9  G](Q'LV:
M0+T4OAV@F0DFLPSF,/6..$.T<L#>5EA4(FTG?3&R!A*JU [2NGVONS?'S&>A
M'\^7S1!@?V/3'B 69&P<2Q>.!(0=F1/W&O$N'5*=C/AXM>D/0;EG)PS=Y-X9
M_N[*<6Y=!(MD$T;X*@N=PZPNB_PS3GR0MA2<1'3GP[]H8V--Q!!9(=0C3$!>
MVKX/HL4/W&$DP1U=!#.EUU!J(2788HQR(A.:DZ>L+-VT>ZV=\3[1X6;<2EDV
M,N(D'J9H'D<?E])4%,>KEJW4WAWY$I!2[2)"X:/.>0.&C#\#:\J0:8X">;([
MMJ<(BU:I:.$DS'BYY,3'+[;_(YQ/9P/T90^=4NKNYG*,!5SRFS.9CH%8#?VJ
M*4,"([]D10P$Z'W_CAGWE\ \3^Q^-EG\XLO97M)JQ U*FPD#SZ5\2;84'G9W
M9R[%'$@99M-UXLSL/B)GXW4F[4HZP)#%\%W&4+2RZA+[8^B.N64LHG7ER<=S
M1+<%RKQ&^GREY:-E4G?B]*ZBD&8PAZTYM'_(:"FV6C"[F(-*OB+1)%<,9/NS
MDAF;,H8R9>)9B(RPF*)$IJ^2$"+IF.VK6\HH)W=0PM89B.:J(D@LV1!I%X1[
M04C$\/\J%1:YJ>AQ*NE"3VY#AIV#/BA:-G!DBA'.)Z[GVB%NCT(Y]?#&1O*>
MJE#5VS&.I%:8+H5\I$:HN5^K95+AD/K0850XR 6(K7YPJSD&TC%1&'G>MSFF
M:!Y%H>UX5EH#K0HGE5C()""XZ('FHE*QE)P0![&Y"4@4SOC#CW)#*@:%5!*W
M?;'RF'91LFZ1XI+,EPJS0Q*I\C*_P=!M_?1TLT&+1O*UE0,M) -[@MF. 25U
M:GN8T@H3<\J=!ED 6B;F)<+@FI>E::FC>%TY$X=HB-(I[>D2R2$NGA)]FN_@
M:8P^2_Y+?6A@EQVU<N,<PZN90!,-2QD=FN.8 7^*W"^P"W?!( @%_[_J771.
M>H>Q6Q>$<_@5>(PR-^B;#K O&M>(_3C<HH6\?*(? 8M6NAET+5A8Y/AM:=D9
M![*2/LIU+(H3L8U%,BM9N>[XT0YZF9%;XZ9XP!_B/"=DG2,0H $W)B:AJCSQ
MW #"]NXBF2XLR$,))\R85;5 L#<(=#0TO\&]P(8@QN5@'"#^JA;:EGFVJCQ(
M9@)E2H.RXNTT #48Q-O$T>56[(+CV<4>N'D?\<T)V7M)YYM^S5+IX.KW2SCH
MI)3,]\\9^F5Y@W*'V3]A#2CS\"B&R)*"Z+4F*QS&T,AI_&X-UKP0+MG21"AQ
M$!M8WHR4?<S4P:3WB4,5'<*T):RQV#:'[::1X<X 2P!1V6K\0J(&.^;)7Y:,
M[ZIWE^I,HTMO2\->PPI"O!\#D:_/K\"2!N(B/-5X3OQW[!G09AMIB*ELNN$+
M1=.F$T?5J5QBVW;,H'E;7NWD!3J.U6^9IN&\]KN#;5E$$62DQ2')N<2@_'H2
MD$78>NCE$MUQ9J"5,?H!=]/$EI-(>$"T ^P$H55/<PQ8TJ8LCA*T3W69,_FM
M":JD/[2%.R,PL&$&5LLX"J \BGOGI0M;%#.T1$\A&)#24.V$ #.UJL=H#/8[
M_9CZ$NC7DH$(E28AVR6DX_L:!RXJH ]9ZY-*-#5D0N7E4O1F8@X6Z6H+M=2+
M%C7(B<O9:0_)88I"DKK>Q;6G4@*39P)[(DE<13TT"+\G%V6\]K?'""X"STF>
M*7:8=*,?U,& =)"WPQ&&@1-1[QMN8V7@U>%.CK@A6DV:$CT64!J8BC;Q IGD
MB^B?6$],O\H6%0M)BEYHD4RO72BTE[%^TN%[F*Q;3@WH1MHK'>0[+C;&30VL
M,$6?"M)S->K>$,SGO>#"&@XHW(5[(*-RZ<;(0E&J*#%"*>5\6VVD,8LE,'6[
MV6I_2O\N][7HM855D]V/'4EO6''#U!K6<I3U,?5L7T! $:Y3$M3IN4"-=P?^
ML .GOF;<^YI,660&HJ_W%&WPN0]"U*&\,JES)'*4=Y3PBB@AS\,06<FK;[J3
MJ4?RBC/ETCYOK."+=E3QXJDB5@AR&BU%A:V+*'5W=_HO_?1CGN# =0_N''9&
M.GX4YS"2,JKA$:#E@_U;$^P"W2!;1@R/;2I1F+:V6A9?<Y?%EY/%5]EE\2U-
M<,\$+"!<>ER5*+-Y$];^:[?MO\A>N^A1 J,=PV'H^07;V?#0;J9<.X[/6HEP
MC$O.,P*CD; S])2)/\ND"L2=MC6OM,B9)D->#AM[',<<4#;BGA_JI]%',N>2
M^6\2OE!Q]OA-G#OA8XF&K=(;8GP;+BZEY"+UFS?HZCI-[D]7[<^W>']4..FU
M7PRDR2*",?((QF1% ]XB&LR*6&?D.#_08SO#O+RA.Z0O! @A^ZA%I%T&<:@[
MCN;=DF"$E$B#?77FZ.W&:"CAKVK!VSB"JA=415IX.W;[Q@HO78Z!/<0@L8;]
M#5.0!(&>YPDZC1V\\K1<2E]3F9F63//"U0LMBU (XQ@2&^+H!N14,VS5/IF@
M4Y_NJNZJIU3 T=P;N9['3G#J3AIAZU^7??167FQ/.R_C_@LN"JT8J"6*<Y=B
MQ_T"<%WJ% Q#N@19(N)^\?GRZ:TT';6(P9A[N:+S\L9V/=+WA0/_UNG#6</I
MPFV]O;TM^97);%"",? V6B+K$;X[\F\(HC0R1;?E^ ;CDV^*M^%))(@GCK,:
MQ02TA(10(*$[)_)KM1H)OTGV"Q=$@?R<8N0%'-V(.?HD[G2V\S*^0MK0>$&4
ML"64<-/E \D]PYY. ]?G.@.,B2N5=D<8+YXPXKQZ"TA XQOO,6;JH2-I%)(?
M@(.;8,-@:?F=2&RDLO>]+ $Q^ \B!)%5$[J4\2#*5Z2RHB?[$-<9N],=2;UX
MD@(U#K;,Q;H)!!<(!LX0(4C(08F:O^,H^10DL24LPV6D"L%?+,U\2(%.Q('[
MG<_[55"-5N"3X298V>YX: 6:Y"/)JKBOR,]]OVD@_$VZKH:>_]4L 4SETA*G
M]#Q_@<2@E_Q8G"]*>*#!A/Q<?6PMI)+:R+A&^X1M44YLT^M$YRIS-)Q+E''.
M!65C7? !X9!CAQYCG<<H:2+/W)7-3K H5?PNN7ACYRA+.<JZNI?Q37G$\OVK
M*O_J*7P7Y@*#/C$_8V>IOP59-W)_"M1\.Q24D&VS)CBDM-OHX3N#HKJ,1D7Y
MB>IW5*DC*L:TK$:5A[M3K%\\V<3$P!KP#PY9Z4YIX11&7J-%N1(LAHJ9'-\9
MN1I0:]:KZ.^KW(/89ZZYZ&4Z*D;,9G<"TXVH<T=I+Y[2-#\ U?IPIP]2HI)%
MOEH(( $":.APP\RI!&_2&!:7N48B]IK(5D]9 ]I\I@$"+6(02/-DCA*-*F.>
M9^Q,PU= C7%"?$&%'+(E)(J;)*M#H)Z1$X8"\S61/I5E6^9T'D9SVU=<$RT;
MI:4)CBI@?G:)586)5:U=8E5.8E5UEUBUK8E5!1X5:GJ1GYHC3;/EW2=)^,H\
M_T7^J\AR+)H&IC<0W!CW"/&<:_1WR)I&ESVNT;P?^U-%*6T83$/7GND9%USS
M1"Y_=^)R(:)%M0GQSVD> 4&9C4P$QT9+ Y%D\V*&)L&\"4LF!0P"T[H.D=%2
MLH5I(]Y(I#F(TMR=>77,Y W)@;?0%MX4D08B6GN'9ZCYU3+-0#.*62[Q6 +S
M)A+8U4!"= @(I\ >.)$*I\/V(7E@(?=@X$QGU"E\$/<,,@2:V)UE*N-4O3M
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MSC#DJK:8>BR"3G@M/+^R+3?K83%VFAZ&^FB^=_?8U,*HZ=Q'DP^.!5&#782
MFCGD/D' 7"U<9.D*BT&J4.(C$P>*H6X%."ZWQ_5@AOO<>B>WSRYUQ!7=M:(Y
MN5I4T[V8Y%3WK(AQB >$CPTSSV\/K:05=3F 1<.JXS4*^+1;QQNA-BPVCEOS
M6C&\L&4J#%31APLC>)&I=U? 1I^91EYQ^T *[?@XPGNM6R:N+YB+;IE"*H*P
M1;:"KR=ON=AW)$S\=(AV#7;302M%ME;WW!&< Z8'3OG?!FB_+O\$?FF3'3-$
MQ.$;#,N+[]!^@'W&8^/6Q?KB]F+>,".QK#J!Q2V&F(&@T,_??",&9U?$BN$!
MIN ALP$"ZHN#*)1GP#D2EFXLY*1$D.F0/!B)!QW/,<90OY]&+,7"<^.F[DB?
MD.@/I=J4VGKK(JV%*?8_S2%]@\9=M#%D<2&^OK X8%#=MV'""\:.A[W/M;Z.
M$_1]$]M@DT8?7F<?0PT&WX@<3 C!?96LXTWQW?,4'F.6!QN=.(R%63WAT$/4
M?K'M\%J?O<WLCLPH+[(=*=,.MIJW[K\0(KE(8%HRCJ6!T346R2,YJMY50<3C
MXCX)ZCRIA9D*#$?(LXE6Z9UJ7MFI:V:(C$,J@6)@@!P8,<L29C.$01US*.*W
M5V)XY+8X2->>@PG.H)C<@(VB@7OX8_@!_&(D- Y>!+_&I-:QXH\$81OQ8M*O
M^A: UG7!O\][X2@5KR17IU3@+'/,[9'C_4E%-\FJOPWQW;Z!FL_ 2:4N%>A;
M2@^EM#"IK,WBV;^A"[B.T"@8 ;O0:#8TVMB%1E_,-2 _.#&'&^$;3#-C@UFL
M!FFLL2)A89(BHO$1>-J1:1DZ8\:_63@,7(J#4:-&$&T>IK-B -*?V1SD!/4#
ME)"^H]1=,C.C.0DAMB+N<O):A.3BEO!S'_MG6'IS;HR>H@]5B""-93*O3S!,
M9I-2P":7;HBE.]AE0RGYTF6=E(.QRLYMK=.[J/D6\!OA7_CN*ZL#UMAC:4T.
M2>E=0+EA+#R\ BDHM$BU]%"9._+9O+'T&6..$3N_A3C#0*FK.I7&N4#V(NFH
M*229\Z8I%>_!&Q)5V3N:V%0CK7+ Z<:.D%"84R(0F3YY]I/H)T\U(U&^@J8?
M+(R4.EF#B,O*U\D>?-#<\EX+&2$305*33>>P2PE8$L2=@HQ%C(Z?T+D)?M#C
MTD3#' K*LX0-&'BV.Z&$[I%]$ZC&KOH@<8H$9UZ0+>]$5N)!7IA8E<IL S75
M!F9EQM8.Z]@B(BLXC<K;SV-IF$1/*2;DI1>J.;4I8B8%<T1'G2G5=,6$<3SA
M5312'L L#R<'(TZ?@U?HGQ&, ,?5C%*ID9.+T=6Y8^;EP6 P#Z/8@V@9X^ 6
M-X*ZE8%>S13-JR/^GMXEH!,R>HCD*E6.8)/8F(!V(#X^4!_S9+-[^,E\W]]3
MOM:A,79L#V@T=D4, E&=@*N+WQ.[L?(V-^T:)75:C<3T," R<V-V"DL"BQDX
M I#MM2M<!-+^6C O/&_;%QXN=L&$PODB?H7N%%CH8$^//)(IK_G2H@*?AI'(
MSV9_R# 8S$5+>^W^T3F!TJ<[Q6CY?(QP8K&+C!)OE,TT,E64V5$]NH:ZX]M8
M1*+"F3;4#E)?J7#[B9*1 L\-N_1D U-:I9*^^82JIJ_=P;8PK]0ES%Z[(.:Y
MR!Q$0%:>@2[GNQKC^R(T!B7AW[:4$ZW,7-^0#43O4T/QH%'!N@V(/T6"-6I#
MR5ZD%M*CSK]C/TFNO .5UM"H.>Z=D95VK _GJE[4QE$-SQ9Y=)^2I,_RUO4\
M8VK?Z3>+N*EM>O/)E#1D7"3R:[$9TAG 6Y%'KE9*" 4C]JXLELR?#*7WTL]S
MY!K<)^HP":<)5JPY(R+1%?F[O>R.9MDWQY7?_Y=?)!O0BUO,+EPC*9S@?[ )
M\S D'Y+65B4N):N6*TTS-U6?,W7*E5;!U\)/!.P>#(J(_N(9XQ2,J1R!-D46
MO6E/F-35#QW#H9JO# )H>K?Z3M@D5'0SFGN>H.SW<AICK -4T3[ALTLZ!>-T
M2<5UDYK@7LH'M5"Q$0$@>B3+NTP@K7F4M2/3LOU-\;;OBNP6^WF%3,CE';)@
M<>)0V&05>RVE]@OS_'V'@G%4PQD:-G(B& ?XV!C3@8#NZ;+,[!].TJB@L 0U
MO97>8S($74QKZF,F!@5QK\D0#D6?3?C \4.@29J/KA;(\/1/C,DYJ01+RWS_
M90_FX=FW0/JJ8VU JD^$M!;)SS@=.R(.B<]*VZ#OA,*.S^P0=2OEJVK/B(LZ
M+BM8*(,L T:;V)08YE'BV[_GHA5HD)IC=T^$0OP;=Y ^$/AW@NW'!P2"Z(XE
M'>C"*)<H10\]SI[XFWP5P%(<$7 U1XX7T"L/]TQTE,$E3]A[K &/7-@2%XV'
MH ^4:,M\%Y&;0\#:6N-&,[/IO3TN(HK<B )Q(]OUYC 3_5T8N.4@+#MZYC,9
M$L.T1DR')W'H.E'6Y:WQX47!9YEK+5Z/QPLJL(']J88N,[%8/\N3=OA64JZG
MQ%N%U]P47G.EOVGV,"GQXGV:0F@JA5![WN#YR$WFVR 99>I=%!Y)AKT'M"2A
MBPJR"16-B[$Y] #*- J<"#,L7:%8#VB&<'/??]U3="J)@JJ^[O)#V.*T%V\\
M_II4)68/FI.J[\QN490D^(%F=Q.QB_?+C96]?^-OL)9Z3M4(0#ADY,(&9Z\6
MG[]8%.9^X9Z0),/EYU& @9NND4#J'"BS!7= 8T%I.MB)IN5%DZ:I/DY %5WD
M8)1;L2Q9@KH(1;'Z,!@X0\0CT&HD*1+'-"XN0VSI$^_'\")*1[A^>!DY9</(
M=RX@7T710<J\Z4Z0-\%MA NKO,DB*TH.!:O5W!?E7U1*!KY TBL6%-'&@_1#
M%TAR#)9-P&;T,D@2YB072:>D)('XK4FSG!P#J9R$*"4(/I'TM6/FHN\&>7V9
MZ6.J2B22)O/8_\H;M& _/N7P9(,[A /AP:;&EAZ9*MR8D=Q9<+CDP4,F.':G
MVIG;9E?]JBM,33@DT&8=;T0:!?$=G (,.I\IXSU+_<8H3]1KWG%+]#P.2=-(
M>I!8$H#1(78SQQ>)*A:%U&@ZF*^7\^ L,&R0[C=N)(0*9TB-XA>0&4TI '?Q
M^N(EQRJ=+9>J3D=><]05T\=/FZV=_MTG ^/KW005)464^IBV0E_-(@&54FE+
M9B?!;G1^0O:+P7+#G)'Q..0(QJ+ O>ZR$Z3'"4%(C[&SF7V<H:/UI68'QC57
M[8?H 1*/DJ<9%=Q%[Z7#H@N?<IF3YTDXNW$!&<$6:*E!@H?6&Y*'9NTQ&(](
M?S!#?O;##VX]9WBM5I%<%Q@$2CEB!DD"G'TQ>E8HVP6I^$%*]TN&#C+Q"Z+R
MJ3, Z:2ZJ(I9 M=UV<A/IRY8XG+(^9%[9V!/B=UAY;A#R8BH,UAB0Y$B:%-1
MG3!8G1#[5JVH?9N1SU)ID/0&WO$WI"6L)5NBLLN6R,F6:.ZR)5[,-5#5$:*$
MY:T52)S%U8.5=-4=FL.JHD=4^*@2G61I4:(Z2 ^%R-^=T0/']( JI6"/ =F#
MEI;+EID01E[E0 2MP_7!,(N"TN"4\L19BWE3D<I:%,L\^1@9!J8]VR==2J9(
MIYQ99!@ID2E<3?HH2<P5R@)TA"-9V[Z$#HMZ+RI\<):6RF ,1>  SP,EFB$B
M(ZA2"VV!\(#FD5,R8_LO;\U)5S Y 1)>#FWZ(M3MYYE(G/1BB!@!%K-6&U17
MG0@MALZ-"_1)H6B%=B02^54M8P:1!JL O$0]@!A'969S^%?-S-"?99<\S&@^
MQ2F(VOV\0G.**<2$IR]/NNHU$XO'I9B#MH Q9\&J8@89)T@O2GO&(E,MV<Q=
MY!"!E',(."!T='-!98?'N>'"Z\'A85)I,,TC57LABUA518(L.: #T2HB8V,E
M)M4?:.>I='T8&$,!\B)$>KXPA3]N[(&M#,;(!<'M.:"+<4%4Z/;)-63$97GQ
MAZIP K],%4]H,3CQ"3ZDBALX5B=_@U]AW4*F(@%/,XZ?"#) @UN&[#7OI190
MQA)?&B .5*?"YNKA]'$7!YO0YZN'Y@T.6N/!S4,P=>&="8""(C"I1!+_/?@$
M2'VF*+,1]X&W@Y@;AK*-("T)JE;L<NG#I<#=E,%YM/V+\0?$M?:P3@R3621R
M!CUL8OX#?>^#0#*Q+FYVMQ^Y/\WWM>:>D4G32$WJ#:GHL6["Y;1O4#<Y0?@:
MQ@.HM LT$P':L+)F(GZWBF;2@5OE,27B=$@O$</DZ259;/-\Q20Q$Z]0,1&/
M/5(QD1@7SZR8Y.S^4HH)_VY%Q:36R"@FFEP?2C=8E-)34DJ&)I?Q/3EJA@;>
M$4]6N6?T2;("D54?S"=2'XR$^K!^H69FA5J]9E7J[:10,])O&+!0B^X3:JU2
MI5XHU&1J%J.)5&KRON+>MM(/8A1@,9Q.WP%619<)J[UC%H#%(E(M*%+ S)44
M,&/S"IC$10!>WJI^*M+"C*?0PF)^5J2%&4DM[&W)_O[G<X7!?2YAS[ZCR:$[
MFS&5A (=1ASH>,W0)HSR<FB#1- 0+5[O>K]2YJ& DA,L78+@Z=F+PII.4D8F
M15)<,!0ZBW,%(D<I2LN"ZH@.&0JR 4]&!I;>(  >T6FQP'SM='LD126#HL1:
MB#T$#<$9*C\)B?IQX T1<CB!^%B\>:PW+\CG= DC&&:4U"!MD/@@?Y2@(6%D
MV 3.Z<PX60BGL\_J65S_+%+0!U@EXRBTP8+N IJ$QC#CW,/\.9;X,CU+04[2
MMI$FA(8#*$:<L<?:$SSK3EWB^\(2#[C A?&1XGW#:G*"1 )1^\.Y,Z\#V^,7
M:B"C9 F,'6]J#D/<*&T B9. DM^>48*0!;H0_(X+6(821@!3^F"K8+-Y=\:@
M\H"ZA+H3(L>@'HHQZN$<WX]PXDK!2!<TY_5BX.Q;.ER#B:4/FH&C)K^8**@@
M$#4FPGY#Q<0,41W&B#>O2=87\6*X!N1ZC!#IF%)8<&Y&XMQ,F*"0R0*R0LQ:
MI%#*71-A3BP4T78$TR)FH>AC,'&<&8U I_6VF*/[N:MP<*_@-D6<+!>5#.2+
M]USNI&GLIFH,9&47QYN1)JFT#,QOFQ(LY&MGVFLU51HLR\H>L 2PTQQ9;4/!
M:94&BV @^"%?0QOH >M,WE?9".#?4>U G$(QTI*#V@P!2&@G\QFAG!'D@C.8
MAR[G7KROT5@&4>%DHM*M*!WFFA,]\3N,B/*7MVC-@0)O#@,*@H/>?4-D-DXL
M5&3=UU5NZW+#&_KP!4-3>2YM@++O"&!.=U+JZ^7PI@CZ:\.@ <)9,&3"82H3
M:S%#Y) 2>@6QX.").TP\N''#V5PE.216*](NZ#>W;$"*W!S")$J7"\6 0S(1
M(YLB.8^4Y.)?,P=E"<>% D-0P5RXYXC,S+@/8,EQOH4H<LMDJ DZ9#8O($15
M$A4;PRR"/FXEFWB*CE'9"/VFND7)5(@5.T;]G[^TFZWVPNYMZK7"\H^C3*J#
MDL*/$SDPDO=@CAI>1;JG&D7@#;"UPA7)X.#93\NW*UJJ-]>R![>CDTW2B<2W
M%+EVF'BG91=29J3PN!FB\)O0G8!,N,SAQ1#+@_G:?4D]J^4X57<Y3CDY3JU=
MCM/2!+?CANOBA@J*FYBA"$9;#%D0L-Z-Z.)V".:KA-E&42E"[ *7D%P!A-N2
M LH0.FE*C=P^SK@CG$>*4<^>1DXQW63DJI&0JV9&KNY(Y,63R #C5&3JIXF%
MO_%L/:"J*>!&/M>@%!EANG*PG"OXA>_>$C"$ZL]D.%<'!?T$C^[HZZ73%T9S
ML0!7GK=P6U&M;?+@T6TB$%^Y38<"T$6MG:H@N"2325&U 1:E<>P7H3]D&%H!
M\E!MA$"FH?BXBJSK^"E1@2 T*',+F6,J( ^+X@3)['M=O>-/G$\F!RAM'6%O
M$),[QSOD1D:FVICJF324'W$F6'?/"$Z1BE.HGL_H_13A 2Z<BYU,!.PS W5>
MT1Q](L!FR6O-)=@%D]!.,\H9@5 F$@[87&06L0@9.4E@=F3]O ;Y>541F\*R
ME6CYR28S\$Z9ETC(][)KC\ I0R0E@4:$B$^X,#*@T3.G@Y8))+^L6[!D?%\\
M794!DXVWNC%6+.9O<#<X=#%G"@/1CX-EU82M(')U9 6[\AX;C;B!#'S?IX%O
M EK[-+CE!#-D()39G/ O<Q\K=%-+/Z^5]/*RK\F=N)X=IB49!ZO282=#+_PL
M$(/"(1W<(O8X15$8\!O#(OR7I3G'EUD>$2 YH>."1^.]1%:Q0T?KGI1Z;(]]
MZ^S=MZB3@2-:H$=XCAYP,U] ^K C..7&OR<:8' T0 <9XAI>49:YVD)YTX&"
M8/-BT9",^TE_/@PY]V7TU- *9L=X4?\=A.Y,%4:3<'E;\:;^YS/M+HC[VV&>
M!'SN*\,)_>G8X7[/'QI8=O*:@_.%#:J,18UZ"'+(#[)L17!WCLK'00W6$2/1
M:)- \%37'@%_3DEUVG!Z1GQL8"V<E%VPEC<5*='48N5@',!!H)W[T93_>H<.
M,5":A5\LUEC3VC/K5!E793_MJOQDBE7$/CK\\IUXP2/WNX9[OOA6RVWFJ_I4
M;SWMG/04>R %=LG]S-VM>UC""L/??UQ9+S$MZ-M%Y_3*/.Q<B66]@B6=?C_Y
MTKLPS[Z:O_;##Y^-RU[W^\71U5'O4GSP_?2P=W'\Y]'I-_5![Y^]B^[19>]0
M?')V?G5T=BI_(+[M?#GNB4_>_V5OZ?TB@W3#F_6RA]^BHU;?/_"PU[5CP+A!
M+/A_>U=]M['=XY4G:5RN^?SBJ*O6_]>G7_\+)<C4EIX?772T#Q)LECP?+)55
M: Q>@RC _A!%>!!^-/_2[?9Z7[^^6WKF4ATX^"7>)'19L31<1HW9KU#HZG)&
MG@55@+;"[LDY_+*^ ]&7E;?U>K7'MLRUF1J38@?O/E>;5KMYL+SD$,-5BV;X
M*_()7?'9C]S_.GS>^.U\^OE]!2XP_@/^"P^O=I,WN$-/M^F5IE4YJ&S+)-<_
M9#M_V5@KM24SW,20M7NY0;6=YK4KBYBGYI[KVJ2\C4FU"U_M0FQB8H).R\NS
MPP?SP.HC>. FEK[F+>1F],\^FS6OJE%JMYY]+IN]A;7*!M7!1S$QO=1N2[;N
M-+AA7U_C ;K>!NFT4J]9K25)]7%LK/;*V9AUT%I.&KR@135+]>JSSV6S5_&Y
M%*TMY%';JF0=H(90>P(657_=+ HV<:=J;?F:7IJJ=8%--88Q%.66;5]ENSC9
M4YB+C=?-Q!AG[MEGL^95(>#=L\]EHY<PR\)V#&H+=:VGX%#-U\VAZDVKV7P]
M&LG;U;(2R=VO*IEN83WIQ=QS]O5R0SF'92L=J@TL=-!^J/,!K9R4!LJI)96;
M01/+5D)FY@>KV*YDM05L,ZN6RTVK3W\6G!9%035*!V)\;-UGWNF)3UC*EE7Y
MB,H23!>4J/G!>4LH3X&D0;GRGFJ<(? 5!<:AGH%-"&"48?])]+B8")@;PCF,
ML0T%V*'K#T(!/LB5'6:M*3!ZN?.D$2,?)F /2VM+MEOB"A?8:DN10SX%5-,4
ML,F5"&#*I<[3#'R:2TJ?J:[I.!DRG%JHO? 3K.V96WJ$SI"F G^E/*-EA>P:
MGR-BD0H(4G,%"-)#9\ CB^N8Q+75*F-H*L05[,'8=:@00L(CZ9BS$]>#66"'
MT))9F!H._UUJ&SA-7+ G"?%/,^%).!*]HF &+YLRZUM+F4_'7 KI,46+-)WG
MH<<4+=),7B4]-EZ*K*OL1%WN 3:W]0#UAA$;5%2*-G<3]B3_MY2I]B[PB6VX
MENUALUD1W:BV0S?*03<ZV*$;;?GE*/+%]#]SZXV>*A24G3?.[3OS M605U[8
MJ;J[1A,P'QRM5:XQB*%WJY5/%@)Z(E  E]AC!]DD6G*R7-.S]1ZII-"1K C
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M@"//Q3QI!L#Q/",;\T!H%P\1A+A]O>?A&O$!L6O4Y'WU9C4B0H2Q6R["Z@C
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MCC@-X3,N'$DN /;+-CVNJ\ILL]Y$XX[>]B6PP^$NJ^));DEUA5O2#?R(.M7
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M?*P+ZK^$J9)5)O[@A$$\Y@%<O3#PM)_EO,,@\!VU;ZP["O"C(U#LS KH*AI
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M[?U=]C[QI9XF^237U$E\1KZS"F]OX7U,2#8EGHB$<UPO*+5%T=Q0E@?A!:"
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MU/>5/6!1E!(,JN"E+$",/O*.R6],59H8);?+S-TNVE;,,^=2+ZQ5-X^.+),
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M>?6_VLM_JF I"_J#"=S/>@:,1M-3UCJ]FO7^)ZF(F7K?G\&8K,"UU\O<.8K
MHW:KLC]W/I@F7#$:!VV8DI!V$/N8Y?\F3-F!29IO9M6&$5$:3+.X2GB#FZ\O
M3UM3B[0-S71WZ)L+H;5("MM"R(#*G:T?$_\'V-4&<E8X.0$2^O7X3O6A:,_"
MHMOZ!ZRMG/:&VK%;;.77HLT]*;]._0102P<(I= $_,\"  !5"0  4$L#!!0
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MP7OD^>_\LC3DJ[WREN_TJN^[/3 8E!ETO^1OK-*+K7\#4$L'"($?!TP""
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M>+9FQAV/F["_?L_QA3@D:=JJM'W8O!#F<LYWSGSGQN"M^VXRK-<&;QUKA)]
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M]JMS:1.*YN#6 !N3P QNV#A00R>A&4'-K@!U+;N3W%GH&%6T.NQK1C-ZKZG
M=H173$3-ZC6.$E*"0FZU54F*KLXM;=_DB)?)#X_!LP@8T_B8+WGYISWS!? ?
M4$L'"'#E#I(_!0  "!0  %!+ P04  @(" #K@[]4                #0
M &EM86=E7S P,2YJ<&?-NG507%^[)7R@<0W!H7$(! DN#32-2_! < @)$-P=
M @TD0' (E@0/[I#@&H*[N]-(<'=HAM^M>>^\=>M.U<Q4?57?[EI_=&\Y9VUY
MGK7.Z8>9AQ7@R4MY)7D !04%,'W\  _S@ R A8&!B8&.A8F)B8V-A8-'@H^'
MBXM'^928D(2&BHZ6A@H,IF=^P4K/R,D$!K,)/^?DX140$*!CA4!%^,1?\ OP
M_3,("C8V-AXN'@4^/@4? YB![_^Z//P&B+" *%0G$ HC@$J$ B)">>@ Z
M!1WE/PKP/PL**@@-'0,3"QL'][%!]1, %04$0D4#H:.CH3W6^CW6 VA$Z$\9
M>*4PB#7?8C(ZD_ %QF5A,4E7MI&^&CUBYG_G$H2-0T9.04G%\HR5[3F[@*"0
ML A$5$963EY!4>FEEO9K'5T]?0,S<XOWEE;6-JYN[AZ>7MX^'S\%AX1^#@O_
M$I^0F)3\]=OW']DYN7GY!85%/W]55=?4UM4W_&GOZ.SJ[NGM&QN?F)R:GIF=
M6UU#K&]L;OW=WCD^.3T[O[B\NK[YAQ<* $+Y5_EO>1$]\D)%0P.A8?[#"P75
M\Y\&1&CH#+P83Z4T,=\Z$S/R!6*12,=E5;9A,_&_.B)]YS**0\8LL,IR_ ^U
M_V#V?T8LZ/^)V7\2^U^\Y@ \$,KCXH&( !AP></V(P#G$9!6"EM/*L+0[Q>S
MVGWC"CA-K2[0 W)?LXHA6P)U:J6\'1[K6@PNI<#/1B8&HG_"66*[:2<XE6,5
M!JM2_1/G^M$\B<2U9+_([X;J:O2U+] V[Q19S6E+R _R#>+7?/A2P7;R:]H1
M[$^"TC9\3*WY?<"H/8<EM^3&O7./7]FI[ %H9*^?P>KI=QORG4Q36(MJ#@[>
M&*W@DT,;Q,%HB&+^FG\SP "AV +.RR;/HJ!)@K8<QI6%BB,=.8SIF<Z_H=L_
M_S9H'W*HYNGWC#^QX)/,J:?![MD,@."64]AH>GEVB$82XBK;%G8ZVI722F=7
MR: Y4(JX+KAJ'R#IEZQTA9][$DWDS-K$*@"*_IY*YA^^=! 0TZ@S-I[FS2KA
M)1U:@V2X^>2/G^L3@N,B:2.NM2UEQPRX&:KZ^1T#;[-1]Q BU\[1?'!1 %'>
MPK!0HJ5D]N-+G'&[S:"K)]B<?W\Q<4A>F$ =(Z?I*OY"A"7CEDHGBJ5>PV!'
M<)&F$E6'$NKB1%[8Z9ZO.)[C3;G'I9\C^84W4*^"!@41*](]EO8L,5^=(MH0
M5S>*;D#;2SN@NQA0P%P*$*%>#NLG*!GCJHK(G9=QL9!WXU<9W3<AATC5-]2@
M@*<M5YOMFV2R<2]^?N_MK[+'RWF*D_H4:R5&1B?EY;B)]P&=>M5I&;G=3V_<
M!JD%WB[%F\D4965;-C)<0ZN5,*^3-<DB&(HDV=\?X0#;?X/39IDNG]R\5L]\
M!9L0BFH]SJF5\KZ"8VPLF)"G^7$7;WA__=4W7^<?Q@J65JJ3+0DO-II>A!,-
M*-%+F*AC>H'2Z\_*E81T2IG$YCL&QK I$C Y,4!^D@C!*+J@,\7S>L'@*CIK
M=X;8  T+5/ +6 /0K6X#]$V(6WP09_4LD',D#;ZOOM$;J&56B:MT0V_1 2)%
MH'+O8\*X+9V2R#VX"XPB>DU/]W@J>ZGX/C*&L*96H$M!"07_$KZU9>9&2XIM
M4O-4HN[*-;J)BR3^71 =D_O5-& [*83:]:O6WFX-TTYQ- P'0.1?)=$K7XH*
M#-3\/9%5.4:>/W7%K=S:0*G?JK%Y+NX+I_U183C#<M[T<_%)+U\V>KB 4SB?
MYQ?J<OC+_9PQM]NO?:IOK9GM[[@=<NA2/*6AWC>G:J)^Z:\[<U"^J/[]P])7
MPUOGW-;M VR1=]'-T8)3=,??S3O4'AFT"S259.5%@0.@N'PQ[B5AR&<+#<%5
MHRD#7ZP^O?.MPCFNZGHZ2^>Y2;-;->YFR\6M]%&Y^I-?$I[]4V 6LAB_XSKD
M9Z,[YK8E_<7Z8B!T@VVDT,C20]1M&&8 ('37W/B:3]I^++WD.M"98AS[$;;0
MNX%@OFL5+M<<5'P B'C&.*FTQ$..2_8G#]8B^3,=^9U9UT']=@ZW"^\:AO?2
M1,3Z.+EDOY!:T_5JZ$5+L8+74EY$Y2Y4+7E\LV;-"$WV:\C@#96>!<<=[DJ"
M@SZH!N:<PGZ6?>GO7WAF'4OS +R_E8PL<Y$PBCP;8N?(".^U)7EGC+.W)-"H
M6J06*>W]3G+^5V3BVY/SLK_;4^+Q%G8NW@,<]XLM&8L4-\Z:+5%Y"Q]^;4]%
MXV+,'17C!09XTTBN!4 HD0P+S1T<9CFAM7ZJ=GCQB]W4=*UU>T/:F_Q1,X,^
M-!9PL^W.C;BS7>D3OJ824Z-ZDT_'O311-B,H<B0:_PFCPPA!VS1"*=]=O3%]
MLK4E7O++CWUQL1#P:C3TV)A4JSY<[-,\(T>>5#M>Y,=8.&KF"&9Z1MCXW%)U
MZ6:4,V=I@2I.)S%[E49^$M^L@R%?-*9-!I+,K_&-#9G3]J!@9_,?*6SE@KMZ
M3S+*%VKDU-3E8XV0JF:AU58_,UN&I]ZMXNQ.#\#2NCNBO)I^U*U\F7"OD9'5
M_A3%H;4)ZK+@XOHXG03YB#2'^38)\ 27ZJ^E':%#YCS%6E0=OBO<>@5FL_)Q
M08_E-147-495GIXH<N)OB:2Y3[ _SRWSY4W]?L>;SE']>/"W:J*G_"2F#*VN
MHLD#]77_8OW.L>=0]U[RK*RV-A:O<45-LD!NBZS[:J 3XEZ%P(BM8G<J9$?:
M.'@DUQU6$)N@K"&OLI#"-GOTAHH@E@A._1HV2K.)XZ6R_YQ&3.A:Q+V"R@AK
MW=@41I..1H08@#4L@A8U&+EB;GY9!O%_)@!RDBD47U*LT=:T;VIB&,;K6(\/
M:&EIMAT]*-D_-+5RL'];]_D\6IL@_TA<AZQR99_06%%NL4*3;*7EY:>^6))"
M1!Y FUU)@A+%W5%76L;]KFZ<"@6H(^KE&K#YV:16U)]ZE\T)$:1-0Z0TZ]F0
MU[2]K8F0MYW9S]709]%QA]"?\"5.I[&J6XG75-:P2Z%1:*^#+2'@+9!$72'C
MN-U;O(K9^8X0&%N1;"8)\A"4#V4##>Y)L.R,J^;(N:,7]1+S[>)257:9>3.>
MU"-9(FLA*^'C,6O>Z<MNHN"?"[Q+E5P3LA0#JNPU=P@QC0V?:(Y:0]S7]G_&
MZ&7,B2B&05;[,T[0(I&J4M$YKJ0IG3ANKAJ11'G%-A%0W<JM!B8Q>8=RQCX#
M\O.O[3$E_F_")2ZR80Z_[''CFRN6EG-5+8[)E'>+?16K0@U[\\S97V2[R9UT
M!%Z"/I[4LD,&/114*I9R] T+=19R9%LYS!P4:)R[QU+(XO/GT6T-.:R$:M:)
M.HJ#Y+$I:!37 D2*N</"DRY*G=^*QU%[#23;](!>CF '?1J2ES]\:T"&%']_
M]&F)/EZ=2):%:)[)^-D+_L@GBQ!6.@W;S*:1L_Y=R%[>ST]M[(D6V@#"82D[
MUKG+3Z3HQC*X*HI).5D]:/9][1<9@3 1 F8'"!,%DFC$(Y/ 87[-K^I$O_;"
MOF]V08ZX:G[BZT!<57BC5"^,B0!:5)T<4UZ-S]%)E:I$PF%A@=^9\^IG#_$'
MN]_U,LNXB4,*@HMYR>]24/4-GPTV>OS)=E@B!WN@(<8%XJP-[*M>M3GFSW:2
MM%]6EN 4/0"' &1W*4#\8'I-/F<Z"=?;T1K-689O1[]OKTYVB90B%7W^XY!/
M>)T$YSPUQ0O8SZWKVF^A<V;4J(I,]O4PR'4@X&+;*&J19"CDL>5*,V"FH4ZQ
M%:,FD2A[92EG_'+IS#HI:Q_Q' <K@='BH_D+'FJF@D>UX8UDJ)I^/\:A4//6
MC2GZ52^;NV$<;E!6H,JZF00RH>LJ_^G,H-.<^''MP0#.--'::Y<= JEK[Q@*
M\1..TO$[:,[V+OO\S&\J_>_Z--DZEN]=KEDI1=XYIR>^,3@*B2DUR,T=_/&#
M";44"\OW>)QB_?A0DFI*^.GB]I&Z  8V2Y1^-O.'3Y$(IK'R26H.-K=;-GNN
M[)/5(%[P2SZG3%.\[\V2Z"2:_PVZ+.18/N.(,$^Q3-4%T/W,_Q8Z\][QW,:_
MV? H$W_GK1V!WONZ0O>(;8<_*7]^8O1=VW[JKH--I3B#CY'(E4[GS7KM=YZD
M3*G1W=N2-).D79VEZOE&H@OR1HYH\J'.[ IOQVM\II4MO?'/?RY(NE"W.OGA
M \8_PMF _[^@Y';WUD]T85",5&6%C?I;C J*+LT?AO<PQLAX(_O)#H/<727.
M@>"Z& @'U04]0<XE-!A0+1QPR/U<%3S2TE$3&83AW>_:V^T0].O0(47U9]+F
M\RD(^89D"LWO80W"ON=$:]K"&(R571X63#WOVS"=]Z>K7T^1.X1QM&&=+"9J
MY$A8L=;1GY_G3(Z,Z4Z4)?.D?#/A2"D7,>[ 0% !6+UOC/-/SPJJK07%;)5M
M@],WGD5O1^M8S="E8O1=7BO1#658H[=]WQAX17]KI[AN@$W >_, -,\5,2AW
M5]$:X=I<\BGA#6*CZNP&=R^"40VO*L.[V%_*#I8%3T]PO\[R32TQT99_M5L5
MS!5"G<P$L5O1F4Q;G]/)W$LW'U4ZV3.IPRRDB>9(UZXQY*]1E5"]""B6X9?K
M>@!D+A7>I)396N7(82_]T4B)+6>UHFT=JMEL)-%2UFH(LCJ@UU]EB N1 I6J
M&F6$"*(ZL%0F1.4*=_!&BTWKJV3^?[.4 PT3)?O"]S\DBR*?;!"^XK^+ JQ'
M]3%-QG[C.6BC"H.J'H#07:ECC 04+F^J_1T]*F#ZQT_YUMQ8[.88S,QUJI#=
M3BJ:Q)):8=%/O/,=PF(5(J"33/P^CH@'(/C7RIL;2KO'L)+\ .!@=KY!/7X
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MDQT#TO-/NDG'U0/R@N\Q01)-/AJ8_0WN_7-W7?0]9FVOG+J_[[Z<+S*O\O9
ML8 2^/BI^J!/__9[Z<?>MR1V+RK6[W8R^)OPE!M:>:A_XC\LNA#'GF:IA@:.
MKU&32-7TP"1:8Z/_]>N[2!E3FKF<A2EO?'J*G^TGR-)BPUFY3_T5\9I8 2+:
MV%4%A??R77Q&J26\7<0VXXQFO/X!L'@ _GRI6XY;-["OJN5/D%WR.$Y%T#P
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M8#[,_@]02P<(O&[:V(PN  !+,0  4$L#!!0 " @( .N#OU0
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MP\&N)G.=R#6*W!1"63AF.W8VC7SN G'V.E<)E+:;VC;5 J7+R4J& GX&*>!
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M)482\Y.)44BGZ=M+ O+F4^V-4()Q_[G'*(R\"9JZW/;]/U!+!PB2]YX(SAX
M '9H 0!02P,$%  (" @ ZX._5                !4   !N;71C+3(P,C$P
M.3,P7V-A;"YX;6SM75MSXK@2?M]?X<-Y.:>F&'/);$)JLEN$0"89$@B$)).M
MK2G'%D&)+3&2S"6_?B5C6"Z6;8P<8&J>AG%,=^O[I.Y6Z\+G/T>.K0T H1"C
MDTS^8RZC 61B"Z+GDTRGG2VW*Q<7F3__T+3?/O\GF]7. 0+$8,#2GL9:!3O]
MM@FU6V(@VL7$T?['G/]K6:W'6/]8UX?#X4>3OT--2 #%+C$!%0^T;)8+G(JL
M$" $'FNW+M"NC+%6S&N%W'&^<%P\TCJW%?Z?0F'RE=\^VQ"]/AD4:-QN1$\R
M<YI&3\3^B,FS7LCEBOKTQ<SDS>.1>+#P_K#HO9TOE4JZ]]?9JQ0&O<C%YO6'
MJWK;[ ''R$)$F8%,H8#"8^H]K&/38!Z2D79ITC?$_[+3U[+B439?R!;S'T?4
MRDQPT[3/!-N@!;J:9_DQ&_?!289"IV\+@[QG/0*Z)QGD,),+*>1SI6).B/BO
M>/*=?*]@1+$-+8']J6&+IK1[ +",)D1W6A>S1F "GR$R[ F#CDNA*5C4Q7NZ
M5(S^1PJ&7O"^Z8 VXY\=@#:Q=5F2,%>]O16#]FHV'FY@Z$R$KHY[T84MUP:X
MVR2@;W!%R,*LQT<VI8#16^-)B%K+Y%@B>1.$_:9AFZ[MC90ZMW:A'6#$ +*
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M4@-B.!>K"W.8=J%P-A-@TRU85_$H8.U+LYCNN@8!V$#436_!F8$!5KJTI[[
MM3&5Z=IFN.82@&;;).U=8IG69@=\1NZTJI8CMQ=%XI:!E"H^JU&F+PQPK=I8
M"@-MAJIO'YG=8GZ'ILC^Y&[ W.XJTVMGZZZ0^Z457ZGL"_$I'9#+TP.7."A&
M65'%@V!9U)09<"G-<#Z=N"IX@(B+")J]\K%VU7,(KS!]P:)0%6@*$2A_^C]Z
M.?SH!(B%QQ1U4^@_S$*O_A>5W\P2T-O/@FZ0>JP_N\M"FV\(*F=D?H+? .Y9
M^(F<8;IFVK[5;.R!8=! QC3])G&  I]*$M=<6AM3$89=/("$7CD:5KG!U!.$
M--\15!:1W93DL80M*,\<&DX%UL:UREW4U;J&X_DIDK2X+E5G<>D&JJ(&VSV0
MB7 ?TH@];@),,[F)C$WKLAF S105#($N;+X]$^L81U\0+B^[66VBGLM1^6MF
M+<)6SW+:JM7#$+@W$I.DC/ZZI/[=#6V"/%\0WX#%V\X?LB9E%V'A[YU'N/Z%
ME&8',[%934-;R<.A-?..P!)0YPO(/&U%DE.TQJJH&<CCS3:$XOI'_3JL[_MI
MVM%>1(!3;2L,KU-,UBS-#5P4 7?\B,9>98@H35DM0I3$*;,62N?-\=()\\HU
M3NA=.4F*4;3(33.M8ZJ=8Y+G0- JCE'@NP8K6O$9Z1ZV&0SS*@S I^HV \N9
MQD)EU0[0'?A(';CV/+L_1,P^DO,$#E]J%QNH+)%=I<FL\-,U1C%9W.P_YXO<
M7CA!>2%A:LK#R*3=9"%]H"U,$T+U-$H?DME#E"95K.^(RHZ#5D^>X24SY1G;
MW$I 9TRM3K@"\#+WT_M?D;?I>NW@;;2X]9>AO_!=&KC?LCW?Y*;3BXBQ%27'
M=$J;DRR.8]RP:#BMGQ7\(-X86=14=A26:T+K/6E'<]:@>>K'=-!D+S>T2M1X
MZ^<S2_$QM884F=N[#M":";6',468Q[H';399NT,G.'8">MU\NT*TJ,XBPNNL
M&*1.^PPQV>Y5QJONKT!/]W),@@=GU>@+7=]5]KP4=#6U:U&@A-@X%T">TY[7
MG* [#2LZ4<UQUP]?:)(R=0+BL=$]U#1*-M"JOJW4?_-[B:X45@-W1"JO%=K6
MA7F,[MIO_GJ-\"EZ1$'$;OEF2XRRMTB=&V\^.:6-0X*,UH4\GZ[:'B%#Q\I\
M5E1"N2=( 2-3AFO_?5,X<11D2\B?:\NAQ*I3NECQ-/G3^$&#PT0[:+1.SY2U
MYW&Q>]SN5UB]'CX');D2^/OV^VFR1;ONN_84*0?.TF!+@C<H8(V(Z+,<*S7_
M0%D6M2M,S?]APNBO$UF^QU6^QM;30&DLKSN0"55;GT.U,]YUO(H"(EI\2ABX
M?C+@O%*EE@4/TAW06,^O7F8#F[*V")O?P>3YV@P/EM%PJQ^K')KC/.%G]:'O
MG&>D[;:5)(S[;GV<AE1&;!(UM09Z65FO:RE28J/\80]HH]P,Z 80(G87S6*%
M:8Q:X(3Z+X@<@L;.+?W<--\2.63-G6,$[&R^QDLJM'ZN$<$WPM,\#0Y ?Z3$
M@SM['')>;](QY0KQV R)2JD2-!F$TLW';NTU@=J:<20<J,9XS=I^QC_>LI^V
MNG-\PF$BY*CFLQC371S1+/2L!(\,$L5N!QVEB))AD$N>$-3NXF\0S8;+^MC?
M;@(_R=:#VD6\D(C-;5M.19)@&"KP?!^C^>(L3ORUTTK[&KRZ&L1M-A936BU-
M4(#SN':Q**%+5F,6?WSCQU].,/+\A/X$'M_#YS3^%2*%EY&BJG19ABFB?:N6
M&3"]1FJPGL3\IA3&*($>;-)5P;CLVO@1.?0&@-X)9ZS-JD^>K\5&Q4HJ5$!2
M(GM+IX9BF* @0&Z2.D%9*UW#49"A,P%_3AX3T )LA9#<:O5FUY4TVPEH4!U*
MF;Z%6O?+ZPU9W:SH"#[UXTT4.\%\<1F%RTO_$7E9 R>SBM4283H.BQ["PK)P
M>IY,T4XOOL..MVO3U6JW1YO,/]&@T/,(LQ2=11J4(6_9E06TTP,HVE0V5EA]
MY%/F/=C>NWM.R?KY&7:<N&PF<V3D U4<W,%N3W93*$9D/+245R5P+P^)-K12
MQ1PGM 5+ 5BH#[XWRRUQXHBD'U"(L!/0,&)O3>"*V0'WL6A4;7@'UA1B,NM2
M%^1"[2;Z5F8/U*8M*H?-9#3'!ZK036^9'1W=G#DX)-+16IHLILRLBD3<IN+*
M"%$K] 7=;?*I(B>.0O)CW@M@'W<]RNRG='.GCFVA8T'QGE'FZM\Q-WQ  .:$
MWV++"[[L,$HVR$H64W[IY\U#<AQ),<YJ"EU%(2[^D[TK,OR,WZG""3B="P03
MVI&)^]&?1OWR,8'NP^@A1I@=;B_"39K0!X+0)5_U9>O"321($2?C39E1D*%'
MZ5MWA;PT0//%C S0\X.4^NJW5$@F^-DSK6J.O*Q'WYI(F!>C:;HBQDY-\ ).
MQRB9T(Y,2^/Q%#*I.@S?ZYETO-I52PP4]<S[O 2)4@P<,A8-L'8M$FF(C,1=
M\<H_#-1/#RF[)Q\X-?6A96@GO$3$\4/U,L/%#K[]2&L8DC^-^M\Z$DRX/I 6
MX!+Q8>,L$K3;R Z]5E",DXKC0B:&1^]]/5D#V+V,"-'*$B+_M5L^ZOQL.(!#
M:@EI( J]G[4]TG.*&V*OZQ=D/.&25H;(#L]&K:2.!/NWDD/4/0AKF;;9H/%(
M>X]$FFQ),!4HI=I@CZX26+G)?4NUP"J']%9QJCU90B%CJP6.%0I^J6 YSF3Z
MGO).NZN, RKV56BN:#211Z(?;V>T(M22$=]';20U[M8\0+6"8=K@CC#C6*U^
MF.9BV0$VP3)B%80H::-[1S\OBU=]\O7$!'"-<WOH+BLV]);[>W6QFN]0Y4K9
MG4>X5;BJ8D%C&O?KYB\GNU]L4J%YY+2NPWY<NGV.P6K!#? Z9I;F 6P/T?9@
MN@5B]F2^H3_&>9]BLY?4  +9N[,V.=GT]6.D!7278,64?W*P5Q6,1BMDMQ9Q
MG*ZSO]O[)!H@W*%58H36G:&D>M'<WW4]9P+?$ZW$3/Y1&"I5Z6SZQ'LW6\JJ
MDVG'.HKBGX.N**==_C._NV9QNO-%<>266(O<=T0I4G:MLWP]3R5XY,H;#C&I
MG7(7;;'GF/5,-E>V3%L.FV<)C=JM^GC+/+39+>8Z\ YMXC5==ZH]6RQH/^I'
M5/*Y(=MF(])V/ZZ(ABA6LSP52\(.PUSFQF[@5"@NTHD\77'^>YH%:E),<P(H
M(CU2:UJ,)UHL'!\_TJA^\F/1A]4/"1(I<[;7>8!_%#IE3LA#F1.B6WD2(BF%
MH(%82W+@Z0PKF[:9!\O;&2$\F5P&_6<G"+J7O9&)9R3=JFO;B,*$+/FS+$3G
MEY<Q6K(N6]#;2CF&XVWYXU]]A&FA@^TE?>*=/?O&EET_4X.39D6^Q&[Z@%Z1
MOT5A3,B:FT2UI=DY@03@&W,JNNJUQ6U13MD>:VH22/$VZ$ 4$^"55QLF9QY(
MK1-13;P>C$T%O2J)\?MKV\HVK&FT<-(@L:IJBK'88QRD:I:-&3.1WWRL.<C0
M:NW@9/,21<NN=6JR"T+SYKC"]>W>%/?V4!7WMJ$X^-I,75S?[4UQ[PY5<>\:
MBNO-F-)+F#,>JMT?I6U/3Z8.19V(FDKHN%U%.+E#>'T<81P]T6QQZ NO#@X6
MU2<;@MZ%BYE*'L4]4D6R<H[M[MN@K: DU_%K2AH_F0 ;:Q>+[BZ,-631T,GN
MJK%YF4AHA,NT4C,D8*;>9V:_O&G4>16N9A<6XK#@[%E20CH/9XWJ)52<:@F3
M;.?)=B&UE%2#_!57)Y.G)87*8+@?6\M7,Z_=\@&=CYR9 ,DFOVMG:^ VE\?%
M3FR#U!3EA,K708+5"9-KYR4E63\\Y-U%30'N-U%X$<<I39V46E/J5&TM-AF]
MZ (%?@CC"T*YGSW3P@RI'Z_R^W--/770FJ9VND !/U]5Y(Q9*#H_<XK.E_4Z
MCS)6V)O4Z%K*GI=6E196XH!%=9VM:";!15@YCM/R7/0DF"6STFXB&,627H0T
MM='K1QX7J29%%EWULL1:M&#5V) 7HH2(&&_(!&2%UG(G?) '7BGD=IIQN4+)
M)>%2E'/3]JWE*>L:KB)BCA*+I>2K?V'1HQJD@G*V-P  #A3-!*W$_\M-@>H'
M]JK?@.!;'SSL*U#>(+(5^RX%<M=W8SCQZ4/=B81D!2XUS EIXN0B[Q/A2-/<
MV]D'4BJ0(#-MC<C@))F*,>Q"1.LBQ%H=)A#LVQ (O16;SDI<*5+D.O%J$=#+
M[+) $<YRAY(H6:&HJ,$7T!I\NWO$ 4Y,5\W-2GFD/'/I+KI;-2H :KHVP_GI
M+@S"[-KQO?,(S]:L4U3FW5*OEC"K/.G-%_42AVIWBL/96%]\8'-BMR0!P#?A
MH)7B%\.,:87F^J#D3*@<)6LN'=SL+W4JB1UX($GF\= LG_GB/L[?>.</"1D_
M'<W9L\N.L62D3(3Y0^ OG2RO6V4A#^-P@&MX(.3 U8#K4U!GH5:7I!5E@<SA
M]G)46'AC<7L>LMJ,,:W-J.;Z 'D^G.*01KT??9ZZ3W!U<HWI!_P0U\_+_N$.
M5/O5)SP!R":\F/J&+34E&Y\<H#XZD3$6'%F7YS.B:D?>C)Q#G26Z012%XA]I
MR-(;HZM-@OTH;F_WM 9EM"%5QA=V5M# )^J)TWS;:T2VRN;+K=E9T<7^&YX5
MG=J0>GNTYD&M\]8+T8+X1\PM"@I+!W(U5+1VF"\(S .N1-0H:E[O]#:I*"KM
MG-+H*?0K<K#D)JE&<P0/-@HZJVR2BM 9Z<$C*\7=4P2NP(+F@2NPA XZ5%U-
M"J(R^#6XHVK?ES6JPQUZ,@WBS*CPG&Q,X!HLB8[""S&IPQU\,D^ !M7H/\(O
MQ)+HX:NQA$\<#:5YK)05!?C@(,W6WN6I[AR7;FQ60]?$K<T%?>%6C#5L?C--
M_+N';R9FNB[85?.>4^IZ[ HE]EQ#SC3A7'%=2=XQ#LM$9#QW?06S%T5@&R1@
M9F_F]RA$%BACUY"74;BD?&F?!=KLT=GXB1,TWY"@=PLYIA;] 0F5R2(G5Z+9
MVIW0-48;Q_><T*./9MC9M9X;^%J6$Y[EO<3RS&J]:Z!^6EJQH#G)HN69E$#-
M;^R9%$682]O?&K61].>B0N!\0?ZD\1ZTC#6P#>GF83V*0EH= JS,O3M1L>K3
MX"0E L"_)? 934]+?:@9*\-1YU<7%EA9O:Q&<2Y75ED_>N-^J/'+5K #]N-*
M,05>B]E+4Q5$95@.;G\BZIT+?;Z09VSL[,<OZZF@9+U.Q"#E.%443GMCW]"@
M-ME:FX).XCM:AO8?Z?*9ZE.XZ!5>P0/4<RMIRY?GDD&[6H++1IW*SBE4PU*A
M>MT /.4J1RHB:J$8I"R>4E4<5?'\2,:Y3M=@,[1.S\I9CK/L"D0;(X:^I6,L
MG&=84&OT1@EJ?<1&7K:O:/!18<[C^Q@MTH :>;EK!O[75AL&J+H8(B2,-,=K
M2D;XGSWG-0D^1)'WY.\\*+ >)Q(L[75&U/4,Y9 T=OB=K2.<^%_SA,ZF,, J
M%#";U+*3!7"D?=W*,_ &TPR.9.L00G^D/FNI#E"#XSHG.PN]LX*L]JUT#ZDA
M=7-33'"E_5A"[]Q_IC_%'W 4@Y_2N7S&<;$M5E2M9B0?-4,MW?(G'_]KUF$Q
M31"^C1;)DX.1"74)V8T@&%%5:6((C5V$%Z+2CL])55X3NA,PF^)Z$^$'W)JV
MC"&9N6ZZ3EDX_RG:8.3Z76_4/3%I7 (CN>>64X,$'A([/.C":<7*F%LV98#-
M5-0E!]ZHRXXX64DWE+\= _AB>9&XXC5:TPWC4=$- ,OI73M; D @)4SC$_L!
MY0)D2P/2'*NA1(UJP!D+=2+[?//122JPKO+Q=$#FC]]4!X BG#)O?EN4F341
MA]'+:A0F6D)-<KC!IT_<1%LGV$6_2BV(YC=C\!UE5T)KO.#I#+6 C5RL2A,!
M@Z$N?&83T9 L=!*Y"UH7?CR.6;,5UXCF))E.S8[)8IFK\H=1^IM>'AF'T2,*
M4XCZNT6LW4U&4=/?Y%$98*VD! ,+F>P5W-;L%D#0%3+9^E6CP:PY-[,ZL?O4
MH*\#8.S9W+C?$.G"Y()"X 3L[2GV'WU%=TE,Q<[T5\!<%@TC#ZH-^<H_W&@9
MTFM;Z,(T8GZCUY<"=)(EE\?0PFI3-EW(FEF%WE-6#]U98I1U-H1(&^&W>2"^
M2UZ!?59R'-Z*2H6)7N^(1G'A>9K$"4'/#Y?7V ]=?^/(73))$;(>6C],?]R2
MS-VH&6ARE&7<L0=SEOJ5-U2:AS3/JVQO<9PF1*Q+?^UG586PXZ'\-^6V)0 V
MAZ)J",0-- NH]#0ANRV*8WK9G\\\,KY&@Y.RP%0F-!EJ2D?=V;.,,R5 &1[*
MY(#5 FS1MJ:A:HQ31?=B*J,XI,$;=QYF8X].BNG]\(-#1**M@U 8LT?7_&VL
MTJ]3PQ6BE(\IY9,*Y5.4.'X02PIPV9W7P_.+0#D.:'PS4(:.I!^#([XSO2Q;
MN3[FID>]!0^,&@"RA30C@(E,Z#8A&P$E?TE_F6I$,HE(*?"7S\E8+)8PR<C,
M<JI'!O<@;.0.CL/QM);R8U:K.:\])-YTY#$IS&T)116PF6G;V\M4+A$*5%M6
M$J5,*$PJJ4K7:GY (<*92^VM"4[4<TO\1Y2_-LGG!RGH3HZGC:A6);M35: D
MC*;J+=V@&)'AK0C_4]K2.V*A929U*,/1ZIN&L@JE,(2];RB?;0/V[\AC[<I:
MVW<N _03N!Q3F^=/4RZO*NZRUM?NJ31B'30W@1.2LS=[(JJ<1P?<S%?:<]+H
MU5E.7+>QB8":;G6(3@W.Z,W$DAF X^WN5_*GL]F3@[V\[VCEGODJ-6 OX>6S
M?M,G.2_JY>[ M63&F044M-$^X.R9'./\&%UCWP6O5+(GJ4=Q)VEW^O5KU51\
M+Y/N03R !^4!E+U.3J*0X9<Z :UR^-;$%-WS",80AZD[6_>M;-!89P/K[H((
M[),#N,L>A\9K/QMRVD]:L&LNFVHS%O\]5.8/]"DKO@BO$?8CST1*J D)O]4-
MN5-;,C7VC4RM6$G:,?F%@)*/(!G=Q$2$U*TP^EYS?A:I2\@[36E)V4P6)G9<
MP20NQ/&@IYFZ %-US32@SK7^G_OUK$3SMA!PDF9)3?A\KOWEWU^]>O'?GS]^
M^N%__ON?[B9]_C7\X;WW]<?'Y:_;\/XT??KP(W[_X]_?_NO^;AL'/SZZ7U\'
M?TN.DEOTMZ\_OOOR_,:]3%[_=G[^]O;O1X_/QR>_OG[T;O'#O_[\[/UC_O<W
MT6^?KHXVT3].__;U\;5[O#ISH\7]E_7[FX]__==??[I\EUYZ-[?O3][^]OSN
M1R?ZZ>1A_;?[\T^+Z_F/7[XZ[C^VE]Y[_(^KZ/1HC3ZB^;MX]?$\>?,?_M%B
M_?Z'V?'S[?J/R^6U\^X/+SSQMG^>11\V[_'UF]/S/R\6J]OPI]6EE[Q^MSC[
M]'C]Z:>__NWIG]'1S>?/P>K^]/77._]^\>'/9U_"[=%_W/SS//G'S6]_X,\_
M_.>[G_Z1_OCKU;^.CM!C\OGHZ<O)V[_]_?1?E[/ET?7Z_.GR*5R\"^,_WL__
M>(V]S_-_+3Z>WOUP<A.LX_]Y<7)[\^K5(=Y$ 2^<?/7_.*ISU7F$%XC5SJ%Q
M7&?/&Q]G-22*,8W,]17+>Z#>QW ]YO/O)VB?P[3D8]J.C(YEJIZ0W0F03^OW
M(&8U0V/OMVZ-3"K>"YH%N28V)^WIK[COAZV?8NS^36'&F6$_V8EE2!O%_#'S
M8#1 Z$\HI@N 66;DLA0+^E=C?RV7%ON;O)>75VHQ+\?U'"26?T)>X\#!?(M1
M($/U7\QJZ *)0UT/Y7%)>I36'^T!!S;IEZYQ0%C.?_@NU.97]FRYQ&CI)&C4
M@0#ZX_ANSY6T7DQEP5N:M<#<IWQ1.MFB=.(X76>#3HF41$LK=!PX[A?R!?DP
MSD-XR39%!KV./!0 5+]J&(;93H;[F*90W]5ER'6?R?"1RJ 9Z0O'UX9%*A/0
M*W(7\_-3%! RM*CG#9F38[$]"A+;/_: 3TH0@Z2B=(.!QSI^0I_HH_()Q8*.
MX7;(_/PTI&2)T./1V-%3XEIX9(^=BA6MR3N"I\;I&=&ZQHTUD0*5_<:/OYQC
MA,IB,R.?K9WR?I^M@S4N&[-L[;!!125P$8A9/F!*6+4S 0<<)&Y*^NR0>$_H
M#TP&E*%HX?&#-N=(MKLZ4C$KC7VW<L+\Q'I%"QG10^NX7C^4Y1Z#IZ4PJT 6
MO+IR9;+V1S9!Z^'(DYF?#;'M'U-'-SF;BC6::6AD!'G$#]WQ)S8[VY*/P*L:
MW0SMT"]L^47S0\@NI"<W/QMB?[>>0L6.O=ID46F[X<7K55DDIRHRVOB4B.SZ
M2:N,2H/7I7HI25T&NN%QZCP5*T7J$#?T@-=3%'*@7NLU(+7PA"CYJ*3_&">_
MWU!K(%O=D7Q0L<WDOW9VN4[+D/H4JC<.F-%4E0UH8%\I2N+R-<5DD*_5"[-0
M9K%S.M7 5"C@-@!/N2J)BHA:J((HBZ=494-5/#^2<:[3-=@,K=.S<F/"678%
MHHT10Q<99"R<9UA0:_1&"6I]Q-#G[&$AY6)'EW\]"1WMKRB+[7J"8-[2OG0'
M7OJ5B5\+B27'H;R(?S7FBL9CL5^B+L8Q(N<5&DXHESLR@/RA3) A"(_O8;2>
M]4SEG5",O:S4!S#U]JYHB2L4&['T?/FG$C2O,P*+[WDFYN^^]2]3.6I,7EY6
M@:;[GGKO;EY#&&NWS]-P\IJJD^G(#.+A98R'.'$YA8-0L  D.S6;AI0:8_]X
MZB2HC&L:F2^F*KVMA)B1^6/*2@<M.,0@:3"E>^86.3@W97[(Y)=[+I(D=0#^
MN!)R$D5Z1N5_E-7M1N*"M.6Q%Z Q#3>D0X/"DCHZ<[#O#,DI1REG.CB4#D/O
MDJA)59_9?_D9R2N$_12CD1;F(-S:_:E.HG(-F*-13GD07Z--;>*NIBIVXN(N
M6I8^DW07!JBF+.[7T[_:$L$#799$N(64,@S>>'>4#G_CK:!FL9"&J#QMI:[B
M&$MI0HL_^6EG3_&2)31@MG#-74&:VB%OX3U;!O^"<A^Q 6?L[XS$!>2D#\(I
MUX6U4#+_*@_6+8#0\Q#Z!Z'L00 7&N^Y"!Q1?;KI/[4##NP KJQ'B&JY(D2W
MDO8Z\*;KM8/]KRCVPT6$UPPKYR%*DQQR\GVYZG7R> JMG 1.',\7Q>:!;RB$
M+3T"+2P!,_WTTD["'=DY9D:PWTP=-<U55V ?2H-S;N".I9DW.DN35417@'=/
M%A-NU!$DQY;:'JB4O3/XY#E,0H,V79@7)+]@Q*?(@7H"SGT!D+4MZ6DMN\?^
MG.)*:"W7:0]+&6@F\K6[SY[?@T252^@:P52TD"0V_8DHE;ZF?0.<. G;R;,W
M?"IT%-+[/Q.;9B\O4_/#U-[7#YRI@BD-;D8VHFX>INX\Y;81F6E:50\')Z%)
M!],)N$WF:L6N6051C*R)T]%.OI[E<TH5=%*G;>=21LHR5#70  36RVE?07<!
M+W-M;SJW7(RHP2-#]VW]OE0R#[6ULOO4QENH-<U4$-M#HNS=4Z2KG]VGWY1^
M*HB!)[5V<"/ZT%Y!U8^_)>-6 TV<SJFLH1 ]-0)H4JR@HY[/]__:OT\E]>$F
MDZDX7%'^H\IBZOG\&U-4!3=A7A^$HF[]YP%ZVGUM)<;2IJ8JP E3_8;N3>H;
MDN5SB_Q[5==@@?M0,!99291*^$1\%R5.((4L[]M)8<P%0,*W&AHCU/4Z?^DO
MT*\T-DTG**B?H$4/3%$I:CA)EAS561B5R JYI)J.SR:X'.K#EO",[/9H<*/0
M]0.?[6X1X45^"27.,_ECD]).<4FR0F1Y)RG1]7:!R&B<H/PM["0(J)=#58[Y
MXH)QN'.>3W(Y9LG="MT6<IQG<I2_13MB:/=\@..LN5Q*8L<H).I.9DG.I>3:
M[O'"&9<DJ5&T+36@\W(IRD(*WDLA#WUCO2%S$:Y0,E_D['-QY.:HD,K!JU$"
M2#/7;*=^_ ?9*/V%3W.1L[8[L]!C^<I2RNLE</!ZZX?/S,W;#8J)2^.N3C#R
M_$3.!6Q^,XX&-.;TTL+(P/T:.PVWXG0E+5[GIZ-H:V'2R'4#9N12C99CR0*G
M@R!Z<D+)BX".SP[>B'5!)7-_IG$QLU@@&@)?B"1W-]/\R'JO;I/*:$,D=T-F
M[61%R"-,S"PY)9%#)$IB)_0(,@^T9:^/XO+4-.#0=)JS()#,& NRQ5[N6&@>
MB&2I:FT.;>(J0O*_'L/&K:B.G;/$Q\1(&%*+WWQ#UF'BA\O+*(Y/'$S.^1&F
MF3,Q\[_I, C!QKWFX)@8;3$LV3GAU*W&SNACO!^5?X@B[\D/ L*7^.=.N/2)
M.<K^R;2:^UC;RK4<IMM>,$V%J[6D(#\4?T<SW,(846\?/R)JAV:NB\F!+.XX
MP,)K6$&2:2I<!6J9PRZ4_K-C7<VZ%">^/>B\C[NU(]Q@1?=B"GM\5IAOM138
MT,MOP^+N1^N3*$[VO^;513P48Z"A'.BS/G^OPL3_,+[%,R837?,Y0N*3_D!]
M"$]JD'KA'> F>&:2A7(/CE>%[S6.B(>?;&D $+WJIE'VFSSAV;Q.^=QM1O?*
M37:Q3GNP-=8+O9"DO)VJR&-(I9VL[ 9 Z&NP&S?0[GI<"RZZXX;?\+C7XX=@
M7?F@0I]M:KMW.8,8_RND=D78_GJB"A%A(CR"[/\2?(Z73NA_S6K.A-Z50\O_
M18O\"BP*X[P.D&;)&7+ CM*0WJ5=1X'OFO.?>ACI-"P@VYB+D!>?DYEQ[6P)
M5 'YJX0^:T0A^6F)G?5EY,@]E4H3LQI$+595.<7ET9&Y(=WSC/\090&6+L+A
M;G+K^A[5]4.(Q@0ZKSA,7F,4$\\G?V$[)Q*%KI^%-67U. VM!1B9=(]-)^DZ
M#1SZ_'?F8!K,6E04 QXEGX_5900Z(6H5G?BX2N66[OMUE54UVT:+6W\9^D10
M>AYHF1B]W27;J5487'97.>,]L.J1U@O!4>'54>8,8@AE43-#RZ95UPQ @;N0
M' T !U= TS.-W,/Q\?:.?&Z@/(L,1W-Z%Y9I&;@"JN91"ELC#[9<SI2OD6(N
M,AP-;H)2U5T4YKJ4&JM@VE(C>/T7245:K 5C3HTFZL/$./E=J3PD^:"B)_)?
M.QW5:1G2PCXL9 ,4T'N]DK9\*1X9R/=0?*?7B'7.HQJ6\F5=AN I9W 4$;5@
M363QE+()JGA^).-<IVNP&5JG9^6PR5EV!:*-$<L\O"B#ZCS#@EJC-TI0ZR,V
M60R0[91&BILUJ5N]*E%PG)O5YFH(F:HN'"UH!79TBAY1$)G3"9_/%+73@QIP
M78>"8U[98%&&[=YFAW?HLS2?C\7GJL%W*!(H0INZ_)EL$\5^$I\]NX@F[N<9
M)@%M.9MBR<9R0B+VTM%@+K?$*)DHWU',A4O?1:%+>\TL,4(=:ZJ_8$KG]U/7
M2"\V$A4Z0*\F[F.T2%F)D'U=3%0X'H+5DT)6,N!SSP\L)]%Z[2=LXCFA1RO&
MD+'3*5E]5=$RS6+*:L\I*O1TTS+%/.3?3F1IF3I,=S^7:&BE-%K2Z%AI#7.#
M B>A?:#(0KS#3A@[+) @/MY6_\7 ZX@"8V/;EMP-H.+TKIHX%73-=,>H\C'R
M'M+!P'J3%/5)S5.:T5>/-B/P1PZ.=BP^:D#KQL13!EOV]*@]7Y0>9ML$<G:P
MKN^L]>+0-6!\!$"OB+O8=%DI.:AM-M8031D>J/*]D0#F<+>14077BOD8AJ^D
MD?C^W*EC*[K?..&J5GU_Y_S^SOG]G7-T3W)FWSF9,?KH;*/2DBN42N_ZSE;2
M=*]W4^Y:G2,UT+;FL^.A<XP\[+M?XBA4P+3[2WL= O@'VUV%Y^[!&IFJ-]'6
M"9)MOBKRMMHQ+1X]#^5NOOHIV)J^0VZ^!)@8.;7Q>=X]10/U0"D<EAX8)D:R
M$WMXTKXU0S7!:%@J<&5(%1DL,FF*ZA=-&=>\[ ;T%5.=^,06" \B\;N3CB(N
M"1S+K$$*2I+L7G^VIF]G,UHQ!WDTJX\51&+[&K"F5+E;>RX>J$MEE,U4*[U$
M3HQVCA^*7>QOI&O\\K^V]_8[Q/+UH"%1H507_MN-(UFYM_+K$P8X'V^.Z(\&
M$+VA291!YU;2AVS],XLUD0=#W  @A_HGH,N9[#1(I%H%VY*=W*&W^=$$W:/V
MP'-XW\,]-U"Z*M.W^OL3A+0VW.+(-;)LY<TFVZ2=X-@):,F4VQ5"R46XB/":
M[>/5H!J-+%\A?;42T KT!E16H@7OY@M:,Y56/[E%^-%W47P;!1[Q97"2I[D#
MNXB23&W6M%?79BV37Q)50^6%-QBYO@G%U4A;C/,<I)PZ/K(=:_9LKEC=VK*&
M)37(["A1*4]4L59:94T:Y$Q5*N&QT;I8OG:V[@JY7UJU:%3//5*$[%T[BY2S
MJ],C!8CLL_^>Y_AO_GJ-<"6-I')PJX2W*L\2(=V6'],[5Q3(Z3GB0@;R@:V2
MI SNK-VAK>HJ*:>X+#H %3^4'V3+NCZW+@H=[$= 81K== UJ32YL0VVB%F^X
M')! ?1_&)R=_'\8;LK_3;F?RL:@BA7!I[R-4B1/7T3O[2O3YJ)C(&N:R PD
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M:YHFG,D>P/N@*+.H.%QMR4"4?ETF1G W5/G)Z%#TLJUH,*8!^%U%!7X&*#,
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M^OGV+@WE.:@5IER)"3<4ROL<_U3BI'CWM&#%&^$P+DL_BY@0OIY6-T>L_5I
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M)%GW*;DU\GICBX3,VB#6R-^FS%WQ6JSCB5A::34^WCUO'N$*R.2 -9>@TU@
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MYTL8DZ;-$&VW!BUC+N)^,-IH/2PM'%!E'X+=(KM9E[13*'5'%H %FB!H,]9
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MS*$"'VM4);#Z-@DF@T/[4$>]9'8QOE-B,90QE!UNGB WKA.DHN$T]43!C/B
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M>W-5X3S-SM+ROMB6<=V*,32[HS(C:ZXMS#F9%]7.JCO2:O>H[HOJSGX_B"6
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MVJS)4JS6BS)C4<IRK.;&6[=X6G$@U/=I0A3C6;H+HL%CU+-4PAN/,;-1'7.
M)F5 4@V/V$%-8_1WUMQKTK!42L-:>/R9VD.$]S16WOSRCQ'.R$P>#XM QVSL
M^0UP&:J,>%,_J=9TH#;YAY/OQ\CS 3TKZ:M>5I,OD^U]B88H>R^&V/N747 ?
MQ5$106H.'3V\2F[PILQ @9(&'](DJ_])W[V^@]SZI4 \F:\%_ ,MA$]E7(G^
M%Z@APN#?(8/^3FGX/L"='5W<CV26E9[^9N8$-BZ)Q7)1X-W<CT;/R]OL9XA+
M?T<-ZQK?$AN&?DB=@5 ]$MPGEGQN=#CT=Q@0T1'_';Z\$2KG_OKZ\C$,*,%Y
MZPV1IL'=/L41>I>:HUUC,*PP.2<HHKR(-D&,.A8!Q]AQ?C[.D4!]&#Z<E^6[
M<[>;1QR6,;[:GD=)5&#ZNMU%4A#J<+^/P6\)$\1@8*>:49\O8?TS1J!ZD9B0
MJ)Y';(G4ZG!D1OC( C,&0"\]S&RU+$$JH;W8WJXSI,. @0X_HGU8 <(5;:L&
M<N[MEKJ+,^5M07@$![8*NCE<0N,H318),<C'FCLH*D.=E!/Y$T=-)U3WXFVH
M'D"F)<GQ^T>R1;"N! K!4V*K04&W';S'Q0CC(HCBO%:MZ3:'9O?0;--IAMD+
M7IR]673Q=+;1')EO\W(M2\T^H@.@[@CHBVJ,+]$1ZN[I=*0C.A3JCH6JP3P'
M!Y8!5GL?=E9QV%W%GH$%@=FPX)?CV-&?GV]WWP_?(/D<OR&NU;*0:"9M0H]I
M'.(L/\/;:!,5(S8^L0R+H,J&,MQS;(@[,*TG,2C[&BIROPSV:?X[5%$5?@\5
M=10T^7*C_<,+]"= HH]RV]6U2[2S&-)B,[ =P,UYX&0^ET0W5[M_!@A7Z/(I
M*VT;NX/7,T=["/UM?E(6CVD6_8S#CPGAJW.-CU[P?/>,LTV4X^LLVF :2ES$
MDUV"0\<GC@M,093G435'M#VB'=9QXKX@T'K!Q(66VOKP\30.\OQJ6^677F4W
MT<-CL40P7#*0PQBCF L!8FD'T/)5%Z@)3#NMY(!<+;]>64/Y].UCAUS"2P6N
M%8.Y34B2,V..*N^>H9E(E>@:>W V^+K.TCW.B@-HPN(D"9OG9^](YT7V=9T1
MW2)-@R,!W"[3Y*$Z'+GK'8WX/@"V$&\7<+HK8A>#*W>[(#NDV]OH(8F(R0MC
MM.]DPYO8$<XK*]@@7&!.UJ5'9<R=R(]BA$#'=4CU'E*OB'7\*I^'Q1-EWGI*
M=BMH]4RBR5"&$0 [TBX.[B;P-RM6>1OUJO$J\>[M5W-*-8HX*'!X'1 %OL@.
MSAG L6,]YD!8:H(V1+0E=U/V4UU")*%^20GN)"WO$),&5]OFRB /%Z);5]R>
MKF+LW-%%=2+Z;?W&/]2KWEZ0$L[13M9PNRHJZ,V$(('WWD#9X,3*JM*EY6R#
MTF1(Y!^VO6FJ<*^_S&!R#AU#(39@,ED?RXN=ZB',;"(3>B[31PSXF@JW51QL
M6,C5 ';3XA60MER_M/LQR?=X0VOTZ]LWB@QS,6TG*1=2%E2/)?O-C=.23)UY
M+I^CO<T+@8H/P6ZAB%6?N,LDRO[0HA+34-L$6JWCQ(<OBUYX:3PKVPR4OT6[
M';R;]H3CE$:H6C/*U-31).5R!])C20 +UAEU>J/6-A:;.JYW'3,)-AN.P=)8
M12F5],UL' -R[G+\])F:"#'^V8M["\=<J/IXXX5O+%,STJRXP]GN#-\O=PPC
M&L5YB@27#9') ZV/H#F"]B\0]%C)W0"%V/K)"N))V[K\S;-ZUX2K*,_3[$ ?
M\2#6>'5NV!:;M(@"6)-WZ[#9LBGTW]K'%UN*U5,OX-#5Q\PM56D0P8-+-Q47
M'0]OTN):;<)68YH&'R8-X6ZSGL;H,@#G[^N?!<AEH8S)"VVQ^X-W?!<5<!WV
M(@FCIR@L@_B'J'BDQP#P]L-CM+]+WR5%9'*LHPA[F([HPO>UX$MT( !4X/2Q
MI>.U -8$&=<!%)N%L7^&A9M4>0)?P -#_]M#V^8Z.%"[^%.0A?3_P+(Y2<)%
M8S.+L.@RPK/$! 2? ^VP+I-Y.7RIDX-G6.,)7MX9IH^H14\8@N59L%G.U9,.
MY=C?D_$B@&W;!=5]5E'&4$>"710JIS[ATI+H-N!,-[P=G_&J>;&_4.K_9%=?
M8'HW/B>?YTJIFWE3FJ164P1 Y1_I (KK!*T*5&)?QV!Q;#/,J^1U.M(BVQMG
M ,>;VI@#U?4$5N!Y#;N86#R<&PC#&=I[%@%X,90<F%17VSMBB^5PPW&ANC@:
M SJU^I7LB!12P#S:]0!(7Y0]DUQO >8O3#!'_8&UE!F87$W _[T /3EI7)=>
M[NZ_A06DH+.*F_Q:IH\20#SC9ST@4A@^&NLR\T<>IIL2@@O4S.+)ZV2SR4H:
M@R#M8V#AF!?)8:W0GC7[RMO2]]D=K3)O-@O89NI5C>F7CT-^)$BXS#NXJ0';
M;5U?:)MF* <::%R$Z"N?!WV*&8XEH[,B\^LIM:3HDD. N\!D@() !Q3[50)'
MY1?))BY#J%%<%A_2XC+:160&=RFQ'4)<M<S5PHPJVO#Y0!>H(!W2=(*H'N %
MNB\+E*0%BMD@J$A?H +&J7OE?N4]>9W&D)AIZ3V@YC3('VD&<@X/0E_C#)Y]
M"Q[P#4'X%;P4O<$X%"(#>L.77'5'^Z8_R@@!@,>^(O&5SV-.K4F.CS,-UF;V
MTVRUY!XA!G^1-$7+&Z!5>T>-1J'P* 'RY:(MU(Q_HJ^/--\Q"JJ=LO[FO_*:
M?Z8]V[$4S=;)QS?(>=7V#.>;+-K+]MA3[L.^8=O1GW&CF!$O<4"] GXD4V01
MV=#@B)AI>8DTVJ8HH&V]"F#(.&_1^9/S86?VF&E5K=YJM]N.5\M", ?YP@_G
MZF$CH5D[L,5=;<49/'?=IPXE8JE(@;6XZ:1([=L4J82F2!4I-1Q(2UIMT^NG
M8CI]0>*3Q1+ZT6E:O+(GY$22OBA0AO>$0<A7S\O]/J9:.XC;FH-9=8.<2#I)
MDZ,-V(K1;@^'T)T_;7J0X<$$4T;6#Q"V8-;8Z*ZW-UA0UBA#6H+?"+]W)CUP
M YE%20U)</VC#7IW?>O5&QC,5""QX5*L0"9799$700*VZW5&UC7:!\) U^E(
M&&G;FWQG5?>O?%Z:5<].*1OQDOB5U^#SKOQ\X4?5>%W%(T;PG!1\79!%3#1G
M_<]]FE&+X04*BJ[+QOX_H*>CT/T^(+0W&.6/&!<HI'[X%@7H4Q85!4XJ'8M!
MM>Z# _D#P ,B.%$1!7%\0"$A]RDJ'LD'FR88'7"0036X>WQ("4<P!-2X"JCG
ML3EL","B+8I3XF5E+]"GQVCSB#8!^=@QPL\;ZGV%-/P7H.;J:F4@ V,P!/GC
M+LT(R_"4%GND[ LB)W@<BO#3M1.^I+-G/!25WH%_D;4N,643_L7"T^O -A\)
M,F#+L./>/#S#6YQE0:QAE3=-N1:Y:QEP&!^MNG!R/GP@Q@P$).#ID[O@F1;$
M^X"%/F<;F$W@2Z^ZHR)X)NH WN'Q&[,1SD<@!N',Y\XOT)9$S<EW69KGITP/
M*X1QC[>@R0)V2E!I*%#1[!_P^T^@GJFZ'HN,:#?F&]+P.E'1Q'(J-VP;+_".
M[ %0%BR,X.UO3,G +K$)LNQ QH6<VQQM(.6D4K-YO9MX]8QEZRD$@WCQ?2G!
MEJ>K>@.\!-ZZJT]?+(*7(XGXQ:>0BV,E!S8H-H!VW-FQ8\)Q'S"K@H;FRBI1
M8R0A;PHFOX(/F7!YFN:%T.>J6Q,8L-;$),I[VMV7U/K\"X7"FZ;K_( SO$_S
MJ,C?/9,/BC!TCHF)"/;E14+?==5Q>'-J75:VZ_VA,G:IS0[1C=KR)F8OG QU
M&T=L$)_6D'SZ'-GIK)=S*4;Y3V40T]VM/K@AW_(56>I,^/ET^K1'V* ;4^CF
M42:2R8SEH9RY^VWQ79 EY*L&ZYD]& !/(&\(5V=17!;B;^JN_3 JXS5B[Q<2
M_XWN3]O*D2-*/$I#^ _" ?G46 8)<4S)]U2PK?'3(ZX#2R#2D(U,FC/6:%_6
M#?X'1',H^%,-#UW(YTU<:V8M$1^5]"(;: SI61$QN> 0&WIM@PVNO<UME)#!
MB;?,]EEZ7O45?3![PQLXZJD"FQG3Z%KK!4.ODOCKO9A.6&9U!('-B 9Z*+FO
MT)EX6:H G3F/P5,0Q;7M(6>V^K<)SU0T \+5K(O'H$"?TC(.T6/PA(D=12#0
M)4O,HW)7$X;0 %7+';XH6&MZ;&)$M3'PP'6I/7&\$PB'B'KH+KQ/TTKU=8Y4
MC-[G[%KEOR.V YPI@%\(J1<BI=*THQ8RY)_XT^Q#GL=+S9V4AYCEN]T^3@\8
MY]TD-G6HI^G6?TUP#7$?Q8S&HM!9 1^2H0="?ZGW_'.VYR0/G<2(-!G$PVL[
M6R@V2A.UYM"VIOJBFSD">U[W  %(HYJVWZ#2E%49BW[R$COW''MO+EUMZ;M,
M\8'PP]YE$OJ0S3M7>_K.567(E$WW*I[N-QB@FMQ8@%JKX7K':E+-3JH #>1[
M#D^N/N[3Y*(R341".V]/>8*&5'MJWCW=*PFYQM3Q&!DPGOM(II:KYR-BSV45
M^'OW#$9@&>6/.TG(6"A>$"G"/1I^M:[F1/5D*5H@KQ)D::*]% UI'D1'=NR,
MDYL!X3//03DUL;3DB^$^SM#)W:W#4<UI/W%/!HF\U?,/=RE+O\^+C%)7G,&?
M=Y.@:0B/73AN4B6H0SK,BNZF,L%-"!J88./5UQW6H(QG6#<Q6F83B@<CNYG$
MU?;N$;?V@T:R8P<P8VN*G]OH$0'B^8D%JUH3Y\9OA[.JG)R.?FX?1%Z'/FZ9
MERU]?X)>]L:R*#-<6UE7R0D!P'V4X!#"0L*%_U#N[B$39UO'S""XMJ6D>/:I
M>S%(9S66B,8BN/\.*%/7=9#R?103#9LFN"K E1,;"Y=92GZCE<992:<->NYJ
M@K"'L7LE9'^K:7IU$?6G+A"E_JJY=AN_@^_]C.R2'2UPC;./223T(&@7EN/7
M9@3Z=14DLQA)1#EC]R)(\UQUZQ%.KYJ=Y0%Z\&XYNE_W#NN<E1Y-S+T9WV/B
MG+!^3>NZX>LXV&"9HRP\@Q\) ,&*@,T.=-&^)NS[DU#,6RXN\4JY%^'%;@].
MO.IN:=6,>WG4]>H/6!ZM-7=*SK?T)O7Q+4[P-BI.BBKA M*5RB+-#K*S+]:;
M'GS=L_XT29Q1H(?4E,3@5,R',+2F.9:1P>IX^"B238:#')]A]M_.96.]#(BH
M(H#"BD+_5K9OB8DFQQ.3?"%<[^?P4<<QWA1E$#=/<\/CL8<[_%R\C27N_5F4
M;^(44IWH]8GVY=T][0]N380ZY&$+HO0]2TLY88[4-!?)@U)D.OD=*R+3Q)":
MG+3&;'S"6;U=GA2J8Y6:;%.<IA/$:P-_G2LV*2'?FAA$L_(<62^RGK Z7!Q,
M7FT?VI>PG03Q#7["28G5N0MU!U3U6,O]<>%$^)(23]G'=TH<ZG-<N]*2E8?P
MPA8W@05_:2)#GGF+S)F4AQAU_8%!\O0%I",DF%9[A <,!+>+Z6D-F8#.I?V:
M/$LJ!\MCTPQ![P$JK_D2*W\MM_EG6JLQ&.:4@6<,W>*B8-?UAS/1]L>[D$%!
M^*\RIR_8=C=2N0_N$Q?Z\Y?"P'09?83PN_SFW3/X)M7IA)5KB"0W_OOZH9^I
MT.2/U74?(NSYUJ')E*7RU5LO[U+E:R/>16*-^GZ:6P&_ILMJ/G"#-9$CP'1M
MW1M>,FZMM#E7ZE)=OBI)&VEPS15;MU1G^:Q' EZ3$E>NP#0A^ZOOTIPJ;SLF
M(F0V?D^\<$ABW=Z0'[)H ]5FZ=_@[HGR,Q[>OZ&IH4^,)/PQ:XC6#8#L*K2W
MV4H(Y6ZSH#XW<C-^V=V<A6!096UX/,B<LB@S(:*[PMZT/[!,U1>MX""]2TEO
M'Z=EL8W33S3?AOIE4=43A5%&U%]\8+I^>"<N2*H2:W7YG<,:=O?![*6"':V2
MAR!DPTZ;\BRM%]H_ .I6X(5*1N$Z1#"8BT0(W%E[_'3J[+GNYI\/3'A60$QQ
M8ZJK3NLL0I5C5-5;&]^7\B=)X_60R-IR;7ULL)=P"MG4%-8HJMS+BXOI46Q3
M7/D%O[BR>[$*9S42FF+^SC]0RL]E%-Q',=EG;A_3K"APMM/P87)H>P2-*['$
M-16/WY=H.GPY".?M[<NXH25;J_,^M0S8PF>LSFMU=NK73QS/@K_TG(FZMQ$H
M)[?[0';?;T,!@G)HA:#@1X;AN,QKP*7EF[^XG2EY4"@/]+;)W6.4A==!5AS.
ML6;237WXO\_2IZ@J4-NI;@%F= S4FZA)94W#*5A6U^X2%-R$'(H@2FA9B+1G
M;;>E0]J;0KF_\S+N^G'$+%QE#V&32YSG)QO2J*2'36>P7Y,5E5Y_[HL^AA2/
MH"5!-O:6AM]/33PUCE14Z^!#Q^4YQFWQM=Z^5R?:GY7X/'K"?\6!L&;324]6
M&+-WU'*X8A7E-!4+OL3[.'I@A2?8UPK;4Y580'_3J7KW_[7WI;UQ*TF"?X7
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M!J6<%0VD3=B:2"7,EWZPE_RLL@PEXX@%%H/P3M0PZ1L?V6A[2.)FDT8YOW;
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MD3,VD#]"1)JQU)M(@? )4;/)1Y ,811CO]1="%3&=Q8921!8@SS=(09(?\1
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M9E]>8RXI2V( -)@33Q%4FSLTR=3'MN82<U5R-;4YG!6BR=&SSTT:-9FZ66@
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MSY0.XBF"EJ@PZ.WNO/)&PRB-PT-(3/W0AA!JH-G99K-_VHO*'1?LN6*;3-;
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M-H@^L(8-PL0$T0;1!EZ*2,KZ"W@</_BIV@]^E;-6B9B7?%B*@NO!RK;)@T3
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MR8.!4'<D7L(MMSE=>A'^*K8'+PHNO22EB"SF&[Z=LK]3U=]A>AGS,-R_)^Q
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M<<R^!X27*W;@>DQ)O"7?)M.U8(!9HBC _*'[*/3\+^P+-FB<,T?9W2I:KDF
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M7'35],EM.JZ:C*_YOF#( 4 MC_94D*U(T&;8?<EU<:"#6&9$1_=F*6$:W&&
M0FYV3(Y\ />-9/ON8@QPY\EK_EX,@NHH9V[7**Y:S9U2@XO?!P%SO .W=Z@G
M VO;<0L3S6_3TU!O@J=_)M0HC>13Z!K%X##+8^B@7_1W9&VO@ %@JD[O0A2
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M&,RY13LD/$LM<'C4V<SWTW4J$IA.$!O;QVV!)SW1KYT$IO!\) =3OQS N]@
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M^^>O;X)/?[[:'G_W&S[YZ\\?WAVA\[/S'_[WV?'-]8L74[AN#R^\:LE@\&4
M':1B>WG7^E2=/B+JXQA=4>R#%V$[$-?V/<]V5;4?4M@"&MK:>S<\U3OEJ>X:
M]!V32$@Z]4)>6_K-&)I\X!E8CSC75>I#(VTE(62$97S.)H8C9MJ*%\?I[L4U
M/FTWBK6Z]=8QLYDN8SJM]_Q]-#Z/KL2V/T95@#$X_"8/_U:H --ZQM&_6&E6
M4S)4 3F?Q",FL+9" @N6K*2IQ$7&*0I.4MX9(.-93"\NR2XNV Z@=5&= 2<M
M10TYYZKQ5XB&/W9VN&(R3FYR:LP[J90'QC=7Z.^<O+F<$;I HI 9#Z\[?=Q@
MFA7<*>8^,>-QF-^G>#2;@Y@KZ??FN^XDM71*._"H<WF2&_*XZ.>J_\[)_;GQ
ME@&>63?*H]ZWIJ*M,!4^>^U7IVJJGW4%[%MF4U;+P0WUF]75(40+#=9^=JJ7
M=I:/W#CX&T0M ;TK!L0"7RZ=^59P*]04HG"KNI:.\0:AH(SC#.^<SHV$0J%:
M4)EB!S^_/Z&8KR%A-R-?)#;ROYIZJ)@TV]_>^2V/:*&\&H])S>-[FLKKT,7?
M<#)VL[ GJ>=R(5,:CU =E58.'C.E+ ))X]9Z*!7@Q-P-'9B&_';K1.5%;C+A
M+L."F"V75+BP)QV9I3^//\X%><@+53=_J[-<]N$A7]U>MKJ].$[7F712)C0<
M)2MT%'K^%_8%^S#.LVG8N<BDLR8!"DT+K]:VE]F>@8\QKZ5R6V4@UY",@0^<
M <W,&[AQ;=S)=I5H2GP76OR)A(P,+WU_S31W*MN3 L>6;V+@&@FR9ZD@;J=^
MF;%)TC?%2=F>PXQ:]WJ-K\0C(0S8HF,R._(),V4"=E2[LA]7^+7]".O>=ER%
M&[84@45MOL;QES.*T*Z^W<2UN97?/[39#&[ C!9[EQX^'292!H,H$9!&.*D7
M!U!^P-LA?+TC+JZT'QEQPR(!,A0MG'B\_5ZRW1>VC$6CF=N5%^7WZTM>/I%?
ML:?U,*3,MW5C3D&E0+8#=62!T^*GI<?5?!5GU+C&MN5;]>1TN(ZJ[=Z X\TT
M#WOEYH5C*MSDW+;]-CDU;@$7L(/'Y'0Y\]D[I\@UMO_8B_M1U;AE0/:@.9CA
M-)U@9QVC^ \-[@56/P&_/>39XB-AWH&G<4?6?/++:^^;W8J[J.A60E^1D.$5
MGZ %]G'2J+G8*@,ICG6)*_K\-,:Y4*_>KCN ]3OT@-+MRJ1JJ4&C'+L*<#%-
M?KWF&Y!LW77V0>DL8'_:GP-56M8*V!JL)0Y$32( !=/U )&OR"P#2:7:\N&!
M:56SBK1KQ9.+HN;*LON ([Q.UV#2J]*SM)/TBJ\V8SM%Q@4CWB.LZ"OT)BGZ
MZHRAFRHYMG.:&0'5PMX'R5\:OAIV/R% )S,I\F*U2+BAH6>4[:2*F<7'@4HD
M_Q6BN158#O'DX9_BE_A:.D+L/L2CF^7RY@S(NZX])I*%.A]MQ(F7IN10RI L
MUZYKY<%1AK,WK.0%=<_3E00@G1G8<D:,H>2'!M]&2=OQ+)6LY&#[<]+!S<L:
M,W8>B29O7-8A ZMS"V!79KR9F(XY!:>Q'Q .6$E7^U6Q:]NF^,<3+T&[>,J)
MF8&JW#OB0![5%%1&7*,NK;E^U_CBA_46>33?+7$DIBCWSB-)RO6K@JS$H*JR
M3L/@V=5/GHC-T^3'&>?K@>V>%N0T:K&"A"SV78D["J'+[34=E-Q6"4EI@547
M50U^.(RKY#"%R*29<=K /AQD!I5'39XRN\[FW7(!,6B:U%RV=Q5D9E"-T_#@
MR.:Q#UI6P['S:\<=>CUB@:Q("77$[]@T/N+WE)[N$5^2%E@-2"O=2DK5TZ=8
M+1^:?;<UTA[J!K4B(7>LW?FG>=9(4WN*-D//0031B6LBOI!/?:D8$P@N<E:M
M#@B90<U!T]J<JA$PI^+O1HDKRDD[K32ZX@0LQ0=E($.H@ E]I_7 2+"%,@"X
M1"=4IM?]*!W B;G^[C1!D>Z6#93SV5ZJ8IRNUQ[%7U&,HP6A:S&2=T?2),>&
M?;_;0TP3&6]V@YWO!YOQP0J/3GG#TDMSU!O#('?_./3B>)<O-Z?77(E:TAV-
M]Y2>@31='*T4&XMP3/8OII/P:*2<Y8VJ3R%JB8]P?JGLVCE+DQ7A<P@^LHV!
MUFI$QT?;BG6@E$1I['HRX]#6*2:_RH>]2(880:1U'EKCFG,Y(?Q4G8[&=7)H
M6^-&7.= JMH-;BTC5MM+T):7*>,"*.5?/E7\6N5D)Y&V>N6,M%';?VKG+<$&
M<B5QV2A\6^'E]H'H0K?_]-N!KB0N&TD>55X85-KKKOSQ-[-E5B0&EA.AA&"$
M'FHOWRE5P+#G<QMO; <"L4]H8)D2ID#B>Y7%V//YMP1D26A@*0&&0-[@1P,<
M]U];<FY80K(D-:AD -V;*Q.S\ UG#Z5\]B3B[Z1C>#UZQ[)ZKBHZ+_J%IF^F
MAH9HYOS+%^M10*]*V_K=7T9ORYC51 /5T,@1C1WR8Y?,<R-WA+II;5V3Y%S\
M#>L8LB>6DKRS2)62ISV^)8D72DF^ZUMW,.B<O:4N3Q(OHA=X@7[F,7 Z41K]
M!*=W9K:"IB8DP (H&@NK]-HMEV#4\IEKRZDZ9RA7C>V'>XI\$ODXQ&((LL 1
M^R64>(_L/YN4=RA-DA5B^TB2,F78+A";MA?N?HLR P.B=T^9B?GB7)"_]1Z/
M<R9FR>T*W11,G&5,['Z+MTC2[O$#-[+ZOKBC<X0BM,#)+,D'V W8;/;5,25)
M4O:;;8^ -5^CLJ*$-6EE2T2+5L8Y@Y<HF2]RYG)FY91VD,J3!5="@#9JVYW@
M^'=V*N,%YMGA6;NV612(X&DI2'L)/%DT^\5FX_GJF@F7"69US(;"B9P)6O_&
M>N#12&@U9 -G^2B7V6^$;4ING*V?VF]I--)>V2XHN+<I->!X=9Y,L&%('KQ(
MTOW1\MF3W1#;1 3U!J7DI%HL$ ^A+GB5\U/5/[+=H684B)JB 7Q;LGH!#'+6
MV66.W8=1$GM1P*1WQ_O:8Q27+G=Z=[N3G#X3W$S09T?]Q9Z^YKU-EJJJG[9)
M5X6_[J^M6P>*, @[K5L68%Y=G?>;!E_S#5O#"8Z6%R2.CSU*MPM"><I&+"X.
M?*:,8,WY:_S4H\V&C0UR4*_+[R#Z IZ67KPG)'C 8<CX8_<,+UIBMI=E_S2V
M+O0-;<4?;:8 O9*TW<&UP2W[H?@[GJ05Q8A?8N@]XIO>S/<INWW&+;=T>#50
MX,1!K5"1LZWWBC[FLRMM93\K;KL'4(R^T>W<38VUH5>@=OP&"LI;R0>-@MRU
M&+='/1V3.#G\[J'.XI/85C20L>7NZ#Y"*;.=1C<[Q" N[AZY>.!";PU!&[RB
M0H+7=7-U[<8H*\<)68PE_JXH8?><9,L#5OF#! ^:V_#HN8, WSVZW508N34Q
MC'Z/=#5NC5UMQXW48><%++$]$O:M0]F.B-&'NEUR&LN\$U>80WCH,0+^1.Y\
MQW!^9^^6J,9=KPMW'=_M3AD%AY=(S7?;_-I%O'ID 78/L_!L,:=++\)?L^HR
M47#I\0*99)'[)TD4YZ6!E(O+%/H]\WV21MS5>45"[(]G_?4,I/AJQPY6'Z$@
M/F-:<^5MF9Q"]E<)?ZXB$?MI2;WU!?'DWLJEB5E.11K&B:\">=% .JX/O2C>
MDRQ*V$<T*NF_COJ7UQ>C&#/9!L6M^ZK$_7QQQMB)?)S%UV45;4=:*3 \Z3XJ
M'*?K-/3XR^^I1WDX=E&$#'B6W>-87FF@*E')MNF6+%S2B(VG=5$ :DL6-W@9
M838C?M]I;%??X$&E))B6RF==00'J9-5O%$J#7+27/H/@_Z)2Z&SBQZ\.X+7*
M9GJ+H]/7<+2]99^/D+4K,Z*M>X3VLBOOUE(B!2@M!@HWYVR40F$R(UH^MQ76
M@!3.95E6ZW+I0+8C.TH6=IVZFU T9&0I>W.734X6O)HK.D'W*"3CH=<]CILX
M]LC-4AO[F":_*E7M9!^4D&-_VJ-6I64E^-?H@*O) J LA182\BM)!@O+]2=:
M]:LB[)8*$\K/-YS8!QSA=;H&DUZ5GJ7]IE=\M1G;*=4H&/$>845?H3=)T5=G
M#+=Y.[9EZEZ&:_53]*R0O+;%8A>3?(.6PM<$;(5TC^/"/:[A@B@;)#TB!"S7
MHOAVMR$Q3N+31Q_QJ@QY7D[(FQ*E5++EX2 1!Q9;*W##TK%T-2@TZ0+[*/)Y
M0?LE1:AE.?:7VFG]WE6P>F5BR> ?O,%\C-$B%?5E#N4I*8WH_(8J)5; BC$V
MGC6.R7J-$Z'&7A3PHD1,2%S!*V\96D]L>\JS.F4<^R'A>]Q(KQMJ8ZLOO&&I
MR3]TR-)2?>H<IJOVH*%"SW;(FY;N\:4O#2Q JY9K%/*HJ"N/;3&WU(MB3P0P
MQ$?;\K^,\*JA,+"=TUIQ>97W;!6A0K1,,05^E'>,E@%LKTAU9>]"U?RUXK,7
MH#,&-<7^EYA$"C6<V[^T60I53ZX=$K!TW>!>]OEB9T\W=[P.--J^L_)^KK%?
MM<[91I&D&B-M^Y&<^/<;S<'EWZ- +;+N:$.DJ+0?O"W9D5380MJ^LZ*T T)K
MG9^-<FQ/ZU5+8ZMH?\K2N'"&NFZ\/YZS_GC.FM1SUK07K-+-NY31K'J?N"9;
M+TRVN:SSIL8QKR0]C^1\#_T4)FI+M?KL!F1AZP&DFZW;!V(($:?P-" 2LK"5
M/=S#%F\"9@J2H#%-2T,5I4P<8&\=6JZ3C+N\@ 2TVZ1*W*6UU24?N]59+G""
MEUDW*90D87;/6/.7F!FO(H,"GL$E*@D)+P4PG*JC3]6^Z 5<6<10%514].$"
M>3':W[]1[%.\D2[TV_VU)<M7$[(>*=@H"RO8N=EXDI5[2[_NH-CS>4)5=U66
M\S674=AZ;/7)N_J9K8NRB>!K$[?4\>\#XWD5;G<<R7GJZA\Y9,4U)YQ+_ON#
MFFU\:!6E+_^^0]*N3#,7]#L7<\YOTLTFLR&\\,@+>=V/FQ5"R7FT('0M1BMG
MN*HF6PX25RL;K4#/H*H4+SPW7_!2J3R6X ;1>^RC^(:$ ;.S:)+G4(,'L$@-
M:JUVOCJ4E1QQ29%:KCO,AO3Q&.A62-L*B#1"L"H<P&>A0^]XHI[MKB(EW_7%
M9:E4AZ>RX6E5WZ@1'*N@1M<PJ@O@RMOZ*^1_:=144;VX21&R&3PQA(PH-B,E
M#<#^8X=> ;_@]1K14A9CZ8I::+Z*^G334SK=)<BH*O;@3.6#-B5):9@=@Y0;
M%J@9HQ?5H,V#KT5Y=>&K419"@_!,_GRY*W5SXZ/(HY@ Q1ZTT[5EQ:FMA^)I
MMT,V!RX2(3C)&?@8Q1MFC/#&<_+AE$-(==*VLTP&M7('3[=0&@%/2K>WG.X\
M:HT"Z6SM4_]JPN)KF:*M1\F"E=L'HB'M_5<.2+LT15O=))P/0%7?R4>-/S64
M_Q\QJ-+IM4W %;:+GL\G*,&^R=HIE[#+$PR]Z-);CU* K$QZ:@;Z8'&QBEP
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MJ -J'_<FGG*9T9'R417# :O?NK]8.Z528'3H0*;J[J&SM<;N^Q8:0BC0.&B
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M975R;V]N92YH=&U02P$"%  4  @(" #K@[]4"*&6C^$"  #9!P  '0
M          #,. , 9C$P:S(P,C%A,65X,C,M,5]N975R;V]N92YH=&U02P$"
M%  4  @(" #K@[]4I= $_,\"  !5"0  '0                #X.P, 9C$P
M:S(P,C%A,65X,C,M,E]N975R;V]N92YH=&U02P$"%  4  @(" #K@[]4@1\'
M3 ((  #?*@  '0                 2/P, 9C$P:S(P,C%A,65X,S$M,5]N
M975R;V]N92YH=&U02P$"%  4  @(" #K@[]4-K5HR? '   B*@  '0
M          !?1P, 9C$P:S(P,C%A,65X,S$M,E]N975R;V]N92YH=&U02P$"
M%  4  @(" #K@[]4_B=1]U(%   [%   '0                ":3P, 9C$P
M:S(P,C%A,65X,S(M,5]N975R;V]N92YH=&U02P$"%  4  @(" #K@[]4<.4.
MDC\%   (%   '0                 W50, 9C$P:S(P,C%A,65X,S(M,E]N
M975R;V]N92YH=&U02P$"%  4  @(" #K@[]4O&[:V(PN  !+,0  #0
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2      T #0"- P  Q L%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
